<SEC-DOCUMENT>0001193125-23-106541.txt : 20230419
<SEC-HEADER>0001193125-23-106541.hdr.sgml : 20230419
<ACCEPTANCE-DATETIME>20230419164109
ACCESSION NUMBER:		0001193125-23-106541
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		15
FILED AS OF DATE:		20230419
DATE AS OF CHANGE:		20230419

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-271204
		FILM NUMBER:		23830465

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d454025d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-271204 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to&nbsp;3,290,000 Shares of Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to
this prospectus, we are registering the offer and sale, from time to time, of up to 3,290,000 shares of common stock, par value $0.0001 per share (the &#147;Common Stock&#148;), of Scilex Holding Company, a Delaware corporation (&#147;Scilex&#148;),
by YA II PN, Ltd., a Cayman Islands exempt limited partnership (the &#147;Selling Securityholder&#148;). The shares included in this prospectus consist of shares of Common Stock that we may issue to the Selling Securityholder upon the conversion of
certain convertible debentures (the &#147;Convertible Debentures&#148;) in an aggregate amount of $25,000,000 issued to the Selling Securityholder pursuant to a securities purchase agreement that we entered into with the Selling Securityholder on
March&nbsp;21, 2023 (the &#147;Securities Purchase Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registration of the securities covered by this prospectus does
not mean that the Selling Securityholder will offer or sell any of the shares of Common Stock. The Selling Securityholder may offer, sell, or distribute all or a portion of its shares of Common Stock that may be issued upon conversion of the
Convertible Debentures publicly or through private transactions at prevailing market prices or at negotiated prices. The Selling Securityholder can offer all, some or none of their shares of Common Stock, thus we have no way of determining the
number of shares of Common Stock they will hold after this offering. We will not receive any proceeds from the sale of shares of Common Stock by the Selling Securityholder pursuant to this prospectus. For additional information regarding the methods
of sale, you should refer to the section titled &#147;<I>Plan of Distribution</I>&#148; beginning on page 238 of this prospectus. We will bear all costs, expenses and fees in connection with the registration of the shares of Common Stock offered
hereby. The Selling Securityholder will bear all commissions and discounts, if any, attributable to its sales of the shares of Common Stock offered hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder may be deemed to be an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the U.S. Securities
Act of 1933, as amended (the &#147;Securities Act&#148;), and any profits on the sales of shares of our Common Stock by the Selling Securityholder and any discounts, commissions or concessions received by the Selling Securityholder may be deemed to
be underwriting discounts and commissions under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is listed on the Nasdaq Capital Market under the
symbol &#147;SCLX&#148;. On April&nbsp;18, 2023, the last reported sales price per share of our Common Stock was $14.44. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;) and, as such, we have elected to comply with certain reduced public company reporting requirements for this
prospectus and future filings with the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may amend or supplement this prospectus from time to time
by filing amendments or supplements as required. You should read this prospectus, together with additional information described under the heading &#147;<I>Where You Can Find More Information</I>&#148;, and any amendments or supplements carefully
before you invest in any of our securities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN
OUR COMMON STOCK INVOLVES SUBSTANTIAL RISKS. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &#147;<A HREF="#tx454025_13">RISK FACTORS</A>&#148; BEGINNING ON PAGE&nbsp;14 OF THIS PROSPECTUS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is April 19, 2023 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">PAGE</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">iv</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">v</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_3">CERTAIN DEFINED TERMS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">vii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_4">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_5">The Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_6">Our Marketed Product and Pipeline</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_7">Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_8">Recent Developments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_9">Emerging Growth Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_10">Summary Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_11">Corporate Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_12">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_13">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_14">Risks Related to our Limited Operating History, Financial Condition and Capital
 Requirements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_15">Risks Related to our Commercial Operations and Product
Development</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_16">Risks Related to our Business and Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_17">Risks Related to our Intellectual Property</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_18">Risks Related to Government Regulations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_19">Risks Related to our Relationship with Sorrento</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_20">Risks Related to Ownership of our Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_21">PRIVATE PLACEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_22">MARKET AND INDUSTRY DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_23">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_23a">DETERMINATION OF OFFERING PRICE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_24">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_25">Market Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_26">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_27">Securities Authorized for Issuance under Equity Compensation
Plans</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_28">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
 OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_29">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_30">Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_31">Recent Developments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_32">Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on Our
Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_33">Comparability of Our Results and Our Relationship with
Sorrento</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_34">Sorrento Chapter 11 Filing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_35">Components of Our Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_36">Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_37">Comparison of Years Ended December&nbsp;31, 2022 and 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_38">Liquidity and Capital Resources</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_39">Critical Accounting Estimates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_40">Recent Accounting Pronouncements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_41"><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet
Arrangements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_42">Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_43">Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_44">Emerging Growth Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_45">Smaller Reporting Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_46">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_47">The Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_48">Our Marketed Product and Pipeline</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">PAGE</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_49">Our Strategy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_50">Our Management Team</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_51">Our Product Portfolio</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_52">Commercialization and Market Access</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_53">Clinical Development Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_54">Medical Affairs</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_55">Manufacturing and Supply Chain</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_56">Competition</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_57">Material Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_58">Intellectual Property</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_59">Government Regulation and Product Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_60">Employees and Human Capital Resources</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_61">Facilities and Properties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_62">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_63">Our Corporate History</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_64">Website</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_65">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_66">Executive Officers and Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_67">Family Relationships</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_68">Board Composition</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_69">Controlled Company Exemption</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_70">Director Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_71">Role of Board in Risk Oversight Process</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_72">Board Leadership Structure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_73">Board Diversity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_74">Committees of our Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_75">Code of Business Conduct and Ethics</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_76">Compensation Committee Interlocks and Insider Participation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_77">Limitation of Liability and Indemnification of Directors and
Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_78">EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_79">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_80">Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_81">Narrative Disclosure to Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_82">Potential Payments upon Termination or Change in Control</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_83">Perquisites, Health, Welfare and Retirement Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_84">Pension Benefits and Nonqualified Deferred Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_85">Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End
</FONT> 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_86">Equity-Based Incentive Plans</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_87">Emerging Growth Company Status</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_88">Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_89">Director Compensation Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_90">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_91">Certain Relationships of Vickers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_92">Certain Relationships of Legacy Scilex</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_93">PRINCIPAL SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_94">SELLING SECURITYHOLDER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_95">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_96">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_97">U.S. Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_98"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_99">Foreign Account Tax Compliance Act</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">PAGE</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_100">DESCRIPTION OF OUR SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_101">General</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_102">Authorized and Outstanding Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_103">Our Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_104">Our Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_105">Registration Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_106">Anti-Takeover Matters in our Governing Documents and Under Delaware
Law</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_107">Conflicts of Interest</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_108">Rights of Appraisal and Payment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_109">Stockholders&#146; Derivative Actions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_110">Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_111">Public Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_112">Transfer Agent and Registrar</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_113">Listing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_114">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_115">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_116">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx454025_117">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information we have provided in this prospectus, any applicable prospectus
supplement and any related free writing prospectus. Neither we nor the Selling Securityholder have authorized anyone to provide you with information different from that contained in this prospectus, any applicable prospectus supplement or any
related free writing prospectus. We and the Selling Securityholder take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. No dealer, salesperson or other person is
authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You must not rely on any unauthorized information or representation. This
prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any
related free writing prospectus is accurate only as of the date on the front of the applicable document, regardless of the time of delivery of this prospectus or any sale of a security. Since the date of this prospectus and the documents
incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>For Investors Outside the United States</B>: The Selling Securityholder is offering to sell, and seeking offers to buy, the securities
offered by this prospectus only in jurisdictions where offers and sales are permitted. Neither we nor the Selling Securityholder have done anything that would permit this offering or the possession or distribution of this prospectus in any
jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the
offering of the securities offered by this prospectus and the distribution of this prospectus outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> that we filed with the Securities and
Exchange Commission (the &#147;SEC&#148;) using the &#147;shelf&#148; registration process. Under this shelf registration process, the Selling Securityholder may, from time to time, sell the securities offered by it described in this prospectus. We
will not receive any proceeds from the sale by such Selling Securityholder of the securities offered by it described in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part to
add information to, or update or change information contained in, this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the
prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with
the additional information to which we refer you in the section of this prospectus titled &#147;<I>Where You Can Find More Information</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholder have authorized anyone to provide you with any information or to make any representations other than
those contained in this prospectus, any post-effective amendment, any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholder take
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholder will make an offer to sell these securities in any jurisdiction where the offer or
sale is not permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, we consummated the previously-announced business combination (the &#147;Business
Combination&#148;) pursuant to that certain Agreement and Plan of Merger, dated as of March&nbsp;17, 2022 (as amended, restated or supplemented from time to time, including by Amendment No.&nbsp;1 to Agreement and Plan of Merger, dated as of
September&nbsp;12, 2022) (the &#147;Merger Agreement&#148;), by and among us, Vantage Merger Sub Inc., our then-wholly owned subsidiary (the &#147;Merger Sub&#148;), and the <FONT STYLE="white-space:nowrap">pre-Business</FONT> Combination Scilex
Holding Company (&#147;Legacy Scilex&#148;). Pursuant to the terms of the Merger Agreement, we effected a deregistration under the Cayman Islands Companies Act (as revised) and a domestication under Section&nbsp;388 of the Delaware General
Corporation Law, as amended (the &#147;DGCL&#148;), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware (the &#147;Domestication&#148;), and, on the terms and subject to the conditions set
forth in the Merger Agreement and in accordance with the DGCL, Merger Sub merged with and into Legacy Scilex (the &#147;Merger&#148; or the &#147;Business Combination&#148;), with Legacy Scilex surviving as our wholly owned subsidiary. In connection
with the Business Combination, we changed our name from Vickers Vantage Corp. I to Scilex Holding Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates
otherwise, references in this prospectus to the &#147;Company,&#148; &#147;Scilex,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; and similar terms refer to Scilex Holding Company, a Delaware corporation formerly known as Vickers Vantage
Corp. I, and its consolidated subsidiaries. References to &#147;Legacy Scilex&#148; refer to the private Delaware corporation that is now our wholly owned subsidiary, named Scilex, Inc. (formerly known as Scilex Holding Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &#147;<I>Where You Can Find More Information</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements contained in this prospectus may constitute &#147;forward-looking statements&#148; for purposes of federal securities laws.
Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements appear in a number of places in this prospectus including, without limitation, in the sections of this
prospectus titled &#147;<I>Business</I>&#148; and &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>.&#148; In addition, any statements that refer to projections, forecasts or other
characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as &#147;plan,&#148; &#147;believe,&#148;
&#147;expect,&#148; &#147;anticipate,&#148; &#147;contemplate,&#148; &#147;intend,&#148; &#147;outlook,&#148; &#147;estimate,&#148; &#147;forecast,&#148; &#147;project,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;may,&#148;
&#147;might,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and other similar words and expressions (including the negative of any of the foregoing), but the absence of
these words does not mean that a statement is not forward-looking. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on information available as
of the date of this prospectus and our management&#146;s current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks and uncertainties and other factors, many of which are outside the control of the
Company and our directors, officers and affiliates. There can be no assurance that future developments will be those that have been anticipated. Accordingly, forward-looking statements should not be relied upon as representing our views as of any
subsequent date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual
results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in &#147;<I>Risk Factors,</I>&#148; our
periodic filings with the SEC and the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our public securities&#146; liquidity and trading; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise financing in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any legal proceedings that may be instituted against us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain qualified directors, officers, employees and key personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to compete effectively in a highly competitive market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competition from larger biotechnology companies that have greater resources, technology, relationships and/or
expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to protect and enhance our corporate reputation and brand; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact from future regulatory, judicial and legislative changes in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to research, discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to grow and manage growth profitably; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain intellectual property protection and not infringe on the rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to execute our business plans and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the continuing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and other similar
disruptions in the future; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors detailed under the section of this prospectus titled &#147;<I>Risk Factors</I>.&#148;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should one or more of these risks or uncertainties materialize or should any of the
assumptions made by our management prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the continuing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update, add or
to otherwise correct any forward-looking statements contained herein to reflect events or circumstances after the date they were made, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or
otherwise, except as may be required under applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_3"></A>CERTAIN DEFINED TERMS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Board</I>&#148; means the board of directors of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Business Combination</I>&#148; means the merger contemplated by the Merger Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Bylaws</I>&#148; means the Bylaws of Scilex Holding Company, effective as of November&nbsp;10, 2022.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Certificate of Designations</I>&#148; means the Certificate of Designations of the Company, designating
the series of preferred stock, par value $0.0001 per share, of the Company as &#147;Series A Preferred Stock&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Certificate of Incorporation</I>&#148; means the Restated Certificate of Incorporation of Scilex Holding
Company, filed with Secretary of State of the State of Delaware on November&nbsp;10, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Closing</I>&#148; means the closing of the Business Combination. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Closing Date</I>&#148; means date of the Closing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Code</I>&#148; means the Internal Revenue Code of 1986, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Common Stock</I>&#148; means the common stock, par value $0.0001 per share, of Scilex.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Continental</I>&#148; means Continental Stock Transfer&nbsp;&amp; Trust Company, our transfer agent.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Debt Exchange Agreement</I>&#148; means the Contribution and Satisfaction of Indebtedness Agreement,
dated as of September&nbsp;12, 2022, by and among Sorrento, Legacy Scilex and Scilex Pharmaceuticals, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>DGCL</I>&#148; means the General Corporation Law of the State of Delaware, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Domestication</I>&#148; means the change of our domicile pursuant to a transfer by way of continuation
of an exempted company out of the Cayman Islands and a domestication into the State of Delaware as a corporation, and our <FONT STYLE="white-space:nowrap">de-registration</FONT> in the Cayman Islands. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Effective Time</I>&#148; means the time at which the Business Combination became effective.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Equity Incentive Plan</I>&#148; means the Scilex Holding Company 2022 Equity Incentive Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>ESPP</I>&#148; means the Scilex Holding Company 2022 Employee Stock Purchase Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Exchange Act</I>&#148; means the Securities Exchange Act of 1934, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>founder shares</I>&#148; means the 3,450,000 outstanding Vickers Ordinary Shares held by the Sponsors
and the following directors of Vickers: Pei Wei Woo, Suneel Kaji and Steve Myint, which were converted into 3,450,000 shares of Common Stock in connection with the Domestication. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Funding Commitment Letter</I>&#148; means that certain letter agreement, dated as of October&nbsp;17,
2022, between Sorrento and Legacy Scilex. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>GAAP</I>&#148; means accounting principles generally accepted in the United States of America.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Initial Shareholders</I>&#148; means the Sponsors, Pei Wei Woo, Suneel Kaji and Steve Myint, each as the
holders of founder shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>IPO</I>&#148; refers to the initial public offering of 13,800,000 Units of Vickers consummated on
January&nbsp;11, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>IRS</I>&#148; means the United States Internal Revenue Service. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Legacy Scilex Board</I>&#148; means the board of directors of Legacy Scilex. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Legacy Scilex Common Stock</I>&#148; means the common stock of Legacy Scilex, par value $0.0001 per
share, prior to the Effective Time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Legacy Scilex Preferred Stock</I>&#148; means the Series A Preferred Stock, par value $0.0001 per share,
of Legacy Scilex issued to Sorrento prior to the Effective Time pursuant to the Debt Exchange Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Maxim</I>&#148; means Maxim Group LLC, the representative of the underwriters in the IPO.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Merger Agreement</I>&#148; means that certain Agreement and Plan of Merger, dated as of March&nbsp;17,
2022, by and among us, Merger Sub and Legacy Scilex, as it may be amended or restated from time to time, including by the Merger Agreement Amendment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Merger Agreement Amendment</I>&#148; means that Amendment No.&nbsp;1 to Agreement and Plan of Merger,
dated as of September&nbsp;12, 2022, by and among us, Merger Sub and Legacy Scilex. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Merger Sub</I>&#148; means Vantage Merger Sub Inc., a Delaware corporation that was a wholly owned
subsidiary of Vickers prior to the Closing and that, pursuant to the Business Combination, was merged with and into Legacy Scilex, with Legacy Scilex continuing as our wholly owned subsidiary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Nasdaq</I>&#148; means The Nasdaq Stock Market LLC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Nasdaq Listing Rules</I>&#148; means the rules and listing standards of Nasdaq. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Private Placement Warrants</I>&#148; means the 6,840,000 warrants sold in a private placement to Vickers
Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd consummated on January&nbsp;11, 2021 (of which 2,736,000 were forfeited pursuant to the Sponsor Support Agreement and 3,104,000 were transferred to Sorrento pursuant to the Warrant
Transfer Agreement, in each case in connection with the Business Combination). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>public shareholders</I>&#148; means the holders of the public shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>public shares</I>&#148; means the Vickers Ordinary Shares which were sold as part of the IPO, whether
they were purchased in the IPO or in the aftermarket, including any of our Initial Shareholders to the extent that they purchase such public shares (except that our Initial Shareholders will not have conversion or tender rights with respect to any
public shares they own). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Public Warrants</I>&#148; means the redeemable warrants that were included in the Units that entitle the
holder of each whole warrant to purchase one Vickers Ordinary Share at a price of $11.50 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>SEC</I>&#148; means the U.S. Securities and Exchange Commission. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Securities Act</I>&#148; means the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Series A Preferred Stock</I>&#148; means the preferred stock, par value $0.0001 per share, of the
Company, designated as Series A Preferred Stock pursuant to the Certificate of Designations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sorrento</I>&#148; means Sorrento Therapeutics, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sorrento Group</I>&#148; means Sorrento together with its affiliates, subsidiaries, successors and
assigns (other than us and our subsidiaries). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sorrento Trigger Event</I>&#148; means the time that the Sorrento Group first ceases to beneficially own
more than 50% in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sponsors</I>&#148; means Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sponsor Support Agreement</I>&#148; means that certain Sponsor Support Agreement, dated March&nbsp;17,
2022, by and among the Initial Shareholders and with Scilex, Inc. (f/k/a Scilex Holding Company). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Stockholder Agreement</I>&#148; means the Stockholder Agreement, dated as of September&nbsp;12, 2022,
between Vickers and Sorrento. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Trust Account</I>&#148; means the Trust Account of Vickers that held the proceeds from Vickers&#146;s
IPO and the private placement of the Private Placement Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Units</I>&#148; means the units of Vickers, each of which consisted of one Vickers Ordinary Share and <FONT
STYLE="white-space:nowrap">one-half</FONT> of one redeemable warrant upon the consummation of an initial business combination, which </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">viii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
units, if not separated into its component securities as of immediately prior to the Effective Time were, without any action on the part of the holder, separated automatically into its component
securities, comprised of one share of Common Stock and <FONT STYLE="white-space:nowrap">one-half</FONT> of one warrant to purchase one share of Common Stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Vickers</I>&#148; means Vickers Vantage Corp. I, our predecessor company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Vickers Debt Agreement</I>&#148; means that certain Debt Contribution Agreement, dated as of
October&nbsp;17, 2022, by and among Vickers and the Sponsors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Vickers Ordinary Shares</I>&#148; means (i)&nbsp;the ordinary shares, par value $0.0001 per share, of
Vickers prior to the Domestication and (ii)&nbsp;the Common Stock following the Domestication. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Warrant Transfer Agreement</I>&#148; means that certain Warrant Transfer Agreement, dated as of
October&nbsp;17, 2022, by and among Sorrento, the Sponsors, Vickers and Maxim. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ix </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_4"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. Because it is only a
summary, it does not contain all of the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this
prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus carefully, including the sections of this prospectus titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148;. You should also carefully read the information in this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_5"></A>The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are an innovative revenue-generating company focused on acquiring, developing and commercializing <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain management products for the treatment of acute and chronic pain. We target indications with
high unmet needs and large market opportunities with <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched
our first commercial product in October 2018 and are developing our late-stage pipeline, which includes a pivotal Phase 3 candidate, a Phase 2 candidate, and a Phase 1 candidate that is expected to enter Phase 2 studies in 2023. Our commercial
product, ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the &#147;FDA&#148;) for the relief of
neuropathic pain associated with post-herpetic neuralgia (&#147;PHN&#148;), which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription
lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. We license the rights to ZTlido from and rely exclusively on Oishi
Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation (&#147;Itochu,&#148; and together with Oishi, the &#147;Developers&#148;) pursuant to the Product Development Agreement and Commercial Supply Agreement. We have acquired
two FDA approved <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain products for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults, which we plan to commercialize in the U.S.
in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are <FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (10 mg, dexamethasone sodium phosphate
viscous gel) (&#147;SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>&#148;), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; <FONT
STYLE="white-space:nowrap">(ii)&nbsp;SP-103</FONT> (lidocaine topical system) 5.4%, <FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain
(&#147;LBP&#148;); and <FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules)
<FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;),</FONT> a novel <FONT STYLE="white-space:nowrap">low-dose</FONT> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were
completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2023. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in
the United States. However, the Conversion Price will be subject to adjustment by reason of stock splits, stock dividends or similar transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, we entered into a License and Commercialization Agreement (the &#147;Romeg Agreement&#148;) with RxOmeg Therapeutics,
LLC (a/k/a Romeg Therapeutics, Inc.) (&#147;Romeg&#148;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1)&nbsp;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid
formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&nbsp;an exclusive, transferable license to use the trademark
&#147;GLOPERBA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&#148;. GLOPERBA is an <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting
an estimated 8.7&nbsp;million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of
pain and can be disabling with tenderness, warmth and swelling. <FONT STYLE="white-space:nowrap">Non-steroidal</FONT> anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
first line to treat acute gout. The U.S. is observed to have a high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. We are planning to
commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. We have a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S. For more information on Scilex,
please see the section of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Romeg License and Commercialization Agreement.</I>&#148; On February&nbsp;12, 2023, we acquired from BioDelivery Sciences International, Inc. and
Collegium Pharmaceutical, Inc. the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (celecoxib oral solution) and the
commercialization thereof in the United States and Canada. ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM </SUP>is a first-line treatment and the only <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ready-to-use</FONT></FONT> oral solution for the acute treatment of migraine, with or without aura, in adults. We are planning to commercialize ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> in the U.S. in
2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established mechanisms that have deficiencies in safety,
efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act for each of these pipeline product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our marketed product, ZTlido, has multiple advantages over currently available prescription and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> (&#147;OTC&#148;) lidocaine patches, of which over 147&nbsp;million and 136&nbsp;million of such patches were sold in the United States in 2021 and 2020,
respectively, according to Symphony Healthcare. We have sold 6,336,032 and 7,011,112 ZTlido patches in the United States in 2020 and 2021, respectively. We acquired <FONT STYLE="white-space:nowrap">SP-102</FONT> from Semnur Pharmaceuticals, Inc.
(&#147;Semnur&#148;) in March 2019 and are developing <FONT STYLE="white-space:nowrap">SP-102</FONT> to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by <FONT
STYLE="white-space:nowrap">off-label</FONT> epidural steroid injections (&#147;ESI&#148;), which are administered over 12&nbsp;million times annually in the United States. See the section of this prospectus titled &#147;<I>Business &#151; Material
Agreements &#151; Semnur Merger Agreement</I>&#148; for a description of our acquisition of Semnur and our ongoing obligations to Semnur&#146;s former equityholders. SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> has been granted
fast track designation by the FDA and, if approved, could become the only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESI for the treatment of sciatica. According to a report by Decision Resources Group, it was estimated that over
4.8&nbsp;million patients would suffer from sciatica in the United States in 2022. <FONT STYLE="white-space:nowrap">SP-103</FONT> has also been granted fast track designation by the FDA and, if approved, could become the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP. We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> as a novel delayed-release formulation of
<FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used <FONT
STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia. There are no <FONT STYLE="white-space:nowrap">low-dose</FONT> formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable
effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. We believe our currently approved product and future product candidates, if approved, could uniquely address what we believe are the significant
unmet needs of the targeted populations. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_6"></A>Our Marketed Product and Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates our current commercial product and novel product candidates, for which we have worldwide commercialization
rights, except with respect to Japan for ZTlido and <FONT STYLE="white-space:nowrap">SP-103.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g454025g00a15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our
telephone number is (650) <FONT STYLE="white-space:nowrap">516-4310.</FONT> For additional information about us, please see the sections of this prospectus titled &#147;<I>Business</I>&#148; and &#147;<I>Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section of this prospectus titled &#147;<I>Risk Factors</I>&#148; in
this prospectus for a discussion of some of the risks related to the execution of our business strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_7"></A>Business Combination
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022 (the &#147;Closing Date&#148;), Vickers consummated the previously announced Business Combination pursuant
to the terms of the Merger Agreement, by and among Vickers, Merger Sub and Legacy Scilex. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement,
(i)&nbsp;prior to the Closing, Vickers changed its jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the
&#147;Domestication&#148;) and (ii)&nbsp;at the Closing, and following the Domestication, Merger Sub merged with and into Legacy Scilex (the &#147;Merger&#148;), with Legacy Scilex as the surviving company in the Merger, and, after giving effect to
such Merger, Legacy Scilex became a wholly owned subsidiary of Vickers. The Merger was approved by Vickers&#146;s shareholders at a meeting held on November&nbsp;9, 2022. In connection with the Business Combination, Vickers changed its name to
&#147;Scilex Holding Company.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Merger Agreement, at the Effective
Time, (i)&nbsp;each outstanding share of Legacy Scilex Common Stock outstanding immediately prior to the Effective Time was automatically cancelled in exchange for the right to receive 0.673498 shares of our Common Stock, (ii)&nbsp;each share of
Legacy Scilex Preferred Stock outstanding immediately prior to the Effective Time was cancelled in exchange for the right to receive (a)&nbsp;one share of Series A Preferred Stock and <FONT STYLE="white-space:nowrap">(b)&nbsp;one-tenth</FONT> of one
share of our </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock, and (iii)&nbsp;each option to purchase shares of Legacy Scilex Common Stock outstanding as of immediately prior to the Effective Time was converted into the right to receive a
comparable option to purchase shares of our Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on the Nasdaq Capital
Market under the symbols &#147;SCLX&#148; and &#147;SCLXW,&#148; respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of holders of our Common Stock and Warrants are
governed by the Certificate of Incorporation, the Bylaws and the DGCL, and, in the case of the Warrants, the Warrant Agreement, dated January&nbsp;6, 2021, between Vickers and Continental (the &#147;Warrant Agreement&#148;). See sections of this
prospectus titled &#147;<I>Description of Our Securities</I>&#148; and &#147;<I>Certain Relationships and Related Party Transactions</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_8">
</A>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>First Quarter 2023 Preliminary Unaudited Financial Results </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;3, 2023, we filed a Current Report on Form 8-K providing certain preliminary unaudited financial results as of and for the three
months ended March 31, 2023, based on then currently available information. Our independent registered public accounting firm has not reviewed or audited these preliminary estimated financial results. Our actual results may differ materially from
these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the responsibility of the Company. We have not fully completed our review of these preliminary financial
results as of and for the three months ended March 31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such Current Report on Form 8-K, we estimated that: ZTlido gross sales
for the first quarter of 2023 were in the range of $26.7 million to $28.3 million, compared to $18.4 million in the first quarter of 2022, representing growth in the range of 45% to 54%; net sales for the first quarter of 2023 were in the range of
$9.9 million to $11.0 million, compared to net sales of $6.8 million in the first quarter of 2022, representing growth in the range of 45% to 62%. Historically, sales for ZTlido are low during the first quarter of the year due to deductibles with
managed healthcare plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Debentures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;21, 2023 (the &#147;Agreement Date&#148;), we entered into the Securities Purchase Agreement with the Selling Securityholder, in
connection with the issuance and sale by us, from time to time, of the Convertible Debentures in an aggregate principal amount of up to $25,000,000. The Convertible Debentures have been or will be, as applicable, issued and sold in three tranches as
follows: (i) $10,000,000 upon the signing of the Securities Purchase Agreement (the &#147;First Closing Date&#148;), which has been funded, (ii) $7,500,000 upon the filing of the registration statement of which this prospectus forms a part with the
SEC, and (iii) $7,500,000 at the time the registration statement of which this prospectus forms a part is declared effective by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible Debentures bear interest at an annual rate of 7.00% and will mature on December&nbsp;21, 2023. The Convertible Debentures
provide that at any time on or after a Convertible Debenture is issued and remains outstanding, any portion of the outstanding and unpaid principal amount of the Convertible Debentures, together with any accrued but unpaid interest, may be converted
into shares of our Common Stock, at a conversion price of $8.00 per share (the &#147;Conversion Price&#148;). The Selling Securityholder has waived the reset provision on the Conversion Price set forth in the Convertible Debentures. However, the
Conversion Price will be subject to adjustment by reason of stock splits, stock dividends or similar transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible
Debentures may not be converted into shares of Common Stock to the extent such conversion would result in the Selling Securityholder and its affiliates having beneficial ownership of more than 4.99% of our then outstanding shares of Common Stock;
provided that this limitation may be waived by the </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Selling Securityholder upon not less than 65 days&#146; prior notice to us. In addition, we shall not issue any Common Stock pursuant to the transactions contemplated by the Convertible
Debentures or any other transaction documents executed in connection therewith (including any shares issued pursuant to a conversion) if the issuance of such shares of Common Stock would exceed 29,016,448 (which number of shares represents 19.9% of
the aggregate number of shares of Common Stock issued and outstanding as of the Agreement Date) (the &#147;Convertible Debenture Exchange Cap&#148;). The Convertible Debenture Exchange Cap will not apply under certain circumstances, including if we
obtain the approval of our stockholders as required by the applicable rules of the Nasdaq Capital Market for issuances of shares of Common Stock in excess of such amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Convertible Debentures and subject to certain conditions set forth therein, we have the right, but not the
obligation, in our sole discretion, to redeem, upon five business days&#146; prior written notice to the Selling Securityholder (the &#147;Redemption Notice&#148;), all or any portion of the amounts outstanding under the Convertible Debentures;
provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by us, plus the redemption premium
of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Convertible Debentures also contain certain customary representations, warranties, covenants, and events of default including, among other things, upon cross-defaults under other debt documents, bankruptcy or insolvency events, delisting of the
Common Stock or if we become delinquent in our periodic report filings with the SEC. If an event of default occurs and is continuing, the full unpaid principal amount of the Convertible Debentures, together with interest and other amounts owing in
respect thereof, to the date of acceleration shall become, at the Selling Securityholder&#146;s election by notice to us, immediately due and payable in cash (save for bankruptcy and insolvency events of default, upon the occurrence of which the
full unpaid principal amount of the Convertible Debentures, together with interest and other amounts owing in respect thereof to the date of acceleration, shall automatically become due and payable, in each case without presentment, demand, protest
or other notice of any kind). See the section of this prospectus titled &#147;<I>Private Placement</I>&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration statement of which this prospectus forms a part registers the resale by the Selling Securityholder of up to 3,290,000 shares
of Common Stock that may be issued upon the conversion of the Convertible Debentures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>
License </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2023, we acquired from BioDelivery Sciences International, Inc. (&#147;BDSI&#148;) and Collegium
Pharmaceutical, Inc. (&#147;Collegium&#148;, and together with BDSI, the &#147;Collegium Sellers&#148;) the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> (celecoxib oral solution) (the &#147;Product&#148;) and its commercialization in the United States and Canada (the &#147;Territory&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the Company assumed various rights and obligations under that certain asset purchase agreement, dated
August&nbsp;3, 2021 (the &#147;DRL APA&#148;), between BDSI and Dr.&nbsp;Reddy&#146;s Laboratories Limited, a company incorporated under the laws of India (&#147;DRL&#148;), including a license from DRL including an irrevocable, royalty-free,
exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> and patents of DRL related to the Product and necessary or used to exploit the Product in the Territory. Additionally, under the Purchase Agreement, the Collegium Sellers granted
the Company an irrevocable, royalty-free, exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> related to the Product and necessary or used to exploit the Product in the Territory. No cash consideration was or will be payable to the
Collegium Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include obligations to pay royalties to DRL for sales of the Product in the Territory for all indications and additional amounts if
certain milestones are achieved. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Committed Equity Financings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>B. Riley Purchase Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;8, 2023, we entered into a standby equity purchase agreement (the &#147;B. Riley Purchase Agreement&#148;) with B. Riley Principal Capital II, LLC (&#147;B. Riley&#148;), a Delaware limited liability company. Pursuant to the B. Riley
Purchase Agreement, we have the right to sell to B. Riley up to $500,000,000 of shares of our Common Stock, subject to certain limitations and conditions set forth in the B. Riley Purchase Agreement, from time to time during the term of the B. Riley
Purchase Agreement. Sales of Common Stock to B. Riley under the B. Riley Purchase Agreement, and the timing of any such sales, are at our option, and we are under no obligation to sell any securities to B. Riley under the B. Riley Purchase
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the satisfaction of the conditions to B. Riley&#146;s purchase obligation set forth in the B. Riley Purchase Agreement,
we have the right, but not the obligation, from time to time at our discretion until the first day of the month following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which the B. Riley Registration Statement (as
defined below) was initially declared effective by the SEC, to direct B. Riley to purchase a specified amount of shares of Common Stock (each such sale, a &#147;B. Riley Advance&#148;) by delivering an irrevocable written notice to B. Riley (each, a
&#147;B. Riley Advance Notice&#148;). Pursuant to the terms of the B. Riley Purchase Agreement, we filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-269205)</FONT>
(as it may be amended or supplemented from time to time, the &#147;B. Riley Registration Statement&#148;) related to the B. Riley Purchase Agreement with the SEC on January&nbsp;12, 2023 (following the execution of the B. Riley Purchase Agreement).
The B. Riley Registration Statement was initially declared effective by the SEC on January&nbsp;20, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock, if
any, that we elect to sell to B. Riley pursuant to a B. Riley Advance will be purchased at a price equal to 98% of the VWAP (as defined below) during the period (such period, the &#147;B. Riley Pricing Period&#148;) beginning at 9:30:01 a.m., New
York City time, on the date of purchase of shares of Common Stock issued and sold to B. Riley pursuant to a B. Riley Advance Notice (such shares, the &#147;B. Riley Advance Shares&#148;) or such later time publicly announced as the official open of
the primary (or &#147;regular&#148;) trading session on the Nasdaq Capital Market on such purchase date (the &#147;Purchase Commencement Time&#148;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such
earlier time publicly announced as the official close of the primary (or &#147;regular&#148;) trading session on the Nasdaq Capital Market on such purchase date, (ii)&nbsp;immediately at such time following the Purchase Commencement Time for such
purchase that the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&nbsp;if we so elect in the
applicable B. Riley Advance Notice for such B. Riley Advance (such election, a &#147;Limit Order Discontinue Election&#148;), such time the sale price of the shares of Common Stock traded on the Nasdaq Capital Market during such B. Riley Pricing
Period is less than the applicable minimum price threshold determined in accordance with the B. Riley Purchase Agreement. For purposes of the B. Riley Purchase Agreement, &#147;VWAP&#148; means, for the Common Stock for a specified period, the
dollar volume-weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg through its &#147;AQR&#148; function, subject to certain exceptions, qualifications and limitations. &#147;Advance Share
Volume Maximum&#148; means, with respect to a B. Riley Advance, if such B. Riley Advance is designated in the B. Riley Advance Notice as a (i)&nbsp;purchase-Type A, a number of shares of Common Stock that is equal to the quotient obtained by
dividing (a)&nbsp;the B. Riley Advance Share amount to be purchased by B. Riley, by (b) 0.10, or (ii)&nbsp;purchase-Type B, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&nbsp;the B. Riley Advance Share
amount to be purchased by B. Riley, by (b) 0.25 (in each case, subject to certain adjustments). We may also specify a certain minimum acceptable price per share in each B. Riley Advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any B. Riley Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, a
B. Riley Advance may be for a number of shares of Common Stock not to exceed (i)&nbsp;with respect to a B. Riley Advance, purchase-Type A, such number of shares of Common </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock that is equal to the lesser of: (a) 1,000,000, and (b)&nbsp;the product of (1) 0.10, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on the Nasdaq
Capital Market during the B. Riley Pricing Period for such purchase-Type A, and (ii)&nbsp;with respect to a B. Riley Advance, purchase-Type B, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000 and (b)&nbsp;the
product of (1) 0.25, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during the B. Riley Pricing Period for such purchase-Type B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement also provides that we have the right, but not the obligation, to sell to B. Riley, from time to time subject
to certain limitations, at our sole and absolute discretion an additional number of shares of Common Stock (each such additional sale, a &#147;B. Riley Additional Advance&#148;) at a purchase price per share equal to 98% of the VWAP during the
Additional Pricing Period (as defined in the B. Riley Purchase Agreement) by delivering an irrevocable written notice to B. Riley (each, a &#147;B. Riley Additional Advance Notice&#148;). The purpose of the B. Riley Additional Advance is to allow us
to execute more than one advance request on a purchase date with B. Riley as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each B. Riley Additional Advance is generally subject to terms and conditions
consistent with those of a B. Riley Advance, except for, among other things, the time period of the pricing period for such B. Riley Additional Advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no upper limit on the price per share that B. Riley could be obligated to pay for the Common Stock we may elect to sell to B. Riley
in any B. Riley Advance or B. Riley Additional Advance. We will control the timing and amount of any sales of Common Stock to B. Riley. Actual sales of shares of our Common Stock to B. Riley under the B. Riley Purchase Agreement will depend on a
variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Common Stock, and determinations by us as to the appropriate sources of funding for our company and its
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the B. Riley Purchase Agreement, we may not sell any shares of Common Stock thereunder and B. Riley
shall not have the obligation to purchase shares of Common Stock thereunder to the extent (but only to the extent) that after giving effect to such purchase and sale, the aggregate number of shares of Common Stock issued thereunder would exceed
28,128,422 shares of Common Stock, which number of shares is equal to 19.9% of the aggregate amount of Common Stock issued and outstanding as of the date of the B. Riley Purchase Agreement (the &#147;B. Riley Exchange Cap&#148;), unless (i)&nbsp;we
obtain stockholder approval to issue shares of Common Stock in excess of the B. Riley Exchange Cap in accordance with the applicable Nasdaq Listing Rules or (ii)&nbsp;the average price of all applicable sales of shares of Common Stock under the B.
Riley Purchase Agreement equals or exceeds $4.87, which represents the &#147;Minimum Price&#148; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules). Moreover, we may not issue or sell any shares of Common Stock to B. Riley under the
B. Riley Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by B. Riley and its affiliates (as calculated pursuant to Section&nbsp;13(d) of the Exchange Act and Rule
<FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated thereunder), would result in B. Riley beneficially owning more than 4.99% of the outstanding voting power or number of shares of Common Stock (the &#147;B. Riley Beneficial Ownership
Limitation&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for B. Riley&#146;s commitment to purchase shares of Common Stock at our direction upon the terms and
subject to the conditions set forth in the B. Riley Purchase Agreement, we previously paid B. Riley Principal Investments, LLC, a subsidiary of B. Riley, a structuring fee in the amount of $10,000 and issued 250,000 commitment shares to B. Riley
(the &#147;B. Riley Commitment Shares&#148;). As of the date of this prospectus, we have sold 127,241 shares of our Common Stock pursuant to advances under the B. Riley Purchase Agreement. See the section of this prospectus titled
&#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations &#151; Recent Developments</I>&#148; for additional information regarding the B. Riley Purchase Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>A&amp;R Yorkville Purchase Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;17, 2022, we entered into a standby equity purchase agreement (the &#147;Original Purchase Agreement&#148;) with the Selling Securityholder. On February&nbsp;8, 2023, we entered into an amended and restated
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
standby equity purchase agreement with the Selling Securityholder (the &#147;A&amp;R Yorkville Purchase Agreement&#148;), amending, restating and superseding the Original Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Yorkville Purchase Agreement, we have the right, but not the obligation, to sell to the Selling Securityholder up to
$500,000,000 of shares of Common Stock, from time to time at our sole and absolute discretion (each such sale, a &#147;Yorkville Advance&#148;) by delivering written notice to the Selling Securityholder (each, a &#147;Yorkville Advance Notice&#148;)
until the first day of the month following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which the Yorkville Registration Statement (as defined below) was initially declared effective by the SEC. Pursuant to the
terms of the Original Purchase Agreement, we filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607)</FONT> (as it may be amended or supplemented from time to
time, the &#147;Yorkville Registration Statement&#148;) related to the Original Purchase Agreement with the SEC on November&nbsp;30, 2022 (following the execution of the Original Purchase Agreement). The Yorkville Registration Statement was
initially declared effective by the SEC on December&nbsp;9, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any Yorkville Advance, a
Yorkville Advance may be for a number of shares of Common Stock not to exceed 200% of the average of the daily trading volume of the Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five
trading days immediately preceding the date of the Yorkville Advance Notice. The shares of Common Stock, if any, that we elect to sell to the Selling Securityholder pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the
VWAP (as defined below) during the applicable pricing period (each, a &#147;Yorkville Pricing Period&#148;) for such Yorkville Advance, which shall be the period commencing upon receipt by the Selling Securityholder of the Yorkville Advance Notice
(or the open of regular trading hours, if later) and ending on 4:00 p.m. on the same day. For purposes of the A&amp;R Yorkville Purchase Agreement, &#147;VWAP&#148; means, for a specified period, the volume weighted average price of the Common Stock
on the Nasdaq Capital Market for such period as reported by Bloomberg L.P. through its &#147;AQR&#148; function. There is no upper limit on the price per share that the Selling Securityholder could be obligated to pay for the Common Stock we may
elect to sell to it in a Yorkville Advance. We will control the timing and amount of any sales of Common Stock to the Selling Securityholder. Actual sales of shares of our Common Stock to the Selling Securityholder under the A&amp;R Yorkville
Purchase Agreement will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Common Stock, and determinations by us as to the appropriate sources
of funding for our company and its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the A&amp;R Yorkville Purchase Agreement, we may not sell any
shares of Common Stock thereunder and the Selling Securityholder shall not have the obligation to purchase shares of Common Stock thereunder to the extent (but only to the extent) that after giving effect to such purchase and sale, the aggregate
number of shares of Common Stock issued thereunder would exceed 28,078,672 shares of Common Stock, which number of shares is equal to 19.9% of the aggregate amount of Common Stock issued and outstanding as of the date of the Original Purchase
Agreement (the &#147;Yorkville Exchange Cap&#148;), unless (i)&nbsp;we obtain stockholder approval to issue shares of Common Stock in excess of the Yorkville Exchange Cap in accordance with the applicable Nasdaq Listing Rules or (ii)&nbsp;the
average price of all applicable sales of shares of Common Stock under the A&amp;R Yorkville Purchase Agreement equals or exceeds $8.77, which represents the &#147;Minimum Price&#148; (as such term is defined in Rule 5635 of the Nasdaq Listing
Rules). Moreover, we may not issue or sell any shares of Common Stock to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by the Selling
Securityholder and its affiliates (as calculated pursuant to Section&nbsp;13(d) of the Exchange Act, and Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated thereunder), would result in the Selling Securityholder beneficially owning more
than 4.99% of the outstanding voting power or number of shares of Common Stock (the &#147;Yorkville Beneficial Ownership Limitation&#148;). </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We previously paid YA Global II SPV, LLC, a subsidiary of the Selling Securityholder, a
structuring fee of $10,000 and issued the Selling Securityholder 250,000 shares of Common Stock as a commitment fee pursuant to the Original Purchase Agreement (the &#147;Yorkville Commitment Shares&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, no Yorkville Advances were requested or completed under the Original Purchase Agreement.
Subsequent to December&nbsp;31, 2022, we sold 85,000 shares of Common Stock under the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds of approximately $0.6&nbsp;million on February&nbsp;16, 2023. See the section of this prospectus
titled &#147;<I>Management&#146;s Discussion and Analysis of Financial</I> <I>Condition and Results of Operations&#151;Recent Developments</I>&#148; for additional information regarding the A&amp;R Yorkville Purchase Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_9"></A>Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our Business
Startups Act of 2012 (the &#147;JOBS Act&#148;). As an emerging growth company, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth
companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with
new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required
to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
<FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will
be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new
guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. In addition, we are in the process of evaluating the benefits of relying on the other
exemptions and reduced reporting requirements provided by the JOBS Act, as more fully described in the section of this prospectus titled &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations &#151;
Emerging Growth Company</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of: (i)&nbsp;the last day of the fiscal
year (a)&nbsp;following the fifth anniversary of the closing of the IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market
value of our common equity that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equals or exceeds $700&nbsp;million as of the last business day of our most recently completed second fiscal quarter; and (ii)&nbsp;the date on which
we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. References herein to &#147;emerging growth company&#148; have the meaning associated with it in
the JOBS Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_10"></A>Summary Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are currently a single commercial product company that is heavily dependent on the commercial success of
ZTlido and we may be unable to generate sufficient revenue to support our operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and have incurred significant losses since our inception. We anticipate that
we will incur continued losses for the foreseeable future. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial
doubt about our ability to continue as a going concern. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Commercial Operations and Product Development
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw
materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we
may not be able to find an alternative source on commercially reasonable terms, or at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our
future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product
candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our clinical
trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ZTlido and GLOPERBA may have undesirable properties that could result in significant negative consequences, and
our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to
our Business and Operations </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to retain our key executives, it may delay our development efforts and harm our business,
financial condition and results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any disruption in our research and development facilities could adversely affect our business, financial
condition and results of operations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Intellectual Property </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are substantially dependent on the intellectual property we <FONT STYLE="white-space:nowrap">in-license</FONT>
from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <FONT
STYLE="white-space:nowrap">SP-103</FONT> would be harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We recently entered into the Romeg Agreement for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> of
certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize
GLOPERBA would be harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope
of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks
Related to Government Regulations </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we
are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in
significant expense and limit our ability to commercialize such products. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Relationship with Sorrento
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Certain of our directors and officers may have actual or potential conflicts of interest because of their
positions with Sorrento. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are controlled by Sorrento, whose interests may differ from those of our public shareholders.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sorrento has recently filed for bankruptcy protection, which may impair our relationship with Sorrento.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to the Ownership of our Common Stock </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our operations and performance do not meet the expectations of investors or securities analysts, the market
price of our securities may decline. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to
emerging growth companies will make our Common Stock less attractive to investors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, will qualify for,
and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The issuances of additional Common Stock under certain of our contracts and arrangements may result in dilution
of holders of our Common Stock and have a negative impact on the market price of our Common Stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_11"></A>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the name &#147;Vickers Vantage Corp. I&#148; on February&nbsp;21, 2020 as a Cayman Islands exempted company for the
purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On November&nbsp;9, 2022, we changed our jurisdiction of incorporation by
deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. On November&nbsp;9, 2022, we changed our name to &#147;Scilex Holding Company&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our telephone number is (650) <FONT
STYLE="white-space:nowrap">516-4310.</FONT> Our website address is <I>www.scilexholding.com</I>. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this
prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You
may obtain any of the documents filed by us with the SEC at no cost from the SEC&#146;s website at <I>http://www.sec.gov.</I> </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_12"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock to be Offered by the Selling Securityholder </P></TD>
<TD>Up to 3,290,000 shares of Common Stock, issuable upon conversion of the Convertible Debentures. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3pt; margin-top:-2pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock Outstanding before this Offering<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>
</P></TD>
<TD>145,811,298 shares of Common Stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock to be Outstanding after Giving Effect to the Issuance of 3,290,000 Shares of Common Stock
</P></TD>
<TD>149,101,298 shares of Common Stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We are not selling any of the shares of Common Stock being offered by this prospectus and will receive no proceeds from the sale of the shares by the Selling Securityholder. All of the proceeds from the sale of Common Stock offered by this
prospectus will go to the Selling Securityholder at the time it offers and sells such shares. We will pay the expenses of registration of the shares of our Common Stock covered by this prospectus, including legal and accounting fees. See
&#147;<I>Use of Proceeds</I>.&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Market for our Common Stock </P></TD>
<TD>Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#147;SCLX&#148;. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#147;<I>Risk Factors</I>&#148; beginning on page 14 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in the securities being offered by this prospectus.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of Common Stock that is outstanding before this offering is based on an aggregate of
145,811,298 shares outstanding as of March&nbsp;31, 2023, and excludes: <B><I></I></B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">744,201 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2017 Scilex
Pharmaceuticals Inc. Equity Incentive Plan (the &#147;Scilex Pharma 2017 Plan&#148;) with a weighted average exercise price of $0.84 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">16,190,448 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2019 Stock
Option Plan of Legacy Scilex (the &#147;2019 Stock Option Plan&#148;) with a weighted average exercise price of $1.73 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11,003,787 shares of Common Stock issuable upon the exercise of the Warrants, with an exercise price of $11.50
per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14,820,000 shares of Common Stock issuable upon the exercise of stock options outstanding under the Equity
Incentive Plan with a weighted average exercise price of $8.08 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 5,456,666 shares of Common Stock available for future issuance under the Equity Incentive Plan (which
number of shares accounts for the annual increase on January&nbsp;1, 2023 (but does not include a possible increase in any subsequent year) pursuant to the provisions of such plan which provides for a possible annual increase on January&nbsp;1 of
each year beginning on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to up to 4% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding year nor
does such number include any amendment to such plan that increases the authorized number of shares available under such plan); </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 2,875,759 shares of Common Stock available for future issuance under the ESPP (which number of shares
includes the annual increase on January&nbsp;1, 2023 (but does not include a possible increase in any subsequent year) pursuant to the provisions of such plan which provides for a possible annual increase on January&nbsp;1 of each year beginning on
January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to up to 1% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding year); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 1,400,000 shares of Common Stock available for future issuance under the Scilex Holding Company 2023
Inducement Plan (the &#147;Inducement Plan&#148;). </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_13"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the
following risk factors, as well as the other information set forth in this prospectus, including matters addressed in the section of this prospectus titled &#147;Cautionary Note Regarding Forward-Looking Statements&#148;. If any of these risks
actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks
and uncertainties described in this prospectus, any prospectus supplement, any post-effective amendment or in any document incorporated by reference herein or therein are not the only risks and uncertainties that we face. We may face additional
risks and uncertainties that are not presently known to us, or that we currently deem immaterial. The following discussions should be read in conjunction with our financial statements and the notes to the financial statements included therein.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_14"></A>Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are currently a single commercial product company that is heavily dependent on the commercial success of ZTlido and we may be unable to generate
sufficient revenue to support our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido is our only product approved for commercial sale and we are entirely
dependent upon its sales to generate revenue. In February 2018, we obtained regulatory approval for ZTlido for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and we began commercializing ZTlido in
the United States in October 2018. As a result, it is difficult to evaluate our current business and predict our future prospects. We cannot assure that ZTlido will gain market acceptance among physicians, health care payors, patients and the
medical community, which is critical to our commercial success. We have limited experience engaging in commercial activities and limited relationships with physicians, hospitals and payors. Market acceptance of ZTlido depends on a number of factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance by physicians, major operators of clinics and patients of the drug as a safe and effective treatment
for the relief of neuropathic pain associated with PHN; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability, cost and potential advantages of alternative treatments, including less expensive generic
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of coverage, adequacy of reimbursement and favorability of pricing policies by third-party
payors and government authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of other competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product labeling or any product inserts required by the FDA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of adverse side effects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to successfully commercialize ZTlido, we will need to expand our marketing efforts to develop new relationships and expand existing
relationships. Physicians may decide not to prescribe ZTlido for a variety of reasons, including changes in available offerings, adverse publicity, perceived safety issues, inadequate coverage or reimbursement for ZTlido or the utilization of
products developed by other parties, all of which are circumstances outside of our control. Demand for ZTlido may not increase as quickly as we predict, and we may be unable to increase our revenue to the level that we currently expect. Even if we
succeed in increasing market acceptance of ZTlido, maintaining and creating relationships with physicians, we may be unable to reach or sustain a level of profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to effectively promote ZTlido will also depend on pricing and cost-effectiveness, including our ability to produce at a
competitive price. In addition, our efforts to educate the medical community and third-party payors on the benefits of ZTlido may require significant resources, may be constrained by FDA rules and policies on product promotion and may never be
successful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history and have incurred significant losses since our inception. We
anticipate that we will incur continued losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a limited operating history. Prior to March
2019, our operations were conducted through Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;), which was formed in September 2012 and is now our wholly owned subsidiary. In March 2019, we effected a corporate reorganization and acquired
Semnur, which was formed in June 2013. Since our inception, we have focused on organizing and staffing our company, business planning, raising capital, identifying potential <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain therapy candidates,
undertaking preclinical studies and clinical trials of our product candidates and establishing research and development and manufacturing collaborations. All of our revenue to date is attributable to sales of ZTlido, and we expect that sales of
ZTlido will account for all of our revenue for at least the near term. Our relatively short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and
significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We will encounter risks and difficulties frequently experienced
by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. Our ability to execute on our business model and generate revenues depends on a
number of factors including our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully complete ongoing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials
and obtain regulatory approvals for our current and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify new acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully identify new product candidates and advance those product candidates into <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raise additional funds when needed and on terms acceptable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract and retain experienced management and advisory teams; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support
clinical, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> manufacturing and planned future commercialization efforts and operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launch commercial sales of our product candidates, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities
of product candidates manufactured at acceptable cost and quality levels and in compliance with the FDA, and other regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party
payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve market acceptance of product candidates in the medical community and with third-party payors and
consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot successfully execute any one of the foregoing, our business may not succeed or become profitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant net losses, with net losses of $23.4&nbsp;million, $88.4&nbsp;million and $47.5&nbsp;million
for the years ended December&nbsp;31, 2022, 2021 and 2020, respectively. As of December&nbsp;31, 2022, we had an accumulated deficit of approximately $375.9&nbsp;million. For the foreseeable future, we expect to continue to incur significant
expenses related to the commercialization of ZTlido and GLOPERBA and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research and development of our product candidates, <FONT STYLE="white-space:nowrap">SP-102</FONT> (10 mg dexamethasone sodium phosphate viscous gel) (&#147;SEMDEXA&#148;), <FONT
STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4% <FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> (4.5mg, <FONT STYLE="white-space:nowrap">low-dose</FONT>
naltrexone hydrochloride delayed-release capsules) <FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;).</FONT> We anticipate that our expenses will increase substantially due to the completion of the pivotal Phase 3 trial for SEMDEXA, commencement
of the Phase 2 clinical trial for <FONT STYLE="white-space:nowrap">SP-103</FONT> and multiple Phase 1 trials for <FONT STYLE="white-space:nowrap">SP-104.</FONT> Consequently, we expect to incur substantial losses for the foreseeable future and may
never become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to risks incidental to the development of new biopharmaceutical products, and we may encounter
unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our
failure to become and remain profitable could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as Vickers was a shell company prior to the completion of the Business Combination, we are currently ineligible to use short form
registration statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and will not be eligible to file such a registration statement until, among other things, at least 12 calendar months have lapsed since November&nbsp;17, 2022, the date we
filed a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> disclosing that we ceased to be a shell company. Our inability to use Form <FONT STYLE="white-space:nowrap">S-3</FONT> may significantly impair our ability to raise necessary
capital to run our operations and progress our product development programs. If we seek to access the capital markets through a registered offering during the period of time that we are unable to use Form <FONT STYLE="white-space:nowrap">S-3,</FONT>
we may be required to publicly disclose the proposed offering and the material terms thereof before the offering commences, we may experience delays in the offering process due to SEC review of a Form <FONT STYLE="white-space:nowrap">S-1</FONT>
registration statement and we may incur increased offering and transaction costs and other considerations. Disclosing a public offering prior to the formal commencement of an offering may result in downward pressure on our stock price. If we are
unable to raise capital through a registered offering, we would be required to conduct our equity financing transactions on a private placement basis, which may be subject to pricing, size and other limitations imposed under the Nasdaq Listing
Rules, or seek other sources of capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be required to make milestone payments to the former stockholders of Semnur in connection with our
development and commercialization of SEMDEXA, which could adversely affect the overall profitability of SEMDEXA, if approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement and Plan of Merger we entered into with Semnur, Sigma Merger Sub, Inc., our prior wholly owned subsidiary,
Fortis Advisors LLC, solely as representative of the holders of Semnur equity, or the Semnur Equityholders, and Sorrento, for limited purposes, we are obligated to pay the Semnur Equityholders up to an aggregate of $280.0&nbsp;million in contingent
cash consideration based on the achievement of certain milestones. A $40.0&nbsp;million payment will be due upon obtaining the first approval of a new drug application by the FDA (&#147;NDA&#148;) of any Semnur product, which includes SEMDEXA.
Additional payments will be due upon the achievement of certain cumulative net sales of Semnur products, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $20.0&nbsp;million payment upon the achievement of $100.0&nbsp;million in cumulative net sales of a Semnur
product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $20.0&nbsp;million payment upon the achievement of $250.0&nbsp;million in cumulative net sales of a Semnur
product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $50.0&nbsp;million payment upon the achievement of $500.0&nbsp;million in cumulative net sales of a Semnur
product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $150.0&nbsp;million payment upon the achievement of $750.0&nbsp;million in cumulative net sales of a Semnur
product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These milestone obligations could impose substantial additional costs on us, divert resources from other
aspects of our business, and adversely affect the overall profitability of SEMDEXA, if approved. We may need </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to obtain additional financing to satisfy these milestone payments, and cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. We expect to significantly increase our spending to continue our
commercialization efforts for ZTlido and GLOPERBA, advance development of our current product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Furthermore, we expect to incur additional costs
associated with operating as a public company. We will also require additional capital to fund our other operating expenses and capital expenditures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, our cash and cash equivalents were approximately $2.2&nbsp;million and we had an accumulated deficit of
approximately $375.9&nbsp;million. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree of success we experience in commercializing ZTlido and GLOPERBA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue generated by sales of ZTlido, GLOPERBA and other products that may be approved, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates,
SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing ZTlido, GLOPERBA and our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current
or future collaboration or license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements
and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which ZTlido, GLOPERBA or any of our product candidates, if approved for commercialization, is
adopted by the physician community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to expand our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing products and product candidates and other market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and types of future products we develop and commercialize; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product liability or other lawsuits related to our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending
intellectual property-related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and scope of our general and administrative expenses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we are able to generate significant revenue, if ever, we expect to finance our
operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at
all. Any additional fundraising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize
our product candidates. Furthermore, any additional equity or equity-related financing may be dilutive to our stockholders, and debt or equity financing, if available, may subject us to restrictive covenants and significant interest costs. If we
raise additional funds through collaborations or strategic alliances with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or technologies, or grant licenses on terms that
may not be favorable to us. If we are unsuccessful in our efforts to raise additional financing on acceptable terms, we may be required to significantly reduce or cease our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as
a going concern. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Note 2 titled &#147;<I>Liquidity and Going Concern</I>&#148; of our consolidated financial statements included
elsewhere in this prospectus, we disclose that there is substantial doubt about our ability to continue as a going concern. In addition, our independent registered public accounting firm included an explanatory paragraph in its report on our
consolidated financial statements as of and for the year ended December&nbsp;31, 2022, which stated that substantial doubt existed about our ability to continue as a going concern. We have negative working capital and have incurred significant
operating losses and negative cash flows from operations and expect to continue incurring losses for the foreseeable future. Further, we had an accumulated deficit of approximately $375.9&nbsp;million as of December&nbsp;31, 2022 and approximately
$352.6&nbsp;million as of December&nbsp;31, 2021. These conditions raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of
this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to become a profitable operating company is dependent upon our ability to generate revenue and obtain
financing adequate to fulfill our development and commercialization activities, and achieving a level of revenue adequate to support our cost structure. We have plans to obtain additional resources to fund our currently planned operations and
expenditures through additional debt and equity financing. Our plans are substantially dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the
success of our marketing of ZTlido and our ability to secure additional payor contracts with terms that are consistent with our business plan. If we are unable to obtain sufficient funding, our financial condition and results of operations will be
materially and adversely affected and we may be unable to continue as a going concern. Future financial statements may disclose substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business
activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified a material weakness in our internal control over financial reporting. Any material weakness may cause us to fail to timely and
accurately report our financial results or result in a material misstatement of our financial statements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the
audit of our consolidated financial statements for the years ended December&nbsp;31, 2022 and 2021, we identified control deficiencies in the design and operation of our internal control over financial reporting that constituted a material weakness.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or
detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2022 and 2021, the material weakness identified in our internal control
over financial reporting related to ineffective control activities in the areas of revenue, business combination, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
debt and derivative liabilities caused by a lack of sufficient accounting resources with appropriate experience and technical expertise to effectively execute controls over certain judgmental and
technical accounting areas. As a result of the material weakness, we hired additional accounting personnel and are implementing remediation measures including, but not limited to, performing a comprehensive assessment of accounting and finance
resource requirements and hiring other personnel with sufficient accounting expertise at Scilex to improve the operating effectiveness of our review controls and monitoring activities, and utilizing external accounting experts as appropriate. Any
potential material misstatements were identified and corrected as audit adjustments in the applicable periods and are properly reflected in our financial statements included in this prospectus. We hired a new Chief Financial Officer in May 2022 at
Legacy Scilex and she became Chief Financial Officer of the Company in connection with the closing of the Business Combination. In addition, we expect to hire additional personnel with accounting expertise and utilize external accounting experts.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, in order to properly manage our internal control over financial reporting, we may need to take additional measures to
further augment our finance resources, and we cannot be certain that the measures we have taken, and expect to take, to improve our internal controls will be sufficient to ensure that our internal controls will remain effective and eliminate the
possibility that other material weaknesses or deficiencies may develop or be identified in the future. If we experience future material weaknesses or deficiencies in internal controls and we are unable to correct them in a timely manner, our ability
to record, process, summarize and report financial information accurately and within the time periods specified in the rules and forms of the SEC, will be adversely affected. Any such failure could negatively affect the market price and trading
liquidity of our Common Stock, lead to delisting, cause investors to lose confidence in our reported financial information, subject us to civil and criminal investigations and penalties, and generally materially and adversely impact our business and
financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we identify future material weaknesses in our internal controls over financial reporting or fail to meet the
demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act as, we may be unable to accurately report our financial results or report them within the timeframes required by law or stock exchange
regulations. Failure to comply with Section&nbsp;404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in
the future, and we are unable to remediate any such material weakness, our business, financial condition and results of operations could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_15">
</A>Risks Related to our Commercial Operations and Product Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We obtain our commercial supply of ZTlido, clinical supply of our product
candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer
to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
rely on a number of sole or single source suppliers and manufacturers, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer and supplier for the commercial supply of ZTlido; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer and supplier for the clinical supply of <FONT STYLE="white-space:nowrap">SP-103;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer and supplier for the clinical supply of <FONT STYLE="white-space:nowrap">SP-104;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supplier of sodium hyaluronate, one of the excipients for SEMDEXA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer for the clinical supply of SEMDEXA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, dated as of May&nbsp;11, 2011, by and among Scilex Pharmaceuticals, Inc. (as successor to Stason
Pharmaceuticals, Inc.), Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation (&#147;Itochu&#148;) (as amended, the &#147;Product Development Agreement&#148;), and the </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Commercial Supply Agreement, dated as of February&nbsp;16, 2017, by and among Scilex Pharma and Oishi and Itochu (as amended, the &#147;Commercial Supply Agreement&#148;), we license the rights
to ZTlido from and rely exclusively on Oishi and Itochu for the manufacturing and supply of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> (collectively, the &#147;Products&#148;). Oishi and Itochu have the right to terminate the Product
Development Agreement and the Commercial Supply Agreement under certain circumstances, including, among other things: (1)&nbsp;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to
cure such material breach within 180 days after notice requesting to cure; (2)&nbsp;if, at any time during the term of the Product Development Agreement and the Commercial Supply Agreement, the market conditions are such that (a)&nbsp;our total net
profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of our net sales of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> for a period of four or more consecutive quarters, or
(b)&nbsp;the economic viability of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as
agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a)&nbsp;and (b) after 30 days of good-faith discussion; and (3)&nbsp;in the event of our
bankruptcy or assignment for the benefit of creditors. As of the date of this prospectus, our net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have
the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement and the Commercial
Supply Agreement are terminated, we would lose access to the intellectual property and proprietary manufacturing process upon which ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> depend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our exclusive Supply Agreement, dated December&nbsp;17, 2015 (the &#147;Genzyme Supply Agreement&#148;), with Genzyme Corporation
(&#147;Genzyme&#148;), we depend on Genzyme to fulfill our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SEMDEXA. Genzyme has the right to terminate the Supply Agreement under certain circumstances,
including, but not limited to: (1)&nbsp;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice of such breach, (2)&nbsp;if our development of SEMDEXA is ceased or we do not file for regulatory
approval for SEMDEXA by January&nbsp;1, 2020, or (3)&nbsp;if Genzyme decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#146; notice. We did not file for regulatory
approval for SEMDEXA by January&nbsp;1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with the preceding clause (3), Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement,
effective as of May&nbsp;31, 2024. Although we are currently in the process of identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate we may not be able to find an alternative
supplier of sodium hyaluronate on commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Master Services Agreement, dated January&nbsp;27, 2017 (as
amended, the &#147;Lifecore Master Services Agreement&#148;), with Lifecore Biomedical, LLC (&#147;Lifecore&#148;), we depend on Lifecore to manufacture clinical supplies of SEMDEXA. Lifecore has the right to terminate the Lifecore Master Services
Agreement under certain circumstances, including, but not limited to: (1)&nbsp;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice; (2)&nbsp;if we (a)&nbsp;become insolvent, (b)&nbsp;cease to
function as a going concern, (c)&nbsp;become convicted of or plead guilty to a charge of violating any law relating to either party&#146;s business, or (d)&nbsp;engage in any act which materially impairs goodwill associated with SEMDEXA or
materially impairs the terminating party&#146;s trademark or trade name; (3)&nbsp;if we fail to pay past due invoices upon 30 days&#146; written notice, or (4)&nbsp;if we reject or fail to respond to a major change proposed by Lifecore that does not
change Semnur&#146;s written and approved acceptance criteria in its product specifications. In the event that Lifecore decides to terminate the Lifecore Master Services Agreement, finding an alternative manufacturer on commercially reasonable
terms, or at all, may be difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Master Services Agreement (the &#147;Tulex Master Services Agreement&#148;) and statement
of work with Tulex Pharmaceuticals Inc. (&#147;Tulex&#148;), we depend on Tulex to develop, test and manufacture clinical supplies of <FONT STYLE="white-space:nowrap">SP-104.</FONT> Tulex has the right to terminate the Tulex Master Services
Agreement under certain circumstances, including, but not limited to: (1)&nbsp;if we are in material breach of the agreement or a statement of work and fail to cure such breach within 15 days after receipt of notice of such breach (or such other
time period expressly stated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the applicable statement of work) or (2)&nbsp;in the event of our insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy,
reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any statement of work (a)&nbsp;without cause upon 30 days prior written notice
to Tulex or (b)&nbsp;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. In the event that the Tulex Master Services Agreement or a statement of work is terminated, we may not be able to find an
alternative manufacturer and supplier on commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the manufacturing facilities used by our
third-party suppliers and manufacturers must continue to comply with FDA regulations and are subject to periodic announced or unannounced inspections. We have limited control over the ability of our third-party suppliers and manufacturers to
maintain adequate quality control, quality assurance and qualified personnel. If our third-party suppliers and manufacturers fail to comply with FDA regulations, the FDA may not authorize the manufacture of our products and product candidates at
these facilities, and we may be unable to find alternative manufacturing facilities in a timely manner or at all. The failure by such third parties to comply with applicable regulations could result in sanctions being imposed on us, including
clinical holds, fines, injunctions, import detention, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of our product, operating restrictions and criminal prosecutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our product candidates may compete with other product candidates and products for access to manufacturing facilities and other
supplies. There are a limited number of manufacturers that operate under current Good Manufacturing Practices (&#147;cGMP&#148;) regulations and that might be capable of manufacturing for us. Also, prior to the approval of our product candidates, we
would need to identify a contract manufacturer that could produce our products at a commercial scale and that could successfully complete FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection and inspections by other health
authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates
are disrupted or delayed, there can be no assurance that alternative sources can serve as adequate replacements or that supplies will be available on terms that are favorable to us, if at all. Any disruption in supply could affect the profitability
of ZTlido and the development of SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
rely on a single third-party logistics distribution provider, Cardinal Health 105, which until recently had also been our only customer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on Cardinal Health 105, LLC (&#147;Cardinal Health 105&#148;) as our third-party logistics distribution provider for ZTlido
in the United States. Cardinal Health 105 also performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable,
inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December&nbsp;31, 2020 and 2021 and the first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105
represented all of our net revenue for such periods. As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional distributors and pharmacies in the second quarter of 2022. Beginning
on April&nbsp;1, 2022, we began selling ZTlido directly to three large distributors, McKesson Corporation (&#147;McKesson&#148;), Cardinal Health 110, LLC (&#147;Cardinal Health 110&#148;) and AmerisourceBergen Corporation
(&#147;AmerisourceBergen&#148;), as well as to numerous pharmacies. If we are unable to maintain a favorable relationship with Cardinal Health 105 (or with any of our three large distributors), we expect that our revenue would decline and our
business would be harmed as a result. We may be unable to control the timing of the delivery of ZTlido to distributors, and any financial uncertainty or loss of key logistic employees of Cardinal Health 105, as our only third-party logistics
provider, may negatively impact our sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We discontinued our use of &#147;title model&#148; services provided by Cardinal Health 105,
but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. Any disruption in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
abovementioned distribution channel would adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to achieve certain milestones in our Product Development Agreement with Itochu and Oishi, we could lose rights that are important to our
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing license and supply agreements impose various milestone and other obligations on us. For example,
under our Product Development Agreement with Itochu and Oishi, if our total net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of our net sales of ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> for a period of four or more consecutive quarters, Itochu and Oishi have the right to terminate the Product Development Agreement if the parties are unable to resolve the concerns after 30 days of good-faith
negotiation. As of the date of this prospectus, our net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product
Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve the milestones under the Product Development Agreement, we may lose our exclusivity rights or the counterparty may have
the right to terminate the agreement, any of which could adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on
third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory
requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently
do not have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as good clinical practice (&#147;GCP&#148;)
requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the
potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations (&#147;CROs&#148;), to conduct <FONT
STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials of our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over
their actual performance. The third parties with whom we contract for execution of our <FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials play a significant role in the conduct of these studies and trials and the subsequent
collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount and timing of resources that they devote to our
programs. Although we rely on these third parties to conduct our <FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with our
investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. For any violations of laws and regulations in the conduct of our preclinical studies and
clinical trials, we could be subject to warning letters or enforcement actions that may include civil penalties up to and including criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for
whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. We face the risk of potential unauthorized disclosure or infringement, misappropriation or other violation of our
intellectual property by CROs, which may reduce our trade secret and intellectual property protection, allow our potential competitors to access, and exploit our proprietary technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If the
third parties conducting our clinical trials do not adequately perform their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced,
or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be
difficult, costly or impossible, and our clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval or successful commercialization in a timely fashion, or at all, for the
applicable product candidate. Our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may in the future enter into collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements, joint ventures, or strategic
alliances with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. In the ordinary course of our business,
we may enter into collaborations, additional <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements (such as, for example, the Romeg Agreement), joint ventures, or strategic alliances to develop proposed products and to pursue new
markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proposing, negotiating and implementing collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements, joint
ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these
opportunities or arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all, and may not realize the anticipated benefits of any such
transactions or arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, with respect to current and future collaborations, we may not be in a position to exercise
sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become,
inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any
agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with our current or future collaborators, they may act in their self-interest,
which may be adverse to our best interest, and they may breach their obligations to us. In addition, we have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our
collaborators&#146; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements
are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such
rights at a premium. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delays in clinical trials could result in increased costs to us and delay our ability to obtain commercial approval and
generate additional revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval for the sale of our product candidates, we must conduct extensive
clinical trials to demonstrate the safety and efficacy of our product candidates for their intended indications. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be
conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining regulatory authorizations to commence a clinical trial or reaching a consensus with
regulatory authorities on trial design; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying prospective clinical investigators or clinical trial sites that have necessary
qualifications, interest and capacity to perform a requested protocol; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of
which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining approval from one or more institutional review boards (&#147;IRBs&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs refusing to approve, suspending or terminating the trial at the investigational site, precluding enrollment
of additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to the clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting suitable subjects to participate in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with GCPs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites,
including delays by third parties with whom we have contracted to perform certain of those functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in subjects completing participation in a trial or returning for post-treatment <FONT
STYLE="white-space:nowrap">follow-up,</FONT> including, for example, as a result of reluctance to visit medical facilities as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites or subjects dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">key investigators departing their clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the
resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects experiencing severe or unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, after an
inspection of our clinical trial operations, trial sites or manufacturing facilities, or for other reasons; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events in our trials or in trials of the same class of agents conducted by other
sponsors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements or guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA to
temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any changes to our manufacturing process that may be necessary or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not
performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors not performing data collection or analysis in a timely or accurate manner; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or
regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by subcontractors in support of our marketing applications.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the
IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct
the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side
effects, participants being exposed to unacceptable health risks, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In
addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which
may impact the costs, timing or successful completion of a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience
delays in testing or marketing approvals. The FDA and other regulatory agencies may impose new or refined testing expectations based on experience and increased knowledge over time. In addition, if we make manufacturing or other changes to our
product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. We do not know whether any of our clinical trials, including our planned clinical trials of
<FONT STYLE="white-space:nowrap">SP-103,</FONT> <FONT STYLE="white-space:nowrap">SP-104</FONT> and SEMDEXA, will begin or continue as planned, will need to be restructured or will be completed on schedule, or at all. We may not have the necessary
capabilities, including adequate staffing, to successfully manage the execution and completion of any clinical trials we initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all.
Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to
successfully commercialize our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face potential business disruptions and related risks resulting from the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which could have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT>
was reported to have surfaced in Wuhan, China. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> is the virus that causes <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The
<FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak has grown into a global pandemic that has impacted countries throughout the world. Financial markets have been experiencing extreme fluctuations that may cause a contraction in available
liquidity globally as important segments of the credit markets react to the development. The pandemic may lead to a decline in business and consumer confidence. The global outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> continues to
rapidly evolve. As a result, businesses have closed or limited operations and limits have been placed on travel. The extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> may impact our business, clinical trials and sales of ZTlido will
depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease and variants, the duration of the outbreak, travel restrictions and social distancing in the
United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are monitoring the potential impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, and if
<FONT STYLE="white-space:nowrap">COVID-19</FONT> or variants of concern continue to spread globally, including in the United States, we may experience disruptions that could severely impact the development of our product candidates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling patients in our clinical trials as patients may be reluctant, or unable, to
visit clinical sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site
investigators, clinical site staff and potential closure of clinical facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreases in patients seeking treatment for chronic pain; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including
interruption in global shipping that may affect the transport of clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
outbreak, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or cause us to discontinue the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk that participants enrolled in our clinical trials will acquire
<FONT STYLE="white-space:nowrap">COVID-19</FONT> while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on
travel imposed or recommended by federal or state governments, employers and others. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarantines, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related
to <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other infectious diseases could impact personnel at third-party suppliers in the United States and other countries, or the availability or cost of materials, which would disrupt our supply
chain. Any manufacturing supply interruption of materials could adversely affect our ability to conduct ongoing and future research and testing activities. For example, we obtain our commercial supply of ZTlido and our clinical supply of <FONT
STYLE="white-space:nowrap">SP-103</FONT> exclusively from Oishi and Itochu in Japan. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may result in delays in the procurement and shipping of ZTlido, which may have an adverse impact on
our operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2021, the Safer Federal Workforce Task Force issued written guidance to implement Executive
Order 14042, which was signed by President Biden on September&nbsp;9, 2021. A number of federal courts have issued orders enjoining enforcement of the Executive Order, including one on a nationwide basis. As a result, the government stated that it
will take no action to enforce the requirements of the Executive Order at this time. As a federal contractor, we have mandated that all of our employees and, in addition, contractors that enter our U.S. buildings and certain other locations, be
fully vaccinated against <FONT STYLE="white-space:nowrap">COVID-19,</FONT> subject to disability and religious exemptions, by December&nbsp;8, 2021. Despite the government&#146;s <FONT STYLE="white-space:nowrap">no-action</FONT> position, we
continue to comply with the Executive Order. We may experience workforce constraints due to shortages of vaccinated personnel, strains on the labor market, limitations on hiring new employees and difficulty retaining and securing employees who are
vaccinated, all of which could negatively affect our business and operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The spread of
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> which has caused a broad impact globally, may materially affect the Company economically. While the potential economic impact brought by, and the duration of,
<FONT STYLE="white-space:nowrap">COVID-19</FONT> may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, which could in the future negatively affect our liquidity. In addition,
a recession or market correction resulting from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially affect our business and the value of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the continued spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> globally could materially and adversely impact our
operations, including without limitation, our manufacturing and supply chain, sales and marketing efforts, sales of ZTlido, travel and employee health and availability, which may have a material and adverse effect on our business, financial
condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain
regulatory approval for our product candidates and the approval may be for a more narrow indication than we seek. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot
commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and
local statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. Even if our product candidates meet the safety and efficacy endpoints in clinical
trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA advisory committee, if convened, recommends <FONT
STYLE="white-space:nowrap">non-approval</FONT> or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory
authority policy or data requirements during the period of product development, clinical trials and the regulatory review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even
if we receive regulatory approval, the FDA may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a Risk Evaluation and Mitigation
Strategy (&#147;REMS&#148;). The FDA may require labeling that includes precautions or contra-indications with respect to conditions of use, or may grant approval subject to the performance of costly post-marketing clinical trials. In addition, the
FDA may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if the results of any clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with
our product candidates, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed or fail in obtaining marketing approval for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval for indications or patient populations that are not as broad as we intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to changes in the way the products are administered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be required to perform additional clinical trials to support approval or be subject to additional post-marketing
testing requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its
distribution in the form of a modified REMS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be sued and held liable for harm caused to patients; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience damage to our reputation. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may find it difficult to enroll or maintain patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of
our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in any clinical trials of our product candidates is
critical to our success. The timing of any clinical trials depends on our ability to recruit patients and to complete required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. If patients are unwilling to participate in our clinical trials
due to negative publicity from adverse events, competitive clinical trials for similar patient populations, or for other reasons, the timeline for recruiting patients, conducting trials and potentially obtaining regulatory approval may be delayed.
We may also experience delays if patients withdraw from a clinical trial or do not complete the required monitoring period. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness
of our product candidates or termination of clinical trials altogether. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is affected by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the eligibility and exclusion criteria for the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that enrolled patients will not complete a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including
difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented and other factors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate in
relation to other available products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conditions for which we currently plan to evaluate our product candidates are
common but the eligibility criteria of our clinical trials limit the pool of available trial participants. For example, we experienced a delay in the enrollment of our now completed SEMDEXA Phase 3 clinical trial in sciatica due to the selective
eligibility criteria in place to reduce the placebo effect and the impacts of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and may experience similar issues with enrollment of our other planned clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our
product candidates, and this competition will reduce the number and types of patients available to it, because some patients who have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a competitor. We may conduct
some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market
opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodically, we make estimates regarding the incidence and prevalence of target patient populations of our product
candidates based on various third-party sources and internally generated analyses and use such estimates in making decisions regarding our product development strategy, including acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT>
product candidates and determining indications on which to focus in preclinical studies or clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These estimates may be
inaccurate or based on imprecise data. For example, the total addressable market opportunities will depend on, among other things, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the
addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which may
significantly harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition and our competitors may discover, develop or commercialize products
faster or more successfully than us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by intense competition and
rapid technological advances. In addition, the competition in the pain management market, and other relevant markets, is intense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido
and our product candidate, <FONT STYLE="white-space:nowrap">SP-103,</FONT> face and will likely face competition from prescription and generic topical lidocaine patches, including Lidoderm<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (a
branded, prescription 5% lidocaine patch product) (&#147;Lidoderm&#148;) and generic lidocaine patches manufactured by Mylan N.V., Teva Pharmaceutical Industries Limited (&#147;Teva&#148;) and Par Pharmaceutical, Inc. Additionally, <FONT
STYLE="white-space:nowrap">SP-103,</FONT> if approved, will likely compete with various opioid pain medications, nonsteroidal anti-inflammatory drugs (&#147;NSAIDs&#148;), muscle relaxants, antidepressants and anticonvulsants particularly as we seek
approval for the treatment of acute LBP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA, if approved, has the potential to become the first
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> epidural steroid product for the treatment of sciatica. While there are currently no FDA approved epidural steroid injections indicated for the treatment of sciatica, we are aware of certain <FONT
STYLE="white-space:nowrap">non-steroid</FONT> product candidates in development. SEMDEXA, if approved, also will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures.
Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the <FONT STYLE="white-space:nowrap">off-label</FONT> and unapproved use of branded and generic injectable steroids.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware
of certain <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, <FONT STYLE="white-space:nowrap">SP-104,</FONT> will likely
face direct competition from these candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will become increasingly competitive in the future. Many of our
competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in developing
product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates, and launching, marketing and selling
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more
resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies
or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining
qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further
as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing,
acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from
commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to <FONT
STYLE="white-space:nowrap">in-license</FONT> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and
commercializing medicines before we do, which would have a material adverse impact on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The third-party payor coverage and reimbursement status of newly approved products is uncertain.
Failure to obtain or maintain coverage and adequate reimbursement for ZTlido, GLOPERBA or our product candidates, if approved, could decrease our ability to generate product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the third-party coverage and reimbursement of existing and newly approved products. Market
acceptance and sales of ZTlido, GLOPERBA and our product candidates, if approved, in domestic markets will depend significantly on the availability of coverage and adequacy of reimbursement from third-party payors, including government programs
(such as Medicare and Medicaid) and private payor healthcare and insurance programs. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Coverage and reimbursement for ZTlido can differ
significantly from payor to payor, and we may not be able to maintain adequate coverage and reimbursement in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further,
obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use
of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be obtained or applied consistently. We may not be able to provide data sufficient to gain acceptance with respect to coverage and
reimbursement. Additionally, coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside of the United States. Assuming that coverage is obtained for a given product, the
resulting reimbursement rates might not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> or <FONT STYLE="white-space:nowrap">co-insurance</FONT> that patients find unacceptably high. Patients, physicians, and other
healthcare providers may be less likely to prescribe, dispense or use, as applicable, any approved product unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for our products will depend significantly on access to third-party payors&#146; drug formularies for which third-party payors
provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded product in
their formularies or otherwise restrict patient access to a branded product when a less costly generic equivalent or other alternative is available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if we obtain adequate levels of reimbursement, third-party payors carefully review and increasingly question the coverage
of, and challenge the prices charged for, products. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined
discounts from list prices and are challenging the prices for products. We cannot be sure that coverage and reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, what the level of
reimbursement will be. If coverage and reimbursement of our product candidates are unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Furthermore, the
requirements governing medical product pricing vary widely from country to country. In some foreign countries, the proposed pricing for a prescription device must be approved before it may be lawfully marketed. Historically, products launched in the
European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product
candidate SEMDEXA is expected to be a physician-administered injectable viscous gel and as such, separate reimbursement for the product itself may not be available. Instead, if SEMDEXA receives regulatory approval, the administering physician may be
reimbursed only for providing the treatment or procedure in which SEMDEXA is used. To the extent separate coverage and reimbursement should become available for SEMDEXA, we anticipate that it will be sold to physicians on a &#147;buy and bill&#148;
basis. Buy and bill products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or
a health insurance company. Healthcare providers may be reluctant to administer our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, if approved, because they would have to fund the purchase of the product and then seek reimbursement, which may be lower than their purchase price, or because they do not want the
additional administrative burden required to obtain reimbursement for the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the codes used by providers to bill for
SEMDEXA, if approved, could also affect reimbursement. <FONT STYLE="white-space:nowrap">J-Codes</FONT> are codes maintained by the Centers for Medicare and Medicaid Services (&#147;CMS&#148;), which are a component of the Healthcare Common Procedure
Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We do not have a specific <FONT STYLE="white-space:nowrap">J-Code</FONT> for any of our product candidates. If our product candidates are
approved, we may apply for one but cannot guarantee that a <FONT STYLE="white-space:nowrap">J-Code</FONT> will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific <FONT
STYLE="white-space:nowrap">J-Code</FONT> is not available, physicians would need to use a <FONT STYLE="white-space:nowrap">non-specific</FONT> miscellaneous <FONT STYLE="white-space:nowrap">J-Code</FONT> to bill third-party payors for these
physician-administered drugs. Because miscellaneous <FONT STYLE="white-space:nowrap">J-Codes</FONT> may be used for a wide variety of products, health plans may have more difficulties determining the actual product used and billed for the patient.
These claims must often be submitted with additional information and manually processed, which can create delays in claims processing times as well as increasing the likelihood for claim denials and claim errors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety of target indications and treatment
approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Apart from our <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product, ZTlido, we currently have several product candidates
that are at various stages of development. We have limited financial and management resources. As a result, we may forego or delay pursuit of opportunities with potential target indications or product candidates that later prove to have greater
commercial potential than our current and planned development programs and product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to progress product candidates
that can address unmet or underserved medical needs and favor those candidates with large market opportunities. However, our resource allocation decisions may cause us to fail to capitalize on viable commercial product candidates or profitable
market opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate
the commercial potential or target market for a particular product candidate, we may be required to relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have
been more advantageous for us to retain sole development and commercialization rights to such future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we
may pursue additional <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of product candidates or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial
technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a successful product candidate, potentially resulting in a diversion of our management&#146;s time and the expenditure of our
resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that
ultimately do not provide a return on our investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug development involves a lengthy and expensive process with an uncertain outcome, and
results of earlier studies and trials may not be predictive of future trial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to
design and implement, and can take many years to complete, in part because it is subject to rigorous regulatory requirements. The FDA or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical
trials of our product candidates. They may also not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agree with the scope of our proposed investigational plan. In addition, the outcome of our clinical trials is risky and uncertain. Failure can occur at any time during the clinical trial process.
The results of preclinical studies and early clinical trials may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite
having progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the pharmaceutical industry to suffer significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles,
notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This product candidate
development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early and late stage clinical trials towards approval and
commercialization, it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these types of changes are
common and are intended to optimize the product candidates for late stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve their intended objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Phase 3 trial was completed for SEMDEXA for the treatment of sciatica, a Phase 2 trial commenced in the second quarter of 2022 for <FONT
STYLE="white-space:nowrap">SP-103,</FONT> and multiple Phase 1 trials were initiated in the first quarter of 2022 for <FONT STYLE="white-space:nowrap">SP-104.</FONT> We may not have the necessary capabilities, including adequate staffing, to
successfully manage the execution and completion of such clinical trials in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Our clinical trials may produce negative or inconclusive
results, and, in the future, we may decide, or regulators may require us, to conduct additional clinical trials and preclinical studies in addition to those we have planned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, we announced final results from our Phase 3 trial for SEMDEXA, which results reflect achievement of primary and secondary
endpoints, and we intend to use the results to support an NDA submission seeking approval for the treatment of sciatica. However, the FDA may disagree with our assumptions and require us to conduct an additional Phase 3 trial before submitting an
NDA. Our failure to adequately demonstrate the safety and effectiveness of our product candidates would prevent receipt of regulatory clearance or approval and, ultimately, the commercialization of that product or indication for use. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our clinical trials that we announce or publish from time
to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> or preliminary data from our clinical
trials, which are based on a preliminary analysis of then-available data. Preliminary or interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient
enrollment continues and more patient data become available. Preliminary or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. In some instances, there can be significant variability in safety or efficacy results between different clinical trials or clinical trial sites for the same product candidate due to numerous factors, including changes in trial procedures
set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial procedures and the rate of dropout among clinical trial participants. As a result, interim
and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. Data disclosures
must be carefully managed to conform to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations on preapproval promotion and laws related to clinical trial registration and posting of results. In addition, the information we choose to publicly disclose regarding a particular
study or clinical trial is based on what is typically extensive information, and stockholders may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine
not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product, product candidate or our business. If the
<FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and
commercialize, our product candidates may be harmed, which could harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical
trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through
lengthy, complex and expensive <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials that the applicable product candidate is both safe and effective for use in
each target indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety
concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business,
financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities will
interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities for support of a marketing approval, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential
approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in
any other jurisdiction, which would limit our ability to realize their full market potential. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products in
any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis regarding safety and efficacy.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However,
the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory
approval in one country does not guarantee regulatory approval in any other country. In cases where data from United States clinical trials are intended to serve as the basis for marketing approval in the foreign countries, the standards for
clinical trials and approval may be different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and
validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increased costs for us and require additional preclinical studies or clinical trials, which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and
could delay or prevent the introduction of our products in those countries. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets
are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be impeded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
business may suffer reputational harm due to failures of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure of any of our product candidates
could have a lasting negative impact on our reputation, which could, in turn, impact our ability to successfully enter into future licensing arrangements or other transactions with potential counterparties, raise future capital or attract key
personnel to join us. As a result, our business and prospects would be materially harmed and our results of operations and financial condition would likely suffer materially. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido and GLOPERBA may have undesirable properties that could result in significant negative consequences, and our product candidates may cause
undesirable side effects that could delay or prevent their regulatory approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with pharmaceuticals generally, it
is likely that there may be side effects and adverse events associated with ZTlido, GLOPERBA and our product candidates. In the event that ZTlido or GLOPERBA is identified to have undesirable side effects, a number of potentially significant
negative consequences could occur. Regulatory authorities may withdraw their approval of the product or seize the product. Restrictions may be imposed on the manufacturing or marketing of ZTlido or GLOPERBA or any component thereof, including the
imposition of a REMS plan that may require creation of a Medication Guide outlining the risks of such side effects for distribution to patients, as well as elements to assure safe use of the product, such as a patient registry and training and
certification of prescribers. Any of these events could damage our reputation and prevent us from achieving or maintaining market acceptance of ZTlido or GLOPERBA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the clinical trials we conduct with our product candidates, patients may experience changes in their health, including illnesses, injuries,
discomforts or a fatal outcome. Often, it is not possible to determine whether the product candidate being studied caused or was associated with these conditions. In addition, it is possible that as we test our clinical products in larger, longer
and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well
as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that our product candidates reveal an unacceptable severity and prevalence of these or other side effects, the clinical trials
could be suspended or terminated and the FDA could order us to cease further development of or deny approval of our product candidates, for any or all targeted indications. The drug-related side effects could affect patient recruitment or the
ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and results of operations significantly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido, GLOPERBA and our product candidates are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or
manufacturing problems that result in delays in our development or commercialization programs, limit the supply of our product candidates, or otherwise harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently depend on contract manufacturers to conduct the manufacturing and supply activities for ZTlido, GLOPERBA and our product
candidates. Manufacturing these product candidates require facilities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Several factors could cause production interruptions,
including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If contaminations are discovered in our supply of ZTlido, GLOPERBA or our product candidates or in the manufacturing facilities, such
manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We may not be successful in securing additional sources at all or on a timely basis, which could materially harm our
development timelines. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay,
require us to begin new clinical trials at additional expense or terminate clinical trials completely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks
associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues,
compliance with cGMP, lot consistency and timely availability of raw materials. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could
result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our manufacturers may encounter problems hiring and retaining the experienced scientific, quality assurance, quality-control and
manufacturing personnel needed to operate our complex manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our manufacturing process or
facilities could make us a less attractive collaborator for potential partners, including larger biotechnology companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in our
manufacturing process could restrict our ability to meet potential future market demand for products, which could harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_16"></A>Risks Related to our Business and Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract,
retain and motivate key executives to accomplish our business objectives, we may experience constraints that will significantly impede our ability to raise additional capital and our ability to implement our overall business strategy. In particular,
we are highly dependent upon our executive officers, including Jaisim Shah, our President and Chief Executive Officer, Henry Ji, Ph.D., our Executive Chairperson, and Elizabeth Czerepak, our Executive Vice President, Chief Financial Officer and
Chief Business Officer. The loss of services of these executive officers could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials and the successful commercialization of ZTlido and
GLOPERBA. We do not carry &#147;key person&#148; insurance on any of our executive officers or other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition for key
executives in the biotechnology and pharmaceuticals field is intense, due to the limited number of individuals who possess the skills and experience required by our industry. Many of the pharmaceutical companies against which we compete for
qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They may also provide more diverse opportunities and better chances for career advancement. Some of these
characteristics may be more appealing to qualified candidates than what we have to offer. In addition, regulation or legislation impacting the workforce, such as the proposed rule published by the Federal Trade Commission which would, if issued,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generally prevent employers from entering into <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements with employees and require employers to rescind existing <FONT
STYLE="white-space:nowrap">non-compete</FONT> agreements, may lead to increased uncertainty in hiring and competition for talent. Further, we may experience employee turnover as a result of the ongoing &#147;great resignation&#148; occurring
throughout the U.S. economy, which has impacted job market dynamics. New hires require training and take time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain
sufficient numbers of qualified individuals. Moreover, we conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce
competition for qualified personnel. As such, we could have difficulty attracting and retaining experienced executives and may be required to expend significant financial resources in our recruitment and retention efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may need to increase the size of our company and may not effectively manage our growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, we had approximately 90 full-time employees. We may need to continue to expand our managerial, operational, sales
and marketing, finance and other resources in order to manage our operations, clinical trials, research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities,
including <FONT STYLE="white-space:nowrap">co-promotion</FONT> activities. Future growth would impose significant added responsibilities on members of management, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our internal development efforts effectively, including the clinical, FDA and internal regulatory review
process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improving our operational, financial and management controls, reporting systems and procedures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our
ability to effectively manage any future growth, if any, which may cause a significant strain on our management, and our operational, financial and other resources. Our ability to manage our growth effectively will require us to implement and
improve our operational, financial and management systems and to expand, train, manage and motivate our employees. These demands may require the hiring of additional management personnel and the development of additional expertise by management. Any
increase in resources devoted to research and product development without a corresponding increase in our operational, financial and management systems could have a material adverse effect on our business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured
liabilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we endeavor to obtain appropriate insurance coverage for insurable risks that we identify, we do not carry
insurance for all categories of risk that our business may encounter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insurance coverage is becoming increasingly expensive. We have
observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles and lower coverage limits. We may not be
able to maintain insurance coverage at a reasonable cost, or in sufficient amounts to protect us against losses due to liability. While we maintain property, casualty and general liability coverage, we do not carry specific biological or hazardous
waste insurance coverage and our insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held
liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know if we will be able to maintain existing insurance with adequate levels of
coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing and marketing of ZTlido and GLOPERBA and clinical testing of our product candidates may expose us to
individual product liability claims, class action lawsuits or actions, and other individual or mass tort claims. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product
testing, manufacturing, marketing or sale. In addition, physicians may misuse our products with their patients if they are not adequately trained, potentially leading to injury and increased risk of product liability. Any such product liability
claims may include allegations of defects in manufacturing, defects in design, a failure to warn of risks inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection
acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates, if approved. Even successful defense would require
significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue from product sales; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our product candidates or products that we develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on labeling, the marketing or manufacturing of the product, withdrawal of the product from the
market or voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against
potential product liability claims could prevent or inhibit the commercialization of any products we develop. We currently carry product liability insurance covering use in our clinical trials in the amount of $10.0&nbsp;million in the aggregate.
Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance
coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that
exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable
cost or in sufficient amounts to protect us against losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any disruption in our research and development facilities could adversely affect our
business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are in the San Francisco Bay Area,
California. Our facilities may be affected by natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters. Earthquakes are of particular significance since our facilities are located in an </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
earthquake-prone area. We are also vulnerable to damage from other types of disasters, including power loss, attacks from extremist organizations, fires, floods and similar events. If our
facilities are affected by a natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disaster, we may be forced to curtail our operations and/or rely on third-parties to perform some or all of our research and development activities. Although we
believe we possess adequate insurance for damage to our property and the disruption of our business from casualties, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable
terms, or at all. In the future, we may choose to expand our operations in either our existing facilities or in new facilities. If we expand our worldwide manufacturing locations, there can be no assurance that this expansion will occur without
implementation difficulties, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to grow our business through acquisitions and may fail to realize the anticipated benefits of
any acquisition, and acquisitions can be costly and dilutive. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our ability to continually enhance and
broaden our product offerings in response to changing customer demands, competitive pressures, technologies and market pressures. Accordingly, from time to time we may expand our business and intellectual property portfolio through the acquisition
of new businesses and technologies. We cannot assure that we will achieve anticipated benefits from any acquisition to justify the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition within our industry for acquisitions of businesses, technologies and assets may become intense. Even if we are able to identify an
acquisition that we would like to consummate, we may not be able to complete the acquisition on commercially reasonable terms or the target may be acquired by another company. We may enter into negotiations for acquisitions that are not ultimately
consummated. Those negotiations could result in diversion of management time and significant <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of any acquisition depends on, among other things, our ability to combine our business with an acquired business in a manner that
does not materially disrupt existing relationships and that allows us to achieve development and operational synergies. If we are unable to achieve these objectives, the anticipated benefits of an acquisition may not be realized fully, or at all, or
may take longer to realize than expected. In particular, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses or acquire
intangible assets that could result in significant future amortization expenses. As a result, an acquisition may not be accretive to our stock value or development pipeline in the near or long term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to incur higher development and regulatory costs, and additional costs integrating the operations and personnel of any companies we
acquire, which cannot be estimated accurately at this time. If the total costs of the integration of our companies and advancement of acquired product candidates and technologies exceed the anticipated benefits of the acquisition, our business,
financial condition and results of operations could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>International components of our business expose us to business, legal,
regulatory, political, operational, financial and economic risks associated with conducting business outside of the United States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently collaborate with international manufacturing partners and may potentially expand our business internationally in the future. The
purchase and shipment of components from international sources subjects us to U.S. and foreign governmental trade, import and export, and customs regulations and laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with these regulations and laws is costly and exposes us to penalties for <FONT STYLE="white-space:nowrap">non-compliance.</FONT>
Other laws and regulations that can significantly impact us include various anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (the &#147;FCPA&#148;), as well as export controls laws. Any failure to comply with applicable legal and
regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges,
seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting business internationally involves a number of risks, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">multiple, sometimes conflicting and changing laws and regulations such as tax laws, export and import
restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in enforcing our intellectual property rights and in defending against third-party threats and
intellectual property enforcement actions against us, our distributors or any of our third-party suppliers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us or our distributors to obtain appropriate licenses or regulatory approvals for the sale or use of
our product candidates, if approved, in various countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost and availability of shipping and other means of product transportation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency exchange rate fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in duties and tariffs, license obligations and other <FONT STYLE="white-space:nowrap">non-tariff</FONT>
barriers to trade; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the imposition of new trade restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities associated with managing multiple payor-reimbursement regimes or
<FONT STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak
of disease, boycotts, curtailment of trade and other business restrictions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to comply with the FCPA, including its books and records provisions and its anti-bribery provisions, and
similar anti-bribery and anti-corruption laws in other jurisdictions, for example by failing to maintain accurate information and control over sales or distributors&#146; activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, negatively
impact our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The increasing use of social media platforms presents new risks and challenges.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Social media is increasingly being used to communicate about our research, product candidates, investigational medicines and the
diseases our product candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates
uncertainty and risk of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their
experience in an ongoing blinded clinical study or to report an alleged adverse event. When such disclosures occur, there is a risk that we may fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to
defend our business or the public&#146;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate
disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Furthermore, our employees, affiliates and/or business partners may use social media for their personal use, and their
activities on social media or in other forums could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are accurate, could adversely impact us. If any of these events were to
occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would suffer in the event of a system failure. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have implemented and maintain security measures, our computer systems and those of our CROs and other contractors and consultants are
vulnerable to computer viruses, unauthorized access, cybersecurity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attacks, and other security incidents, including as perpetrated by hackers, or as the result of natural disasters, terrorism, war, or telecommunications or electrical failures. While we have not
experienced any such system failure or a security breach to date, if such an event were to occur, it could result in a material disruption of our product development programs or a loss of our trade secrets or other proprietary information. For
example, the loss of clinical trial data from completed, ongoing, or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce such data. To the extent that any
disruption or security breach were to result in the loss of or damage to our data or applications, or the unauthorized disclosure of confidential or proprietary information, including personal data, we could incur material legal liability or be the
subject of legal claims, suffer damage to our reputation, lose or harm our intellectual property rights, and delay the continued research, development and commercial efforts of ZTlido, GLOPERBA and our product candidates, if approved. If we are held
liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of cybersecurity matters or some other matter, that claim could have a material adverse effect on our business,
financial condition, and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a security incident or privacy violation that leads to the unauthorized
acquisition, interruption, modification, loss, theft, corruption, interference, or other unauthorized disclosure of, or prevents access to, personal data, including patient data or other protected health information, could harm our reputation,
compel us to comply with federal or state breach notification laws and foreign equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents, and otherwise subject us to liability under laws and
regulations that protect personal data, resulting in increased costs or loss of revenue. Our ability to effectively manage and maintain our internal business information, and to ship products to customers and invoice them on a timely basis, depends
significantly on our enterprise resource planning system and other information systems. Portions of our information technology systems may experience interruptions, delays, or cessations of service or produce errors in connection with ongoing
systems implementation work. Cybersecurity attacks in particular are continually evolving and include, but are not limited to, malicious software, ransomware, attempts to gain unauthorized access to data under our custody or control, and other
electronic security breaches that could lead to disruptions in systems, misappropriation of confidential or otherwise protected information, and corruption of data. If we are unable to prevent such cybersecurity attacks or privacy violations or
implement satisfactory remedial measures, our operations could be disrupted, we may suffer loss of reputation, we may be the subject of governmental investigations, legal claims, or litigation, or we may incur financial loss or other regulatory
penalties, each of which may not be covered by our insurance. In addition, these breaches and other unauthorized access to our systems can be difficult to detect, and any delay in identifying any such event may lead to increased harm of the type
described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and results of
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As widely reported, global credit and financial markets have experienced volatility and disruptions in the past
several years and especially in 2020 and 2021 due to the impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic
growth, increases in unemployment rates and uncertainty about economic stability. For example, an overall decrease in or loss of insurance coverage among individuals in the United States as a result of unemployment, underemployment or the repeal of
certain provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#147;ACA&#148;), may decrease the demand for healthcare services and pharmaceuticals. If fewer
patients seek medical care because they do not have insurance coverage, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition and cash flows could be
adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurances that further deterioration in credit and financial markets and confidence in economic
conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a
timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and price of our Common Stock, and could require us to delay or abandon clinical development plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to the environmental, social and
governance matters, including related social expectations and concerns, may impose unexpected costs or results in reputational or other harm that could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is an increasing focus from certain investors, employees, regulators, listing exchanges and other stakeholders concerning corporate
responsibility and sustainability matters, specifically related to environmental, social and governance (&#147;ESG&#148;) factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in some cases,
investors may choose not to invest in us if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing investor
demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors, particularly
institutional investors, use these ratings to benchmark companies against their peers, and major institutional investors have publicly emphasized the importance of ESG measures to their investment decisions. Topics taken into account in such
assessments include, among others, companies&#146; efforts and impacts on climate change and human rights, ethics and compliance with law, diversity and the role of companies&#146; board of directors in supervising various sustainability issues. In
light of investors&#146; increased focus on ESG matters, if we are perceived as lagging with respect to ESG initiatives, these investors may engage with us to improve ESG disclosures or performance and may also make voting decisions, or take other
actions, to hold us and our Board accountable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are rapid and ongoing developments and changing expectations relating
to ESG matters, and the criteria by which our corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to
or are unable to adequately recognize and respond to such developments and governmental, societal, investor and consumer expectations relating to such ESG matters, we may miss corporate opportunities, become subject to additional scrutiny or incur
unexpected costs. We may face risk of litigation or reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also face reputational damage if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services.
A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our Common Stock from consideration by certain investors who may elect to invest with our competitors instead. Ongoing focus on corporate
responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our
business, financial condition or results of operations, including the sustainability of our business over time, and could cause the market value of our Common Stock to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our emphasis on ESG issues may not maximize short-term financial results and may yield financial results that conflict with the
market&#146;s expectations. We may in the future make business decisions that may reduce our short-term financial results if we believe that the decisions are consistent with our ESG goals, which we believe will improve our financial results over
the long-term. These decisions may not be consistent with the short-term expectations of our stockholders and may not produce the long-term benefits that we expect, in which case our business, financial condition and results of operations could be
harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_17"></A>Risks Related to our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are substantially dependent on the intellectual property we <FONT STYLE="white-space:nowrap">in-license</FONT> from Oishi and Itochu, and if we lose
the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <FONT STYLE="white-space:nowrap">SP-103</FONT> would be harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. Pursuant to the Product
Development Agreement, we have been granted an exclusive, worldwide license (except with respect to Japan) under current and future intellectual property rights relating to ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> lidocaine tape
products and the lidocaine in such products, including, among other things: (1)&nbsp;any patent applications, continuation applications, any issued or issuing patents, as well as any foreign patent applications, (2)&nbsp;all <FONT
STYLE="white-space:nowrap">know-how,</FONT> work product, trade secrets, inventions, data, processes, techniques, procedures, compositions, devices, methods, formulas, protocols and information, whether patentable or not, (3)&nbsp;copyrightable
works, copyrights and applications, registrations and renewals, (4)&nbsp;logos, trademarks, service marks, and all applications and registrations relating thereto, (5)&nbsp;other proprietary rights, (6)&nbsp;abbreviated new drug applications or
other applications to market, and (7)&nbsp;any regulatory exclusivities or supplemental protection certificates. Our ability to commercialize ZTlido and develop <FONT STYLE="white-space:nowrap">SP-103</FONT> depends on the effectiveness and
continuation of the Product Development Agreement. If we lose the right to license the intellectual property rights granted by the Product Development Agreement, our ability to develop ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> as
well as new product candidates based on the licensed intellectual property would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Product Development Agreement imposes
various development, regulatory and/or commercial diligence obligations, payments and other obligations. Oishi and Itochu have the right to terminate the Product Development Agreement under certain circumstances, including, among other things:
(1)&nbsp;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&nbsp;if, at any time during the term of
the Product Development Agreement, the market conditions are such that (a)&nbsp;our total net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of our net sales of ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> for a period of four or more consecutive quarters, or (b)&nbsp;the economic viability of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> is affected significantly as evidenced by documentation and
substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses
(a)&nbsp;and (b) after 30 days of good-faith discussion; and (3)&nbsp;in the event of our bankruptcy or assignment for the benefit of creditors. As of the date of this prospectus, Scilex&#146;s net profits for ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus,
neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or lack of economic viability, we will be required
to transfer all licensed intellectual property rights, including those relating to ZTlido and <FONT STYLE="white-space:nowrap">SP-103,</FONT> to Oishi and Itochu or their designee, at our own cost and expense. The loss of such licenses could
materially harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We recently entered into the Romeg Agreement for the <FONT
STYLE="white-space:nowrap">in-licensing</FONT> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is
terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently entered into the Romeg Agreement for
the <FONT STYLE="white-space:nowrap">in-licensing</FONT> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA. Pursuant to the Romeg Agreement, we have been granted (1)&nbsp;the right to manufacture,
promote, market, distribute and sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&nbsp;an exclusive, transferable license to use the
trademark &#147;GLOPERBA.&#148; Under the Romeg Agreement, among other things, Romeg granted us (1)&nbsp;a transferable license, with the right to sublicense, under the patents and <FONT STYLE="white-space:nowrap">know-how</FONT> specified therein
to (a)&nbsp;commercialize the pharmaceutical product comprising liquid </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#147;Initial Licensed Product&#148;) in the United States (including its territories) (the
&#147;Territory&#148;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#147;Licensed Products&#148;) and commercialize any such products and
(c)&nbsp;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory; and (2)&nbsp;an exclusive, transferable license, with right to sublicense, to use the trademark &#147;GLOPERBA&#148; and logos, designs,
translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The license to <FONT STYLE="white-space:nowrap">know-how</FONT> is exclusive for purposes of developing and
commercializing Licensed Products in the Territory during the royalty term, but is otherwise <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> The license to patents is exclusive for purposes of developing and commercializing Licensed Products
in the Territory until July&nbsp;1, 2027 and, thereafter, is <FONT STYLE="white-space:nowrap">co-exclusive</FONT> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and
ends on the later of (i)&nbsp;expiration of the last to expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii)&nbsp;the tenth anniversary of the date of the Romeg Agreement. Our
ability to commercialize GLOPERBA and develop Licensed Products depends on the effectiveness and continuation of the Romeg Agreement. If we lose the right to license the intellectual property rights granted by the Romeg Agreement, our ability to
develop GLOPERBA as well as new product candidates based on the licensed intellectual property would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement
imposes various development, regulatory and/or commercial diligence obligations, payments and other obligations. Romeg has the right to terminate the Romeg Agreement under certain circumstances, including, among other things: (a)&nbsp;in the event
we are in material breach of the Romeg Agreement, unless we have cured any such breach within 60 days after any notice thereof was provided; (b)&nbsp;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum
quarterly royalties or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we have made such payment in full or delivered such quarterly report within such 30 day
period; (c)&nbsp;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; (d)&nbsp;by written notice to us if sales of Licensed
Products do not commence or continue within specified periods agreed to by the parties; or (e)&nbsp;in the event of our bankruptcy or assignment for the benefit of creditors. If the Romeg Agreement is terminated for certain reasons, such as our
material breach of the agreement, our bankruptcy, or our failure to timely pay milestone payments, we will be required upon Romeg&#146;s request to transfer all licensed intellectual property rights, including those relating to GLOPERBA and the
Licensed Products, to Romeg or its designee, within thirty days after the termination of the Romeg Agreement at a price to be agreed upon by the parties. The loss of such licenses could materially harm our business, financial condition and results
of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential disputes over intellectual property rights that we have licensed may prevent or impair our ability to maintain our current
licensing arrangements on acceptable terms. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property rights is of high importance to our business and
involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property rights of the
licensor that are not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense intellectual property rights to third parties under collaborative development
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidates, and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual
property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, financial condition and results of operations may be adversely affected. We may enter into
additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third
parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates, if approved.
Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product
candidates. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are
unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property
related to ZTlido, GLOPERBA and our product candidates. Our success depends in part on our ability to obtain and maintain patent protection in the United States, for GLOPERBA, and in the United States and other countries with respect to ZTlido and
our product candidates. We seek to protect our proprietary position by filing and/or <FONT STYLE="white-space:nowrap">in-licensing</FONT> patent applications in the United States and abroad related to our development programs and product candidates.
The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents and patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents
with claims that protect ZTlido, GLOPERBA and our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been
found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover ZTlido, GLOPERBA and our product candidates, third parties may
challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of
rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection
could be reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or
any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Patent and Trademark Office (&#147;PTO&#148;) and various foreign governmental patent agencies require
compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the <FONT STYLE="white-space:nowrap">non-compliance</FONT> with which can result in abandonment or lapse of a patent or patent
application, and partial or complete loss of patent rights in the relevant jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise
may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made
significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope
of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S.
courts, allowing foreign competitors a better opportunity to create, develop and market competing products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other parties may have designed around our claims or developed technologies that may be related or competitive to
our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could
dominate our patent position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the
practice of our technologies or the successful commercialization of any products or product candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">because patent applications in the United States and most other countries are confidential for a period of time
after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an interference proceeding can be provoked by a third party or instituted by the PTO to determine who was the
first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March&nbsp;16, 2013. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all
necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensors will fail to identify patentable aspects
of our research and development output before it is too late to obtain patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or <FONT
STYLE="white-space:nowrap">in-license</FONT> with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for ZTlido,
GLOPERBA and our product candidates, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our ability to commercialize ZTlido, GLOPERBA and our product candidates. Any such outcome could have a
materially adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights to product components and
processes and brands for our development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Presently we have intellectual property rights, through licenses from third parties related to ZTlido,
<FONT STYLE="white-space:nowrap">SP-103,</FONT> and GLOPERBA. Because our programs for ZTlido, GLOPERBA, <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> may require the use of additional proprietary
rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these proprietary rights. In addition, our product candidates may require
specific formulations to work effectively and efficiently and these rights may be held by others. It may also be commercially advantageous to use trademarks held by others. We may be unable to acquire or
<FONT STYLE="white-space:nowrap">in-license</FONT> proprietary rights related to any compositions, formulations, methods of use, processes or other intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property rights from third parties that we identify as being necessary for our product candidates. Even if we are able to obtain a license to such proprietary rights, it may be <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where we obtain licenses from or collaborate with third parties, we may not have the right to control the preparation, filing and
prosecution of patent and trademark applications, or to maintain the patents covering technology that we license from third parties and associated trademark registrations, or such activities, if controlled by us, may require the input of such third
parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents, trademarks and applications may not be prosecuted and enforced
in a manner consistent with the best interests of our business, in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents and trademarks, or any patents and trademark registrations that may
issue from such applications. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give our licensor
the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, or loss of trademark rights, could have a material adverse impact on our business. Our business would suffer if any
such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents or trademarks against infringing third parties, if the licensed patents or other rights are found to be invalid or
unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the
freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their
merit, that we are infringing or otherwise violating the licensor&#146;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may
be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and
commercialize products, we may be unable to achieve or maintain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party proprietary
rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in
order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. We may be unable to negotiate a
license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the third-party may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our ability to pursue our
program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on
reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights
to required third-party intellectual property rights on commercially reasonable terms, our ability to commercialize our products, and our business, financial condition and results of operations could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees (including former employees of our licensors), collaborators or other third parties have an
interest in our patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a patent application can result in the patents issuing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where
foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding
<FONT STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements
to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use,
valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and
other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Claims that we infringe, misappropriate, or violate the intellectual property rights of third parties may give rise to costly and
lengthy litigation, and we could be prevented from selling products, forced to pay damages, and defend against litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third
parties may assert patent or other intellectual property infringement or misappropriation claims against us or our strategic partners, licensors or licensees with respect to ZTlido, GLOPERBA and our product candidates. If ZTlido, GLOPERBA or any of
our product candidates, methods, processes and other technologies are alleged to infringe on or be improperly based on the proprietary rights of other parties, we could face adverse consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants,
including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. We cannot assure that any of our current or future
product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by one of our current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods
for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent
applications which may later result in issued patents that our product candidates or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. Parties making claims against us for infringement or
misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these
claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion of our valuable management and employee resources from our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our
intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability.
Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against certain intellectual
property infringement claims brought by third parties. Any claims of patent infringement asserted by third parties would be time-consuming and could: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">result in costly litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">divert the time and attention of our technical personnel and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cause development delays; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevent us from commercializing our product candidates until the asserted patent expires or is held finally
invalid or not infringed in a court of law; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be
possible on a cost-effective basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which
may include treble damages if we are found to have been willfully infringing such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to pay the attorney&#146;s fees and costs of litigation to the party whose intellectual property
rights we may be found to be infringing; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable
terms, or at all. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are sued for patent infringement, we would need to demonstrate that our products or methods
either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do either. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of
clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#146;s time and attention in pursuing these
proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the
validity of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain <FONT
STYLE="white-space:nowrap">non-infringing</FONT> technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our
product candidates to market and be precluded from manufacturing or selling our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that others have
not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">some patent applications in the United States may be maintained in secrecy until the patents are issued;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications in the United States and elsewhere can be pending for many years before issuance, or
unintentionally abandoned patents or applications can be revived; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pending patent applications that have been published can, subject to certain limitations, be later amended in a
manner that could cover our technologies, our product candidates or the use of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification of third-party patent rights that may be relevant to our technology is difficult because patent
searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications in the United States are typically not published until 18 months after the priority date; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publications in the scientific literature often lag behind actual discoveries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the
patent&#146;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to
market our products. Further, we may incorrectly determine that our technologies, products, or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#146;s pending patent application will issue
with claims of relevant scope. Our determination of the expiration date of any patent in the United States or internationally that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours,
and others may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offer for sale or import our product candidates and future approved products or impair our competitive position. Numerous third-party U.S. and foreign issued patents and pending patent
applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or
manufacture of our product candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent
application on inventions similar to ours, we may have to participate in an interference proceeding declared by the PTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible
that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions.
Other countries have similar laws that permit secrecy of patent applications, and may be entitled to priority over our applications in such jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we were to prevail, any litigation or administrative proceeding could be costly and time-consuming and would divert the attention of
our management and key personnel from our business operations. Furthermore, as a result of a patent infringement suit brought against us or our strategic partners or licensees, we or our strategic partners or licensees may be forced to stop or delay
developing, manufacturing or selling technologies, product candidates or potential products that are claimed to infringe a third party&#146;s intellectual property unless that party grants us or our strategic partners&#146; or licensees&#146; rights
to use its intellectual property. Ultimately, we may be unable to develop some of our product candidates or may have to discontinue development of a product candidate or cease some of our business operations as a result of patent infringement
claims, which could severely harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or
enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may
infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of
our management and key personnel. For example, on June&nbsp;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp. and Apotex, Inc. (together, &#147;Apotex&#148;) in the U.S. District Court for the Southern District
of Florida alleging infringement of certain Orange Book patents covering ZTlido. See the section of this prospectus titled &#147;<I>Business &#151; Legal Proceedings</I>&#148; for additional information regarding such proceedings. Any claims we
assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent
infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a
risk that, even if the validity of such patents is upheld, the court will construe the patent&#146;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent
claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude
third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our business, financial condition and results of operations. Similarly, if we assert trademark infringement claims, a court may
determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of
such trademarks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against
further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims,
which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we
receive as a result of the proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third party
is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high
or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other
<FONT STYLE="white-space:nowrap">non-litigious</FONT> action or solution. Any of the foregoing may have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our intellectual property rights are invalidated or circumvented, our business, financial condition and results of operations will be adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our long-term success depends on our ability to continually discover, develop and commercialize innovative new
pharmaceutical products. Without strong intellectual property protection, we would be unable to generate the returns necessary to support the enormous investments in research and development and capital as well as other expenditures required to
bring new product candidates to the market and for commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellectual property protection varies throughout the world and is
subject to change over time. In the United States, for small molecule drug products, such as ZTlido and GLOPERBA, the Hatch-Waxman Act provides generic companies powerful incentives to seek to invalidate our pharmaceutical patents. As a result, we
expect that our U.S. patents on major pharmaceutical products will be routinely challenged, and there can be no assurance that our patents will be upheld. Defense of these claims, regardless of their merit, would involve substantial litigation
expense and would be a distraction to management and other employees. We face generic manufacturer challenges to our patents outside the United States as well. In addition, competitors or other third parties may claim that our activities infringe
patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay damages for past infringement or royalties on future
sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition and our business,
financial condition and results of operations may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have registered trademarks with the PTO for the mark
&#147;ZTlido,&#148; &#147;SCILEX&#148; and &#147;RESPONSIBLE BY DESIGN,&#148; and we have filed trademark applications for the marks &#147;SEMNUR PHARMACEUTICALS&#148; and &#147;SEMDEXA&#148; in the United States. We also have trademark
registrations for ZTlido in the UK and Greece, we have a pending trademark application for ZTlido in China and we are appealing a decision refusing to register a trademark application for ZTlido in China. In China, we detected a third-party
trademark registration for ZTlido and filed an invalidation proceeding &#151; Invalidation of TM Registration No.&nbsp;36299669 &#147;ZTlido&#148; in Class&nbsp;5 in the name of
<FONT STYLE="font-family:pmingliu">&#31206;&#30343;&#23798;&#24646;&#39423;&#21830;&#36031;&#26377;&#38480;&#20844;&#21496;</FONT><FONT STYLE="font-family:Times New Roman">(Qinhuangdao Hengjun Trading Co., Ltd.) (the &#147;China ZTlido Trademark
Invalidation Proceeding&#148;). The China ZTlido Trademark Invalidation Proceeding is pending. Our trademarks or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared generic or determined to be infringing on other
marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In
addition, there could be potential trade name or trademark infringement, dilution or tarnishment claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade
names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely
affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual
property, particularly patents. Obtaining and enforcing patents in the biotechnology and pharmaceutical industries involve both technological and legal complexity. Therefore, obtaining and enforcing biotechnology and pharmaceutical patents is
costly, time-consuming and inherently uncertain. In addition, the America Invents Act (the &#147;AIA&#148;), which was passed in September 2011, resulted in significant changes to the U.S. patent system. An important change introduced by the AIA is
that, as of March&nbsp;16, 2013, the United States transitioned from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> to a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the
same invention. Under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, assuming the other requirements for patentability are met, the first inventor to file a patent application
generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the PTO after that date but before us could therefore be awarded a patent
covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and diligent in filing patent
applications, but circumstances could prevent us from promptly filing patent applications on our inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other
changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the PTO. This applies to all of our U.S. patents, even those
issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in PTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a
PTO proceeding sufficient for the PTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, a third party may attempt to use the PTO procedures to invalidate our patent claims that would not have been invalidated if first
challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs
surrounding the prosecution of our or our licensors&#146; patent applications and the enforcement or defense of our or our licensors&#146; issued patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may become involved in opposition, interference, derivation, <I>inter partes </I>review or other proceedings challenging our or our
licensors&#146; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
rights, allow third parties to commercialize ZTlido, GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent
protection available in certain circumstances or weakening the rights of patent owners in certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in
the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the PTO, the laws and regulations governing patents could change in
unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, the Biden administration recently indicated its support for a proposal at the World
Trade Organization to waive patent rights with respect to <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines. Any waiver of our patent or other intellectual property protection by the U.S. and other foreign governments could have a material
adverse effect on our competitive position, business, financial condition and results of operations. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but, the complexity
and uncertainty of European patent laws has also increased in recent years. For example, in Europe, a new unitary patent system takes effect June&nbsp;1, 2023, which will significantly impact European patents, including those granted before the
introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (&#147;UPC&#148;).
As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining
as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single <FONT STYLE="white-space:nowrap">UPC-based</FONT> revocation challenge that, if successful, could invalidate
the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. Complying with these laws and regulations could limit our ability to obtain new patents in the future that
may be important for our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to
maintain patent applications and issued patents. For example, periodic maintenance fees on any issued patent are due to be paid to the PTO and other foreign patent agencies in several stages over the lifetime of the patent. The PTO and various
foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by
payment of a late fee or by other means in accordance with the applicable rules, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely
file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees, and failure to
properly legalize and submit formal documents. If we or any of our licensors fail to maintain the patents or patent applications covering ZTlido, GLOPERBA and our product candidates, our competitors may be able to enter the market, which would have
an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Confidentiality agreements with employees may not adequately
prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To help protect our proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> and our inventions for which patents may be unobtainable or
difficult to obtain, or prior to seeking patent protection, we rely on trade secret protection and confidentiality agreements. To this end, we require all our employees to enter into agreements that prohibit the disclosure of confidential
information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements typically limit the rights
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the third parties to use or disclose our confidential information. We also typically obtain agreements from these parties that provide that inventions conceived by the party in the course of
rendering services to us will be our exclusive property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, current or former employees may unintentionally or willfully disclose
our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information
increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our competitive position is based, in
part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our
business, financial condition and results of operations. Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> is expensive, time-consuming and
unpredictable, and the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our trade
secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or other proprietary information is disclosed, the value of our trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and other proprietary rights would be significantly impaired
and our business and competitive position would suffer. Moreover, our third-party licensing partners may retain rights in some of our proprietary or joint trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> patented inventions or other
proprietary information, including rights to sublicense and rights of publication, which may adversely impact our ability to obtain patents and protect trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or other proprietary information.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their
current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our
employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors, as well as our academic partners. Although we try
to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that these individuals or we have used or
disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer. We may also be subject to claims that patents and applications that we may file to protect
inventions of our employees or consultants are rightfully owned by their former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights or personnel. An inability to incorporate such technologies or features would have a material adverse effect on our business, financial condition and results of operations and may prevent us
from successfully commercializing ZTlido, GLOPERBA and our product candidates, if approved. Moreover, any such litigation or the threat of such litigation may adversely affect our ability to hire employees or contract with independent contractors. A
loss of key personnel or their work product could hamper or prevent our ability to commercialize ZTlido, GLOPERBA and our product candidates, if approved. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who
may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops
intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached,
and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, individuals executing agreements with us may have
preexisting or competing obligations to a third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our position as a relatively small company may cause us to be at a significant disadvantage in
defending our intellectual property rights and in defending against infringement claims by third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation relating to
the ownership and use of intellectual property is expensive, and our position as a relatively small company in an industry dominated by very large companies may cause us to be at a significant disadvantage in defending our intellectual property
rights and in defending against claims that ZTlido, GLOPERBA or any of our product candidates infringes or misappropriates third-party intellectual property rights. However, we may seek to use various post-grant administrative proceedings, including
new procedures created under the AIA, to invalidate potentially overly-broad third-party rights. Even if we can defend our position, the cost of doing so may adversely affect our ability to grow, generate revenue or become profitable. In the course
of the ongoing litigation or any future additional litigation to which we may be subject, we may not be able to protect our intellectual property at a reasonable cost, or at all. The outcome of litigation is always uncertain, and in some cases could
include judgments against us that require us to pay damages, enjoin us from certain activities or otherwise affect our legal, contractual or intellectual property rights, which could have a significant adverse effect on our business, financial
condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement may prevent or delay our drug discovery and
development efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation involving patent and other intellectual property rights in the
biotechnology and pharmaceutical industries, including PTO administrative proceedings, such as <I>inter partes</I> reviews, and reexamination proceedings before the PTO or oppositions and revocations and other comparable proceedings in foreign
jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand
and more patents are issued, the risk increases that ZTlido, GLOPERBA or our product candidates may give rise to claims of infringement of the patent rights of others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite safe harbor provisions, third parties may assert that we are employing their proprietary technology without authorization. There may
be third-party patents, of which we are currently unaware, with claims to materials, formulations, methods of doing research, methods of manufacture or methods for treatment related to the use or manufacture of ZTlido, GLOPERBA or our product
candidates. Because patent applications can take many years to issue, there may be currently pending unpublished patent applications which may later result in issued patents that ZTlido, GLOPERBA or our product candidates may infringe. In addition,
third parties may obtain patents in the future and claim that the use of our technologies infringes these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of ZTlido, GLOPERBA or
any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license
under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly,
if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent
may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license, limit our uses, or until such patent expires or is finally determined to be held invalid or unenforceable. In either case,
such a license may not be available on commercially reasonable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive
or other equitable relief, which could effectively block our ability to further commercialize ZTlido and GLOPERBA, or develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve
substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, cease marketing ZTlido or GLOPERBA, or developing our product candidates, limit our uses, pay
royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on
commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of ZTlido, GLOPERBA or our product candidates, if approved. We may
fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further commercialize ZTlido or GLOPERBA, or develop and commercialize one or more of our product candidates, which
could harm our business, financial condition and results of operations significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we have wrongfully hired an
employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist
us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies
including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their
former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could
adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements for patentability and the patent enforcement differ in many countries. Filing, prosecuting and defending patents on ZTlido and
all of our product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.
Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other
jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but
enforcement in some countries is not as strong as that in the United States. These products may compete with ZTlido and our product candidates, if approved, in jurisdictions where we do not have any issued patents and our patent claims or other
intellectual property rights may not be effective or sufficient to prevent them from so competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ongoing conflict in Ukraine and
related sanctions could significantly devalue our Ukrainian and Russian patent applications. Recent Russian decrees may significantly limit our ability to enforce Russian patents. We cannot predict when or how this situation will change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign
jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals and methods of
treatment of the human body, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign
jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and
could provoke third </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many countries have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant
licenses to third parties. Furthermore, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to
grant a license to a third party, which could materially diminish the value of those patents and limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to
obtain a significant commercial advantage from the intellectual property that we develop or license, which could adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or
obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, and inventions agreements with
employees, consultants and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and
technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may not provide an
adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, in 2010, the FDA, as part of its Transparency Initiative,
recommended steps that the FDA could take to increase transparency, including with respect to making additional information publicly available on a routine basis, which may include information that we may consider to be trade secrets or other
proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our
proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of
misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a
competitor, and any recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect
our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Competitors and other third parties could attempt to replicate some or
all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual
property rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and
time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. In addition, some courts inside and outside the United
States are less willing or unwilling to protect trade secrets. Moreover, trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in
the art from company to company or academic to industry scientific positions. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technology or information to compete with us, which could harm our competitive position. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this
information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other
confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance
on third parties may require us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to help manufacture and supply our products and product candidates, and we expect to collaborate with third
parties on the continuing development of future product candidates, we must, at times, share trade secrets with them. We also expect to conduct research and development programs that may require us to share trade secrets under the terms of our
partnerships or agreements with CROs. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use restrictions and obligations, including, material transfer agreements, consulting agreements,
confidentiality agreements or other similar agreements with our advisors, contractors, service providers and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose
our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets
become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our
<FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business,
financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, third-party
contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade
secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#146;s discovery of our trade secrets would impair our competitive
position and have an adverse impact on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights and regulatory
exclusivity rights do not necessarily address all potential threats to our competitive advantage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection
for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we do not adequately protect our intellectual property
and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and
results of operations. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Others may be able to make products that are similar to ZTlido, GLOPERBA or our product candidates but that are
not covered by the claims of the patents that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We or our licensors or strategic partners might not have been the first to make the inventions covered by the
issued patent or pending patent application that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We or our licensors or strategic partners might not have been the first to file patent applications covering
certain of our inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our pending patent applications may not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may
be held invalid or unenforceable, as a result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not develop additional proprietary technologies that are patentable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future,
for example with respect to proper priority claims, inventorship, claim scope or requests for patent term adjustments. If we or our partners, collaborators, licensees or licensors, whether current or future, fail to establish, maintain or protect
such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of
any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such
applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and results of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual
questions, and has been and will continue to be the subject of litigation and new legislation. Publications in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are
typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our own patents or pending patent applications, or that we were
the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent
applications may not result in patents being issued that protect ZTlido, GLOPERBA and our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our
patents or narrow the scope of our patent protection. If these changes were to occur, they could have a material adverse effect on our ability to generate revenue. For example, the complexity and uncertainty of European patent laws have also
increased in recent years. In Europe, a new unitary patent system takes effect June&nbsp;1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system,
European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty
of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC
will be potentially vulnerable to a single <FONT STYLE="white-space:nowrap">UPC-based</FONT> revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the
long-term effects of any potential changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we may be subject to a third-party
<FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the PTO or become involved in opposition, derivation, reexamination, <I>inter partes </I>review, post-grant review or interference
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and
litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize ZTlido,
GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of
protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and potentially licensed
patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could
limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of ZTlido, GLOPERBA or our product candidates. Generally, patents are granted a term of 20
years from the earliest claimed <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. In certain instances, patent term can be adjusted and increased to recapture a portion of delay incurred by the PTO in examining the patent
application. The scope of patent protection may also be limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the
development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient
rights to exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_18"></A>Risks Related to Government Regulations
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain
regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain marketing approval from the FDA for a product candidate is unpredictable but typically takes many years following
the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities, and its outcome is inherently uncertain. In addition, approval policies, regulations, or the type and amount
of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. For example, we believe that the data from our Phase 3 CLEAR trial will be sufficient to
support a 505(b)(2) NDA submission for SEMDEXA. However, the FDA may disagree and may require us to conduct additional clinical studies before we are able to submit the NDA, even though we believe the data from the CLEAR trial are adequate. Our
future success depends on our ability to develop, receive regulatory approval for, and introduce new products or product enhancements that will be accepted by the market in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA can delay, limit or deny approval of a product candidate for many reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may disagree with the design or implementation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to such authorities&#146; satisfaction that a product candidate is safe and
effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or ambiguous results from our clinical trials may not meet the level of statistical significance
required for approval by the FDA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may disagree with our interpretation of data from preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may not agree that the data collected from clinical trials of our product candidates are acceptable or
sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States, and such authorities may impose requirements for additional preclinical studies or clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may disagree regarding the formulation, labeling and/or the specifications of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may decline to approve the manufacturing processes or facilities of third-party manufacturers
with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data
insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete
the FDA regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates,
which would significantly harm our business, financial condition and results of operations. In addition, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the
price we intend to charge for our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or
desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than an NDA submitted for ZTlido in the United States, which was approved by the FDA in February 2018, we have not previously submitted
an NDA to the FDA for any product candidate, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even
if our clinical trials are successful. If we do not receive regulatory approvals for our product candidates, our business, financial condition and results of operations will be substantially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section&nbsp;505(b)(2) regulatory approval pathway,
or if the requirements for such product candidates under Section&nbsp;505(b)(2) are not as we expect, the approval pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly greater
complications and risks than anticipated, and in either case may not be successful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our product candidates SEMDEXA, <FONT
STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104,</FONT> we may seek FDA approval through the Section&nbsp;505(b)(2) regulatory pathway. The Hatch-Waxman Act added Section&nbsp;505(b)(2) to the Federal Food, Drug
and Cosmetic Act (the &#147;FDCA&#148;). Section&nbsp;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant
has not obtained a right of reference. Section&nbsp;505(b)(2) allows an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#146;s prior conclusions regarding the safety and effectiveness of approved compounds, which
could expedite the development program for our product candidates by potentially decreasing the amount of data that we would need to generate in order to obtain FDA approval. If the FDA does not agree that the Section&nbsp;505(b)(2) regulatory
pathway is acceptable as we anticipated, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if FDA accepts our plan to pursue the Section&nbsp;505(b)(2) regulatory pathway, we cannot assure that our product candidates will
receive the requisite approvals for commercialization. In addition, the pharmaceutical industry is highly competitive, and Section&nbsp;505(b)(2) NDAs are subject to special requirements designed to protect the patent and market exclusivity rights
of sponsors of previously approved drugs that are referenced in a Section&nbsp;505(b)(2) NDA. These requirements may give rise to patent litigation against us and mandatory delays in approval of our NDAs for up to 30 months or longer depending on
the outcome of any litigation. Further, a manufacturer of an approved product may file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. FDA imposes strict
requirements on such petitions in part to dissuade companies from improperly using these petitions to delay approval of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competing drug products. Nonetheless, if successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a
petition, the FDA may delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section&nbsp;505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product
development or earlier approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in
significant expense and limit our ability to commercialize such products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after a product is approved, we will remain subject
to ongoing FDA and other regulatory requirements governing the manufacturing, testing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, import, export, record-keeping and reporting of safety and other
post-market information. The holder of an approved NDA is obligated to monitor and report adverse events and, among other things, any failure of a distributed product to meet the specifications in the NDA. The holder of an approved NDA must also
submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review,
in addition to other potentially applicable federal and state laws. In addition, the FDA may impose significant restrictions on the approved indicated uses for which the product may be marketed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These requirements include submissions of safety and other post-marketing information and reports, registration and listing, as well as
continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. The future discovery of previously unknown problems with a product, including adverse events of unanticipated type, severity or frequency, or with our
third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investigation or additional study obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">communications to prescribers or patients about specific information or issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or
voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning or untitled letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or
suspension or revocation of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our product candidates and
generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. We may not be able to regain compliance, or we may only be able to regain compliance after a lengthy delay, significant
expense, lost revenues and damage to our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other regulatory authorities&#146; policies may change, and
additional laws or government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our ability to generate revenue and achieve or sustain profitability. Changes in law or
government regulations may also alter the competitive landscape, potentially to our disadvantage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain manufacturers in the market in
which we compete distribute certain products without completing the FDA approval process. For example, we believe certain lidocaine topical patches, plaster or poultice products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketed OTC and without FDA approval, require approval and compete inappropriately with ZTlido. In December 2018, we filed a citizen&#146;s petition asking the FDA to clarify its requirements
and take enforcement action against such products. The FDA has generally held the position that requests for enforcement action via citizen petition are not allowed, which may reduce the likelihood of the FDA taking action explicitly in response to
our December 2018 petition. Furthermore, we believe the labeling and marketing of certain OTC lidocaine patches products are false and deceptive, which could cause significant damages to our business and a diminution of goodwill in our intellectual
property. In addition, on March&nbsp;7, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#147;CARES Act&#148;) was signed into law, which included statutory provisions reforming FDA&#146;s mechanisms for regulating OTC drugs. Under
the CARES Act, the FDA considers a drug to be generally recognized as safe and effective (&#147;GRASE&#148;) if it meets certain requirements, including items such as the active ingredient, indication for use, dosage, route of administration, and
labeling set forth in the OTC monograph and related rulemakings. Historically, the FDA was required to establish, revise, and amend an OTC monograph by
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">notice-and-comment</FONT></FONT> rulemaking, which was lengthy and resource-intensive. The CARES Act replaces the rulemaking process with a final administrative order process.
Administrative orders may be initiated by the FDA or at the request of a drug manufacturer or any other person. After a period for public comment on the administrative order, the FDA is able to issue a final administrative order, rather than a
regulation, permitting the drug to be marketed over the counter. As this process is much more streamlined and less burdensome, this may benefit the manufacturers of lidocaine topical patches to obtain GRASE status from the FDA and thereby legally
market these products <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> and compete with ZTlido. The FDA recently responded to our citizen&#146;s petition by denying it in light of the new
administrative order process under the CARES Act for considering OTC drug products. In February 2021, we filed a complaint against certain manufacturers of OTC lidocaine patches to seek an award of damages and the entry of injective relief enjoining
further dissemination of such false and deceptive advertisement. That litigation is currently scheduled for trial in December 2023. On June&nbsp;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc.
(together, &#147;Apotex&#148;) in the U.S. District Court for the Southern District of Florida (the &#147;ZTlido Patent Litigation&#148;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#147;ZTlido Patents&#148;).
The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA, seeking approval to market a generic version of ZTlido prior to the expiration of the
ZTlido Patents and alleging that the ZTlido Patents are invalid, unenforceable and not infringed. We are seeking, among other relief, an order that the effective date of an FDA approval of Apotex&#146;s ANDA be no earlier than the expiration of the
asserted patents listed in the Orange Book, the latest of which expires on May&nbsp;10, 2031. Apotex is subject to a 30-month stay preventing them from selling a generic version. The stay should expire no earlier than November&nbsp;11, 2024. Trial
in this patent litigation has not yet been scheduled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also cannot predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, recent U.S.
administrations have taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine regulatory and
oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be
implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#146;s ability to engage in oversight and implementation activities in the normal
course, our business, financial condition and results of operations may be negatively affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A fast track product designation, breakthrough
therapy designation or other designation to facilitate product candidate development may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive
marketing approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product sponsor may apply for fast track designation from the FDA if a product is intended for the treatment
of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
address an unmet medical need for this condition. The FDA has broad discretion whether or not to grant this designation. We have received fast track designation for SEMDEXA for the treatment of
sciatica and <FONT STYLE="white-space:nowrap">SP-103</FONT> for the treatment of acute LBP. Even though SEMDEXA and <FONT STYLE="white-space:nowrap">SP-103</FONT> have received fast track designation, we may not experience a faster process, review
or approval compared to conventional FDA procedures. A fast track designation does not expedite clinical trials, or mean that regulatory requirements are less stringent or provide assurance of ultimate marketing approval by the FDA. Instead, fast
track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review of individual sections of an NDA submitted to the FDA as they
become finalized. The FDA may rescind the fast track designation if it believes that the designation is no longer supported by data from our clinical development program. The FDA may also withdraw any fast track designation at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied for breakthrough therapy designation and expect to seek priority review for SEMDEXA for the treatment of sciatica. A
breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough
therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in potentially less efficacious control
regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a
product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to provide such designation. In any event, the receipt of a breakthrough therapy designation may not result in a faster
development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if SEMDEXA qualifies as a breakthrough therapy for sciatica,
the FDA may later decide that SEMDEXA no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If approved, our products candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (the &#147;BPCIA&#148;), which
created an abbreviated approval pathway under section 351(k) of the Public Health Service Act (the &#147;PHSA&#148;) for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT>
reference biological product. Under the BPCIA, a section 351(k) application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In
addition, the approval of a biosimilar or interchangeable product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period
of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full Biologics License Application (&#147;BLA&#148;) for the competing product submitted under section 351(a) of the PHSA containing
the competing sponsor&#146;s own <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#146;s biological product. The
law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether approval of a biological product qualifies for reference product exclusivity turns on whether FDA consider the approval a &#147;first
licensure&#148;. Not every licensure of a biological product is considered a &#147;first licensure&#148; that gives rise to its own exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also
been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our product candidates in a way that is similar to traditional generic substitution for <FONT
STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, our product candidates may
become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in funding for the FDA could
hinder its ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business, financial condition and
results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors,
including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a
result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other regulatory authorities may also slow the time necessary for new drugs to be reviewed and/or approved by
necessary government agencies, which would adversely affect our business, financial condition and results of operations. For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has
shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely
review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020, the FDA announced its
intention to postpone most inspections of foreign manufacturing facilities, and on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&nbsp;10, 2020, the FDA
announced its intention to resume certain <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. Increased cases associated with a <FONT
STYLE="white-space:nowrap">COVID-19</FONT> variant led the FDA to again pause inspections, although the FDA announced in February 2022 that it would resume routine domestic surveillance inspections and that it would proceed with certain foreign
surveillance inspections where country conditions permit. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a
prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the
ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties,
private litigation or adverse publicity and could negatively affect our operating results and business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our collaborators
are subject to federal, state and foreign data protection laws and regulations. In the United States, such laws may include, but are not limited to, U.S. state personal data breach notification laws, state health information privacy laws, and
federal and state consumer protection laws, including Section&nbsp;5 of the FTC Act, each of which govern the collection, use, disclosure and protection of health-related and other personal information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are not subject to HIPAA, as we are neither a Covered Entity nor Business Associate (as such terms are defined in HIPAA), we may
have access to very sensitive data regarding patients who participate in, or whose tissue samples or other biospecimens are used in, our clinical trials. The maintenance of this data imposes upon us administrative and financial burdens and
litigation risks. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data that are subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
HIPAA and other privacy, data security and consumer protection laws. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually
identifiable health information maintained by a Covered Entity in a manner that is not authorized by HIPAA, and we may be subject to other civil and/or criminal penalties if we obtain, use, or disclose information in a manner not permitted by other
privacy and data security and consumer protection laws. Our ability to use or disclose information may be limited by the scope of an authorization signed by clinical trial subjects or the terms of the contract that we enter into with providers or
other data sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, U.S. states are constantly adopting new laws or amending existing laws relating to data privacy and
security and consumer protection, which requires our frequent attention. For example, the CCPA creates new individual privacy rights for California consumers and places increased privacy and security obligations on entities handling personal data of
consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#146; data collection, use and sharing practices, provide such consumers new ways to
<FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales or transfers of personal information, and provide consumers with a private right of action in connection with certain types of security incidents. The CCPA has been amended by the
CPRA, which largely took effect on January&nbsp;1, 2023. The CPRA also created a new state agency (the CPPA) vested with authority to implement and enforce the CCPA. New implementing regulations are expected to be introduced by the CPPA. Virginia
also recently enacted a similar state privacy law, the Virginia Consumer Data Privacy Act (the &#147;VDCPA&#148;), and Colorado, Connecticut and Utah also have similar laws in place. New legislation enacted in various other states will continue to
shape the data privacy environment nationally. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international, or other
state laws, and such laws may differ from each other, which may complicate compliance efforts. The effects on our business of the CCPA, VDCPA, and other similar state privacy laws and general consumer protection authorities are potentially
significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to so comply. Privacy laws and regulations are constantly evolving and there are a number of legislative
proposals at both the state and federal levels that could impose new obligations or limitations in areas affecting our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FTC
also sets expectations for failing to take appropriate steps to keep consumers&#146; personal information secure, or failing to provide a level of security commensurate to promises made to individual about the security of their personal information
(such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section&nbsp;5(a) of the FTC Act. The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity
and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that
merits stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#146; personal information. Any failure to honor promises, such
as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to
enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">International data protection laws, including the GDPR, may also apply to health-related and other personal information obtained outside of
the United States. The GDPR imposes several data protection requirements in the EU, as well as fines for violations that can reach up to the greater of &#128;20&nbsp;million or 4% of annual global revenue. The regulation imposes numerous
requirements for the collection, use, storage and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used,
the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information,
including the right to access, correct and delete their data. In addition, the GDPR includes restrictions on cross-border data transfers. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional
mechanisms to ensure compliance with the GDPR, including as implemented by individual countries in the EEA. Further, the UK&#146;s departure from the EU (Brexit) has led and could also lead to further legislative and regulatory changes and may
increase our compliance costs. Presently, the processing of personal data of UK data subjects is governed by the UK GDPR, which authorizes similar fines to the EEA GDPR and potentially divergent enforcement actions for certain violations. On
June&nbsp;28, 2021, the European Commission adopted an adequacy decision for the UK, allowing for the relatively free exchange of personal information between the EU and the UK, however the European Commission may suspend such adequacy decision if
it considers that the UK no longer provides for an adequate level of data protection. Other jurisdictions outside the EEA are similarly introducing or enhancing privacy and data security laws, rules, and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our
contracts, increase our compliance costs, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We cannot guarantee that we are or will be in compliance with all applicable
international regulations as they are enforced now or as they evolve. Claims that we have violated individual privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could
be expensive and time-consuming to defend against and could result in adverse publicity that could harm our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business involves the use of hazardous materials and we and third-parties with whom we contract must comply with environmental laws and regulations,
which can be expensive and restrict how we do business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities involve the controlled storage,
use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use,
manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our manufacturers&#146; facilities pending their use and disposal. We cannot
eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly
<FONT STYLE="white-space:nowrap">clean-up</FONT> and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures
utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. We do not carry
specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.
Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources and state or federal or other applicable authorities may curtail our use of certain materials
and/or interrupt our business operations. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research,
development or production efforts. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities,
including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements, which could have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, illegal activity or other misconduct by our employees, independent contractors, consultants, commercial
partners and vendors. Misconduct by employees could include intentional, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reckless and/or negligent conduct that fails to comply with the laws and regulations of the FDA, EU Member States, EMA and other similar foreign regulatory bodies, provide true, complete and
accurate information to the FDA, EMA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, comply with laws and
regulations, including, but not limited to the FCPA and internal policies restricting payments to government agencies and representatives, report financial information or data accurately or disclose unauthorized activities to us. In particular,
sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a
wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by employees, independent contractors, consultants, commercial partners and vendors could also
involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees,
independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or FDA debarment or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business, financial condition and results of operations, including the imposition of significant fines or other sanctions and serious harm to our reputation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency and disclosure, or
sunshine, laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future arrangements with healthcare professionals, clinical sites and clinical investigators, consultants, customers, patient
organizations and third-party payors may subject us to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our
current activities with clinical study investigators and research subjects, as well as our current and future sales, marketing, patient assistance and education programs. In addition, we may be subject to physician payment transparency laws and
patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. The laws that may affect our ability to operate include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the furnishing, recommending, or arranging for an item or service for which payment may be made
under a federal healthcare program, such as the Medicare and Medicaid programs &#151; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or special intent to violate the law in order to have committed a
violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws, including the False Claims Act, which prohibit, among other things,
individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used a false statement material to a false or fraudulent
claim, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. The False Claims Act has been used to assert liability on the basis of kickbacks and other improper referrals,
improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, and improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses (i.e., uses not expressly approved by the FDA in a drug&#146;s label);
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, which imposes criminal liability for, among other things, knowingly and willfully executing, or attempting
to execute, a scheme to defraud any healthcare benefit program, including private third party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment
for health care benefits, items or services &#151; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA and its implementing regulations, which imposes certain requirements relating to the privacy, security and
transmission of individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and
medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to
physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals and, beginning in 2022, certain other healthcare professionals, as well as ownership and investment interests held by the physicians
described above and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical
devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal government price reporting laws, which require drug manufacturers to calculate and report complex pricing
metrics to government agencies, including CMS and Department of Veterans Affairs (&#147;VA&#148;), where such reported prices may be used in the calculation of reimbursement and/or discounts on marketed products paid by government healthcare
programs. Participation in these programs and compliance with the applicable requirements may result in potentially significant discounts on products subject to reimbursement under federal healthcare programs and increased infrastructure costs, and
may potentially limit a drug manufacturer&#146;s ability to offer certain marketplace discounts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Prescription Drug Marketing Act, which restricts the manner in which manufacturers may disseminate
complimentary drug samples to healthcare practitioners, requires physical and accounting controls, and establishes penalties for improper sample distribution; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">state law equivalents of each of the above federal laws, such as licensing, anti-kickback, false claims, consumer
protection and unfair competition laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s
voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug
manufacturers to file reports with states regarding pricing information and marketing expenditures, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and
entities, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any future research and development of our product candidates outside the United States, and any future
sales of our product or product candidates once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of
our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or
the courts, and their provisions are open to a variety of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interpretations. Efforts to ensure that our business practices and arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any
action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we
may be subject to, without limitation, civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries
or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> imprisonment, contractual damages, reputational harm, diminished profits and future earnings and
curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition and results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is
found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business,
financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the
promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to have improperly promoted <FONT
STYLE="white-space:nowrap">off-label</FONT> uses of ZTlido, GLOPERBA or our product candidates, if approved, or if we are found to have improperly engaged in <FONT STYLE="white-space:nowrap">pre-approval</FONT> promotion prior to the approval of
such product candidates, we may become subject to significant liability. Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription
products, such as ZTlido, GLOPERBA and our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s approved
labeling. If we receive marketing approval for our product candidates for our proposed indications, physicians may nevertheless use our product for their patients in a manner that is inconsistent with the approved label, if the physicians believe in
their professional medical judgment it could be used in such manner. However, if we are found to have promoted our product for any <FONT STYLE="white-space:nowrap">off-label</FONT> uses, the federal government could levy civil, criminal and/or
administrative penalties, and seek fines against us. The FDA, Department of Justice or other regulatory authorities could also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us
under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of ZTlido, GLOPERBA or our product candidates, if approved, we could become subject to significant liability, which would
materially adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare reform measures could hinder or prevent our
product candidates&#146; commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and we expect there will continue to be, a number of legislative and
regulatory changes to health care systems in the United States and abroad that could impact our ability to sell our products profitably. The United States government and other governments have shown significant interest in pursuing healthcare
reform. For example, in 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. Healthcare reform measures like the ACA may adversely impact the pricing of
healthcare products and services in the United States or internationally and the amount of reimbursement available from governmental agencies or other third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been ongoing efforts to modify the ACA and its implementing regulations. For example, tax legislation enacted
at the end of 2017 includes provisions that, effective January&nbsp;1, 2019, eliminated the tax penalty for individuals who do not maintain sufficient health insurance coverage, or the <FONT STYLE="white-space:nowrap">so-called</FONT>
&#147;individual mandate.&#148; It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration or efforts, if any, to modify the ACA or its implementing regulations,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or portions thereof, will impact our business. Litigation and legislation over the ACA and other healthcare reform measures are likely to continue, with unpredictable and uncertain results.
Further, additional legislative changes to and regulatory changes under or related to the ACA remain possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other
legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of, on average, 2%
per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020, through
May&nbsp;31, 2022, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary
suspension during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. The American Taxpayer Relief Act of 2012 further reduced
Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop
new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S.
Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the
relationship between pricing and manufacturer patient programs, as addressed further in the risk factor below titled &#147;<I>If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other
governmental pricing programs applicable to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business,
financial condition, results of operations and future prospects</I>.&#148; While any proposed measures may require authorization through additional legislation to become effective, Congress and the Biden administration have each indicated that it
will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal health
care programs and commercial payers will pay for healthcare products and services, which could result in reduced demand for ZTlido, GLOPERBA and our product candidates, if approved, or additional pricing pressures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage
importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition and results of operations. In addition, regional
healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has
been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These or other reforms could reduce the ultimate demand for ZTlido, GLOPERBA and our product
candidates, if approved, or put pressure on our product pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we or such third parties are not able to maintain regulatory compliance, ZTlido may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program
or other governmental pricing programs applicable to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our
business, financial condition, results of operations and future prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pricing and rebate calculations vary across products
and programs, are complex, and are often subject to interpretation by manufacturers, governmental or regulatory agencies and the courts. Such interpretation can change and evolve over time. In the case of Medicaid pricing data, if a manufacturer
becomes aware that its reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, the manufacturer is obligated to resubmit the corrected data for up to three years after those data originally were
due. Such restatements and recalculations increase costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and could result in an overage or underage in rebate liability for past quarters. Price recalculations
also may affect the ceiling price at which a manufacturer is required to offer its products under the 340B program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A failure to comply
with reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively affect financial results. CMS issued a final regulation, which became effective on April&nbsp;1, 2016, to implement the
changes under the ACA to the Medicaid Drug Rebate Program. The final regulation has increased and will continue to increase costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a
material adverse effect on the results of operations, particularly if CMS challenges the approach a manufacturer has taken in the implementation of the final regulation. Other regulations and coverage expansion by various governmental agencies
relating to the Medicaid Drug Rebate Program may have a similar impact. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers have obligations to report the average sales price
for certain of drugs to the Medicare program as a part of the agreement to participate in the Medicaid Drug Rebate program. For calendar quarters beginning January&nbsp;1, 2022, manufacturers are required to report the average sales price for
certain drugs under the Medicare program regardless of whether they participate in the Medicaid Drug Rebate program. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for products and the resulting
Medicare payment rate, and could negatively affect results of operations. Starting in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologics, or biosimilar biological products, reimbursed under Medicare Part B and
packaged in single-dose containers or <FONT STYLE="white-space:nowrap">single-use</FONT> packages, for units of discarded drug reimbursed by Medicare Part B in excess of 10% of total allowed charges under Medicare Part B for that drug. Manufacturers
that fail to pay refunds could be subject to civil monetary penalties of 125&nbsp;percent of the refund amount. Congress further could enact a Medicare Part B inflation rebate, under which manufacturers would owe additional rebates if the average
sales price of a drug were to increase faster than the pace of inflation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health Resources and Services Administration (&#147;HRSA&#148;)
issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January&nbsp;1,
2019. Implementation of this regulation has affected manufacturer obligations and potential liability under the 340B program. Manufacturers are also required to report the 340B ceiling prices for covered outpatient drugs to HRSA, which then
publishes them to 340B covered entities. Any charge by HRSA that a manufacturer has violated the requirements of the program or the regulation could negatively affect financial results. Moreover, under a final regulation effective January&nbsp;13,
2021, HRSA newly established an administrative dispute resolution (&#147;ADR&#148;) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against
diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that can be appealed to a federal court. An ADR proceeding could subject a manufacturer to onerous procedural
requirements and could result in additional liability. Further, any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the ACA or otherwise could affect our 340B ceiling price calculations
and negatively affect results of operations. The U.S. Court of Appeals for the Third Circuit (the &#147;Third Circuit&#148;) ruled in January that, under Section 340B, manufacturers are not required to provide the discounted drugs to an unlimited
number of contract </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pharmacies, but can impose limitations on the availability to the hospital&#146;s own pharmacy and one contract pharmacy. The Third Circuit also upheld the ADR rules. Two other cases are pending,
one in the U.S. Court of Appeals for the Seventh Circuit and one in the U.S. Court of Appeals for the District of Columbia Circuit. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Civil
monetary penalties can be applied if a manufacturer (i)&nbsp;is found to have knowingly submitted any false price or product information to the government, (ii)&nbsp;is found to have made a misrepresentation in the reporting of its average sales
price, (iii)&nbsp;fails to submit the required price data on a timely basis, or (iv)&nbsp;is found to have knowingly and intentionally charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate
the Medicaid Drug Rebate Agreement, or HRSA, or to terminate the 340B program participation agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for the manufacturer&#146;s covered outpatient drugs. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers are required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D
beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. Congress could enact legislation that sunsets this discount program and replaces it with a new manufacturer discount program. Under either program,
civil monetary penalties could be applied if a manufacturer fails to provide these discounts in the amount of 125&nbsp;percent of the discount that was due. Furthermore, the Inflation Reduction Act (&#147;IRA&#148;), PL 117-169, seeks to limit
manufacturers&#146; price increases for drugs reimbursed by Medicare to not more than the rate of inflation, at least where those increases would otherwise affect payments under Medicare. Under the provisions, beginning in October 2022, if a
manufacturer increases the price of a drug reimbursed under Medicare by more than the rate of inflation (as measured by the consumer price index), the manufacturer must pay rebates to the federal government equal to the amount by which the increase
exceeds the rate of inflation in the relevant period. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Congress could also enact additional changes that affect our overall rebate
liability and the information we report to the government as part of price reporting calculations. The IRA also requires the U.S. Department of Health and Human Services (&#147;HHS&#148;) to negotiate prices for a small number of single-source
brand-name drugs or biologics without generic or biosimilar competitors that are covered under Medicare Part D (starting in 2026) and Part B (starting in 2028). The number of drugs affected is limited to ten Part D drugs for 2026, another fifteen
Part D drugs for 2027, another fifteen Part D and Part B drugs for 2028, and another twenty Part D and Part B drugs for 2029 and later years. The drugs for which prices are negotiated will be selected from the set of fifty drugs having the highest
cost impact on Medicare. The relevant set of fifty have not yet been identified, and the drugs for which negotiations will occur in the future will be identified later by HHS. Drugs that are less than 9 years (for small-molecule drugs) or 13 years
(for biological products) from their FDA approval or licensure date are excluded from the negotiation process. Small biotech drugs, defined as those which account for 1% or less of Part D or Part B spending and account for 80% or more of spending
under each part on that manufacturer&#146;s drugs, are also excluded until 2029. CMS has issued initial guidance on the implementation of the provisions. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to applicable law, knowing provision of false information in connection with price reporting or contract-based requirements under the
VA Federal Supply Schedule and/or Tricare programs can subject a manufacturer to civil monetary penalties. These programs and contract-based obligations also contain extensive disclosure and certification requirements. If a manufacturer overcharges
the government in connection with its arrangements with Federal Supply Schedule or Tricare, the manufacturer may be required to refund the difference to the government. Failure to make necessary disclosures or to identify contract overcharges can
result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and/or response to a government investigation or enforcement action, would be expensive and time-consuming, and could
have a material adverse effect on our business, financial condition, results of operations and future prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to obtain prior FDA
authorization for any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any brand names we intend to use for our product candidates will require authorization from the FDA regardless of whether we have secured a
formal trademark registration from the PTO. The FDA typically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conducts a review of proposed product brand names, including an evaluation of potential for confusion with other product names. The FDA may also object to a product brand name if it believes the
name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the
benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not
infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner, or at all, which would limit our ability to successfully commercialize our
product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws,
customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business,
financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are subject to certain anti-corruption laws, including the FCPA, and
other anti-corruption laws that apply in countries where we conduct business, including performing clinical trials. The FCPA and other anti-corruption laws generally prohibit us and our employees and intermediaries from bribing, being bribed or
making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We, our commercial partners and our affiliates operate in a number of jurisdictions that pose a risk of
potential FCPA violations and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature,
scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including
the FCPA or other legal requirements, such as trade control laws. Any investigation of potential violations of the FCPA, other anti-corruption laws or trade control laws by U.S., European Union or other authorities could have an adverse impact on
our reputation, our business, financial condition and results of operations. Furthermore, should we be found not to be in compliance with the FCPA, other anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties,
disgorgement and other sanctions and remedial measures, as well as the accompanying legal expenses, any of which could have a material adverse effect on our reputation and liquidity, as well as on our business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to recently enacted state laws in California that require gender and diversity quotas for boards of directors of public
companies headquartered in California. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, California enacted Senator Bill 826 (&#147;SB 826&#148;), which
generally requires public companies with principal executive offices in California to have at least two female directors on its board of directors if the company has at least five directors, and at least three female directors on its board of
directors if the company has at least six directors. SB 826 has been challenged in legal proceedings and on May&nbsp;13, 2022, the Superior Court of California for the County of Los Angeles entered an order striking down SB 826, holding that the
statute violates the Equal Protection Clause of the California Constitution. The California Secretary of State has appealed the order and such appeal is currently pending. On September&nbsp;16, 2022, the appellate court ruled to temporarily stay
enforcement of the trial court&#146;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to SB 826, pending a further order of the appellate court. On December&nbsp;1, 2022,
the appellate court vacated the temporary stay order and on February&nbsp;3, 2023, a record on appeal was filed and such appeal is currently pending. To the extent that this ruling of the appellate court permits the Secretary of State of California
to collect and report diversity data, we may be required to comply with additional disclosure requirements. However, ultimate enforceability of SB 826 remains uncertain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on September&nbsp;30, 2020, California enacted Assembly Bill 979 (&#147;AB
979&#148;), which generally requires public companies with principal executive offices in California to include specified numbers of directors from &#147;underrepresented communities&#148;. A director from an &#147;underrepresented community&#148;
means a director who self-identifies as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, Alaska Native, gay, lesbian, bisexual or transgender. By December&nbsp;31, 2021, each public company with
principal executive offices in California was required to have at least one director from an underrepresented community. By December&nbsp;31, 2022, a public company with more than four but fewer than nine directors will be required to have a minimum
of two directors from underrepresented communities, and a public company with nine or more directors will need to have a minimum of three directors from underrepresented communities. On April&nbsp;1, 2022, the Superior Court of California for the
County of Los Angeles entered an order striking down AB 979, holding that the statute violates the Equal Protection Clause of the California Constitution. On June&nbsp;6, 2022, a notice of appeal was filed. On September&nbsp;16, 2022, the appellate
court ruled to temporarily stay enforcement of the trial court&#146;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to AB 979, pending a further order of the appellate
court. On December&nbsp;1, 2022, the appellate court vacated the temporary stay order and on February&nbsp;3, 2023, a record on appeal was filed and such appeal is currently pending. To the extent that this ruling of the appellate court permits the
Secretary of State of California to collect and report diversity data, we may be required to comply with additional disclosure requirements. Litigation regarding AB 979 will continue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure that we can recruit, attract and/or retain qualified members of our Board and meet gender and diversity quotas under Nasdaq
Listing Rules or any California law that may become applicable to the Company, which may expose us to financial penalties and adversely affect our reputation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_19"></A>Risks Related to our Relationship with Sorrento </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Sorrento. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Jaisim Shah, Dr.&nbsp;Henry Ji, Mr.&nbsp;Dorman Followwill, Ms.&nbsp;Laura&nbsp;J. Hamill,
<FONT STYLE="white-space:nowrap">Dr.&nbsp;Tien-Li</FONT> Lee, Mr.&nbsp;David Lemus and Mr. Tommy Thompson serve on our Board. Mr.&nbsp;Jaisim Shah and Dr.&nbsp;Henry Ji, who are our executive officers, are also members of the board of directors of
Sorrento (and in the case of Dr.&nbsp;Henry Ji, the positions of President, Chief Executive Officer and Chairman of the board of directors of Sorrento). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our Board has determined that Mr.&nbsp;Dorman Followwill, Ms.&nbsp;Laura&nbsp;J. Hamill,
<FONT STYLE="white-space:nowrap">Dr.&nbsp;Tien-Li</FONT> Lee, Mr. David Lemus and Mr. Tommy Thompson are &#147;independent directors&#148; within the meaning of applicable regulatory and stock exchange requirements in the United States, both
Mr.&nbsp;David Lemus and Mr.&nbsp;Dorman Followwill have served, and continue to serve, as directors of Sorrento (and in the case of Mr.&nbsp;Dorman Followwill, the Lead Independent Director of Sorrento) and Tommy Thompson has served, and continues
to serve, as special consultant to the Chief Executive Officer of Sorrento, Dr.&nbsp;Henry Ji. Further, <FONT STYLE="white-space:nowrap">Dr.&nbsp;Tien-Li</FONT> Lee is the founder, the Chief Executive Officer and a director of Aardvark, which has
been involved in an asset purchase transaction with Sorrento in connection with Sorrento&#146;s acquisition of Aardvark&#146;s delayed burst release low dose naltrexone formulation asset and intellectual property rights. As part of Sorrento&#146;s
investment in Aardvark relating to such asset purchase transaction, Sorrento paid cash for shares of Aardvark&#146;s Series B Preferred Stock, resulting in Sorrento holding approximately 8% of Aardvark&#146;s ownership interest as of
December&nbsp;31, 2021. Also as part of such investment, Dr.&nbsp;Henry Ji joined the board of directors of Aardvark in May 2021. Sorrento and Aardvark may enter into more commercial arrangements in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such directors and officers may own shares of Sorrento common stock, options to purchase shares of Sorrento common stock or other
Sorrento equity awards. These individuals&#146; holdings of Sorrento common stock, options to purchase shares of Sorrento common stock or other equity awards of Sorrento may be significant for some of these persons compared to these persons&#146;
total assets. Their position at Sorrento and the ownership of any Sorrento equity or equity awards creates, or may create the appearance of, conflicts of interest </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when these directors and officers are faced with decisions that could have different implications for Sorrento than the decisions have for us. For example, potential conflicts of interest could
arise in connection with the resolution of any dispute that may arise between Sorrento and us regarding the terms of the agreements governing the transition services and the relationship thereafter between the companies. Potential conflicts of
interest may also arise if we enter into commercial arrangements with Sorrento in the future. As a result of these actual or apparent conflicts, we may be precluded from pursuing certain growth initiatives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sorrento currently performs or supports many of our important corporate functions. Our financial statements may not necessarily be indicative of the
conditions that would have existed or our results of operations if we had been operated as an unaffiliated company of Sorrento, and we will incur incremental costs as a stand-alone public company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the process of replicating and replacing certain functions, systems and infrastructure to which we no longer have the same access
after the Business Combination. We are also making investments and hiring additional employees to operate without the same access to Sorrento&#146;s existing operational and administrative infrastructure. These initiatives are costly to implement.
Due to the scope and complexity of the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimate, and the timing of the incurrence of these costs is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento currently performs or supports many important corporate functions for our company. Our financial statements reflect charges for these
services on an allocation basis. As a result, our consolidated financial statements may not be reflective of conditions that would have existed or what our results of operations would have been had we been a stand-alone public company and no longer
a majority-owned subsidiary of Sorrento. Pursuant to agreements we expect to enter into with Sorrento, we expect that Sorrento will continue to provide us with some of the services related to these functions on a transitional basis in exchange for
agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Sorrento. We are also incurring additional costs as a stand-alone public company. As a stand-alone public company, our total
costs related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and
an enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to
replace these services or enter into appropriate third-party agreements on terms and conditions, including costs, comparable to those that we will receive from Sorrento under our agreements with Sorrento. Additionally, after the agreements
terminate, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits from Sorrento. When we begin to operate these functions separately, if we do not have our own
adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. In addition, we have historically
received informal support from Sorrento, which may not be addressed in our agreements with Sorrento. The level of this informal support will diminish or cease following the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are controlled by Sorrento, whose interests may differ from those of our public shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, Sorrento controls approximately 52.1% of our voting power (including shares of our Series A Preferred Stock
held by Sorrento but excluding shares issuable upon exercise of warrants to purchase shares of our Common Stock), which means that, based on its percentage of voting power, Sorrento controls the vote of all matters submitted to a vote of our
stockholders. This control will enable Sorrento to control the election of the members of our Board and all other corporate decisions. In particular, for so long as Sorrento continues to own a majority of the outstanding shares of our capital stock
entitled to vote generally in the election of directors, Sorrento will be able to cause or prevent a change of control of the Company or a change in the composition of our Board and could preclude any unsolicited acquisition of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended and Restated Registration Rights Agreement entered into in
connection with the Business Combination (the &#147;Registration Rights Agreement&#148;) and our Certificate of Incorporation, Sorrento has certain rights, and the ability to take certain actions, that are not otherwise available to all of our
stockholders. For example, the Registration Rights Agreement provides Sorrento the right, subject to certain conditions, to demand that we file a registration statement or request that their shares of our Common Stock be covered by a registration
statement that we are otherwise filing. See the section of this prospectus titled &#147;<I>Description of Our Securities&#151;Registration Rights</I>&#148; for additional information regarding these rights. We have filed a registration statement on
Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268603)</FONT> which was initially declared effective by the SEC on December&nbsp;27, 2022, in order to satisfy these obligations. In addition,
until such time as Sorrento first ceases to own greater than 50% of the outstanding voting power of the outstanding shares of our capital stock entitled to vote generally in the election of directors, the Certificate of Incorporation effectively
provides Sorrento with the ability to fill vacancies on our Board, remove directors (with or without cause), call a special meeting of our stockholders, amend the Certificate of Incorporation (subject to approval of our Board) and amend our Bylaws.
The directors so elected will have the authority, subject to the terms of our indebtedness and applicable rules and regulations, to issue additional stock, implement stock repurchase programs, declare dividends and make other decisions. See the
section of this prospectus titled &#147;<I>Description of Our Securities &#151; Anti-Takeover Matters in our Governing Documents and Under Delaware Law</I>&#148; for additional information regarding Sorrento&#146;s ability to take such actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even when Sorrento ceases to control a majority of the total voting power of Scilex, for so long as Sorrento continues to own a significant
percentage of our Common Stock and for so long as the Sorrento Group owns any shares of Series A Preferred Stock, Sorrento will still be able to significantly influence the composition of our Board and the approval of actions requiring stockholder
approval. Accordingly, for such period of time, Sorrento will have significant influence with respect to our management, business plans and policies. Because of the significant ownership position held by Sorrento, our classified board structure and
the rights granted to Sorrento under the Stockholder Agreement, new investors may not be able to effect a change in our business or management. The concentration of ownership and availability of the foregoing rights could deprive our stockholders of
an opportunity to receive a premium for their shares of common stock as part of a sale of the Company and ultimately might affect the market price of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the interests of Sorrento may not be aligned with those of our other stockholders and this could lead to actions that may not be
in the best interests of our other stockholders. For example, Sorrento may have different tax positions or strategic plans for the Company, which could influence its decisions regarding whether and when we should dispose of assets or incur new or
refinance existing indebtedness. Additionally, Sorrento&#146;s significant ownership in the Company may discourage someone from making a significant equity investment in the Company, or could discourage transactions involving a change in control.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Sorrento and its affiliates engage in a broad spectrum of activities, including investments in our industry generally. In
the ordinary course of their business activities, Sorrento and its affiliates may engage in activities where their interests conflict with our interests or those of our other stockholders, such as investing in or advising businesses that directly or
indirectly compete with certain portions of our business or those businesses that are suppliers or customers of ours. The Certificate of Incorporation provides that, to the fullest extent permitted by law, none of Sorrento and its affiliates and any
person or entity who, while a stockholder, director, officer or agent of us or any of our affiliates, is a director, officer, principal, partner, member, manager, employee, agent and/or other representative of Sorrento and its affiliates (each an
&#147;Identified Person&#148;) will have any duty to refrain from (i)&nbsp;engaging in a corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be
competing with us or any of our affiliates or (ii)&nbsp;otherwise investing in or providing services to any person that competes with us or our affiliates engaging, directly or indirectly, in the same or similar business activities or lines of
business in which we operate. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or
similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competing with us or any of our affiliates. This means that Sorrento may pursue acquisition opportunities that may be complementary to our business and, as a result, those acquisition
opportunities may not be available to us. In addition, Sorrento may have an interest in pursuing acquisitions, divestitures and other transactions that, in its judgment, could enhance its investment, even though such transactions might involve risks
to our stockholders or may not prove beneficial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on December&nbsp;30, 2022, Sorrento announced that its board of directors
authorized Sorrento to dividend to Sorrento equityholders of record as of January&nbsp;9, 2023 an aggregate of 76,000,000 shares of our Common Stock that were held by Sorrento. Subsequent to such dividend Sorrento continues to hold approximately
53.3% of our voting power, including shares of our Series A Preferred Stock and shares issuable upon exercise of warrants to purchase shares of our Common Stock, which shares have the rights, preferences and privileges described below, and Sorrento
would still have significant rights that are not otherwise available to holders of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sorrento, as the holder of Series A Preferred
Stock, has rights, preferences and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock is issued only to Sorrento and is not convertible into shares of our Common Stock. The holders of Series A
Preferred Stock have rights, preferences and privileges that are senior, or in addition, to the rights, preferences and privileges of the holders of our Common Stock, including the right to receive, in the event of a change of control, liquidation
dissolution or winding up of the Company, a preference amount out of the assets available for distribution to stockholders before any distribution can be made to holders of our Common Stock. The preference amount is $10.00 per share (subject to
adjustment as set forth in the Certificate of Designations). If our Board declares or pays a dividend on our Common Stock, the holders of Series A Preferred Stock will participate, on a deemed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-common</FONT></FONT></FONT> stock basis, in such dividend with the holders of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Series A Preferred Stock have certain voting rights over our corporate actions including, among others, any change to the
shares of Series A Preferred Stock into cash or other property, the issuance of equity securities that rank on a parity with or senior to Series A Preferred Stock with respect to dividend rights or rights upon liquidation, dissolution or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Company and the amendment of the Certificate of Incorporation in a manner that adversely affects the holders of shares of Series A Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, for so long as the Sorrento Group beneficially owns any shares of Series A Preferred
Stock, among other things, (i)&nbsp;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#147;Stockholder Designee&#148; and collectively, the
&#147;Stockholder Designees&#148;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board
in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of our Board, or the size of our Board and (ii)&nbsp;we are required to take all actions reasonably necessary, and not otherwise
prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for
any Stockholder Designee that has been removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of our Board. Notwithstanding the foregoing, the parties have agreed to ensure that our
Board complies with all applicable requirements of the stock exchange, including independence requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement
also provides that we are prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of our Board, the
incurrence of certain amounts of indebtedness and the payment of dividends on our Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information on the terms of the Series A Preferred Stock, see the section of this
prospectus titled &#147;<I>Description of Our Securities &#151; Our Preferred Stock</I>&#148; and the section of this prospectus titled &#147;<I>Certain Relationships and Related Party Transactions &#151; Certain Relationships of Vickers &#151;
Stockholder Agreement with Sorrento.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sorrento has recently filed for bankruptcy protection, which may impair our relationship with
Sorrento. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2023, Sorrento, together with its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc.,
commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. While the Company is majority-owned by Sorrento, the Company is not a debtor in
Sorrento&#146;s voluntary Chapter 11 filing. As of December&nbsp;31, 2022, the Company had a $1.8&nbsp;million receivable from Sorrento, which was fully reserved. Sorrento&#146;s filing for bankruptcy protection may impair our relationship with
Sorrento. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_20"></A>Risks Related to Ownership of our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the factors listed below could have a negative impact on your investment in our securities, and our securities may trade at
prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors affecting the trading price of our securities may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize ZTlido, GLOPERBA or our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the status and cost of our marketing commitments for ZTlido, GLOPERBA and our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements regarding results of any clinical trials relating to our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to the use of ZTlido, GLOPERBA or any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws or regulations applicable to ZTlido, GLOPERBA or our product candidates, including but not
limited to clinical trial requirements for approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal disputes or other developments relating to proprietary rights, including patents, litigation matters and
our ability to obtain patent protection for ZTlido, GLOPERBA or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical
trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our dependence on third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of the introduction of new products by our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions and trends in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements concerning product development results or intellectual property rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future issuances of common stock or other securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed any financial guidance or expectations regarding product development milestones that we
may provide to the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to meet or exceed the estimates and projections of the investment community; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets and other factors that may be unrelated to our operating performance or
the operating performance of our competitors, including changes in market valuations of similar companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or
our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by the Company or by any securities analysts who might cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuation of the market values of any of our potential strategic investments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuances of debt or equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with our contractual obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our Common Stock by us or our stockholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about the Company or its industry or positive or negative recommendations or
withdrawal of research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to effectively integrate the operations of Semnur; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our relationship with Sorrento; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effects of natural or <FONT STYLE="white-space:nowrap">man-made</FONT> catastrophic events;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effects of public health crises, pandemics and epidemics, such as the ongoing
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control, such as the government closure of Silicon Valley
Bank and Signature Bank, and liquidity concerns at other financial institutions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the global equity markets in
general have recently experienced extreme price and volume fluctuations, including as a result of the ongoing COVID-19 pandemic, economic uncertainty and increased interest rates, inflation, the government closure of Silicon Valley Bank and
Signature Bank, and liquidity concerns at other financial institutions that may be unrelated to our operating performance. Continued market fluctuations could result in extreme volatility in the price of our Common Stock, which could cause a decline
in the value of our Common Stock. Price volatility of our Common Stock might worsen if the trading volume of our Common Stock is low. In the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies
following periods of volatility in the market prices of these companies&#146; stock. Such litigation, if instituted against the Company, could cause us to incur substantial costs and divert management&#146;s attention and resources from our
business. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#147;<I>Risk Factors</I>&#148;, could have a dramatic and material adverse impact on the market price of our Common
Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have not paid cash dividends in the past and we do not expect to pay cash dividends in the foreseeable future. Any return on investment
may be limited to the capital appreciation, if any, of our Common Stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid cash dividends on our Common Stock and
we do not anticipate paying cash dividends on our Common Stock in the foreseeable future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other obligations depends upon the
receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. In addition, our ability to pay dividends </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be limited by covenants in future outstanding indebtedness that we or our subsidiaries may incur. Since we do not intend to pay dividends, a stockholder&#146;s ability to receive a return on
such stockholder&#146;s investment will depend on any future appreciation in the market value of our Common Stock. There is no guarantee that our Common Stock will appreciate or even maintain the price at which our stockholders have purchased it.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales, or the perception of future sales, of a substantial number of shares of our Common Stock may cause the price of our Common Stock to
decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our Common Stock, the trading
price of our Common Stock could decline and it could impair our ability to raise capital through the sale of additional equity securities. Except as described below and unless otherwise waived by the Company and the applicable parties to the
Registration Rights Agreement, Sorrento and certain directors and equityholders of Vickers, including the Sponsors, are currently subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions that restrict their ability to transfer certain
of their shares of our Common Stock or any security convertible into or exercisable or exchanged for our Common Stock until 180 days from the Effective Time, subject to certain exceptions. In connection with the Closing of the Business Combination,
the Company, the Sponsors and Sorrento agreed to waive compliance with the <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions under the Registration Rights Agreement and any other applicable agreement that restricted the transfer of our
Common Stock solely with respect to 1.5&nbsp;million shares of our Common Stock held by the Sponsors as of such Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described
elsewhere in this prospectus, on December&nbsp;30, 2022, Sorrento announced that its board of directors authorized Sorrento to dividend to Sorrento equityholders of record as of January&nbsp;9, 2023 an aggregate of 76,000,000 shares of our Common
Stock that were held by Sorrento. Such shares are subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction and may not be sold, pledged or otherwise transferred until May&nbsp;11, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the restrictions on resale end, the market price of shares of our Common Stock could drop significantly if the holders of these shares of
Common Stock sell them or are perceived by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future offerings of our shares of Common Stock or other securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operating results may fluctuate significantly. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating results to be subject to quarterly, and possibly annual, fluctuations. Our net loss and other operating results will be
affected by numerous factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in the level of expenses related to our development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the addition or termination of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any intellectual property infringement lawsuit in which we may become involved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments affecting ZTlido, GLOPERBA or our product candidates, regulatory approvals of our product
candidates, and the level of underlying demand for such products and purchasing patterns; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or
receive under these arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our quarterly or annual operating results fall below the expectations of investors
or securities analysts, the price of our Common Stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our Common Stock to fluctuate substantially. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 10, 2023, the Federal Deposit Insurance Corporation (FDIC) announced that Silicon Valley Bank had been closed by the
California Department of Financial Protection and Innovation and on March 12, 2023, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Signature Bank was closed by the New York State Department of Financial Services and the FDIC was named receiver. Although we do not maintain any bank accounts with Silicon Valley Bank or
Signature Bank, we regularly maintain cash balances at third-party financial institutions in excess of the FDIC insurance limit. Any failure of a depository institution to return any of our deposits, or any other adverse conditions in the financial
or credit markets affecting depository institutions, could impact access to our invested cash or cash equivalents and could adversely impact our operating liquidity and financial performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our stock, our
stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock will be influenced by the research and
reports that industry or securities analysts publish about the Company or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. Since we became public through a merger, securities analysts
of major brokerage firms may not provide coverage of the Company since there is no incentive to brokerage firms to recommend the purchase of our Common Stock. If no or few securities or industry analysts commence coverage of the Company, the trading
price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover it issues an adverse opinion regarding the Company, our business model, our intellectual property or
our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of the Company or fail to publish reports on us
regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising
additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to ZTlido or our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue additional equity securities to fund future expansion and pursuant to equity incentive or employee benefit plans. We may also
issue additional equity for other purposes. These securities may have the same rights as our Common Stock or, alternatively, may have dividend, liquidation or other preferences to our Common Stock. The issuance of additional equity securities,
whether upon conversion of the Convertible Debentures into Common Stock or pursuant to the B. Riley Purchase Agreement, the A&amp;R Yorkville Purchase Agreement (pursuant to each of which we may also sell up to $500&nbsp;million of shares of our
Common Stock, or an aggregate of $1.0&nbsp;billion, as more fully described elsewhere in this prospectus) or otherwise, will dilute the holdings of existing stockholders and may reduce the share price of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Equity Incentive Plan, which became effective on November&nbsp;9, 2022, we are authorized to grant equity awards to our
employees, directors and consultants. In addition, pursuant to the ESPP, which became effective on November&nbsp;9, 2022, we are authorized to sell shares to our employees. Further, pursuant to the Inducement Plan, which was adopted on
January&nbsp;17, 2023, we are authorized to grant equity awards to individuals as a material inducement to join the Company. A total of 20,276,666, 2,875,759 and 1,400,000 shares of our Common Stock have been reserved for issuance under the Equity
Incentive Plan, the ESPP and the Inducement Plan, respectively. In addition, the Equity Incentive Plan and ESPP provide for annual automatic increases in the number of shares reserved thereunder, in each case, beginning on January&nbsp;1, 2023. As a
result of such annual increases, our stockholders may experience additional dilution, which could cause the price of our Common Stock to fall. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the Business Combination, certain stockholders of Vickers and
Legacy Scilex can each demand that we register their registrable securities under certain circumstances and will each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective
registration statement under the Securities Act covering such securities and certain of our other securities. We have filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-268603)</FONT> which was initially declared effective by the SEC on December&nbsp;27, 2022, in order to satisfy these obligations. The registration of these securities will permit the public sale of such
securities, subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of our Common Stock trading in the public market
may have an adverse effect on the market price of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaboration, licensing or other
similar arrangements, we may have to relinquish valuable rights to ZTlido or our product candidates, or grant licenses on terms unfavorable to the Company. If adequate funds are not available, our ability to achieve profitability or to respond to
competitive pressures would be significantly limited and we may be required to delay, significantly curtail or eliminate the development of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders, directors and executive officers will own a significant percentage of our capital stock, and have significant influence over
our management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors, executive officers, holders of 5% or more of our capital stock and their respective beneficially
own, in the aggregate, approximately 56.7% of our outstanding voting stock (which percentage gives effect to the dividend of 76,000,000 shares of our Common Stock by Sorrento to certain of its equityholders). This concentration of voting power may
make it less likely that any other holder of our Common Stock will be able to affect the way we are managed and could delay or prevent an acquisition of the Company on terms that other stockholders may desire. This could prevent transactions in
which stockholders might otherwise recover a premium for their shares over current market prices. See &#147;<I>Risk Factors &#151; We are</I> <I>controlled by Sorrento, whose interests may differ from those of our public shareholders</I>&#148; above
for additional information regarding Sorrento&#146;s influence and control in the Company. See &#147;<I>Principal Securityholders</I>&#148; for information regarding the ownership of our outstanding Common Stock by our directors, executive officers,
and current beneficial owners of 5% or more of our voting securities and their respective affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have in the past and may in the future be
subject to short selling strategies that may drive down the market price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Short sellers have in the past and
may attempt in the future to drive down the market price of our common stock. Short selling is the practice of selling securities that the seller does not own but may have borrowed with the intention of buying identical securities back at a later
date. The short seller hopes to profit from a decline in the value of the securities between the time the securities are borrowed and the time they are replaced. As it is in the short seller&#146;s best interests for the price of the stock to
decline, many short sellers (sometime known as &#147;disclosed shorts&#148;) publish, or arrange for the publication of, negative opinions regarding the relevant issuer and its business prospects to create negative market momentum. Although
traditionally these disclosed shorts were limited in their ability to access mainstream business media or to otherwise create negative market rumors, the rise of the Internet and technological advancements regarding document creation, videotaping
and publication by weblog (&#147;blogging&#148;) have allowed many disclosed shorts to publicly attack a company&#146;s credibility, strategy and veracity by means of <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;research reports&#148;
that mimic the type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the past, led to selling of shares in the market. Further, these short seller publications are not
regulated by any governmental, self-regulatory organization or other official authority in the U.S. and they are not subject to certification requirements imposed by the SEC. Accordingly, the opinions they express may be based on distortions,
omissions or fabrications. Companies that are subject to unfavorable allegations, even if untrue, may have to expend a significant amount of resources to investigate such allegations and/or defend themselves, including shareholder suits against the
company that may be prompted by such allegations. We may in the future be the subject of shareholder suits that we believe were prompted by allegations made by short sellers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss and tax credit carryforwards may be subject to limitation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a change of more than 50% in the ownership of a company&#146;s stock, by value, over a three-year period constitutes an ownership
change for U.S. federal income tax purposes. An ownership change may limit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our ability to use our net operating loss carryforwards attributable to the period prior to the change. We have experienced a corporate reorganization in the past, some ownership changes as a
result of the Business Combination and may experience some subsequent changes in the future in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our <FONT
STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability for the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tax Cuts and JOBS Act of 2017 (the &#147;TCJA&#148;), as amended by the CARES Act, includes changes to U.S. federal tax rates and the
rules governing net operating loss (&#147;NOL&#148;) carryforwards. The TCJA, as modified by the CARES Act, limits a taxpayer&#146;s ability to utilize NOL carryforwards to 80% of taxable income (as calculated before taking the NOLs, and certain
other tax attributes, into account) for taxable years beginning after December&nbsp;31, 2020. In addition, NOLs arising in tax years ending after December&nbsp;31, 2017 and before January&nbsp;1, 2021 may be carried back to each of the five taxable
years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December&nbsp;31, 2020 may not be carried back. NOLs arising in tax years beginning after December&nbsp;31, 2017 can be carried forward indefinitely. NOLs
generated in tax years beginning before January&nbsp;1, 2021 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January&nbsp;1, 2018 will continue to have a
<FONT STYLE="white-space:nowrap">two-year</FONT> carryback and <FONT STYLE="white-space:nowrap">20-year</FONT> carryforward period. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is expected
to be utilized. The changes in the carryforward/carryback periods, as well as the new limitation on use of NOLs may significantly impact our ability to utilize our NOLs to offset taxable income in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating
results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates
and assumptions that affect the amounts reported in our combined consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual
circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of
our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in the Certificate of Incorporation and the Bylaws and under Delaware law could make an acquisition of
our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws and the DGCL contains provisions that could make it more difficult for a third party to acquire
the Company, even if doing so might be beneficial to our stockholders. Among other things, these provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow our Board to authorize the issuance of undesignated preferred stock, the terms of which may be established
and the shares of which may be issued without stockholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for a classified board of directors with staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, at any time after the Sorrento Group first ceases to beneficially own more than 50% in voting power
of the then-outstanding shares of our capital stock entitled to vote generally in the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
election of directors (the &#147;Sorrento Trigger Event&#148;), directors may only be removed for cause, and only by the affirmative vote of holders of at least 66 2/3% in voting power of all the
then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit stockholder action by written consent from and after the Sorrento Trigger Event; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, at any time after the Sorrento Trigger Event, special meetings may only be called by or at the
direction of the Chairperson of the Board, the Board or the Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, at any time after the Sorrento Trigger Event, any alteration, amendment or repeal, in whole or in
part, of any provision of the Bylaws by our stockholders will require the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a
single class; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for nominations for elections to the Board and for proposing matters that
can be acted upon by stockholders at stockholder meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL generally prohibits a Delaware
corporation from engaging in any of a broad range of business combinations with any interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder. We have expressly elected not to be
governed by Section&nbsp;203 of the DGCL until the occurrence of a Sorrento Trigger Event. At that time, such election shall be automatically withdrawn and we will thereafter be governed by Section&nbsp;203 of the DGCL, except that the restrictions
on business combinations of Section&nbsp;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of its percentage ownership of our Common Stock. These provisions
could discourage, delay or prevent a transaction involving a change in control of the Company. These provisions could also discourage proxy contests and make it more difficult for our stockholders to elect directors of their choosing and cause us to
take other corporate actions they desire, including actions that our stockholders may deem advantageous. In addition, because our Board is responsible for appointing the members of our management team, these provisions could in turn affect any
attempt by our stockholders to replace current members of our management team. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These anti-takeover provisions and other provisions in the
Certificate of Incorporation, the Bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of the Board or initiate actions that are opposed by our then-current board of directors and could also
delay or impede a merger, tender offer or proxy contest involving the Company. The existence of these provisions could negatively affect the price of our Common Stock and limit opportunities for a stockholder to realize value in a corporate
transaction. For information regarding these and other provisions, see the section of this prospectus titled &#147;<I>Description of Our Securities.</I>&#148; In addition, if prospective takeovers are not consummated for any reason, we may
experience negative reactions from the financial markets, including negative impacts on the price of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Certificate of
Incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders and the federal district courts of the United States as the exclusive forum for
litigation arising under the Securities Act, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with the Company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of
the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter
jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom, will, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on our
behalf; (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders; (iii)&nbsp;any action asserting a claim against us or any of
our current or former directors, officers, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees or stockholders arising pursuant to any provision of the DGCL, the Certificate of Incorporation or the Bylaws; (iv)&nbsp;any claim or cause of action seeking to interpret, apply,
enforce or determine the validity of the Certificate of Incorporation or the Bylaws; (v)&nbsp;any action or proceeding asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL
confers jurisdiction to the Court of Chancery of the State of Delaware and (vi)&nbsp;any action asserting an &#147;internal corporate claim,&#148; as that term is defined in Section&nbsp;115 of the DGCL; <I>provided that</I>, for the avoidance of
doubt, the foregoing forum selection provision will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that, unless we consent in writing to the selection of an alternative forum, to the fullest
extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The Certificate of Incorporation further
provides that any person or entity purchasing or otherwise acquiring any interest in shares of our Common Stock is deemed to have notice of and consented to the provisions of the Certificate of Incorporation described above. See the section of this
prospectus titled &#147;<I>Description of Our Securities &#151; Anti-Takeover Matters in our Governing Documents and Under Delaware Law &#151; Exclusive Forum</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forum selection provisions in the Certificate of Incorporation may have the effect of discouraging lawsuits against our directors and
officers. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In
addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If the enforceability of our forum selection provisions were to be challenged, it may incur additional costs associated with
resolving such challenge. While we currently have no basis to expect any such challenge would be successful, if a court were to find its forum selection provisions to be inapplicable or unenforceable with respect to one or more of these specified
types of actions or proceedings, we may incur additional costs associated with having to litigate in other jurisdictions, which could result in a diversion of the time and resources of our employees, management and board of directors, and could have
an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company, and we cannot be certain if
the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take
advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of
the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and
stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our Common Stock less attractive because we may rely on these exemptions. If some investors find our Common Stock less attractive
as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an
emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the closing of the IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or
(c)&nbsp;in which we are deemed to be a large accelerated filer, which requires the market value of our Common Stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> to equal or exceed $700&nbsp;million as of the last business
day of the second fiscal quarter of such year, and (2)&nbsp;the date on which we have issued more than $1&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies. We have irrevocably elected not to avail </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not
emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly
affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a controlled company within the meaning of the Nasdaq Listing Rules and,
as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento controls a majority of the voting power of our outstanding shares of Common Stock. As a result, we are a &#147;controlled
company&#148; within the meaning of the corporate governance standards of Nasdaq. Under these corporate governance standards, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or
another company is a &#147;controlled company&#148; and may elect not to comply with certain corporate governance requirements. For example, controlled companies, within one year of the date of the listing of their common stock: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to have a board that is composed of a majority of &#147;independent directors&#148; as defined
under the Nasdaq Listing Rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to have a compensation committee that is composed entirely of independent directors or have a
written charter addressing the committee&#146;s purpose and responsibilities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to have director nominations be made, or recommended to the full board of directors, by its
independent directors or by a nominating and corporate governance committee that is composed entirely of independent directors, and to adopt a written charter or a board resolution addressing the nominations process. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we do not presently intend to rely on these exemptions, we may opt to utilize these exemptions in the future as long as we remain a
controlled company. Accordingly, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cease to be a &#147;controlled company&#148; in the future, we will be required to comply with the Nasdaq listing standards, which may
require replacing a number of our directors and will require development of certain other governance-related policies and practices. These and any other actions necessary to achieve compliance with such rules may increase our legal and
administrative costs, will make some activities more difficult, time-consuming and costly and may also place additional strain on our personnel, systems and resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to related compliance
initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incur significant legal, accounting and other expenses that Legacy Scilex did not incur as a private company, and
these expenses may increase even more after we are no longer an &#147;emerging growth company.&#148; We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection
Act (the &#147;Dodd-Frank Act&#148;), as well as rules and regulations adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, we
expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. For example, we expect these rules and
regulations to make it more difficult and more expensive for the Company to obtain directors&#146; and officers&#146; liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or
estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also make it more difficult for us to attract and retain qualified persons to serve on the Board, our board committees or as executive officers. Advocacy efforts by stockholders and third parties
may also prompt additional changes in governance and reporting requirements, which could further increase costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we expect
that we will need to implement an enterprise resource planning (&#147;ERP&#148;) system. An ERP system is intended to combine and streamline the management of our financial, accounting, human resources, sales and marketing and other functions,
enabling it to manage operations and track performance more effectively. However, an ERP system would likely require us to complete many processes and procedures for the effective use of the system or to run our business using the system, which may
result in substantial costs. Any disruptions or difficulties in implementing or using an ERP system could adversely affect our controls and harm our business, financial condition and results of operations, including our ability to forecast or make
sales and collect our receivables. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we are required to incur additional costs and obligations in order to comply with SEC rules that implement
Section&nbsp;404 of the Sarbanes-Oxley Act. Under these rules, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we will be required
to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaging in a process to
document and evaluate its internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan
to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a
continuous reporting and improvement process for internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing the standards that must
be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of our testing, our
management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. See &#147;<I>Risk Factors &#151; We have identified a material weakness in our internal control
over financial reporting.</I> <I>Any material weakness may cause us to fail to timely and accurately report our financial results or</I> <I>result in a material misstatement of our financial statements.</I>&#148; above for additional information
regarding a previously identified material weakness. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for
public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a
result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to
disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of our management&#146;s time
and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their
application and practice, regulatory authorities may initiate legal proceedings against us and there could be a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to meet Nasdaq&#146;s continued listing requirements could result in a delisting of our Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to satisfy Nasdaq&#146;s continued listing requirements, such as the corporate governance requirements or the minimum closing bid
price requirement, Nasdaq may take steps to delist our Common Stock. Such a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delisting would likely have a negative effect on the price of our Common Stock and would impair a stockholder&#146;s ability to sell or purchase our Common Stock when a stockholder wishes to do
so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our Common Stock to become listed again, stabilize the market price or improve the liquidity of our
Common Stock, prevent our Common Stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Nasdaq&#146;s listing requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive U.S. federal income tax reform could adversely affect the Company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to tax laws, which changes may have retroactive application, could adversely affect the Company or holders of our Common Stock. In
recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TCJA,
which was enacted in 2017, included changes to U.S. federal tax rates, imposed significant additional limitations on the deductibility of interest, allowed for the expensing of capital expenditures, and put into effect the migration from a
&#147;worldwide&#148; system of taxation to a modified territorial system. On March&nbsp;27, 2020, President Trump signed into law the CARES Act, which included certain changes in tax law (including to the TCJA) intended to stimulate the U.S.
economy in light of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. On August&nbsp;16, 2022,
President Biden signed into law the Inflation Reduction Act of 2022, which contained certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations, an excise tax of 1% on certain corporate stock <FONT
STYLE="white-space:nowrap">buy-backs,</FONT> and an excise tax with respect to certain drug sales for failing to offer a price that is not equal to or less than the negotiated &#147;maximum fair price&#148; under the law or for taking price
increases that exceed inflation. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. The impact of these tax reforms on holders of our Common Stock is uncertain
and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The issuances of additional shares of Common Stock under certain of our contracts and arrangements may result in dilution of holders of our Common Stock
and have a negative impact on the market price of our Common Stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Yorkville Purchase Agreement, we may
issue and sell up to $500,000,000 of shares of Common Stock to the Selling Securityholder. The price at which we may issue and sell shares will be at 98% of the VWAP of our Common Stock during the applicable pricing period for any Yorkville Advance,
which shall be the period commencing upon receipt by the Selling Securityholder of the Yorkville Advance Notice and ending on 4:00 p.m. on the same day, subject to certain caps on the number of shares of Common Stock that we may sell for any
Yorkville Advance as set forth in the A&amp;R Yorkville Purchase Agreement. For purposes of the A&amp;R Yorkville Purchase Agreement, &#147;VWAP&#148; means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq
Capital Market for such period as reported by Bloomberg L.P. through its &#147;AQR&#148; function. The shares of Common Stock issuable under the A&amp;R Yorkville Purchase Agreement have been registered for resale on the Yorkville Registration
Statement (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607).</FONT> Without giving effect to the Yorkville Exchange Cap or any other potential future issuance other than pursuant to the A&amp;R Yorkville Purchase Agreement (although the
Selling Securityholder may acquire and resell additional shares of Common Stock pursuant to the Convertible Debentures, as discussed below), and assuming that (a)&nbsp;we issue and sell the full $500,000,000 of shares of Common Stock under the
A&amp;R Yorkville Purchase Agreement to the Selling Securityholder, (b)&nbsp;the Yorkville Beneficial Ownership Limitation is waived, and (c)&nbsp;the issue price for such sales is $8.77 per share (which price represents the lower of the official
closing price of our Common Stock on Nasdaq on November&nbsp;16, 2022, the trading day immediately preceding the date of the Original Purchase Agreement, and the average official closing price of our Common Stock on Nasdaq for the five consecutive
trading days ending on November&nbsp;16, 2022, the trading day immediately preceding the date of the Original </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Purchase Agreement), such additional issuances would represent in the aggregate approximately 57 million additional shares of Common Stock or approximately 28% of the total number of shares of
Common Stock outstanding as of March&nbsp;31, 2023, after giving effect to only such issuance. If the per share issue price is $2.00, such additional issuances would represent in the aggregate approximately 250 million additional shares of Common
Stock or approximately 63% of the total number of shares of Common Stock outstanding as of March&nbsp;31, 2023, after giving effect to only such issuance. If the Yorkville Beneficial Ownership Limitation is not waived, at a $8.77 and $2.00 issue
price per share of Common Stock, such issuances would represent approximately 7.28 million additional shares of Common Stock, or approximately 4.99% of the total number of shares of Common Stock outstanding as of March&nbsp;31, 2023. As of the date
of this prospectus, we have sold 85,000 shares of our Common Stock pursuant to advances under the A&amp;R Yorkville Purchase Agreement. The timing, frequency, and the price at which we issue shares of Common Stock under the A&amp;R Yorkville
Purchase Agreement are subject to market prices and management&#146;s decision to sell shares of Common Stock, if at all. For more information on the A&amp;R Yorkville Purchase Agreement, please see the section of this prospectus titled
&#147;<I>Prospectus Summary&#151;Recent Developments&#151;Committed Equity</I> <I>Financings&#151;A&amp;R Yorkville Purchase Agreement</I>&#148; and &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#151;Recent Developments&#151;A&amp;R Yorkville Purchase Agreement.</I>&#148; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Securities Purchase Agreement,
we have agreed to issue Convertible Debentures in an aggregate principal amount of up to $25,000,000, which are convertible into shares of our Common Stock. Without giving effect to any other potential future issuance other than pursuant to the
Convertible Debentures and assuming that (a)&nbsp;the full amounts with respect to the conversion of the Convertible Debentures are paid in shares of our Common Stock (without giving effect to the interest and fees accrued thereunder) and
(b)&nbsp;the Conversion Price at which we issue shares is $8.00 per share, such issuances would represent in the aggregate approximately 3.1&nbsp;million additional shares of Common Stock or approximately 2% of the total number of shares of Common
Stock outstanding as of March&nbsp;31, 2023, after giving effect to only such issuances. The Conversion Price may decrease in certain circumstances pursuant to the terms of the Convertible Debentures, including the event of default provisions. As a
result, additional shares of Common Stock may be issuable upon conversion of the Convertible Debentures. The timing and frequency at which we issue shares of Common Stock under the Convertible Debentures is subject to the Selling
Securityholder&#146;s decision to convert the Convertible Debentures into shares of Common Stock. For more information on the Convertible Debentures, please see the section of this prospectus titled &#147;<I>Prospectus Summary&#151;Recent
Developments&#151;Convertible Debentures,</I>&#148; &#147;<I>Private Placement</I>&#148; and &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Recent Developments&#151;Convertible
Debentures.</I>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time as the Convertible Debentures have been repaid or converted, we are prohibited from selling any
shares of Common Stock pursuant to the B. Riley Purchase Agreement without the Selling Securityholder&#146;s prior consent. Pursuant to the B. Riley Purchase Agreement, we may issue and sell up to $500,000,000 of shares of Common Stock to B. Riley.
The price at which we may issue and sell shares will be at 98% of the VWAP of our Common Stock during the applicable pricing period, subject to certain caps on the number of shares of Common Stock that we may sell for any B. Riley Advance or B.
Riley Additional Advance as set forth in the B. Riley Purchase Agreement. Such pricing period shall begin at the Purchase Commencement Time and end at 3:59 p.m. New York City Time, or such earlier time publicly announced as the official close of the
primary (or &#147;regular&#148;) trading session on the Nasdaq Capital Market on such purchase date, with the ending time subject to certain exceptions on Advance Share Volume Maximum and Limit Order Discontinue Election. For purposes of the B.
Riley Purchase Agreement, &#147;VWAP&#148; means, for the Common Stock for a specified period, the dollar volume-weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg through its
&#147;AQR&#148; function, subject to certain exceptions, qualifications and limitations. The shares of Common Stock issuable under the B. Riley Purchase Agreement have been registered for resale on the B. Riley Registration Statement (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-269205).</FONT> Without giving effect to the B. Riley Exchange Cap or any other potential future issuance other than pursuant to the B. Riley Purchase Agreement, and assuming that (a)&nbsp;we issue and sell
the full $500,000,000 of shares of Common Stock under the B. Riley Purchase Agreement to B. Riley, (b)&nbsp;the B. Riley Beneficial Ownership Limitation is waived, and (c)&nbsp;the issue price for such sales is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$4.87 per share (which price represents the lower of the official closing price of our Common Stock on Nasdaq on January&nbsp;6, 2023, the trading day immediately preceding the date of the B.
Riley Purchase Agreement, and the average official closing price of our Common Stock on Nasdaq for the five consecutive trading days ending on January&nbsp;6, 2023, the trading day immediately preceding the date of the B. Riley Purchase Agreement),
such additional issuances would represent in the aggregate approximately 103 million additional shares of Common Stock or approximately 41% of the total number of shares of Common Stock outstanding as of March&nbsp;31, 2023, after giving effect to
only such issuance. If the per share issue price is $2.00, such additional issuances would represent in the aggregate approximately 250 million additional shares of Common Stock or approximately 63% of the total number of shares of Common Stock
outstanding as of March&nbsp;31, 2023, after giving effect to only such issuance. If the B. Riley Beneficial Ownership Limitation is not waived, at a $4.87 and $2.00 issue price per share of Common Stock, such issuances would represent approximately
7.28 million additional shares of Common Stock, or approximately 4.99% of the total number of shares of Common Stock outstanding as of March&nbsp;31, 2023. As of the date of this prospectus, we have sold 127,241 shares of our Common Stock pursuant
to advances under the B. Riley Purchase Agreement. The timing, frequency, and the price at which we issue shares of Common Stock under the B. Riley Purchase Agreement are subject to market prices and management&#146;s decision to sell shares of
Common Stock, if at all. For more information on the B. Riley Purchase Agreement, please see the section of this prospectus titled &#147;<I>Prospectus Summary&#151;Recent Developments&#151;Committed Equity Financings&#151;B. Riley Purchase
Agreement</I>&#148; and &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Recent Developments&#151;B. Riley Purchase Agreement.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we issue securities, such recipients, upon effectiveness of a Form <FONT STYLE="white-space:nowrap">S-1</FONT> registration
statement (or other available registration statement) registering such securities for resale, may resell all, some or none of such shares in their discretion and at different prices subject to the terms of the applicable agreement. As a result,
investors who purchase shares from such recipients at different times will likely pay different prices for those shares, and so may experience different levels of dilution (and in some cases substantial dilution) and different outcomes in their
investment results. Investors may experience a decline in the value of the shares they purchase as a result of future issuances or issuances and sales made by us to such aforementioned parties or others at prices lower than the prices such investors
paid for their shares. In addition, if we issue a substantial number of shares to such parties, or if investors expect that we will do so, the actual sales of shares or the mere existence of an arrangement with such parties may adversely affect the
price of our securities or make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance, if any, of Common Stock would not affect the rights or privileges of our existing stockholders, except that the economic and
voting interests of existing stockholders would be diluted, potentially substantially. Although the number of shares of Common Stock that existing stockholders own would not decrease as a result of these additional issuances, the shares of Common
Stock owned by existing stockholders would represent a smaller percentage of the total outstanding shares of Common Stock after any such issuance, potentially significantly smaller. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Warrants are exercisable for our Common Stock, which would increase the number of shares eligible for future resale in the public market and result
in dilution to our stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March 31, 2023, outstanding warrants to purchase an aggregate of 11,003,787 shares of our
Common Stock are exercisable in accordance with the terms of the Warrant Agreement governing those securities. The exercise price of these Warrants is $11.50 per share. To the extent such Warrants are exercised, additional shares of our Common Stock
will be issued, which will result in dilution to the holders of our Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market, or the fact that such
Warrants may be exercised, could adversely affect the prevailing market prices of our Common Stock. However, there is no guarantee that the Warrants will ever be in the money prior to their expiration, and as such, the Warrants may expire worthless.
See below risk factor, &#147;<I>The Warrants may never be in the money, they may expire worthless and the terms of the Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such
amendment</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Warrants may never be in the money, they may expire worthless and the terms of the Warrants may be
amended in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
the date of this prospectus, the exercise price for our Warrants is $11.50 per share of Common Stock. On April&nbsp;7, 2023, the closing price of our Common Stock on the Nasdaq Capital Market was $12.90. If the price of our shares of Common Stock
remains below $11.50 per share, which is the exercise price of our Warrants, we believe our warrantholders will be unlikely to cash exercise their Warrants, resulting in little or no cash proceeds to us. There is no guarantee that our Warrants will
be in the money prior to their expiration and, as such, our Warrants may expire worthless. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Warrants were issued in
registered form under the Warrant Agreement between Continental, as warrant agent, and Vickers. The Warrant Agreement provides that the terms of the Warrants may be amended without the consent of any holder to cure any ambiguity or correct any
defective provision or correct any mistake, but requires the approval by the holders of a majority of the then-outstanding Warrants to make any change that adversely affects the interests of the registered holders of Warrants. Accordingly, we may
amend the terms of the Warrants in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment. Although our ability to amend the terms of the Warrants with the consent of majority of the
then-outstanding Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the Warrants, convert the Warrants into cash, shorten the exercise period, or decrease the number of
shares of our Common Stock purchasable upon exercise of a Warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may redeem any unexpired Warrants prior to their exercise at a time that is
disadvantageous to you, thereby making the Warrants worthless. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the ability to redeem outstanding Warrants at any time
after they become exercisable and prior to their expiration, at a price of $0.01 per Warrant, provided that the closing price of our Common Stock equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, rights
issuances, subdivisions, reorganizations, recapitalizations and the like) on each of the 20 trading days within any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">30-trading-day</FONT></FONT> period commencing after the Warrants
become exercisable and ending on the third trading day prior to the date on which notice of redemption is given. If and when the Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the
underlying securities for sale under all applicable state securities laws. Redemption of the outstanding Warrants could force the holders thereof to: (i)&nbsp;exercise such Warrants and pay the exercise price therefor at a time when it may be
disadvantageous for a holder to do so; (ii)&nbsp;sell such Warrants at the then-current market price when a holder might otherwise wish to hold such Warrants; or (iii)&nbsp;accept the nominal redemption price that, at the time the outstanding
Warrants are called for redemption, is likely to be substantially less than the market value of such Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may redeem
the Warrants at any time after they become exercisable and prior to their expiration for a number of shares of our Common Stock determined based on the fair market value of our Common Stock. The value received upon exercise of the Warrants
(1)&nbsp;may be less than the value the holders would have received if they had exercised their Warrants at a later time where the underlying share price is higher and (2)&nbsp;may not compensate the holders for the value of the Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_21"></A>PRIVATE PLACEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration statement of which this prospectus forms a part registers the resale by the Selling Securityholder of up to 3,290,000 shares
of Common Stock that can be issued upon the conversion of the Convertible Debentures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible Debentures bear interest at an
annual rate of 7.00% and will mature on December&nbsp;21, 2023 (the &#147;Maturity Date&#148;). The Convertible Debentures provide that at any time on or after a Convertible Debenture is issued and remains outstanding, any portion of the outstanding
and unpaid principal amount of the Convertible Debentures, together with any accrued but unpaid interest, may be converted into shares of our Common Stock, at a conversion price of $8.00 per share (the &#147;Conversion Price&#148;). The Selling
Securityholder has waived the reset provision on the Conversion Price set forth in the Convertible Debentures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible Debentures
may not be converted into shares of Common Stock to the extent such conversion would result in the Selling Securityholder and its affiliates having beneficial ownership of more than 4.99% of our then outstanding shares of Common Stock; provided that
this limitation may be waived by the Selling Securityholder upon not less than 65 days&#146; prior notice to us. In addition, we shall not issue any Common Stock pursuant to the transactions contemplated by the Convertible Debentures or any other
transaction documents executed in connection therewith (including any shares issued pursuant to a conversion) if the issuance of such shares of Common Stock would exceed the Convertible Debenture Exchange Cap of 29,016,448 shares (which number of
shares represents 19.9% of the aggregate number of shares of Common Stock issued and outstanding as of the Agreement Date). The Convertible Debenture Exchange Cap will not apply under certain circumstances, including if we obtain the approval of our
stockholders as required by the applicable rules of the Nasdaq Capital Market for issuances of shares of Common Stock in excess of such amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Convertible Debentures and subject to certain conditions set forth therein, we have the right, but not the
obligation, in our sole discretion, to redeem, upon five business days&#146; prior written notice to the Selling Securityholder (the &#147;Redemption Notice&#148;), all or any portion of the amounts outstanding under the Convertible Debentures;
provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by us, plus the redemption premium
of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Convertible Debentures also contain certain customary representations, warranties, covenants, and events of default including, among other things, upon cross-defaults under other debt documents, bankruptcy or insolvency events, delisting of the
Common Stock or if we become delinquent in our periodic report filings with the SEC. If an event of default occurs and is continuing, the full unpaid principal amount of the Convertible Debentures, together with interest and other amounts owing in
respect thereof, to the date of acceleration shall become at the Selling Securityholder&#146;s election by notice to us immediately due and payable in cash (save for bankruptcy and insolvency events of default, upon the occurrence of which the full
unpaid principal amount of the Convertible Debentures, together with interest and other amounts owing in respect thereof to the date of acceleration, shall automatically become due and payable, in each case without presentment, demand, protest or
other notice of any kind). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence and during the continuance of any event of default, interest will accrue on the
outstanding principal balance of the Convertible Debentures at a rate of 15% per annum. In addition to any other remedies, to the extent that the Convertible Debentures remain outstanding following an event of default or the Maturity Date, the
Selling Securityholder will continue to have the right, but not the obligation, to convert the Convertible Debentures at the lower of the (i)&nbsp;Conversion Price or (ii)&nbsp;a price per share equal to 95% of the lowest daily VWAP during the five
consecutive trading days immediately preceding the date of such conversion, but not lower than $2.00 per share, at any time after (x)&nbsp;an event of default (provided that such event of default is continuing) or (y)&nbsp;the Maturity Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future debt that we incur may contain additional and more restrictive negative covenants
and financial maintenance covenants. These restrictions could limit our ability to obtain debt financing, repurchase stock, pay dividends, refinance or pay principal on our outstanding debt, complete acquisitions for cash or debt or react to changes
in our operating environment or the economy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our failure to comply with our obligations or the agreements governing any future
indebtedness may result in an event of default under the applicable agreement. A default, if not cured or waived, may permit acceleration of some or all of our other indebtedness and trigger other termination and similar rights under other
contracts. We cannot be certain that we will be able to remedy any defaults and, if our indebtedness is accelerated, we cannot be certain that we will have sufficient funds available to pay the accelerated indebtedness or that we will have the
ability to refinance the accelerated indebtedness on terms favorable to us or at all, any of which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder will receive all the proceeds from the sale of shares of Common Stock under this prospectus. We will not receive
any proceeds from these sales. We have agreed to bear the certain expenses relating to the registration of the shares of our Common Stock being registered herein for the Selling Securityholder. We have also paid an affiliate of the Selling
Securityholder a <FONT STYLE="white-space:nowrap">one-time</FONT> due diligence and structuring fee of $15,000 in connection with the due diligence and structuring of the transactions by the Selling Securityholder under the Securities Purchase
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>Plan of Distribution</I>&#148; elsewhere in this prospectus for more information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_22"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain information contained in this prospectus relates to or is based on studies, publications, surveys and other data obtained from
third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this prospectus, we have not independently verified the market and industry data contained in this
prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Notwithstanding the foregoing, we are liable for the
information provided in this prospectus. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this prospectus titled &#147;<I>Risk
Factors</I>&#148;. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_23"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares of Common Stock offered by the Selling Securityholder pursuant to this prospectus will be sold by the Selling Securityholder
for its own account. We will not receive any of the proceeds from these sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder will pay any underwriting
discounts, selling commissions or transfer taxes incurred in disposing of such shares of Common Stock and the expenses of any attorney or other advisor they decide to employ. We will bear all other costs, fees and expenses incurred in effecting the
registration of the shares of Common Stock covered by this prospectus. These may include, without limitation, all registration, filing, stock exchange fees, printing expenses, all fees and expenses of complying with applicable securities laws and
the fees and disbursements of our counsel and of our independent registered public accounting firm and reasonable fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_23a"></A>DETERMINATION OF OFFERING PRICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot currently determine the price or prices at which shares of our Common Stock may be sold by the Selling Securityholder under this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_24"></A>MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_25"></A>Market Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on Nasdaq under the symbols &#147;SCLX&#148; and &#147;SCLXW,&#148; respectively.
Prior to the consummation of the Business Combination, Vickers&#146;s Ordinary Shares, units and warrants were each listed on Nasdaq under the symbols &#147;VCKA,&#148; &#147;VCKAU&#148; and &#147;VCKAW,&#148; respectively. At the Effective Time,
without any action on the part of the holder, each Unit then outstanding separated automatically into its component securities, comprised of one share of Common Stock and <FONT STYLE="white-space:nowrap">one-half</FONT> of one warrant to purchase
one share of Common Stock. As of March&nbsp;31, 2023, there were 313 holders of record of our Common Stock and two holders of record of our Warrants, which amount does not include participants of The Depository Trust Company or beneficial owners
holding shares through nominee names. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_26"></A>Dividend Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividend on shares of our Common Stock. We anticipate that we will retain all of our future earnings, if
any, to fund the development and growth of our business. Any future determination to pay dividends on our capital stock will be at the discretion of our Board. It is the present intention of our Board to retain all earnings, if any, for use in our
business operations and, accordingly, our Board does not anticipate declaring any dividend in the foreseeable future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other
obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. Further, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or
our subsidiaries incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_27"></A>Securities Authorized for Issuance under Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Equity Incentive Plan and the ESPP were the only compensation plans under which securities of the Company
were authorized for future grants. Each of the&nbsp;Equity Incentive Plan and the ESPP were approved by our stockholders. In March 2019, the 2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#147;Scilex Pharma 2017 Plan&#148;), which was
adopted by the board of directors and stockholders of Scilex Pharma on June&nbsp;26, 2017, as amended and restated on July&nbsp;5, 2018, terminated in connection with a corporate reorganization that was effected in March 2019. However, the Scilex
Pharma 2017 Plan continues to govern awards outstanding thereunder. Additionally, the 2019 Stock Option Plan, which was adopted by the board of directors and stockholders of Legacy Scilex on May&nbsp;28, 2019 and June&nbsp;24, 2019, respectively, as
amended on December&nbsp;21, 2020, terminated at the Closing of the Business Combination. However, the 2019 Stock Option Plan continues to govern awards outstanding thereunder. On January&nbsp;17, 2023, the Compensation Committee adopted the
Inducement Plan. The Inducement Plan has not been approved by our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information as of
December&nbsp;31, 2022 with respect to our existing and predecessor plans, excluding the Inducement Plan which was adopted after December&nbsp;31, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(a)&nbsp;Number&nbsp;of&nbsp;Securities<BR>to&nbsp;be&nbsp;Issued&nbsp;Upon<BR>Exercise&nbsp;of&nbsp;Outstanding<BR>Options, Warrants and<BR>Rights</B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(b)&nbsp;Weighted-<BR>Average<BR>Exercise&nbsp;Price<BR>of&nbsp;Outstanding<BR>Options,<BR>Warrants and<BR>Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(c) Number of<BR>Securities&nbsp;Remaining<BR>Available for Future<BR>Issuance Under<BR>Equity&nbsp;Compensation<BR>Plans (Excluding<BR>Securities
Reflected<BR>in Column (a))</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by
stockholders<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,939,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,084,983</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)(4)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,939,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,084,983</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)(4)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the following plans: the Equity Incentive Plan, the ESPP, the Scilex Pharma 2017 Plan and the 2019
Stock Option Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount is based on the weighted-average exercise price of vested and unvested stock options outstanding under
the Scilex Pharma 2017 Plan and the 2019 Stock Option Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2022, a total of 14,622,712 shares of our Common Stock were reserved for future
issuance pursuant to the Equity Incentive Plan, which number excludes (x) 16,195,178 shares subject to outstanding awards granted under the 2019 Stock Option Plan reflected in column (a)&nbsp;above that, following the effective date of the Equity
Incentive Plan return to the Equity Incentive Plan under the circumstances described therein and (y)&nbsp;the&nbsp;5,653,954 shares that were added to the&nbsp;Equity Incentive Plan as a result of the automatic annual increase on January&nbsp;1,
2023. The&nbsp;Equity Incentive Plan provides that the number of shares of our Common Stock reserved and available for issuance under the Equity Incentive Plan will automatically increase on January&nbsp;1 of each year for a period of ten years,
beginning on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to the lesser of (A) 4% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding year, (B)
7,311,356 shares of our Common Stock (subject to the adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (C)&nbsp;such number of shares of our Common Stock determined by our Board or our Compensation
Committee prior to January&nbsp;1 of a given year. All of the foregoing share numbers are subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. Shares subject to awards granted under the Equity
Incentive Plan that expire or terminate without being exercised in full will not reduce the number of shares available for issuance under the Equity Incentive Plan. The settlement of any portion of an award in cash will not reduce the number of
shares available for issuance under the Equity Incentive Plan. Shares of our Common Stock withheld under an award to satisfy the exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of
shares available for issuance under the Equity Incentive Plan. With respect to a stock appreciation right, only shares of our Common Stock that are issued upon settlement of the stock appreciation right will count towards reducing the number of
shares available for issuance under the Equity Incentive Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&nbsp;because of a failure to meet a contingency or condition
required for the vesting of such shares; (ii)&nbsp;to satisfy the exercise, strike or purchase price of an award; or (iii)&nbsp;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or
reacquired will revert to and again become available for issuance under the Equity Incentive Plan. We no longer make grants under the Scilex Pharma 2017 Plan or the 2019 Stock Option Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2022, a total of 1,462,271 shares of our Common Stock have been reserved for issuance
pursuant to the ESPP, which number excludes the 1,413,488 shares that were added to the ESPP as a result of the automatic annual increase on January&nbsp;1, 2023. The ESPP provides that the number of shares of our Common Stock reserved and available
for issuance under the ESPP will automatically increase on January&nbsp;1 of each year for a period of up to ten years, commencing on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to the lesser of (A) 1%
of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding calendar year; (B) 1,827,839 shares of our Common Stock (subject to the adjustment for recapitalizations, stock splits, stock dividends
and similar transactions); and (C)&nbsp;such number of shares of our Common Stock determined by our Board or our Compensation Committee prior to January&nbsp;1 of a given year, provided however, that our Board may act prior to January&nbsp;1 of a
given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (A)&nbsp;to (C) above. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_28"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of our financial condition and results of operations should be read together with the consolidated
financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our
actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set
forth in the sections of this prospectus titled &#147;Risk Factors&#148; and &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_29">
</A>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing <FONT
STYLE="white-space:nowrap">non-opioid</FONT> management products for the treatment of acute and chronic pain. We believe that our innovative <FONT STYLE="white-space:nowrap">non-opioid</FONT> product portfolio has the potential to provide effective
pain management therapies that can have a transformative impact on patients&#146; lives. We target indications with high unmet needs and large market opportunities with <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment
of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018 and are developing our late-stage pipeline. Our commercial product, ZTlido is a
prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the
limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. We market ZTlido through a dedicated
sales force of <FONT STYLE="white-space:nowrap">60-70</FONT> sales representatives, targeting 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We <FONT
STYLE="white-space:nowrap">in-licensed</FONT> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> prophylactic treatment for painful gout flares in adults, in the U.S.
We are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
development pipeline consists of three product candidates, <FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (&#147;SEMDEXA&#148;) (10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used
corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, <FONT STYLE="white-space:nowrap">(ii)&nbsp;SP-103</FONT> (lidocaine topical system) 5.4%, a Phase 2, next-generation, triple-strength formulation of ZTlido, for
the treatment of acute LBP, and <FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules), a novel
<FONT STYLE="white-space:nowrap">low-dose</FONT> delayed-release naltrexone hydrochloride formulation for treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to
commence in 2023. SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> has been granted fast track designation by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> alternative to <FONT
STYLE="white-space:nowrap">off-label</FONT> ESIs, which are administered over 12&nbsp;million times annually in the United States. <FONT STYLE="white-space:nowrap">Top-line</FONT> results from the completed Phase 3 study have been received in
November 2021 and reflected achievement of primary and secondary endpoints. <FONT STYLE="white-space:nowrap">SP-103</FONT> has also been granted fast track designation by the FDA and, if approved, could become the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP. <FONT STYLE="white-space:nowrap">SP-103</FONT> is a triple-strength lidocaine topical system designed to deliver a dose of lidocaine threefold
higher than any lidocaine topical product that we are aware of, either approved or in development. We are examining <FONT STYLE="white-space:nowrap">SP-103</FONT> as a treatment for acute LBP, a condition with high unmet need which, as of 2019,
affected over 22&nbsp;million patients in the United States. According to the CDC in 2020, LBP was the most common type of pain reported by patients, with 25% of U.S. adults reporting LBP in the prior 3 months. We initiated a Phase 2 trial of <FONT
STYLE="white-space:nowrap">SP-103</FONT> in acute LBP in the second quarter of our fiscal year 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third
parties for the manufacture, assembly, testing, packaging, storage and distribution of our product. We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates
from sole or single source suppliers </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and manufacturers. Prior to April 2022, we relied on a single third-party logistics distribution provider, Cardinal Health, for ZTlido distribution in the United States. Cardinal Health purchased
and shipped ZTlido to customer wholesale distribution centers. Cardinal Health also performed order management services on our behalf. On April&nbsp;2, 2022, we announced the expansion of our direct distribution network to national and regional
wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our
inception, we have invested substantial efforts and financial resources on acquiring product and technology rights while building our intellectual property portfolio and infrastructure. We acquired Semnur and its lead product candidate, SEMDEXA, in
the first quarter of 2019, and we intend to continue to explore and evaluate additional opportunities such as these to grow our business. We have incurred significant operating losses as a result of such investment efforts, including the development
of SEMDEXA, conducting of Phase 3 trials for SEMDEXA, and the development of <FONT STYLE="white-space:nowrap">SP-103.</FONT> Our ability to generate revenue sufficient to achieve profitability will depend on the successful commercialization of our
product, ZTlido, and the development of our product candidates. For the years ended December&nbsp;31, 2022, 2021, and 2020, we had a net loss of $23.4&nbsp;million and $88.4&nbsp;million, and $47.5 million respectively. As of December&nbsp;31, 2022,
we had an accumulated deficit of approximately $375.9&nbsp;million. As of December&nbsp;31, 2022, we had cash and cash equivalents of approximately $2.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to make investments in our sales and marketing organization and expand digital marketing efforts to broaden awareness of
ZTlido and GLOPERBA and in research and development, clinical trials and regulatory affairs to develop our product candidates, SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103,</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> (acquired from
Sorrento in May 2022). As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue, if ever, we expect to finance our operations through a
combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms, or at
all. If adequate funds on acceptable terms are not available when needed, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or delay, scale back or discontinue the development of one or more of our product
candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_30"></A>Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, we consummated the previously announced Business Combination pursuant to the Agreement and Plan of Merger, dated as
of March&nbsp;17, 2022 (as amended by Amendment No.&nbsp;1 to Agreement and Plan of Merger, dated September&nbsp;12, 2022, together, the &#147;Merger Agreement&#148;), by and among Vickers, Vantage Merger Sub Inc. (&#147;Merger Sub&#148;), a wholly
owned subsidiary of Vickers and Legacy Scilex. Pursuant to the terms of the Merger Agreement, a business combination (herein referred to as the &#147;Business Combination&#148; or &#147;reverse recapitalization&#148; for accounting purposes) between
Vickers and Legacy Scilex was effected through the merger of Merger Sub with and into Legacy Scilex with Legacy Scilex surviving the merger as Vickers&#146;s wholly owned subsidiary. In connection with the Business Combination, Vickers changed its
name from Vickers Vantage Corp. I to Scilex Holding Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Business Combination, New Scilex (as defined below)
received net proceeds of approximately $3.4&nbsp;million. Additionally, all existing related party indebtedness and payables between Legacy Scilex, Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;), and Sorrento, totaling $290.6&nbsp;million,
was converted into equity interests in New Scilex in connection with the consummation of the Business Combination and pursuant to the terms of the Contribution and Satisfaction of Indebtedness Agreement, dated as of September&nbsp;12, 2022, by and
among Sorrento, Legacy Scilex and Scilex Pharma (the &#147;Debt Exchange Agreement&#148;) (see Note 12 titled &#147;<I>Related Party Transactions</I>&#148; to our consolidated financial statements included elsewhere in this prospectus for additional
information). The Company operates as &#147;Scilex Holding Company&#148; and was listed on the Nasdaq Capital Market under the new ticker symbol &#147;SCLX&#148; on November&nbsp;11, 2022. Scilex Holding Company following the completion of the
Business Combination is sometimes referred to herein as &#147;New Scilex&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse recapitalization in accordance with
U.S. GAAP. Under this method of accounting, Vickers was treated as the &#147;acquired&#148; company for accounting purposes and the Business Combination was treated as the equivalent of Legacy Scilex issuing stock for the net assets of Vickers,
accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with no goodwill or other intangible assets recorded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_31">
</A>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>First Quarter 2023 Preliminary Unaudited Financial Results </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 3, 2023, we filed a Current Report on Form&nbsp;8-K providing certain preliminary unaudited financial results as of and for the three
months ended March&nbsp;31, 2023, based on then currently available information. Our independent registered public accounting firm has not reviewed or audited these preliminary estimated financial results. Our actual results may differ materially
from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the responsibility of the Company. We have not fully completed our review of these preliminary financial
results as of and for the three months ended March&nbsp;31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
such Current Report on Form&nbsp;8-K, we estimated that: ZTlido gross sales for the first quarter of 2023 were in the range of $26.7&nbsp;million to $28.3&nbsp;million, compared to $18.4&nbsp;million in the first quarter of 2022, representing growth
in the range of 45% to 54%; net sales for the first quarter of 2023 were in the range of $9.9&nbsp;million to $11.0&nbsp;million, compared to net sales of $6.8&nbsp;million in the first quarter of 2022, representing growth in the range of 45% to
62%. Historically, sales for ZTlido are low during the first quarter of the year due to deductibles with managed healthcare plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible
Debentures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;21, 2023 (the &#147;Agreement Date&#148;), we entered into the Securities Purchase Agreement with the
Selling Securityholder, in connection with the issuance and sale by us, from time to time, of the Convertible Debentures in an aggregate principal amount of up to $25,000,000. The Convertible Debentures have been or will be, as applicable, issued
and sold in three tranches as follows: (i) $10,000,000 upon the signing of the Securities Purchase Agreement (the &#147;First Closing Date&#148;), which has been funded, (ii) $7,500,000 upon the filing of the registration statement of which this
prospectus forms a part with the SEC and (iii) $7,500,000 at the time the registration statement of which this prospectus forms a part is declared effective by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible Debentures bear interest at an annual rate of 7.00% and will mature on December&nbsp;21, 2023. The Convertible Debentures
provide that at any time on or after a Convertible Debenture is issued and remains outstanding, any portion of the outstanding and unpaid principal amount of the Convertible Debentures, together with any accrued but unpaid interest, may be converted
into shares of our Common Stock, at a conversion price of $8.00 per share (the &#147;Conversion Price&#148;). The Selling Securityholder has waived the reset provision on the Conversion Price set forth in the Convertible Debentures. However, the
Conversion Price will be subject to adjustment by reason of stock splits, stock dividends or similar transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible
Debentures may not be converted into shares of Common Stock to the extent such conversion would result in the Selling Securityholder and its affiliates having beneficial ownership of more than 4.99% of our then outstanding shares of Common Stock;
provided that this limitation may be waived by the Selling Securityholder upon not less than 65 days&#146; prior notice to us. In addition, we shall not issue any Common Stock pursuant to the transactions contemplated by the Convertible Debentures
or any other transaction documents executed in connection therewith (including any shares issued pursuant to a conversion) if the issuance of such shares of Common Stock would exceed 29,016,448 (which number of shares represents 19.9% of the
aggregate number of shares of Common Stock issued and outstanding as of the Agreement Date) (the &#147;Convertible Debenture Exchange Cap&#148;). The Convertible Debenture Exchange Cap will not apply under certain circumstances, including if we
obtain the approval of our stockholders as required by the applicable rules of the Nasdaq Capital Market for issuances of shares of Common Stock in excess of such amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Convertible Debentures and subject to certain conditions set
forth therein, we have the right, but not the obligation, in our sole discretion, to redeem, upon five business days&#146; prior written notice to the Selling Securityholder (the &#147;Redemption Notice&#148;), all or any portion of the amounts
outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being
redeemed by us, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible Debentures also contain certain customary representations, warranties, covenants, and events of default including, among other
things, upon cross-defaults under other debt documents, bankruptcy or insolvency events, delisting of the Common Stock or if we become delinquent in our periodic report filings with the SEC. If an event of default occurs and is continuing, the full
unpaid principal amount of the Convertible Debentures, together with interest and other amounts owing in respect thereof, to the date of acceleration shall become, at the Selling Securityholder&#146;s election by notice to us, immediately due and
payable in cash (save for bankruptcy and insolvency events of default, upon the occurrence of which the full unpaid principal amount of the Convertible Debentures, together with interest and other amounts owing in respect thereof to the date of
acceleration, shall automatically become due and payable, in each case without presentment, demand, protest or other notice of any kind). See the section of this prospectus titled &#147;<I>Private Placement</I>&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration statement of which this prospectus forms a part registers the resale by the Selling Securityholder of up to 3,290,000 shares
of Common Stock that can be issued upon the conversion of the Convertible Debentures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>
License </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2023, we acquired from BioDelivery Sciences International, Inc. (&#147;BDSI&#148;) and Collegium
Pharmaceutical, Inc. (&#147;Collegium&#148;, and together with BDSI, the &#147;Collegium Sellers&#148;) the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> (celecoxib oral solution) (the &#147;Product&#148;) and its commercialization in the United States and Canada (the &#147;Territory&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the Company assumed various rights and obligations under that certain asset purchase agreement, dated
August&nbsp;3, 2021 (the &#147;DRL APA&#148;), between BDSI and Dr.&nbsp;Reddy&#146;s Laboratories Limited, a company incorporated under the laws of India (&#147;DRL&#148;), including a license from DRL including an irrevocable, royalty-free,
exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> and patents of DRL related to the Product and necessary or used to exploit the Product in the Territory. Additionally, under the Purchase Agreement, the Collegium Sellers granted
the Company an irrevocable, royalty-free, exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> related to the Product and necessary or used to exploit the Product in the Territory. No cash consideration was or will be payable to the
Collegium Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include obligations to pay royalties to DRL for sales of the Product in the Territory for all indications and additional amounts if
certain milestones are achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. Riley Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2023, we entered into the B. Riley Purchase Agreement with a wholly-owned subsidiary of B. Riley Principal Investments, LLC
(&#147;B. Riley&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the B. Riley Purchase Agreement, we have the right, but not the obligation, to sell to B. Riley up to
$500,000,000 of shares of Common Stock, from time to time at our sole and absolute discretion (each such sale, a &#147;B. Riley Advance&#148;) at any time during the 36 months following the date on which the B. Riley Registration Statement (as
defined below) was initially declared effective by the SEC, subject to the terms of the B. Riley Purchase Agreement. To request a B. Riley Advance, we would submit an advance notice to B. Riley (each, a &#147;B. Riley Advance Notice&#148;)
specifying the number of shares we intend to sell to B. Riley. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-269205)</FONT> related to the B. Riley Purchase Agreement was
initially filed with the SEC on January&nbsp;12, 2023 and was initially declared effective by the SEC on January&nbsp;20, 2023 (as it may be amended or supplemented from time to time, the &#147;B. Riley Registration Statement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock, if any, that we elect to sell to B. Riley pursuant to a B. Riley Advance will be purchased at a price equal to 98%
of the VWAP (as defined below) during the period (such period, the &#147;B. Riley Pricing Period&#148;) beginning at 9:30:01 a.m., New York City time, on the date of purchase of shares of Common Stock (the &#147;B. Riley Advance Shares&#148;) or
such later time publicly announced as the official open of the primary (or &#147;regular&#148;) trading session on Nasdaq on such purchase date (the &#147;Purchase Commencement Time&#148;) and ending at the earliest of (i) 3:59 p.m., New York City
Time, on the purchase date or such earlier time publicly announced as the official close of the primary (or &#147;regular&#148;) trading session on Nasdaq on such purchase date, (ii)&nbsp;immediately at such time following the Purchase Commencement
Time for such purchase that the total number (or volume) of shares of Common Stock traded on Nasdaq during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&nbsp;if we so elect in the applicable
B. Riley Advance Notice for such B. Riley Advance (such election, a &#147;Limit Order Discontinue Election&#148;), such time the sale price of the shares of Common Stock traded on the Nasdaq Capital Market during such B. Riley Pricing Period is less
than the applicable minimum price threshold determined in accordance with the B. Riley Purchase Agreement. For purposes of the B. Riley Purchase Agreement, &#147;VWAP&#148; means, for the Common Stock for a specified period, the dollar
volume-weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg through its &#147;AQR&#148; function, subject to certain exceptions, qualifications and limitations. &#147;Advance Share Volume
Maximum&#148; means, with respect to a B. Riley Advance, if such B. Riley Advance is designated in the B. Riley Advance Notice as a (i)&nbsp;purchase-Type A, a number of shares of Common Stock that is equal to the quotient obtained by dividing
(a)&nbsp;the B. Riley Advance Share amount to be purchased by B. Riley, by (b) 0.10, or (ii)&nbsp;purchase-Type B, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&nbsp;the B. Riley Advance Share amount to be
purchased by B. Riley, by (b) 0.25 (in each case, subject to certain adjustments). We may also specify a certain minimum acceptable price per share in each B. Riley Advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any B. Riley Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, a
B. Riley Advance may be for a number of shares of Common Stock not to exceed (i)&nbsp;with respect to a B. Riley Advance, purchase-Type A, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000, and (b)&nbsp;the product
of (1) 0.10, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during the B. Riley Pricing Period for such purchase-Type A, and (ii)&nbsp;with respect to a B. Riley Advance,
purchase-Type B, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000 and (b)&nbsp;the product of (1) 0.25, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital
Market during the B. Riley Pricing Period for such purchase-Type B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement also provides that we have the right,
but not the obligation, to sell to B. Riley, from time to time subject to certain limitations, at our sole and absolute discretion an additional B. Riley Advance Notice (each, a &#147;B. Riley Additional Advance&#148;). To request an additional
purchase, we would submit an additional B. Riley Advance Notice to B. Riley specifying the number of shares we intend to sell to B. Riley. The purpose of the B. Riley Additional Advance is to allow us to execute more than one advance request on a
purchase date with B. Riley as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each B. Riley Additional Advance is generally subject to terms and conditions consistent with those of a B. Riley Advance,
except for, among other things, the time period of the pricing period for such B. Riley Additional Advance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also specify a certain
minimum acceptable price per share in each B. Riley Advance or B. Riley Additional Advance. In no event is B. Riley obligated to purchase any shares that would result in it owning more than 4.99% of the then-outstanding voting power or number of
shares of Common Stock. Moreover, under the applicable Nasdaq Listing Rules, in no event will we issue to B. Riley shares that, in the aggregate, would exceed the 19.9% B. Riley Exchange Cap, unless we have received stockholder approval for such
issuance or such issuance is otherwise permitted by applicable Nasdaq Listing Rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Riley&#146;s obligation to purchase shares of Common Stock pursuant to the B. Riley
Purchase Agreement is subject to a number of conditions, including that a registration statement be filed with the SEC registering the resale of the B. Riley Commitment Shares and the shares to be issued pursuant to any B. Riley Advance or B. Riley
Additional Advance under the Securities Act, and that the registration statement is declared effective by the SEC. As consideration for B. Riley&#146;s commitment to purchase shares of Common Stock at our direction upon the terms and subject to the
conditions set forth in the B. Riley Purchase Agreement, we issued to B. Riley 250,000 shares of Common Stock. Subsequent to the execution of the B. Riley Purchase Agreement on January&nbsp;8, 2023 and through the date of this prospectus, we have
sold 127,241 shares of our Common Stock pursuant to advances under the B. Riley Purchase Agreement for aggregate net proceeds to the Company of approximately $1.0&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A&amp;R Yorkville Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;17, 2022, we entered into a standby equity purchase agreement (the &#147;Original Purchase Agreement&#148;) with the Selling
Securityholder. The Selling Securityholder is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. On February&nbsp;8, 2023, we entered into an amended and restated standby equity purchase agreement with the
Selling Securityholder (the &#147;A&amp;R Yorkville Purchase Agreement&#148;), amending, restating and superseding the Original Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Yorkville Purchase Agreement, we have the right, but not the obligation, to sell to the Selling Securityholder up to
$500,000,000 of shares of Common Stock, from time to time at our sole and absolute discretion (each such sale, a &#147;Yorkville Advance&#148;) by delivering written notice to the Selling Securityholder (each, a &#147;Yorkville Advance Notice&#148;)
until the first day of the month following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which the Yorkville Registration Statement (as defined below) was initially declared effective by the SEC. Pursuant to the
terms of the Original Purchase Agreement, we initially filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607)</FONT> (as it may be amended or supplemented from
time to time, the &#147;Yorkville Registration Statement&#148;) related to the Original Purchase Agreement with the SEC on November&nbsp;30, 2022 (following the execution of the Original Purchase Agreement). The Yorkville Registration Statement was
initially declared effective by the SEC on December&nbsp;9, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock purchased pursuant to a Yorkville Advance
will be purchased at a price equal to 98% of the VWAP (as defined below) during the applicable pricing period (each, a &#147;Yorkville Pricing Period&#148;) for such Yorkville Advance, which shall be the period commencing upon receipt by the Selling
Securityholder of the Yorkville Advance Notice (or the open of regular trading hours, if later) and ending on 4:00 p.m. on the same day. For purposes of the A&amp;R Yorkville Purchase Agreement, &#147;VWAP&#148; means, for a specified period, the
volume weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg L.P. through its &#147;AQR&#148; function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Yorkville Advance may be for a number of shares of Common Stock not to exceed 200% of the average of the daily trading volume of the
Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five trading days immediately preceding the date of the Yorkville Advance Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder&#146;s purchase of shares of Common Stock under the A&amp;R Yorkville Purchase Agreement would be subject to
certain limitations, including that the Selling Securityholder may not purchase shares that would result in it (together with its affiliates) owning more than 4.99% of the outstanding voting power or number of shares of Common Stock after such
purchase or that would result in it owning more than 19.9% of the Company&#146;s aggregate amount of Common Stock issued and outstanding as of the date of the Original Purchase Agreement (the &#147;Yorkville Exchange Cap&#148;). The Yorkville
Exchange Cap will not apply under certain circumstances, including if the average price of all applicable sales of Common Stock under the A&amp;R Yorkville Purchase Agreement equals or exceeds a certain minimum price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We previously paid the Selling Securityholder a structuring fee of $10,000 and issued
250,000 shares of Common Stock to the Selling Securityholder as a commitment fee pursuant to the Original Purchase Agreement (the &#147;Yorkville Commitment Shares&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder&#146;s obligation to purchase shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement is
subject to a number of conditions, including that a registration statement be filed with the SEC registering the resale of the Yorkville Commitment Shares and the shares to be issued pursuant to any Yorkville Advance under the Securities Act, and
that such registration statement is declared effective by the SEC. Pursuant to the terms of the Original Purchase Agreement, the Company previously filed the Yorkville Registration Statement with the SEC on November&nbsp;30, 2022, which was
initially declared effective by the SEC on December&nbsp;9, 2022. During the year ended December&nbsp;31, 2022, no Yorkville Advances were requested or completed under the A&amp;R Yorkville Purchase Agreement. Subsequent to December&nbsp;31, 2022,
the Company sold 85,000 shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds to the Company of approximately $0.6&nbsp;million on February&nbsp;16, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_32"></A>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are closely monitoring the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and its potential impact on our business. In an effort
to protect the health and safety of our employees, we took proactive action from the earliest signs of the outbreak, including implementing social distancing policies at our facilities, facilitating remote working arrangements and imposing employee
travel restrictions. The extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> may impact our business, clinical trials and sales of ZTlido will depend on future developments, which are highly uncertain and cannot be predicted with
confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of
actions taken in the United States and other countries to contain and treat the disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_33"></A>Comparability of Our Results and
Our Relationship with Sorrento </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently operate as a majority-owned subsidiary of Sorrento. As a result, our consolidated
financial statements may not be reflective of what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento. In particular, certain legal, finance, human resources and
other functions have historically been provided to us by Sorrento at cost plus an agreed-upon markup. We expect that Sorrento may continue to provide us with some of the services related to these functions on a transitional basis in exchange for
agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Sorrento. We will also incur additional costs as a stand-alone public company. As a stand-alone public company, our total costs
related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and an
enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_34"></A>Sorrento
Chapter 11 Filing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2023, Sorrento, together with its wholly-owned direct subsidiary, Scintilla Pharmaceuticals,
Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. While the Company is majority-owned by Sorrento, the Company is not a debtor in
Sorrento&#146;s voluntary Chapter 11 filing. As of December&nbsp;31, 2022, the Company had a $1.8&nbsp;million related party receivable from Sorrento related to certain invoices paid on behalf of Sorrento, which was fully reserved. The Company will
evaluate the collectability of this receivable on a quarterly basis going forward. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_35"></A>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue consists
solely of product sales of ZTlido in the United States. For product sales of ZTlido, we record <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> sales adjustments for government and commercial rebates,
chargebacks, wholesaler and distributor fees, sales returns, special marketing programs, and prompt payment discounts. We expect that any net revenue we generate will fluctuate from year to year as a result of the unpredictability of the demand for
our product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Costs and Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cost of Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue consists
of the cost of purchasing ZTlido from our manufacturing partners, inventory write-downs related to expiration dates for <FONT STYLE="white-space:nowrap">on-hand</FONT> inventory, cost of shipments, and royalty payments to our manufacturers. We
expect the cost of revenue to fluctuate with related sales revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are expensed when incurred and consist primarily of costs incurred for our research activities, including the
development of our product candidates, and include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">salaries, benefits and other related costs, including stock-based compensation expense for personnel engaged in
research and development functions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to outside consultants. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase, as we will incur incremental expenses associated with our product candidates that
are currently under development and in clinical trials. Product candidates in later stages of clinical development generally have higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Accordingly,
we expect to incur significant research and development expenses in connection with our Phase 3 clinical trial for SEMDEXA, our ongoing Phase 2 clinical trials for <FONT STYLE="white-space:nowrap">SP-103,</FONT> and initiation of Phase 2 trials for <FONT
STYLE="white-space:nowrap">SP-104.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist primarily of costs related to our contract sales force, salaries and other related costs,
including stock-based compensation, for personnel in our executive, marketing, finance, corporate and business development and administrative functions. Selling, general and administrative expenses also include professional fees for legal, patent,
accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses from Sorrento for rent and maintenance of facilities and other operating costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our selling, general and administrative expenses will vary year over year in the future as we adapt our commercial strategies
to changes in the business environment. We also expect to incur increased expenses as a result of the Business Combination and operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and
listing standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to adjust the size of our
administrative, finance and legal functions to adapt to the changes above and the anticipated growth of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Intangible Amortization Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense consists of the amortization expense of intangible assets recognized on a straight-line basis over the
estimated useful lives of the assets. Our intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Gain) Loss on Derivative
Liability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability consists of the changes to fair value of derivative liabilities between reporting
periods relating to certain embedded derivative features within the Scilex Pharma Notes, and is recorded as other income or expense. See Note 7 titled &#147;<I>Debt</I>&#148; and Note 12 titled &#147;<I>Related Party Transactions</I>&#148; to our
consolidated financial statements appearing elsewhere in this prospectus for a description of the Scilex Pharma Notes. Gain on derivative liability also included the remeasurement of the warrant derivative liability. See Note 4 titled &#147;<I>Fair
Value Measurements</I>&#148; to our consolidated financial statements appearing elsewhere in the prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Gain) Loss on Debt Extinguishment, Net
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net consists of gains earned or losses incurred as a result of exercising our optional prepayment
rights, which are treated as partial extinguishments, and the Early Paydown Provision, which is treated as a debt extinguishment, under the Scilex Pharma Notes, offset, for the year ended December&nbsp;31, 2021, by a gain on debt extinguishment as a
result of the forgiveness of the loan in the amount of $1.6&nbsp;million received from Bank of America in May 2020 pursuant to the Paycheck Protection Program of the CARES Act (the &#147;PPP Loan&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense
consists of interest related to the Scilex Pharma Notes and related party note payables to Sorrento. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Loss (gain) on Foreign Currency Exchange </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss (gain) on foreign currency exchange relates to foreign exchange losses on payments made to our foreign supplier, Itochu Chemical Frontier
Corporation (&#147;Itochu&#148;), a manufacturer and supplier of lidocaine tape products, including ZTlido and <FONT STYLE="white-space:nowrap">SP-103.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_36"></A>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our results of operations for the years ended December&nbsp;31, 2022 and 2021 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B>(in thousands, except for per share amounts)<B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating costs and expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating costs and expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other (income) expense:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) gain on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other (income) expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares during the period&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For financial information and discussions pertaining to the year ended December&nbsp;31, 2020, refer to the
initial filing of the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607),</FONT> which was initially filed on November&nbsp;30, 2022 and initially declared effective
by the SEC on December&nbsp;9, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_37"></A>Comparison of Years Ended December&nbsp;31, 2022 and 2021 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the
years ended December&nbsp;31, 2022<B> </B>and 2021 was $38.0&nbsp;million and $31.3&nbsp;million, respectively. The increase of $6.7&nbsp;million was driven by the increased volume of gross product sales of ZTlido by approximately 50% offset by
increase in rebates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the years ended December&nbsp;31, 2022 and 2021 was $10.8&nbsp;million and $3.6&nbsp;million, respectively, and relates to
product sales. The increase of $7.2&nbsp;million was primarily due to an approximately 50% increase in gross revenue for the years ended December&nbsp;31, 2022 compared to the year ended December&nbsp;31, 2021, royalty expense of $4.5&nbsp;million
beginning in the second quarter of 2022, and the sale of $0.5&nbsp;million of fully reserved inventory in May 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the years ended December&nbsp;31, 2022 and 2021 (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase<BR>(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SP-102</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">SP-102</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SP-103</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">SP-103</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SP-104</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">SP-104</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GLOPERBA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total GLOPERBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Research and Development Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&nbsp;31, 2022 and 2021 were $9.1&nbsp;million
and $9.2&nbsp;million, respectively. The $0.1&nbsp;million decrease was primarily attributed to the phasing out of the Phase 3 <FONT STYLE="white-space:nowrap">SP-102</FONT> trial in 2022, and was partially offset by the clinical trial costs of
Phase 2 <FONT STYLE="white-space:nowrap">SP-103</FONT> in 2022, the Phase 1 <FONT STYLE="white-space:nowrap">SP-104</FONT> study in the first two quarters of 2022, and the development costs for GLOPERBA in the last quarter of 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the years ended December&nbsp;31, 2022 and 2021 were $64.9&nbsp;million and
$50.6&nbsp;million, respectively. The increase of approximately $14.3&nbsp;million was primarily due to a $7.5&nbsp;million increase in legal expenses related to the ZTlido patent infringement in which the Company was the plaintiff,
$1.1&nbsp;million increase in travel and entertainment expenses, $3.1&nbsp;million increase in consulting expenses, $2.1&nbsp;million increase in insurance expense related to a directors and officers (D&amp;O) insurance policy incurred after the
Business Combination, $0.6&nbsp;million increase in personnel expense, and a $1.8&nbsp;million increase related to a related party receivable reserve, offset by a $0.4&nbsp;million decrease in contracted services, $1.2&nbsp;million decrease in
marketing expense, and a $0.3&nbsp;million decrease in other expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intangible Amortization Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense for each of the years ended December&nbsp;31, 2022 and 2021 was $3.9&nbsp;million and $3.7&nbsp;million,
respectively. The increase of $0.2&nbsp;million is related to the amortization of acquired licenses for the exclusive license of GLOPERBA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(Gain) Loss on Derivative Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability for the years ended December&nbsp;31, 2022 and 2021 was $(8.3) million and $0.3&nbsp;million, respectively.
The gain and loss recognized during the years ended December&nbsp;31, 2022 and 2021, respectively, was attributed to changes in the fair value of our derivative liability pertaining to the Scilex Pharma Notes due to revised sales forecasts and the
derivative warrant liability associated with the Private Warrants assumed in the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(Gain) Loss on Debt Extinguishment, Net
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net for the years ended December&nbsp;31, 2022 and 2021 was $(28.6) million and
$12.5&nbsp;million, respectively. The gain and loss incurred during the years ended December&nbsp;31, 2022 and 2021, respectively, was attributed to Scilex Pharma&#146;s repurchase of the Scilex Pharma Notes of $20.0&nbsp;million and
$41.4&nbsp;million in February 2022 and June 2022, respectively, as well as the Early Paydown Provision of $39.7&nbsp;million in September 2022 (see Note 7 titled &#147;<I>Debt</I>&#148; to our consolidated financial statements included elsewhere in
this prospectus for additional information) and $20.0&nbsp;million in each of February 2021 and April 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&nbsp;31, 2022 and 2021 was $9.6&nbsp;million and $11.8&nbsp;million, respectively. The decrease
recognized during the years ended December&nbsp;31, 2022 and 2021, respectively, was attributed to the payment of Scilex Pharma Notes in September 2022 and the conversion of related party notes payable with Sorrento that was outstanding as of the
closing of the Business Combination into shares of Preferred Stock and Common Stock pursuant to the Debt Exchange Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax Expense
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expense for the years ended December&nbsp;31, 2022 and 2021 was $4&nbsp;thousand and $5&nbsp;thousand, respectively.
The lower income tax expense during the year ended December&nbsp;
31, 2022 was primarily due to an increase in share-based compensation tax benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_38"></A>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, we had cash and cash equivalents of approximately $2.2&nbsp;million. In connection with the completion of the
Business Combination, we received approximately $3.4&nbsp;million from the balance of the Vickers&#146;s Trust Account (the &#147;Trust Account&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have funded our operations primarily through the issuance of the Scilex Pharma Notes, related party notes with Sorrento, and the 2020
revolving credit facility. We also have deferred consideration related to the GLOPERBA license acquired in 2022. The following table summarizes the aggregate indebtedness of these issuances as of December&nbsp;31, 2022 and December&nbsp;31, 2021 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related Party Notes with Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020 Revolving Credit Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Consideration with Romeg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total indebtedness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Scilex Pharma Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the irrevocable standby letter of credit, issued by
Sorrento to Scilex Pharma (the &#147;Letter of Credit&#148;), as required under the terms of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Indenture (as defined below) as a result of actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes (as defined below) through December&nbsp;31, 2021 being less than
a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan and Scilex Pharma
became subject to a minimum cash requirement of $10.0&nbsp;million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $20.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;2, 2022, Sorrento and the Company entered into a Consent Under and Amendment No.&nbsp;4 with U.S. Bank Trust Company, National
Association (as successor in interest to U.S. Bank National Association), as trustee (the &#147;Trustee&#148;) and collateral agent (the &#147;Agent&#148;), and the beneficial owners of those certain senior secured notes due 2026 issued by Scilex
Pharma in September 2018 (the &#147;Scilex Pharma Notes&#148;) listed on the signature pages thereto (the &#147;Holders&#148;), which amended that certain Indenture, dated September&nbsp;7, 2018, by and among Scilex Pharma, Sorrento, the Trustee and
the Agent, as amended (the &#147;Indenture&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the amendment to the Indenture (1)&nbsp;on June&nbsp;3, 2022, Scilex
Pharma repurchased $41.4&nbsp;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2)&nbsp;the Holders agreed that Scilex Pharma can repurchase the remaining principal amount of
the Scilex Pharma Notes at any time on or before September&nbsp;30, 2022 for $41.4&nbsp;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Holders will forgive and discharge $28.0&nbsp;million of the
aggregate principal amount of the Scilex Pharma Notes, (3)&nbsp;the minimum cash requirement under the Indenture was reduced to $5.0&nbsp;million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4)&nbsp;the maximum
aggregate principal amount of that certain intercompany promissory note issued by Scilex Pharma to Sorrento on October&nbsp;5, 2018 was increased from up to $25.0&nbsp;million to up to $50.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $1.7&nbsp;million. On
September&nbsp;28, 2022, Scilex Pharma repurchased all of the outstanding aggregate principal amount of the Scilex Pharma Notes. As of immediately prior to the repurchase, the aggregate principal amount of the Scilex Pharma Notes was approximately
$67.7&nbsp;million, and Scilex Pharma repurchased the Scilex Pharma Notes for an aggregate cash payment of $39.7&nbsp;million as the holders of the Scilex Pharma Notes forgave and discharged an aggregate of $28.0&nbsp;million of principal amount of
the Scilex Pharma Notes in connection with the repurchase. See Note 7 titled &#147;<I>Debt</I>&#148; to our consolidated financial statements elsewhere in this prospectus for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarterly principal payments, based on a percentage of projected net sales of ZTlido, optional and contingently accelerated repurchases, and
the Early Paydown Provision under the Scilex Pharma Notes since January&nbsp;1, 2021 are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Three Months Ended,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Principal<BR>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2021*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;30, 2021*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;30, 2022*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;30, 2022*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total payments since January&nbsp;1, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes repurchase or Early Paydown Provision during the period (see Note 7 titled &#147;<I>Debt</I>&#148; to
our consolidated financial statements elsewhere in this prospectus). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Deferred Consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have $3.7&nbsp;million of deferred consideration related to minimum royalty payments that were included in the initial measurement of
consideration transferred for the GLOPERBA license (see Note 3 titled &#147;<I>Acquisitions</I>&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information). Deferred consideration minimum royalty
payments begin the first full quarter following June&nbsp;14, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other contractual obligations include the following: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ZTlido Royalties </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex Pharma is a
party to the Product Development Agreement with the Developers, pursuant to which the Developers will manufacture and supply lidocaine tape products, including the Products, for Scilex Pharma. Pursuant to the Product Development Agreement, Scilex
Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. During the year ended December&nbsp;31, 2022, Scilex Pharma made royalty payments in the amount of $2.3&nbsp;million. As of
December&nbsp;31, 2022, Scilex Pharma had ending balances of accrued royalty payables of $2.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Scilex
Pharma is in a net profit position, as defined in the Product Development Agreement, Scilex Pharma will first attempt to make aggregate royalty payments with cash generated from its operations. If these sources are insufficient, Scilex Pharma may
seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contingent Consideration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
$280.0&nbsp;million, $13.0&nbsp;million, and $23.0&nbsp;million in aggregate contingent consideration obligations in connection with the SEMDEXA, GLOPERBA, and <FONT STYLE="white-space:nowrap">SP-104</FONT> acquisitions (see Note 3 titled
&#147;<I>Acquisitions</I>&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information), respectively, that are contingent upon achieving certain specified milestones or the occurrence of certain
events. Contingent consideration obligations are comprised of regulatory milestones and additional payments that will be due upon the achievement of certain amounts of net sales (see Note 3 titled &#147;<I>Acquisitions</I>&#148; to our consolidated
financial statements included elsewhere in this prospectus for additional information). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Standby Equity Purchase Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;8, 2023, we entered into the A&amp;R Yorkville Purchase Agreement with Yorkville, whereby we have the right, but not the
obligation, to sell to Yorkville up to $500.0&nbsp;million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable
pursuant thereto has been declared effective by the SEC, subject to the terms therein. The registration statement filed with the SEC in connection with the Original Purchase Agreement was initially declared effective by the SEC on December&nbsp;9,
2022 and we are now able to offer and sell shares of our Common Stock under that agreement, subject to the limitations set forth therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2023, we entered into the B. Riley Purchase Agreement with B. Riley, whereby we have the right, but not the obligation, to
sell to B. Riley up to $500.0&nbsp;million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto has
been declared effective by the SEC, subject to the terms therein. The registration statement filed with the SEC in connection with the B. Riley Purchase Agreement was initially declared effective by the SEC on January&nbsp;20, 2023 and we are now
able to offer and sell shares of our Common Stock under that agreement, subject to the limitations set forth therein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Liquidity Needs
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may use all our
available capital resources sooner than we expect. The amount and timing of our future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree of success we experience in commercializing ZTlido and GLOPERBA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue generated by sales of ZTlido, GLOPERBA, and other products that may be approved, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates,
SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103,</FONT> and <FONT STYLE="white-space:nowrap">SP-104;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing ZTlido, GLOPERBA and our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current
or future collaboration or license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements
and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which ZTlido, GLOPERBA, or any of our product candidates, if approved for commercialization, is
adopted by the physician community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to expand our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing products and product candidates and other market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and types of future products we develop and commercialize; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product liability or other lawsuits related to our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending
intellectual property-related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and scope of our general and administrative expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should our sales of ZTlido, GLOPERBA and other product candidates not materialize at the anticipated rate contemplated in our business plan,
we will need to raise additional capital in order to continue to fund our research and development, including our plans for clinical and preclinical trials and new product development, as well as to fund operations generally. We will seek to raise
additional funds through various potential sources, such as equity and debt financings and license agreements. As discussed above, following the completion of the Business Combination, we entered into the A&amp;R Yorkville Purchase Agreement and the
B. Riley Purchase Agreement. The registration statements filed with the SEC in connection with the Original Purchase Agreement and the B. Riley Purchase Agreement were initially declared effective by the SEC on December&nbsp;9, 2022 and
January&nbsp;20, 2023, respectively, and we are now able to offer and sell shares of our Common Stock under both agreements (subject to the limitations set forth therein), which will provide us with an additional source of liquidity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the liquidity provided by revenue generating products, Yorkville Advances under the A&amp;R Yorkville Purchase Agreement and B.
Riley Advances and B. Riley Additional Advances under the B. Riley </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Purchase Agreement, we will receive up to an aggregate of approximately $126.5&nbsp;million from the exercise of the Warrants (at an exercise price of $11.50 per share of Common Stock), assuming
the exercise in full of all of the Warrants for cash, but will not receive any proceeds from the sale of the shares of our Common Stock issuable upon such exercise. However, our ability to generate proceeds will depend on the market price of our
Common Stock. If the price of our Common Stock falls and remains below $11.50 per share, we believe warrant holders will be unlikely to cash exercise their Warrants, resulting in little or no cash proceeds to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities held by Sorrento and the Sponsors that were previously registered for resale on a registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268603)</FONT> filed with the SEC on November&nbsp;30, 2022, which was initially declared effective by the SEC on December&nbsp;27, 2022 represent a
significant percentage of our outstanding Common Stock. As the restrictions on resale end, the Sponsors and Sorrento (who holds 66,476,412 shares of our Common Stock representing approximately 44% of the shares of our Common Stock outstanding as of
March&nbsp;31, 2023 (assuming the full exercise of all outstanding Warrants held by Sorrento and the Sponsors)) are able to sell all of the shares of our Common Stock and any Warrants registered for resale thereunder for so long as such registration
statement is available for use. The sale, or indication of an intention to sell, substantial amounts of our Common Stock or Warrants could result in a significant decline in the public trading price of our securities and impair our ability to raise
capital through the sale of additional equity securities. Even if the current trading price of our Common Stock is at or significantly below the price at which the units were issued in Vickers&#146;s IPO, the Sponsors and Sorrento may have an
incentive to sell because they will still profit on sales due to the lower price at which they purchased their shares compared to the public stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can give no assurances that we will be able to secure additional sources of funds to support our operations on acceptable terms, or at all,
or, if such funds are available to us, that such additional financing will be sufficient to meet our needs. These conditions, among others, raise substantial doubt about our ability to continue as a going concern. If we raise additional funds by
issuing equity or convertible debt securities, including pursuant to the A&amp;R Yorkville Purchase Agreement and the B. Riley Purchase Agreement, it could result in dilution to our existing stockholders or increased fixed payment obligations. In
addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we incur additional indebtedness, we could become subject to covenants that would
restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions
that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but we may have to relinquish valuable rights to ZTlido, GLOPERBA, or our
product candidates or grant licenses on terms that are not favorable to us. Any of the foregoing could significantly harm our business, financial condition and results of operations. If we are unable to raise additional capital in sufficient amounts
or on terms acceptable to us, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or delay, scale back or discontinue the development of one or more of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also need to take certain other actions to allow us to maintain our projected cash and projected financial position including but not
limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <FONT STYLE="white-space:nowrap">SP-102,</FONT>
<FONT STYLE="white-space:nowrap">SP-103,</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> and other discretionary costs. Although we believe such plans, if executed and coupled with the above described sources of liquidity, should provide
us with financing to meet our needs, successful completion of such plans is dependent on factors outside of our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate
that we will continue to incur net losses into the foreseeable future as we support our clinical development to expand approved indications, continue our development of, and seek regulatory approvals for, our product candidates, and expand our
corporate infrastructure. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. See Note 2 titled
&#147;<I>Liquidity and Going Concern</I>&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information. Net proceeds </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from the Trust Account in connection with the Business Combination, together with our existing cash and cash equivalents and proceeds from any Yorkville Advances made under the A&amp;R Yorkville
Purchase Agreement or any B. Riley Advances or B. Riley Additional Advances made under the B. Riley Purchase Agreement, may be insufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the next 12
months. If these sources are insufficient to satisfy our liquidity requirements, we may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
summarizes our cash flows for each of the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flow Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used for) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For financial information and discussions pertaining to the year ended December&nbsp;31, 2020, refer to the
initial filing of the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607),</FONT> which was initially filed on November&nbsp;30, 2022 and initially declared effective
by the SEC on December&nbsp;9, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, net cash used for operating activities was approximately $21.3&nbsp;million, primarily from our net
loss of $23.4&nbsp;million, other <FONT STYLE="white-space:nowrap">non-cash</FONT> reconciling items of $43.6&nbsp;million related to depreciation and amortization, stock-based compensation, <FONT STYLE="white-space:nowrap">non-cash</FONT> operating
lease cost, <FONT STYLE="white-space:nowrap">non-cash</FONT> interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net gain on debt extinguishment, and a gain on derivative
liabilities and offset by changes in operating assets and liabilities that provided $45.7&nbsp;million of cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2021, net cash used for operating activities was approximately $28.7&nbsp;million, primarily from our net loss of $88.4&nbsp;million offset by other <FONT STYLE="white-space:nowrap">non-cash</FONT> reconciling items of
$46.1&nbsp;million related to depreciation and amortization, principal increase to the Scilex Pharma Notes, stock-based compensation, <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease cost,
<FONT STYLE="white-space:nowrap">non-cash</FONT> interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net loss on debt extinguishment, and a loss on derivative liabilities,
and by changes in operating assets and liabilities that provided $13.6&nbsp;million of cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, net cash used for investing activities was approximately $2.1&nbsp;million attributed to cash paid
for the acquisition of GLOPERBA licenses from Romeg and $7.0&nbsp;thousand attributed to cash paid for property and equipment purchases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2021, no cash was used for investing activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, net cash provided by financing activities was approximately $21.2&nbsp;million and is primarily
related to $51.9&nbsp;million in proceeds from related party payables, $62.5&nbsp;million in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeds from related party note payables, $9.9&nbsp;million in proceeds from the CNH Revolving loan, $96.0&nbsp;thousand in proceeds from the exercise of stock options, and $3.4&nbsp;million in
proceeds from the Business Combination, offset by $18.8&nbsp;million repayment on CNH Revolving Loan, $84.8&nbsp;million repayment of the Scilex Pharma Notes, and $2.9&nbsp;million on transaction costs payment related to the Business Combination.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2021, net cash provided by financing activities was approximately $28.2&nbsp;million and was
primarily related to $47.9&nbsp;million in proceeds from related party payables, $47.8&nbsp;million in proceeds from the CNH Revolving Loan, $14.7&nbsp;million in proceeds from related party note payable with Sorrento, and offset by
$48.8&nbsp;million repayment of the CNH Revolving Loan and $33.4&nbsp;million repayment of the Scilex Pharma Notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_39"></A>Critical
Accounting Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This management&#146;s discussion and analysis of our financial condition and results of operations are based
upon our consolidated financial statements which are prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the
reported amounts of revenue and expenses during the reporting period. We continually evaluate our estimates and judgments and base them on historical experience and other factors that we believe to be reasonable under the circumstances. Materially
different results can occur as circumstances change and additional information becomes known. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the following accounting
policies and estimates are most critical to aid in understanding and evaluating our reported financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue to date has been generated from product sales of ZTlido. We do not have significant costs associated with obtaining contracts with
our customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue when control of the products is transferred to the customers in an amount that reflects the
consideration we expect to receive from the customers in exchange for those products. In accordance with FASB ASC Topic 606 &#147;<I>Revenue from Contracts with Customers</I>&#148;, this process involves identifying the contract with a customer,
determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A
performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified
in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. We recognize revenue
for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our performance obligations with respect to sales of ZTlido are satisfied at a certain point in time, and we consider control to have
transferred upon delivery to the customer. We consider control to have transferred upon delivery to the customer because, upon delivery, the customer has legal title to the asset, physical possession of the asset has been transferred to the
customer, the customer has significant risks and rewards in connection with ownership of the asset, and we have a present right to payment from the customer at that time. Invoicing typically occurs upon shipment and the length of time between
invoicing and the date on which payment is due is not significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established
for commercial and government rebates, fees, and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in our customer contracts, customary
industry practices and current government regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rebates and Chargebacks </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rebates are discounts that we pay under either government or private health care programs. Government rebate programs include state Medicaid
drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which we pay rebates and fees for access to
and position on that provider&#146;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated with commercial healthcare
providers. Both types of rebates vary over time. We record a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. We monitor the sales trends and adjust for these rebates
on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are recorded as accrued rebates and fees under current liabilities within the Company&#146;s consolidated balance
sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prompt Payment Discounts </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
provide our customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based
on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Service Fees </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compensate our customers
and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received are not distinct from our sale of products to the customers, and therefore, these payments have been recorded as a
reduction of revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product Returns </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are obligated to accept the return of products sold that are damaged or do not meet certain specifications. We currently estimate our
product returns using historical trends and product return rates typically experienced in the industry and record this estimate as a reduction of revenue in the period the related product revenue is recognized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Co-payment</FONT> Assistance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive
<FONT STYLE="white-space:nowrap">co-payment</FONT> assistance. We accrue for <FONT STYLE="white-space:nowrap">co-payment</FONT> assistance based on actual program participation and estimates of program redemption using data provided by third-party
administrators. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on our consolidated balance sheets at their fair value on the date of issuance and are revalued on each
balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities included embedded derivatives that were identified and required bifurcation from the Scilex Pharma Notes and separate
accounting as a single compound derivative. Certain of these embedded </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
features include default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The Scilex Pharma Notes were
fully extinguished in September 2022 and, as such, there were no remaining derivative liabilities associated with the Scilex Pharma Notes as of December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At closing of the Business Combination, the Company assumed a derivative warrant liability of $2.5&nbsp;million related to Private Warrants
(See Note 8 titled &#147;<I>Stockholders&#146; Equity</I>&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information). The warrant liability associated with the Private Warrants was valued using
the Black-Scholes option pricing model, which is considered to be Level&nbsp;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected
volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
account for stock-based compensation in accordance with FASB ASC Topic 718 &#147;<I>Compensation &#150; Stock Compensation</I>&#148;, which establishes accounting for equity instruments exchanged for employee and consulting services. Under such
provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line-method, over the employee&#146;s requisite service period (generally
the vesting period of the equity grant) or <FONT STYLE="white-space:nowrap">non-employee&#146;s</FONT> vesting period. We account for forfeitures as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life
assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate
of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. We use these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of
stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legacy Scilex Common Stock Valuation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing of the Business Combination, the estimated fair value of the Legacy Scilex Common Stock was determined by the board of
directors of Legacy Scilex (the &#147;Legacy Scilex Board&#148;), considering our most recently available third-party valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#146;s assessment of additional objective and subjective
factors that it believed were relevant, and factors that may have changed from the date of the most recent valuation through the date of the stock option grant. Prior to the Business Combination, given the absence of a public trading market for the
Legacy Scilex Common Stock, the valuations of the Legacy Scilex Common Stock were determined in accordance with the &#147;American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held Company Equity
Securities Issued as Compensation.&#148; The Legacy Scilex Board exercised its reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of fair value of the Legacy Scilex Common Stock, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Independent valuations of the Legacy Scilex Common Stock performed at periodic intervals by an independent
third-party valuation firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The likelihood of achieving a liquidity event, such as an initial public offering or sale of the company and the
potential value of a strategic merger or sale at different time points, given prevailing market conditions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our historical operating and financial performance as well as our estimates of future financial performance,
including the regulatory status of ZTlido and GLOPERBA and the timing and probability of continuing growth since commercialization of ZTlido and GLOPERBA under different operational scenarios; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The status of research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our stage of development and commercialization and our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Industry information such as market trends and macro-economic events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Valuations of comparable companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adjustments to recognize a relative lack of marketability of the Legacy Scilex Common Stock; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional objective and subjective factors relating to our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dates of our valuations did not always coincide with the dates of our stock option grants. In determining the exercise prices of the stock
options at each grant date, the Legacy Scilex Board considered, among other things, the most recent valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#146;s assessment of additional objective and subjective factors we believed
were relevant as of the grant date. The additional factors considered when determining any changes in fair value between the most recent valuation and the grant dates included our operating and financial performance and current business conditions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying the valuations represented management&#146;s best estimate, which involved inherent uncertainties and the
application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of the Legacy Scilex Common Stock and Legacy Scilex&#146;s stock-based compensation expense could have been
materially different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since a public trading market for our Common Stock has been established in connection with the closing of the
Business Combination, it is no longer necessary for our Board to estimate the fair value of our Common Stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our Common Stock will
be determined based on the quoted market price of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_40"></A>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 1 titled &#147;<I>Nature of Operations and Basis of Presentation</I>&#148; of the notes to our consolidated financial statements
included elsewhere in this prospectus for a discussion of recent accounting pronouncements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_41"></A><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have, during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
arrangements, as defined under applicable SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_42"></A>Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our related party transactions, see the section of this prospectus titled &#147;Certain Relationships and Related Party
Transactions&#148; and Note 12 titled &#147;<I>Related Party Transactions</I>&#148; to our consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_43"></A>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exposure to
market risk is confined to our cash and cash equivalents. We have cash and cash equivalents and invest primarily in high-quality money market funds, which we believe are subject to limited credit risk. Due to the low risk profile of our investments,
an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to April&nbsp;2, 2022, sales to our sole customer and third-party logistics distribution provider, Cardinal Health, represented 100% of
our net revenue. On April&nbsp;2, 2022, we announced the expansion of our direct distribution network to national and regional wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for us.
Additionally, during the year ended December&nbsp;31, 2022, we purchased inventory from our sole supplier, Itochu. This exposes us to concentration of customer and supplier risk. We monitor the financial condition of our customers, limit our credit
exposure by setting credit limits, and have not experienced any credit losses for the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_44"></A>Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#147;emerging growth company&#148; as defined in the JOBS Act is eligible to take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies. Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any
such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public
companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business
could significantly affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are in the process of evaluating
the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an emerging growth company we may take advantage of certain exemptions from
various reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirement to obtain an attestation and report from our auditors on the
assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board
requiring mandatory audit firm rotation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will qualify and will remain as an emerging growth company
until the earlier of (i)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the closing of the IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or (c)&nbsp;in which we are
deemed to be a large accelerated filer, which means the market value of our common equity of that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equals or exceeds $700&nbsp;million as of the last business day of our most recently
completed second fiscal quarter; and (ii)&nbsp;the date on which we have issued more than $1.00&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. References herein to
&#147;emerging growth company&#148; have the meaning associated with it in the JOBS Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_45"></A>Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two
years of audited financial statements. We expect that we will not be a smaller reporting company to the extent we remain a majority-owned subsidiary of Sorrento. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_46"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_47"></A>The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are an innovative revenue-generating company focused on acquiring, developing and commercializing <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain management products for the treatment of acute and chronic pain. We target indications with
high unmet needs and large market opportunities with <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched
our first commercial product in October 2018 and are developing our late-stage pipeline, which includes a pivotal Phase 3 candidate, a Phase 2 candidate, and a Phase 1 candidate that is expected to enter Phase 2 studies in 2023. Our commercial
product, ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the &#147;FDA&#148;) for the relief of
neuropathic pain associated with post-herpetic neuralgia (&#147;PHN&#148;), which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription
lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. We license the rights to ZTlido from and rely exclusively on Oishi
Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation (&#147;Itochu,&#148; and together with Oishi, the &#147;Developers&#148;) pursuant to the Product Development Agreement and Commercial Supply Agreement. We have acquired
two FDA approved <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain products for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults, which we plan to commercialize in the U.S.
in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are <FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (10 mg, dexamethasone sodium phosphate
viscous gel) (&#147;SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>&#148;), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; <FONT
STYLE="white-space:nowrap">(ii)&nbsp;SP-103</FONT> (lidocaine topical system) 5.4%, <FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain
(&#147;LBP&#148;); and <FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules)
<FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;),</FONT> a novel <FONT STYLE="white-space:nowrap">low-dose</FONT> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were
completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2023. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in
the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, we entered into a License and Commercialization Agreement (the &#147;Romeg Agreement&#148;)
with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#147;Romeg&#148;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1)&nbsp;the right to manufacture, promote, market, distribute and sell pharmaceutical products
comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&nbsp;an exclusive, transferable license to use the trademark
&#147;GLOPERBA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&#148;. GLOPERBA is an <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting
an estimated 8.7&nbsp;million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of
pain and can be disabling with tenderness, warmth and swelling. <FONT STYLE="white-space:nowrap">Non-steroidal</FONT> anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S.
is observed to have a high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. We are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. We
have a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S. states. For more information on Scilex, please see the sections of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151;
Romeg License and</I> <I>Commercialization Agreement.</I>&#148; On February&nbsp;12, 2023, we acquired from BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. the rights to certain patents, trademarks, regulatory approvals,
data, contracts, and other rights related to ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (celecoxib oral solution) and the commercialization thereof in the United States and Canada. ELYXYB<SUP
STYLE="font-size:75%; vertical-align:top">TM </SUP>is a first-line treatment and the only <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> oral
solution for the acute treatment of migraine, with or without aura, in adults. We are planning to commercialize ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> in the U.S. in 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established
mechanisms that have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic
Act for each of these pipeline product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our marketed product, ZTlido, has multiple advantages over currently
available prescription and OTC lidocaine patches, of which over 147&nbsp;million and 136&nbsp;million of such patches were sold in the United States in 2021 and 2020, respectively, according to Symphony Healthcare. We have sold 6,336,032 and
7,011,112 ZTlido patches in the United States in 2020 and 2021, respectively. We acquired <FONT STYLE="white-space:nowrap">SP-102</FONT> from Semnur Pharmaceuticals, Inc. (&#147;Semnur&#148;) in March 2019 and are developing <FONT
STYLE="white-space:nowrap">SP-102</FONT> to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by <FONT STYLE="white-space:nowrap">off-label</FONT> epidural steroid injections
(&#147;ESI&#148;), which are administered over 12&nbsp;million times annually in the United States. See the section of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Semnur Merger Agreement</I>&#148; for a description of
our acquisition of Semnur and our ongoing obligations to Semnur&#146;s former equityholders. SEMDEXA has been granted fast track designation by the FDA and, if approved, could become the only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESI
for the treatment of sciatica. According to a report by Decision Resources Group, it was estimated that over 4.8&nbsp;million patients would suffer from sciatica in the United States in 2022. <FONT STYLE="white-space:nowrap">SP-103</FONT> has also
been granted fast track designation by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP. We are developing
<FONT STYLE="white-space:nowrap">SP-104</FONT> as a novel delayed-release formulation of <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet medical need given
the low response rates of commercially available therapies. Naltrexone is routinely used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia. There are no <FONT STYLE="white-space:nowrap">low-dose</FONT> formulations commercially
available in the United States. Our patented formulation is designed to overcome undesirable effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. We believe our currently approved product and future
product candidates, if approved, could uniquely address what we believe are the significant unmet needs of the targeted populations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_48">
</A>Our Marketed Product and Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates our current commercial product and novel product candidates, for
which we have worldwide commercialization rights, except with respect to Japan for ZTlido and <FONT STYLE="white-space:nowrap">SP-103.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g00a15.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_49"></A>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our vision is to become the leading pain management company delivering novel <FONT STYLE="white-space:nowrap">non-opioid</FONT> and <FONT
STYLE="white-space:nowrap">non-addictive</FONT> treatments to provide safe, effective and durable relief of multiple pain conditions. To accomplish this, the principal elements of our strategy are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Maximize the commercial potential of ZTlido</B>. We have assembled an integrated commercial organization using
a dedicated sales force and sales management, marketing and managed care capabilities to support continued uptake of ZTlido. We leverage a sales force of approximately <FONT STYLE="white-space:nowrap">60-70</FONT> people, targeting over 10,000
primary care physicians, pain specialists, neurologists, and palliative care physicians who we believe treat the majority of PHN patients. Additionally, we are utilizing
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-patient</FONT></FONT> marketing strategies to expand awareness and utilization of ZTlido. Our managed healthcare account executives have extensive experience in negotiating
contracts and have already achieved significant uptake by adding ZTlido to key formularies such as CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United
Healthcare Commercial, Optum Rx Select Commercial, Anthem Blue Cross Blue Shield (&#147;BCBS&#148;), BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North
Dakota. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Commercialize and successfully <FONT STYLE="white-space:nowrap">re-launch</FONT> GLOPERBA</B><SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP><B> for gout in the U.S.</B>: We will utilize our current commercial infrastructure comprised of our sales, marketing, and managed health care functions to promote GLOPERBA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> for gout to approximately 3,000 healthcare providers (&#147;HCPs&#148;) in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe
colchicine for gout, allowing for efficient dual promotion of Gloperba and ZTlido. The principal elements of the GLOPERBA strategy are as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Educate the market on the need for and value of simplified and precise colchicine dose adjustments to allow
individualized, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">patient-by-patient</FONT></FONT> therapy. Scilex will leverage its <FONT STYLE="white-space:nowrap">in-person</FONT> sales forces, medical affairs teams, and
omni-channel HCP engagement campaigns to drive awareness of GLOPERBA&#146;s features and benefits. In addition, target providers, rheumatologists and primary care physicians treating various comorbidities, will be provided with tools to help them
identify and prescribe GLOPERBA to appropriate patients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Increase access to GLOPERBA for subsets of patients in prophylactic treatment of gout, specifically those with
comorbidities and GI intolerance. Our managed healthcare account executives will negotiate contracts with key payer and pharmacy customers to achieve uptake of key formularies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Develop and commercialize SEMDEXA as a novel epidural injection for the first approved treatment of
sciatica</B>. We are developing SEMDEXA to address the limitations associated with the available corticosteroid epidural injectable products that are used <FONT STYLE="white-space:nowrap">off-label.</FONT> Many of these products contain potentially
neurotoxic preservatives and particulates, and are administered over 12&nbsp;million times annually despite a warning on the label of serious neurologic complications, including loss of vision, stroke, paralysis and death. These products carry
warnings required by the FDA that the safety and efficacy of epidural administration has not been established. SEMDEXA has received fast track designation from the FDA and, if approved, could become the first
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> epidural steroid product with long-term patent protection, which we also believe would create significant barriers to entry. Due to the novelty of our formulation as well as the associated patents
and trade secrets, future potential competitors could be required to conduct extensive preclinical studies and costly comparative clinical trials. A full <FONT STYLE="white-space:nowrap">6-month</FONT> data analysis was completed in February 2022
and we have recently completed a pivotal Phase 3 study with final results received in March 2022, which results reflect achievement of primary and secondary endpoints. We believe these final results are supportive of a breakthrough therapy
designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program leading to market approval. We intend to submit a request to the FDA for a type D meeting in
order to clarify the expectations </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
regarding the size of the safety database needed for a NDA given that at this time no safety concerns have been identified during the course of clinical development, and to agree on acceptance of
<FONT STYLE="white-space:nowrap">SP-102</FONT> Phase 3 trial data as pivotal evidence of efficacy to support product registration. We have extensive clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data (including those obtained
from multiple Phase 2 clinical trials) with the novel viscous gel formulation of <FONT STYLE="white-space:nowrap">SP-102.</FONT> We expect to present the robust data collected over the course of our multi-year clinical development program to the FDA
as part of a New Drug Application (&#147;NDA&#148;). We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pursue clinical development of <FONT STYLE="white-space:nowrap">SP-103</FONT> for the first approved topical
treatment in patients with acute LBP</B>. We are developing <FONT STYLE="white-space:nowrap">SP-103</FONT> as a triple-strength lidocaine topical system for the treatment of acute LBP, to be used where we believe a high-dose strength and superior
adhesive qualities of a topical system may provide a greater therapeutic benefit than currently available therapies. <FONT STYLE="white-space:nowrap">SP-103</FONT> is designed to use ZTlido&#146;s delivery and adhesion technology to deliver a dose
of lidocaine that is threefold higher than any other approved lidocaine topical products. We initiated a Phase 2 trial in acute LBP in the second quarter of 2022. <FONT STYLE="white-space:nowrap">SP-103</FONT> has been granted fast track designation
by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pursue clinical development of <FONT STYLE="white-space:nowrap">SP-104</FONT> for the treatment of
fibromyalgia, which has very few approved therapies that are marginally effective and have unpleasant side-effects</B>. We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> for fibromyalgia.
<FONT STYLE="white-space:nowrap">Low-dose</FONT> naltrexone hydrochloride delayed-release capsules are routinely used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia and other chronic pain conditions such as complex regional
pain. <FONT STYLE="white-space:nowrap">SP-104</FONT> addresses the shortcomings of using the high-dose commercial products and pharmacy-compounded products by delivering a <FONT STYLE="white-space:nowrap">low-dose</FONT> of naltrexone hydrochloride
(approximately 11 times less than the commercial product) in a delayed-release formulation that bypasses the stomach and releases the drug in the gut (upper intestine). These product characteristics mitigate against the known safety issues
associated with the high-dose commercial products and immediate release pharmacy-compounded products, and the overall reliability issues associated with pharmacy-compounded products. <FONT STYLE="white-space:nowrap">SP-104</FONT> has completed two
Phase 1 studies to characterize the pharmacokinetics and safety of the product, and we expect to commence Phase 2 studies in 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand our product portfolio by developing or acquiring <FONT STYLE="white-space:nowrap">non-opioid</FONT>
assets that leverage our novel delivery and adhesion technologies or our existing commercial infrastructure</B>. We are continuously evaluating opportunities to leverage our research and development experience to develop <FONT
STYLE="white-space:nowrap">non-opioid</FONT> therapeutics for pain management indications that are not adequately served with existing treatment options. We also seek to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire <FONT
STYLE="white-space:nowrap">non-opioid</FONT> therapeutics that can both complement our existing product portfolio and benefit from our existing commercial infrastructure. In evaluating marketed and clinical-stage expansion opportunities, we intend
to pursue therapeutics that address markets served by our established target physician audience and that can be commercialized by our existing sales force. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leverage our management team&#146;s experience to further develop and commercialize its current and future
product portfolio</B>. Our management team has held senior positions at leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd. (&#147;Teva&#148;), Novartis Pharmaceuticals,
Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. Our team has substantial experience in rapidly progressing new drugs to clinical proof of concept, completing successful pivotal registration programs and successfully
commercializing products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our innovative <FONT STYLE="white-space:nowrap">non-opioid</FONT> product
portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#146; lives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_50"></A>Our Management Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled a management team of experienced biopharma industry veterans, who have deep scientific, business and leadership expertise in
pharmaceutical industry, in addition to strong transactional and business development track records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team is led by our
Chief Executive Officer and President, Jaisim Shah, with strategic guidance from our Executive Chairperson, Henry Ji, Ph.D. They collectively have over 60 years of global biopharmaceutical and biotechnology experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jaisim Shah has over 30 years of industry success in leading product development&nbsp;&amp; commercializing innovative therapies and creating
companies with documented success in development and commercialization of some of today&#146;s most recognized pharmaceutical brands. He is a seasoned life science executive and board director with extensive accomplishments at Bristol-Myers Squibb,
Roche, PDL Biopharma, Sorrento, Pfizer/Upjohn, Scilex, and <FONT STYLE="white-space:nowrap">start-ups</FONT> such as Elevation and Semnur Pharmaceuticals. Mr.&nbsp;Shah has been Chief Executive Officer and President of Semnur Pharmaceuticals
(acquired by Scilex Pharmaceuticals) since its inception in 2013. He has served as Chief Executive Officer and President of Legacy Scilex and Scilex Pharmaceuticals since March 2019 and of Scilex since November 2022. Mr.&nbsp;Shah also serves on the
board of directors of Sorrento Therapeutics Inc. and Scilex. Most recently, Mr.&nbsp;Shah served as Chief Business Officer of Elevation Pharmaceuticals where he focused on financing, business strategy, mergers and acquisitions, and business
development. He led the sale of Elevation to Sunovion Pharmaceuticals in 2012. At Facet Biotech and PDL BioPharma, he served from 2000 to 2009 as Chief Business Officer and also held the position of senior vice president of marketing and medical
affairs. During this time, he completed numerous licensing/partnering and strategic transactions including with Roche, Bristol-Myers Squibb, Otsuka, and Biogen Idec. His leadership in marketing and portfolio management including leading the
commercial enterprise helped the company make large improvements to meet its profitability potential. At Bristol-Myers Squibb, as vice president of global marketing from 1997 to 2000, Mr.&nbsp;Shah received the &#147;Presidents Award&#148; for
completing one of the most significant collaborations in the company&#146;s history. Prior to working with Bristol-Myers Squibb, Mr.&nbsp;Shah led international marketing for oncology and virology and was global business leader for corporate
alliances at Roche from 1991 to 1997 with Genentech and IDEC, and prepared products for worldwide launch and <FONT STYLE="white-space:nowrap">pre-launch</FONT> at F. <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche AG in Switzerland. He has
played a key role in the formulation of long-range plans and <FONT STYLE="white-space:nowrap">pre-launch</FONT> and launch strategies for such brands as Abilify<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Pegasys<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and Rituxan/MabThera<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, each of which have generated well over $1&nbsp;billion in sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Henry Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento
Therapeutics, Inc.&#146;s (&#147;Sorrento&#148; and, together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries), the &#147;Sorrento Group&#148;) intellectual property. Our Chief Financial Officer,
Elizabeth Czerepak, has more than 35 years of finance and operational expertise across pharmaceuticals, biotechnology and venture capital. Our research efforts are guided by highly experienced scientists and experts. Our management team contributes
a diverse range of experiences from leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport,
Inc. and Chiron Corp. With this leadership, we believe we are well positioned to achieve our vision of becoming the leading pain management company delivering novel <FONT STYLE="white-space:nowrap">non-opioid</FONT> and <FONT
STYLE="white-space:nowrap">non-addictive</FONT> treatments to provide safe, effective and durable relief of multiple pain conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, we are supported by impressive teams across all levels of the organization. We hire and develop world-class talent from diverse backgrounds in biopharma, academia, technology and finance to ensure we have all of the capabilities to design
and deliver effective first-class pain management therapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_51"></A>Our Product Portfolio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our marketed product,
ZTlido, is a lidocaine topical system approved for the relief of neuropathic pain associated with PHN. ZTlido was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved
adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. We launched ZTlido in October 2018 with an integrated commercial organization and we believe its differentiated therapeutic
profile, combined with our competitive pricing strategy and our active direct marketing efforts have driven, and will continue to drive, accelerated sales growth and increased market uptake. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prescription Lidocaine Patch Market Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief of
neuropathic pain associated with PHN. PHN is a chronic neuropathic pain syndrome that results as a complication following an infection of herpes zoster, also known as shingles. Herpes zoster symptoms resolve after a few weeks, but the pain caused by
the nerve injury can persist for months to years surrounding the affected area. According to Evaluate Ltd., there were over 3.5&nbsp;million people living with PHN conditions in the United States in 2021. Lidocaine patches have also been used in
patients with other types of pain, such as diabetic neuropathy, osteoarthritis and pain associated with surgery, cancer or trauma, and often in patients with LBP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, there were more than 147&nbsp;million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. Of
this, five lidocaine patch manufacturers accounted for approximately 92% of the total prescriptions, according to Symphony Healthcare. We believe that the PHN market will continue to expand with the introduction of our lidocaine topical system,
ZTlido, which is supported by our commercial organization, by prescribing trends away from opioid use, and by continued growth in the population of patients aged 45 years and older who are at greater risk of suffering from PHN. Unlike Lidoderm, the
FDA has not determined that any other products are therapeutically equivalent to ZTlido, and accordingly, a prescription for ZTlido may not be able to be substituted by a generic product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Treatment Landscape and Limitations of Existing Treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recommended first-line treatment for the relief of neuropathic pain associated with PHN includes topical lidocaine, gabapentinoids (which have
been associated with the potential for abuse as well as numerous adverse events), antidepressants and a multi-modal approach. Topical lidocaine and gabapentinoids are preferred for combination therapies due to their low propensity for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">drug-to-drug</FONT></FONT> interactions. For example, an eight-week combination use with pregabalin (Lyrica) has been proven to reduce pain in half for patients who had inadequate relief on
monotherapy, despite titration of pregabalin to effect. This efficacy boost was achieved without tolerability issues or adding to side effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A survey analyzing treatment patterns for neuropathic pain associated with PHN found that recommended first-line therapeutics were used in
only 29% of patients examined from 2010 to 2014, while the remaining patients were started on various <FONT STYLE="white-space:nowrap">off-label</FONT> treatments, including nonsteroidal anti-inflammatory drugs (&#147;NSAIDS&#148;) and opioids.
These drugs can have adverse effects, especially on elderly patients, which represent the majority of PHN patients. For example, opioids carry a well-characterized risk of abuse and misuse and the potential for serious side effects, such as
respiratory depression, constipation and others, including death. According to the Centers for Disease Control and Prevention, over 75% of the 100,306 drug overdose deaths during the <FONT STYLE="white-space:nowrap">12-month</FONT> period ending in
April 2021 involved opioids. Similarly, tricyclic antidepressants, which can be effective in managing the neuropathic pain associated with PHN, can result in significant systemic side effects and cardiotoxicity, posing risks to the elderly and
patients with heart disease, epilepsy or glaucoma. These side effects make topical lidocaine products an attractive first-line treatment option from a safety perspective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety of lidocaine patches is well-supported in medical literature. Unlike transdermal
medications that are designed to achieve systemic drug levels via absorption through the skin or mucosal membrane, leading to effects away from the application site, topical lidocaine has a local effect at the site of application. Because drug
application is localized to the immediate area surrounding the patch, systemic absorption from a topical patch is low, reducing the risk of systemic side effects and lowering the potential for drug interactions relative to other systemic
pharmacologic therapies. Due to the low systemic exposure and minimal systemic side effects reported in clinical trials, we believe a topical lidocaine patch is well-suited for patients being treated with multiple medications or at a higher risk of
side effects, including the elderly or those with chronic conditions. As a localized treatment, lidocaine patches have been used concomitantly with other medications in patients for whom monotherapy is inadequate. Furthermore, we believe medication
administered topically rather than orally can improve patient compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While lidocaine patches have certain advantages over the
treatment alternatives discussed above, certain patches have limitations that may impact efficacy. For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FDA Adverse Event Reporting System
(&#147;FAERS&#148;). Because the drug is incorporated in the adhesive for these products, patches must maintain adhesion or risk compromising the ability to deliver their full drug dose. As a result, establishing strong adhesion is a key factor for
patient compliance and satisfaction. In draft guidance issued in July 2021, the FDA recommended that developers of topical and transdermal delivery systems (&#147;TDSs&#148;) conduct studies to characterize the adhesion performance of the product
with suggested data requirements. Likewise, the FDA issued a draft guidance in October 2018 outlining the adhesion data requirements for generic TDSs. This guidance, along with Scilex&#146;s past experience with regulatory agencies, shows the
FDA&#146;s interest and the importance of adhesion performance of these products. There are also dermal safety requirements that force developers to carefully balance adhesion performance against dermal safety. ZTlido is the first TDS product
approved by the FDA that was able to demonstrate the targeted adhesion performance with an overall benign dermal safety profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following figure depicts data derived from FAERS as of December&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For many of the competing lidocaine patches, a common drawback is the usage of hydrogel technology that
limits the overall pharmaceutical efficiency of the product, requiring more total drug to be loaded into the patch to deliver sufficient drug to achieve a therapeutic effect. For example, Lidoderm has a drug load of 700 mg drug but only delivers
3&plusmn; 2% of that drug load. Consequently, adhesive thickness must be increased in order to have a drug load sufficient to deliver a therapeutic dose of drug to the skin. As adhesive thickness increases, the product&#146;s pliability can be
compromised to the extent that the patch loses adhesion as the skin moves and wrinkles through normal patient activity. The weight of the hydrogel patches (largely due to high water content) further contributes to the challenge in maintaining
adhesion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The greater drug load also poses a risk of accidental exposure. For example, with a
bioavailability of 3 &plusmn; 2% of the 700 mg drug load for Lidoderm, there is over 650 mg of drug remaining on the patch at the end of the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period, as captured in a bolded warning on
the product label. If improperly disposed of, the residual drug poses the potential risk to children, pets and others of accidental exposure to a toxic amount of lidocaine, although we believe the risk with this formulation has not been evaluated.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to prescription lidocaine patches, there are commercially-available OTC topical lidocaine products in the market, but none of
these OTC products have been reviewed or approved by the FDA. Notably in 2003, the FDA proposed amending the tentative final monograph for OTC external analgesic drug products to clarify the status of patches (and poultices and plasters), noting
that the dosage forms had not been determined to be generally recognized as safe and effective for any analgesia at that time. Therefore, the FDA would likely not consider these OTC products to be compliant with the monograph and do not have legal
marketing status. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Solution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
novel adhesion and delivery technology provides significantly improved adhesion compared to Lidoderm, manufactured by Endo Pharmaceuticals, and generic alternatives marketed by Mylan N.V. (&#147;Mylan&#148;), while providing bioequivalent delivery
of lidocaine via an efficient drug delivery system. Our product is lighter, thinner and provides for a better patient experience without compromise to dermal safety and with no presentation of dermal sensitization. Below is a comparison of the key
advantages of ZTlido to Lidoderm and generic lidocaine patches manufactured by Teva and by Mylan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Key Advantages of ZTlido vs. Lidoderm and Associated
Generics </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: DIA = <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Drug-in-adhesive</FONT></FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Source: A Scilex-sponsored
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> comparative adhesion study
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(SCI-LIDO-ADH-003)</FONT></FONT></FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido has been strategically designed to address poor adhesion, a leading complaint
associated with other currently marketed topical lidocaine products. ZTlido uses an advanced <FONT STYLE="white-space:nowrap">hot-melt</FONT> technology, which uses premixing and <FONT STYLE="white-space:nowrap">hot-melt</FONT> mixing of various
excipients and lidocaine, followed by current Good Manufacturing Practices (&#147;cGMP&#148;) compliant coating, lining, cutting and filling processes. In clinical studies, the technology provided significantly improved adhesion over Lidoderm<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (a branded, prescription 5% lidocaine patch product) (&#147;Lidoderm&#148;) and Mylan&#146;s generic lidocaine patch at 12 hours after application. In a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> study of 44 subjects, ZTlido showed statistically significant adhesion at <FONT STYLE="white-space:nowrap">all-time</FONT> points compared to Lidoderm. Further, ZTlido maintained greater than 90%
mean adhesion over the labeled <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period while Lidoderm fell below this benchmark within 3 hours. ZTlido also showed superior adhesion when compared to Mylan&#146;s generic lidocaine patch.
In this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study, ZTlido maintained greater than 90% mean adhesion throughout the labeled <FONT STYLE="white-space:nowrap">12-hour</FONT> administration
period, while Mylan&#146;s generic product had a mean adhesion score of only 80% immediately after application, which progressively worsened over time. The formulation components are also carefully selected to achieve the target adhesion profile
without creating dermal sensitization and maintaining a benign irritation profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In two separate studies, adhesion performance of
ZTlido was compared to Lidoderm (with 44 subjects) and to Mylan&#146;s generic lidocaine patch (with 24 subjects), as depicted in the diagrams below. Both studies were performed with healthy volunteers using a standard clinical adhesion protocol
where adhesion could not be enhanced (i.e., no reinforcement, pressing or reattaching). The level of adhesion was measured immediately after application (Time 0), and at 3, 6, 9 and 12 hours after application. ZTlido was the only lidocaine product
to achieve over 90% adhesion over 12 hours after application in these studies. Maintaining 90% adhesion was a requirement for ZTlido&#146;s NDA approval. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proprietary adhesive system utilized for ZTlido allows for a more efficient delivery of the drug from
the patch to the skin. This was supported by a clinical study in which our product achieved a bioequivalent dose of lidocaine while using a reduced drug load (36 mg for ZTlido versus 700 mg for Lidoderm). The drug delivery efficiency of ZTlido
lessens the danger of accidental exposure. After 12 hours after application, ZTlido contains approximately 18 mg of residual lidocaine. In comparison, each Lidoderm patch leaves over 650 mg in the patch at the end of the <FONT
STYLE="white-space:nowrap">12-hour</FONT> administration period. If improperly disposed of, the residual drug poses a risk of accidental exposure to a toxic amount of lidocaine to children, pets and others, although the risk with this formulation
has not been evaluated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The drug delivery efficiency of ZTlido also enables it to be manufactured as a thinner product relative to
Lidoderm and Teva&#146;s generic lidocaine patch. We strategically leveraged this property of ZTlido by utilizing a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thin patch design with a nonwoven backing cloth that allows for better adhesion of the product. The improved adhesion performance, thinner profile and incorporation of a flexible backing material
allows for a product that maintains contact with the skin in contoured areas of the body, when encountering torsional strains arising from normal body movements and during contact with clothing and bedding. While Mylan&#146;s generic lidocaine patch
is also thinner than Lidoderm, it incorporates a film backing material that makes the product inflexible with body movements, contributing to its rapid loss in adhesion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adhesion profile of ZTlido allows the product to be used under moderate exercise conditions (tested in 4 sessions of <FONT
STYLE="white-space:nowrap">30-minutes</FONT> of stationary bike exercise, cumulatively 2 hours) as captured in the ZTlido label. No ZTlido patches fell off during the entire <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period.
Lidoderm and the associated generics have not produced any public data on the use of their products by active pain patients under such conditions. ZTlido is also labeled to allow patients to shower and bathe while wearing the patch, which is
supported by an adhesion or pharmacokinetic study showing that, while some degree of lifting is observed in these environments, the patches were able to be pressed back down or reattached in the cases where the product completely detached, with no
clinically meaningful change in pharmacokinetics. In contrast, Lidoderm and the associated generics are labeled with the effects of water exposure being unknown. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although ZTlido, Lidoderm and the associated generics are all labeled to not be used with heat (e.g., heating pad or blanket), the <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> ZTlido label states that users may apply ZTlido to a treatment site after moderate heat exposure, such as after 15 minutes of heating pad use on a medium setting. This authorized use of ZTlido is of
value as heat therapy is widely used in treating pain. In contrast, Lidoderm and the associated generics are not labeled for use with heat. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe ZTlido has other favorable features compared to Lidoderm and associated generic lidocaine patches such as the inclusion of a
perforated release liner and the absence of cold flow. The perforated release liner allows for easier removal of the liner before application, which we believe provides convenience to patients who have dexterity challenges. In contrast, Lidoderm and
generic lidocaine patches incorporate a single-sheet release liner, requiring patients to pick at the corners and edges to breach and remove before application. Cold flow is the propensity of the adhesive to migrate from the edges of the product
under normal conditions, either in the product envelope or while on the skin. This can lead to difficulties in removing the product from the envelope and/or movement of the product, while on the skin, away from the intended administration site. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched ZTlido in October 2018 with support from an integrated commercial organization using a dedicated sales force and sales management,
marketing and managed care capabilities. We market ZTlido through a dedicated <FONT STYLE="white-space:nowrap">65-person</FONT> sales force, targeting over 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians
who we believe treat the majority of PHN patients. We are utilizing a multi-channel marketing strategy to expand awareness and utilization of ZTlido. Our managed healthcare account executives have achieved success in adding ZTlido to key
formularies, including CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial, Anthem BCBS, BCBS Louisiana and
Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We believe the benefits of ZTlido, combined with our competitive pricing strategy and our active direct marketing
efforts, have driven, and will continue to drive, accelerated sales growth and increased market uptake. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several
investigator-initiated research studies to explore the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) is a Phase 3, novel, injectable viscous gel formulation of a widely used
corticosteroid for epidural injections to treat sciatica. No ESIs are currently approved by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sciatica Market Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A particularly debilitating complication of back pathology is sciatica, which is a condition caused by mechanical compression of the nerve
root, or by the effects of inflammatory mediators arising from a degenerative disc that results in inflammation and damage to the nerve roots. This nerve root compression in the lumbar segment of the spine causes shock-like or burning low back pain
(&#147;LBP&#148;) combined with pain radiating down along the sciatic nerve through the buttocks and down one leg, sometimes reaching the foot. This often severe and debilitating leg pain is usually associated with symptoms of neuropathy-like
numbness and tingling. The estimated lifetime incidence of sciatica ranges from 10% to 40% of the U.S. population, and about <FONT STYLE="white-space:nowrap">one-third</FONT> of these cases will develop symptoms lasting over a year. According to a
report by Decision Resources Group, it was estimated that over 4.8&nbsp;million patients would suffer from sciatica in the United States in 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Treatment Landscape and Limitations of Existing Treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the U.S. population ages, the incidence of sciatica and the need for interventions are expected to continue to increase. For example, from
2000 to 2018, ESIs in Medicare beneficiaries increased by more than 125%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there are numerous etiologies of sciatica, and
therapies may differ based on the etiology, pain management interventions for sciatica are usually multi-modal. Among the pain management interventions, ESI is considered to be efficacious and has been widely used by physicians across multiple
specialties, including anesthesiology, physical medicine and rehabilitation and pain medicine. However, there is no ESI therapy approved by the FDA for sciatica to date, and particulate formulations of glucocorticoids have been associated with
severe adverse events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with sciatica have a wide range of invasive and <FONT STYLE="white-space:nowrap">non-invasive</FONT>
treatment options. Surgical intervention options include vertebroplasy, spinal laminectomy, discectomy, microdiscectomy, foraminotomy, intradiscal electrothermal therapy, nucleoplasty, radiofrequency denervation, spinal fusion and artificial disc
replacement. These options are generally the last line of treatment because they can result in prolonged recovery time, may not be successful in reducing pain or addressing the underlying cause, and may result in permanent loss of flexibility. For
these reasons, less invasive interventions are usually implemented first. Less invasive interventions may include (i)&nbsp;nonpharmacological therapies such as physical therapy, stretching exercises, spinal manipulations or chiropractic therapy,
traction, acupuncture, transcutaneous electrical nerve stimulation, and biofeedback; (ii)&nbsp;oral pharmaceutical therapies such as NSAIDs, muscle relaxants, opiates, antidepressants, and anticonvulsants; and (iii)&nbsp;injectable pharmaceutical
therapies such as <FONT STYLE="white-space:nowrap">off-label</FONT> use of ESIs or nerve blocks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ESIs for various back pain syndromes are
one of the most common procedures performed in the United States and lumbosacral radicular ESI procedures represent 88% of total ESI procedures. ESIs are used when a patient&#146;s pain is inadequately controlled with oral pain medications, topical
systems or interventions such as physical therapy. ESIs have demonstrated efficacy in reducing pain, restoring function, reducing the need for other health care and avoiding back surgery. However, in addition to not being <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> for the treatment of lumbosacral radicular pain, currently-used ESIs also present various risks and challenges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When administering an ESI, many physicians use a particulate steroid (including methylprednisolone acetate, triamcinolone acetonide, or
betamethasone sodium phosphate or betamethasone sodium acetate) instead of a <FONT STYLE="white-space:nowrap">non-particulate</FONT> steroid (dexamethasone sodium phosphate) because early studies suggested that the duration of pain relief was longer
with the particulates and fewer repeat injections were required, even though dexamethasone is considered an otherwise potent and therapeutically beneficial therapy. Particulate in injectable products is defined as extraneous undissolved particles
present in injectable solution products. An example of such particulate is precipitate of insoluble drug form, or suspended drug particle. These steroid particles or their aggregates have at least two mechanisms for neurological damage:
(1)&nbsp;they can act as emboli if injected into an artery and are of sufficient size to block small terminal arterioles supplying the brain or spinal cord; and (2)&nbsp;several particulate steroids have an immediate and massive effect on
microvascular perfusion because of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
formation of red blood cell aggregates. These emboli can cause rare but catastrophic neurologic injuries including stroke and spinal cord injury that can result in increased pain, severe
permanent disability or death. In addition, fungal meningitis has occurred from the injection of steroids manufactured in a compounding pharmacy that did not adhere to sterility standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has been evaluating serious neurologic events with ESIs since 2009, and in 2014, the FDA required a class warning on the currently <FONT
STYLE="white-space:nowrap">off-label</FONT> use of injectable corticosteroids to include information about the risk of serious neurologic events with ESIs. The warning on product labels for all injectable glucocorticoids states that the product is
to be used for intramuscular or intravenous purposes only, and specifically includes a warning for serious neurologic adverse reactions with epidural administration. These serious neurologic events have been reported with and without use of
fluoroscopy. The class warning also includes a statement that safety and effectiveness of epidural administration of these corticosteroids have not been established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain third-party payors have also provided limited coverage of ESIs to date. Based on coverage criteria established by different health
care plans and certain Medicare Administrative Contractors, an ESI is considered medically necessary and therefore reimbursable only when certain specific criteria are met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Solution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT
STYLE="white-space:nowrap">SP-102</FONT> to address problems associated with currently available corticosteroid products that are used in practice but not approved for epidural injection or the treatment of lumbosacral radicular pain. <FONT
STYLE="white-space:nowrap">SP-102</FONT> is a Phase 3 sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a <FONT STYLE="white-space:nowrap">pre-filled</FONT> glass syringe for delivery
via an epidural injection. <FONT STYLE="white-space:nowrap">SP-102</FONT> allows for the use of the potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates.
The product is also formulated without the use of preservatives and packaged in a <FONT STYLE="white-space:nowrap">pre-filled</FONT> syringe, so as to confer greater physician convenience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently-used steroids carry a class warning and are not approved to be administered epidurally for the treatment of sciatica. In fact, there
are further warnings that the safety and efficacy of the use of these products following epidural administration has not been established. Their formulations include neurotoxic preservatives, surfactants, suspensions or particulates that carry risks
of serious neurologic complications. Unlike currently-used steroids, <FONT STYLE="white-space:nowrap">SP-102</FONT> does not contain neurotoxic preservatives, surfactants, suspensions or particulates that carry risk of serious neurologic
complications, which we believe may improve safety and the extent of pain relief. By using dexamethasone sodium phosphate, the soluble form of the potent dexamethasone, we believe <FONT STYLE="white-space:nowrap">SP-102</FONT> may substantially
reduce the risk of embolic events in case of inadvertent intra-arterial administration and enable repeat injections. We expect the injectable viscous gel product, <FONT STYLE="white-space:nowrap">SP-102,</FONT> which uses a biocompatible,
biodegradable, novel excipient and is protected by multiple patents and patent applications and trade secrets, to prolong the residence time at the injection site and result in extended local activity. We believe
<FONT STYLE="white-space:nowrap">SP-102,</FONT> if successfully developed and approved, has the potential to reduce the disability related to lumbosacral radicular pain and help delay or avoid spine surgery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, <FONT STYLE="white-space:nowrap">SP-102</FONT> could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESI
product. We believe an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapy for the treatment of sciatica could potentially benefit from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-market</FONT></FONT>
advantage if it can be shown to reduce or delay the need for expensive and potentially risky interventions such as spinal surgery and decrease the use of opioids. <FONT STYLE="white-space:nowrap">SP-102</FONT> benefits from our substantial
intellectual property portfolio and other technical barriers to entry for potential competitors. Further, we are a party to an exclusive supply agreement for a proprietary biocompatible viscosity-enhancing excipient sodium hyaluronate in <FONT
STYLE="white-space:nowrap">SP-102.</FONT> Our complex manufacturing process, specialized equipment and <FONT STYLE="white-space:nowrap">know-how</FONT> for sterile viscous product candidates are also key to our competitive edge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently evaluating data on <FONT STYLE="white-space:nowrap">SP-102</FONT> from a pivotal Phase 3 Corticosteroid Lumbar Epidural
Analgesia (&#147;CLEAR&#148;) trial, which was designed to evaluate the safety and efficacy in the proposed indication. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The CLEAR clinical trial is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica at over 40 sites across the United States, with a primary
objective to evaluate the analgesic effect on average leg pain (as measured by the Numeric Pain Rating Scale in the affected leg) following a single epidural injection of <FONT STYLE="white-space:nowrap">SP-102,</FONT> compared to an intramuscular
injection of placebo over four weeks. A full <FONT STYLE="white-space:nowrap">6-months</FONT> data analysis was completed in February 2022 and we announced final results from the study in March 2022, which results reflect achievement of primary and
secondary endpoints. We believe these final results are supportive of a breakthrough therapy designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program
leading to market approval. We intend to submit a request to the FDA for a type D meeting in order to clarify the expectations regarding the size of the safety database needed for a NDA given that at this time no safety concerns have been identified
during the course of clinical development, and to agree on acceptance of <FONT STYLE="white-space:nowrap">SP-102</FONT> Phase 3 trial data as pivotal evidence of efficacy to support product registration. We also presented the pivotal Phase 3 trial
results at the American Society of Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 3 CLEAR
trial summary results, which results reflect achievement of primary and secondary endpoints, are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT>
(SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy), demonstrated a rapid onset of pain relief, measured by Numeric
Pain Rating Scale of average daily pain in the affected leg, with improvement against placebo over the first 4 weeks, following a single transforaminal injection, LS Mean (SEM) difference <FONT STYLE="white-space:nowrap">-1.08</FONT> (0.17), with a <FONT
STYLE="white-space:nowrap">p-value</FONT> &lt; 0.001. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT>
(SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) showed continued reduction of pain beyond one month, and the median time to open-label repeat injection was 99 days (95% CI: 78, 129 days) according to a Kaplan-Meier estimation.
By contrast, <FONT STYLE="white-space:nowrap">off-label</FONT> injectable steroids typically provide pain relief for periods ranging from less than a week and up to one month, and then a repeat injection may be required. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The key secondary endpoint of Oswestry Disability Index, the gold standard for measuring degree of disability and
estimating quality of life, showed a 28% improvement at 4 weeks on <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) compared to baseline (minimal clinically meaningful improvement <FONT
STYLE="white-space:nowrap">8%-12%)15.</FONT> The LS Mean (SEM) difference as compared to placebo was <FONT STYLE="white-space:nowrap">-6.28</FONT> (1.49), with a <FONT STYLE="white-space:nowrap">p-value</FONT> &lt; 0.001. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were no adverse events (&#147;AEs&#148;) of special interest reported, such as paraplegia, hematoma, or
infection at the injection site, which events are associated with the <FONT STYLE="white-space:nowrap">off-label</FONT> use of <FONT STYLE="white-space:nowrap">non-approved</FONT> injectable steroid preparations. Of the 354 patients receiving at
least a single injection of <FONT STYLE="white-space:nowrap">SP-102,</FONT> there were 125 (35.3%) patients experiencing treatment emergent adverse events (&#147;TEAEs&#148;), with 32 (9.0%) patients experiencing treatment-related AEs, 16 (4.5%)
patients experiencing medication-related AEs, 23 (6.5%) patients experiencing procedure-related AEs, four (1.1%) patients experiencing serious AEs, and one (0.3%) patient experiencing AEs related to early withdrawal. Of the 47 patients only
receiving a single placebo injection (and no repeat injection of <FONT STYLE="white-space:nowrap">SP-102),</FONT> there were 14 (29.8%) patients experiencing TEAEs with (i)&nbsp;two (4.3%) patients experiencing treatment-related AEs, (ii)&nbsp;two
(4.3%) patients experiencing medication-related AEs, (iii)&nbsp;one (2.1%) patient experiencing procedure-related AEs, (iv)&nbsp;one (2.1%) patient experiencing serious AEs, (v)&nbsp;one (2.1%) patient experiencing AEs related to early withdrawal,
and (vi)&nbsp;one (2.1%) patient death. TEAEs occurring in &#8805; two percent of patients were headache <FONT STYLE="white-space:nowrap">(SP-102:</FONT> 13 (6.4%), 17 events; placebo: 11 (5.5%), 11 events), injection site pain <FONT
STYLE="white-space:nowrap">(SP-102:</FONT> 4 (2.0%), four events; placebo: zero (0.0%), 0 events), upper respiratory tract infection <FONT STYLE="white-space:nowrap">(SP-102:</FONT> two (1.0%), 2 events; placebo: four (2.0%) events), sinusitis <FONT
STYLE="white-space:nowrap">(SP-102:</FONT> 4 (2.0%), four events; placebo zero (0.0%), 0 events) and hypertension <FONT STYLE="white-space:nowrap">(SP-102:</FONT> four (2.0%), four events; placebo: one (0.5%), two events). The C.L.E.A.R trial also
established the safety of repeat injections, as patients who experienced <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> radicular pain between 4 and 23 weeks were allowed to receive open-label
additional <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) injection. The safety analysis was comparable between treatment groups through 4, 12 and 24 weeks of study period.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase 3 <FONT STYLE="white-space:nowrap">SP-102</FONT> C.L.E.A.R Trial&#151;Primary
Endpoint </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-103</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SP-103</FONT> to be a triple-strength, <FONT STYLE="white-space:nowrap">non-aqueous</FONT>
lidocaine topical system for the treatment of acute LBP. <FONT STYLE="white-space:nowrap">SP-103</FONT> leverages the same adhesive drug delivery formulation and manufacturing as ZTlido along with comparable backing material, perforated release
liner and container-closure system. The increase in drug load is offset by a corresponding decrease in the adhesive diluent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acute LBP Market Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safe and effective treatment of acute LBP addresses a high unmet need and creates large market opportunities. LBP affects about 70% of
people in resource-rich countries at some point in their lives. Acute LBP can be self-limiting, however. One year after an initial episode, as many as 33% of people still have moderate-intensity pain and 15% have severe pain. Acute LBP has a high
recurrence rate with 75% of those with a first episode having a recurrence. Although acute episodes may resolve completely, they may increase in severity and duration over time. Americans spent approximately $134.5&nbsp;billion in 2016 on treating
LBP and neck pain, which was the highest expenditure among 154 conditions studied by the Department of Institute for Health Metrics and Evaluation at the University of Washington. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Treatment Landscape and Limitations of Existing Treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Centers for Disease Control and Prevention, in 2018, 28.0% of men and 31.6% of women aged 18 years old and older had lower
back pain in the past three months. The percentage of women who had lower back pain increased as age increased. Among men, the percentage increased with age through age 74 years and then decreased. Women in the age groups 18&#151;44, 45&#151;64, and
75 years and older were more likely to have lower back pain in the past three months than were men in the same age groups, but percentages were similar between men and women in the age group <FONT STYLE="white-space:nowrap">65-74</FONT> years.
Although most patients recover quickly with minimal treatment, proper evaluation is imperative to identify rare cases of serious underlying pathology. Certain red flags should prompt aggressive treatment or referral to a spine specialist, whereas
others are less concerning. Serious red flags include significant trauma related to age (i.e., injury related to a fall from a height or motor vehicle crash in a young patient, or from a minor fall or heavy lifting in a patient with osteoporosis or
possible osteoporosis), major or progressive motor or sensory deficit, <FONT STYLE="white-space:nowrap">new-onset</FONT> bowel or bladder incontinence or urinary retention, loss of anal sphincter tone, saddle anesthesia, history of cancer metastatic
to bone and suspected spinal infection. Without clinical signs of serious pathology, diagnostic imaging and laboratory testing often are not required. Although there are numerous treatments for nonspecific acute LBP, most have little evidence of
benefit. Patient education and medications such as nonsteroidal anti-inflammatory drugs, acetaminophen and muscle relaxants are beneficial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our
Solution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our triple-strength <FONT STYLE="white-space:nowrap">SP-103</FONT> is an investigational,
<FONT STYLE="white-space:nowrap">non-aqueous</FONT> lidocaine topical system undergoing clinical development in acute LBP conditions. If approved, we believe that <FONT STYLE="white-space:nowrap">SP-103</FONT> could become the lidocaine topical
product for acute LBP indications. All current uses of topical lidocaine products for LBP are <FONT STYLE="white-space:nowrap">off-label.</FONT> This program builds on the learnings from ZTlido because both products share the same adhesive drug
delivery formulation and manufacturing technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SP-103</FONT> to deliver a dose of
lidocaine that is at least threefold higher than any approved lidocaine topical products (including the approved ZTlido, which has a drug load of 36 mg lidocaine). We manufacture <FONT STYLE="white-space:nowrap">SP-103</FONT> to have a drug load of
108 mg lidocaine in a similar adhesive formulation as ZTlido, along with comparable backing material, perforated release liner and container-closure system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT> has demonstrated delivery of threefold the level of drug of ZTlido, and consequently delivers
threefold the level of drug of Lidoderm and associated generics by extrapolation. <FONT STYLE="white-space:nowrap">SP-103</FONT> has been granted fast track designation by the FDA and, if approved, could become the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP. We believe <FONT STYLE="white-space:nowrap">SP-103,</FONT> if successfully developed and approved, may be able to address the limitations of
prescription lidocaine patches in treating acute LBP by delivering a higher dose of lidocaine to the application site, but with systemic exposure of drug remaining well below established safety thresholds.
<FONT STYLE="white-space:nowrap">SP-103</FONT> has three times the drug load of ZTlido (108 mg versus 36 mg) in the adhesive system and can potentially deliver threefold the level of the drug within a targeted area, with the convenience of a single
topical system. This level of dosage for <FONT STYLE="white-space:nowrap">SP-103</FONT> is comparable to the maximum approved daily dosage of ZTlido, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or three topical systems for up to 12 hours during a <FONT STYLE="white-space:nowrap">24-hour</FONT> period. By contrast, delivering higher levels of drug with other lidocaine patches is
encumbered by the underlying hydrogel technology that constrains the level of drug that can be loaded into the adhesive of those products. The level of drug product in such patches can be increased only with a thicker adhesive layer, which can
result in a loss of adhesion performance and flexibility. Further, increasing product dimensions can allow delivery of the drug over a larger area, but does not increase drug delivery to a localized area under the topical system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the acute LBP market presents an attractive commercial opportunity due to the large patient population, lack of any approved drugs
and high level of unmet medical need. We believe developing and commercializing a topical <FONT STYLE="white-space:nowrap">non-opioid</FONT> product targeting this segment of the pain population represents a commercially attractive strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend initially to evaluate <FONT STYLE="white-space:nowrap">SP-103</FONT> in a Phase 2 trial in subjects who have acute LBP. The study
design is planned as an enriched-enrollment, randomized, double-blind, <FONT STYLE="white-space:nowrap">two-period</FONT> cross-over, multicenter study of <FONT STYLE="white-space:nowrap">SP-103</FONT> and placebo in subjects with acute LBP. The
study consists of a <FONT STYLE="white-space:nowrap">7-day</FONT> open-label <FONT STYLE="white-space:nowrap">run-in</FONT> period where all subjects receive active treatment. Responders to treatment then will be randomized to blinded Treatment A,
consisting of 30 days treatment with <FONT STYLE="white-space:nowrap">SP-103</FONT> or Treatment B, consisting of 30 days treatment with placebo patch with no lidocaine. We initiated the Phase 2 trial in the second quarter of 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-104</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> for the treatment of fibromyalgia.
<FONT STYLE="white-space:nowrap">Low-dose</FONT> naltrexone hydrochloride delayed-release capsules are routinely used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia and other chronic pain conditions such as complex regional
pain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fibromyalgia Market Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fibromyalgia affects an estimated 10&nbsp;million people in the United States and an estimated 3% to 6% of the world population. While it is
most prevalent in women, it also occurs in men and children of all ethnic groups. Fibromyalgia is the second most common disorder that rheumatologists encounter, seen in 15% of evaluated patients. Approximately 8% of patients cared for in primary
care clinics have fibromyalgia. Prominent fibromyalgia researchers and specialists estimate the economic burden of fibromyalgia in the United States to be between $12&nbsp;billion to $14&nbsp;billion each year and the condition accounts for a loss
of 1% to 2% of the national overall productivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential Complications of Fibromyalgia </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a <FONT STYLE="white-space:nowrap">non-exhaustive</FONT> list of complications of fibromyalgia: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extreme allodynia with high levels of distress; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">opioid or alcohol dependence; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marked functional impairment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severe depression and anxiety; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obesity and physical deconditioning; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">metabolic syndrome. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although fibromyalgia is frequently grouped with arthritis-related conditions, there is no
apparent inflammation or damage to the joints, muscles or other tissues. The diagnostic criteria for fibromyalgia are detailed in the chart below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently approved products for pain in fibromyalgia, including duloxetine, pregabalin and milnacipran,
have limited efficacy. Responders applying such products can only demonstrate a 27% to 40% reduction of symptoms, which is far below the commonly accepted threshold of 50% to prove efficacy in treating fibromyalgia. In light of this, we believe new
treatments with higher efficacy are needed to improve management of fibromyalgia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Solution </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-104</FONT> has key clinical data supporting its use in fibromyalgia. There are investigational trials that
support use and development of <FONT STYLE="white-space:nowrap">SP-104</FONT> for fibromyalgia. Currently there are no <FONT STYLE="white-space:nowrap">low-dose</FONT> formulations (i.e., less than 5 mg) available. Physicians currently use the
commercially available high-dose tablets (50 mg) and have compounding pharmacies aliquot lower doses for patients. Pharmacy-compounding is inherently inaccurate and does not involve analyses to confirm that the aliquoted product has the target level
of drug, and there is no assurance as to content uniformity within a batch as well as other quality attributes critical for pharmaceutical product performance. This approach can lead to errors in dosing and challenges with titration. The commercial
products and pharmacy-compounded products also allow for the immediate release of the drug in the stomach, which can lead to compliance challenges due to severe side effects. Common side effects for naltrexone include hyperalgesia, dysphoria,
insomnia and anxiety. All these issues culminate into patient compliance issues and result in the eventual abandonment of an otherwise viable therapy to treat this debilitating disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">SP-104</FONT> uses delayed burst release technology
that bypasses the stomach and releases the drug in the gut (upper intestine). When taking <FONT STYLE="white-space:nowrap">SP-104</FONT> at night before bed, peak drug levels are achieved at night during sleep, allowing the patient to avoid
conscious perception of hyperalgesia and other side effects. The combination of the delayed-release and administration at night may also maximize efficacy as most endorphin/ enkephalin release is during sleep, which maximizes the product&#146;s
potential to elicit compensatory response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to develop <FONT STYLE="white-space:nowrap">SP-104</FONT> for fibromyalgia.
Phase 1 studies are designed to characterize the pharmacokinetic and safety profile of <FONT STYLE="white-space:nowrap">SP-104,</FONT> and Scilex intends to initiate a Phase 2 study in 2023. If successful, we believe
<FONT STYLE="white-space:nowrap">SP-104</FONT> can become a pivotal treatment for management of fibromyalgia, which represents a large commercial opportunity with high unmet demands. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_52"></A>Commercialization and Market Access </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales&nbsp;&amp; Marketing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
built a robust and integrated commercial infrastructure using a dedicated sales force and sales management, marketing and managed care capabilities, to maximize the potential of our current marketed product, ZTlido, and our two other <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> products, GLOPERBA and ELYXYB, and to commercialize our product candidates, if approved. We are focused on achieving accelerated sales growth and increased market uptake for ZTlido in the topical
lidocaine product market, where we believe we have the only actively promoted product. Our dedicated <FONT STYLE="white-space:nowrap">65-person</FONT> sales force has broad experience in pain management and is exclusively focused on promoting
ZTlido. Our sales representatives leverage their established relationships to call on over 10,000 target pain specialists, neurologists, select primary care providers and palliative care physicians who Scilex believes treat the majority of PHN
patients. We believe these same call points provide treatment for the sciatica and acute LBP patients that could benefit from SEMDEXA and <FONT STYLE="white-space:nowrap">SP-103,</FONT> if approved. Our sales representatives typically have over 10
years of experience in promoting a broad scope of pain management products that Scilex intends to leverage as our product candidates are commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, ZTlido had gained approximately 11.4% market share of the lidocaine patch prescription market across the
territories we cover in the United States. The total prescriptions of ZTlido for the year ended December&nbsp;31, 2022 grew by more than 50.4% over the year ended December&nbsp;31, 2021, according to Symphony Healthcare&#146;s national prescription
data. Our experienced sales representatives and managers are supported by our marketing team, whose members have successfully launched over 20 products with large pharmaceutical, biotechnology and specialty pharmaceutical companies. Our marketing
team has developed a multi-channel marketing strategy to promote the continued uptake of ZTlido by highlighting its significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT>
administration period. We are also promoting ZTlido with a marketing campaign that engages patients seeking relief for neuropathic pain associated with PHN through social media and medical and consumer journals. Further, our marketing function is
supported by an experienced analytics team that leverages its experience in forecasting and analytics to draw insights from healthcare databases to inform our marketing strategy. As part of our broader commercial strategy, our marketing analytics
team is conducting market research to support the launch of <FONT STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104,</FONT> if any of these candidates is approved. We
believe that our sales force, supporting commercial infrastructure and established relationships with our targeted physician audience will provide a strategic advantage in pursuing potential partnerships to commercialize other <FONT
STYLE="white-space:nowrap">non-opioid</FONT> pain management therapeutics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market Access </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a patient-centric market access function with robust capabilities across the market access continuum, including payor
sales, contracting and marketing strategies, supplemental patient assistance programs and responsible drug pricing to support patients&#146; access to ZTlido. Our team of managed healthcare account executives has demonstrated experience in
establishing products on formularies and have currently prioritized and targeted select payor accounts representing approximately 275&nbsp;million of the over 300&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lives, with the remaining 25&nbsp;million to be considered in the future. Currently, ZTlido is covered for over 200&nbsp;million lives in the United States and coverage continues to improve. As
of January 2023, we have secured coverage for ZTlido on CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial,
Anthem BCBS, BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We continue to negotiate coverage with large payors and pharmacy benefit managers
in all books of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZTlido Formulary Coverage&#151;Over 90% of Lives Covered or In Negotiation </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We utilize an outside vendor to administer a patient assistance program directed at patients with
commercial insurance or those paying <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket.</FONT></FONT> With the copay assistance program, qualifying patients do not have to pay any copayment for their ZTlido
prescription. We utilize an external vendor and train the sales force to work proactively with clinician office managers in completing required forms for prior authorization for ZTlido. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_53"></A>Clinical Development Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Highlights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated ZTlido in over 600 subjects in clinical trials to support marketing approval and promotional campaigns for the relief of
neuropathic pain associated with PHN in the United States. Our studies sought to investigate the bioequivalence of ZTlido compared to Lidoderm, adhesion performance and the dermal safety and tolerability of ZTlido under a range of application times
and settings. Based on these studies, we concluded that ZTlido: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrated bioequivalence to Lidoderm in study
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PK-002A;</FONT></FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">showed greater than or equal to 90% adhesion in over 90% of the subjects at the end of the <FONT
STYLE="white-space:nowrap">12-hour</FONT> administration period in study <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-001;</FONT></FONT></FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">showed superior adhesion to Lidoderm and Mylan&#146;s generic lidocaine patch in studies <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-AHD-002</FONT></FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-003;</FONT></FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">was not meaningfully impacted by heat or exercise in study <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-HEX-001;</FONT></FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">was able to be used under showering and bathing conditions in study <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-004;</FONT></FONT></FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">did not show clinically meaningful dermal irritation in study <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SCI-LIDO-DERM-001.</FONT></FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ZTlido Study Details </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pivotal Bioequivalence
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Study&#151;SCI-LIDO-PK-002A</FONT></FONT></FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a comparative single-dose pharmacokinetic (&#147;PK&#148;) study between ZTlido and Lidoderm designed as a <FONT
STYLE="white-space:nowrap">two-way</FONT> cross-over in 54 healthy subjects. In this trial design, each subject received a single dose of three ZTlido or three Lidoderm patches followed by a washout period and the administration of the other
product. The purpose of this study was to establish bioequivalence between the products, which was determined by the statistical comparability of Cmax and AUC as shown in the figure below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This was considered the pivotal clinical trial for ZTlido, as it provided the pharmaceutical bridge between the two products and showed that
ZTlido had comparable safety and efficacy to Lidoderm. As a result of successfully establishing the pharmaceutical bridge, no stand-alone clinical efficacy studies were required by the FDA to determine ZTlido&#146;s analgesic effects for
ZTlido&#146;s approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mean Lidocaine Plasma Concentration Time Profiles&#151;Semilog Scale </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pivotal Adhesion
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Study&#151;SCI-LIDO-ADH-001</FONT></FONT></FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, single-period, single-application adhesion performance study in 54 healthy, human subjects to
assess the adhesion performance of ZTlido over the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period of the product. The study also investigated whether ZTlido met an FDA established adhesion performance benchmark of greater than
or equal to 90% adhesion in greater than or equal to 90% of subjects in the study at the end of the administration period. At the end of the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period, over 90% of the subjects (49 out of
the 54 subjects) maintained greater than or equal to 90% adhesion, with no adverse events reported during the study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZTlido Maintained Greater Than 90% Adhesion Over the
<FONT STYLE="white-space:nowrap">12-Hour</FONT> Time Period </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study was considered the pivotal adhesion study for marketing approval and is summarized in the
product label. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Head-to-Head</FONT></FONT> Adhesion Study versus <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Lidoderm&#151;SCI-LIDO-ADH-002</FONT></FONT></FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open label, single-treatment, three-period, single-application adhesion performance study in 44 healthy, human subjects to
evaluate the adhesion performance of ZTlido compared to the adhesion performance of Lidoderm over a <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior mean adhesion scores compared to Lidoderm at 3, 5, 9 and 12 hours after application.
ZTlido maintained a mean percent adhesion performance greater than 90% over the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period, while Lidoderm fell below 90% mean adhesion within three hours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZTlido Demonstrated Superior Adhesion Compared to Lidoderm </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01b34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Head-to-Head</FONT></FONT> Adhesion Study versus
Mylan&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Generic&#151;SCI-LIDO-ADH-003</FONT></FONT></FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, <FONT STYLE="white-space:nowrap">two-period,</FONT> single-application adhesion performance study
in 24 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of a generic lidocaine patch 5% manufactured by Mylan over a <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. The
purpose of this study was to compare the adhesion performance of ZTlido against a topical lidocaine product involving a <FONT STYLE="white-space:nowrap">non-aqueous</FONT> formulation. We selected Mylan&#146;s generic lidocaine patch as a comparator
because it has similar product characteristics, including a <FONT STYLE="white-space:nowrap">non-aqueous</FONT> polymer <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">drug-in-adhesive</FONT></FONT> system allowing for a thinner
patch and a lower drug load as compared to Lidoderm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior adhesion performance
compared to Mylan&#146;s generic lidocaine patch. ZTlido maintained a mean adhesion greater than 90% over the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period, while the generic product had a mean adhesion score of only 80%
immediately after application, which declined to a mean adhesion score of 27% at 12 hours after application. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZTlido Demonstrated Superior Adhesion Compared to Mylan&#146;s Generic Lidocaine Patch
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PK and Adhesion Study under Exercise and Heat <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Conditions&#151;SCI-LIDO-HEX-001</FONT></FONT></FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, randomized,
three-treatment, three-sequence, three-period, cross-over, PK and adhesion performance study of three ZTlido topical systems applied to separate areas in 12 healthy, human subjects during physical exercise, exposure to heat and under normal
conditions, respectively. The three treatment periods were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment A sought to assess the PK and adhesion performance of ZTlido under physical exercise conditions. In
this treatment period, subjects were instructed to perform exercise for 30 minutes on a stationary bike achieving a heart rate of 108 beats per minute, with continuous heart monitoring during exercise. Subjects were instructed to perform exercise
immediately after the application of the topical system and at 2.5, 5.5 and 8.5 hours following application of the topical system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment B sought to assess the PK and adhesion performance of ZTlido under heat conditions. In this treatment
period, a heating pad adjusted to the medium setting was applied for 20 minutes immediately after application of the topical system and at 8.5 hours following application of the topical system. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment C sought to assess the PK and adhesion performance of ZTlido under normal conditions. In this treatment
period, topical systems were applied to the <FONT STYLE="white-space:nowrap">mid-lower</FONT> back and worn for 12 hours. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In treatment A, adhesion and PK performance were not compromised by exercise, as reflected in the product label. In treatment B, heat had an
effect on PK but had no effect on adhesion. In Treatment C, normal PKs were observed and greater than 90% of subjects showed greater than 90% adhesion. No meaningful irritation was observed across all treatments across all time points in any of the
subjects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of heat and exercise on PK is presented in the figure below. It was observed that
heat had an effect on Cmax, but the drug returned to normal levels after removal of heat and there was no clinically meaningful observed effect on AUC. Heat did not appear to have a deleterious or catastrophic effect on topical system performance,
either as a dose-dump (i.e., immediate and complete release of all drug from the product), or as reduced drug delivery (i.e., much lower systemic exposure). There was no significant effect on PK observed with exercise when compared to subjects under
normal conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZTlido Demonstrated Consistent* PK Performance under Exercise and Heat Conditions </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a36.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Defined as no clinically meaningful changes by meeting bioequivalence criteria </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dermal Sensitization and Irritation <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Study&#151;SCI-LIDO-DERM-001</FONT></FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a provocative dermal sensitization and irritation human clinical trial, also referred to as a repeat insult topical system test,
intended to elicit the worst-case dermal safety of ZTlido by extended wearing of the product over multiple days. In this trial, we compared the sensitization potential, and the overall irritation profiles of ZTlido and Lidoderm in 218 normal and
healthy subjects. We used a <FONT STYLE="white-space:nowrap">7-point</FONT> scale where a score of 0 indicated no irritation and a score of 7 was considered a strong reaction spreading beyond the application site. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, results showed that the adhesion quality of ZTlido did not compromise dermal safety. The study reported that ZTlido did not
show potential for dermal sensitization and showed an overall benign irritation profile. Both ZTlido and Lidoderm had a mean irritation score well below 1, which is defined as barely perceptible erythema. This study allowed for the ZTlido label to
adopt the same local tolerance language as labeled for Lidoderm. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Photoallergy and Phototoxicity
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Studies&#151;SCI-LIDO-PHOT0-001</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PHOTO-002</FONT></FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a <FONT STYLE="white-space:nowrap">6-week</FONT> randomized study,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PHOTO-001,</FONT></FONT> to evaluate the potential of ZTlido and its comparator, Lidoderm, to induce a photoallergic skin reaction in 54 healthy volunteers. In this study, we
observed that ZTlido was not photoallergenic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a <FONT STYLE="white-space:nowrap">4-day,</FONT> randomized study, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PHOTO-002,</FONT></FONT> to evaluate the irritation potential of ZTlido and its comparator, Lidoderm, when application to skin is followed by light exposure in 32 healthy
volunteers, using a phototoxicity patch test. In this study, we observed that ZTlido was not phototoxic. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Studies for ZTlido </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Water Stress Study (Shower and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Swimming)&#151;SCI-LIDO-ADH-004</FONT></FONT></FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a single-dose study in 24 subjects to examine the adhesion and lidocaine delivery (pharmacokinetics) of ZTlido when it is exposed
to two separate water stress conditions of (1)&nbsp;showering (10 minutes) and (2)&nbsp;swimming (15 minutes). The study showed that while some degree of product lifting was observed, the product could be pressed back down or reattached with no
further diminished adhesion performance or drug delivery. This study led to a change in the product label indicating that patients may use the product while showering or bathing. This provides significant patient convenience as Lidoderm and the
associated generics are labeled to avoid contact with water such as bathing, swimming or showering, as these products may not stick if they get wet. With ZTlido, patients can engage in these activities within the
<FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investigator-Sponsored Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to evaluate the clinical benefits of using ZTlido in patients with carpal
tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently conducted a Phase 3 pivotal study of <FONT STYLE="white-space:nowrap">SP-102.</FONT> The Corticosteroid Lumbar
Epidural Analgesia for Radiculopathy (&#147;CLEAR&#148;) study is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica to compare the epidural administration of
<FONT STYLE="white-space:nowrap">SP-102</FONT> to placebo. We announced final results from this study in March 2022. We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las
Vegas, Nevada in May 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Highlights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> has been evaluated in a number of preclinical studies and clinical trials as a potential
treatment for sciatica. Key findings from the preclinical studies and clinical trials include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Repeat injections of <FONT STYLE="white-space:nowrap">SP-102</FONT> showed continued pain reduction with no
unexpected adverse events based on preliminary results from the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-102-03</FONT></FONT> study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT> showed an extended local activity with epidural administration in
the <FONT STYLE="white-space:nowrap">ES-1504</FONT> study; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT> showed an extended residence time and tolerability in the
1014-1512 and the 1014-2847, preclinical studies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The introduction of <FONT STYLE="white-space:nowrap">SP-102</FONT> into blood vessels did not result in
neurological complications in the UPD003-IS21 preclinical toxicology study. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) Study Details Phase 3 Pivotal Clinical
Trial&#151;CLEAR </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently conducted a pivotal, randomized, double-blind, placebo-controlled Phase 3 trial, CLEAR, that enrolled 401
patients with sciatica at over 40 sites across the United States. The study includes an open-label extension where subjects will be followed for up to 24 weeks after treatment to evaluate the safety of administering
<FONT STYLE="white-space:nowrap">SP-102</FONT> in a larger patient population. After week 4, subjects who met certain pain criteria received open-label <FONT STYLE="white-space:nowrap">SP-102</FONT> to investigate the safety of repeat injections and
the duration of pain relief following injection. This well-controlled, randomized trial was designed to demonstrate evidence of the analgesic effect and safety of <FONT STYLE="white-space:nowrap">SP-102.</FONT> The schematic of this Phase 3 trial is
demonstrated in the flowchart below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary objective of this study was to evaluate the analgesic effect of <FONT
STYLE="white-space:nowrap">SP-102</FONT> on average leg pain, measured using the Numeric Pain Rating Scale (&#147;NPRS&#148;) following a single transforaminal injection. These results were compared to an intra-muscular injection of placebo over a
four-week period. The secondary objectives of this study include (i)&nbsp;evaluation of the degree of disability over time as measured by the Oswestry Disability Index; (ii)&nbsp;characterization of the change of the subject&#146;s radiculopathy
symptoms and overall condition, using a combination of PainDETECT, modified Brief Pain Inventory, Clinical Global Impression of Change, and Patient Global Impression of Change and (iii)&nbsp;evaluation of the safety of a single and repeat <FONT
STYLE="white-space:nowrap">SP-102</FONT> injections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schematic of <FONT STYLE="white-space:nowrap">CLEAR&#151;SP-102</FONT> (SEMDEXA)
Phase 3 Pivotal Trial </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a38.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enrollment was completed in the second half of 2021. We announced final data from this study in March 2022.
The Pivot Phase 3 trial has met the primary efficacy and key secondary efficacy endpoints: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the primary endpoint of change in average daily pain (as measured by the Numeric Pain Rating Scale) in the
affected leg over four weeks following the initial injection, the LS Mean (SE) group difference of <FONT STYLE="white-space:nowrap">-1.08</FONT> (0.17) compared to placebo with a <FONT STYLE="white-space:nowrap">p-value</FONT> less than 0.001.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The two key secondary endpoints assessing Oswestry Disability Index (&#147;ODI&#148;) and Time to open label
repeat injection have been demonstrated for <FONT STYLE="white-space:nowrap">SP-102.</FONT> The LS Mean (SE) group difference in ODI compared to placebo at week 4 was <FONT STYLE="white-space:nowrap">-6.28</FONT> (1.49) with a <FONT
STYLE="white-space:nowrap">p-value</FONT> less than 0.001. A Cox proportional hazard model showed significantly longer duration of initial <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) treatment compared to placebo Hazard Ratio (95% CI)
0.49 (0.36, 0.65), with a <FONT STYLE="white-space:nowrap">p-value</FONT> less than 0.001. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Repeat Dose
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Study&#151;SP-102-03</FONT></FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <FONT
STYLE="white-space:nowrap">single-arm,</FONT> pharmacodynamics (&#147;PD&#148;) and safety study of repeat epidural injections of <FONT STYLE="white-space:nowrap">SP-102</FONT> in patients with sciatica. We conducted this study to characterize
repeat dose PD with respect to hypothalamic-pituitary-adrenal suppression using plasma cortisol levels, white blood cell count and blood glucose levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The study enrolled 19 subjects, of which 15 received repeat <FONT STYLE="white-space:nowrap">SP-102</FONT> epidural injections 4 to 8 weeks
after the initial injection. Four of the subjects did not experience recurrent pain and thus did not require a repeat injection. The daily average, current and worst pain in the affected leg and back showed continuous reduction throughout the <FONT
STYLE="white-space:nowrap">28-day</FONT> observation period for both treatments. Based on a preliminary review of the results, <FONT STYLE="white-space:nowrap">SP-102</FONT> injections were generally well-tolerated and there were no new unexpected
adverse events observed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mean Percentage Change in Sciatica-Related Leg Pain as Measured by NPRS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g454025g01a39.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Trial of <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) Compared to Reference Listed <FONT
STYLE="white-space:nowrap">Drug&#151;ES-1504</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <FONT STYLE="white-space:nowrap">single-arm,</FONT> <FONT
STYLE="white-space:nowrap">two-period,</FONT> fixed sequential-dose study to evaluate the PK, PD and safety of <FONT STYLE="white-space:nowrap">SP-102</FONT> when administered by epidural injection. <FONT STYLE="white-space:nowrap">SP-102</FONT> was
compared to intravenous dexamethasone sodium phosphate injection in subjects with lumbosacral radiculopathy. There were 12 subjects enrolled in this study, all of whom received <FONT STYLE="white-space:nowrap">SP-102</FONT> followed by the
intravenous dexamethasone sodium phosphate injection (Reference Listed Drug) administered one month later. A Reference Listed Drug is an approved drug product to which new versions are compared to show that they are bioequivalent. The purpose of
this study was to establish the pharmaceutical bridge between <FONT STYLE="white-space:nowrap">SP-102</FONT> and the Reference Listed Drug. The Tmax observed with the administration of <FONT STYLE="white-space:nowrap">SP-102</FONT> was four hours,
compared to 15 minutes observed with intravenous dexamethasone. The PD parameters and safety results of both products were similar, and <FONT STYLE="white-space:nowrap">SP-102</FONT> did not prolong cortisol suppression time. <FONT
STYLE="white-space:nowrap">SP-102</FONT> also maintained analgesic effects throughout a <FONT STYLE="white-space:nowrap">one-month</FONT> observation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall systemic exposure of dexamethasone was similar, whether administered as <FONT STYLE="white-space:nowrap">SP-102</FONT> or injected
intravenously, with a mean AUCinf of 0.916 &micro;g*h/mL (observed with <FONT STYLE="white-space:nowrap">SP-102)</FONT> compared to 0.943 &micro;g*h/mL (observed with intravenously-administered dexamethasone). Notably, there was a <FONT
STYLE="white-space:nowrap">16-fold</FONT> increase in the time to maximum serum concentration (&#147;Tmax&#148;) following epidural injection of <FONT STYLE="white-space:nowrap">SP-102.</FONT> The median Tmax was 4.00 hours for <FONT
STYLE="white-space:nowrap">SP-102</FONT> compared to 0.25 hours for the comparison group. All 12 subjects with sciatica showed continuous reduction in back and leg pain during the <FONT STYLE="white-space:nowrap">one-month</FONT> observation period
following a single epidural injection of <FONT STYLE="white-space:nowrap">SP-102.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study demonstrated that at an equivalent initial dose of dexamethasone, the systemic
exposure to dexamethasone following epidural injection of <FONT STYLE="white-space:nowrap">SP-102</FONT> did not exceed the exposure following intravenous injection of the Reference Listed Drug. The PD effects, measured as white blood cell count,
cortisol levels and glucose levels, as well as the safety profile, were similar between the two treatments. <FONT STYLE="white-space:nowrap">SP-102</FONT> injections were generally well-tolerated and did not result in new unexpected side effects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Toxicology Studies&#151;Study Nos. 1014-1512 and 1014-2847 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted PK and toxicology studies in two <FONT STYLE="white-space:nowrap">non-rodent</FONT> animal species to assess <FONT
STYLE="white-space:nowrap">SP-102</FONT> administered via epidural and intrathecal routes with single and multiple dose regimens. Pharmacokinetically, a prolonged increase in the active dexamethasone metabolite was consistent with the extended
residence time of the viscous gel formulation of <FONT STYLE="white-space:nowrap">SP-102</FONT> at the site of injection. There were no new unexpected toxicology findings apart from well-characterized toxicity findings commonly observed with
administration of dexamethasone sodium phosphate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Toxicology Study&#151;UPD003-IS21 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a preclinical toxicology study designed to simulate the accidental introduction of epidural steroids into arterial blood vessels
providing blood supply to the spinal cord, which is a major cause of neurological complications associated with current administration of suspension steroids containing particulates.A2 mL (10 mg of dexamethasone) injection of <FONT
STYLE="white-space:nowrap">SP-102</FONT> was injected over <FONT STYLE="white-space:nowrap">1-2</FONT> minutes into the vertebral artery of large animal species. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-and</FONT> post-dose angiography showed no remarkable changes and all animals survived for approximately
24 hours until euthanasia. The veterinary animal health report and the pathology report concluded there were no vascular, spinal cord or brain injuries associated with injection into the vertebral artery of the animals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hydrodynamic <FONT STYLE="white-space:nowrap">Study&#151;SP-PC002</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a hydrodynamic study of <FONT STYLE="white-space:nowrap">SP-102</FONT> in <FONT STYLE="white-space:nowrap">non-rodent</FONT>
animal species, which showed that epidural administration of <FONT STYLE="white-space:nowrap">SP-102</FONT> demonstrated an increased local residence half-life and a decreased flow from the injection site. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Intravascular Injection <FONT STYLE="white-space:nowrap">Study&#151;SEM-005</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a study to evaluate the accidental intravascular injection of <FONT STYLE="white-space:nowrap">SP-102</FONT> into the vertebral
artery of <FONT STYLE="white-space:nowrap">non-rodent</FONT> animals. There were no adverse clinical signs associated with the accidental intra-arterial injection of <FONT STYLE="white-space:nowrap">SP-102</FONT> following a <FONT
STYLE="white-space:nowrap">24-hour</FONT> survival period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4%
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT> is an investigational, <FONT STYLE="white-space:nowrap">non-aqueous</FONT>
lidocaine topical system undergoing clinical development in acute LBP. As a higher strength topical lidocaine system, <FONT STYLE="white-space:nowrap">SP-103</FONT> will build on the learnings from ZTlido because both products share the same
adhesive drug delivery formulation and manufacturing technology. The clinical program involves evaluating the safety and efficacy of <FONT STYLE="white-space:nowrap">SP-103</FONT> for the treatment of acute LBP. A Phase 1 study was completed that
demonstrated bioequivalent pharmacokinetics between the administration of a single <FONT STYLE="white-space:nowrap">SP-103</FONT> and the administration of three commercial ZTlido. The study also showed linear kinetics among multiple applications of
<FONT STYLE="white-space:nowrap">SP-103</FONT> (i.e., 1, 2 or 3 patches) over a <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. Adhesion performance was assessed and found to be comparable between <FONT
STYLE="white-space:nowrap">SP-103</FONT> and ZTlido. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, we plan to evaluate <FONT STYLE="white-space:nowrap">SP-103</FONT> in
the following studies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-103-02</FONT></FONT> is a Phase 2 study of <FONT
STYLE="white-space:nowrap">SP-103</FONT> in subjects with acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, <FONT STYLE="white-space:nowrap">two-period,</FONT> cross-over, multicenter study of <FONT
STYLE="white-space:nowrap">SP-103</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
versus placebo. The study is expected to consist of a <FONT STYLE="white-space:nowrap">7-day</FONT> open-label <FONT STYLE="white-space:nowrap">run-in</FONT> period where all subjects receive
active treatment. Responders to treatment will then be randomized to receive blinded treatment of either <FONT STYLE="white-space:nowrap">SP-103</FONT> or placebo. This study will inform on the pivotal Phase 3 study design to support market
approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In addition to a pivotal Phase 3 program, we intend to perform a <FONT STYLE="white-space:nowrap">3-day</FONT> PK
study of <FONT STYLE="white-space:nowrap">SP-103,</FONT> an adhesion performance study of <FONT STYLE="white-space:nowrap">SP-103</FONT> and an investigational study to evaluate the effects of heat and exercise on the PK and adhesion of <FONT
STYLE="white-space:nowrap">SP-103</FONT> to support the NDA submission. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 2 trial of <FONT
STYLE="white-space:nowrap">SP-103</FONT> was initiated in the second quarter of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-104</FONT> (4.5mg, <FONT
STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two Phase 1 trials have been
completed for <FONT STYLE="white-space:nowrap">SP-104</FONT> at investigative sites in New Zealand: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-104-01</FONT></FONT> is a food effect and
bridging pharmacokinetic study comparing <FONT STYLE="white-space:nowrap">SP-104</FONT> to Naltrexone HCL Tablets conducted on approximately 18 healthy adult subjects. The study is designed to be an open-label, three-period, three-treatment,
randomized study to characterize the PK and safety and tolerability of <FONT STYLE="white-space:nowrap">SP-104</FONT> under fasting and fed conditions. Subjects are randomly administered a single dose of one of three treatments and followed for PK
and safety for a period of time followed by a washout period before receiving one of the other treatments. All subjects receive all three treatments. The study characterize the single-dose clinical studies and ultimately the commercial label. The
study also serves as a &#147;pharmaceutical bridge&#148; between <FONT STYLE="white-space:nowrap">SP-104</FONT> and the commercial reference listed drug (the &#147;RLD&#148;) (Naltrexone HCI tablets, USP 50 mg) to support the eventual
Section&nbsp;505(b)(2) NDA. Assuming that the rate and extent of drug exposure for <FONT STYLE="white-space:nowrap">SP-104</FONT> will be lower than that observed for the RLD, this study allows us to rely upon the FDA&#146;s findings of safety for
the RLD instead of having to perform extensive nonclinical animal safety toxicology studies and establish an extensive clinical safety database. Our development program can focus on establishing efficacy of
<FONT STYLE="white-space:nowrap">SP-104</FONT> in the treatment of fibromyalgia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-104-02</FONT></FONT> is a Phase 1 study of <FONT
STYLE="white-space:nowrap">SP-104</FONT> conducted on approximately 52 healthy human subjects. The study is designed to be a double-blind, randomized, <FONT STYLE="white-space:nowrap">two-period,</FONT>
<FONT STYLE="white-space:nowrap">two-treatment</FONT> crossover study to evaluate the safety of <FONT STYLE="white-space:nowrap">SP-104,</FONT> compared to immediate release naltrexone capsules. The primary purpose of the study is to test the
hypothesis that, when taken at night, the delayed release of 4.5 mg Naltrexone mitigates against adverse events known for the drug and could affect patient compliance in maintaining treatment for their fibromyalgia. In a small (n=52) cross-over
trial in healthy volunteers comparing <FONT STYLE="white-space:nowrap">SP-104</FONT> (naltrexone hydrochloride delayed-release 4.5 mg) to naltrexone hydrochloride immediate release 4.5 mg (the &#147;compared drug&#148;), there were no serious
adverse effects, no AEs leading to discontinuation, no meaningful differences in physical examinations, vital signs, or laboratory parameters between treatments, no severe AEs for either treatment. Of the 52 patients receiving at least a single
injection of <FONT STYLE="white-space:nowrap">SP-104,</FONT> there were 21 (40%) patients experiencing at least one TEAE, 14 (27%) patients experiencing at least one treatment-related TEAE, 12 (23%) patients experiencing at least one
treatment-related TEAE within 72 hours after first administration of <FONT STYLE="white-space:nowrap">SP-104.</FONT> Notable AEs of special interest were nausea and headache within 72 hours after first administration of <FONT
STYLE="white-space:nowrap">SP-104.</FONT> <FONT STYLE="white-space:nowrap">SP-104</FONT> administered at night before bed resulted in a lower number of subjects with at least one AE (p = 0.0414), and an even lower number of subjects with at least
one AE within 72 hours after the first administration of <FONT STYLE="white-space:nowrap">SP-140</FONT> when compared to the compared drug. There was a lower number of subjects with AEs of special interest within 72 hours after administration of <FONT
STYLE="white-space:nowrap">SP-104</FONT> (n=9; 12 events) versus the compared drug (n=15; 20 events). Notable AEs of special interest observed within 72 hours after administration of the applicable drug are nausea
<FONT STYLE="white-space:nowrap">(SP-104:</FONT> n=0; the compared drug: n=3) and headache <FONT STYLE="white-space:nowrap">(SP-104:</FONT> n=6; the compared drug: n=12). The study randomized subjects to one of two treatments followed by a washout
period and then receipt of the other treatment, which allows all subjects to act as their own control. The study will support intellectual property, inform on clinical study design and contribute to safety characterization to support market
applications. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We completed both studies in the second quarter of 2022. We plan to use data collected from
these studies to support an Investigational New Drug application with the FDA, which is expected to enable further clinical development and initiation of a planned multi-center placebo-controlled registration trial in the field of fibromyalgia. The
registration trial is designed to be a Phase 3, randomized double-blind, placebo-controlled, parallel group, multicenter study that meets the regulatory requirements of an &#147;adequate and well-controlled&#148; study to establish the efficacy of <FONT
STYLE="white-space:nowrap">SP-104</FONT> in the treatment of fibromyalgia. Depending on the outcomes, this registration trial alone may be efficient in supporting market approval of <FONT STYLE="white-space:nowrap">SP-104</FONT> or as an additional
Phase 3 study may be required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_54"></A>Medical Affairs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Medical Affairs team includes <FONT STYLE="white-space:nowrap">in-house</FONT> medical expertise, health economics and third-party payor
support. The Medical Affairs team works with our clinical team to identify sites for clinical trials, support the investigator teams and develop publication plans for clinical and real-world ZTlido data and our product candidates. Our Medical
Affairs team also works with Key Opinion Leaders, professional societies and patient advocacy groups to educate on and support the appropriate use of pain therapeutics, including topical pain products. Further, our Medical Affairs team provides our
sales organization with therapeutic knowledge and product training. The Medical Affairs team and Promotional Review Committee review all promotional materials for scientific accuracy. Medical Affairs team also develops lifecycle planning and works
with our clinical team to determine registration or supportive studies, oversee post-approval studies and support investigator-sponsored trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_55">
</A>Manufacturing and Supply Chain </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage
and distribution of our product. Our technical team has extensive pharmaceutical development, manufacturing, analytical, quality and distribution experience and is qualified and capable of managing manufacturing and supply chain operations. Our
Quality System, Standard Operating Procedures and contract manufacturing organizations (&#147;CMOs&#148;) comply with cGMP and regulatory requirements. We selected our CMOs for specific competencies having met our development, manufacturing, quality
and the FDA regulatory requirements. These CMOs manufacture our clinical supplies and commercial batches. We currently have no plans to build our own manufacturing or distribution infrastructure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido is a single-layer, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">drug-in-adhesive</FONT></FONT> topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a
polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) in Japan. We have exclusive worldwide rights to Oishi&#146;s proprietary formulation and manufacturing
technologies except with respect to Japan. ZTlido is manufactured using premixing and <FONT STYLE="white-space:nowrap">hot-melt</FONT> mixing of various excipients and lidocaine, followed by cGMP compliant coating, lining, cutting and filling
processes. ZTlido is packaged as a carton of 30 topical systems, into individual child-resistant envelopes. See the section of this prospectus titled &#147;<I>Business&#151;Material Agreements&#151;Itochu and Oishi Product Development
Agreement</I>&#148; and &#147;<I>Business&#151;Material Agreements&#151;Itochu and Oishi Commercial Supply Agreement</I>&#148; for additional information regarding the manufacturing and supply chain of ZTlido. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once production is complete, commercial product shipments are sent to the United States, where our exclusive third-party logistics
distribution provider, Cardinal Health 105, LLC (&#147;Cardinal Health 105&#148;), ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to retail pharmacies on the same day, or
within 24 hours. We currently contract with multiple pharmaceutical distributors throughout the United States, including McKesson Corporation (&#147;McKesson&#148;), Cardinal Health 110, LLC (&#147;Cardinal Health 110&#148;) and AmerisourceBergen
Corporation (&#147;AmerisourceBergen&#148;). Distributors have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements in place that provide us with access to large retail chains, including CVS, Walgreens, Rite Aid and Walmart, as well as independent pharmacies. In addition to all order fulfillment,
Cardinal Health 105 performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security
(DSCSA serialization) inquiries and recall assistance. In the years ended December&nbsp;31, 2020, 2021, and first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all of our net revenue for such
periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional
distributors and pharmacies in the second quarter of 2022. We currently hold wholesaler licenses and commenced selling directly to our main distributor customers as well as pharmacies from the second quarter of 2022. In April 2022, we discontinued
our use of &#147;title model&#148; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> is a Phase 3 sterile dexamethasone sodium phosphate injectable viscous gel drug product
containing dexamethasone sodium phosphate equivalent to 10 mg dexamethasone in a <FONT STYLE="white-space:nowrap">pre-filled</FONT> glass syringe with a 2 mL deliverable volume. <FONT STYLE="white-space:nowrap">SP-102</FONT> also contains sodium
hyaluronate, which is a novel, biocompatible, viscosity-enhancing excipient and is listed in the European Pharmacopeia. We have an exclusive supply agreement for sodium hyaluronate for <FONT STYLE="white-space:nowrap">SP-102</FONT> from the
manufacturer and supplier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> is manufactured by a single-source manufacturer, which supports
the clinical development, including the completed Phase 3 clinical trial of <FONT STYLE="white-space:nowrap">SP-102.</FONT> In March 2022, we announced final results of the Phase 3 clinical trial, satisfying the primary efficacy and key secondary
efficacy endpoints. The manufacturing process is proprietary and includes trade secrets. We plan to engage our existing contract manufacturer, Lifecore, for the commercial production of <FONT STYLE="white-space:nowrap">SP-102,</FONT> if approved. We
plan to use the biocompatible proprietary excipient supplied by Sanofi-Aventis U.S. LLC (&#147;Sanofi&#148;) sodium hyaluronate, pursuant to the Genzyme Supply Agreement, and engage Sanofi for commercial supply of dexamethasone sodium phosphate for <FONT
STYLE="white-space:nowrap">SP-102,</FONT> if approved. See the section of this prospectus titled &#147;<I>Business&#151;Material Agreements&#151;Genzyme Supply Agreement</I>&#148; and &#147;<I>Business&#151;Material Agreements&#151;Lifecore Master
Services Agreement</I>&#148; for additional information regarding the manufacturing and supply of the proprietary excipient and contact manufacturing of <FONT STYLE="white-space:nowrap">SP-102</FONT> product, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-103</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT> contains 5.4% lidocaine (108 mg lidocaine) and is manufactured for clinical supply by Oishi,
using the same manufacturing processes as used for ZTlido. If our Phase 2 and Phase 3 trials are successful, we plan to submit the <FONT STYLE="white-space:nowrap">SP-103</FONT> manufacturing protocols in a supplemental new drug application. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-104</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SP-104,</FONT> a novel <FONT STYLE="white-space:nowrap">low-dose,</FONT> naltrexone
hydrochloride delayed release formulation for treating fibromyalgia. <FONT STYLE="white-space:nowrap">SP-104</FONT> is 4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed release capsule product in clinical
development, currently undergoing Phase 1 studies. It is manufactured by a contract manufacturer, Tulex Pharmaceuticals Inc. (&#147;Tulex&#148;), located in Cranbury, NJ. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_56"></A>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry is highly competitive and subject to rapid and significant technological change. The large size and expanding scope of the pain
management market makes it an attractive therapeutic area for biopharmaceutical businesses. Our potential competitors include pharmaceutical, biotechnology and specialty pharmaceutical companies. Many of these companies have drug pipelines, readily
available capital, and established research and development organizations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, <FONT STYLE="white-space:nowrap">SP-103,</FONT> if
approved, face and will likely face competition from prescription, generic, and OTC topical lidocaine patches, including Lidoderm and generic lidocaine patches manufactured by Teva, Mylan and Par Pharmaceutical, Inc. Additionally, <FONT
STYLE="white-space:nowrap">SP-103,</FONT> if approved, will likely compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants and anticonvulsants, particularly as we seek approval for the treatment of acute LBP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102,</FONT> if approved, has the potential to become the first
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> epidural steroid product for the treatment of sciatica. While there are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESIs indicated for the treatment of sciatica, we are aware
of certain <FONT STYLE="white-space:nowrap">non-steroid</FONT> product candidates in development. <FONT STYLE="white-space:nowrap">SP-102,</FONT> if approved, will compete with various opioid pain medications, NSAIDs, muscle relaxants,
antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the <FONT STYLE="white-space:nowrap">off-label</FONT> and
unapproved use of branded and generic injectable steroids. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical
development for the treatment of fibromyalgia, we are aware of certain <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, <FONT
STYLE="white-space:nowrap">SP-104,</FONT> will likely face direct competition from these candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will
become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as
well as significantly greater experience in: developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining the FDA and other regulatory approvals of product candidates, formulating and manufacturing
product candidates and launching, marketing and selling product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and
pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their
products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These
competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or
necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced
or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved,
our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to <FONT
STYLE="white-space:nowrap">in-license</FONT> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and
commercializing medicines before we do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of ZTlido,
<FONT STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> are likely to be their efficacy, durability, safety, price and the availability of reimbursement from
government and other third-party payors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_57"></A>Material Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Itochu and Oishi Product Development Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to the Product Development Agreement with Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation
(&#147;Itochu,&#148; and together with Oishi, the &#147;Developers&#148;). Pursuant to the Product Development Agreement, the Developers agreed to develop, exclusively for us, lidocaine tape products, including ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> (the &#147;Products&#148;). Pursuant to the Product Development Agreement, we obtained the rights to market, sell and distribute the Products in global markets outside of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In carrying out the development responsibilities, the Developers agreed to, among other things, (1)&nbsp;source and provide the active
pharmaceutical ingredient for the Products for manufacturing, (2)&nbsp;develop a stable final dosage form of the Products suitable for regulatory approvals, (3)&nbsp;conduct product development activities necessary to support the filing of
applications for regulatory approvals for the Products and (4)&nbsp;conduct manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> activities and preclinical studies for the Products. We are responsible for, among other things,
(a)&nbsp;conducting all pivotal human clinical trials for the Products, (b)&nbsp;completing all regulatory filings, correspondence and meetings with the FDA or other applicable governmental authorities with respect to the Products and
(c)&nbsp;commercially launching the Products. We maintain the ultimate responsibility and decision-making control with regard to the marketing and pricing of the Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties agreed to cooperate in good faith to determine whether to seek or maintain patent protection with respect to the Products, the
active pharmaceutical ingredient, any associated method of use, method of manufacturing, or any other invention that could reasonably be expected to affect the commercialization or value of the Products. The Developers have the first right to pursue
patent protection for any invention by them. All parties will jointly agree on the appointment of the patent representatives in each country outside of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the expiration or termination of the Product Development Agreement, the Developers granted us an exclusive, royalty-free, sublicensable,
worldwide license (except with respect to Japan) under its current and future intellectual property rights relating to the Products and the lidocaine in such Products. As consideration for the Developers&#146; development obligations under the
Product Development Agreement, we agreed to pay a contingent quarterly royalty between 25% and 35% to the Developers based on the net quarterly profits of the Products. In the event that the net profits of any of the first four calendar quarters
after the commercial launch equals a negative amount (a &#147;Net Loss&#148;), we are allowed to carry over such Net Loss to apply against all future calendar quarters until such Net Loss is covered, all calculated in accordance with accounting
principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). Under the Product Development Agreement, if our total net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five
percent of our net sales of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> for a period of four or more consecutive quarters, the Developers have the right to terminate the Product Development Agreement and the Commercial Supply
Agreement. As of the date of this prospectus, our net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product
Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, if we receive any licensing fees from any third-party sublicensees, we are
obligated to pay the same proportions of such licensing fee to the Developers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current term of the Product Development Agreement will
continue until October&nbsp;2, 2028, which is the 10th anniversary of the first commercial sale of ZTlido. Afterwards, the agreement will renew automatically for subsequent successive <FONT STYLE="white-space:nowrap">one-year</FONT> renewal periods
unless we or the Developers terminate it upon <FONT STYLE="white-space:nowrap">six-month</FONT> written notice. In addition, we or the Developers may terminate the Product Development Agreement if (1)&nbsp;the other party is in material breach of
the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within 180 days after notice requesting to cure; (2)&nbsp;the FDA determines that the formulation of the Products
would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&nbsp;the market conditions are such that (a)&nbsp;our total net
profits of the Products are equal to or less than five </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
percent of our net sales of the Products for a period of four or more consecutive quarters, or (b)&nbsp;the Products&#146; economic viability is affected significantly as evidenced by
documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us and the Developers, and the parties are unable to resolve the concerns under the foregoing clauses (a)&nbsp;and (b) after 30
days of good-faith discussion; (4)&nbsp;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&nbsp;we or either one of the Developers are bankrupt or make assignment for
the benefit of creditors. Additionally, we may terminate the Product Development Agreement if (i)&nbsp;any of the pivotal human clinical trials for any of the Products fail, or (ii)&nbsp;the FDA issues a &#147;Refusal to File&#148; for any of the
Products&#146; regulatory approval application and, after reasonable consultation with the Developers, we believe that it is commercially unreasonable to <FONT STYLE="white-space:nowrap">re-file.</FONT> The Developers may terminate the Product
Development Agreement if we fail to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, we and the Developers have agreed, subject to certain exceptions, to indemnify each other against any
third-party liabilities arising out of (1)&nbsp;any breach of our respective representations, warranties or obligations under the Product Development Agreement, (2)&nbsp;any failure by either of us to comply with all applicable laws, or (3)&nbsp;our
respective negligence or willful misconduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Product Development Agreement and
its amendments in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Itochu and Oishi Commercial Supply Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;16, 2017, Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;) entered into the Commercial Supply Agreement with
Itochu and Oishi (the &#147;Commercial Supply Agreement&#148;). Pursuant to the Commercial Supply Agreement, Oishi agreed to manufacture, store, handle and perform quality control testing of the Products (as defined in the Product Development
Agreement) at its facility in Japan. Itochu agreed to purchase Products from Oishi and handle the shipping of the Products. Both Oishi and Itochu agreed to provide us with certain technical support regarding the Products as reasonably requested by
us, including but not limited to analytical test methods, method development, physical and chemical properties, and use of the Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Itochu and Oishi Commercial Supply Agreement, we pay per item transfer prices for ZTlido, ZTlido professional samples and ZTlido
placebo samples, in each case subject to certain minimum order quantities. We are required to provide a <FONT STYLE="white-space:nowrap">12-month</FONT> rolling purchase forecast of the estimated quantities of the Products in writing on a monthly
basis. Oishi is required to promptly notify us and Itochu if it lacks the capacity to meet the forecast. All Products ordered by us will be in the form of a firm written purchase order. During the years ended December&nbsp;31, 2022, 2021 and 2020,
we purchased inventory in the amount of $6.7&nbsp;million, $5.7&nbsp;million, and $0.8&nbsp;million, respectively, under the Itochu and Oishi Commercial Supply Agreement. The significant increase in inventory purchased in fiscal year 2021 was
largely due to an excess of in stock inventory in fiscal year 2020 that was sold throughout fiscal year 2020 and the early part of fiscal year 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Itochu and Oishi Commercial Supply Agreement will remain in effect until the termination of the Product Development Agreement.
Additionally, either we or the Developers may terminate the Itochu and Oishi Commercial Supply Agreement (1)&nbsp;if the other party is in material breach of the agreement and the breach is not substantially cured within 60 days after receiving
written notice specifying the nature of the breach, or (2)&nbsp;in the event of any of the parties&#146; insolvency, bankruptcy or assignment for the benefit of creditors. Any third-party claim arising out of a breach by a party of any
representation, warranty or obligation under the Itochu and Oishi Commercial Supply Agreement, or a failure by a party to comply with applicable laws, or the negligence or willful misconduct of a party, will be subject to and governed by the Product
Development Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Itochu and Oishi Commercial Supply
Agreement and its amendments in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective
terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Genzyme Supply Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;17, 2015, through our wholly owned subsidiary, Semnur, we entered into that certain exclusive Supply Agreement (the
&#147;Genzyme Supply Agreement&#148;) with Genzyme Corporation (&#147;Genzyme&#148;), an affiliate of Sanofi-Aventis U.S. LLC. Pursuant to the Genzyme Supply Agreement, Genzyme agreed to produce and provide sodium hyaluronate, one of the excipients
for SEMDEXA, and we agreed to purchase 100% of our clinical and commercial requirements for sodium hyaluronate in specified territories, including the United States and all countries of the European Union (&#147;EU&#148;), exclusively from Genzyme.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Genzyme Supply Agreement, we agreed to pay a per gram price for clinical supply of sodium hyaluronate. For commercial
supply, the price will depend on the quantity of order. The pricing for both the clinical supply and the commercial supply of sodium hyaluronate is subject to readjustments each year on January&nbsp;1, provided that in no case will the price be
increased by more than 5% each year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Genzyme Supply Agreement provides for a five year exclusivity period in favor of us and will
remain in effect until 10 years after the effective date unless earlier terminated in accordance with the terms thereof, with automatic renewal for additional five year periods (on an exclusive basis), if the respective requirements for exclusivity
are met by us as set forth therein, and for additional <FONT STYLE="white-space:nowrap">two-year</FONT> periods thereafter unless either party gives notice of a termination not less than 18 months prior to the expiration of the then-current term.
Either party may terminate the Genzyme Supply Agreement if (1)&nbsp;the other party is in material breach of the agreement and fails to cure within 30 days, or (2)&nbsp;if the development of SEMDEXA is ceased or we do not file for regulatory
approval for SEMDEXA by January&nbsp;1, 2020. Additionally, Genzyme may terminate the Genzyme Supply Agreement if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24
months&#146; notice. We did not file for regulatory approval for SEMDEXA by January&nbsp;1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with Genzyme&#146;s right terminate the Genzyme Supply Agreement
if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons, Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement, effective as of May&nbsp;31, 2024. Although we are
currently in the process of identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate we may not be able to find an alternative supplier of sodium hyaluronate on commercially
reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Genzyme Supply Agreement, we and Genzyme have agreed, subject to certain exceptions, to indemnify each other
against any third-party liabilities arising out of (1)&nbsp;any material breach of our respective representations, warranties and obligations thereunder, or (2)&nbsp;our respective gross negligence or willful misconduct. In addition, we have agreed
to indemnify Genzyme against any third-party liabilities arising out of the development, manufacture, storage, handling, use, marketing, distribution, offer for sale, sale, promotion or other commercialization of sodium hyaluronate by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Genzyme Supply Agreement in the form filed as an exhibit to the registration statement
of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lifecore Master
Services Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;27, 2017, through our wholly owned subsidiary, Semnur, we entered into that certain Master
Services Agreement (as amended, the &#147;Lifecore Master Services Agreement&#148;), with Lifecore Biomedical, LLC (&#147;Lifecore&#148;). Pursuant to the Lifecore Master Services Agreement, Lifecore is responsible for clinical trial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material manufacturing and development services for SEMDEXA as set forth in each separate statement of work (each a &#147;Lifecore Statement of Work&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties entered into a Lifecore Statement of Work on January&nbsp;27, 2017, pursuant to which Lifecore agreed to provide, among other
things, (1)&nbsp;project management support, (2)&nbsp;development services, (3)&nbsp;clinical trial materials, and (4)&nbsp;stability studies. We paid Lifecore for the development and clinical trial material manufacturing services, which was
invoiced at the completion of each service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of Lifecore&#146;s development and clinical trial material manufacturing
obligations, we granted Lifecore a nonexclusive, worldwide and royalty-free license under our owned or controlled intellectual property rights necessary to manufacture SEMDEXA, without additional right, title or interest in our intellectual
property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement contains customary reciprocal indemnification obligations for Lifecore and Semnur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement expired on December&nbsp;31, 2022, and we are currently negotiating a new agreement with Lifecore. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Lifecore Master Services Agreement and the amendment thereto in the forms filed as
exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendment for a complete understanding of all of their respective terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Semnur Merger Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, Legacy Scilex acquired Semnur pursuant to an Agreement and Plan of Merger with Semnur (as amended, the &#147;Semnur Merger Agreement&#148;), Sigma Merger Sub, Inc., a wholly owned subsidiary of Legacy Scilex (&#147;Sigma Merger
Sub&#148;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#147;Semnur Equityholders&#146; Representative&#148;), and for limited purposes, Sorrento. Pursuant to the Semnur Merger Agreement, Sigma Merger Sub
merged with and into Semnur (the &#147;Semnur Merger&#148;), with Semnur surviving as Legacy Scilex&#146;s wholly owned subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with transactions contemplated by the Semnur Merger Agreement, Sorrento and each of the other holders of outstanding shares of capital stock of Scilex Pharma, contributed each share of Scilex Pharma capital stock it owned to Legacy Scilex
in exchange for one share of common stock of Legacy Scilex (&#147;Legacy Scilex Common Stock&#148;), par value $0.0001 per share (the &#147;Contribution&#148;). As a result of the Contribution, and prior to the consummation of the Semnur Merger,
Scilex Pharma became a wholly owned subsidiary of Legacy Scilex and Sorrento became the owner of approximately 77% of Legacy Scilex&#146;s issued and outstanding capital stock. As a result of the Semnur Merger, Scilex Pharma and Semnur became wholly
owned subsidiaries of Legacy Scilex. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the closing of the Semnur Merger, Legacy Scilex issued to the holders of Semnur&#146;s capital
stock (the &#147;Semnur Equityholders&#148;) and options to purchase Semnur&#146;s common stock, upfront consideration with a value of $70.0&nbsp;million. The upfront consideration was comprised of the following: (i)&nbsp;a cash payment of
approximately $15.0&nbsp;million, and (ii) $55.0&nbsp;million in shares of Legacy Scilex Common Stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#147;Stock Consideration&#148;). A portion of the cash
consideration otherwise payable to the Semnur Equityholders was set aside for expenses incurred by the Semnur Equityholders&#146; Representative, and 4,749,095 shares of Legacy Scilex Common Stock otherwise issuable to Semnur Equityholders were
placed in escrow with a third party as security for the indemnification obligations of the Semnur Equityholders under the Semnur Merger Agreement. The expense fund and escrow have since been released per the terms of the escrow agreement. The Semnur
Equityholders that received the Stock Consideration were required to sign an exchange and registration rights agreement with Legacy Scilex, which is further described below. Following the issuance of the Stock Consideration, Sorrento ownership in
Legacy Scilex was diluted to approximately 58% of Legacy Scilex&#146;s issued and outstanding capital stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Semnur Merger Agreement, and upon the terms and subject to the conditions
contained therein, Legacy Scilex also agreed to pay the Semnur Equityholders up to $280.0&nbsp;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $40.0&nbsp;million payment that will be
due upon obtaining the first approval of a NDA of a Semnur product by the FDA and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (i)&nbsp;a $20.0&nbsp;million payment upon
the achievement of $100.0&nbsp;million in cumulative net sales of a Semnur product, (ii)&nbsp;a $20.0&nbsp;million payment upon the achievement of $250.0&nbsp;million in cumulative net sales of a Semnur product, (iii)&nbsp;a $50.0&nbsp;million
payment upon the achievement of $500.0&nbsp;million in cumulative net sales of a Semnur product, and (iv)&nbsp;a $150.0&nbsp;million payment upon the achievement of $750.0&nbsp;million in cumulative net sales of a Semnur product. As of the date of
this prospectus, none of the foregoing payments have been triggered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Semnur Merger Agreement also provided that following the
consummation of Legacy Scilex&#146;s first bona fide equity financing with one or more third-party financing sources on an arms&#146; length basis with gross proceeds to Legacy Scilex of at least $40.0&nbsp;million, certain of the former Semnur
optionholders will be paid cash in lieu of: (i)&nbsp;the 352,972 shares of Legacy Scilex Common Stock otherwise issuable to such former Semnur optionholders pursuant to the Semnur Merger Agreement, and (ii)&nbsp;any shares that would otherwise be
issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Semnur Merger Agreement, with such shares in each case valued at $1.16 per share. The Semnur optionholders subsequently agreed, under the terms of the
Exchange Agreement (as defined and described below) to forego the foregoing right to any such payment in exchange for the right to participate in the Share Exchange (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2019, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights
Agreement with Legacy Scilex (as amended, the &#147;Exchange Agreement&#148;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within 18 months following the closing of the Semnur Merger,
100% of the outstanding equity of Legacy Scilex had not been acquired by a third party or Legacy Scilex had not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of Legacy Scilex capital
stock on a major stock exchange that met certain requirements, then holders of the Stock Consideration could collectively elect to exchange, during the <FONT STYLE="white-space:nowrap">60-day</FONT> period commencing the date that was the 18 month
anniversary of the closing of the Semnur Merger (the &#147;Share Exchange&#148;), the Stock Consideration for shares of Sorrento&#146;s common stock with a value of $55.0&nbsp;million based on a price per share of Sorrento&#146;s common stock equal
to the greater of (a)&nbsp;the <FONT STYLE="white-space:nowrap">30-day</FONT> trailing volume weighted average price of one share of Sorrento&#146;s common stock as reported on Nasdaq as of the consummation of the Share Exchange and (b) $5.55
(subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#147;Exchange Price&#148;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento and the Semnur
Equityholders&#146; Representative on September&nbsp;28, 2020, on October&nbsp;9, 2020, Sorrento paid $55.0&nbsp;million in cash to the Semnur Equityholders in lieu of issuing $55.0&nbsp;million of shares of Sorrento&#146;s common stock at the
Exchange Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Semnur Merger Agreement (including the amendment thereto) in the
forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the Semnur Merger Agreement (including the amendment thereto) for a complete understanding of all of their respective terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aardvark Asset Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase agreement (the &#147;Aardvark Asset Purchase Agreement&#148;) with Aardvark
Therapeutics, Inc. (&#147;Aardvark&#148;), pursuant to which, among other things, Sorrento acquired Aardvark&#146;s Delayed Burst Release Low Dose Naltrexone <FONT STYLE="white-space:nowrap">(DBR-LDN)</FONT> asset and intellectual property rights,
for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Assets&#148;), which includes a Statement of Work dated November&nbsp;18, 2020 (the &#147;Tulex
Statement of Work&#148;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of <FONT STYLE="white-space:nowrap">SP-104</FONT> for Sorrento. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development
efforts related to <FONT STYLE="white-space:nowrap">SP-104</FONT> and on May&nbsp;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#147;Bill of Sale&#148;), pursuant to which Sorrento
sold, conveyed, assigned and transferred to Legacy Scilex all of its rights, title and interest in and to the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (including PCT/US2021/053645 and all patents and patent applications that claim
priority rights thereto) and Legacy Scilex assumed all of Sorrento&#146;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Acquisition&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition, Legacy Scilex issued a promissory note in the aggregate
principal amount of $5,000,000 to Sorrento (the &#147;Promissory Note&#148;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and
(b)&nbsp;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#147;Consideration Shares&#148;) or any combination thereof, at Legacy Scilex&#146;s sole discretion,
and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within
60 days of the issuance of such Consideration Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is
obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy
Scilex&#146;s sole discretion) (the &#147;Development Milestone Payment&#148;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#147;Commercial
Product&#148;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to
reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of
the date of this prospectus, none of the foregoing payments have been triggered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the
SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, MD, a member of our Board, is the founder, chief executive officer and a member of the
board of directors of Aardvark. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Aardvark Asset Purchase Agreement, Bill of Sale
and Promissory Note in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the forms of these agreements for a complete understanding of all of their respective terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tulex Master Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, in connection with the <FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition, Legacy Scilex acquired the Tulex
Statement of Work, pursuant to which Tulex, among other things, develops, tests and manufactures clinical supplies of <FONT STYLE="white-space:nowrap">SP-104</FONT> for Legacy Scilex. The Tulex Statement of Work is governed by the terms of a master
services agreement (the &#147;Tulex Master Services Agreement&#148;). The Tulex Master Services Agreement was novated to Legacy Scilex on June&nbsp;15, 2022 and will remain in effect until five years after the effective date, unless terminated early
by either party. Either party may terminate the Tulex Master Services Agreement or a Tulex Statement of Work by written notice (1)&nbsp;if the other party is in material breach of the agreement or a Tulex Statement of Work and fails to cure such
breach within 15 days after receipt of notice of such breach (or such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other time period expressly stated in the applicable Tulex Statement of Work) or (2)&nbsp;in the event of the other party&#146;s insolvency, bankruptcy, reorganization, liquidation or
receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any Tulex
Statement of Work (1)&nbsp;without cause upon 30 days prior written notice to Tulex or (2)&nbsp;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. A termination or expiration of a single Tulex Statement
of Work will not cause the automatic termination of the agreement or of any other Tulex Statement of Work. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party under the Tulex
Master Services Agreement agreed to indemnify the other party, its affiliates and each of their respective officers, directors, employees, contractors and agents against any third-party liabilities arising out of (1)&nbsp;such party&#146;s breach of
the Tulex Master Services Agreement or a Tulex Statement of Work or (2)&nbsp;the negligence or willful misconduct on the part of such party, its officers, directors, employees, agents or other representatives in connection with the Tulex Master
Services Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Tulex Master Services Agreement in the form filed as an
exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shah Investor LP Assignment Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2013, through Semnur, we entered into an Assignment Agreement (the &#147;Assignment Agreement&#148;) with Shah Investor LP
(&#147;Shah Investor&#148;). Mahendra Shah, Ph.D., who served on our board of directors from March 2019 to October 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned to us certain
intellectual property related to pharmaceutical compositions of corticosteroids (the &#147;Assigned IP&#148;). As consideration for the Assigned IP, we agreed to pay a contingent quarterly royalty in the
<FONT STYLE="white-space:nowrap">low-single</FONT> digits to Shah Investor based on the quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed utilizing the Assigned IP (a &#147;Royalty
Product&#148;). We expect that SEMDEXA, if approved, will constitute a Royalty Product. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as a Royalty Product is covered by a valid patent in the
country of sale or for ten years following the first commercial sale of the first Royalty Product in the United States, whichever is longer. We also agreed to use commercially reasonable efforts to maximize the scope and coverage of the patents
contained in the Assigned IP. As of the date of this prospectus, no royalty payments have been made as we have not yet commercialized any applicable products and therefore such payments have not been triggered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Assignment Agreement will remain in effect on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis until royalties are no longer due on any
Royalty Product. Either party may terminate the Assignment Agreement upon sixty days&#146; prior written notice, in the event the other party seeks to avoid a provision of the Assignment Agreement by asserting that such provision is invalid, illegal
or otherwise unenforceable, unless such assertion is eliminated and the effect of such assertion cured within such sixty day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
foregoing is a summary of the material terms of the Assignment Agreement in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of
all of its terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Romeg License and Commercialization Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective June&nbsp;14, 2022, we entered into a License and Commercialization Agreement (the &#147;Romeg Agreement&#148;) with RxOmeg
Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.). Pursuant to the Romeg Agreement, Romeg granted to us (1)&nbsp;the right to manufacture, promote, market, distribute and sell the Licensed Products (as defined below) in the United States and
(2)&nbsp;an exclusive, transferable license to use the trademark &#147;GLOPERBA&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Romeg Agreement, among other things, Romeg granted us (1)&nbsp;a transferable
license, with the right to sublicense, under the patents and <FONT STYLE="white-space:nowrap">know-how</FONT> specified therein to (a)&nbsp;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic
treatment of gout in adult humans (the &#147;Initial Licensed Product&#148;) in the United States (including its territories) (the &#147;Territory&#148;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical
ingredient (together with the Initial Licensed Product, the &#147;Licensed Products&#148;) and commercialize any such products and (c)&nbsp;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory; and
(2)&nbsp;an exclusive, transferable license, with right to sublicense, to use the trademark &#147;GLOPERBA&#148; and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product
solely in the Territory. The license to <FONT STYLE="white-space:nowrap">know-how</FONT> is exclusive for purposes of developing and commercializing Licensed Products in the Territory during the royalty term, but is otherwise <FONT
STYLE="white-space:nowrap">non-exclusive.</FONT> The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Territory until July&nbsp;1, 2027 and, thereafter, is
<FONT STYLE="white-space:nowrap">co-exclusive</FONT> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i)&nbsp;expiration of the last to expire
of the patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii)&nbsp;the tenth anniversary of the date of the Romeg Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg Agreement, we agreed to pay Romeg (1)&nbsp;an
<FONT STYLE="white-space:nowrap">up-front</FONT> payment of $2.0&nbsp;million, (2)&nbsp;upon our achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&nbsp;million and (3)&nbsp;certain
royalties, at rates that do not exceed ten percent, based on annual net sales of the Licensed Products by us during the royalty term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Romeg Agreement will remain in effect until it is terminated in accordance with the terms thereof. We may terminate the Romeg Agreement (1)&nbsp;upon written notice to Romeg, if we elect (or are required) to withdraw the Initial Licensed Product
from the market as a result of serious adverse reactions from use of such product, which termination will be effective 30 days following the date of such notice or (2)&nbsp;at any time, without cause, upon written notice to Romeg, which termination
will be effective 120 days following the date of such notice, provided that a termination fee of up to $2.0&nbsp;million shall be paid to Romeg depending on when during the 10 year period following the date of the agreement any such termination
notice set forth in the immediately preceding clause (2)&nbsp;has been provided. Romeg may terminate the Romeg Agreement (a)&nbsp;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties
or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we has made such payment in full or delivered such quarterly report within such 30 day period;
(b)&nbsp;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; or (c)&nbsp;by written notice to us if sales of Licensed
Products do not commence or continue within specified periods agreed to by the parties. In addition, either party may terminate the Romeg Agreement (1)&nbsp;in the event the other party materially breaches the agreement, unless the breaching party
has cured any such breach within 60 days after any notice thereof was provided or (2)&nbsp;in the event the other party (a)&nbsp;files in any court or agency a petition in bankruptcy or insolvency, (b)&nbsp;is served with an involuntary petition
against it in any insolvency proceeding and such involuntary petition has not been stayed or dismissed within 90 days after its filing, or (c)&nbsp;makes an assignment of substantially all of its assets for the benefit of its creditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement contains customary reciprocal indemnification obligations for Romeg and us. Additionally, we agreed, subject to certain
exceptions, to indemnify Romeg against any loss arising out of the manufacture or commercialization of any Licensed Product by or on behalf of us or our affiliates, marketing partners, sublicensees or subcontractors on or after the date of the
license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Romeg Agreement, which is in the form filed as an exhibit to the
registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_58"></A>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and <FONT
STYLE="white-space:nowrap">know-how,</FONT> to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other
methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our novel adhesion and delivery technology, inventions, improvements and product candidates that are important to the
development and implementation of our business. Our patent portfolio is intended to cover our product candidates, their methods of use and processes for their manufacture, and any other inventions that are commercially important to our business. We
also rely on trade secret protection of our confidential information and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our novel adhesion and delivery technology, platforms and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, patents are granted a term of 20 years from the earliest claimed <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing
date. In certain instances, patent term can be adjusted to recapture a portion of delay by the PTO in examining the patent application or extended to account for term effectively lost as a result of the FDA regulatory review period, or both. We
cannot provide any assurance that any patents will be issued from our pending or future applications or that any patents will adequately protect our product or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio, consisting of owned and/or licensed IP as of December&nbsp;31, 2022 contains approximately sixteen issued and unexpired
U.S. patents, six pending U.S. patent applications, and one pending Patent Cooperation Treaty (PCT) application. Our portfolio also includes certain foreign counterparts of these patents and patent applications including Australia, Brazil, Canada,
China, Hong Kong, India, Indonesia, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Russian Federation, Singapore, South Africa, Taiwan, Ukraine, and certain countries within the European Patent Convention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to ZTlido and <FONT STYLE="white-space:nowrap">SP-103,</FONT> our patents and patent applications cover compositions and methods
of treatment. With respect to our product candidate SEMDEXA, our patents and patent applications include formulations and methods of treatment. The patents are U.S. Pat. Nos. 10,500,284, 10,117,938, and 11,020,485, all of which expire in 2036. With
respect to <FONT STYLE="white-space:nowrap">SP-104,</FONT> our pending Patent Cooperation Treaty application is WO 2022/076470 (and all patents and patent applications that claim priority rights thereto), which covers oral delayed burst formulations
of <FONT STYLE="white-space:nowrap">low-dose</FONT> naloxone or naltrexone and related methods of treatment. We continue to seek to maximize the scope of our patent protection for all our programs. We have six issued U.S. patents and two pending
U.S. patent applications relating to lidocaine topical system compositions and methods of treating pain with lidocaine topical system compositions. The patents are U.S. Pat. Nos. 9,283,174, 9,925,264, 9,931,403, 10,765,749, 10,765,640 and 11,278,623
all of which expire in 2031. Related to GLOPERBA, our licensed patents include U.S. Pat. Nos. 9,907,751, 10,226,423, 10,383,820, and 10,383,821, which relate to liquid colchicine formulations for oral administration and associated methods of use.
U.S. Pat. No.&nbsp;10,226,423 expires in 2037. The remaining patents related to GLOPERBA expire in 2036. We believe that we have certain <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets relating to our technology and product
candidates. We rely on trade secrets to protect certain aspects of our technology related to our current and future product candidates. However, trade secrets can be difficult to protect. We seek to protect our trade secrets, in part, by entering
into confidentiality agreements with our employees, consultants, scientific advisors, service providers, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of
our premises and physical and electronic security of our information technology systems. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks, Trade Secrets and Other Proprietary
Information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file trademark applications and pursue registrations in the United States and abroad when appropriate. We own
registered U.S. trademarks for the marks &#147;SCILEX,&#148; &#147;ZTlido&#148; and &#147;RESPONSIBLE BY DESIGN.&#148; We also own pending trademark applications for &#147;SEMNUR PHARMACEUTICALS&#148; and &#147;SEMDEXA&#148; in the United States. We
also license the GLOPERBA trademark as discussed in relation to the Romeg Agreement described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also depend upon the skills, knowledge and experience of our scientific and technical
personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> we rely on trade secret protection and confidentiality agreements to protect our
interests. Our policy is to require each of our employees, consultants and advisors to execute a confidentiality and inventions assignment agreement before beginning their employment, consulting or advisory relationship with us. The agreements
generally provide that the individual must keep confidential and not disclose to other parties any confidential information developed or learned by the individual during the course of the individual&#146;s relationship with us except in limited
circumstances. These agreements generally also provide that we will own all inventions conceived by the individual in the course of rendering services to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors.
Further, we are a party to an exclusive supply agreement for a proprietary biocompatible excipient with no generic equivalent. Our complex manufacturing process, specialized equipment and <FONT STYLE="white-space:nowrap">know-how</FONT> for sterile
viscous product candidates are also key to our competitive edge. We believe that our competitors will be required to conduct lengthy and costly preclinical and clinical trials to establish products with comparable safety and efficacy to SEMDEXA.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_59"></A>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local levels, and in other countries and jurisdictions, extensively
regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and
reporting, marketing and export and import of products such as those we are marketing and developing. <FONT STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103,</FONT> <FONT STYLE="white-space:nowrap">SP-104</FONT> and
any other product candidate that we develop must be approved by the FDA or otherwise authorized for marketing before they may be legally marketed in the United States and by the corresponding foreign regulatory agencies before they may be legally
marketed in foreign countries. The processes for obtaining marketing approvals, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial
resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug Development Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the FDCA and implementing regulations. Drugs are also subject to other federal, state and
local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial
resources. Failure to comply with the applicable requirements at any time during the product development process, approval process or after approval, may subject an applicant or its products to a variety of administrative or judicial sanctions, such
as inspection scrutiny, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or
distribution, injunctions, fines, refusals of government contracts, or reimbursements, restitution, disgorgement of profits or civil or criminal penalties. The process required by the FDA before a drug may be marketed in the United States generally
involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory
Practices (&#147;GLPs&#148;) or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an Investigational New Drug Application (&#147;IND&#148;), which must become effective
before human clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board (&#147;IRB&#148;) covering each clinical site before each trial may be
initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials according to the laws and regulations
pertaining to the conduct of human clinical trials, collectively referred to as Good Clinical </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Practice (&#147;GCP&#148;) requirements to establish the safety and efficacy of the proposed drug for its intended use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an NDA or other marketing application (collectively, an &#147;NDA&#148;), for a proposed
new drug, including its specific formulation and labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug is
produced to assess compliance with the FDA&#146;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential FDA audit of the preclinical study and clinical trial sites that generated the data in support of the
NDA; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing novel compounds with potential therapeutic value in humans, the drug candidate enters the preclinical
testing stage, also referred to as preclinical studies. Preclinical studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the drug candidate.
The conduct of the preclinical studies must comply with federal laws and requirements including GLPs. The IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, and any available
clinical data or literature, to the FDA as part of the IND. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the
effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA,
unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold within that <FONT STYLE="white-space:nowrap">30-day</FONT> time period. In such a case, the IND
sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns, <FONT
STYLE="white-space:nowrap">non-compliance,</FONT> or for additional reasons. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend
or terminate such trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the drug candidate to healthy subjects or patients with the target
disease under the supervision of qualified investigators, generally physicians not employed by the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial,
subject selection and exclusion criteria, dosing procedures, and the parameters to be used to collect data and to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports must be submitted to
the FDA and investigators for suspected adverse reactions that are serious and unexpected. Clinical trials must be conducted in accordance with applicable statutes, the FDA&#146;s regulations and GCP requirements. Further, each clinical trial must
be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to
individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to and signed by each clinical trial subject or his or her
legal representative and must monitor the clinical trial until it is completed. In some instances, additional oversight boards, such as a data safety monitoring board, are required to evaluate interim data and determine whether a study should
continue or be modified or terminated. Information about many clinical trials is required to be publicly reported on www.ClinicalTrials.gov or similar databases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 1</I></B>. The drug is initially introduced into healthy human subjects and tested for safety, dosage
tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
indication of its effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy
volunteers, the initial human testing may be conducted only in patients having the specific disease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 2</I></B>. The drug is evaluated in a limited patient population to identify possible adverse effects
and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 3</I></B>. The drug is administered to an expanded patient population in adequate and well-controlled
clinical trials to generate sufficient data to statistically confirm the safety and efficacy of the product for potential approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of
the product. Generally, at least two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. In some cases, the FDA may approve a drug based on the results of a single adequate and well-controlled Phase 3
trial for excellent design and which provided highly reliable and statistically strong evidence of important clinical benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval studies, also referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used
to gain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the status of drug development and results of the clinical trials must be submitted at least annually to the FDA,
and written IND safety reports must be submitted to the FDA and the investigators for suspected adverse reactions that are serious and unexpected (including increased rate of occurrence of such adverse reactions), findings from other studies that
suggest a significant risk in humans exposed to the drug, or any findings from tests in laboratory animals that suggests a significant risk for human subjects or patients. Phase 1, Phase 2 and Phase 3 clinical trials may not yield positive results,
or may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects are
being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has
been associated with unexpected serious harm to study subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the development of a new drug, sponsors are given opportunities to
meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to
share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase 2 meeting to discuss their Phase 2
clinical results and present their plans for the Phase 3 clinical trials that they believe will support approval of the new drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the
chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality
batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and
stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Review and Approval Processes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of product development, preclinical studies and clinical trials for the claimed indications are incorporated into an NDA. The FDA
may grant deferrals for the development and submission of pediatric data or full or partial waivers after the initial submission of a pediatric study plan following an end of Phase 2 meeting. In addition, descriptions of the manufacturing process
and controls, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are also submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to
the payment of substantial user fees and a waiver of such fees may be obtained under certain limited circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews the
NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#146;s identity, strength,
quality and purity. Under the Prescription Drug User Fee Act (&#147;PDUFA&#148;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a standard, original NDA for a new molecular entity to
review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#147;filing&#148; decision after the application is submitted. The FDA
conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information
rather than accepting an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory
committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an
advisory committee, but it considers such recommendations carefully when making decisions. During the drug approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (&#147;REMS&#148;) is necessary to assure the
safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required. A REMS could include medication guides, physician communication plans or
elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or
dispensing of products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will generally inspect the facilities at which the product is to be
manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information.
Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial
marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response
Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical
trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are
submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be significantly limited to
specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the
product labeling. In addition, the FDA may require post-approval studies, referred to as Phase 4 testing, which involves clinical trials designed to further assess a product&#146;s safety and effectiveness and may require testing and surveillance
programs to monitor the safety of approved products that have been commercialized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA administers a number of different programs that enable the agency and sponsors in various ways to expedite the development or agency
review of a new drug product. Among these, the FDA has a fast track designation that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. New drugs are eligible for fast track designation if
they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. As an example of the modified processes available to a fast track product, the
FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and
determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA
programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy
exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority
review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of other NDAs under its current PDUFA review goals.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or
conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than
irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or
lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform additional adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently
requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-use</FONT> submission of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast track designation, priority
review and accelerated approval do not change the standards for approval but may expedite the development or approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Food
and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#147;breakthrough therapies&#148; that may be eligible to receive breakthrough therapy designation. A sponsor may seek the FDA designation of a product
candidate as a &#147;breakthrough therapy&#148; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the
product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track
program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria
are met. If a product is designated as breakthrough therapy, the FDA will work with the sponsor to expedite the development and review of such drug. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With passage of the 21st Century Cures Act in December 2016, Congress authorized the FDA to
accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or
life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation
include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained fast track designation for SEMDEXA for the treatment of lumbosacral radicular pain and have applied for breakthrough therapy
designation for the treatment of lumbosacral radicular pain based on the <FONT STYLE="white-space:nowrap">top-line</FONT> results obtained from the pivotal Phase 3 trial, which results reflect achievement of primary and secondary endpoints. We
intend to submit a request to the FDA for a type D meeting in order to clarify the expectations regarding the size of the safety database needed for a NDA given that at this time no safety concerns have been identified during the course of clinical
development, and to agree on acceptance of <FONT STYLE="white-space:nowrap">SP-102</FONT> Phase 3 trial data as pivotal evidence of efficacy to support product registration. We have also obtained fast track designation for <FONT
STYLE="white-space:nowrap">SP-103</FONT> for the treatment of acute LBP. We may seek additional designations for SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103</FONT> or our other product candidates. Even if a product qualifies for one or more of
these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown risks or problems with a product may
result in labeling changes, restrictions on the product or even complete withdrawal of the product from the market. After approval, most changes to the approved product, such as adding new indications, certain manufacturing changes and additional
labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state
agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a
condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any drug products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things,
record-keeping requirements, reporting of adverse experiences or quality issues with the product, providing the FDA with updated safety and efficacy information, satisfaction of post-approval requirements or commitments, product sampling and
distribution requirements, and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include, among other things, standards for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, prohibitions against promoting drugs for uses, or in patient populations, that are not described in the drug&#146;s approved labeling,
which is known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use,&#148; rules for conducting industry-sponsored scientific and educational activities, and promotional activities involving the internet. Failure to comply with
post-approval requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although physicians may
prescribe legally available drugs for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with the applicable U.S.
requirements at any time during the product development process, approval process or after approval, may subject an applicant, manufacturer or product to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions
could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution,
disgorgement of profits, or civil or criminal penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hatch-Waxman Amendments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;505 of the FDCA describes three types of NDAs that may be submitted to request marketing authorization for a new drug, the first
being a 505(b)(1) NDA. A 505(b)(1) NDA is an application that contains full reports of investigations of safety and effectiveness. A 505(b)(2) NDA likewise contains full reports of investigations of safety and effectiveness relevant to a product,
but some of the data are not owned by or licensed to the applicant. Section&nbsp;505(j) establishes an abbreviated approval process for generic versions of approved drug products through the submission of an abbreviated new drug application
(&#147;ANDA&#148;). An ANDA generally provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form, and with the same labeling and route of administration as the listed drug and has been shown
to be bioequivalent to the listed drug. ANDA applicants are required to conduct bioequivalence testing to confirm chemical and therapeutic equivalence to the branded reference drug. Generic versions of drugs can often, and sometimes must, be
substituted by pharmacists under prescriptions written for the branded reference drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 505(b)(2) NDA is an application that contains
full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant, and for which the applicant has not obtained a right of reference.
This regulatory pathway enables the applicant to rely, in part, on the FDA&#146;s findings of safety and efficacy for an existing product, or published literature, in support of its application. Additional preclinical and clinical data may also be
submitted. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, or for any new indication sought by the 505(b)(2) applicant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA at least one of the following (1)&nbsp;no patent
information on the drug product that is relied upon by the ANDA or 505(b)(2) NDA (known as the reference drug) has been submitted to the FDA; (2)&nbsp;such patent has expired; (3)&nbsp;the date on which such patent expires; or (4)&nbsp;such patent
is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the drug product for which the ANDA or 505(b)(2) NDA is submitted. This last certification is known as a Paragraph IV Certification. If the NDA holder for the
reference drug or patent owner(s) asserts a patent challenge to the Paragraph IV Certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the Paragraph IV Certification, the expiration
of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#146;s favor or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <FONT
STYLE="white-space:nowrap">30-month</FONT> stay. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#146;s or patent
owner&#146;s decision to initiate patent litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to, and distinct from the patent protection provisions, the Hatch-Waxman
Amendments establish periods of regulatory exclusivity for certain approved drug products, during which the FDA cannot approve (or in some cases accept) an ANDA or 505(b)(2) application that relies on the branded reference drug. For example, the
holder of an NDA may obtain five years of exclusivity upon approval of a new drug containing a new chemical entity that has not been previously approved by the FDA. The Hatch-Waxman Amendments also provide three years of marketing exclusivity to the
holder of an NDA (including a 505(b)(2) NDA) for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability or
bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for drugs that include the innovation
that required the new clinical data, but generally allows the approval for <FONT STYLE="white-space:nowrap">non-protected</FONT> characteristics and labeling. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition,
which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making
the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA for the drug for the rare disease or condition. After
the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review
and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or
condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such
approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug
supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication not protected by the exclusive approval, but that could be used <FONT
STYLE="white-space:nowrap">off-label</FONT> in the orphan indication. The FDA also has authority to withdraw exclusive marketing rights if the holder of an approved orphan drug cannot assure the availability of sufficient quantities of the drug
within a reasonable time to meet the needs of patients with the disease or condition for which the drug was designated. Once withdrawn under such circumstances, exclusive approval may not be reinstated for that drug. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-Party Payor Coverage, Pricing and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the
prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, sales of a product will depend, in part, on the extent to which third-party payors provide coverage and establish adequate
reimbursement levels for the product. Third-party payors include government payor programs at the federal and state levels, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. In the United
States, no uniform policy of coverage and reimbursement for products exists among third-party payors. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or
reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
products for a particular indication, and which can change over time. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety
and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals.
Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs, in order for the company&#146;s products to be considered as a formulary option. Nonetheless, product candidates may
not be considered by individual payors to be medically necessary or cost-effective. A payor&#146;s decision to provide coverage for a product does not imply that a preferred formulary position or an adequate reimbursement rate will be approved.
Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor
to payor. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of pharmaceuticals continues to generate substantial governmental and third-party payor interest. We expect that the pharmaceutical
industry will experience pricing pressures due to the trend toward managed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
healthcare, the increasing influence of managed care organizations and additional legislative proposals. The U.S. government, state legislatures and foreign governments have shown significant
interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs.
Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as our products and the product candidates that we are developing and
could adversely affect our net revenue and results. See the discussion below under &#147;<I>U.S. Healthcare Reform</I>&#148;, and regarding the Inflation Reduction Act for further information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries. In the European Economic Area (&#147;EEA&#148;) (which is currently
comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein), governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a
large part of the cost of those products to consumers. Some countries in the EEA operate positive and negative list systems under which some medicinal products are selected for coverage (positive list) and others are explicitly listed as excluded
from reimbursement (negative list). To obtain reimbursement or pricing approval, some of these EEA countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product to currently available therapies.
Other EEA countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result,
increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial pressure on pricing within a country.
There can be no assurance that any country that has price controls or reimbursement limitations for products will allow favorable reimbursement and pricing arrangements for any of our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Healthcare Reform </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare
system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Reconciliation Act of 2020 (the &#147;ACA&#148;) was enacted, which is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new
transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, and which substantially changes the way healthcare is financed by both
governmental and private insurers, and significantly impact the U.S. pharmaceutical industry. The ACA, among other things, (1)&nbsp;subjected therapeutic biologics to potential competition by lower-cost biosimilars by creating a licensure framework
for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products, (2)&nbsp;prescribed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,
instilled, implanted or injected, (3)&nbsp;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations,
(4)&nbsp;established annual nondeductible fees and taxes on manufacturers of certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, (5)&nbsp;established a new
Medicare Part D coverage gap discount program, in which manufacturers must agree to offer <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to
eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D, (6)&nbsp;expanded eligibility criteria for Medicaid programs by, among other things, allowing
states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid
rebate liability, (7)&nbsp;expanded the entities eligible for discounts under the 340B Public Health Service Act program, (8)&nbsp;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
funding for such research, and (9)&nbsp;established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending,
potentially including prescription drug spending. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial, Congressional and Administrative
challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, legislation affecting the implementation of certain taxes under the ACA has been signed into law. The
TCJA included a provision that repealed, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage
for all or part of a year that is commonly referred to as the &#147;individual mandate&#148;. Further, the Bipartisan Budget Act of 2018 (the &#147;BBA&#148;), among other things, amended the ACA, effective January&nbsp;1, 2019, to increase from 50%
to 70% the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owned by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug
plans, commonly referred to as the &#147;donut hole&#148;. On June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148;
was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&nbsp;28, 2021, President Biden issued an executive order that initiated a special enrollment period for
purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including
among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on
August&nbsp;16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The
Inflation Reduction Act also eliminates the &#147;donut hole&#148; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost through a newly established manufacturer discount program. It is unclear how additional healthcare reform measures of the Biden administration or
other efforts, if any, to modify or invalidate the ACA or its implementing regulations, or portions thereof, will impact our business. Any health care reform measures will likely take time to unfold, and could have an impact on coverage and
reimbursement for healthcare items and services. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or other policy or the impact of potential legislation or other policy on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative and administrative changes have been proposed and adopted in the United States since the ACA was enacted to reduce
healthcare expenditures. For example, the Budget Control Act of 2011, among other things, in connection with subsequent legislation, reduced Medicare payments to providers, on average, by 2% per fiscal year. These reductions went into effect on
April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020, through May&nbsp;31, 2022, due to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. Moreover, on January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was
signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to
recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may impact the ability of relevant agencies to continue to function at current levels. Amounts allocated to federal
grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay our ability to
develop, market and sell any products we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and
reform government program reimbursement methodologies for drug products. On May&nbsp;16, 2019, CMS adopted a final rule that, among other things, will require Part D plans to adopt Real Time Benefit Tools that are capable of integrating with
electronic prescribing or electronic health record systems and have the capability to inform prescribers when lower-cost alternative therapies are available under a beneficiary&#146;s prescription drug benefit. Similarly, since 2021, Part D
Explanation of Benefits transmittals to members are required to inform Part D beneficiaries about drug prices and lower cost therapeutic alternatives. On August&nbsp;16, 2022, President Biden signed into law the Inflation Reduction Act of 2022,
which among other things, contains two specific provisions affecting pricing for drugs and biologics. The first provision allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D,
beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug manufacturers to
civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#147;maximum fair price&#148; under the law or for taking price increases that
exceed inflation. The legislation also caps Medicare beneficiaries&#146; annual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug expenses at $2,000. The second provision imposes a requirement that
pharma manufacturers provide a rebate to Medicare, if the manufacturer increases price at a rate higher than the measured inflation rate. Medicaid has had a rebate program for several years, but Medicare did not. The intent is to limit price
increases. The new rebate applies to drugs covered by Medicare under Part B or Part D. The rebate obligation applies if the average sales price (for Part B) or average manufacturers price (for Part D) of a single source drug or biologic increases
more than the rate of inflation (as measured by the index for urban consumers). The rebate amount is the total number of units sold in Medicare coverage multiplied by the amount by which the price exceeds the inflation adjusted price. The base year
against which the inflation adjustment is measured is 2021. If the price exceeds the inflation adjusted price, the difference is multiplied by the units sold in Medicare and that amount is to be rebated. A failure to pay the rebate is subject to a
penalty of 125% of the original rebate amount. The provision for Part D takes effect in 2022, with rebates to be paid beginning in 2023. The provision for Part B takes effect in 2023. At the state level, legislatures are increasingly passing
legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures. In some cases, states appear interested in public policy designed to encourage drug importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental
authorities in reference pricing systems and publication of discounts and list prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that other healthcare reform measures
that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenue. Any reduction in reimbursement
from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain
profitability, or commercialize our product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the
FDA, including the Centers for Medicare and Medicaid Services, other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector General), the United States Department of Justice and individual United States
Attorney offices within the Department of Justice, and state and local governments. For example, various activities, including but not limited to sales, marketing and scientific/educational grant programs, must comply with the anti-fraud and abuse
provisions of the Social Security Act, the federal Anti-Kickback Statute, the federal False Claims Act and similar state laws, each as amended. Failure to comply with such requirements could potentially result in substantial penalties to us. Even if
we structure our programs with the intent of compliance with such laws, there can be no certainty that we would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not need to defend against enforcement or litigation, in light of the fact that there is significant enforcement interest in pharmaceutical companies in the United States, and some of the
applicable laws are quite broad in scope. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits any person, including a pharmaceutical manufacturer
(or a party acting on its behalf), from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending, or
arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand
and prescribers, purchasers, and formulary managers on the other. The term &#147;remuneration&#148; is not defined in the federal Anti-Kickback Statute and has been broadly interpreted to include anything of value, including for example, gifts,
discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value. Although there are a number of statutory exemptions and
regulatory safe harbors protecting certain business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject
to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from federal Anti-Kickback Statute liability. The government can establish a violation of the
Anti-Kickback Statute without proving that a person or entity had actual knowledge of this statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from
a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below) or the civil monetary penalties statute, which imposes fines against any person who is determined
to have presented or caused to be presented claims to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Additionally, many states have adopted laws
similar to the federal Anti-Kickback Statute, and some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third-party payor, not only the Medicare and Medicaid programs in at least some
cases, and do not contain safe harbors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal False Claims Act imposes liability on any person or entity that, among other things,
knowingly presents, or causes to be presented, a false or fraudulent claim for payment of government funds, or knowingly makes, uses, or causes to be made or used a false statement material to a false or fraudulent claim, or knowingly conceals or
knowingly and improperly avoids, or decreases an obligation to pay money to the government. The qui tam provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government alleging that the
defendant has submitted a false claim to the federal government and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has increased dramatically. In addition, various states have enacted false
claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program. There are many potential bases for liability under the False Claims Act.
Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The False Claims Act has been used to assert liability on the basis of inadequate care, kickbacks
and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses (i.e., uses not expressly approved by the FDA
in a drug&#146;s label), and allegations as to misrepresentations with respect to the services rendered. Our activities relating to the reporting of discount and rebate information and other information affecting federal, state and third-party
reimbursement of our products, and the sale and marketing of our products and our service arrangements or data purchases, among other activities, may be subject to scrutiny under these laws. We are unable to predict whether we would be subject to
actions under the False Claims Act or a similar state law, or the impact of such actions. However, the cost of defending such claims, as well as any sanctions imposed, could adversely affect our financial performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The healthcare fraud provisions under the U.S. federal Health Insurance Portability and
Accountability Act of 1996 and its implementing regulations (&#147;HIPAA&#148;) impose criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program,
including private third-party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to, or our marketing activities may be limited by, data privacy and security regulation promulgated by both the U.S. federal
government and the U.S. states in which we conduct our business. For example, under HIPAA, the U.S. Department of Health and Human Services imposes upon &#147;covered entities&#148; (broadly, healthcare providers, health plans and healthcare
clearinghouses) and their respective &#147;business associates&#148; (individuals or entities that create, receive, maintain or transmit protected health information on behalf of a covered entity) privacy obligations; requirements to implement
appropriate administrative, physical and technical safeguards to ensure the confidentiality, integrity, and security of electronic protected health information; and breach response notification obligations. We are not subject to HIPAA, as we are
neither a covered entity nor business associate. The Federal Trade Commission (the &#147;FTC&#148;) also requires companies to take appropriate steps to keep consumers&#146; personal information secure and to make accurate statements regarding how
they secure personal information under their custody or control, such as in a privacy notice. The FTC also expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of personal
information it holds, the size and complexity of its business, and the cost of available tools to improve data security and reduce vulnerabilities. Individually identifiable health information, which we process, is considered sensitive data that
merits stronger safeguards. Violations of the foregoing FTC requirements may constitute unfair or deceptive acts or practices under Section&nbsp;5(a) of the Federal Trade Commission Act (the &#147;FTC Act&#148;). While we do not intend to engage in
unfair or deceptive acts or practices, the FTC has the power to enforce public privacy statements as it interprets them. Further, events that we cannot fully control, such as data breaches, may also result in civil penalties, FTC enforcement or
enforcement by U.S. state attorneys general or other regulators. . Various U.S. states have implemented privacy laws and regulations that regulate the use and disclosure of health information and other personal information. For example, the
California Consumer Privacy Act and its implementing regulations (the &#147;CCPA&#148;), established a privacy framework for covered businesses by, among other items, expanding the definition of personal information, establishing new data privacy
rights for consumers that are resident in the State of California, imposing rules on the collection of personal information from minors, and creating a statutory damages framework for violations of the CCPA, including for failure to implement
reasonable security procedures and practices to prevent data breaches. Penalties for violations of the CCPA include civil penalties and may result in related legal claims. The California Privacy Rights Act (&#147;CPRA&#148;), most provisions of
which became operative on January&nbsp;1, 2023, introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency (the &#147;CPPA&#148;). Similarly, the
Virginia Consumer Data Protection Act took effect on January&nbsp;1, 2023; the Colorado Privacy Act will take effect on July&nbsp;1, 2023; the Utah Consumer Privacy Act will take effect on December&nbsp;31, 2023; and the Connecticut Data Privacy Act
will take effect on July&nbsp;1, 2023. The foregoing U.S. state privacy laws impose many similar obligations as the CCPA on our processing of personal information. Other U.S. states are considering similar privacy legislation, and industry
organizations regularly adopt and advocate for new standards in these areas. The uncertainty, ambiguity, complexity, and potential inconsistency surrounding the implementation and interpretation of the CCPA and other enacted or forthcoming U.S.
state privacy laws exemplify the vulnerability of our business to the evolving regulatory environment related to the privacy, security and confidentiality of personal information and protected health information. We may be subject to fines,
penalties, or private actions in the event of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with such laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our activities
outside of the U.S. implicate local, state, provincial, and national data protection standards, impose additional compliance requirements, and generate additional risks of enforcement for <FONT STYLE="white-space:nowrap">non-compliance.</FONT> Such
laws may also restrict the access, use and disclosure of patient health information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect
against security breaches and hackers, or to remediate issues caused by such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breaches. Compliance with these laws is challenging, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an
increasing and substantial cost in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs,
devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers
of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. In addition to this federal requirement, a number of individual states and foreign jurisdictions
require detailed reporting and often public disclosures concerning transfers of value to physicians, other health care providers and family members. Effective January&nbsp;1, 2022, these reporting obligations are extended to include transfers of
value made to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these
laws result in the public disclosure of various types of payments and relationships. Several states have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs, file periodic reports
with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, or register their sales representatives, as well as prohibiting pharmacies and other healthcare entities from providing certain
physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting certain other sales and marketing practices. These laws may affect our sales, marketing and other promotional activities by imposing
administrative and compliance burdens on us. If we fail to track and report as required by these laws or otherwise comply with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where our activities involve foreign government officials, they may also potentially be subject to the Foreign Corrupt Practices Act
(&#147;FCPA&#148;). If we seek to have a product paid for with federal funds under the Medicaid programs or Medicare Part B, various obligations, including government price reporting, are required under the Medicaid rebate provisions of the Omnibus
Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as amended, which generally require products to be offered at substantial rebates/discounts to such programs and certain purchasers. Government price reporting may also
be required with respect to average sales price, which serves as the basis of reimbursement under Medicare Part B. In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and
wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some
states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing
product as it moves through the distribution chain. Many of our current as well as possible future activities are potentially subject to federal and state consumer protection and unfair competition laws. We must also comply with laws that require
clinical trial registration and reporting of clinical trial results on the publicly available clinical trial databank maintained by the National Institutes of Health at www.ClinicalTrials.gov. We are subject to various environmental, health and
safety regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous substances. From time to time, and in the future, our operations may involve the use of hazardous materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be
subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of <FONT STYLE="white-space:nowrap">pre-marketing</FONT> product approvals,
private &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government contracts, integrity oversight and reporting obligations to resolve
allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that
any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and
implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Marketing
Exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hatch-Waxman Exclusivity</I>. Market exclusivity provisions under the FDCA can also delay the submission or the
approval of certain applications of other companies seeking to reference another company&#146;s NDA. If the new drug is a new chemical entity subject to an NDA, the FDCA provides a five-year period of
<FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved
any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. This definition is currently under FDA review. During the exclusivity period, the FDA may not accept for review an
ANDA or a Section&nbsp;505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such an application may be
submitted after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of
marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the
application, such as new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs
containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the
preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pediatric
Exclusivity</I>. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to any existing exclusivity period or patent term. This
<FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity may be granted by the FDA based on the completion of a pediatric clinical trial in accordance with provisions of the FDCA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Europe/Rest of World Government Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other
things, clinical trials, pricing and reimbursement, anti-bribery, advertising and promotion, data privacy and security and any commercial sales and distribution of our future products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior
to the commencement of human clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, for example, a clinical trial application (&#147;CTA&#148;) must be submitted
to each country&#146;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with the EU Clinical Trials Directive 2001/20/EC (the &#147;Clinical Trials
Directive&#148;) and the related national implementing provisions of the relevant individual EEA country&#146;s requirements, the clinical trial described in that CTA may proceed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (the &#147;Clinical
Trials Regulation&#148;) was adopted. The Clinical Trials Regulation entered into force on January&nbsp;31, 2022. The Clinical Trials Regulation is directly applicable in all the EEA countries, repealing the prior Clinical Trials Directive. The new
Clinical Trials Regulation allows a sponsor to start and conduct a clinical trial in accordance with the Clinical Trials Directive during a transitional period of one year after the application date, i.e. January&nbsp;31, 2022. The transition period
for the trials ongoing at the moment of applicability will be a maximum of 3 years after the date of application of the Clinical Trials Regulation. Clinical trials authorized under the current Clinical Trials Directive before January&nbsp;31, 2023
can continue to be conducted under the Clinical Trials Directive until January&nbsp;31, 2025. An application to transition ongoing trials from the current Clinical Trials Directive to the new Clinical Trials Regulation will need to be submitted and
authorized in time before the end of the transitional period. The new Clinical Trials Regulation is intended to simplify and streamline the approval of clinical trials in the EEA. The main characteristics of the regulation include: a streamlined
application procedure through a single entry point, the &#147;EU portal&#148;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized
procedure for the assessment of applications for clinical trials, which is divided into two parts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the
EEA, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCP,
applicable regulatory requirements of each jurisdiction and the medical ethics principles that have their origins in the Declaration of Helsinki. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, medicinal products can be commercialized only after obtaining a Marketing Authorization (&#147;MA&#148;). There are several
procedures for requesting marketing authorization which can be more efficient than applying for authorization on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. There is a
&#147;centralized&#148; procedure allowing submission of a single marketing authorization application to the European Medicines Agency (the &#147;EMA&#148;). If the EMA issues a positive opinion, the European Commission will grant a centralized
marketing authorization that is valid in all EEA countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#147;centralized&#148; procedure is mandatory for certain types of
products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral
diseases. The &#147;centralized&#148; procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in
the interest of public health in the EEA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also a &#147;decentralized&#148; procedure allowing companies to file identical
applications to several EEA countries simultaneously for product candidates that have not yet been authorized in any EEA country and a &#147;mutual recognition&#148; procedure allowing companies that have a product already authorized in one EEA
country to apply for that authorization to be recognized by the competent authorities in other EEA countries. Under the &#147;decentralized&#148; procedure, an identical dossier is submitted to the competent authorities of each of the EEA countries
in which the MA is sought, one of which is selected by the applicant as the Reference Member State (&#147;RMS&#148;). If the RMS proposes to authorize the product, and the other EEA countries do not raise objections, the product is authorized in all
the EEA countries where the authorization was sought. Before granting the MA, the EMA or the competent authorities of the EEA countries make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its
quality, safety and efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many countries outside the United States, procedures to obtain price approvals, coverage and
reimbursement can take considerable time after the receipt of a MA. Many EEA countries periodically review their reimbursement of medicinal products, which could have an adverse impact on reimbursement status. In addition, we expect that
legislators, policymakers and healthcare insurance funds in the EEA countries will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper,
usually generic, products as an alternative to branded </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some EEA countries, including
some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment (&#147;HTA&#148;) of medicinal products is becoming an increasingly
common part of the pricing and reimbursement procedures in some EEA countries, including those representing the larger markets. The HTA process, which is currently governed by national laws in each EEA country, is the procedure to assess
therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products
by the competent authorities of individual EEA countries. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EEA countries, although the HTA Regulation, which
aims to harmonize the clinical benefit assessment of HTA across the EEA, will apply from January&nbsp;12, 2025. If we are unable to maintain favorable pricing and reimbursement status in EEA countries that represent significant markets, our
anticipated revenue from and growth prospects for our products in the EEA could be negatively affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States,
interactions between pharmaceutical companies and physicians are also governed by strict laws, such as national anti-bribery laws of EEA countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#146;
codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, the advertising and promotion of our products are subject to laws governing promotion of medicinal products, interactions with
physicians, misleading and comparative advertising and unfair commercial practices. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#146;s Summary of Product
Characteristics (&#147;SmPC&#148;), as approved by the competent authorities in connection with a marketing authorization approval. The SmPC is the document that provides information to physicians concerning the safe and effective use of the
product. Promotional activity that does not comply with the SmPC is considered <FONT STYLE="white-space:nowrap">off-label</FONT> and is prohibited in the EEA. Other applicable laws at the EEA level and in the individual EU Member States also apply
to the advertising and promotion of medicinal products, including laws that prohibit the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising of prescription-only medicinal products and
further limit or restrict the advertising and promotion of our products to the general public and to health care professionals. Violations of the rules governing the promotion of medicinal products in the EEA could be penalized by administrative
measures, fines and imprisonment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security regulations in the United States, we may be subject to, or our
marketing activities may be limited by, data privacy and security regulations in the EEA, Switzerland, or the United Kingdom (&#147;UK&#148;), where the legislative and regulatory landscape continues to evolve. There has been increased regulator
attention to privacy and data security issues that could potentially affect our business, including through legislation such as the EEA General Data Protection Regulation (&#147;EEA GDPR&#148;) and UK General Data Protection Regulation (&#147;UK
GDPR,&#148; and together, the &#147;GDPR&#148;), which each imposes strict obligations on the processing of personal data, including the transfer of personal data from the EEA, Switzerland, or UK to third countries that the European Commission has
determined does not ensure an adequate level of protection, such as the United States. If we violate the GDPR, we may face significant penalties of up to EUR 10,000,000 or 2% of our total worldwide annual, or for more serious violations, up to EUR
20,000,000 or 4% of our total worldwide annual turnover. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GDPR and other EEA and UK data privacy and security regulations generally
restrict the transfer of personal data from the EEA, United Kingdom and Switzerland, to the United States and certain other third countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal
data. One of the primary safeguards on which companies may rely to import or export personal data from had been the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield and <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield
frameworks administered by the U.S. Department of Commerce. However, the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union (the &#147;CJEU&#148;) in a case known
as &#147;<I>Schrems II</I>.&#148; Following this decision, the Swiss </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Federal Data Protection and Information Commissioner (the &#147;FDPIC&#148;) announced that the <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield does not provide adequate
safeguards for the purposes of personal data transfers from Switzerland to third countries that are deemed as not providing adequate protection, including the United States. While the FDPIC does not have authority to invalidate the <FONT
STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield regime, the FDPIC&#146;s announcement casts doubt on the viability of the <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield as a compliance mechanism for <FONT
STYLE="white-space:nowrap">Swiss-U.S.</FONT> data transfers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CJEU&#146;s decision in <I>Schrems II</I> also raised questions about
whether one of the primary alternatives to the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield, namely the European Commission&#146;s Standard Contractual Clauses, can lawfully be used for personal data transfers from Europe to the
United States or other third countries that are not the subject of an adequacy decision of the European Commission. While the CJEU upheld the adequacy of the Standard Contractual Clauses in principle in <I>Schrems II</I>, it made clear that reliance
on the Standard Contractual Clauses alone may not necessarily be sufficient in all circumstances. Use of the Standard Contractual Clauses must now be assessed on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights
of individuals with respect to the transferred data. In the context of any given transfer, where the legal regime applicable in the destination country may or does conflict with the intended operation of the Standard Contractual Clauses and/or
applicable European law, the decision in <I>Schrems II</I> and subsequent draft guidance from the European Data Protection Board (the &#147;EDPB&#148;) would require the parties to that transfer to implement certain supplementary technical,
organizational and/or contractual measures to rely on the Standard Contractual Clauses as a lawful &#147;transfer mechanism.&#148; However, the draft guidance from the EDPB on such supplementary technical, organizational and/or contractual measures
appears to conclude that any combination of such measures may not be sufficient to allow effective reliance on the Standard Contractual Clauses in the context of transfers of personal data &#147;in the clear&#148; to recipients in countries where
the power granted to public authorities to access the transferred data goes beyond that which is &#147;necessary and proportionate in a democratic society&#148;&#151;which may, following the CJEU&#146;s conclusions in <I>Schrems II</I> on relevant
powers of United States public authorities and commentary in draft EDPB guidance, include the United States in certain circumstances (<I>e.g</I>., where Section&nbsp;702 of the US Foreign Intelligence Surveillance Act applies). Further, the UK
Information Commissioner&#146;s Office (&#147;ICO&#148;) has provided for separate international data transfer mechanisms for restricted transfers of data from the UK: an international data transfer agreement (the UK equivalent of the EU Standard
Contractual Clauses) (&#147;IDTA&#148;) and an international data transfer addendum (which amends the EU Standard Contractual Clauses for purposes of international data transfers from the UK to countries without an essentially equivalent data
protection framework) (the &#147;Addendum&#148;). Both the IDTA and the Addendum came into force in March 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to
implement a valid solution to transfer personal data from the EEA to the United States or other countries that have not been deemed to provide an essentially equivalent level of data protection, we may face increased exposure to regulatory action,
substantial fines, or injunction orders to stop processing personal data from EEA, Swiss, or UK residents. Any inability to import personal data to the United States may also restrict our clinical trials activities in the EU; limit our ability to
collaborate with contract research organizations as well as other service providers, contractors and other companies subject to EU data privacy and security laws; and require us to increase our data processing capabilities in the EU and the UK at
significant expense. Additionally, other countries outside of the EU have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of
delivering our services and operating our business. The types of challenges we face in the EEA, Switzerland, and the UK will likely also arise in other jurisdictions that adopt laws similar to the GDPR or regulatory frameworks of equivalent
complexity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines,
suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions or criminal prosecution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_60"></A>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, we had approximately 90 full-time employees, including five employees who have M.D.s or Ph.D.s. Within our
workforce, seven employees were primarily engaged in research and development, 70 were primarily engaged in sales and marketing and 13 were primarily engaged in general management and administration. None of our employees are represented by labor
unions or covered by collective bargaining agreements. We believe that we maintain good relationships with our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on
identifying, attracting, incentivizing, developing and retaining an exceptional team of highly talented and motivated employees to support our current product pipeline and future business goals. In order to drive innovation, we continuously improve
our human capital management strategies and find ways to foster engagement and growth within our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We regularly benchmark total
rewards we provide against our industry peers to ensure we offer competitive compensation and benefits packages to our employees and potential new hires. The principal purposes of our equity and cash incentive plans are to attract, retain and reward
selected personnel through the granting of stock-based and cash-based compensation awards, as well as provide our employees with the opportunity to participate in our employee stock purchase plan, in order to increase stockholder value and the
success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We strive to build a diverse environment where our employees can thrive and one that inspires exceptional contributions and
professional and personal development in order to achieve our vision to become the leading pain management company that can have a transformative impact on patients&#146; lives. The success of our business is fundamentally connected to the
well-being, health and safety of our employees. In an effort to protect the health and safety of our employees, we took proactive action from the earliest signs of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, which included
implementing social distancing policies at our facilities, facilitating remote working arrangements, requiring proof of vaccination or acceptable exemption, and imposing employee travel restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to develop our efforts related to attracting, retaining and motivating our workforce as we grow and develop. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_61"></A>Facilities and Properties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is currently located in Palo Alto, California, and consists of approximately 6,000 square feet of leased office
space. The lease term expires in October 2024. We also sublease office space in San Diego, California. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate
space for our operations. We believe appropriate additional or alternative space will be available on commercially reasonable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_62">
</A>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may become involved in various legal proceedings, including those that may arise in the
ordinary course of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;23, 2021, we filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S.
LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding
their respective OTC patch products (the &#147;Sanofi-Aventis&nbsp;&amp; Hisamitsu Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements
of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
but which motions the court has largely rejected. Discovery is proceeding. The case is currently scheduled for trial to begin on July&nbsp;24, 2023. We cannot make any predictions about the
outcome in this matter or the timing thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Former Employee Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2021, we filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and
Virpax Pharmaceuticals, Inc. (&#147;Virpax&#148;), a company now headed by Mr.&nbsp;Mack, alleging, among other things, breach by Mr.&nbsp;Mack of his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement with us, breach of fiduciary duty,
and tortious interference by Virpax with that <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement (the &#147;Former Employee Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&nbsp;Mack from
further violating his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement and enjoining Virpax from tortiously interfering with Mr.&nbsp;Mack&#146;s <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement. The case was tried from
September&nbsp;12, 2022 to September&nbsp;14, 2022. Post-trial briefing and closing arguments have been concluded and the case is under submission to the Court. We cannot make any predictions about the outcome in this matter or the timing thereof.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido Patent Litigation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;22, 2022, we filed a complaint against Apotex in the U.S. District Court for the Southern District of Florida (the &#147;ZTlido Patent Litigation&#148;) alleging infringement of the ZTlido Patents. The ZTlido Patent Litigation was
initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Apotex&#146;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and
alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. We are seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#146;s ANDA be no earlier than the expiration of the asserted
patents listed in the Orange Book, the latest of which expires on May&nbsp;10, 2031, and such further and other relief as the court may deem appropriate. Apotex is subject to a <FONT STYLE="white-space:nowrap">30-month</FONT> stay preventing it from
selling a generic version of ZTlido during that time. The stay should expire no earlier than November&nbsp;11, 2024. Trial in the ZTlido Patent Litigation has not yet been scheduled. We cannot make any predictions about the final outcome of this
matter or the timing thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_63"></A>Our Corporate History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex was incorporated in Delaware in February 2019 for the purpose of effecting a corporate reorganization. On March&nbsp;18, 2019,
Legacy Scilex entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharma pursuant to which Legacy Scilex acquired 100% of the outstanding shares of capital stock of Scilex
Pharma in exchange for shares of Legacy Scilex Common Stock (such transaction, the &#147;Contribution&#148;). Pursuant to the Contribution and Loan Agreement, Sorrento provided Legacy Scilex with a loan with an initial principal amount of
$16.5&nbsp;million in the form of a note payable, which loan was used to fund the acquisition of Semnur. Concurrently therewith, Legacy Scilex entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., Legacy Scilex&#146;s
prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, and Sorrento, for limited purposes (as amended, the &#147;Semnur Merger Agreement&#148;). Pursuant to the Semnur Merger Agreement, Sigma
Merger Sub, Inc. merged with and into Semnur (such transaction, the &#147;Semnur Merger&#148;), with Semnur surviving the Semnur Merger as Legacy Scilex&#146;s wholly owned subsidiary. As a result of the Contribution and the Semnur Merger, Scilex
Pharma and Semnur became Legacy Scilex&#146;s wholly owned subsidiaries. Prior to the Contribution and the Semnur Merger, operations of Legacy Scilex were conducted through Scilex Pharma, which was formed in September 2012. Semnur was formed in June
2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the JOBS Act. As an emerging growth company, we are eligible for
exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_64"></A>Website </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
website address is <I>www.scilexholding.com</I>. We do not incorporate the information on, or accessible through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part of this
prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_65"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth certain information, as of the date of this prospectus, concerning the persons who are serving as our directors and
executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_66"></A>Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age and position of each of our directors and executive officers, as of April&nbsp;1, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;Age&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Executive Officers:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jaisim Shah</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>62</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer, President and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Henry Ji, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>58</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Executive Chairperson and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Elizabeth A. Czerepak</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>67</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Directors:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dorman Followwill<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Laura J. Hamill<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>58</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(2)(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>48</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">David Lemus<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tommy Thompson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>81</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Jaisim
Shah</I></B><I>.</I> Mr.&nbsp;Shah has served as our Chief Executive Officer and President and a member of our Board since November&nbsp;10, 2022. Mr.&nbsp;Shah has also served as Legacy Scilex&#146;s President, Chief Executive Officer and a board
member since March 2019. He has more than 25 years of global biopharma experience, including over 15 years in senior management leading business development, commercial operations, investor relations, marketing and medical affairs. He also served as
the Chief Executive Officer and a board member of Semnur from its inception in 2013 until its acquisition by Legacy Scilex in March 2019. Mr.&nbsp;Shah has served on the board of directors of Scilex Pharma since November 2016. Prior to Semnur,
Mr.&nbsp;Shah was a consultant to several businesses, including Sorrento Therapeutics, Inc., a publicly traded company, and was the Chief Business Officer of Elevation Pharmaceuticals, Inc., where Mr.&nbsp;Shah led a successful sale of Elevation to
Sunovion Pharmaceuticals Inc. in September 2012. Prior to Elevation, Mr.&nbsp;Shah was president of Zelos Therapeutics, Inc., where he focused on financing and business development. Prior to Zelos, Mr.&nbsp;Shah was the Senior Vice President and
Chief Business Officer at CytRx Corporation, a biopharmaceutical company. Previously, Mr.&nbsp;Shah was Chief Business Officer at Facet Biotech Corporation and PDL BioPharma, Inc., where he completed numerous licensing/ partnering and strategic
transactions with pharmaceutical and biotech companies. Prior to PDL, Mr.&nbsp;Shah was at Bristol-Myers Squibb, most recently as Vice President of Global Marketing where he received the &#147;President&#146;s Award&#148; for completing one of the
most significant collaborations in the company&#146;s history. Previously, Mr.&nbsp;Shah was at F. <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche AG in international marketing and was global business leader for corporate alliances with
Genentech, Inc. and IDEC Corporation. Mr.&nbsp;Shah previously served as a director of Celularity Inc. from June 2017 to July 2021. He has served as a director of Sorrento Therapeutics, Inc., a publicly traded company, since September 2013.
Mr.&nbsp;Shah holds a M.A. in Economics from the University of Akron and a M.B.A. from Oklahoma University. We believe that Mr.&nbsp;Shah&#146;s extensive operational, executive and business development experience qualifies him to serve on our
Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Henry Ji, Ph.D</I></B>. Dr.&nbsp;Ji has served as our Executive Chairperson and a
member of our Board since November&nbsp;10, 2022. Prior to that, he served as Legacy Scilex&#146;s Executive Chairperson and a board member from March 2019 to November 2022. Dr.&nbsp;Ji has served on the board of directors of Scilex Pharma since
November 2016 and he served as the Chief Executive Officer of Scilex Pharma from November 2016 to March 2019. He <FONT STYLE="white-space:nowrap">co-founded</FONT> and has served as a director of Sorrento Therapeutics, Inc., a publicly traded
company, since January 2006, served as its Chief Scientific Officer from November 2008 to September 2012, as its Interim Chief Executive Officer from April 2011 to September 2012, as its Secretary from September 2009 to June 2011, as its Chief
Executive Officer and President since September 2012 and as Chairman of its board of directors since August 2017. In 2002, Dr.&nbsp;Ji founded BioVintage, Inc., a research and development company focusing on innovative life sciences technology and
product development, and has served as its President since 2002. From 2001 to 2002, Dr.&nbsp;Ji served as Vice President of CombiMatrix Corporation, a publicly- traded biotechnology company that develops proprietary technologies, including products
and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr.&nbsp;Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999
to 2001, Dr.&nbsp;Ji served as Director of Business Development, and in 2001 as Vice President of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and
development. In 1997, Dr.&nbsp;Ji <FONT STYLE="white-space:nowrap">co-founded</FONT> Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until
1999. Dr.&nbsp;Ji previously served as a director of Celularity Inc. from June 2017 to July 2021. Dr.&nbsp;Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento&#146;s
intellectual property. Dr.&nbsp;Ji has a Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. Dr.&nbsp;Ji has demonstrated significant leadership skills as President and Chief Executive
Officer of Stratagene Genomics, Inc. and Vice President of CombiMatrix Corporation and Stratagene Corporation and brings more than 20 years of biotechnology and biopharmaceutical experience to his position on our Board. We believe that
Dr.&nbsp;Ji&#146;s extensive knowledge of the industry in which we operate allows him to bring to our Board a broad understanding of the operational and strategic issues we face. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Elizabeth A. Czerepak</I></B>. Ms.&nbsp;Czerepak has served as our Executive Vice President, Chief Business Officer, Chief Financial
Officer and Secretary since November&nbsp;10, 2022. Prior to that, she served on the Legacy Scilex Board from September 2019 to October 2020 and on the board of directors of Sorrento from October 2021 to May 2022. Ms.&nbsp;Czerepak has over 35 years
of experience in big pharma, biotechnology and venture capital. Since September 2020, she has served as the Chief Financial Officer of BeyondSpring Inc., a global biopharmaceutical company focused on developing innovative immuno-oncology cancer
therapies. From May 2018 to January 2020, Ms.&nbsp;Czerepak served as the Chief Financial Officer and the Chief Business Officer of Genevant Sciences, Inc., a technology-focused lipid nanoparticle delivery company, From 2015 to 2018 she served as
the Chief Financial Officer and Executive Vice President of Corporate Development of Altimmune, Inc., a clinical stage vaccines company, and from 2014 to 2015, she served as the Chief Financial Officer and the Chief Business Officer of Isarna
Therapeutics Inc., which develops selective transforming growth factor beta inhibitors for cancer, ophthalmic and fibrotic diseases. From 2011 to 2014, Ms.&nbsp;Czerepak served as the Chief Financial Officer, Secretary, Principal Accounting Officer
and Head of Human Resources at Cancer Genetics, Inc., a company that develops and commercializes molecular diagnostics. Prior to that, she served as a Managing Director at JPMorgan Chase&nbsp;&amp; Co. and Bear, Stearns&nbsp;&amp; Co., a General
Partner at Bear Stearns Health Innoventures L.P., a venture capital fund and as a NASD (now FINRA) Registered Representative (Series 7 and Series 63). Since February 2020, Ms.&nbsp;Czerepak has served as a director and chair of the audit committee
of Delcath Systems, Inc., an interventional oncology company focused on the treatment of liver cancer. Ms.&nbsp;Czerepak previously served on the board of directors of Spectrum Pharmaceuticals, Inc. from June 2019 to December 2020. She holds a B.A.
magna cum laude in Spanish and Mathematics Education from Marshall University and a M.B.A. from Rutgers University in 1982. In 2020, Ms.&nbsp;Czerepak earned a Corporate Director Certificate from Harvard Business School. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dorman Followwill</I></B>. Mr.&nbsp;Followwill has served as a member of our Board since November&nbsp;10, 2022. Prior to that, he served
as a director of Legacy Scilex from April 2022 to November 2022, as a director of Sorrento since October 2017 and as its lead independent director since August 2020. Mr.&nbsp;Followwill was Senior Partner of Transformational Health at
Frost&nbsp;&amp; Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, from 2016 to September 2020. Prior to that time, he served in various roles
at Frost&nbsp;&amp; Sullivan, including Partner on the Executive Committee managing the P&amp;L of the business in Europe, Israel and Africa, and Partner overseeing the Healthcare and Life Sciences business in North America, since initially joining
Frost&nbsp;&amp; Sullivan to help found the Consulting practice in January 1988. Mr.&nbsp;Followwill has more than 30 years of organizational leadership and management consulting experience, having worked on hundreds of consulting projects across
all major regions and across multiple industry sectors, each project focused around the strategic imperative of growth. He holds a B.A. from Stanford University in The Management of Organizations. We believe that Mr.&nbsp;Followwill&#146;s extensive
knowledge and understanding of the healthcare and life sciences industries qualify him to serve on our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Laura J.
Hamill</I></B>. Ms.&nbsp;Hamill has served as a member of our Board since November&nbsp;10, 2022. Prior to that, she served as a director of Legacy Scilex from April 2022 to November 2022 and has extensive experience in the biopharmaceutical
industry, with over 30 years of global commercial operational roles in a variety of executive leadership positions. Since <FONT STYLE="white-space:nowrap">mid-2019,</FONT> Ms.&nbsp;Hamill has served as the founder and a consultant at Hamill Advisory
Group, LLC. From September 2018 to July 2019, Ms.&nbsp;Hamill served as the Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., a research-based biopharmaceutical company, where she was responsible for leading the
company&#146;s global commercial strategic direction and delivering annual revenue of $20&nbsp;billion. Prior to joining Gilead, Ms.&nbsp;Hamill held a number of U.S. and international executive positions at Amgen Corporation, a biotechnology
company focused on discovering and delivering innovative human therapeutics, from July 2000 to August 2018, most recently as Senior Vice President, U.S. Commercial Operations. During her time at Amgen, Ms.&nbsp;Hamill established the company&#146;s
intercontinental region and managed the company&#146;s international marketing and business operations while living abroad in Switzerland for three years. She also served as a member of the company&#146;s corporate governance team, such as business
development, global commercial operations, the Amgen Foundation and chair for the company&#146;s Senior Women&#146;s Leadership Council. In addition, Ms.&nbsp;Hamill previously held a variety of executive roles in the biopharmaceutical industry,
including positions at Klemtner Inc. and F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG. Ms.&nbsp;Hamill has served on the board of directors of a number of public companies, including AnaptysBio, Inc. since September 2019, <FONT
STYLE="white-space:nowrap">Y-mAbs</FONT> Therapeutics, Inc. since April 2020, Pardes Biosciences, Inc. since August 2021 and BB Biotech AG since March 2022. She previously served as a director at Acceleron Pharma Inc. (acquired by Merck) from
September 2020 to December 2021. Ms.&nbsp;Hamill holds a B.A. in business administration from the University of Arizona. We believe that Ms.&nbsp;Hamill is qualified to serve on our Board because of her extensive leadership experience in the
biopharmaceutical industry and her global commercial operations and strategic planning expertise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D</I></B>. Dr.&nbsp;Lee has served as a member of our Board since
November&nbsp;10, 2022. Prior to that, he served as a director of Legacy Scilex from March 2019 to November 2022 and as a director of Scilex Pharma since November 2018. Dr.&nbsp;Lee has over 20 years of experience as a biotechnology innovator and
executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. He is the founder and has served as the Chief Executive Officer of Aardvark Therapeutics, Inc. since March 2017. Prior to that,
Dr.&nbsp;Lee joined NantKwest, Inc., a publicly-traded immunotherapy company in 2014 and served as its Chief Strategy Officer until March 2017. His experience includes therapeutics for immunology, cardiovascular, oncology, neurology, and infectious
disease indications. Dr.&nbsp;Lee is also an inventor or <FONT STYLE="white-space:nowrap">co-inventor</FONT> of multiple biomedical and biotechnology innovations, licensed or assigned to several companies for development including NantKwest, Inc.,
Simcere Pharmaceutical Group, Cellics Therapeutics, Inc., Sorrento and Aardvark Therapeutics, Inc. Dr.&nbsp;Lee earned his M.D. degree from the University of California, San Diego and his B.A. degree from the University of California, Berkeley in
Molecular Biology. We believe that Dr.&nbsp;Lee is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualified to serve on our Board because of his experience in management roles at life sciences companies and extensive academic and professional background in the field of biotechnology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>David Lemus</I></B><I>.</I> Mr.&nbsp;Lemus has served as a member of our Board since November&nbsp;10, 2022. Prior to that, he served as
a director of Legacy Scilex from April 2022 to November 2022 and as a director of Sorrento since October 2017. Mr.&nbsp;Lemus has served as Chief Executive Officer of IronShore Pharmaceuticals Inc. since January 2020 as well as the founder and Chief
Executive Officer of LEMAX LLC since 2017. He also currently serves as a <FONT STYLE="white-space:nowrap">non-executive</FONT> board member of Silence Therapeutics, plc and BioHealth Innovation, Inc. and served previously on several other boards of
public and private companies as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director. He served from November 2017 to September 2018 as the Chief Operating Officer and Chief Financial Officer of Proteros biosciences GmbH. Previously,
from January 2016 to May 2017, he served as Interim Chief Financial Officer and Chief Operating Officer of Medigene AG. Prior to that time, at Sigma Tau Pharmaceuticals, Inc., he served as Chief Executive Officer from January 2013 to July 2015, as
Chief Operating Officer from March 2012 to December 2012, and as V.P. Finance from July 2011 to February 2012. Mr.&nbsp;Lemus previously served as Chief Financial Officer and Executive V.P. of MorphoSys AG from January 1998 to May 2011. Prior to his
role at MorphoSys AG, he held various positions, including Operations Manager and Controller (Pharma International Division) and Global IT Project Manager (Pharma Division) at F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG, Group
Treasurer of Lindt&nbsp;&amp; Spruengli AG and Treasury Consultant for Electrolux AB. Mr.&nbsp;Lemus received a M.S. from the Massachusetts Institute of Technology Sloan School of Management in 1988 and a B.S. in Accounting from the University of
Maryland in 1984. Mr.&nbsp;Lemus is also a certified public accountant licensed in the State of Maryland. We believe that Mr.&nbsp;Lemus&#146; extensive accounting and financial background and business experience in the life sciences industry
qualify him to serve on our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tommy Thompson</I></B><I>.</I> Mr.&nbsp;Thompson has served as a member of our Board since
November&nbsp;10, 2022. Prior to that, he served on the Legacy Scilex Board from July 2022 to November 2022. Mr.&nbsp;Thompson currently serves as the Chief Executive Officer of Thompson Holdings, a consulting firm. From July 2020 to March 2022,
Mr.&nbsp;Thompson served as University of Wisconsin System President. From 2005 to 2012, Mr.&nbsp;Thompson was a partner in the law firm of Akin Gump Strauss Hauer&nbsp;&amp; Feld LLP in Washington, D.C, and as an Adjunct Senior Advisor from 2017 to
2020. February 2005 to January 2011, Mr.&nbsp;Thompson served as President of Logistics Health, Inc., a provider of medical readiness and homeland security solutions. Prior to entering the private sector in 2005, Mr.&nbsp;Thompson enjoyed a long and
distinguished career in public service. From February 2001 to January 2005, Mr.&nbsp;Thompson served as the former Secretary of the U.S. Department of Health&nbsp;&amp; Human Services, where he served as the nation&#146;s leading advocate for the
health and welfare of all Americans. Prior to that, Mr.&nbsp;Thompson served four terms as Governor of Wisconsin from January 1987 to February 2001, where he was best known for his efforts to revitalize the Wisconsin economy, for his national
leadership on welfare reform, and for his work toward expanding health care access across all segments of society. Mr.&nbsp;Thompson currently serves as Chairman of the board of directors of Physicians Realty Trust (NYSE: DOC) and of TherapeuticsMD,
Inc. and also serves as a member of the board of directors of United Therapeutics Corporation (Nasdaq: UTHR). He previously served on the boards of directors of various other companies, including Logistics Health, Inc. Health Solutions, a health
care consulting company, C. R. Bard, Inc. (NYSE: BCR), Centene Corporation (NYSE: CNC), Plus Therapeutics, Inc. (formerly Cytori Therapeutics, Inc.) (Nasdaq: PSTV), CareView Communications, Inc. (OTCQB: CRVW), Vyant Bio, Inc. (formerly Cancer
Genetics, Inc.) (Nasdaq: VYNT), and Pure Bioscience, Inc. (Nasdaq: PURE). Mr.&nbsp;Thompson received both his B.S. and J.D. from the University of Wisconsin-Madison. We believe that Mr.&nbsp;Thompson is qualified to serve on our Board because of his
experience in public service, particularly his services and knowledge related to the health care industry as a whole, and extensive board experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_67">
</A>Family Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the individuals who serve as our directors or executive
officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_68"></A>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our Board, which currently consists of seven members. Dr.&nbsp;Ji serves as
Executive Chairperson of our Board. The primary responsibilities of our Board are to provide oversight, strategic guidance, counseling and direction to our management. Our Board meets on a regular basis and on an <I>ad hoc</I> basis as required.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Certificate of Incorporation and the Bylaws, our Board is divided into three classes with staggered
three-year terms, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;I directors are Dorman Followwill, David Lemus, and Tommy Thompson, and their term will expire at
the annual meeting of stockholders to be held in 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;II directors are <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D. and Laura J. Hamill and
their term will expire at the annual meeting of stockholders to be held in 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;III directors are Henry Ji, Ph.D. and Jaisim Shah and their term will expire at the annual meeting
of stockholders to be held in 2025. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders, the successors to directors whose terms
will then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election. The authorized number of directors that shall constitute our Board will be determined exclusively by our
Board; <I>provided</I> that, at any time the Sorrento Group beneficially owns, in the aggregate, at least 50% in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors, the
stockholders may also fix the number of directors by resolutions adopted by the stockholders, in each case, subject to certain rights of any holders of our preferred stock to elect directors. Any increase or decrease in the number of directors will
be apportioned among the three classes so that, as nearly equal as practicable, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. No decrease in the number of directors constituting our Board will shorten
the term of any incumbent director. Our directors may be removed with or without cause by the affirmative vote of the holders of a majority in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the
election of such directors; <I>provided, however</I>, that, from and after the Sorrento Trigger Event any such director or all such directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting
power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
applicable law and the Certificate of Incorporation and subject to the rights of the holders of any series of our preferred stock (including pursuant to the Stockholder Agreement), any vacancy on our Board may be filled by our Board or our
stockholders; <I>provided, however</I>, that from and after the Sorrento Trigger Event, any such vacancy shall be filled only by our Board and not by our stockholders. Any director elected in accordance with the preceding sentence shall hold office
until the annual meeting of stockholders for the election of directors of the class to which he or she has been appointed and until his or her successor has been duly elected and qualified, subject, however, to such director&#146;s earlier death,
resignation, retirement, removal or disqualification. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_69"></A>Controlled Company Exemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento controls a majority of the voting power for the election of directors. As a result, we are a &#147;controlled company&#148; within the
meaning of the Nasdaq Listing Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a company of which more than 50% of the voting power is held by an
individual, group or another company is a &#147;controlled company&#148; and may elect not to comply with certain corporate governance standards, including, but not limited to, the requirements (i)&nbsp;that a majority of its board of directors
consist of independent directors, (ii)&nbsp;that its board of directors have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#146;s purpose and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responsibilities and (iii)&nbsp;that director nominees must be selected or recommended for the board&#146;s selection, either by independent directors constituting a majority of the board&#146;s
independent directors in a vote in which only independent directors participate, or a nominating and corporate governance committee comprised solely of independent directors with a written charter addressing the committee&#146;s purpose and
responsibilities. While we do not presently intend to rely on these exemptions, we may opt to utilize these exemptions in the future as long as it remains a controlled company. Accordingly, our stockholders may not have the same protections afforded
to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. If we cease to be a &#147;controlled company&#148; and our shares of Common Stock continue to be listed on Nasdaq, we will be required to comply
with these standards and, depending on our Board&#146;s independence determination with respect to its then-current directors, we may be required to add additional directors to our Board in order to achieve such compliance within the applicable
transition periods. See the section of this prospectus titled &#147;<I>Risk Factors &#151; We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, will qualify for, and may rely on, exemptions from certain
corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements.&#148;</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_70"></A>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a majority of the members of our Board must satisfy Nasdaq&#146;s criteria for &#147;independence.&#148; As a
&#147;controlled company&#148;, we are largely exempted from such requirements. Our Board has determined that each of the directors on our Board, other than Dr.&nbsp;Ji and Mr.&nbsp;Shah (as a result of their positions as our Executive Chairperson
and our Chief Executive Officer, respectively), qualifies as an independent director, as defined by Rule 5605(a)(2) of the Nasdaq Listing Rules and our Board consists of a majority of &#147;independent directors&#148; as defined under the rules of
the SEC and Nasdaq relating to director independence requirements. In addition, we are subject to the rules of the SEC and Nasdaq relating to the membership, qualifications and operations of the audit committee, as discussed below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_71"></A>Role of Board in Risk Oversight Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote a
culture that incorporates risk management into its corporate strategy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations. Management discusses strategic and operational (including
cybersecurity) risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks we face. Throughout the year, senior management reviews
these risks with our Board at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board is responsible for overseeing our overall risk management process. The responsibility for managing risk rests with executive
management while the committees of our Board and our Board as a whole participate in the oversight process. Our Board&#146;s risk oversight process builds upon management&#146;s risk assessment and mitigation processes, which include reviews of
long-term strategic and operational planning, executive development and evaluation, regulatory and legal compliance and financial reporting and internal controls with respect to areas of potential material risk, including operations, finance, legal,
regulatory, cybersecurity, strategic and reputational risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_72"></A>Board Leadership Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide our Board with the discretion to combine or separate the positions of Chief Executive Officer and Executive Chairperson of
our Board. Our Board is chaired by Dr.&nbsp;Ji. Our Board believes that separation of the positions of Chief Executive Officer and Executive Chairperson of our Board creates an environment that encourages objective oversight of management&#146;s
performance and enhances the effectiveness </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our Board as a whole. We believe that this separation of responsibilities provides a balanced approach to managing our Board and overseeing the Company. However, our Board will continue to
periodically review its leadership structure and may make such changes in the future as it deems appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_73"></A>Board
Diversity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating a director candidate&#146;s qualifications, our Board assesses whether a candidate possesses the integrity,
judgment, knowledge, experience, skills and expertise that are likely to enhance our ability, as well as the ability of the committees of our Board, to manage and direct our affairs and business. Our Board may consider many factors, such as personal
and professional integrity, ethics and values; experience in corporate management, such as serving as an officer or former officer of a publicly-held company; and experience as a board member or executive officer of another publicly-held company. In
addition, our Board may consider diversity in identifying potential director nominees, including diversity of expertise and experience in substantive matters pertaining to our business relative to other board members and diversity of background and
perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_74"></A>Committees of our Board </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has an audit committee, compensation committee and nominating and corporate governance committee. Our Board has adopted a charter
for each of these committees, which complies with the applicable requirements of current Nasdaq Listing Rules. Copies of the charters for each committee are available on the investor relations portion of our website. The composition and
responsibilities of each of the committees of our Board are as set forth below. Members will serve on these committees until their resignation or removal or until otherwise determined by our Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit
committee consists of David Lemus, Laura J. Hamill and Dorman Followwill, with David Lemus serving as the chairperson of the committee. Each of the members of the audit committee satisfies the independence requirements under the applicable Nasdaq
Listing Rules and SEC rules. Each member of the audit committee can read and understand fundamental financial statements under the applicable rules and regulations of the SEC and Nasdaq Listing Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responsibilities of the audit committee are included in a written charter. The audit committee assists our Board in fulfilling our
Board&#146;s oversight responsibilities with respect to our accounting and financial reporting processes, the systems of internal control over financial reporting and audits of financial statements and reports, the performance of our internal audit
function, the quality and integrity of our financial statements and reports, the qualifications, independence and performance of our independent registered public accounting firm, and our compliance with legal and regulatory requirements. For this
purpose, the audit committee performs several functions. The audit committee&#146;s responsibilities include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, determining the compensation of, retaining, overseeing and evaluating our independent registered
public accounting firm and any other registered public accounting firm engaged for the purpose of performing other review or attest services for the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to commencement of the audit engagement, reviewing and discussing with the independent registered public
accounting firm a written disclosure by the prospective independent registered public accounting firm of all relationships between the Company, or persons in financial oversight roles with the Company, and such independent registered public
accounting firm or their affiliates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining and approving engagements of the independent registered public accounting firm, prior to commencement
of the engagement, and the scope of and plans for the audit; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the rotation of partners of the independent registered public accounting firm on our audit engagement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and the independent registered public accounting firm any fraud that includes
management or other employees who have a significant role in our internal control over financial reporting and any significant changes in internal controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and overseeing procedures for the receipt, retention and treatment of complaints regarding
accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the results of management&#146;s efforts to monitor compliance with our programs and policies designed
to ensure compliance with laws and rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing our programs, policies and procedures related to our information technology systems, including
information asset security and data protection; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and the independent registered public accounting firm the results of the
annual audit and the independent registered public accounting firm&#146;s assessment of the quality and acceptability of our accounting principles and practices and all other matters required to be communicated to the audit committee by the
independent registered public accounting firm under generally accepted accounting standards, the results of the independent registered public accounting firm&#146;s review of our quarterly financial information prior to public disclosure and our
disclosures in our periodic reports filed with the SEC. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">David Lemus qualifies as an audit committee financial expert
within the meaning of SEC regulations and each of David Lemus, Laura J. Hamill and Dorman Followwill meet the financial sophistication requirements under the Nasdaq Listing Rules. Our independent registered public accounting firm and our management
periodically meet separately with the audit committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee reviews, discusses and assesses its own performance and
composition at least annually. The audit committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its
consideration and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the audit committee complies with all applicable requirements of the
Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
compensation committee consists of <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., Dorman Followwill and Laura J. Hamill, with <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D. serving as the chairperson of the committee. <FONT
STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., Dorman Followwill and Laura J. Hamill each satisfy the independence requirements under the Nasdaq Listing Rules. Each of the members of the compensation committee is a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act and satisfies Nasdaq independence requirements. The compensation committee acts on behalf of
our Board to fulfill our Board&#146;s responsibilities in overseeing our compensation policies, plans and programs; and in reviewing and determining the compensation to be paid to our executive officers and
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The responsibilities of the compensation committee are included in its written charter. The compensation committee&#146;s responsibilities include, among others: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, modifying and approving (or, if it deems appropriate, making recommendations to our Board regarding)
our overall compensation strategy and policies, and reviewing, modifying and approving corporate performance goals and objectives relevant to the compensation of our executive officers and other senior management; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval)
the compensation and terms of employment of our Chief Executive Officer, including seeking to achieve an appropriate level of risk and reward in determining the long-term incentive component of the compensation of the Chief Executive Officer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval)
the compensation and terms of employment of our executive officers and other members of senior management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving (or, if it deems appropriate, making recommendations to our Board regarding) the terms of
employment agreements, severance agreements, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections and other compensatory arrangements for our executive officers and other members of senior
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducting periodic reviews of the base compensation levels of all of our employees generally;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the type and amount of compensation to be paid or awarded to <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the adoption, amendment and termination of our equity incentive plans, stock appreciation
rights plans, pension and profit sharing plans, incentive plans, stock bonus plans, stock purchase plans, bonus plans, deferred compensation plans, 401(k) plans, supplemental retirement plans and similar programs, if any; and administering all such
plans, establishing guidelines, interpreting plan documents, selecting participants, approving grants and awards and exercising such other power and authority as may be permitted or required under such plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our incentive compensation arrangements to determine whether such arrangements encourage excessive
risk-taking, reviewing and discussing at least annually the relationship between our risk management policies and practices and compensation and evaluating compensation policies and practices that could mitigate any such risk. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, once we cease to be an &#147;emerging growth company,&#148; as defined in the JOBS Act, the responsibilities of the compensation
committee will also include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our Board for approval the frequency with which we conduct a vote on executive
compensation, taking into account the results of the most recent stockholder advisory vote on the frequency of the vote on executive compensation, and reviewing and approving the proposals regarding the frequency of the vote on executive
compensation to be included in our annual meeting proxy statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management our Compensation Discussion and Analysis, and recommending to our Board
that the Compensation Discussion and Analysis be approved for inclusion in our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> registration statements and our annual meeting proxy statements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under its charter, the compensation committee may form, and delegate authority to, subcommittees as appropriate. The compensation committee
reviews, discusses and assesses its own performance and composition at least annually. The compensation committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter,
and recommends any proposed changes to our Board for its consideration and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the compensation
committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee consists of <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., Dorman Followwill and
Laura J. Hamill, with Dorman Followwill serving as the chairperson of the committee. <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dorman Followwill and Laura J. Hamill each satisfy the independence requirements under the Nasdaq Listing Rules. The responsibilities of the nominating and corporate governance committee are
included in its written charter. The nominating and corporate governance committee acts on behalf of our Board to fulfill our Board&#146;s responsibilities in overseeing all aspects of our nominating and corporate governance functions. The
responsibilities of the nominating and corporate governance committee include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to our Board regarding corporate governance issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, reviewing and evaluating qualified candidates to serve as directors (consistent with criteria
approved by our Board); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the minimum qualifications for service on our Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating incumbent directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instituting and overseeing director orientation and director continuing education programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serving as a focal point for communication between candidates,
<FONT STYLE="white-space:nowrap">non-committee</FONT> directors and our management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our Board for selection candidates to serve as nominees for director for the annual meeting of
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making other recommendations to our Board regarding matters relating to the directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing succession plans for our Chief Executive Officer and our other executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and overseeing matters of corporate responsibility and sustainability, including potential <FONT
STYLE="white-space:nowrap">long-and</FONT> short-term trends and impacts to our business of environmental, social and governance issues, and our public reporting on these topics; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering any recommendations for nominees and proposals submitted by stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee periodically reviews, discusses and assesses the performance of our Board and the committees
of our Board. In fulfilling this responsibility, the nominating and corporate governance committee seeks input from senior management, our Board and others. In assessing our Board, the nominating and corporate governance committee evaluates the
overall composition of our Board, our Board&#146;s contribution as a whole and its effectiveness in serving our best interests and the best interests of our stockholders. The nominating and corporate governance committee reviews, discusses and
assesses its own performance and composition at least annually. The nominating and corporate governance committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter,
and recommends any proposed changes to our Board for its consideration and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the nominating
and corporate governance committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the
Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_75"></A>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing of the Business Combination, on November&nbsp;10, 2022, our Board approved and adopted a written code of business conduct
and ethics, applicable to directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of our code of
business conduct and ethics is posted on our website at <I>www.scilexholding.com</I>. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of the website address in this prospectus is an
inactive textual reference only. We intend to disclose any amendments to our code of business conduct and ethics, or any waivers of its requirements, on our website to the extent required by the applicable rules and exchange requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_76"></A>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee is currently, or has been at any time in the past year, one of our officers or employees.
Other than Dr.&nbsp;Ji and Mr.&nbsp;Shah, none of our executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers
serving as a member of our Board or compensation committee. Please see the section of this prospectus titled &#147;<I>Executive and Director Compensation</I>&#148; for information regarding the compensation of Dr.&nbsp;Ji and Mr.&nbsp;Shah. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_77"></A>Limitation of Liability and Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the
fullest extent permitted by the DGCL. Consequently, our directors and officers will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors or officers, except liability for the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of our directors, unlawful payments of dividends or unlawful stock repurchases or redemptions in
violation of the DGCL; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal
liability of directors or officers, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our
request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#147;Covered Person&#148;), and who is or was a party to,
is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#146;s actions
in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other
enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income
Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#146; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition,
the Bylaws provide that we may, to the fullest extent permitted by law, (i)&nbsp;advance costs, fees or expenses (including attorneys&#146; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final
disposition of such proceeding, subject to certain exceptions, and (ii)&nbsp;purchase and maintain insurance, at our expense, to protect us and any person who is or was our director, officer, employee or agent or is or was our director, officer,
employee or agent serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or
loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers as determined by our Board. These
agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements also require us to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. We believe that these agreements are
necessary to attract and retain qualified individuals to serve as directors and executive officers. We also maintain directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the indemnification agreements is
not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers, be
insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and
indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of
derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#146;s investment may be adversely affected to the extent we pay the costs of
settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been
informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there
is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for
indemnification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_78"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_79"></A>Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vickers Executive Officers and Director Compensation Prior to Completion of the Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing of the Business Combination, none of Vickers&#146;s executive officers or directors received any cash compensation for
services rendered to Vickers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex and Current Executive Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve our goals, we have designed, and intend to modify as necessary, our compensation and benefits programs to attract, retain,
incentivize and reward deeply talented and qualified executives who share our philosophy and desire to work towards achieving our goals. We believe our compensation programs should promote the success of the Company and align executive incentives
with the long-term interests of our stockholders. This section provides an overview of the material components of our executive compensation programs, including a narrative description of the material factors necessary to understand the information
disclosed in the summary compensation table below. The following is a discussion and analysis of the material components of the compensation arrangements of Scilex&#146;s named executive officers in 2022. As an &#147;emerging growth company&#148; as
defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board or the compensation committee of our Board (the &#147;Compensation Committee&#148;), with input from our Executive Chairperson and
Chief Executive Officer, historically determined the compensation for Scilex&#146;s named executive officers. Our named executive officers for the year ended December&nbsp;31, 2022, were Jaisim Shah, our Chief Executive Officer and President, Henry
Ji, our Executive Chairperson and Elizabeth Czerepak, our Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_80">
</A>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the compensation paid or accrued to
Scilex&#146;s named executive officers for the fiscal years ended December&nbsp;31, 2022 and December&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Qualified</FONT><BR>Deferred<BR>Compensation<BR>Earnings<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Jaisim Shah</B><BR><I>Chief Executive Officer, President and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">773,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,435</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">785,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">579,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,509</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,600</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">881,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Henry Ji, Ph.D.<BR></B><I>Executive Chairperson</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">626,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">626,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Elizabeth Czerepak<BR></B><I>Executive Vice President, Chief Business Officer, Chief Financial
Officer and Secretary</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Does not include for 2022 the amount of any bonuses that may be awarded to our named executive officers as our
Compensation Committee has not, as of the date of the filing of this prospectus, yet determined bonus amounts, if any, that may be awarded our named executive officers for 2022. If any such bonus amounts are determined, we will, in accordance with
the SEC rules and regulations, file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or otherwise disclose the 2022 bonus amounts within four business days after our Compensation Committee has assessed 2022 performance and
determined any bonus awards for 2022 for our named executive officers. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Represents matching contributions made to Mr.&nbsp;Shah under the Company&#146;s 401(k) plan.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Represents discretionary bonus amount awarded to Mr.&nbsp;Shah by the board of directors of Legacy Scilex.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Represents a signing bonus awarded to Ms.&nbsp;Czerepak in connection with her becoming our Executive Vice
President, Chief Business Officer, Chief Financial Officer and Secretary. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_81"></A>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Arrangements with Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex has entered into an offer letter with each of Mr.&nbsp;Shah and Ms.&nbsp;Czerepak. The material terms of the offer letters are described
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shah Offer Letter and Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex entered into an offer letter with Mr.&nbsp;Shah (the &#147;Shah Offer Letter&#148;), dated April&nbsp;19, 2019, pursuant to which
Mr.&nbsp;Shah serves as the Chief Executive Officer of Scilex Pharma. Under the Shah Offer Letter, Mr.&nbsp;Shah&#146;s annual base salary was initially set at $407,925, which was increased to $579,280 in 2020 and to $792,000 on November&nbsp;11,
2022 (but became effective as of March&nbsp;17, 2022). Mr.&nbsp;Shah&#146;s employment with Scilex is <FONT STYLE="white-space:nowrap">at-will,</FONT> and either Scilex or Mr.&nbsp;Shah may terminate the terms and conditions of the employment
relationship at any time, with or without cause and with or without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2019, Scilex issued to Mr.&nbsp;Shah an
option to purchase 8,126,836 shares of Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on March&nbsp;18, 2020, and 1/48th of the total amount of the shares vested and shall vest each month thereafter,
subject to Mr.&nbsp;Shah providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. On December&nbsp;21, 2020, Scilex issued to Mr.&nbsp;Shah an additional option to purchase 1,626,497 shares of
Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on December&nbsp;21, 2021, and 1/48th of the total amount of the shares vested and shall vest each month thereafter, subject to Mr.&nbsp;Shah providing
continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares and exercise prices for Mr.&nbsp;Shah&#146;s options reflect the application of the Exchange Ratio in the Business
Combination. Each of the foregoing options also vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and Mr.&nbsp;Shah&#146;s continuous service terminates due to an involuntary termination of employment without
&#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the applicable option agreement) within 13 months after the effective time of such Change in Control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ji Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex has not
entered into an offer letter or employment agreement in connection with Dr.&nbsp;Ji&#146;s service as our Executive Chairperson. On November&nbsp;11, 2022, our Compensation Committee approved Dr.&nbsp;Ji&#146;s annual base salary of $792,000 and
bonus of $554,400, effective as of March&nbsp;17, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;20, 2019, Scilex issued to Dr.&nbsp;Ji, in connection with his
service as a director, an option to purchase 2,031,708 shares of Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on March&nbsp;18, 2020, and 1/48th of the total amount of the shares vested and shall
vest each month thereafter, subject to Dr.&nbsp;Ji providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares and exercise price for Dr.&nbsp;Ji&#146;s option reflects
the application of the Exchange Ratio in the Business Combination. Each of the foregoing options also vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and Dr.&nbsp;Ji&#146;s continuous service terminates due to
an involuntary termination of employment without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the applicable option agreement) within 13 months after the effective time of such
Change in Control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Czerepak Offer Letter and Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex entered into an offer letter with Ms.&nbsp;Czerepak (the &#147;Czerepak Offer Letter&#148;), dated April&nbsp;27, 2022, pursuant to
which Ms.&nbsp;Czerepak serves as our Executive Vice President, Chief Business Officer, and Chief Financial Officer. Under the Czerepak Offer Letter, Ms.&nbsp;Czerepak&#146;s annual base salary is $300,000 and she was
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
awarded a $50,000 signing bonus. Following the closing of the Business Combination and Scilex&#146;s filing of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8,</FONT>
subject to the Board&#146;s approval, Scilex shall grant Ms.&nbsp;Czerepak an incentive stock option to purchase 350,000 shares of Common Stock, which shall vest over a four year period, whereby 1/4th of the shares subject to the option shall vest
on the date that is one year after the vesting commencement date and an additional 1/48th of the shares subject to the option shall vest on the same date of each month thereafter, subject to Ms.&nbsp;Czerepak providing continuous service (as defined
in the equity incentive plan pursuant to which the option will be granted) on each such vesting date, inclusive. In addition, all of the shares subject to the option will vest upon the occurrence of a change in control (as defined in the Equity
Incentive Plan) that occurs prior to the termination of her continuous service. Ms.&nbsp;Czerepak&#146;s employment with Scilex is <FONT STYLE="white-space:nowrap">at-will,</FONT> and either Scilex or Ms.&nbsp;Czerepak may terminate the terms and
conditions of the employment relationship at any time, with or without cause and with or without notice. However, if Scilex terminates Ms.&nbsp;Czerepak&#146;s employment other than for cause or Ms.&nbsp;Czerepak resigns from her employment with
Scilex for good reason (each, as defined in the Czerepak Offer Letter), subject to Ms.&nbsp;Czerepak&#146;s execution and delivery of a release of claims in a form prescribed by Scilex, and so long as Ms.&nbsp;Czerepak has not been offered a
full-time position at Sorrento with a base salary and annual bonus potential of not less than the combined base salary and target bonus she received from both Scilex and Sorrento, if any, as of immediately prior to the termination of her employment,
Scilex will continue to pay Ms.&nbsp;Czerepak her base salary for a period of twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;14, 2019, Scilex issued to
Ms.&nbsp;Czerepak, in connection with her service as a director, an option to purchase 404,098 shares of Common Stock, with an exercise price equal to $1.73 per share, whereby 1/48th of the shares vested on October&nbsp;23, 2019<B>, </B>and 1/48th
of the total amount of the shares vested and shall vest each month thereafter, subject to Ms.&nbsp;Czerepak providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares
and exercise price for Ms.&nbsp;Czerepak&#146;s option reflects the application of the Exchange Ratio in the Business Combination. Each of the foregoing options also vest in full if there is a Change in Control (as defined in the 2019 Stock Option
Plan) and Ms.&nbsp;Czerepak&#146;s continuous service terminates due to an involuntary termination of employment without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the
applicable option agreement) within 13 months after the effective time of such Change in Control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Arrangements with Executive Officers
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the information provided by Compensia, a national compensation consulting firm engaged by our Compensation Committee to
review and advise on our compensation practices, on November&nbsp;11, 2022, our Compensation Committee approved the following base salaries and target bonuses (on terms and conditions determined by our Board) of our executive officers, effective as
of March&nbsp;17, 2022. No bonuses were awarded to our named executive officers for 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target<BR>Bonus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">792,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">792,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the filing of the Company&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> with respect to the 2022 Equity Incentive Plan, our Board approved the following stock option grants thereunder, subject to the continued service of the individuals: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_82"></A>Potential Payments upon Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, Scilex did not have any arrangement with any of its named executive officers providing for
potential payments, compensation or other benefits upon termination or the occurrence of a change of control, other than the severance provision for Ms.&nbsp;Czerepak and the accelerated vesting provisions pursuant to previously granted options as
described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_83"></A>Perquisites, Health, Welfare and Retirement Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our medical,
vision and dental insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances. We do, however, pay the
premiums for medical, vision and dental insurance for all of our employees, including our named executive officers. Our Board may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best
interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_84"></A>Pension Benefits and Nonqualified Deferred Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are
voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. We made matching contributions to the 401(k) plan totaling $0.3&nbsp;million for each of the years ended December&nbsp;31,
2022 and 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Shah participates in our <FONT STYLE="white-space:nowrap">tax-qualified</FONT> Section&nbsp;401(k) plan and we
provide a 4% matching contribution up to an annual compensation limit ($305,000 in 2022). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not provide any other pension plan for
our employees, and none of Scilex&#146;s named executive officers participated in a nonqualified deferred compensation plan during the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_85"></A>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> 2022 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents certain information concerning outstanding equity awards held by each of Scilex&#146;s named executive officers as
of December&nbsp;31, 2022. Following the Business Combination, each outstanding equity award with respect to our Common Stock reflected in the table below was equitably adjusted in accordance with the terms of the Merger Agreement and the 2019 Stock
Option Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="8" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Option<BR>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Option&nbsp;Exercise<BR>Price per<BR>Share ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/6/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/18/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,618,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">507,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/21/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/21/2020</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">813,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">813,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/21/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/20/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/18/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,904,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/20/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/14/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/23/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">328,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/14/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the Merger Agreement, effective as of the closing of the Business Combination on
November&nbsp;10, 2022, outstanding equity awards were adjusted as follows: (i)&nbsp;each option to purchase Legacy Scilex common stock that was outstanding as of immediately prior to the Effective Time was converted into the right to receive an
option relating to our Common Stock upon substantially the same terms and conditions as were in effect with respect to such option immediately prior to the Effective Time (the &#147;Option&#148;) except that (x)&nbsp;such Option relates to that
whole number of shares of our Common Stock </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(rounded down to the nearest whole share) equal to the number of Legacy Scilex common stock subject to such Option, multiplied by the Exchange Ratio of 0.673498:1, and (y)&nbsp;the exercise price
per share for each such share of our Common Stock equals the exercise price per share of such Option in effect immediately prior to the Effective Time, divided by the Exchange Ratio (rounded up to the nearest whole cent). The numbers in the table
reflect the share numbers outstanding and exercise prices as of December&nbsp;31, 2022, in each case after giving effect to the Exchange Ratio. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each option was granted under the 2019 Stock Option Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each option vested as to 1/4th of the shares subject to the option on the
<FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date and 1/48th of the shares subject to the option vested and shall vest on each monthly anniversary thereafter, subject to full acceleration in the event of
an involuntary termination of employment without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the applicable option agreement) within 13 months following a Change in Control (as
defined in the 2019 Stock Option Plan). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option vested and shall vest as to 1/48th of the shares subject to the option on each monthly anniversary
commencing on October&nbsp;23, 2019, subject to full acceleration in the event of an involuntary termination of employment without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in
the applicable option agreement) within 13 months following a Change in Control (as defined in the 2019 Stock Option Plan). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_86">
</A>Equity-Based Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of Scilex Pharma originally adopted and its stockholders approved the 2017 Scilex Pharmaceuticals Inc. Equity Incentive
Plan (the &#147;Scilex Pharma 2017 Plan&#148;) on June&nbsp;26, 2017. The Scilex Pharma 2017 Plan was amended and restated on July&nbsp;5, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Scilex Pharma 2017 Plan, as amended and restated, provided that Scilex Pharma could grant incentive stock options, <FONT
STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock awards, stock unit awards, stock appreciation rights and other stock awards. The only form of equity award granted under the Scilex Pharma 2017 Plan was options to purchase shares
of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately prior to the corporate reorganization that was effected in March 2019, the maximum number of shares of
common stock of Scilex Pharma that could be issued under the Scilex Pharma 2017 Plan was 24,000,000, of which 18,099,000 remained available for future grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no
additional awards were granted under the Scilex Pharma 2017 Plan. Each option to purchase shares of common stock of Scilex Pharma outstanding and unexercised immediately prior to the Contribution was cancelled and substituted for an option to
purchase the equivalent number of shares of Legacy Scilex Common Stock. Each new option was subject to the same terms and conditions as were in effect immediately prior to the Contribution. No stock options of Scilex Pharma were outstanding
following the reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2023, options to purchase 744,201 shares of our Common Stock were outstanding pursuant
to options previously granted under the Scilex Pharma 2017 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2019 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Legacy Scilex Board adopted the Scilex Holding Company 2019 Stock Option Plan (the &#147;2019 Stock Option Plan&#148;) on May&nbsp;28,
2019. The 2019 Stock Option Plan was approved by Legacy Scilex&#146;s stockholders on June&nbsp;24, 2019. Upon adoption, 30,000,000 shares of Legacy Scilex Common Stock were authorized for issuance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the 2019 Stock Option Plan. The Legacy Scilex Board and Legacy Scilex&#146;s stockholders approved an amendment to the 2019 Stock Option Plan on December&nbsp;21, 2020 to increase the
number of shares authorized thereunder by 15,000,000 shares. As of March&nbsp;31, 2023, options to purchase 16,190,448 shares of our Common Stock were outstanding under the 2019 Stock Option Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Stock Option Plan has terminated at the Closing, and no further awards has been granted under the 2019 Stock Option Plan thereafter.
However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the
material terms of the 2019 Stock Option Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. Under the 2019 Stock Option Plan, an aggregate of 30,000,000
shares of Legacy Scilex Common Stock were initially reserved for future issuance, which number was increased to 45,000,000 in December 2020. The authorized shares are subject to adjustment in the event of a change that occurs with respect to the
common stock without the receipt of consideration by Scilex, including a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split,
reverse stock split, liquidating dividend, combination of shares, exchange of shares, recapitalization, reincorporation, reorganization, change in corporate structure, or similar equity restructuring transaction. Additionally, shares issued pursuant
to awards under the 2019 Stock Option Plan that are repurchased or that are forfeited, as well as shares reacquired as consideration for the exercise or purchase price of an award or to satisfy tax withholding obligations related to an award, will
become available for future grant under the 2019 Stock Option Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>. The 2019 Stock Option Plan provided for the
granting of (1)&nbsp;incentive stock options intended to qualify as incentive stock options under the Code, (2)&nbsp;nonstatutory stock options that do not qualify as an incentive stock option, (3)&nbsp;stock appreciation rights, (4)&nbsp;restricted
stock awards, (5)&nbsp;restricted stock unit awards and (6)&nbsp;other stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility.</I> Incentive stock options could
only be granted to Legacy Scilex&#146;s employees or employees of its affiliates, and stock awards other than incentive stock options may be granted to employees, directors and consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options and Stock Appreciation Rights</I>. The Legacy Scilex Board determined the exercise price for stock options and stock
appreciation rights, provided that the exercise price generally could not be less than 100% of the fair market value of Legacy Scilex Common Stock on the date of grant, subject to certain exceptions relating to the assumption or substitution of
options or stock appreciation rights in connection with a corporate transaction in a manner consistent with Section&nbsp;409A or, if applicable, Section&nbsp;424(a) of the Code. Unless an award agreement provides otherwise, the termination date
shall be: (1)&nbsp;the earlier of 18 months or upon the expiration of the option or stock appreciation right, if termination is due to death; (2)&nbsp;the earlier of 12 months or upon the expiration of the option or stock appreciation right, if
termination is due to disability; or (3)&nbsp;three months, if termination is due to reasons other than for death, disability or cause. If the termination of service is due to cause, the stock option or stock appreciation right will terminate
immediately upon such termination of service, and the participant will be prohibited from exercising the option or stock appreciation right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock and Restricted Stock Unit Awards</I>. Each restricted stock and restricted stock unit award agreement is in the form and
contains such terms and conditions as the Legacy Scilex Board deemed appropriate. Unless otherwise provided in the award agreement, the Legacy Scilex Board held certificates or, if not certificated, other indicia representing the restricted shares.
If a recipient&#146;s service terminates, Legacy Scilex could receive through a forfeiture condition or a repurchase right, any or all of the shares of common stock held by the recipient as of the date of termination. Restricted stock units not yet
vested shall be forfeited upon termination of the recipient&#146;s employment unless otherwise set forth in the award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. Stock options or stock appreciation rights are generally not
transferable except by will or by the laws of descent and distribution or as otherwise provided under the 2019 Stock Option Plan. Restricted stock awards could be transferable by the participant only upon such terms and conditions as are set forth
in the restricted stock award agreement, as the Legacy Scilex Board determines in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. The 2019
Stock Option Plan is administered by our Board, although our Board may delegate the administration of the 2019 Stock Option Plan to a committee. The administrator has full power to determine, among other things: (1)&nbsp;who will be granted awards;
(2)&nbsp;when and how each award will be granted; (3)&nbsp;what type of award will be granted; (4)&nbsp;the provisions of each award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or
shares of common stock under the award; (5)&nbsp;the number of shares of common stock subject to an award; and (6)&nbsp;the fair market value applicable to an award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control/Corporate Transactions</I>. The 2019 Stock Option Plan provides that in the event of a change in control transaction (as
defined in the 2019 Stock Option Plan), a stock award may be subject to additional acceleration of vesting and exercisability as may be provided in the stock award agreement for such stock award or as may be provided in any other written agreement
between us or our affiliate and the participant, but in the absence of such provision, no such acceleration will occur. In addition, the 2019 Stock Option Plan provides that in the event of a corporate transaction (as defined in the 2019 Stock
Option Plan), our Board has the discretion to take a number of actions with respect to awards contingent upon the closing of the transaction, including arranging for the assumption or substitution of awards, arranging for the assignment of
repurchase rights in respect of awards, accelerating the vesting of awards, canceling awards or making payments in respect of awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment</I>. Our Board generally has the authority to amend awards, subject to the award recipient&#146;s consent if the amendment is not
favorable to the participant, except in connection with a capitalization adjustments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2022 Equity Incentive Plan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, our Board adopted, subject to the approval by our stockholders, the Equity Incentive Plan. On
November&nbsp;9, 2022, our stockholders approved the Equity Incentive Plan. The Equity Incentive Plan became effective on November&nbsp;9, 2022, the day immediately preceding the date on which the Closing occurred. As of March 31, 2023, options to
purchase 14,820,000 shares of our Common Stock were outstanding under the Equity Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the
material terms of the Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose of the Equity Incentive Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Equity Incentive Plan is to secure and retain the services of employees, directors and consultants, to provide incentives
for such persons to exert maximum efforts for our success and to provide a means by which such persons may be given an opportunity to benefit from increases in value of our Common Stock through the granting of awards under the Equity Incentive Plan.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan
provides for the grant of incentive stock options (&#147;ISOs&#148;) within the meaning of Section&nbsp;422 of the Code, to our employees and our parent and subsidiary corporations&#146; employees, and for the grant of nonstatutory stock options
(&#147;NSOs&#148;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to our employees, directors and consultants and any of our affiliates&#146; employees and consultants.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum number of shares of our Common Stock that may be issued under the Equity Incentive Plan after it becomes effective will
not exceed (i) 14,622,712 shares of our Common Stock, plus (ii)&nbsp;an additional number of shares of Common Stock equal to the number of shares subject to outstanding awards granted under the 2019 Stock Option Plan, that, following the effective
date of the Equity Incentive Plan, (a)&nbsp;are not issued because the award or any portion of the award expires or otherwise terminates without all of the shares covered by the award having been issued, (b)&nbsp;are not issued because the award or
any portion thereof is settled in cash, (c)&nbsp;are forfeited back to or repurchased by us because of the failure to meet a contingency or condition required for the vesting of such shares, (d)&nbsp;are withheld or reacquired to satisfy the
exercise, strike or purchase price or (e)&nbsp;are withheld or reacquired to satisfy a tax withholding obligation. In addition, the number of shares of our Common Stock that will be reserved for issuance under the Equity Incentive Plan will
automatically increase on January&nbsp;1 of each year for a period of ten years, beginning on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to the lesser of (1) 4% of the total number of shares of our
Common Stock outstanding on December&nbsp;31 of the immediately preceding year, (2) 7,311,356 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (3)&nbsp;such number of
shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&nbsp;1 of a given year. On January&nbsp;1, 2023, the authorized number of shares of our Common Stock referenced in the preceding clause
(i)&nbsp;was increased to 20,276,666 based on the foregoing provisions. Notwithstanding anything to the contrary in the foregoing sentence, the aggregate maximum number of shares of our Common Stock that may be issued on the exercise of ISOs under
the Equity Incentive Plan was initially 14,622,712 shares, which amount was to increase commencing on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to the lesser of (i) 4% of the total number of shares
of Common Stock outstanding on December&nbsp;31 of the preceding year, (ii) 7,311,356 shares of Common Stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (iii)&nbsp;such number of shares
of our Common Stock determined by our Board or the compensation committee of our Board prior to January&nbsp;1 of a given year. On January&nbsp;1, 2023, the authorized number of shares of our Common Stock referenced in the preceding clause
(i)&nbsp;regarding ISOs was increased to 20,276,666 based on the foregoing provisions. All of the foregoing share numbers are subject to adjustment as necessary to implement any changes in our capital structure (as described below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards that will be granted under the Equity Incentive Plan that expire or terminate without being exercised in full will
not reduce the number of shares available for issuance under the Equity Incentive Plan. The settlement of any portion of an award in cash will not reduce the number of shares available for issuance under the Equity Incentive Plan. Shares of Common
Stock withheld under an award to satisfy the exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of shares that will be available for issuance under the Equity Incentive Plan. With
respect to a stock appreciation right, only shares of Common Stock that are issued upon settlement of the stock appreciation right will count towards reducing the number of shares available for issuance under the Equity Incentive Plan. If any shares
of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&nbsp;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&nbsp;to satisfy the exercise,
strike or purchase price of an award; or (iii)&nbsp;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the
Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board, or a duly authorized committee of our Board, administers the Equity Incentive Plan. Our Board, or a duly authorized committee of our
Board, may, in accordance with the terms of the Equity Incentive Plan, delegate to one or more of our officers the authority to (i)&nbsp;designate employees (other than officers) to be recipients of specified awards, and to the extent permitted by
applicable law, the terms of such awards; and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such awards granted to such employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Under the Equity Incentive Plan, our Board, or a duly authorized committee of our Board, will have the authority to determine: award recipients; how and when each award will be granted; the types
of awards to be granted; the provisions of each award, including the period of exercisability and the vesting schedule applicable to an award; the number of shares of Common Stock or cash equivalent subject to each award; the fair market value
applicable to an award; and the terms of any performance award that is not valued in whole or in part by reference to, or otherwise based on, Common Stock, including the amount of cash payment or other property that may be earned and the timing of
payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, (i)&nbsp;our Board will not, without stockholder approval, (a)&nbsp;reduce the exercise or
strike price of an option or stock appreciation right (other than in connection with a capitalization adjustment), and (b)&nbsp;at any time when the exercise or strike price of an option or stock appreciation right is above the fair market value of
a share of our Common Stock, cancel and <FONT STYLE="white-space:nowrap">re-grant</FONT> or exchange such option or stock appreciation right for a new award with a lower (or no) purchase price or for cash, and (ii)&nbsp;a participant&#146;s rights
under any award will not be materially adversely impaired by any amendment without the participant&#146;s written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also
designate a plan administrator to administer the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the Equity Incentive Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options will be granted
under stock option agreements adopted by our Board. Each option will be designated in writing as an ISO or an NSO. Our Board will determine the exercise price for stock options, within the terms and conditions of the Equity Incentive Plan, except
the exercise price of a stock option generally will not be less than 100% (or 110% in the case of ISOs granted to a person who owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or
subsidiary corporations, or a ten percent stockholder) of the fair market value of our Common Stock on the date of grant. Options granted under the Equity Incentive Plan will vest at the rate specified in the stock option agreement as will be
determined by our Board. The terms and conditions of separate options need not be identical. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No option will be exercisable after the
expiration of ten years (or five years in the case of ISOs granted to a ten percent stockholder) or a shorter period specified in the applicable award agreement. Unless the terms of an optionholder&#146;s stock option agreement, or other written
agreement between us and the recipient, provide otherwise, if an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise any
vested options for a period of three months following the cessation of service. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation
of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date of death. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to disability,
the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. An optionholder may not exercise
an option at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the optionholder&#146;s stock option agreement or other written agreement between an optionholder and us, if an
optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&nbsp;the exercise of the
optionholder&#146;s option would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate applicable law, or (ii)&nbsp;the immediate sale of any shares of Common Stock issued upon such exercise would
violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period
to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may an
option be exercised beyond the expiration of its term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of Common Stock issued upon the exercise of a
stock option will be determined by our Board and may include (i)&nbsp;cash or check, bank draft or money order payable to us; (ii)&nbsp;a broker-assisted cashless exercise; (iii)&nbsp;subject to certain conditions, the tender of shares of our Common
Stock previously owned by the optionholder; (iv)&nbsp;a net exercise of the option if it is an NSO; or (v)&nbsp;other legal consideration acceptable to our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless our Board provides otherwise, options or stock appreciation rights generally will not be transferable except by will or the laws of
descent and distribution. Subject to approval of our Board or a duly authorized officer, an option may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations on ISOs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair
market value, determined at the time of grant, of our Common Stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans or plans of our affiliates may not exceed
$100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting
power or that of any of our parent or subsidiary corporations unless (i)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&nbsp;the term of the ISO does not
exceed five years from the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the Equity Incentive Plan, each restricted stock unit award will have such terms and conditions as determined by our
Board. A restricted stock unit award represents a participant&#146;s right to be issued on a future date the number of shares of our Common Stock that is equal to the number of restricted stock units subject to the award. A participant will not have
voting or any other rights as a stockholder of ours with respect to any restricted stock unit award (unless and until shares are actually issued in settlement of a vested restricted stock unit award). A restricted stock unit award will be granted in
consideration for a participant&#146;s services to us or an affiliate, such that the participant will not be required to make any payment to us (other than such services) with respect to the grant or vesting of the restricted stock unit award, or
the issuance of any shares of Common Stock pursuant to the restricted stock unit award. Our Board may determine that restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our Board
and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock (or any combination of our Common Stock and cash), or in any other form of consideration determined by our Board and set forth in the
restricted stock unit award agreement. At the time of grant, our Board may impose such restrictions or conditions on the award of restricted stock units that delay delivery to a date following the vesting of the award. Additionally, dividend
equivalents may be paid or credited in respect of shares of Common Stock covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted
stock unit awards that have not vested will be forfeited once the participant&#146;s continuous service ends for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock awards will be granted under restricted stock award agreements adopted by our Board. A restricted stock award may be
awarded in consideration for cash, check, bank draft or money order, past services to us or any of our affiliates, or any other form of legal consideration that may be acceptable to our Board and permissible under applicable law. Our Board will
determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends may be paid or credited with respect to shares subject to a restricted stock award, as determined by our Board and specified in the
applicable restricted stock award agreement. If a participant&#146;s service relationship with us ends for any reason, we may receive any or all of the shares of Common Stock held by the participant that have not vested as of the date the
participant terminates service with us through a forfeiture condition or a repurchase right. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock appreciation rights will be granted under stock appreciation right agreements adopted by our Board and denominated in shares of Common
Stock equivalents. The terms of separation stock appreciation rights need not be identical. Our Board will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair market
value of our Common Stock on the date of grant. A stock appreciation right granted under the Equity Incentive Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by our Board. Stock appreciation
rights may be settled in cash or shares of our Common Stock (or any combination of our Common Stock and cash) or in any other form of payment, as determined by our Board and specified in the stock appreciation right agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will determine the term of stock appreciation rights granted under the Equity Incentive Plan, up to a maximum of ten years. If a
participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three months following
the cessation of service. If a participant&#146;s service relationship with us or any of our affiliates ceases due to death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally
exercise any vested stock appreciation rights for a period of 18 months following the date of death. If a participant&#146;s service relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any
vested stock appreciation rights for a period of 12 months following the cessation of service. In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. A holder of a stock appreciation right
may not exercise a stock appreciation right at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the stock appreciation right agreement or other written agreement between the
participant and us, if a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period:
(i)&nbsp;the exercise of the participant&#146;s stock appreciation right would be prohibited solely because the issuance of shares upon such exercise would violate applicable law, or (ii)&nbsp;the immediate sale of any shares issued upon such
exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the
exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no
event may a stock appreciation right be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan will permit the grant of performance awards that may be settled in stock, cash or other property. Performance awards
may be structured so that the stock or cash will be issued or paid only following the achievement of certain <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period. Performance awards that
are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, our Common Stock. The performance goals may be based on any measure of performance selected by our Board. The performance
goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the
performance of one or more relevant indices. Unless specified otherwise by our Board at the time the performance award is granted, our Board will appropriately make adjustments in the method of calculating the attainment of performance goals for a
performance period as follows: (i)&nbsp;to exclude restructuring and/or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (iv)&nbsp;to
exclude the effects of any statutory adjustments to corporate tax rates; (v)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles;
(vi)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
divestiture; (viii)&nbsp;to exclude the effect of any change in the outstanding shares of our Common Stock by reason of any stock dividend or split, stock repurchase, reorganization,
recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends;
(ix)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (x)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under
generally accepted accounting principles; and (xi)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of performance goals and to
define the manner of calculating the performance criteria it selects to use for the performance period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the
performance award agreement or the written terms of a performance cash award. Our Board will determine the length of any performance period, the performance goals to be achieved during a performance period and the other terms and conditions of such
awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Stock Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Board will be permitted to grant other awards, based in whole or in part by reference to, or otherwise based on, our Common Stock, either alone or in addition to other awards. Our Board will have the sole and complete discretion to determine the
persons to whom and the time or times at which other stock awards will be granted, the number of shares under the other stock award (or cash equivalent) and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate value of all compensation granted or paid following the effective date of the Equity Incentive Plan to any individual for service
as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any fiscal year, including awards granted under the Equity Incentive Plan (valued based on the grant date fair value for financial reporting purposes) and cash fees
paid by us to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director, will not exceed $750,000 in total value, except such amount will increase to $1,000,000 for the year in which a <FONT STYLE="white-space:nowrap">non-employee</FONT>
director is first appointed or elected to our Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, our
Board will appropriately and proportionately adjust (i)&nbsp;the class(es) and maximum number of shares subject to the Equity Incentive Plan and the maximum number of shares by which the share reserve may annually increase pursuant to the Equity
Incentive Plan; (ii)&nbsp;the class(es) and maximum number of shares that may be issued on the exercise of ISOs; and (iii)&nbsp;the class(es) and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding
awards granted under the Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#146;s award agreement or other written
agreement with us or one of our affiliates or unless otherwise expressly provided by our Board at the time of grant, any awards outstanding under the Equity Incentive Plan may be assumed, continued or substituted for, in whole or in part, by any
surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to our Common Stock issued pursuant to awards may be assigned to the successor (or its parent company). If the surviving
or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards, then (i)&nbsp;with respect to any such awards that are held by participants whose continuous service has not terminated prior to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such awards will be accelerated in full (or, in the case of performance
awards with multiple vesting levels depending on the level of performance, unless provided otherwise in the applicable award agreement, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate
transaction (contingent upon the effectiveness of the corporate transaction) as our board of directors determines (or, if our board of directors does not determine such a date, to the date that is five days prior to the effective time of the
corporate transaction), and such awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse
(contingent upon the effectiveness of the corporate transaction); and (ii)&nbsp;any such awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate
transaction, except that any reacquisition or repurchase rights held by us with respect to such awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event an award will terminate if not exercised prior to the effective time of a corporate transaction, our Board may provide, in its
sole discretion, that the holder of such award may not exercise such award but instead will receive a payment, in such form as may be determined by our Board, equal in value to the excess (if any) of (i)&nbsp;the value of the property the
participant would have received upon the exercise of the award, over (ii)&nbsp;any per share exercise price payable by such holder, if applicable. As a condition to the receipt of an award, a participant will be deemed to have agreed that the award
will be subject to the terms of any agreement under the Equity Incentive Plan governing a corporate transaction involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Equity Incentive Plan, a &#147;corporate transaction&#148; generally will be the consummation, in a single transaction or in a series of related transactions, of (i)&nbsp;a sale or other disposition of all or substantially all, as determined by our
board of directors, of the consolidated assets of us and our subsidiaries; (ii)&nbsp;a sale or other disposition of at least 50% of our outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the
surviving corporation; or (iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into
other property by virtue of the transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided in the Equity Incentive Plan or the form of award agreement, awards granted under the Equity Incentive Plan may
not be transferred or assigned by a participant. After the vested shares subject to an award have been issued, or in the case of a restricted stock award and similar awards, after the issued shares have vested, the holder of such shares is free to
assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of our trading policy and applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clawback/Recovery </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted
under the Equity Incentive Plan will be subject to recoupment in accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are
listed or as is otherwise required by the Dodd-Frank Act or other applicable law and any clawback policy that we otherwise adopt, to the extent applicable and permissible under applicable law. In addition, our Board may impose such other clawback,
recovery or recoupment provisions in an award agreement as our Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the
occurrence of cause. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment or Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may accelerate the time at which an award granted under the Equity Incentive Plan may first be exercised or the time during which an
award grant under the Equity Incentive Plan or any part thereof will vest, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notwithstanding the provisions in the award agreement stating the time at which it may first be exercised or the time during which it will vest. Our Board will have the authority to amend,
suspend, or terminate the Equity Incentive Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments will also require
the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our Board adopts the Equity Incentive Plan. No awards may be granted under the Equity Incentive Plan while it is suspended or after it is terminated.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal Income Tax Consequences Associated with the Equity Incentive Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a general summary under current law of the material federal income tax consequences to participants in the Equity Incentive
Plan. This summary deals with the general tax principles that apply and is provided only for general information. Some kinds of taxes, such as state, local and foreign income taxes and federal employment taxes, are not discussed. Tax laws are
complex and subject to change and may vary depending on individual circumstances and from locality to locality. The summary does not discuss all aspects of income taxation that may be relevant in light of a holder&#146;s personal investment
circumstances. This summarized tax information is not tax advice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Nonstatutory Stock Options</I>. For federal income tax purposes, if
an optionee is granted an NSO under the Equity Incentive Plan, the optionee will not have taxable income on the grant of the option, nor will we be entitled to any deduction. Generally, upon exercise of NSOs, the optionee will recognize ordinary
income, and we will be entitled to a deduction, in an amount equal to the excess of the fair market value of a share of our Common Stock over the option exercise price on the date each such option is exercised. The optionee&#146;s basis for the
stock for purposes of determining gain or loss on subsequent disposition of such shares generally will be the fair market value of our Common Stock on the date the optionee exercises such option. Any subsequent gain or loss will be generally taxable
as capital gains or losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Incentive Stock Options</I>. There is no taxable income to an optionee when an optionee is granted an ISO
or when that option is exercised. However, the amount by which the fair market value of the shares at the time of exercise exceeds the option price will be an &#147;item of adjustment&#148; for the optionee for purposes of the alternative minimum
tax. Gain realized by the optionee on the sale of an ISO is taxable at capital gains rates, and no tax deduction is available to us, unless the optionee disposes of the shares within (a)&nbsp;two years after the date of grant of the option or
(b)&nbsp;within one year of the date the shares were transferred to the optionee. If the shares acquired upon exercise of the ISO are sold or otherwise disposed of before the end of the <FONT STYLE="white-space:nowrap">two-year</FONT> and <FONT
STYLE="white-space:nowrap">one-year</FONT> periods specified above, the excess of the fair market value of a share of our Common Stock over the option exercise price on the date of the option&#146;s exercise will be taxed at ordinary income rates
(or, if less, the gain on the sale), and we will be entitled to a deduction to the extent the optionee must recognize ordinary income. If such a sale or disposition takes place in the year in which the optionee exercises the option, the income the
optionee recognizes upon sale or disposition of the shares will not be considered an item of adjustment for alternative minimum tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An ISO exercised more than three months after an optionee terminates employment, for reasons other than death or disability, will be taxed as
an NSO, and the optionee will recognize ordinary income on the exercise. We will be entitled to a tax deduction equal to the ordinary income, if any, realized by the optionee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock.</I> An individual to whom restricted stock is issued generally will not recognize taxable income upon such issuance, and
we generally will not then be entitled to a deduction, unless an election is made by the participant under Section&nbsp;83(b) of the Code (&#147;Section&nbsp;83(b)&#148;). However, when restrictions on shares of restricted stock lapse, such that the
shares are no longer subject to a substantial risk of forfeiture, the individual generally will recognize ordinary income, and we generally will be entitled to a deduction for an amount equal to the excess of the fair market value of the shares at
the date such restrictions lapse over the purchase price. If a timely election is made under Section&nbsp;83(b) with respect to restricted stock, the participant generally will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognize ordinary income on the date of the issuance equal to the excess, if any, of the fair market value of the shares at that date over the purchase price of such shares, and we will be
entitled to a deduction for the same amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. A participant will not be taxed upon the grant of a stock
appreciation right. Upon the exercise of the stock appreciation right, the participant will recognize ordinary income equal to the amount of cash or the fair market value of the stock received upon exercise. At the time of exercise, we will be
eligible for a tax deduction as a compensation expense equal to the amount that the participant recognizes as ordinary income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance Awards and Other Stock Awards</I>. The participant will have ordinary income upon receipt of stock or cash payable under
performance awards, dividend equivalents, restricted stock units and stock payments. We will be eligible for a tax deduction as a compensation expense equal to the amount of ordinary income recognized by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;162(m) of the Code</I>. Section&nbsp;162(m) of the Code generally limits to $1.0&nbsp;million the amount of
compensation that we may deduct in any calendar year for certain current and former executive officers. For grants under the Equity Incentive Plan, we will not be able to take a deduction for any compensation in excess of $1.0&nbsp;million that is
paid to a covered officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Requirements of Section</I><I></I><I>&nbsp;409A of the Code</I>. Certain awards under the Equity Incentive
Plan may be considered &#147;nonqualified deferred compensation&#148; for purposes of Section&nbsp;409A of the Code (&#147;Section&nbsp;409A&#148;), which imposes certain requirements on compensation that is deemed under Section&nbsp;409A to involve
nonqualified deferred compensation. Among other things, the requirements relate to the timing of elections to defer, the timing of distributions and prohibitions on the acceleration of distributions. Failure to comply with these requirements (or an
exception from such requirements) may result in the immediate taxation of all amounts deferred under the nonqualified deferred compensation plan for the taxable year and all preceding taxable years, by or for any participant with respect to whom the
failure relates, the imposition of an additional 20% income tax on the participant for the amounts required to be included in gross income and the possible imposition of penalty interest on the unpaid tax. Generally, Section&nbsp;409A does not apply
to incentive awards that are paid at the time the award vests. Likewise, Section&nbsp;409A typically does not apply to restricted stock. Section&nbsp;409A may, however, apply to incentive awards the payment of which is delayed beyond the calendar
year in which the award vests. Treasury regulations generally provide that the type of awards provided under the Equity Incentive Plan will not be considered nonqualified deferred compensation. However, to the extent that Section&nbsp;409A applies
to an award issued under the Equity Incentive Plan, the Equity Incentive Plan and all such awards will, to the extent practicable, be construed in accordance with Section&nbsp;409A. Under the Equity Incentive Plan, the administrator has the
discretion to grant or to unilaterally modify any award issued under the Equity Incentive Plan in a manner that conforms with the requirements of Section&nbsp;409A with respect to deferred compensation or voids any participant election to the extent
it would violate Section&nbsp;409A. The administrator also has sole discretion to interpret the requirements of the Code, including Section&nbsp;409A, for purposes of the Equity Incentive Plan and all awards issued under the Equity Incentive Plan.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2022 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, our Board adopted, subject to the approval by our stockholders, the ESPP. On November&nbsp;9, 2022, our stockholders
approved the ESPP. The ESPP became effective on November&nbsp;9, 2022, the day immediately preceding the date on which the Closing occurred. As of the date of this prospectus, we have not commenced any offerings under the ESPP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the ESPP is to
secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our related corporations. The ESPP includes two
components. One component is designed to allow </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligible U.S. employees to purchase our Common Stock in a manner that may qualify for favorable tax treatment under Section&nbsp;423 of the Code (the &#147;423 Component&#148;) and accordingly,
it will be construed in a manner that is consistent with the requirements of Section&nbsp;423 of the Code. We intend (but make no undertaking or representation to maintain) the 423 Component to qualify as an employee stock purchase plan, as that
term is defined in Section&nbsp;423(b) of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment (the <FONT STYLE="white-space:nowrap">&#147;Non-423</FONT> Component&#148;) in
order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by
our Board, it will operate and be administered in the same manner as the 423 Component. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Reserve </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum number of shares of our Common Stock that may be issued under the ESPP will not exceed 1,462,271 shares of our Common
Stock. On January&nbsp;1, 2023, the maximum number of shares of our Common Stock that may be issued under the ESPP was increased to 2,875,759 based on the following provisions of the ESPP. The ESPP provides that the number of shares of our Common
Stock that will be reserved for issuance will automatically increase on January&nbsp;1 of each year for a period of up to ten years, commencing on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to the
lesser of (i) 1% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding calendar year; (ii) 1,827,839 shares of our Common Stock; and (iii)&nbsp;such number of shares of our Common Stock
determined by our Board or the compensation committee of our Board prior to January&nbsp;1 of a given year, provided however, that our Board may act prior to January&nbsp;1 of a given calendar year to provide that there will be no increase for such
calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i)&nbsp;to (iii) above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, up to the maximum number of shares of our Common Stock reserved may be used to satisfy purchases of our Common
Stock under the 423 Component and any remaining portion of such maximum number of shares may be used to satisfy the purchases of our Common Stock under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any purchase right granted under the ESPP terminates without having been exercised in full, the shares of our Common Stock not purchased
under such purchase right will again become available for issuance under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Stock purchasable under the ESPP will be
shares of authorized but unissued or reacquired Common Stock, including shares repurchased by us on the open market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board administers the ESPP. Our Board may delegate some or all of the administration of the ESPP to a committee or committees of our Board.
All references to our Board in summary of the ESPP will include a duly authorized committee of our Board except where the context dictates otherwise. Further, to the extent not prohibited by applicable law, our Board may, from time to time, delegate
some or all of its authority under the ESPP to one or more of our officers or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation.
Our Board will have the authority to determine how and when purchase rights are granted and the provisions of each offering; to designate, from time to time, which of our related corporations will be eligible to participate in the 423 Component or
the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, or which related corporations will be eligible to participate in each separate offering; to construe and interpret the ESPP and purchase rights thereunder, and to establish, amend and
revoke rules and regulations for the ESPP&#146;s administration; to settle all controversies regarding the ESPP and purchase rights granted thereunder; to amend, suspend or terminate the ESPP; to exercise such powers and to perform such acts as it
deems necessary or expedient to promote the best interests of us and our related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporations and to carry out the intent of the ESPP to be treated as an employee stock purchase plan with respect to the 423 Component; and to adopt such rules, procedures and <FONT
STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit or facilitate participation in the ESPP by employees who are foreign nationals or employed or located outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All determinations, interpretations and constructions made by our Board in good faith will not be subject to review by any person and will be
final, binding and conclusive on all persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Offerings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may grant or provide for the grant of purchase rights to eligible employees under an offering (consisting of one or more purchase
periods) on an offering date or offering dates selected by our Board. Each offering will be in the form and will contain those terms and conditions as our Board deems appropriate, and, with respect to the 423 Component, will comply with the
requirements of Section&nbsp;423(b)(5) of the Code. The provisions of separate offerings do not need to be identical, but each offering will include the period during which the offering will be effective, which period will not exceed 27 months
beginning with the offering date, and the substance of the applicable provisions contained in the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a participant has more than
one purchase right outstanding under the ESPP, unless he or she otherwise indicates in forms delivered to us or a third party designee of ours: (i)&nbsp;each form will apply to all of his or her purchase rights under the ESPP, and (ii)&nbsp;a
purchase right with a lower exercise price (or an earlier-granted purchase right, if different purchase rights have identical exercise prices) will be exercised to the fullest possible extent before a purchase right with a higher exercise price (or
a later-granted purchase right if different purchase rights have identical exercise prices) will be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the
discretion to structure an offering so that if the fair market value of a share of our Common Stock on the first trading day of a new purchase period within that offering is less than or equal to the fair market value of a share of our Common Stock
on the first day of that offering, then (i)&nbsp;that offering will terminate immediately as of that first trading day, and (ii)&nbsp;the participants in such terminated offering will be automatically enrolled in a new offering beginning on the
first trading day of such new purchase period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, purchase rights may only be granted to employees, including executive officers, employed by us (or by any of our affiliates or
related corporations as designated by our Board) on the first day of an offering if such employee has been employed by us or by one of our designated affiliates or related corporations for such continuous period preceding such date (not to exceed
two years) as our Board may require. Our Board may (unless prohibited by applicable law) require that employees have to satisfy one or both of the following service requirements with respect to the 423 Component: (i)&nbsp;being customarily employed
by us, or any of our related corporations or affiliates, for more than 20 hours per week and more than five months per calendar year; or (ii)&nbsp;such other criteria as our Board may determine consistent with Section&nbsp;423 of the Code with
respect to the 423 Component. Our Board may provide that each person who, during the course of an offering, first becomes an eligible employee will, on the date or dates specified in the offering which coincides with the day on which the person
becomes an eligible employee or which occurs thereafter, receive a purchase right under that offering, and the purchase right will thereafter be deemed to be part of the offering with substantially identical characteristics. No employee will be
eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee owns stock possessing five percent or more of the total combined voting power or value of all classes of our outstanding capital
stock (or the stock of any related corporation) determined in accordance with the rules of Section&nbsp;424(d) of the Code. As specified by Section&nbsp;423(b)(8) of the Code, an eligible employee may be granted purchase rights only if such purchase
rights, together with any other rights granted under all employee stock purchase plans of ours or any of our related corporations, do not permit such eligible employee&#146;s rights to purchase our stock or the stock of any of our related
corporations to accrue at a rate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which, when aggregated, exceeds $25,000 (based on the fair market value per share of such common stock on the date that the purchase right is granted) for each calendar year such purchase rights
are outstanding at any time. Our Board may also exclude from participation in the ESPP or any offering employees of ours, or of any of our related corporation, who are highly compensated employees, as within the meaning of Section&nbsp;423(b)(4)(D)
of the Code, or a subset of such highly compensated employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the foregoing paragraph to the contrary, in
the case of an offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an eligible employee (or a group of eligible employees) may be excluded from participation in the ESPP or an offering if our Board has determined, in its
sole discretion, that participation of such eligible employee is not advisable or practical for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase Rights; Purchase Price </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first day of each offering, each eligible employee, pursuant to an offering made under the ESPP, will be granted a purchase right to
purchase up to that number of shares of our Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by our Board, which will not exceed 15% of such employee&#146;s earnings (as defined by our Board) during
the period that begins on the first day of the offering (or such later date as our Board determines for a particular offering) and ends on the date stated in the offering, which date will be no later than the end of the offering. Our Board will
establish one or more purchase dates during an offering on which purchase rights granted for that offering will be exercised and shares of Common Stock will be purchased in accordance with such offering. Each eligible employee may purchase of up to
10,000 shares of our Common Stock in an offering (or such lesser number of shares determined by our Board prior to the start of the offering). Our Board may also specify (i)&nbsp;a maximum number of shares of our Common Stock that may be purchased
by any participant on any purchase date during an offering, (ii)&nbsp;a maximum aggregate number of shares of our Common Stock that may be purchased by all participants in an offering and/or (iii)&nbsp;a maximum aggregate number of shares of our
Common Stock that may be purchased by all participants on any purchase date under an offering. If the aggregate number of shares of our Common Stock issuable upon exercise of purchase rights granted under the offering would exceed any such maximum
aggregate number, then, in the absence of any action by our Board otherwise, a pro rata allocation of the shares of our Common Stock (rounded down to the nearest whole share) available, based on each participant&#146;s accumulated contributions,
will be made in as nearly a uniform manner as will be practicable and equitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price of shares of our Common Stock
acquired pursuant to purchase rights will not be less than the lesser of (i) 85% of the fair market value of a share of our Common Stock on the first day of an offering; or (ii) 85% of the fair market value of a share of our Common Stock on the date
of purchase. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Participation; Withdrawal; Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An eligible employee may elect to participate in an offering and authorize payroll deductions as the means of making contributions by
completing and delivering to us or our designee, within the time specified in the offering, an enrollment form provided by us or our designee. The enrollment form will specify the amount of contributions not to exceed the maximum amount specified by
our Board. Each participant&#146;s contributions will be credited to a bookkeeping account for the participant under the ESPP and will be deposited with our general funds except where applicable law requires that contributions be deposited with a
third party. If permitted in the offering, a participant may begin such contributions with the first payroll occurring on or after the first day of the applicable offering (or, in the case of a payroll date that occurs after the end of the prior
offering but before the first day of the next new offering, contributions from such payroll will be included in the new offering). If permitted in the offering, a participant may thereafter reduce (including to zero) or increase his or her
contributions. If required under applicable law or if specifically provided in the offering, in addition to or instead of making contributions by payroll deductions, a participant may make contributions through payment by cash, check or wire
transfer prior to a purchase date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During an offering, a participant may cease making contributions and withdraw from the
offering by delivering to us or our designee a withdrawal form provided by us. We may impose a deadline before a purchase date for withdrawing. Upon such withdrawal, such participant&#146;s purchase right in that offering will immediately terminate
and we will distribute as soon as practicable to such participant all of his or her accumulated but unused contributions and such participant&#146;s purchase right in that offering shall then terminate. A participant&#146;s withdrawal from that
offering will have no effect upon his or her eligibility to participate in any other offerings under the ESPP, but such participant will be required to deliver a new enrollment form to participate in subsequent offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise required by applicable law, purchase rights granted pursuant to any offering under the ESPP will terminate immediately if the
participant either (i)&nbsp;is no longer an employee for any reason or for no reason (subject to any post-employment participation period required by applicable law) or (ii)&nbsp;is otherwise no longer eligible to participate. We will distribute the
individual&#146;s accumulated but unused contributions as soon as practicable to such individual. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by our
Board, a participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between us and one of our designated companies designated to participate in an offering (or between such
designated companies) will not be treated as having terminated employment for purposes of participating in the ESPP or an offering. However, if a participant transfers from an offering under the 423 Component to an offering under the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the participant&#146;s purchase right will be qualified under the 423 Component only to the extent such exercise complies with Section&nbsp;423 of the Code. If a participant
transfers from an offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component to an Offering under the 423 Component, the exercise of the purchase right will remain <FONT STYLE="white-space:nowrap">non-qualified</FONT> under the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component. Our Board may establish different and additional rules governing transfers between separate offerings within the 423 Component and between offerings under the 423 Component and offerings under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component. Unless otherwise specified in the offering or as required by applicable law, we will have no obligation to pay interest on contributions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase of Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each purchase
date, each participant&#146;s accumulated contributions will be applied to the purchase of shares of our Common Stock, up to the maximum number of shares of our Common Stock permitted by the ESPP and the applicable offering, at the purchase price
specified in the offering. Unless otherwise provided in the offering, if any amount of accumulated contributions remains in a participant&#146;s account after the purchase of shares on the final purchase date of an offering, then such remaining
amount will not roll over to the next offering and will instead be distributed in full to such participant after the final purchase date of such offering without interest (unless otherwise required by applicable law). No purchase rights may be
exercised to any extent unless the shares of our Common Stock to be issued upon such exercise under the ESPP are covered by an effective registration statement pursuant to the Securities Act and the ESPP is in material compliance with all applicable
U.S. federal and state, foreign and other securities, exchange control and other laws applicable to the ESPP. If on a purchase date the shares of our Common Stock are not so registered or the ESPP is not in such compliance, no purchase rights will
be exercised on such purchase date, and the purchase date will be delayed until the shares of our Common Stock are subject to such an effective registration statement and the ESPP is in material compliance, except that the purchase date will in no
event be more than 27 months from the first day of an offering. If, on the purchase date, as delayed to the maximum extent permissible, the shares of our Common Stock are not registered and the ESPP is not in material compliance with all applicable
laws, as determined by us in our sole discretion, no purchase rights will be exercised and all accumulated but unused contributions will be distributed to the ESPP participants without interest (unless the payment of interest is otherwise required
by applicable law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to,
shares of our Common Stock subject to purchase rights unless and until the participant&#146;s shares of our Common Stock acquired upon exercise of purchase rights are recorded in our books (or the books of our transfer agent). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a change in our capital structure through actions such as a merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar
transaction, our Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the ESPP; (ii)&nbsp;the class(es) and maximum number of securities by which the share reserve is to increase
automatically each year; (iii)&nbsp;the class(es) and number of shares subject to, and purchase price applicable to, outstanding offerings and purchase rights; and (iv)&nbsp;the class(es) and number of securities that are subject to purchase limits
under each ongoing offering. Our Board will make these adjustments, and its determination will be final, binding and conclusive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate
Transactions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a corporate transaction (as defined below), any then-outstanding rights to
purchase our Common Stock under the ESPP may be assumed, continued, or substituted for by any surviving or acquiring corporation (or its parent company). If the surviving or acquiring corporation (or its parent company) elects not to assume,
continue, or substitute for such purchase rights, then (i)&nbsp;the participants&#146; accumulated payroll contributions will be used to purchase shares of our Common Stock (rounded down to the nearest whole share) within ten business days (or such
other period specified by our Board) before such corporate transaction under the outstanding purchase rights, and such purchase rights will terminate immediately after such purchase, or (ii)&nbsp;our Board, in its discretion, may terminate
outstanding offerings, cancel the outstanding purchase rights and refund the participants&#146; accumulated contributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
ESPP, a &#147;corporate transaction&#148; is generally the consummation, in a single transaction or in a series of related transactions, of: (i)&nbsp;a sale or other disposition of all or substantially all, as determined by our Board, of the
consolidated assets of us and our subsidiaries; (ii)&nbsp;a sale or other disposition of at least 50% of our outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or
(iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue
of the transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During a participant&#146;s lifetime, purchase rights will be exercisable only by a participant. Purchase rights are not transferable by a
participant, except by will, by the laws of descent and distribution, or, if permitted by us, by a beneficiary designation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Withholding </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each participant must make arrangements, satisfactory to us and any applicable related corporation, to enable us or our related corporation to
fulfill any withholding obligation for taxes arising out of or in relation to a participant&#146;s participation in the ESPP. In our sole discretion and subject to applicable law, such withholding obligation may be satisfied in whole or in part by
(i)&nbsp;withholding from the participant&#146;s salary or any other cash payment due to the participant from us or any related corporation; (ii)&nbsp;withholding from the proceeds of the sale of shares of our Common Stock acquired under the ESPP,
either through a voluntary sale or a mandatory sale arranged by us; or (iii)&nbsp;any other method deemed acceptable by our Board. We will not be required to issue any shares of our Common Stock under the ESPP until such obligations are satisfied.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment, Suspension or Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the authority to amend, suspend or terminate the ESPP. Any benefits, privileges, entitlements and obligations under any
outstanding purchase right granted before an amendment, suspension or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
termination of the ESPP will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to whom such purchase rights were granted,
(ii)&nbsp;as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code), or (iii)&nbsp;as necessary to obtain or maintain
favorable tax, listing, or regulatory treatment. Except with respect to certain changes in our capital structure, stockholder approval is required for any amendment to the ESPP if such approval is required by applicable law or listing requirements.
No purchase rights may be granted under the ESPP while it is suspended or after it is terminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2023 Inducement Plan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2023, the Compensation Committee of our Board adopted the Inducement Plan and it became effective on the date
of its adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the Inducement Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose of the Inducement Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
purpose of the Inducement Plan is to advance our interests by providing a material inducement for individuals to join us as employees and to provide a means by which such persons may be given an opportunity to benefit from increases in value of our
Common Stock through the granting of awards under the Inducement Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Awards and Eligibility </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Inducement Plan provides for the grant of NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other
forms of awards. We intend to grant awards pursuant to the Inducement Plan only to persons to whom we may issue shares of our Common Stock without stockholder approval under Section&nbsp;5635 of the Nasdaq Listing Rules. The Inducement Plan provides
that awards may be granted to a natural person to whom we or one of our subsidiaries makes an offer of employment, provided that (i)&nbsp;such person was not previously an employee or us or one of our affiliates, or the person is returning to
employment with us or one of our subsidiaries following a bona-fide period of <FONT STYLE="white-space:nowrap">non-employment;</FONT> and (ii)&nbsp;the grant of an award under the Inducement Plan is a material inducement to the person&#146;s
decision to enter into employment with us or one of our subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An aggregate of 1,400,000 shares of our Common Stock have been reserved for issuance pursuant to awards granted under the Inducement Plan,
subject to adjustment as necessary to implement any changes in our capital structure (as described below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards that
will be granted under the Inducement Plan that expire or terminate without being exercised in full will not reduce the number of shares available for issuance under the Inducement Plan. The settlement of any portion of an award in cash will not
reduce the number of shares available for issuance under the Inducement Plan. Shares of Common Stock withheld under an award to satisfy the exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the
number of shares that will be available for issuance under the Inducement Plan. With respect to a stock appreciation right, only shares of common stock that are issued upon settlement of the stock appreciation right will count towards reducing the
number of shares available for issuance under the Inducement Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&nbsp;because of a failure to meet a contingency or
condition required for the vesting of such shares; (ii)&nbsp;to satisfy the exercise, strike or purchase price of an award; or (iii)&nbsp;to satisfy a tax withholding obligation in connection with an award, the shares that are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forfeited or repurchased or reacquired will revert to and again become available for issuance under the Inducement Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will
delegate administration of the Inducement Plan to a duly authorized committee of our Board (the &#147;Committee&#148;) and to the extent required by applicable law, including the Nasdaq Listing Rules, each member of such Committee will be an
&#147;independent director&#148;, as defined in Section&nbsp;5605(a)(2) of the Nasdaq Listing Rules. Under the Inducement Plan, the Committee will have the authority to determine: award recipients; how and when each award will be granted; the types
of awards to be granted; the provisions of each award, including the period of exercisability and the vesting schedule applicable to an award; the number of shares of Common Stock or cash equivalent subject to each award; and the fair market value
applicable to an award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Inducement Plan, (i)&nbsp;the Committee will not, without stockholder approval, reduce the exercise or
strike price of an option or stock appreciation right (other than in connection with a capitalization adjustment), and (ii)&nbsp;a participant&#146;s rights under any award will not be materially adversely impaired by any amendment without the
participant&#146;s written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also designate a plan administrator to administer the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the Inducement Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options will be granted under stock option agreements adopted by the Committee and each option will be an NSO. The Committee will determine the
exercise price for stock options, within the terms and conditions of the Inducement Plan, except the exercise price of a stock option will generally not be less than 100% of the fair market value of our Common Stock on the date of grant. Options
granted under the Inducement Plan will vest at the rate specified in the stock option agreement as will be determined by the Committee. The terms and conditions of separate options need not be identical. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No option will be exercisable after the expiration of ten years or a shorter period specified in the applicable award agreement. Unless the
terms of an optionholder&#146;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than
disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to
death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date of death. If an optionholder&#146;s
service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In the event of a termination for cause, options
generally terminate upon the termination date. An optionholder may not exercise an option at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the optionholder&#146;s stock option
agreement or other written agreement between an optionholder and us, if an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the
applicable post-termination exercise period: (i)&nbsp;the exercise of the optionholder&#146;s option would be prohibited solely because the issuance of shares of common stock upon such exercise would violate applicable law, or (ii)&nbsp;the
immediate sale of any shares of common stock issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award
would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to
the maximum permitted number of extensions. However, in no event may an option be exercised beyond the expiration of its term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise of a
stock option will be determined by the Committee and may include (i)&nbsp;cash or check, bank draft or money order payable to us; (ii)&nbsp;a broker-assisted cashless exercise; (iii)&nbsp;subject to certain conditions, the tender of shares of our
Common Stock previously owned by the optionholder; (iv)&nbsp;a net exercise of the option; or (v)&nbsp;other legal consideration acceptable to the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the Committee provides otherwise, options or stock appreciation rights generally will not be transferable except by will or the laws of
descent and distribution. Subject to approval of the Committee or a duly authorized officer, an option may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
the terms of the Inducement Plan, each restricted stock unit award will have such terms and conditions as determined by the Committee. A restricted stock unit award represents a participant&#146;s right to be issued on a future date the number of
shares of our Common Stock that is equal to the number of restricted stock units subject to the award. A participant will not have voting or any other rights as a stockholder of ours with respect to any restricted stock unit award (unless and until
shares are actually issued in settlement of a vested restricted stock unit award). A restricted stock unit award will be granted in consideration for a participant&#146;s services to us or an affiliate, such that the participant will not be required
to make any payment to us (other than such services) with respect to the grant or vesting of the restricted stock unit award, or the issuance of any shares of common stock pursuant to the restricted stock unit award. The Committee may determine that
restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to the Committee and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock
(or any combination of our Common Stock and cash), or in any other form of consideration determined by the Committee and set forth in the restricted stock unit award agreement. At the time of grant, the Committee may impose such restrictions or
conditions on the award of restricted stock units that delay delivery to a date following the vesting of the award. Additionally, dividend equivalents may be paid or credited in respect of shares of Common Stock covered by a restricted stock unit
award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested will be forfeited once the participant&#146;s continuous service ends
for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock awards will be granted under restricted stock award agreements adopted by the Committee. A restricted stock award may be
awarded in consideration for cash, check, bank draft or money order, past services to us or any of our affiliates, or any other form of legal consideration that may be acceptable to the Committee and permissible under applicable law. The Committee
will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends may be paid or credited with respect to shares subject to a restricted stock award, as determined by the Committee and specified in
the applicable restricted stock award agreement. If a participant&#146;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the
participant terminates service with us through a forfeiture condition or a repurchase right. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock appreciation rights will be granted under stock appreciation right agreements adopted by the Committee and denominated in shares of
Common Stock equivalents. The terms of separate stock appreciation rights need not be identical. The Committee will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair
market value of our Common Stock on the date of grant. A stock appreciation right granted under the Inducement Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by the Committee. Stock appreciation
rights may be settled in cash or shares of our Common Stock (or any combination of our Common Stock and cash) or in any other form of payment, as determined by the Committee and specified in the stock appreciation right agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will determine the term of stock appreciation rights granted under the
Inducement Plan, up to a maximum of ten years. If a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock
appreciation right for a period of three months following the cessation of service. If a participant&#146;s service relationship with us or any of our affiliates ceases due to death, or a participant dies within a certain period following cessation
of service, the participant or a beneficiary may generally exercise any vested stock appreciation rights for a period of 18 months following the date of death. If a participant&#146;s service relationship with us or any of our affiliates ceases due
to disability, the participant may generally exercise any vested stock appreciation rights for a period of 12 months following the cessation of service. In the event of a termination for cause, stock appreciation rights generally terminate upon the
termination date. A holder of a stock appreciation right may not exercise a stock appreciation right at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the stock appreciation right
agreement or other written agreement between the participant and us, if a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the
applicable post-termination exercise period: (i)&nbsp;the exercise of the participant&#146;s stock appreciation right would be prohibited solely because the issuance of shares upon such exercise would violate applicable law, or (ii)&nbsp;the
immediate sale of any shares issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise
expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum
permitted number of extensions. However, in no event may a stock appreciation right be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Stock Awards
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will be permitted to grant other awards, based in whole or in part by reference to, or otherwise based on, our Common
Stock, either alone or in addition to other awards. The Committee will have the sole and complete discretion to determine the persons to whom and the time or times at which other stock awards will be granted, the number of shares under the other
stock award (or cash equivalent) and all other terms and conditions of such awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, the
Committee will appropriately and proportionately adjust (i)&nbsp;the class(es) and maximum number of shares subject to the Inducement Plan; and (ii)&nbsp;the class(es) and number of shares and exercise price, strike price, or purchase price, if
applicable, of all outstanding awards granted under the Inducement Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#146;s award agreement or other written
agreement with us or one of our affiliates or unless otherwise expressly provided by the Committee at the time of grant, any awards outstanding under the Inducement Plan may be assumed, continued or substituted for, in whole or in part, by any
surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to our Common Stock issued pursuant to awards may be assigned to the successor (or its parent company). If the surviving
or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards, then (i)&nbsp;with respect to any such awards that are held by participants whose continuous service has not terminated prior to the effective
time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of
performance, unless provided otherwise in the applicable award agreement, vesting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction) as the Committee
determines (or, if the Committee does not determine such a date, to the date that is five days prior to the effective time of the corporate transaction), and such awards will terminate if not exercised (if applicable) at or prior to the effective
time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&nbsp;any such awards that are held by persons
other than current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such awards will not terminate and
may continue to be exercised notwithstanding the corporate transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event an award will terminate if not exercised prior to
the effective time of a corporate transaction, the Committee may provide, in its sole discretion, that the holder of such award may not exercise such award but instead will receive a payment, in such form as may be determined by the Committee, equal
in value to the excess (if any) of (i)&nbsp;the value of the property the participant would have received upon the exercise of the award, over (ii)&nbsp;any per share exercise price payable by such holder, if applicable. As a condition to the
receipt of an award, a participant will be deemed to have agreed that the award will be subject to the terms of any agreement under the Inducement Plan governing a corporate transaction involving us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Inducement Plan, a &#147;corporate transaction&#148; generally will be the consummation, in a single transaction or in a series of
related transactions, of (i)&nbsp;a sale or other disposition of all or substantially all, as determined by the Committee, of the consolidated assets of us and our subsidiaries; (ii)&nbsp;a sale or other disposition of at least 50% of our
outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but
the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly
provided in the Inducement Plan or the form of award agreement, awards granted under the Inducement Plan may not be transferred or assigned by a participant. After the vested shares subject to an award have been issued, or in the case of a
restricted stock award and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in
compliance with the provisions herein, the terms of our trading policy and applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clawback/Recovery </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted under the Inducement Plan will be subject to recoupment in accordance with any clawback policy that we are required to adopt
pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Act or other applicable law and any clawback policy that we otherwise adopt, to the
extent applicable and permissible under applicable law. In addition, the Committee may impose such other clawback, recovery or recoupment provisions in an award agreement as the Committee determines necessary or appropriate, including but not
limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of cause. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment or Termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee
may accelerate the time at which an award granted under the Inducement Plan may first be exercised or the time during which an award grant under the Inducement Plan or any part thereof will vest, notwithstanding the provisions in the award agreement
stating the time at which it may first be exercised or the time during which it will vest. The Committee will have the authority to amend, suspend, or terminate the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Inducement Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. No awards may be granted
under the Inducement Plan while it is suspended or after it is terminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_87"></A>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the JOBS Act. As an emerging growth company, we are exempted from certain
requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the
median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_88"></A>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors received the following
compensation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,588</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Ji, our Executive Chairperson, and Mr.&nbsp;Shah, our Chief Executive Officer and President, are not
included in this table, as each of them was an employee of ours and therefore receives no compensation for his service as a director. Dr.&nbsp;Ji&#146;s and Mr.&nbsp;Shah&#146;s compensation as named executive officers are included in the section
above titled &#147;&#151; <I>Summary Compensation Table</I>&#148; above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2022, Dr.&nbsp;Lee held options to purchase an aggregate of 427,670 shares of our
Common Stock (which number of options gives effect to the Exchange Ratio) and none of Mr.&nbsp;Followwill, Ms.&nbsp;Hamill, Mr.&nbsp;Lemus and Mr.&nbsp;Thompson held any options or other equity awards to acquire shares of our Common Stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Between January&nbsp;1, 2022 through April&nbsp;24, 2022, the fees earned by Dr.&nbsp;Lee were pursuant to a
consulting agreement dated October&nbsp;27, 2020, as amended on March&nbsp;17, 2021. Between April&nbsp;25, 2022 through December&nbsp;31, 2022, the fees earned by Dr.&nbsp;Lee were for his service as a member of our board of directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_89"></A>Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has determined the following compensation for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Annual Cash Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairs of the Audit Committee, Compensation Committee and Nominating and Corporate Governance
Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members of the Audit Committee, Compensation Committee and Nominating and Corporate Governance
Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Equity Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All annual cash compensation amounts for our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors are payable in equal quarterly installments in arrears, following the end of each quarter in which the service occurred, <FONT STYLE="white-space:nowrap">pro-rated</FONT> for any partial
months of service. The equity compensation paid to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will vest monthly over a period of 48 months from the date of grant with respect to the initial stock option grants and over a
period of 12 months from the date of grant with respect to the annual stock option grants, in each case, subject to continued service through each vesting date. Additionally, we will reimburse each outside director for reasonable travel expenses
related to such director&#146;s attendance at Board and committee meetings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_90"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&nbsp;1, 2020 and any currently proposed transactions to which Vickers or Legacy
Scilex was or is to be a participant in which the amount involved exceeded or will exceed $120,000, and in which any of Vickers&#146;s or Legacy Scilex&#146;s directors, executive officers or, to Vickers&#146;s or Legacy Scilex&#146;s knowledge,
beneficial owners of more than 5% of Vickers&#146;s or Legacy Scilex&#146;s capital stock, or their immediate family members have had or will have a direct or indirect material interest, other than compensation and other arrangements that are
described under the section of this prospectus titled &#147;<I>Executive and Director Compensation</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_91"></A>Certain
Relationships of Vickers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Founder Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2020, Vickers issued an aggregate of 3,593,750 Vickers Ordinary Shares to an affiliate of the Sponsors for an aggregate
purchase price of $25,000. In August 2020, the affiliate transferred his founder shares to the Sponsors for the same price paid for such shares. On October&nbsp;8, 2020, Vickers effected a share capitalization of 0.2 shares for each share
outstanding, on December&nbsp;7, 2020, the Sponsors forfeited 1,437,500 Vickers Ordinary Shares, which were cancelled by Vickers, and on January&nbsp;6, 2021, Vickers effected a share capitalization of 0.2 shares for each share outstanding,
resulting in 3,450,000 Vickers Ordinary Shares issued and outstanding. All share and <FONT STYLE="white-space:nowrap">per-share</FONT> amounts have been retroactively restated to reflect the share transactions. The founder shares included an
aggregate of up to 450,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#146; over-allotment option is exercised, so that the number of founder shares will equal, on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis, approximately 20% of the issued and outstanding Vickers Ordinary Shares after the IPO. As a result of the underwriters&#146; election to partially exercise their over-allotment option, no
founder shares are currently subject to forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or
sell any of their founder shares until six months after the consummation of the Business Combination or earlier if we consummates a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders
having the right to exchange their Vickers Ordinary Shares for cash, securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Promissory Note </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2020, Vickers issued an unsecured promissory note (the &#147;Promissory Note&#148;) to an affiliate of the Sponsors, pursuant
to which Vickers may borrow up to an aggregate principal amount of $125,000. The Promissory Note is <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable on the earlier of (i)&nbsp;December&nbsp;31, 2020 or (ii)&nbsp;the
completion of the IPO. The outstanding balance under the Promissory Note of $125,000 was repaid subsequent to the closing of the IPO on January&nbsp;14, 2021. Borrowings under the Promissory Note are no longer available to Vickers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Loans </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;20, 2021, the Sponsors loaned Vickers an aggregate of $500,000 for working capital purposes. On January&nbsp;10, 2022, the Sponsors deposited an aggregate of $1,035,000 into the Trust Account, to provide Vickers with an additional
three months to consummate an initial business combination pursuant to Vickers&#146;s Amended and Restated Memorandum and Articles of Association (&#147;Vickers&#146;s Charter&#148;). On January&nbsp;27, 2022, the Sponsors loaned Vickers an
additional aggregate principal amount of $500,000 for working capital purposes. On April&nbsp;10, 2022, the Sponsors deposited an aggregate of $1,035,000 into the Trust Account to provide Vickers with an additional three months to consummate an
initial business combination pursuant to Vickers&#146;s Charter. On June&nbsp;30, 2022, Vickers&#146;s shareholders approved an amendment (the &#147;Extension Amendment&#148;) to its amended and restated memorandum and articles of association to
extend the deadline by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which it must complete an initial business combination from July&nbsp;11, 2022 to January&nbsp;11, 2023. Each extension was made on a monthly basis and was conditioned on the deposit into the
Trust Account of a payment equal to $0.0333 per public share outstanding. In connection with the shareholder vote on the Extension Amendment, Vickers was required to provide its shareholders with the right to redeem their public shares. Holders of
4,073,605 public shares elected to redeem their shares at a per share redemption price of $10.27 thereby reducing the amount in the Trust Account by an aggregate of approximately $41.8&nbsp;million. On July&nbsp;8, 2022, the Sponsors deposited an
aggregate of $323,888.95 into the Trust Account to provide Vickers with an additional calendar month to consummate an initial business combination pursuant to Vickers&#146;s Charter. After the redemption of the 4,073,605 public shares, there were
9,726,395 public shares remaining. On each of August&nbsp;11, 2022, September&nbsp;9, 2022 and October&nbsp;10, 2022, the Sponsors deposited an additional payment of $323,888.95 into the Trust Account to provide Vickers with an additional calendar
month to consummate an initial business combination pursuant to Vickers&#146;s Charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, the Sponsors and
Vickers entered into the Vickers Debt Agreement, which provides that, effective as of immediately prior to the Effective Time, all of the issued and outstanding loans made by the Sponsors to Vickers prior to such Effective Time shall be contributed
by the Sponsors to Vickers in exchange for a number of shares of our Common Stock determined by dividing the aggregate amount of such indebtedness by $10.00. As of immediately prior to the Effective Time, the outstanding indebtedness was
$5.3&nbsp;million, which resulted in the issuance of an additional 533,057 shares of our Common Stock to the Sponsors, in accordance with the Vickers Debt Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advances from Related Party </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2020, an affiliate of the Sponsors advanced Vickers an aggregate of $30,000 to fund expenses in connection with the IPO. The advances
are <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable upon demand. As of June&nbsp;30, 2022 and December&nbsp;31, 2021, there were no advances outstanding. The outstanding amount of $30,000 as of December&nbsp;31, 2020 was
repaid on February&nbsp;26, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Service Fee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing on the effective date of the registration statement of the IPO through the acquisition of a target business, the Sponsors have
provided Vickers with office space and certain office and secretarial services at no cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No compensation of any kind, including any
finder&#146;s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid by us to the Sponsors, officers and directors, or any of their affiliates, prior to, or in connection with any services rendered in order to
effectuate, the consummation of an initial business combination (regardless of the type of transaction that it is). However, these individuals will be reimbursed for any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable
business combinations. Our audit committee will review on a quarterly basis all payments that were made to the Sponsors, officers, directors or our or their affiliates and will determine which expenses and the amount of expenses that will be
reimbursed. There is no cap or ceiling on the reimbursement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by such persons in connection with activities on our behalf. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Agreement with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Vickers entered into the Stockholder Agreement with Sorrento. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns
any shares of Series A Preferred Stock, among other things, (i)&nbsp;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Board (each, a &#147;Stockholder Designee&#148; and collectively, the &#147;Stockholder Designees&#148;), regardless of whether such Stockholder Designee is to be elected to our Board at a
meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members
of our Board or the size of our Board and (ii)&nbsp;we are required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as
more fully described in the Stockholder Agreement. Notwithstanding the foregoing, the parties have agreed that our Board will continue to satisfy all applicable stock exchange requirements applicable to directors, including with respect to director
independence. Sorrento also have the right to designate a replacement director for any Stockholder Designee that has been removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provides that we shall not, and shall cause our subsidiaries not to, among others, without the
prior written consent of Sorrento: (i)&nbsp;amend, alter, modify or repeal (whether by merger, consolidation, by operation of law or otherwise) any provisions of the Certificate of Incorporation (including the Certificate of Designations) or our
Bylaws that increase or decrease the authorized number of directors constituting our Board; (ii)&nbsp;take any action that would have the effect of increasing or decreasing the number of directors constituting our Board; (iii)&nbsp;amend, alter,
modify or repeal (whether by merger, consolidation, reclassification, by operation of law or otherwise) any provisions of the respective charters (and any related organizational documents) of any of the committees of our Board; (iv)&nbsp;file any
voluntary petition under any applicable federal or state bankruptcy or insolvency law on behalf of us or any of our subsidiaries; (v)&nbsp;(A) incur or permit any of our subsidiaries to incur any indebtedness in an aggregate principal amount in
excess of $10,000,000) (with &#147;principal amount&#148; for purposes of this definition to include undrawn committed or available amounts) or (B)&nbsp;enter into, modify, amend or renew (or permit any of our subsidiaries enter into, modify, amend
or renew) any contract or other agreement in respect of indebtedness in an aggregate principal amount in excess of $10,000,000 (with &#147;principal amount&#148; for purposes of this definition to include undrawn committed or available amounts);
(vi) consummate or otherwise enter into any other contract or agreement to effect any change of control, joint venture or corporate reorganization by the Company or any of our subsidiaries; (vii)&nbsp;declare or pay any dividend or distribution on
our Common Stock, other Junior Security or Parity Security; or (viii) purchase, redeem or otherwise acquire for consideration by us, directly or indirectly, any Common Stock, other Junior Security or Parity Security (except as necessary to effect
(A)&nbsp;a reclassification of any Junior Security for or into other Junior Securities, (B)&nbsp;a reclassification of any Parity Security for or into other Parity Securities with the same or lesser aggregate liquidation preference, (C)&nbsp;a
reclassification of any Parity Security into a Junior Security, (D)&nbsp;the exchange or conversion of any Junior Security for or into another Junior Security, (E)&nbsp;the exchange or conversion of any Parity Security for or into another Parity
Security with the same or lesser per share liquidation amount, (F)&nbsp;the exchange or conversion of any Parity Security for or into any Junior Security or (G)&nbsp;the settlement of incentive equity awards (including any applicable withholdings
and the net exercise of options) in accordance with the terms thereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement will terminate and be of no further
force and effect upon the earlier of (i)&nbsp;mutual written agreement of the parties thereto and (ii)&nbsp;the date upon which Sorrento (together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries)) ceases
to own any shares of Series A Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Transfer Agreement with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the execution of the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant Transfer
Agreement pursuant to which, if, prior to the consummation of the Business Combination, the public shareholders had redeemed 50% or more of the public Vickers Ordinary Shares as were outstanding as of March&nbsp;17, 2022, then in addition to the
forfeiture of Warrants by the Sponsors contemplated by the Sponsor Support Agreement, the Sponsors would transfer to Sorrento, and Sorrento would acquire all rights, title and interest in and to all or a portion of the Private Placement Warrants (as
equitably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjusted from time to time in respect of any change in the outstanding Vickers Ordinary Shares into a different number, class or series, including by reason of any reclassification,
recapitalization, share split (including a reverse share split), or combination, exchange, readjustment of shares, or similar transaction, or any share dividend or distribution paid in shares) as determined in accordance with the following schedule:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Redemptions</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Private<BR>Placement<BR>Warrants&nbsp;to&nbsp;be<BR>Transferred to<BR>Sorrento</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Private<BR>Placement<BR>Warrants&nbsp;to&nbsp;be<BR>Retained by<BR>Sponsors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Private<BR>Placement<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">90% or greater</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">85% to 89.99%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,504,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75% to 84.99%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,052,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,052,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">50% to 74.99%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,440,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,840,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Below 50%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,840,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,840,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the public shareholders redeemed an aggregate of 8,576,838
Vickers Ordinary Shares, which redeemed shares, together with the shares redeemed in connection with the Extension Proposal, represented an aggregate of 91.67% of the public Vickers Ordinary Shares outstanding as of March&nbsp;17, 2022. Accordingly,
the Sponsors transferred 3,104,000 Private Placement Warrants to Sorrento pursuant to the Warrant Transfer Agreement and forfeited 2,736,000 Private Placement Warrants pursuant to the Sponsor Support Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_92"></A>Certain Relationships of Legacy Scilex </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Reorganization </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, Legacy Scilex completed a corporate reorganization. In connection with the corporate reorganization, the existing stockholders of Scilex Pharma exchanged their shares for the same number of newly issued shares of Legacy Scilex
Common Stock, pursuant to a Contribution and Loan Agreement. As a result, Scilex Pharma and Semnur became Legacy Scilex&#146;s wholly owned subsidiaries. In connection with the reorganization, each option issued by Scilex Pharma to acquire shares of
common stock granted under the Scilex Pharma 2017 Plan was cancelled and substituted for an option to purchase an equivalent number of shares of Legacy Scilex Common Stock. See the section of this prospectus titled &#147;<I>Business &#151; Our
Corporate History</I>&#148; for further information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Relationship with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, Legacy Scilex was a majority-owned subsidiary of Sorrento. Following the Closing of the Business
Combination, Sorrento continues to beneficially own a significant percentage of our outstanding Common Stock. In connection with the Business Combination, Legacy Scilex and Sorrento entered into certain agreements that relate to Legacy Scilex&#146;s
relationship with Sorrento prior to the Business Combination and provides a framework for our ongoing relationship with Sorrento. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;1, 2017, Scilex Pharma entered into a transition services agreement with Sorrento. Pursuant to this transition services agreement, Sorrento agreed to provide, directly or indirectly, certain administrative, financial, legal, tax,
insurance, facility, information technology and other services to Scilex Pharma. In addition to the services provided under this transition services agreement, Sorrento retains insurance coverage on behalf of Scilex Pharma. For the years ended
December&nbsp;31, 2021 and 2020, the total cost of services and insurance, including an agreed-upon markup, provided to Scilex Pharma was $4.0&nbsp;million and $2.3&nbsp;million, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Itochu and Oishi Product Development Agreement and Commercial Supply Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to the Product Development Agreement with Oishi and Itochu, who are responsible for supplying ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> for development and commercialization purposes. We are also a party to the Itochu </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Oishi Commercial Supply Agreement, pursuant to which Itochu agreed to purchase Products (as defined in the Itochu and Oishi Commercial Supply Agreement) from Oishi and handle the shipping of
the Products. As of December&nbsp;31, 2020, Itochu held approximately 14.7% of Legacy Scilex&#146;s outstanding capital stock, representing a noncontrolling interest. Itochu ceased to be a shareholder of Legacy Scilex on January&nbsp;13, 2021. Its
Managing Executive Officer, Kenji Hakoda, served on the Legacy Scilex Board from March 2019 to October 2020. During the years ended December&nbsp;31, 2021 and 2020, pursuant to the aforementioned Product Development Agreement and the Itochu and
Oishi Commercial Supply Agreement, Legacy Scilex purchased inventory from Itochu in the amount of $5.7&nbsp;million and $1.0&nbsp;million, respectively, on terms Legacy Scilex considers to be arms&#146; length between the parties. See the sections
of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Itochu and Oishi Product Development Agreement</I>&#148; and &#147;<I>Business &#151; Material Agreements &#151; Itochu and Oishi Commercial Supply Agreement</I>&#148; for
additional information regarding such agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indenture and Letter of Credit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;7, 2018, Scilex Pharma entered into the Purchase Agreements with the Purchasers and Sorrento, which is a beneficial owner of
more than 5% of Legacy Scilex&#146;s capital stock. Pursuant to the Purchase Agreements, on September&nbsp;7, 2018, Scilex Pharma, among other things, issued and sold to the Purchasers the Scilex Pharma Notes for an aggregate purchase price of
$140.0&nbsp;million. The Scilex Pharma Notes are governed by the Indenture with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as the Trustee and Collateral Agent, and Sorrento, as guarantor. The Indenture
provides that the holders of the Scilex Pharma Notes will be entitled to receive quarterly payments in an amount equal to a fixed percentage, ranging from 15% to 25%, of the net sales of ZTlido for the prior fiscal quarter on each February&nbsp;15,
May&nbsp;15, August&nbsp;15 and November 15. As security for the Scilex Pharma Notes, Scilex Pharma has granted to the Collateral Agent, for the benefit of the Purchasers, a continuing security interest in and lien on Scilex Pharma&#146;s right,
title, and interest in and to ZTlido and all property and assets of Scilex Pharma that are necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive of Japan). Pursuant to the
Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture. Pursuant to the terms of the Indenture,
Sorrento issued an irrevocable standby letter of credit to Scilex Pharma (as amended, the &#147;Letter of Credit&#148;) which provides that, in the event that (1)&nbsp;Scilex Pharma does not hold at least $29.0&nbsp;million in unrestricted cash
(inclusive of cash equivalents in the collateral account) as of any calendar month ending March&nbsp;31, 2020 through and including the month ending March&nbsp;31, 2021 or at least $35.0&nbsp;million in unrestricted cash (inclusive of cash
equivalents in the collateral account) at the end of any calendar month after March&nbsp;31, 2021, (2) actual cumulative net sales of ZTlido from September&nbsp;7, 2018 through December&nbsp;31, 2021 are less than a specified sales threshold for
such period, or (3)&nbsp;actual cumulative net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes, beginning with the 2022 calendar year, are less than a specified sales threshold for such calendar year, Scilex Pharma,
as beneficiary of the Letter of Credit, will draw, and Sorrento will pay to Scilex Pharma, $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan. The Letter of Credit will terminate upon the
earliest to occur of: (a)&nbsp;the repayment of the Scilex Pharma Notes in full, (b)&nbsp;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&nbsp;the consummation of an
initial public offering on a major international stock exchange by us that satisfies certain valuation thresholds, and (d)&nbsp;the replacement of the Letter of Credit with another letter of credit in form and substance, including as to the identity
and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2020, the parties entered into a Consent Under and Amendment No.&nbsp;3 to Indenture and Letter of Credit
(&#147;Amendment No.&nbsp;3&#148;), which amended: (i)&nbsp;the Indenture, and (ii)&nbsp;the Letter of Credit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2020,
and in connection with Amendment No.&nbsp;3, the aggregate $45.0&nbsp;million in restricted funds held in previously established reserve and collateral accounts were released and Scilex Pharma utilized such funds to repurchase an aggregate of
$45.0&nbsp;million in principal amount of the Scilex Pharma Notes. Scilex </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pharma also repurchased an aggregate of $20.0&nbsp;million in principal amount of the Scilex Pharma Notes on December&nbsp;16, 2020. Pursuant to the foregoing repurchases, the aggregate principal
amount of the Scilex Pharma Notes was reduced by an aggregate of $65.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further related to Amendment No.&nbsp;3, the
Purchasers also consented to Scilex Pharma incurring up to $10.0&nbsp;million of indebtedness in connection with an accounts receivable revolving loan facility with another lender and the incurrence of liens and the pledge of collateral to such
lender in connection therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of
Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 were less than a specified sales threshold for such period. As a result
of the draw notice being issued, Sorrento paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan. Per the terms of the Amendment No.&nbsp;3, in February 2022, Scilex Pharma
repurchased Scilex Pharma Notes in an aggregate amount equal to $20.0&nbsp;million at a purchase price in cash equal to 100% of the principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by
$28.0&nbsp;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 did not equal or exceed a $481.0&nbsp;million sales threshold for such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;2, 2022, Sorrento and Scilex Pharma, entered into a Consent Under and Amendment No.&nbsp;4 to Indenture (&#147;Amendment
No.&nbsp;4&#148;) with the Trustee, Collateral Agent, and the Purchasers, which amended the Indenture. Pursuant to Amendment No.&nbsp;4, (1) on June&nbsp;3, 2022, Scilex Pharma repurchased approximately $41.4&nbsp;million of the aggregate principal
amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof (the &#147;Repurchase&#148;), (2) the Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on
or before September&nbsp;30, 2022 for $41.4&nbsp;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Purchasers will forgive and discharge $28.0&nbsp;million of the aggregate principal amount of the Scilex
Pharma Notes, and (3)&nbsp;the minimum cash requirement under the Indenture was reduced to $5.0&nbsp;million in aggregate unrestricted cash equivalents at the end of each calendar month. Scilex Pharma funded the Repurchase with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> and $15.0&nbsp;million received from Sorrento on June&nbsp;2, 2022. We paid off all the amounts outstanding under the Scilex Pharma Notes as of immediately prior
to the Closing of the Business Combination, which payment was funded by Sorrento and treated as intercompany debt in exchange for Series A Preferred Stock pursuant to the terms of the Debt Exchange Agreement described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2022, we repurchased the remaining outstanding principal balance of the Scilex Pharma Notes with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> and $34.0&nbsp;million received from Sorrento. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Oaktree
Guaranty </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;7, 2018, Sorrento and certain of its domestic subsidiaries entered into a Term Loan Agreement, as
amended on May&nbsp;3, 2019 and December&nbsp;6, 2019 (as amended, the &#147;Oaktree Loan Agreement&#148;) with certain funds and accounts managed by Oaktree Capital Management, L.P. and Oaktree Fund Administration, LLC, as administrative and
collateral agent, for an initial term loan of $100.0&nbsp;million and a delayed draw term loan of $20.0&nbsp;million that was provided to Sorrento on May&nbsp;3, 2019. On April&nbsp;12, 2019, Legacy Scilex and Semnur entered into a Joinder Agreement
to the Oaktree Loan Agreement whereby each entity became a guarantor under the Oaktree Loan Agreement and pledged all of their respective assets (other than equity of Scilex Pharma) as collateral for the loans made to Sorrento under the Oaktree Loan
Agreement. All obligations owed under the Oaktree Loan Agreement were paid off in full on June&nbsp;12, 2020 and both Legacy Scilex and Semnur ceased to be a guarantor under the Oaktree Loan Agreement as of such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intercompany Promissory Note and Sale of Shares to Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2018, Scilex Pharma issued to Sorrento an intercompany promissory note in the amount of approximately $21.7&nbsp;million for
certain amounts previously advanced to Scilex Pharma by Sorrento (the &#147;Intercompany Note&#148;). On October&nbsp;22, 2018, Sorrento purchased from Legacy Scilex 24,117,608 shares of Legacy Scilex Common Stock in exchange for the cancellation of
$21.7&nbsp;million of indebtedness under the Intercompany Note. During 2021 and 2020, Sorrento made advances to Scilex Pharma in the amount of $8.1&nbsp;million and $10.3&nbsp;million, respectively, under the Intercompany Note. As of
December&nbsp;31, 2021 and 2020, the outstanding principal balance under the Intercompany Note was approximately $23.5&nbsp;million and $15.4&nbsp;million, respectively. In connection with Amendment No.&nbsp;4 to the Indenture, the maximum aggregate
principal amount of the Intercompany Note was increased from up to $25.0&nbsp;million to up to $50.0&nbsp;million. As of immediately prior to the Closing of the Business Combination, the outstanding principal balance under the Intercompany Note was
$23.5&nbsp;million, which amount was treated as Outstanding Indebtedness (as defined in the Debt Exchange Agreement discussed below) and contributed to Legacy Scilex in exchange for preferred stock as more fully described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note Payable to Sorrento </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, Legacy Scilex entered into a note payable with Sorrento with an initial principal amount of $16.5&nbsp;million. Legacy Scilex may borrow up to an aggregate of $20.0&nbsp;million of principal amount under the note payable. The
note payable is interest bearing at the lesser of (i) 10% simple interest per annum, and (ii)&nbsp;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in
whole or in part at any time without penalty or premium. The outstanding principal balance of the note payable as of December&nbsp;31, 2021 and 2020 was $19.6&nbsp;million and $13.0&nbsp;million, respectively. Accrued interest of $3.9&nbsp;million
and $2.6&nbsp;million was recognized under related party payable in Legacy Scilex&#146;s consolidated balance sheet as of December&nbsp;31, 2021 and 2020, respectively. During the six months ended June&nbsp;30, 2022 and 2021, Sorrento made advances
to Legacy Scilex in the amount of $27.5&nbsp;million and $0, respectively, under the note payable. The outstanding principal balance of the note payable on June&nbsp;30, 2022 and December&nbsp;31, 2021 was $47.1&nbsp;million and $19.6&nbsp;million,
respectively, which was recorded under the current related party note payable in Legacy Scilex&#146;s consolidated balance sheets. As of June&nbsp;30, 2022 and December&nbsp;31, 2021, Legacy Scilex had ending balances resulting from the accrued
interest on the note payable of $5.6&nbsp;million and $3.9&nbsp;million, respectively, which was recorded under the related party payable in Legacy Scilex&#146;s consolidated balance sheets. The proceeds from the note payable were used to finance
the acquisition of Semnur and to finance Legacy Scilex&#146;s operations. As of immediately prior to the Closing of the Business Combination, the outstanding principal balance under the note payable was $54.3&nbsp;million, which amount was treated
as Outstanding Indebtedness (as defined in the Debt Exchange Agreement discussed below) and contributed to Legacy Scilex in exchange for preferred stock as more fully described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt Exchange Agreement and Related Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Legacy Scilex and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement with
Sorrento (the &#147;Debt Exchange Agreement&#148;), pursuant to which (i)&nbsp;Sorrento shall contribute to Legacy Scilex all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to Legacy
Scilex and Scilex Pharma that remain outstanding as of immediately prior to the Closing of the Business Combination (the &#147;Aggregate Outstanding Amount&#148; or &#147;Outstanding Indebtedness&#148;), including with respect to the Scilex Pharma
Notes, the Intercompany Note, and the other notes payable to Sorrento described above, in exchange for the issuance by Legacy Scilex to Sorrento of preferred stock of Legacy Scilex, (ii)&nbsp;Legacy Scilex shall contribute to Scilex Pharma the
portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii)&nbsp;upon the occurrence of the events described in clauses (i)&nbsp;and (ii), the Aggregate Outstanding
Amount and the Outstanding Indebtedness shall be satisfied in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to,
and contingent upon, the Closing of the Business Combination, Sorrento has elected to contribute the Outstanding Indebtedness to Legacy Scilex in exchange for the issuance by Legacy Scilex to Sorrento of that number of shares of Legacy Scilex
Preferred Stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#147;Exchange Shares&#148; and such transaction, the &#147;Debt Contribution&#148;) that is equal to (i)&nbsp;the Aggregate
Outstanding Amount plus the amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $310,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, Sorrento and Legacy Scilex entered into the Funding Commitment Letter. Pursuant to the terms of the Funding
Commitment Letter, upon the written request of Legacy Scilex (which request Legacy Scilex shall make to the extent necessary to satisfy the closing condition in the Merger Agreement that requires the combined company to have $5,000,001 in net
tangible assets as of immediately following the Effective Time) (the &#147;Net Tangible Assets Condition&#148;), Sorrento shall fund one or more loans to Legacy Scilex in the amount set forth in such written request (a &#147;Loan Request&#148;),
provided, that any amounts funded by Sorrento in respect of any Loan Request shall be treated as Outstanding Indebtedness for all purposes under the Debt Exchange Agreement and included in the calculation of the Aggregate Outstanding Amount
thereunder. The Funding Commitment Letter also provides that in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a) $10,000,000 and (b)&nbsp;an amount that, when taken together
with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. As consideration for the execution of the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant
Transfer Agreement, which is more fully described elsewhere in this prospectus. No Loan Requests were made under the Funding Commitment Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Debt Contribution, Legacy Scilex filed, with the Secretary of State of the State of Delaware, (i)&nbsp;a Certificate of Amendment
to its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of Legacy Scilex from 20,000,000 to 45,000,000 and (ii)&nbsp;a certificate of designation setting forth the designations, powers,
rights and preferences and qualifications, limitations and restrictions of the Exchange Shares. Following the issuance thereof to Sorrento and in connection with the Closing of the Business Combination, such shares were converted into the right to
receive (i)&nbsp;one share of Series A Preferred Stock and <FONT STYLE="white-space:nowrap">(ii)&nbsp;one-tenth</FONT> of one share of our Common Stock, which shares of Series A Preferred Stock shall then have the rights set forth in the Certificate
of Designations. Sorrento is entitled to the rights set forth in the Stockholder Agreement as a result of Sorrento&#146;s ownership thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately prior to the Closing of the Business Combination, the Outstanding Indebtedness (including amounts related to the transfer of
certain liabilities to Sorrento and repayment of Scilex Pharma Notes) was $290,570,964, which was contributed by Sorrento, in accordance with the Debt Exchange Agreement, in exchange for 29,057,097 shares of Legacy Scilex Preferred Stock, which were
in turn converted into the right to receive 29,057,097 shares of Series A Preferred Stock and 2,905,710 shares of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shah Investor
LP Assignment Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex, through Semnur, is a party to the Assignment Agreement with Shah Investor LP, pursuant to
which Shah Investor LP assigned Legacy Scilex certain intellectual property and Legacy Scilex agreed to pay Shah Investor LP a contingent quarterly royalty in the <FONT STYLE="white-space:nowrap">low-single</FONT> digits based on the quarterly net
sales of any pharmaceutical formulations for local delivery of steroids by injection developed utilizing such intellectual property, which would include SEMDEXA. Mahendra Shah, Ph.D., who served on the Legacy Scilex Board from March 2019 to October
2020, is the managing partner of Shah Investor LP. See the section of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Shah Investor LP Assignment Agreement</I>&#148; for additional information regarding the Assignment
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition of <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets from Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase agreement (the &#147;Aardvark Asset Purchase Agreement&#148;) with Aardvark
Therapeutics, Inc. (&#147;Aardvark&#148;), pursuant to which, among other things, Sorrento acquired Aardvark&#146;s Delayed Burst Release Low Dose Naltrexone <FONT STYLE="white-space:nowrap">(DBR-LDN)</FONT> asset and intellectual property rights,
for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Assets&#148;), which includes a Statement of Work dated November&nbsp;18, 2020 (the &#147;Tulex
Statement of Work&#148;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of <FONT STYLE="white-space:nowrap">SP-104.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to
<FONT STYLE="white-space:nowrap">SP-104</FONT> and on May&nbsp;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement, pursuant to which Sorrento sold, conveyed, assigned and transferred to Legacy
Scilex all of its rights, title and interest in and to the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights thereto) and Legacy Scilex assumed all
of Sorrento&#146;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Acquisition&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition, Legacy Scilex issued a promissory note in the aggregate
principal amount of $5,000,000 to Sorrento (the &#147;Promissory Note&#148;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and
(b)&nbsp;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#147;Consideration Shares&#148;) or any combination thereof, at Legacy Scilex&#146;s sole discretion,
and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento,
within 60 days of the issuance of such Consideration Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is
obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy
Scilex&#146;s sole discretion) (the &#147;Development Milestone Payment&#148;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#147;Commercial
Product&#148;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to
reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of
the date of this prospectus none of the foregoing payments have been triggered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the
SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, MD, a member of our Board, is the founder, chief executive officer and a member of the
board of directors of Aardvark. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guaranty of Lease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;8, 2019, Legacy Scilex entered into a new office lease for approximately 6,000 square feet for its executive offices in Palo
Alto, California, as amended on September&nbsp;15, 2019. The term of the lease commenced on September&nbsp;15, 2019 and will expire on November&nbsp;30, 2024. We will be obligated to pay an average of approximately $0.5&nbsp;million in annual rent
over the term of the lease. In connection with the lease, on August&nbsp;8, 2019, Sorrento executed a Guaranty of Lease, guaranteeing the performance of our obligations under the lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intercompany Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the month of December 2022, we paid $1.8&nbsp;million of invoices on behalf of Sorrento for legal fees incurred by Sorrento, which was
fully reserved in our financial statements for the year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officer and Director Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section of this prospectus titled &#147;<I>Executive and Director Compensation</I>&#148; for information regarding the
compensation of our executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into offer letter agreements with our named executive officers, other than Dr.&nbsp;Ji, that, among other things, provide for
certain compensatory and change in control benefits, as well as severance benefits. For a description of such agreements, see the section of this prospectus titled &#147;<I>Executive and Director Compensation &#151; Narrative Disclosure to Summary
Compensation Table &#151; Arrangements with Executive Officers.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitation of Liability and Indemnification of Officers and Directors
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section of this prospectus titled &#147;<I>Management &#151; Limitation of Liability and Indemnification of
Directors and Officers</I>&#148; for information regarding our arrangements to provide indemnification to our officers and directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business
Combination Related Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement, Vickers, Legacy Scilex and Sorrento
entered into a Company Stockholder Support Agreement, pursuant to which Sorrento agreed to vote all Legacy Scilex Common Stock beneficially owned by it, including any additional shares of Legacy Scilex it acquires ownership of or the power to vote,
in favor of the Business Combination and related transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, in connection with the closing of the Business
Combination, Scilex, Sorrento, the Sponsors, and Vickers&#146;s former directors Pei Wei Woo, Suneel Kaji and Steve Myint, entered into the Registration Rights Agreement, whereby, subject to certain exceptions, the parties agreed, among other
things, not to transfer any of our Common Stock or any security convertible into or exercisable or exchanged for our Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&nbsp;one hundred eighty
(180)&nbsp;days from the date of the Registration Rights Agreement or (ii)&nbsp;the date on which we complete a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right
to exchange their shares of our Common Stock for cash, securities or other property. The Registration Rights Agreement governs the registration of certain shares of our Common Stock for resale and includes certain customary demand and
&#147;piggy-back&#148; registration rights with respect to shares of our Common Stock held by the parties thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Person Transaction
Policy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a related person transaction policy that sets forth our procedures for the identification, review,
consideration and approval or ratification of related person transactions. For purposes of our policy, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships,
in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related
person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities and any of their respective immediate family members and any entity owned or controlled by such persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction,
including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information
regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or ratification. The presentation must include
a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or
from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant
stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our code of conduct and ethics, our employees and directors have an affirmative responsibility
to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of our Board, will take into account the
relevant available facts and circumstances including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event that the related person is a director, immediate family
member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit
committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our audit committee, or other
independent body of our Board, determines in the good faith exercise of our discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_93"></A>PRINCIPAL SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of our Common Stock as of March&nbsp;31, 2023 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or &#147;group&#148; known to be the beneficial owner of more than 5% of our outstanding Common
Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our current executive officers and directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a
security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. Shares subject to options and warrants that are currently
exercisable or exercisable within 60 days of March&nbsp;31, 2023 are considered outstanding and beneficially owned by the person holding such options or warrants for the purpose of computing the percentage ownership of that person, but are not
treated as outstanding for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beneficial ownership of our Common
Stock is based on 145,811,298 shares of such common stock outstanding as of March&nbsp;31, 2023. Voting power is based on 145,811,298 shares of Common Stock and 29,057,097 shares of Series A Preferred Stock outstanding as of March&nbsp;31, 2023.
Shares of Series A Preferred Stock are held solely by Sorrento. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, we believe, based on information available to
us, that all persons and entities named in the table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Common<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Total<BR>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% of<BR>Total<BR>Vote</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Directors and Executive Officers</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,363,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,385,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">399,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D.<SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">449,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All Directors and Executive Officers as a Group (8 individuals)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,681,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>5% Beneficial Owners</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sorrento Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66,476,412</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise indicated, the business address of each of the following individuals is 4955 Directors Place,
San Diego, CA 92121. None of the following individuals own shares of Series A Preferred Stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 9,251,177 shares subject to options exercisable within 60 days of March&nbsp;31, 2023 and 112,633
shares held directly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 2,781,708 shares subject to options exercisable within 60 days of March&nbsp;31, 2023 and 603,298
shares held directly. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 399,589 shares subject to options exercisable within 60 days of March&nbsp;31, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 448,503 shares subject to options exercisable within 60 days of March&nbsp;31, 2023 and 1,409 shares
held directly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 20,833 shares subject to options exercisable within 60 days of March&nbsp;31, 2023 and 300 shares
held directly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 20,833 shares subject to options exercisable within 60 days of March&nbsp;31, 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (a) 61,985,795 shares held following completion of Sorrento&#146;s previously announced dividend on
January&nbsp;19, 2023 of shares of our Common Stock then held by Sorrento (of which 2,259,058 shares are being held in abeyance for the benefit of certain holders of warrants to purchase shares of common stock of Sorrento who may be entitled to
receive shares of Common Stock pursuant to the terms of the applicable warrants as a result of the previously declared dividend of shares of Common Stock by Sorrento), (b) 3,104,000 shares subject to Private Placement Warrants and (c) 1,386,617
shares subject to Public Warrants exercisable within 60 days of March&nbsp;31, 2023. &#147;Public Warrants&#148; means the redeemable warrants that were included in the Units that entitle the holder of each whole warrant to purchase one Vickers
Ordinary Share at a price of $11.50 per share. &#147;Units&#148; means the units of Vickers, each of which consisted of one Vickers Ordinary Share and <FONT STYLE="white-space:nowrap">one-half</FONT> of one redeemable warrant upon the consummation
of an initial business combination, which units, if not separated into its component securities as of immediately prior to the Effective Time were, without any action on the part of the holder, separated automatically into its component securities,
comprised of one share of Common Stock and <FONT STYLE="white-space:nowrap">one-half</FONT> of one warrant to purchase one share of Common Stock. The business address of Sorrento Therapeutics, Inc. is 4955 Directors Place, San&nbsp;Diego, CA 92121.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_94"></A>SELLING SECURITYHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and sale by the Selling Securityholder of up to 3,290,000 shares of Common Stock that may be issued by us
to the Selling Securityholder upon the Selling Securityholder&#146;s conversion of the Convertible Debentures. For additional information regarding the issuance of the Convertible Debentures, see the sections titled &#147;<I>Prospectus
Summary&#151;Recent Developments&#151;Convertible Debentures</I>,&#148; &#147;<I>Private Placement</I>&#148; and &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations &#151; Recent Developments</I>&#148;
above. We are registering the shares of Common Stock included in this prospectus pursuant to the provisions of that certain registration rights agreement that we entered into with the Selling Securityholder on March&nbsp;21, 2023 (the
&#147;Yorkville Registration Rights Agreement&#148;) in order to permit the Selling Securityholder to offer the shares included in this prospectus for resale from time to time. Except for the transactions contemplated by the A&amp;R Yorkville
Purchase Agreement and the ownership of the Convertible Debentures pursuant to the Securities Purchase Agreement, and as set forth in the section titled &#147;<I>Plan of Distribution</I>&#148; in this prospectus, the Selling Securityholder has not
had any material relationship with us within the past three years. For additional information regarding the A&amp;R Yorkville Purchase Agreement, see the sections titled &#147;<I>Prospectus Summary&#151;Recent Developments&#151;Committed Equity
Financings&#151;A&amp;R Yorkville Purchase Agreement</I>&#148; and &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Recent Developments&#151;Committed Equity Financings&#151;A&amp;R Yorkville
Purchase Agreement</I>&#148; above. As used in this prospectus, the term &#147;Selling Securityholder&#148; means YA II PN, Ltd., a Cayman Islands exempt limited partnership, and the pledgees, donees, transferees, assignees, successors, designees,
and others who later come to hold any of the Selling Securityholder&#146;s interest in the Common Stock other than through a public sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents information regarding the Selling Securityholder and the shares of Common Stock that may be resold by the Selling
Securityholder from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Securityholder, and reflects holdings as of March&nbsp;31, 2023. The number of shares in the column titled &#147;Number
of Shares of Common Stock Beneficially Owned&#148; lists the number of shares of Common Stock beneficially owned by the Selling Securityholder as the investor under the A&amp;R Yorkville Purchase Agreement, as of March&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares in the column titled &#147;Maximum Number of Shares of Common Stock Being Offered&#148; represents all of the shares of
Common Stock being offered for resale by the Selling Securityholder under this prospectus. The Selling Securityholder may sell some, all, or none of the shares being offered for resale in this offering. If the Selling Securityholder exercises its
right to convert the Convertible Debentures into shares of Common Stock, we do not know how long the Selling Securityholder will hold the shares before selling them, and we are not aware of any existing arrangements between the Selling
Securityholder and any other stockholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the shares of our Common Stock being offered for resale by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Yorkville Registration Rights Agreement with the Selling Securityholder, this prospectus covers the resale
of up to 3,290,000 shares of Common Stock that may be issued to the Selling Securityholder upon conversion of the Convertible Debentures. The number of shares that may actually be issuable upon conversion of the Convertible Debentures pursuant to
the terms thereof may be more than the number of shares being offered by this prospectus. The fourth column in the table below assumes the resale by the Selling Securityholder of all of the shares of Common Stock being offered for resale pursuant to
this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with Rule <FONT STYLE="white-space:nowrap">13d-3(d)</FONT> promulgated
by the SEC under the Exchange Act, and includes shares of our Common Stock with respect to which the Selling Securityholder has sole or shared voting and investment power. The percentage of shares of our Common Stock beneficially owned by the
Selling Securityholder prior to the offering shown in the table below is based on an aggregate of 145,811,298 shares of our Common Stock outstanding on March&nbsp;31, 2023. Except as indicated by the footnotes below, we believe, based on the
information furnished to us, that the Selling Securityholder has sole voting and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investment power with respect to all shares of Common Stock that it beneficially owns, subject to applicable community property laws. Except as otherwise described below, based on the information
provided to us by the Selling Securityholder, the Selling Securityholder is not a broker-dealer or an affiliate of a broker-dealer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Securityholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>of Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Number of<BR>Shares of<BR>Common<BR>Stock<BR>Being<BR>Offered</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of Common<BR>Stock<BR>Beneficially Owned<BR>After&nbsp;the&nbsp;Offered<BR>Shares&nbsp;of&nbsp;Common<BR>Stock Are<BR>Sold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">YA II PN, Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,290,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the remaining Yorkville Commitment Shares that we issued to the Selling Securityholder in
consideration for entering into the Original Purchase Agreement. The Selling Securityholder may not convert the Convertible Debentures to the extent such conversion would cause the aggregate number of shares of Common Stock beneficially owned by the
Selling Securityholder and its affiliates to exceed 4.99% of our then outstanding shares of Common Stock, provided that this limitation may be waived by the Selling Securityholder upon not less than 65 days&#146; prior notice to us. We are also
prohibited from issuing shares of Common Stock (including any shares issued pursuant to a conversion) if the issuance of such shares of Common Stock would exceed the 19.9% Convertible Debenture Exchange Cap of 29,016,448 shares.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes the sale of all shares being offered pursuant to this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">YA II PN, Ltd. is a fund managed by Yorkville Advisors Global, LP (&#147;Yorkville LP&#148;). Yorkville
Advisors Global II, LLC (&#147;Yorkville LLC&#148;) is the General Partner of Yorkville LP. All investment decisions for YA II PN, Ltd. are made by Yorkville LLC&#146;s President and Managing Member, Mr.&nbsp;Mark Angelo. The business address of YA
II PN, Ltd. is 1012 Springfield Avenue, Mountainside, NJ 07092. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_95"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock covered by this prospectus are being offered by the Selling Securityholder. The shares may be sold or distributed
from time to time by the Selling Securityholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market
prices, at negotiated prices, or at fixed prices, which may be changed. We will not receive any of the proceeds from the sale of the securities by the Selling Securityholder. The aggregate proceeds to the Selling Securityholder will be the purchase
price of shares of our Common Stock less any discounts and commissions borne by the Selling Securityholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder
may sell or otherwise dispose of its shares of our Common Stock offered by this prospectus in one or more of the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokers&#146; transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions involving cross or block trades; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through brokers, dealers, or underwriters who may act solely as agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;at the market&#148; into an existing market for our Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in other ways not involving market makers or established business markets, including direct sales to purchasers
or sales effected through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in privately negotiated transactions; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed
brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#146;s registration or qualification requirement is available and
complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder may be deemed to be an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of
the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has informed us that it intends to use one or more registered broker-dealers to effectuate
all sales, if any, of our Common Stock issuable upon conversion of the Convertible Debentures. Such sales will be made at prices and at terms then prevailing or at prices related to the then-current market price. Such registered broker-dealer may,
in some circumstances (for instance if such registered broker-dealer&#146;s involvement is not limited to receiving commission not in excess of the usual and customary distributors&#146; or sellers&#146; commissions), be considered to be an
underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act. The Selling Securityholder has informed us that each such broker-dealer may receive commissions from the Selling Securityholder for executing such sales for the Selling
Securityholder and, if so, such commissions will not exceed customary brokerage commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brokers, dealers, underwriters, or agents
participating in the distribution of the shares of our Common Stock offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the
shares sold by the Selling Securityholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of shares of our Common Stock sold by the Selling Securityholder may be less than or in excess of
customary commissions. Neither we nor the Selling Securityholder can presently estimate the amount of compensation that any agent will receive from any purchasers of shares of our Common Stock sold by the Selling Securityholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We know of no existing arrangements between the Selling Securityholder or any other stockholder, broker, dealer, underwriter, or agent
relating to the sale or distribution of the shares of our Common Stock offered by this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time file with the SEC one or more supplements to this prospectus or
amendments to the registration statement of which this prospectus forms a part to amend, supplement, or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information
relating to a particular sale of shares offered by this prospectus by the Selling Securityholder, including with respect to any compensation paid or payable by the Selling Securityholder to any brokers, dealers, underwriters, or agents that
participate in the distribution of such shares by the Selling Securityholder, and any other related information required to be disclosed under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay the expenses incident to the registration under the Securities Act of the offer and sale of the shares of our Common Stock covered
by this prospectus by the Selling Securityholder. We have paid an affiliate of the Selling Securityholder a <FONT STYLE="white-space:nowrap">one-time</FONT> due diligence and structuring fee of $15,000 in connection with the due diligence and
structuring of the transactions by the Selling Securityholder under the Securities Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the
Selling Securityholder and certain other persons against certain liabilities in connection with the offering of shares of our Common Stock issuable upon conversion of the Convertible Debentures, including liabilities arising under the Securities
Act, or, if such indemnity is unavailable, to make the maximum contribution to the payment and satisfaction of such liabilities. The Selling Securityholder has agreed to indemnify us against liabilities under the Securities Act that may arise from
certain misrepresentation or breach of covenants by the Selling Securityholder or, if such indemnity is unavailable, to make the maximum contribution to the payment and satisfaction of such liabilities. Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that, in the opinion of the SEC, this indemnification is against public policy as expressed in the Securities Act, and is
therefore unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has represented to us that at no time prior to the date of the Securities Purchase
Agreement has the Selling Securityholder or any entity managed or controlled by the Selling Securityholder engaged in or effected, in any manner whatsoever, directly or indirectly, for its own account or for the account of any of its affiliates, any
short sale or any transaction that establishes a net short position with respect to our Common Stock. The Selling Securityholder has agreed that, from and after the date of the Securities Purchase Agreement and ending when no Convertible Debentures
remain outstanding, none of the Selling Securityholder, its officers, or any entity managed or controlled by the Selling Securityholder will enter into or effect, directly or indirectly, any of the foregoing transactions for its own account or for
the account of any other such person or entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Securityholder that it is required to comply with Regulation
M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the Selling Securityholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing,
or attempting to induce any person to bid for or purchase, any security that is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a
security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This offering will terminate on the date that all shares of our Common Stock offered by this prospectus have been sold by the Selling
Securityholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_96"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S. federal income tax considerations generally applicable to the purchase, ownership and
disposition of our Common Stock into which the Convertible Debentures may be converted. This discussion is based on provisions of the Code, the Treasury Regulations promulgated thereunder (whether final, temporary, or proposed), administrative
rulings of the IRS, and judicial decisions, all as in effect on the date hereof, and all of which are subject to differing interpretations or change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or
listing of all potential U.S. federal income tax consequences relating to the purchase, ownership and disposition of our Common Stock into which the Convertible Debentures may be converted. In addition, this discussion does not address all aspects
of U.S. federal income tax consequences to particular holders nor does it take into account the individual facts and circumstances of any particular holder that may affect the U.S. federal income tax consequences to such holder, and accordingly, is
not intended to be, and should not be construed as, tax advice. This discussion does not address the U.S. federal 3.8% Medicare tax imposed on certain net investment income or any aspects of U.S. federal taxation other than those pertaining to the
income tax (such as the gift or estate tax), nor does it address any tax consequences arising under any U.S. state and local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. Holders should consult their own tax advisors regarding such
tax consequences in light of their particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No ruling has been requested or will be obtained from the IRS with respect
to the U.S. federal income tax consequences to a holder of the purchase, ownership or disposition of our Common Stock; thus, there can be no assurance that the IRS will not challenge the U.S. federal income tax treatment described below or that, if
challenged, such treatment will be sustained by a court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is limited to considerations relevant to holders that hold our
Common Stock as &#147;capital assets&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be important to holders
in light of their individual circumstances, including holders subject to special treatment under the U.S. tax laws, such as, for example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks or other financial institutions, underwriters, or insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities who elect to apply a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts and regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, qualified retirement plans, individual
retirement accounts, or other <FONT STYLE="white-space:nowrap">tax-deferred</FONT> accounts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expatriates or former long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subchapter S corporations, partnerships or other pass-through entities or investors in such entities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or traders in securities, commodities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grantor trusts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. persons whose &#147;functional currency&#148; is not the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who received our Common Stock through the issuance of restricted stock under an equity incentive plan or
through a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan or otherwise as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who own (directly or through attribution) 5% or more (by vote or value) of the outstanding securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our Common Stock as a position in a &#147;straddle,&#148; as part of a &#147;synthetic
security&#148; or &#147;hedge,&#148; as part of a &#147;conversion transaction,&#148; or other integrated investment or risk reduction transaction; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlled foreign corporations, passive foreign investment companies, or foreign corporations with respect to
which there are one or more United States shareholders within the meaning of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.367(b)-3(b)(1)(ii);</FONT> or </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this discussion, the term &#147;U.S. Holder&#148; means a beneficial owner of our Common Stock that is, for U.S. federal income tax
purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or other entity that is classified as a corporation for U.S. federal income tax purposes) that is
created or organized in or under the laws of the United States or any State thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (i)&nbsp;if a court within the United States is able to exercise primary supervision over the
administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (ii)&nbsp;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person for
U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; means a
beneficial owner of our Common Stock, that is neither a U.S. Holder nor a partnership (or an entity or arrangement treated as a partnership) for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, including for this purpose any entity or arrangement that is treated as a partnership for U.S. federal income tax purposes,
holds our Common Stock, the U.S. federal income tax treatment of a partner in such partnership will generally depend on the status of the partner and the activities of the partnership. A holder that is a partnership and the partners in such
partnership should consult their own tax advisors with regard to the U.S. federal income tax consequences of the ownership and disposition of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE
OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK. IN ADDITION, THE U.S. FEDERAL INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS OF OUR COMMON STOCK MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT
AND INTERPRETATIONS OF COMPLEX PROVISIONS OF U.S. FEDERAL INCOME TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE. HOLDERS OF OUR COMMON STOCK SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM
OF THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK INCLUDING THE APPLICABILITY AND EFFECTS OF U.S. FEDERAL, STATE, LOCAL, AND OTHER TAX LAWS. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_97">
</A>U.S. Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pay distributions or make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to
U.S. Holders of shares of our Common Stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income
tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#146;s adjusted tax basis in our Common
Stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the Common Stock and will be treated as described under &#147;<I>U.S. Holders-Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of
Common Stock</I>&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S. Holder that is a taxable corporation will generally qualify for
the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period
requirements are met, dividends we pay to a non-corporate U.S. Holder will generally constitute &#147;qualified dividends&#148; that will be subject to tax at the preferential tax rate accorded to long-term capital gains. <FONT
STYLE="white-space:nowrap">Non-corporate</FONT> U.S. Holders that do not meet a minimum holding period requirement or that elect to treat the dividend income as &#147;investment income&#148; pursuant to Section&nbsp;163(d)(4) of the Code (dealing
with the deduction for investment interest expense) will not be eligible for the reduced rates of taxation applicable to qualified dividends. In addition, the rate reduction will not apply to dividends if the recipient of a dividend is obligated to
make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the minimum holding period has been met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would
have taxable income equal to the entire dividend amount, and <FONT STYLE="white-space:nowrap">non-corporate</FONT> holders may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified
dividend income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder generally will recognize gain or loss on the sale, taxable exchange or other taxable disposition of our Common Stock, including
on a redemption that is treated as a sale or exchange under Section&nbsp;302 of the Code. Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#146;s holding period for the Common Stock so
disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1)&nbsp;the sum of the amount of cash and the fair market value of any property received in such disposition and (2)&nbsp;the U.S.
Holder&#146;s adjusted tax basis in its Common Stock so disposed of. A U.S. Holder&#146;s adjusted tax basis in its Common Stock will generally equal the U.S. Holder&#146;s acquisition cost for such Common Stock, less any prior distributions treated
as a return of capital. The deductibility of capital losses is subject to limitations. Long-term capital gains recognized by <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders are generally eligible for reduced rates of tax. If the
U.S. Holder&#146;s holding period for the Common Stock so disposed of is one year or less, any gain on a sale or other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax
rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized by a U.S. Holder on the sale or exchange of our Common Stock will generally be treated as U.S. source gain or loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_98"></A><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
general, any distributions (including constructive distributions) we make to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of shares of our Common Stock, to the extent paid out of our current or accumulated earnings and profits (as
determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s
conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is eligible for a reduced rate
of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable). Special certification and other requirements apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that are pass-through entities rather than corporations or
individuals. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its shares of our Common Stock and, to the
extent such distribution exceeds the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis, as gain realized from the sale or other disposition of the Common Stock, which will be treated as described under &#147;<I><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders-Gain on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</I>&#148; below. In addition, if we determine that we are likely to be classified as a &#147;United States real property
holding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation&#148; (see &#147;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders-Gain on Sale, Exchange or Other Taxable Disposition of Common Stock</I>&#148; below), we will withhold 15%
of any distribution that exceeds our current and accumulated earnings and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are effectively connected with such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (or, if a tax treaty applies, are
attributable to a U.S. permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder) will generally not be subject to U.S. withholding tax, provided such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder complies with certain certification and disclosure requirements (generally by providing an IRS Form <FONT STYLE="white-space:nowrap">W-8ECI).</FONT> Instead, such dividends generally will be
subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to U.S. Holders. If the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a corporation, dividends that are
effectively connected income may also be subject to a &#147;branch profits tax&#148; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income or withholding tax in respect of
gain recognized on a sale, taxable exchange or other taxable disposition of our Common Stock, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the conduct of a trade or business by the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is an individual who is present in the United States
for 183 days or more in the taxable year of disposition and certain other conditions are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are or have been a &#147;United States real property holding corporation&#148; for U.S. federal income tax
purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder held our Common Stock and, in the case where shares of our Common Stock
are regularly traded on an established securities market, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has owned, directly or constructively, more than 5% of our Common Stock at any time within the shorter of the five-year period
preceding the disposition or such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period for the shares of our Common Stock. There can be no assurance that our Common Stock will be treated as regularly traded on an established
securities market for this purpose. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will be subject to tax at generally
applicable U.S. federal income tax rates as if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder were a U.S. resident. Any gains described in the first bullet point above of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is
a foreign corporation may also be subject to an additional &#147;branch profits tax&#148; at a 30% rate (or lower applicable treaty rate). Gain described in the second bullet point above will generally be subject to a flat 30% U.S. federal income
tax. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the third bullet point above applies to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder and applicable exceptions are not
available, gain recognized by such holder on the sale, exchange or other disposition of our Common Stock will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our Common Stock from such holder may be
required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their tax advisors regarding the application of these rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_99"></A>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 1471 to 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred to
as the &#147;Foreign Account Tax Compliance Act&#148; or &#147;FATCA&#148;) a 30% withholding tax generally applies with respect to certain dividends in respect of and, subject to the proposed Treasury Regulations described below, gross proceeds
from a sale or disposition of, securities which are held by or through certain foreign financial institution (including investment funds), unless any such institution (a)&nbsp;enters </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain
U.S. persons and by certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (b)&nbsp;if required under an intergovernmental agreement between the
United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and the applicable foreign
country may modify these requirements. Accordingly, the entity through which our Common Stock are held will affect the determination of whether such withholding is required. Similarly, dividends in respect of, and (subject to the proposed Treasury
Regulations discussed below) gross proceeds from the sale or other disposition of, Common Stock held by an investor that is a <FONT STYLE="white-space:nowrap">non-financial</FONT> <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity that does not
qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either (i)&nbsp;certifies to the applicable withholding agent that such entity does not have any &#147;substantial United States
owners&#148; or (ii)&nbsp;provides certain information regarding the entity&#146;s &#147;substantial United States owners,&#148; which will in turn be provided to the U.S. Department of Treasury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends.
While withholding under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities (including Common Stock), proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds
entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult their tax advisors regarding the possible implications of FATCA on their investment in our Common
Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale or other disposition of
our shares of Common Stock. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding
requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well. Backup withholding is not an
additional tax. The amount of any backup withholding from a payment to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be allowed as a credit against such holder&#146;s U.S. federal income tax liability and may entitle such holder to
a refund, provided that the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX
MATTERS THAT MAY BE IMPORTANT TO YOU. EACH PROSPECTIVE PURCHASER OF OUR COMMON STOCK SHOULD CONSULT ITS TAX ADVISOR ABOUT THE TAX CONSEQUENCES OF AN INVESTMENT IN OUR COMMON STOCK BASED ON YOUR CIRCUMSTANCES. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_100"></A>DESCRIPTION OF OUR SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_101"></A>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following description summarizes the most important terms of our securities.<B> </B>The following summary does not purport to be complete and is subject to the Certificate of Incorporation, the Bylaws and the provisions of applicable law. A copy of
the Certificate of Incorporation and a copy of the Bylaws are attached as exhibits to the registration statement of which this prospectus forms a part. The stockholders are encouraged to read the applicable provisions of the DGCL, the Certificate of
Incorporation and the Bylaws in their entirety for a complete description of the rights and preferences of our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_102"></A>Authorized and Outstanding Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes the issuance of (i) 740,000,000 shares of Common Stock, $0.0001 par value per share and (ii)
45,000,000 shares of preferred stock, $0.0001 par value per share (the &#147;Preferred Stock&#148;), of which 29,057,097 shares have been designated as Series A Preferred Stock. As of March&nbsp;31, 2023, there were 145,811,298 shares of Common
Stock and 29,057,097 shares of Series&nbsp;A Preferred Stock issued and outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_103"></A>Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides the following with respect to the rights, powers, preferences and privileges of our Common Stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders
of our Common Stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by our Board upon the shares of our capital stock, which dividends may be paid either in cash, in property or in shares of our
capital stock, subject to preferences that may be applicable to preferred stock, if any, then outstanding. Subject to applicable law and the Certificate of Incorporation, our Board will have full power to determine whether any dividends shall be
declared and paid to stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our Common Stock will be entitled to one vote for each share of our Common Stock held of record by such holder on all matters on
which stockholders generally are entitled to vote, except for any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding classes or series of our Preferred Stock if the holders of such affected
classes or series are entitled, either separately or together with the holders of one or more other such classes or series, to vote thereon pursuant to the Certificate of Incorporation or the DGCL. Any action or matter presented to the stockholders
at a duly called or convened meeting, at which a quorum is present, will be decided by the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to
vote thereon, except that our directors will be elected by a plurality of the votes cast. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right to Receive Liquidation Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a liquidation, dissolution or winding up of the Company, the holders of our Common Stock will be entitled to share ratably in
all assets remaining after payment of liabilities, subject to prior distribution rights of our Preferred Stock, if any, then outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No
Preemptive or Similar Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock have no preemptive or conversion rights or other subscription rights. There are no
redemption or sinking fund provisions applicable to our Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and <FONT STYLE="white-space:nowrap">Non-Assessable</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding Vickers Ordinary Shares and the shares of our Common Stock issued in the Business Combination are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_104"></A>Our Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes our Board, subject to limitations prescribed by Delaware law, to issue up to 45,000,000 shares of
preferred stock in one or more series, to determine and fix from time to time the number of shares to be included in each such series and to fix the designations, powers, rights and preferences of the shares of each such series, and the
qualifications, limitations and restrictions thereof, including voting rights (if any), dividend rights, dissolution rights, conversion rights, exchange rights and redemption rights, in each case without further vote or action by our stockholders.
The number of authorized shares of our Common Stock and our Preferred Stock may be increased or decreased (but not below the number of the shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of our
outstanding stock entitled to vote thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred stock with voting or conversion rights that
could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other
things, have the effect of delaying, deferring or preventing a change in control and may adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. Other than the Series A Preferred
Stock issued to Sorrento in connection with the Closing of the Business Combination, there are no other Preferred Stock outstanding and we have no current plans to issue any other shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Number and Designation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed
the Certificate of Designations, designating 29,057,097 shares of our preferred stock as &#147;Series A Preferred Stock&#148;. As of the date of this prospectus, 29,057,097 shares of the Series A Preferred Stock have been issued to Sorrento pursuant
to the terms of the Merger Agreement and such shares have all of the rights, preferences and privileges set forth in the Certificate of Designations as more fully described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rank </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock
shall rank (i)&nbsp;senior to all of our Common Stock, and to all other classes or series of our capital stock, except for any such other class or series, the terms of which expressly provide that it ranks on parity with the Series A Preferred Stock
as to dividend rights and rights on liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company (&#147;Junior Securities&#148;); and (ii)&nbsp;on parity with each class or series of our capital stock, created
specifically ranking by its terms on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company (&#147;Parity Securities&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the
Series A Preferred Stock shall not be entitled to dividends unless we pay dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are
paid to holders of our Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Series A Preferred Stock into Common Stock and had held such shares of Common Stock on the record date
for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a change of control, liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, whether
voluntary or involuntary, before any payment or distribution of our property or assets (whether capital or surplus) shall be made to or set apart for the holders of Junior Securities, the holders of Series A Preferred Stock shall be entitled to
receive an amount per share of Series A Preferred Stock equal to the greater of (i)&nbsp;the sum of $10.00 (which amount shall be appropriately adjusted in the event of any stock split, stock combination or other similar recapitalization of the
Series A Preferred Stock) and all accrued and unpaid dividends and (ii)&nbsp;the amount such share of Series A Preferred Stock would be entitled to receive pursuant to the change of control, liquidation, dissolution or
<FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company assuming that such share had been converted into shares of Common Stock in a Deemed Conversion (as defined below). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion and Redemption Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Series A Preferred Stock will not be convertible into Common Stock or any of our other securities and will not be redeemable by
the Company; provided, however, a number of the rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designations will be determined based on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-Common</FONT></FONT></FONT> Stock basis or otherwise assume that the shares of Series A Preferred Stock are converted into shares of Common Stock. Accordingly, the number of
shares of Common Stock that each share of Series A Preferred Stock is deemed to be (or otherwise being treated as) converted into for the purpose of affecting the various rights, preferences and privileges of the Series A Preferred Stock set forth
in the Certificate of Designation (a &#147;Deemed Conversion&#148;), whether in connection with a change of control or otherwise, shall be equal to the result obtained by dividing (i)&nbsp;stated value by (ii) $10.00 (subject to anti-dilution
adjustments). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting and Other Preferred Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or as set forth in the Certificate of Designations, the holders of shares of Series A Preferred Stock will
be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Series A Preferred Stock will be
entitled to one vote for each share of Common Stock that such share of Series A Preferred Stock would otherwise be convertible into pursuant to a Deemed Conversion on the record date for the determination of the stockholders entitled to vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of at least a
majority of the outstanding shares of Series A Preferred Stock (a)&nbsp;change the Series A Preferred Stock (whether by merger, consolidation, reclassification or otherwise) into cash, securities or other property except in accordance with the terms
of the Certificate of Designations; (b)&nbsp;create, authorize or issue any Parity Security or other equity security the terms of which provide that it ranks senior to the Series A Preferred Stock with respect to dividend rights or rights upon
liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, or increase the authorized amount of any such other class or series; or (c)&nbsp;amend the Certificate of Incorporation or the Certificate of Designations
in any manner that adversely affects the holders of Series A Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Agreement with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns
any shares of New Scilex Series A Preferred Stock, among other things, (i)&nbsp;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#147;Stockholder
Designee&#148; and collectively, the &#147;Stockholder Designees&#148;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu
of meeting) or appointed by the Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Board, or the size of the Board and (ii)&nbsp;we will be required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to
be so nominated, elected or appointed to the Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the Board and the
right to appoint a representative of Sorrento to attend all meetings of the committees of the Board. Notwithstanding the foregoing, the parties have agreed to ensure that the Board complies with all applicable requirements of the stock exchange,
including independence requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provides that we will be prohibited from taking certain actions
without the consent of Sorrento. Such actions include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of the Board, the incurrence of certain amounts of indebtedness and the payment of dividends
on our Common Stock. For more information on the Stockholder Agreement, see the section of this prospectus titled &#147;<I>Certain Relationships and Related Party Transactions &#151; Certain Relationships of Vickers &#151; Stockholder Agreement with
Sorrento</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_105"></A>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the Closing of the Business Combination, certain of our
stockholders are able to demand that we register their registrable securities under certain circumstances and each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective
registration statement under the Securities Act covering the resale of all such registrable securities. We have filed the registration statement of which this prospectus forms a part in order to satisfy the foregoing obligations. The registration of
these securities will enable the public sale of such securities, subject to certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of common stock trading in
the public market may have an adverse effect on the market price of our securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_106"></A>Anti-Takeover Matters in our Governing
Documents and Under Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law, along with the Certificate of Incorporation and the Bylaws, all
of which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of the Company. These provisions are expected to discourage coercive takeover practices and inadequate takeover bids.
These provisions are also designed, in part, to encourage persons seeking to acquire control of the Company to first negotiate with our Board. However, these provisions could have the effect of delaying, discouraging or preventing attempts to
acquire the Company, which could deprive our stockholders of opportunities to sell their shares of our Common Stock at prices higher than prevailing market prices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Authorized but Unissued Capital Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorized but unissued shares of our Common Stock and our Preferred Stock are available for future issuance without stockholder approval,
subject to any limitations imposed by the rules of the Nasdaq Listing Rules. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and
unreserved Common Stock and Preferred Stock could make more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Certificate of Incorporation provides that our Board are divided into three classes, with the classes as nearly equal in number as practical and each class serving three-year staggered terms. The directors in each class serve for a three-year term
(except that the term of our current Class&nbsp;I directors shall expire at the first annual meeting of stockholders following the Closing of the Business Combination and the term of our current Class&nbsp;II
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors shall expire at the second annual meeting of stockholders following the Closing of the Business Combination), with one class being elected each year by the stockholders. This system of
electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of the Company, because it generally makes it more difficult for stockholders to replace a majority of the
directors. See the section of this prospectus titled &#147;<I>Management</I>&#148; for more information on the classified board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Certificate of Incorporation also provides that the total number of directors shall be determined from time to time exclusively by our Board; provided that, at any time prior to a Sorrento Trigger Event, the stockholders may also fix the number of
directors by resolution adopted by the stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors; Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, except as otherwise required by law or the Certificate of Incorporation, directors may be
removed with or without cause by the affirmative vote of the holders of a majority in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of such directors; provided, however, that, from and
after the Sorrento Trigger Event, any such director or all such directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock
entitled to vote thereon, voting together as a single class, in each case subject to the rights of holders of any series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, except as otherwise provided therein or by law, any vacancy resulting from the
death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, may be filled by a majority of the directors then in office, although less than a quorum, or by our stockholders; provided,
however, that from and after the Sorrento Trigger Event, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, shall be filled only by a majority
of the directors then in office, although less than a quorum, and shall not be filled by our stockholders, in each case subject to the rights of the holders of any series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of the Company or changes
in our management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that we will opt out of Section&nbsp;203 of the DGCL until the occurrence of a Sorrento Trigger
Event, at which time we shall immediately and automatically become governed by Section&nbsp;203 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL
prohibits persons deemed to be &#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date such persons become interested stockholders, unless
the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who,
together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a
merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our
Board, including discouraging attempts that might result in a premium over the market price for the shares of Common Stock held by stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that the restrictions on business combination of Section&nbsp;203 of the DGCL will not apply to
Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of the percentage of ownership of the total voting power of all the then-outstanding shares of our capital stock entitled to vote generally in
the election of directors beneficially owned by them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Cumulative Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative
voting. The Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our capital stock entitled to vote generally in the election of directors will be able to elect all of our
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special Stockholder Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that special meetings of stockholders may only be called by order of the Chairperson of our Board,
our Board or the Chief Executive Officer; provided, however, that at any time prior to the Sorrento Trigger Event, special meetings of our stockholders shall also be called by or at the direction of our Board or the Chairperson of our Board at the
request of Sorrento, in each case subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. The Bylaws prohibits the conduct of any business at a special meeting other than as specified in
the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Nominations and Stockholder Proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws establishes advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as
directors, other than nominations made by or at the direction of our Board or a committee of our Board. In order for any matter to be &#147;properly brought&#148; before a meeting, a stockholder will have to comply with advance notice requirements
and provide us with certain information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, to be timely, a stockholder&#146;s notice must be delivered to our secretary at our
principal executive offices not earlier than the close of business on the 120th day nor later than the close of business on the 90th day prior to the first anniversary of the preceding year&#146;s annual meeting (in the case of the first annual
meeting of stockholders held after January&nbsp;1, 2023, the date of the preceding year&#146;s annual meeting of the stockholders shall be deemed to be June&nbsp;30, 2022); provided, however, that, if the date of the annual meeting is advanced more
than 30 days prior to or delayed by more than 60 days after the anniversary of the preceding year&#146;s annual meeting, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier
than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting and the 10th day following the day on which public announcement of the date
of such meeting is first made by us. The Bylaws also specifies requirements as to the form and content of a stockholder&#146;s notice. The Bylaws allows any previously scheduled stockholders meeting to be postponed, adjourned or canceled by
resolution of our Board; provided, however, that with respect to any special meeting of stockholders scheduled at the request of Sorrento, our Board is not allowed to postpone, reschedule or cancel without the prior written consent of Sorrento. In
addition, the Bylaws allows the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations
are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to influence or obtain control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;228 of the DGCL and the terms of the Certificate of Incorporation, any action required or permitted to be taken by our
stockholders must be effected by a duly called annual or special meeting of such stockholders; provided, however, that prior to the Sorrento Trigger Event, any action required or permitted to be taken at any annual or special meeting of our
stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents, setting forth the action so taken, is signed by or on behalf of the holders of record of outstanding stock having not less than the
minimum number of votes that would be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted, is delivered to us in accordance with the DGCL, in each case subject
to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Certificate of
Incorporation or Bylaws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any
matter is required to amend a corporation&#146;s certificate of incorporation or bylaws, unless a corporation&#146;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, upon the occurrence of the Sorrento Trigger Event, the affirmative vote of the holders of at
least 66 2/3% of the voting power of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the following provisions of the Certificate of
Incorporation: Article V (Board of Directors), Article VI (Consent of Stockholders in Lieu of Meeting; Special Meetings of Stockholders), Article VII (Limitation of Liability), Article VIII (Corporate Opportunities and Competition), Article IX
(Exclusive Forum), Article X (Section 203 of the DGCL) and Article XI (Amendment of Certificate of Incorporation and Bylaws), and no other provision may be adopted, amended or repealed that would have the effect of modifying or permitting the
circumvention of the provisions set forth in any of such Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws provide that, our
Board is authorized to make, alter and repeal the Bylaws, without the consent or vote of the stockholders, by an approval of a majority of the total authorized number of directors. Upon the occurrence of the Sorrento Trigger Event, the affirmative
vote of the holders of at least 66 2/3% of the voting power of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the DGCL, the Certificate of Incorporation and the Bylaws could have the effect of discouraging others from attempting
hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing
changes in the composition of our Board and our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Forum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate
of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter
jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall, to the
fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of the Company, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our current or
former directors, officers, employees or stockholders to us or our stockholders, (iii)&nbsp;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of
the DGCL or of the Certificate of Incorporation or the Bylaws, (iv)&nbsp;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws, (v)&nbsp;any action or proceeding
asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi)&nbsp;any action asserting an
&#147;internal corporate claim,&#148; as that term is defined in Section&nbsp;115 of the DGCL. The foregoing exclusive forum provisions will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have
exclusive jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, unless we consent in writing to
the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe these provisions benefit us by providing increased consistency in the application of applicable law
in the types of lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#146; certificates of
incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations
thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in the Certificate of Incorporation to be inapplicable or unenforceable in such action. We may
incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our
capital stock shall be deemed to have notice of and consented to the forum provisions in the Certificate of Incorporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitation of Liability
and Indemnification of Directors and Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the
liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors,
except liability for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal
liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our
request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#147;Covered Person&#148;) and who is or was a party to,
is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#146;s actions
in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other
enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income
Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#146; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition,
the Bylaws provide that we may, to the fullest extent permitted by law, (i)&nbsp;advance costs, fees or expenses (including attorneys&#146; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final
disposition of such proceeding, subject to certain exceptions, and (ii)&nbsp;purchase and maintain insurance, at our expense, to protect us and any person who is or was a director, officer, employee or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent of the Company or is or was a director, officer, employee or agent of the Company serving at our request as a director, officer, employee or agent of another corporation, limited liability
company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under
the DGCL or the provisions of the Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors, executive officers
and certain other employees as determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification
agreements also require us to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. Our Board believes that these agreements are necessary to attract and retain qualified
individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of
Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers, be
insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and
indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of
derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#146;s investment may be adversely affected to the extent we pay the costs of
settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been
informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_107"></A>Conflicts of Interest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the
corporation or its officers, directors or stockholders. The Certificate of Incorporation provides that, to the fullest extent permitted by law, no Identified Person (as defined therein) will have any duty to refrain from (i)&nbsp;engaging in a
corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates or (ii)&nbsp;otherwise investing in or providing
services to any person that is engaged in the same or similar business activities as we or our affiliates or competes with us or our affiliates. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to
offer to us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us
or any of our affiliates. Subject to the preceding sentences and to the fullest extent permitted by applicable law, neither we nor any of our subsidiaries shall have any rights in any business interests, activities or ventures of any Identified
Person, and we waive and renounce any interest or expectancy therein, except with respect to opportunities offered solely and expressly to our officers in their capacity as such. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_108"></A>Rights of Appraisal and Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of the
Company. Pursuant to Section&nbsp;262 of the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined
by the Delaware Court of Chancery. However, appraisal rights are not available in all circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_109"></A>Stockholders&#146; Derivative Actions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any of our stockholders may bring an action in the Company&#146;s name to procure a judgment in its favor, also known as a
derivative action, provided that the stockholder bringing the action is a holder of our capital stock at the time of the transaction to which the action relates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_110"></A>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
the effective time of the Domestication, each warrant to purchase Vickers Ordinary Shares that was issued and outstanding immediately prior to the effective time of the Domestication and not terminated pursuant to its terms was converted into a
warrant to purchase shares of our Common Stock on the same terms and conditions as are in effect with respect to such warrant immediately prior to the effective time of the Domestication. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_111"></A>Public Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Public Warrant entitles the registered holder thereof to purchase one share of our Common Stock at a price of $11.50 per share, subject to
adjustment as described in this prospectus. We may, in our sole discretion, lower the warrant exercise price at any time prior to the expiration date for a period of not less than 20 business days and any such reduction will be applied consistently
to all of the warrants, provided that we will provide at least 20 days&#146; prior written notice to registered holders of the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, no Public Warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance
of the Common Stock issuable upon exercise of the warrants and a current prospectus relating to such Common Stock. Notwithstanding the foregoing, if a registration statement covering the issuance of the Common Stock issuable upon exercise of the
Public Warrants is not effective within 90 days from the consummation of the Business Combination, warrantholders may, from the 91st day after the consummation of the Business Combination until such time as there is an effective registration
statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from
registration is not available, holders will not be able to exercise their warrants on a cashless basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants will expire five
years from the consummation of the Business Combination (i.e., November&nbsp;10, 2027) at 5:00 p.m., New York City time or earlier upon redemption or liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may call the warrants for redemption (excluding the Private Placement Warrants), in whole and not in part, at a price of $0.01 per warrant:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time while the warrants are exercisable, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon not less than 30 days&#146; prior written notice of redemption to each warrantholder, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for share <FONT
STYLE="white-space:nowrap">sub-divisions,</FONT> share dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period commencing after the warrants become exercisable and ending on the third trading day
prior to the date on which notice of redemption is given, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, there is an effective registration statement covering the Common Stock issuable upon exercise of
the Public Warrants, and a current prospectus relating thereto, available throughout the <FONT STYLE="white-space:nowrap">30-day</FONT> redemption. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not exercise such redemption right if the issuance of the Common Stock upon exercise of the warrants is not exempt from registration or
qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. The right to exercise will be forfeited unless the warrants are exercised </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such
holder&#146;s warrant upon surrender of such warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption criteria for our warrants have been established at a price which is
intended to provide warrantholders a reasonable premium to the initial exercise price and provide a sufficient differential between the then-prevailing per share price of our Common Stock and the warrant exercise price so that if the per share price
of our Common Stock declines as a result of our redemption call, the redemption will not cause the per share price of our Common Stock to drop below the exercise price of the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we call the warrants for redemption as described above, our management will have the option to require all holders of warrants to exercise
their warrants on a &#147;cashless basis.&#148; In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&nbsp;the product of the
number of shares of Common Stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the fair market value by (y)&nbsp;the fair market value. The &#147;fair market value&#148; for this purpose shall
mean the average reported closing price of the shares of our Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. For example, if a holder held
150 warrants to purchase 150 shares of our Common Stock and the fair market value on the trading date prior to exercise was $15.00, that holder would receive 35 shares of our Common Stock without the payment of any additional cash consideration.
Whether we will exercise our option to require all holders to exercise their warrants on a &#147;cashless basis&#148; will depend on a variety of factors including the price of our Common Stock at the time the warrants are called for redemption, our
cash needs at such time and concerns regarding dilutive share issuances. Requiring a cashless exercise in this manner will reduce the number of shares of our Common Stock to be issued and thereby lessen the dilutive effect of a warrant redemption.
We believe this feature is an attractive option to use if we do not need the cash from the exercise of the Public Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants
are issued in registered form under a warrant agreement (the &#147;Warrant Agreement&#148;) between Continental, as warrant agent, and us. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder
to cure any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the registered holders of a majority of the then-outstanding warrants (including the Private Placement Warrants) in order to make any
change that adversely affects the interests of the registered holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price and number of shares of Common Stock issuable
on exercise of the warrants may be adjusted in certain circumstances including in the event of (i)&nbsp;a stock dividend or split up, (ii)&nbsp;a consolidation, combination, reverse stock split or reclassification of the Common Stock,
(iii)&nbsp;extraordinary dividend or (iv)&nbsp;reclassification or reorganization of the outstanding Common Stock or an merger or consolidation of us with or into another corporation. However, the warrants will not be adjusted for issuances of
shares of Common Stock at a price below the par value per share issuable upon exercise of the warrants. Whenever the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, the warrant exercise price will be
adjusted by multiplying such warrant exercise price immediately prior to such adjustment by a fraction (x)&nbsp;the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to
such adjustment, and (y)&nbsp;the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant
agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified check or bank draft payable to
the order of the warrant agent or wire transfer, for the number of warrants being exercised. The warrantholders do not have the rights or privileges of holders of shares of Common Stock and any voting rights until they exercise their warrants and
receive shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
After the issuance of shares of Common Stock upon exercise of the warrants, each holder will be entitled to one vote for each share of Common Stock held of record on all matters to be voted on by
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, no Public Warrants will be exercisable for cash and we will not be obligated to issue shares of
Common Stock upon exercise of a warrant unless the shares of Common Stock issuable upon such warrant exercise have been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the
warrants. Under the terms of the Warrant Agreement, we have agreed to use our best efforts to meet these conditions and to maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants until the expiration of the
warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants, holders will be unable to exercise their warrants and we will
not be required to settle any such warrant exercise. If the prospectus relating to the Common Stock issuable upon the exercise of the warrants is not current or if the Common Stock is not qualified or exempt from qualification in the jurisdictions
in which the holders of the warrants reside, we will not be required to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and the warrants may expire worthless. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrantholders may elect to be subject to a restriction on the exercise of their warrants such that an electing warrantholder would not be
able to exercise their warrants to the extent that, after giving effect to such exercise, such holder (together with such holder&#146;s affiliates) would beneficially own in excess of 9.8% of the Common Stock outstanding immediately after giving
effect to such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder
would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number of shares of Common Stock to be issued to the warrantholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Private Placement Warrants are identical to the Public Warrants except that such Private Placement Warrants are exercisable for cash (even if a registration statement covering the issuance of the Common Stock issuable upon exercise of such warrants
is not effective) or on a cashless basis, at the holder&#146;s option, and will not be redeemable by us, in each case so long as they are still held by the initial purchasers or their affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the warrants does not purport to be complete and is qualified in its entirety by
reference to the copy of the Warrant Agreement that is filed as an exhibit to the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_112">
</A>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock is Continental. The transfer agent&#146;s
address is 1 State Street, 30th Floor, New York, New York 10004. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx454025_113"></A>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our Common Stock and Public Warrants are listed on Nasdaq under the symbols &#147;SCLX&#148; and &#147;SCLXW&#148; respectively. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_114"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered by this prospectus will be passed upon for us by Paul Hastings LLP, Palo Alto, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_115"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Scilex Holding Company at December&nbsp;31, 2022 and 2021, and for each of the three years in the
period ended December&nbsp;31, 2022, appearing in this prospectus, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph
describing conditions that raise substantial doubt about the Company&#146;s ability to continue as a going concern as described in Note 2 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such
report given on the authority of such firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_116"></A>WHERE YOU CAN FIND MORE
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> including exhibits, under the
Securities Act, with respect to the securities offered by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our securities, you should refer
to the registration statement of which this prospects is a part and the exhibits to such registration statement. The descriptions in this prospectus of the provisions of documents filed as exhibits to this prospectus are only summaries of those
documents&#146; material terms. You can read copies of such documents, along with copies of reports, proxy statements and other information filed by us with the SEC at the SEC&#146;s website at<I> http://www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.scilexholding.com. Through our website, we make available, free of charge, annual, quarterly and current
reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is
not incorporated into, this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx454025_117"></A><A NAME="index"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin454025_1">Report of Independent Registered Public Accounting Firm (PCAOB ID:
42)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin454025_2">Consolidated Balance Sheets as of December&nbsp;31, 2022 and
2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin454025_3">Consolidated Statements of Operations for the Years Ended December&nbsp;
31, 2022, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin454025_4">Consolidated Statements of Stockholders&#146; Equity / (Deficit) for the Years
 Ended December&nbsp;31, 2022, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin454025_5">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2022, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin454025_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin454025_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the stockholders and the Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex
Holding Company </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Scilex Holding Company (the Company) as of December&nbsp;31, 2022 and 2021, the related
consolidated statements of operations, stockholders&#146; equity/(deficit) and cash flows for each of the three years in the period ended December&nbsp;31, 2022, and the related notes (collectively referred to as the &#147;consolidated financial
statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2022 and 2021, and the results of its operations and its cash flows for
each of the three years in the period ended December&nbsp;31, 2022, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The
Company&#146;s Ability to Continue as a Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company
will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has negative working capital, has suffered losses from operations, has recurring negative cash flows from operations, and has stated that substantial
doubt exists about the Company&#146;s ability to continue as a going concern. Management&#146;s evaluation of the events and conditions and management&#146;s plans regarding these matters are also described in Note 2. The consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of
expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test
basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San
Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;7, 2023 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin454025_2"></A>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS OF DECEMBER&nbsp;31, 2022 AND 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except for par value and share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY/(DEFICIT)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued rebates and fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term portion of deferred consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and contingencies (See Note 10)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; equity/(deficit):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value, 45,000,000 shares authorized; 29,057,097 and 0 issued and
outstanding at December&nbsp;31, 2022 and December&nbsp;31, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 740,000,000 shares authorized; 141,348,856 and 132,858,484 shares
issued and outstanding at December&nbsp;31, 2022 and December&nbsp;31, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(375,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(352,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity/(deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(223,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and stockholders&#146; equity/(deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin454025_3"></A>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2022, 2021, AND 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except for net loss per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating costs and expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating costs and expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other (income) expense:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other (income) expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares during the period&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin454025_4"></A>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY / (DEFICIT) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2022, 2021, AND 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;Legacy&nbsp;Common&nbsp;Stock&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(216,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(90,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Retroactive application of the recapitalization due to the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2019, after the effect of Business Combination</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(216,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Distribution to Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cancellation of shares held in escrow related to Semnur Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Adjustment to shares issued in Semnur Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(352,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(223,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Aardvark <FONT STYLE="white-space:nowrap">SP-104</FONT> license transfer from Sorrento, net of
discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Aardvark <FONT STYLE="white-space:nowrap">SP-104</FONT> discount amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued pursuant to the terms of the Debt Exchange Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued as a result of the Business Combination, net of transaction activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">412,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(375,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin454025_5"></A>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2022, 2021, AND 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used for operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Amortization of debt issuance costs and debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt
discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,866</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(Gain) loss on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Forfeitures of Private Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts receivables, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,066</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued rebates and fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash used for operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acquisition consideration paid in cash for Romeg intangible asset acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash used for investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction costs paid related to the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayment of principal on the Scilex Pharma Notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayment on other loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from other loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net change in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash and cash equivalents at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash and cash equivalents at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Supplemental disclosures:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Related party debt converted to equity pursuant to Debt Exchange Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred consideration for Romeg intangible asset acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> consideration in Semnur acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other loan forgiveness</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Promissory Note issued to Sorrento in exchange for the
<FONT STYLE="white-space:nowrap">SP-104</FONT> license, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Fair value adjustment to derivative liability in troubled debt restructuring</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acquisition of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of shares to Yorkville pursuant to Yorkville Purchase Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> distribution to Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrual for transaction costs related to the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction costs obligation assumed by Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin454025_6"></A>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of Operations and Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Organization and Principal Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding
Company (&#147;Scilex&#148; and together with its wholly owned subsidiaries, the &#147;Company&#148;) is the successor entity to Vickers Vantage Corp. I (&#147;Vickers&#148;). Vickers was formed on February&nbsp;21, 2020 as a Cayman Islands exempted
company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Scilex was originally formed in 2019 and is a majority-owned
subsidiary of Sorrento Therapeutics, Inc. (&#147;Sorrento&#148;). Scilex has two wholly owned subsidiaries, Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;) and Semnur Pharmaceuticals, Inc. (&#147;Semnur&#148;). The Company is a commercial
biopharmaceutical company focused on acquiring, developing and commercializing <FONT STYLE="white-space:nowrap">non-opioid</FONT> management products for the treatment of acute and chronic pain. The Company launched its first commercial product in
October 2018, ZTlido (lidocaine topical system) 1.8% (&#147;ZTlido&#148;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing
significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. The Company <FONT STYLE="white-space:nowrap">in-licensed</FONT> the exclusive right to commercialize
GLOPERBA (colchicine USP) oral solution, an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The
Company is currently developing three product candidates, <FONT STYLE="white-space:nowrap">SP-102</FONT> (10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural
injections to treat lumbosacral radicular pain, or sciatica <FONT STYLE="white-space:nowrap">(&#147;SP-102&#148;</FONT> or &#147;SEMDEXA&#148;), <FONT STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4% <FONT
STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> for the treatment of acute low back pain, and <FONT STYLE="white-space:nowrap">SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release
capsules) <FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;),</FONT> a novel formulation for the treatment of fibromyalgia. Since inception, the Company has devoted substantially all of its efforts to the development of <FONT
STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103,</FONT> <FONT STYLE="white-space:nowrap">SP-104,</FONT> and the commercialization of ZTlido. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Business Combination</B><I> </I><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;17, 2022, Scilex entered into an Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) with Vickers and Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#147;Vickers Merger Sub&#148;). Pursuant to the terms of
the Merger Agreement, Vickers Merger Sub merged with and into Scilex, Inc. (f/k/a Scilex Holding Company and now a wholly owned subsidiary of Scilex) (&#147;Legacy Scilex&#148;), with Legacy Scilex surviving the merger and becoming a wholly-owned
subsidiary of Vickers (collectively, the &#147;Business Combination&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, Vickers consummated the Business Combination
pursuant to the terms of the Merger Agreement. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, Scilex received net proceeds of approximately $3.4&nbsp;million. Additionally, all
existing related party indebtedness between Legacy Scilex and Sorrento totaling $290.6&nbsp;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt
Exchange Agreement (see Note 12). The Company, as the successor entity of Vickers, will operate as &#147;Scilex Holding Company&#148; and was listed on the Nasdaq Capital Market under the new ticker symbol &#147;SCLX&#148; on November&nbsp;11, 2022.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the closing of the Business Combination, 197,566,338 and 25,151,428 shares of Legacy Scilex Common Stock (&#147;Legacy Scilex Common Stock&#148;) and
Legacy Scilex stock options, respectively, were converted to 133,060,534 shares of Common Stock (&#147;Common Stock&#148;) as part of the consideration using the 0.673498:1 ratio of the Company Common Stock to Legacy Scilex Common Stock (the
&#147;Common Stock Exchange Ratio&#148;) and 16,939,436 shares of Common Stock were reserved for Legacy Scilex optionholders. Pursuant to the terms of the Debt Exchange Agreement (see Note 12), $290.6&nbsp;million was converted to 29,057,097 shares
of Preferred Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(&#147;Preferred Stock&#148;) and 2,905,710 shares of Common Stock. In addition, pursuant to the terms of the debt agreement entered between the Vickers Venture Fund VI Pte Ltd, Vickers Venture
Fund VI (Plan) Pte Ltd (&#147;Sponsors&#148;) and Vickers (&#147;Vickers Debt Agreement&#148;), the aggregate amount of loans that the Sponsors funded Vickers to finance the transaction costs (&#147;Working Capital Loans&#148;) at the closing of the
Business Combination of $5,330,557 was converted to 533,057 shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse
recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers was treated as the &#147;acquired&#148; company for accounting purposes and the Business Combination was treated as the equivalent of the Company issuing stock
for the net assets of Vickers, accompanied by a recapitalization. Upon the closing of the Business Combination, the net assets of Vickers were recorded at historical cost, with no goodwill or other intangible assets recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s legal, accounting and other fees directly attributable to the Business Combination were initially capitalized within prepaid expenses and
other current assets on the consolidated balance sheets, of which $9.1&nbsp;million has been offset against the equity proceeds in the Business Combination and $0.4&nbsp;million was attributed to the liability-classified Private Warrants and, as
such, were expensed upon the closing of the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis of Presentation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#147;U.S. GAAP&#148;) and include all adjustments necessary for the fair presentation of the Company&#146;s financial position for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and
transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these
estimates are reasonable; however, actual results may differ from these estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes
its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any
losses on such accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and
liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2: Quoted prices for similar instruments that are directly or indirectly observable in the
marketplace. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3: Significant unobservable inputs which are supported by little or no market activity and that are
financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to
the fair value measurement. The Company&#146;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of
different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of
the instruments could realize in a current market exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and 2021, the carrying amount of cash equivalents approximates
their fair value based upon quoted market prices. Certain of the Company&#146;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or
short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables
from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts
receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by
reducing the allowance for expected credit losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines inventory cost on a <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out</FONT> basis. The
Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical
experience, sales trends, and specific categories of inventory and expiration dates for <FONT STYLE="white-space:nowrap">on-hand</FONT> inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in
which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#146;s judgment, the Company capitalizes <FONT STYLE="white-space:nowrap">pre-launch</FONT>
inventory costs prior to regulatory approval. As of December&nbsp;31, 2022 and 2021, the Company&#146;s inventory was primarily comprised of finished goods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and
equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold
improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisitions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for business
combinations using the acquisition method of accounting, which requires that assets acquired, including <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (&#147;IPR&amp;D&#148;) projects and liabilities assumed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as
goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the
measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the
transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not
recognized at the acquisition date. In an asset acquisition, <FONT STYLE="white-space:nowrap">up-front</FONT> payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s
consolidated statements of operations unless there is an alternative future use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has acquired and may continue to acquire the rights to
develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and
development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently
as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill and Other Long-Lived
Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for
impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors
to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market
considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than
its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to
perform the quantitative goodwill impairment test. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived and intangible assets with definite lives, such as property and
equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <FONT STYLE="white-space:nowrap">non-generic</FONT> and generic
competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is
measured by comparison of the assets&#146; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an
impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingent Consideration
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of
the acquisition, and is determined using a discounted cash flow model or Monte&nbsp;Carlo simulation model. The significant inputs of such models are not observable in the market, such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent
consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance
with Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 480, <I>Distinguishing Liabilities from Equity,</I> and Topic 815, <I>Derivatives and Hedging</I>, contingent consideration
arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public Warrants and Private Placement
Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Business Combination, the Company assumed public and private placement warrants (&#147;Public Warrants&#148; and
&#147;Private Warrants&#148;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#147;SEC&#148;) on January&nbsp;11, 2021) whereby holders of the public and
private placement warrants are entitled to acquire ordinary shares of Vickers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Business Combination, the Public Warrants were accounted
for as equity per FASB ASC Subtopic <FONT STYLE="white-space:nowrap">No.&nbsp;815-40,</FONT> <I>Contracts on an Entity&#146;s Own Equity</I>. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at
each subsequent balance sheet date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic <FONT
STYLE="white-space:nowrap">815-40.</FONT> The Private Warrants are not considered indexed to the Company&#146;s stock per ASC Subtopic <FONT STYLE="white-space:nowrap">815-40</FONT> as the fair value calculation applicable upon a cashless exercise
of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fixed-for-fixed</FONT></FONT> option contract. Therefore,
Private Warrants are recognized as derivative liabilities at their estimated fair value on November&nbsp;10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet date, with fair value changes
recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future
net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Liabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative liabilities are
recorded on the Company&#146;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting
periods recorded as other income or expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research
and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs. Nonrefundable advance payments for goods and
services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, <I>Research and
Development.</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions
of the FASB ASC Topic 740, <I>Income Taxes</I>,<I> </I>addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subtopic <FONT STYLE="white-space:nowrap">740-10,</FONT> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be
sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the
related financial amounts, using currently enacted tax rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has deferred tax assets, which are subject to periodic recoverability
assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&nbsp;31, 2022 and 2021, the Company maintained a full valuation allowance
against its deferred tax assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company determines if an arrangement is a lease at inception. Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets and liabilities are recognized at the commencement
date based on the present value of lease payments over the lease term. As the Company&#146;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining
the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#146;s lease terms may include options to extend or terminate the lease when it is reasonably
certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s revenue is
generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#146;s performance obligation with respect to sales of ZTlido is satisfied at a
point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been
transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing
and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&nbsp;31, 2022 and 2021 were not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor
fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#146;s customer
contract, customary industry practices and current government regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rebates and Chargebacks </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug
rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access
to and position on that provider&#146;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with
commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and
chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#146;s consolidated balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prompt Payment Discounts </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides its
customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual
gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Service Fees </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company compensates its customer and
others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#146;s sale of products to the customer and, therefore, these payments have been
recorded as a reduction of revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product Returns </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company
may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer
and record this estimate as a reduction of revenue in the period the related product revenue is recognized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Co-Payment</FONT> Assistance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <FONT STYLE="white-space:nowrap">co-payment</FONT>
assistance. The Company accrues for <FONT STYLE="white-space:nowrap">co-payment</FONT> assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Customer Concentration Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to
April&nbsp;2, 2022, sales to the Company&#146;s sole distributor represented 100% of net revenue. On April&nbsp;2, 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The
distributor continued to provide traditional third-party logistics functions for the Company. The Company had four customers during the year ended December&nbsp;31, 2022, which individually generated 10% or more of the Company&#146;s total revenue.
These customers accounted for 83% of the Company&#146;s revenue for the year ended December&nbsp;31, 2022, individually ranging between 19% to 24%. As of December&nbsp;31, 2022, these customers represented 90% of the Company&#146;s outstanding
accounts receivable, individually ranging between 24% to 36%. Additionally, during the fiscal years ended December&nbsp;31, 2022 and 2021, the Company purchased inventory from its sole supplier, Itochu. This exposes the Company to concentration of
customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the years ended December&nbsp;31, 2022, 2021, and 2020.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
accounts for stock-based compensation in accordance with FASB ASC Topic 718, <I>Compensation&#151;Stock Compensation</I> which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions,
stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#146;s requisite service period (generally the vesting
period of the equity grant) or <FONT STYLE="white-space:nowrap">non-employee&#146;s</FONT> vesting period. The Company accounts for forfeitures as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company
determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the
Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option
pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as
components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its
chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily
in the development of <FONT STYLE="white-space:nowrap">non-opioid</FONT> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates
its business as a single reportable segment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the <FONT STYLE="white-space:nowrap">two-class</FONT>
method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, basic net loss per share attributable to common stockholders is computed by dividing the
net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially
dilutive impact of stock options and warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company has reported losses for all periods presented, all potentially dilutive securities are
antidilutive and accordingly, basic net loss per share equals diluted net loss per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, the FASB issued ASU <FONT STYLE="white-space:nowrap">2021-08,</FONT> <I>Business Combinations (Topic 805): Accounting for Contract Assets and
Contract Liabilities from Contracts with Customers</I>, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU
<FONT STYLE="white-space:nowrap">2021-08</FONT> is effective for fiscal years beginning after December&nbsp;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Liquidity and Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management
has assessed the Company&#146;s ability to continue as a going concern for at least one year after the date the financial statements are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, Scilex acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note&nbsp;3). The Company anticipates the cash needed for the development of Semnur&#146;s primary product candidate in development, <FONT
STYLE="white-space:nowrap">SP-102,</FONT> as well in the development of <FONT STYLE="white-space:nowrap">SP-103,</FONT> will be in excess of the Company&#146;s cash available </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and
commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets (see Note 3). <FONT STYLE="white-space:nowrap">SP-104</FONT> has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be
responsible for funding all development and commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, the Company entered into a license and commercialization
agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates incurring costs
related to the commercial launch and marketing of GLOPERBA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Scilex and Scilex Pharma entered into a Debt Exchange Agreement
(see Note 12) with Sorrento, pursuant to which all related party indebtedness that remained outstanding as of immediately prior to the closing of the Business Combination was converted into equity interests in the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2022, the Company exercised the Early Paydown Provision (see Note 7) to fully extinguish the Scilex Pharma Notes (see Note 7). In August 2022 and
September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $41.4&nbsp;million. Pursuant to Amendment No.&nbsp;4 (see Note 7), a principal balance of $28.0&nbsp;million was forgiven by the Scilex Pharma
Note Purchasers (see Note 7) upon the Company&#146;s exercise of the Early Paydown Provision. The Company funded the principal payments with <FONT STYLE="white-space:nowrap">cash-on</FONT> hand and $34.0&nbsp;million received from Sorrento on
September&nbsp;28, 2022 (see Note 7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Company&#146;s negative working capital was $15.2&nbsp;million, including cash
and cash equivalents of approximately $2.2&nbsp;million. During the year ended December&nbsp;31, 2022, the Company had operating losses of $50.6&nbsp;million and cash flows used for operations of $21.3&nbsp;million. The Company had an accumulated
deficit of approximately $375.9&nbsp;million as of December&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has plans to obtain additional resources to fund its currently
planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic
transactions. The Company entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. (&#147;Yorkville&#148;) on November&nbsp;17, 2022 (as amended and restated on February&nbsp;8, 2023), and a Standby Equity Purchase Agreement with B.
Riley Principal Capital II, LLC (&#147;B. Riley&#148;) on January&nbsp;8, 2023 whereby the Company has the right, but not the obligation, to sell to Yorkville and B. Riley up to $500.0&nbsp;million each of shares of its Common Stock at its request
any time during the 36 months following the date on which the registration statement related to each such purchase agreement has been declared effected by the SEC, subject to certain conditions (see Note 8 and Note 14). The Company&#146;s plans are
also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#146;s marketing of ZTlido. Should the Company&#146;s sales of
ZTlido not materialize at the expected rate contemplated in the Company&#146;s business plan, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other factors, the Company believes that there are a number of ongoing and
potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical
development programs for <FONT STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103,</FONT> and <FONT STYLE="white-space:nowrap">SP-104,</FONT> and other discretionary costs. Although the Company believes such plans, if
executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#146;s control. As such, management cannot conclude that such plans will be effectively
implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#146;s
ability to continue as a going concern for one year after the date the financial statements are issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Acquisitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2022, the Company entered into a bill of sale and assignment and assumption agreement (the &#147;Bill of Sale&#148;), with Sorrento. Pursuant
to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#146;s Delayed Burst Release Low Dose Naltrexone
<FONT STYLE="white-space:nowrap">(&#147;DBR-LDN&#148;)</FONT> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the
<FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Assets&#148;). These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#147;Aardvark&#148;) in April 2021 pursuant to an asset purchase agreement (the
&#147;Aardvark Asset Purchase Agreement&#148;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#146;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the
<FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Acquisition&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the <FONT STYLE="white-space:nowrap">SP-104</FONT>
Acquisition, the Company issued a promissory note in the aggregate principal amount of $5.0&nbsp;million to Sorrento (the &#147;2022 Promissory Note&#148;). Upon issuance of the note, the Company recorded a related party note payable of
$4.1&nbsp;million, net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The 2022 Promissory Note matures seven years from the date of issuance and bears interest at
the rate equal to the lesser of (a) 2.66% simple interest per annum and (b)&nbsp;the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company&#146;s common stock or any combination thereof, at the
Company&#146;s sole discretion, and may be prepaid in whole or in part at any time without penalty. On November&nbsp;10, 2022, the 2022 Promissory Note was converted to equity, pursuant to the terms of the Debt Exchange Agreement (See Note 12). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new
drug application for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (which amount may be paid in shares of the Company&#146;s common stock or cash, in the Company&#146;s sole discretion) (the &#147;Development Milestone Payment&#148;) and
(ii) $20,000,000, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (the &#147;Sales Milestone Payment&#148;). The Company will also pay Aardvark
certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets. The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic 815, <I>Derivatives and Hedging</I>, and will not be
recognized until the contingencies are realized in accordance with the Company&#146;s accounting policy for contingent consideration in an asset acquisition. The Development Milestone Payment represents a liability within the scope of ASC Topic 480,
<I>Distinguishing Liabilities from Equity</I>, which will be measured at fair value each reporting period. As of December&nbsp;31, 2022, the contingent consideration of $0.2&nbsp;million associated with Development Milestones Payment was recognized
under other long-term liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GLOPERBA License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, the Company entered into a license agreement (the &#147;Romeg License Agreement&#148;) with RxOmeg Therapeutics, LLC (a/k/a Romeg
Therapeutics, Inc.) (&#147;Romeg&#148;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (1)&nbsp;a transferable license, with the right to sublicense, under the patents and
<FONT STYLE="white-space:nowrap">know-how</FONT> specified therein (with such license to <FONT STYLE="white-space:nowrap">know-how</FONT> being exclusive for the limited purposes specified therein) to (i)&nbsp;commercialize the pharmaceutical
product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#147;Initial Licensed Product&#148; or &#147;GLOPERBA&#148;) in the United States of America (including its territories) (the
&#147;Territory&#148;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#147;Licensed Products&#148;) and commercialize any such products and (iii)&nbsp;manufacture Licensed Products
anywhere in the world, solely for commercialization in the Territory; and (2)&nbsp;an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection
with the commercialization of the Initial Licensed Product solely in the Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg License Agreement, the Company paid Romeg an <FONT
STYLE="white-space:nowrap">up-front</FONT> license fee of $2.0&nbsp;million, and has agreed to pay Romeg (a)&nbsp;upon the Company&#146;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to
$13.0&nbsp;million, (b)&nbsp;certain royalties in the <FONT STYLE="white-space:nowrap">mid-single</FONT> digit to <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentages based on annual net sales of the Licensed Product by the Company
during the applicable royalty term under the Romeg License Agreement, and (c)&nbsp;minimum quarterly royalty payments totaling $7.1&nbsp;million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending
on the later of (i)&nbsp;expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii)&nbsp;the tenth anniversary of the effective date of the Romeg License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is
the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $5.7&nbsp;million, which is comprised of the upfront license fee of $2.0&nbsp;million and a deferred
consideration of $3.7&nbsp;million that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent sales milestones and sale volume-based future royalties were determined to meet a scope exception
for derivative under ASC Topic 815, and will not be recognized until the contingencies are realized. No contingent consideration was recognized as a liability or included in the fair value of the assets as of December&nbsp;31, 2022. The Company
determined the useful life of the intangible asset to be 15 years, which approximates the life of the licensed patents covering the Initial Licensed Product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents
the Company&#146;s financial assets and liabilities that are measured at fair value (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value measurements at December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted</B><br><B>Prices<BR>in&nbsp;Active<BR>Markets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs&nbsp;(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs&nbsp;(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;1,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;1,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value measurements at December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices<BR>in&nbsp;Active<BR>Markets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs&nbsp;(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs&nbsp;(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash and cash equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market
accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Derivative liabilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded a gain of
$8.3&nbsp;million, loss of $0.3&nbsp;million, and gain of $0.8&nbsp;million on derivative liabilities for the years ended December&nbsp;31, 2022, 2021, and 2020, respectively, which was attributed to compound derivative liabilities associated with
the Scilex Pharma Notes (see Note 7) and Private Warrants. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $30.4&nbsp;million immediately after entry into Amendment No.&nbsp;4 (see Note 7) associated
with the Scilex Pharma Notes on June&nbsp;2, 2022. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including
consideration of the terms of Amendment No.&nbsp;4. Significant Level&nbsp;3 assumptions used in the measurement included a 6.1% risk adjusted net sales forecast and an effective debt yield of 21.5%. The Scilex Pharma Notes were fully extinguished
in September 2022 (see Note 7) and, as such, there were no remaining loan derivative liabilities associated with the Scilex Pharma Notes as of December&nbsp;31, 2022. At the closing of the Business Combination, the Company assumed a derivative
warrant liability of $2.5&nbsp;million related to Private Warrants (See Note 8). The fair value of derivative warrant liability related to Private Warrants was $1.2&nbsp;million as of December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the year
ended December&nbsp;31, 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Re-measurement</FONT> of fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Re-measurement</FONT> of fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private Warrant liability acquired as part of the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeiture of Private Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value measurement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrant Liability Measurement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level&nbsp;3 fair value measurement. The
primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are
publicly available as well as the implied volatility of the Public Warrants. A summary of the inputs used in valuing the derivative warrant liabilities is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>November&nbsp;10,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.94</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Call option value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contingent Consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Development Milestone Payment represents a liability under the scope of ASC Topic 480, <I>Distinguishing Liabilities from Equity</I>, as it pertains to a
potential contractual obligation to settle a fixed value in a variable number of shares of Common Stock. Upon the achievement of FDA approval for a new drug application for <FONT STYLE="white-space:nowrap">SP-104,</FONT> the Company will transfer
$3.0&nbsp;million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with Development Milestone Payment was estimated using a probability-weighted discounted cash
flow method. Significant Level&nbsp;3 assumptions included the likelihood of receiving FDA approval for <FONT STYLE="white-space:nowrap">SP-104,</FONT> expected timing for receipt of FDA approval for <FONT STYLE="white-space:nowrap">SP-104,</FONT>
and a discount rate of 10.0%. As of December&nbsp;31, 2022, the fair value of contingent consideration related to the Development Milestone Payment was $0.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no transfers between fair value measurement levels during the years ended December&nbsp;31, 2022, 2021, and 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Property and Equipment, Net </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment
consisted of the following as of December&nbsp;31, 2022 and 2021 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense for each of the years ended December&nbsp;31, 2022, 2021, and 2020 was $40&nbsp;thousand,
$39&nbsp;thousand, and $40&nbsp;thousand, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Goodwill and Intangible Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and December&nbsp;31, 2021, the Company had recorded goodwill of $13.5&nbsp;million. The Company performed a qualitative test for
goodwill impairment during the fourth quarter of 2022. Based upon the results of the qualitative testing, the Company concluded that it is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that the fair value of the Company&#146;s
goodwill was in excess of the carrying value and therefore performing the first step of the <FONT STYLE="white-space:nowrap">two-step</FONT> impairment test was unnecessary. The conclusion has not changed as of December&nbsp;31, 2022 and no goodwill
impairment was recognized for the years ended December&nbsp;31, 2022 and 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s intangible assets, excluding goodwill, are composed of
patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. A summary of the
Company&#146;s identifiable intangible assets as of December&nbsp;31, 2022 and December&nbsp;31, 2021 is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;carrying&nbsp;amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Intangibles,&nbsp;net</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired licenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;carrying&nbsp;amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Intangibles,&nbsp;net</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from
Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of $5.7&nbsp;million was assigned to acquired licenses with an amortization period of approximately 15
years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the weighted average remaining life for identifiable intangible assets was 10.4 years. Aggregate amortization
expense was $3.9&nbsp;million, $3.7&nbsp;million, and $3.7&nbsp;million for the years ended December&nbsp;31, 2022, 2021, and 2020, respectively. Patent rights and acquired technology are amortized over a
<FONT STYLE="white-space:nowrap">15-year</FONT> period. Assembled workforce is amortized over a <FONT STYLE="white-space:nowrap">5-year</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimated future amortization expense related to intangible assets at December&nbsp;31, 2022 is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Debt </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Purchase Agreements and Indenture </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
September&nbsp;7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#147;2018 Purchase Agreements&#148;) with certain investors (collectively, the &#147;Scilex Pharma Note Purchasers&#148;). Pursuant to the 2018 Purchase
Agreements, on September&nbsp;7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due 2026 in an aggregate principal amount of $224.0&nbsp;million (the &#147;Scilex Pharma
Notes&#148;) for an aggregate purchase price of $140.0&nbsp;million (the &#147;Offering&#148;). The Scilex Pharma Notes were governed by an indenture (as amended, the &#147;Indenture&#148;) with Scilex Pharma, as issuer, U.S. Bank National
Association, a national banking association, as trustee (the &#147;Trustee&#148;) and collateral agent (the &#147;Collateral Agent&#148;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally
guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#147;Guarantee&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal amount of the Scilex Pharma Notes increased by $28.0&nbsp;million on February&nbsp;15, 2022 as a result of actual cumulative net sales of ZTlido
from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 not equal or exceeding $481.0&nbsp;million. As a result, the Company recorded the increase of $28.0&nbsp;million in principal and
<FONT STYLE="white-space:nowrap">non-operating</FONT> expense at December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;14, 2022, Scilex Pharma issued to
Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 were less than a specified
sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan and Scilex Pharma became
subject to a minimum cash requirement of $10.0&nbsp;million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $20.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No.&nbsp;4 to Indenture (the &#147;Amendment No.&nbsp;4&#148;)
with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment No.&nbsp;4, (1) on June&nbsp;3, 2022, Scilex Pharma repurchased approximately
$41.4&nbsp;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2)&nbsp;the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the
Scilex Pharma Notes at any time on or before September&nbsp;30, 2022 for $41.4&nbsp;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge $28.0&nbsp;million
of the aggregate principal amount of the Scilex Pharma Notes (the &#147;Early Paydown Provision&#148;), (3) the minimum cash requirement under the Indenture was reduced to $5.0&nbsp;million in aggregate unrestricted cash equivalents at the end of
each calendar month, and (4)&nbsp;the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to Sorrento on October&nbsp;5, 2018 was increased from up to $25.0&nbsp;million to up to $50.0&nbsp;million. The Company funded
the repurchase with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> and $15.0&nbsp;million received from Sorrento on June&nbsp;2, 2022. The Company concluded that the Amendment No.&nbsp;4 was a troubled
debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No.&nbsp;4, and accordingly, no gain
was recognized in the quarter ended June&nbsp;30, 2022. Due to a decrease of $30.4&nbsp;million in the fair value of the Scilex Notes Derivative caused by the Amendment No.&nbsp;4, the carrying value of the Scilex Notes was increased by
$30.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes. In August and
September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $1.7&nbsp;million and $39.7&nbsp;million, respectively. Pursuant to Amendment No.&nbsp;4, $28.0&nbsp;million of principal amount on the Scilex
Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The Company funded the repurchase with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> and $34.0&nbsp;million received from Sorrento on September&nbsp;28, 2022. The Company recorded a gain on debt extinguishment of $28.6&nbsp;million as a
result of the extinguishment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borrowings of the Scilex Notes consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;December&nbsp;31,&nbsp;2021&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carrying value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long term portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company made principal payments of $106.0&nbsp;million, $45.9&nbsp;million, and $69.8&nbsp;million during the years ended
December&nbsp;31, 2022, 2021, and 2020, respectively. The amount of debt discount and debt issuance costs included in interest expense for the years ended December&nbsp;31, 2022, 2021, and 2020 was approximately $3.1&nbsp;million, $7.9&nbsp;million
and $10.7&nbsp;million, respectively. The Company recorded a gain on debt extinguishment of $28.6&nbsp;million, a loss on debt extinguishment of $12.5&nbsp;million, and no gain/loss on debt extinguishment in connection with its repayments of
principal made during the years ended December&nbsp;31, 2022, 2021, and 2020, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Notes Payable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 12). On March&nbsp;18, 2019, the Company entered into a note payable with
Sorrento (see Note 12). On February&nbsp;14, 2022, Sorrento paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan (see Note 12). On May&nbsp;12, 2022, the Company issued
Sorrento a promissory note of $5.0&nbsp;million in exchange for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (see Note 3). On November&nbsp;10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento
was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 12). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Revolving Credit Facility </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#147;Credit Agreement&#148;) with CNH Finance Fund I, L.P. (&#147;CNH&#148;) which provides Scilex Pharma with the ability to incur indebtedness under an
accounts receivable revolving loan facility in an aggregate amount of $10.0&nbsp;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement,
interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.75%. All indebtedness incurred and outstanding will be due and payable in full on January&nbsp;1, 2024; unless the
Credit Agreement is earlier terminated. As of December&nbsp;31, 2021, the outstanding balance was $8.8&nbsp;million. On February&nbsp;16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective March&nbsp;18, 2022.
Upon termination, all principal balances and interest accrued were settled. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated statement of stockholders&#146; equity has been retroactively adjusted for all periods to reflect the Business Combination and reverse
recapitalization described in Note 1. The balances as of December&nbsp;31, 2022 and 2021 from the consolidated financial statements of the Company as of that date, share activity (Preferred Stock, Common Stock, and additional <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital)</FONT></FONT> and per share amounts were retroactively adjusted, where applicable, using the Common Stock Exchange Ratio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination, pursuant to the terms of the Amended and Restated Certificate of Incorporation, the Company authorized
740,000,000 shares of Common Stock with a par value of $0.0001. As of December&nbsp;31, 2022 and December&nbsp;31, 2021, there were 141,348,856 shares issued and 132,858,484 of Common Stock outstanding, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, all previously issued and outstanding shares of Legacy Scilex Common Stock and Legacy Scilex stock
options were converted into shares of Common Stock pursuant to the Common Stock Exchange Ratio. The Company has retroactively adjusted shares issued and outstanding prior to November&nbsp;10, 2022 to give effect to the Common Stock Exchange Ratio to
determine the number of shares of Common Stock into which they were converted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the Common Stock are entitled to one vote for each share of the Common Stock held at all meetings of stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Common stockholders are entitled to
receive dividends whenever funds are legally available and when declared by the Company&#146;s board of directors. No dividends have been declared as of December&nbsp;31, 2022. The Stockholder Agreement, dated as of September&nbsp;12, 2022, between
Vickers and Sorrento (the &#147;Stockholder Agreement&#148;), provides that the Company will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, the payment of dividends on shares of
the Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject
to the rights of the holders of Preferred Stock, in the event of our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> holders of Common Stock are entitled to share equally in the assets available for distribution after
payment of all creditors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the
closing of the Business Combination, $290.6&nbsp;million of all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento were cancelled in exchange for the issuance of preferred shares of Scilex (&#147;Series A Preferred
Shares&#148; or &#147;Series A Preferred Stock&#148;). In connection with the closing of the Business Combination, all issued Scilex Series A Preferred Shares were cancelled and converted into the right to receive 1) one share of domesticated parent
preferred shares (&#147;New Scilex Preferred Stock&#148; or &#147;Preferred Stock&#148;) par value of $0.0001 per share, and 2) <FONT STYLE="white-space:nowrap">one-tenth</FONT> of one domesticated parent common stock (&#147;New Scilex Common
Stock&#148; or &#147;Common Stock&#148; and such transaction including cancellation of all the existing related party indebtedness in exchange for Preferred Stock and Common Stock, the &#147;Conversion&#148; or &#147;Contribution&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Conversion, Legacy Scilex filed a Second Amended Certificate of Incorporation (defined below) to increase the authorized number of shares to
45,000,000 shares and a Certificate of Designation (&#147;Certificate of Designation&#148;) to designate the rights, preferences, and privileges of Scilex Series A Preferred Shares. In connection with the closing of the Business Combination, the
Company filed the Certificate of Designation and issued 29,057,097 shares of the Series A Preferred Stock to Sorrento. As of December&nbsp;31, 2022, there were 29,057,097 shares of Preferred Stock outstanding. There were no Preferred Stock
outstanding at December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Board of Directors have authority to issue such shares of Preferred Stock in one or more
series, to establish, from time to time the number of shares to be included in each such series, and to fix the dividend, voting, and other rights, preferences, and privileges of the shares. Other than the Series A Preferred Stock issued
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to Sorrento in connection with the closing of the Business Combination, there are no other Preferred Stock outstanding and the Company has no current plans to issue any other shares of preferred
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of shares of
Preferred Stock will be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Preferred Stock
will be entitled to one vote for each share of Common Stock that such share of Preferred Stock would otherwise be convertible into pursuant to a deemed conversion on the record date for the determination of the stockholders entitled to vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Stockholder Agreement, holders of Series A Preferred Stock have the right to designate each director to be nominated, elected or appointed to
the Board of Directors of the Company. The Series A Preferred Stock also has certain protective provisions, such as requiring a written consent of the holders of Series A Preferred Stock to change or amend their rights, powers, privileges,
limitations and restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the Preferred Stock are not entitled to dividends unless the Company pays dividends to holders of the Common Stock and shall be entitled to receive,
when, as and if declared by our Board, such dividends (whether in cash or other property) as are paid to holders of the Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of
Preferred Stock into Common Stock and had held such shares of Common Stock on the record date for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the rights of the
holders of parity shares (if any), in the event of our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> holders of Preferred Stock rank senior to the Common Stock and are entitled to share equally in the assets
available for distribution after payment of all creditors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assumed Public Warrants and Private Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the consummation of the Business Combination, holders of the Public Warrants and Private Warrants are entitled to acquire Common Stock of the
Company. The warrants are exercisable on the later of (a)&nbsp;the completion of a Business Combination and (b) 12 months from the closing of Vickers&#146;s Initial Public Offering. The warrants will expire five years after the completion of the
Business Combination or earlier upon redemption or liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant entitles the holder to purchase one share of Common Stock for $11.50 per
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the reported last sale price of the Common Stock equals or exceeds $18.00 per share for any 20 trading days within a <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $0.01 per warrant upon not less
than 30 days&#146; prior written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders
that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the warrants. As of December&nbsp;31, 2022, there are 6,899,988 Public Warrants outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, 3,104,000 Private Warrants were transferred to Sorrento pursuant to the Warrant Transfer Agreement
between Vickers, the Sponsors, Sorrento and Maxim Group, LLC where Sorrento acquired all rights, title and interests to such Private Warrants (&#147;Warrant Transfer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement&#148;). As of December&nbsp;31, 2022, there are 4,104,000 Private Warrants outstanding, of which 3,104,000 Private Warrants are held by Sorrento and 1,000,000 Private Warrants are held
by Sponsors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legacy Scilex Common Stock and Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, Legacy Scilex had the authority to issue 200,000,000 shares of common stock, par value $0.0001 per share and 20,000,000
shares of preferred stock, par value $0.0001 per share per the Certificate of Incorporation dated February&nbsp;27, 2019. The Certificate of Incorporation was amended and restated on March&nbsp;4, 2019 (&#147;First Amended Certificate of
Incorporation&#148;), in which Legacy Scilex had the authority to issue 350,000,000 shares of common stock, par value $0.0001 per share and 20,000,000 shares of preferred stock, par value $0.0001 per share. The First Amended and Restated Certificate
of Incorporation was amended and restated on November&nbsp;10, 2022 (&#147;Second Amended Certificate of Incorporation&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Second
Amended Certificate of Incorporation, Legacy Scilex had the authority to issue 785,000,000 shares, consisting of 740,000,000 shares of common stock and 45,000,000 shares of preferred stock. Immediately prior to the Conversion, there were 197,566,338
shares of Legacy Scilex Common Stock outstanding and 29,057,097 shares of Series A Preferred Stock, par value $0.0001 per share, of Legacy Scilex outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Yorkville Standby Equity Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
November&nbsp;17, 2022, the Company entered into a Standby Equity Purchase Agreement (the &#147;Yorkville Purchase Agreement&#148;) with Yorkville, whereby the Company has the right, but not the obligation, to sell to Yorkville up to
$500.0&nbsp;million of shares of its Common Stock at its request any time during the 36 months following the execution of the Yorkville Purchase Agreement, subject to certain conditions. Pursuant to the Yorkville Purchase Agreement, the shares of
Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a sale of Common Stock (each such sale, a &#147;Yorkville Advance&#148;) will be purchased at a price equal to 98% of the lowest daily volume weighted average price of
the Common Stock for any trading day (&#147;VWAP&#148;) during the two consecutive trading days commencing on the date of delivery of a written purchase notice to Yorkville (each, a &#147;Yorkville Advance Notice&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#146;s commitment to purchase shares of Common Stock at the Company&#146;s direction upon the terms and subject to the
conditions set forth in the Yorkville Purchase Agreement, upon execution of the Yorkville Purchase Agreement, the Company issued 250,000 shares of Common Stock to Yorkville and paid $10.0&nbsp;thousand in structuring fees. The registration statement
on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607)</FONT> related to the Yorkville Purchase Agreement was filed with the SEC on November&nbsp;30, 2022 and was declared effective by the SEC
on December&nbsp;9, 2022. As of December&nbsp;31, 2022, there were no shares sold to Yorkville under the Yorkville Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to Note 14
&#147;Subsequent Event&#148; below for a subsequent event related to the Yorkville Purchase Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Stock Incentive and Employee Benefit Plans
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated statements of stockholders&#146; equity / (deficit) have been retroactively adjusted for all periods to reflect the Business
Combination and reverse recapitalization described in Note 1. The balances as of December&nbsp;31, 2022, 2021, 2020 from the consolidated financial statements of the Company as of that date, share activity (stock options) and per share amounts were
retroactively adjusted, where applicable, using the Common Stock Exchange Ratio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#147;Scilex Pharma 2017 Plan&#148;). The Scilex Pharma
2017 Plan reserved 24.0&nbsp;million shares of Scilex Pharma common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each
month thereafter. The Scilex Pharma 2017 Plan was amended and restated on July&nbsp;5, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the corporate reorganization in March
2019, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma&#146;s common stock outstanding and unexercised immediately prior to reorganization was cancelled and substituted for that number of options to acquire
Legacy Scilex Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2019 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#147;2019 Stock Option Plan&#148; or &#147;Prior
Plan&#148;) on May&nbsp;28, 2019. The 2019 Stock Option Plan was approved by the Company&#146;s stockholders on June&nbsp;7, 2019. As of December&nbsp;31, 2019, 30.0&nbsp;million shares of Scilex Common Stock of the Company were reserved for
issuance pursuant to the 2019 Stock Option Plan. Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares
on each monthly anniversary thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the consummation of the Business Combination, the 2019 Stock Option Plan was terminated and no further
awards were granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted under the terms of the Equity Incentive Plan (defined below). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2022 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#147;Equity Incentive Plan&#148;) on October&nbsp;17,
2022. The 2022 Equity Incentive Plan was approved by the stockholders and became effective on November&nbsp;9, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total number of common shares
for which incentive stock options (&#147;ISOs&#148;) may be granted under the Equity Incentive Plan is not to exceed 14,622,712 shares plus a number of shares of Common Stock equal to the number of shares subject to outstanding stock awards granted
under the Prior Plan (&#147;Returning Shares&#148;), if any, as such shares become available from time to time, which the amount will be increased commencing on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount
equal to the lesser of (i) 4% of the total number of shares of Common Stock outstanding on December&nbsp;31 of the preceding year, (ii) 7,311,356 shares of Common Stock, and (iii)&nbsp;such number of shares of the Common Stock determined by the
Board or the compensation committee of the Board prior to January&nbsp;1 of a given year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, there were no options to purchase
shares of Common Stock outstanding under the Equity Incentive Plan and options to purchase 16,939,436 shares of the Common Stock were outstanding under previous plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded within operating expenses was $5.3&nbsp;million, $5.8&nbsp;million, and $5.4&nbsp;million for the years ended
December&nbsp;31, 2022, 2021, and 2020, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total unrecognized compensation costs related to unvested employee and <FONT
STYLE="white-space:nowrap">non-employee</FONT> stock option grants as of December&nbsp;31, 2022 was $2.7&nbsp;million and the weighted average period over which these grants are expected to vest is 1.4 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2022 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, the Board adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#147;ESPP&#148;). The ESPP was approved by the
stockholders and became effective on November&nbsp;9, 2022. The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum
efforts toward the success of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase the
Common Stock in a manner that may qualify for favorable tax treatment under Section&nbsp;423 of the Internal Revenue Code of 1986 (&#147;Code&#148;) (the &#147;423 Component&#148;) and accordingly, it will be construed in a manner that is consistent
with the requirements of Section&nbsp;423 of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment (the <FONT STYLE="white-space:nowrap">&#147;Non-423</FONT> Component&#148;) in
order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by
the Board, it will operate and be administered in the same manner as the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board administers the ESPP and will have the authority to
determine how and when purchase rights are granted and the provisions of each offering. Initially, the total number of shares of the Common Stock that may be issued under the ESPP will not exceed 1,462,271 shares of the Common Stock. The number of
shares of the Common Stock that will be reserved for issuance will automatically increase on January&nbsp;1 of each year for a period of up to ten years, commencing on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an
amount equal to the lesser of (i) 1% of the total number of shares of the Common Stock outstanding on December&nbsp;31 of the immediately preceding calendar year; (ii) 1,827,839 shares of the Common Stock; and (iii)&nbsp;such number of shares of the
Common Stock determined by the Board or the compensation committee of the Board prior to January&nbsp;1 of a given year, provided however, that the Board may act prior to January&nbsp;1 of a given calendar year to provide that there will be no
increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i)&nbsp;to (iii) above. As of December&nbsp;31, 2022, there were no shares outstanding under the ESPP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Valuation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company calculates the fair
value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the
expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant. The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and
nonemployees for the year ended 2020 is set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="25%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted&#151;average grant date fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected stock-price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.53</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per share of common stock on date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected dividend yield</I>. The Company bases the expected dividend yield assumption on the fact that the Company has
never paid cash dividends and has no present intention to pay cash dividends on the Company&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected stock-price volatility</I>.
The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the transdermal patch industry. In selecting
the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches. Management further considered the development stage of the peer group companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risk-free interest rate</I>. The Company bases the risk-free interest rate assumption on the U.S.
Treasury&#146;s rates for U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> bonds with maturities similar to those of the expected term of the award being valued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected term of options</I>. The expected term of options represents the period of time when options are expected to be outstanding. Because the Company
does not have historic exercise behavior, the Company determines the expected term assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary
vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following represents a summary of the options outstanding at December&nbsp;31, 2022, 2021, and 2020 and changes during the years then
ended (in thousands, other than weighted-average exercise price): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise&nbsp;price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Benefit Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are
voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $0.3&nbsp;million for each of the years ended
December&nbsp;31, 2022, 2021, and 2020, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Development Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2013,
Scilex Pharma became a party to a product development agreement (as amended, the &#147;Product Development Agreement&#148;) with two parties (the &#147;Developers&#148;), one of which is ITOCHU CHEMICAL FRONTIER Corporation (&#147;Itochu&#148;),
pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> (the &#147;Products&#148;), for Scilex Pharma. The Developers initially developed, and have
intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for
sourcing and supplying lidocaine for development and commercialization purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Product Development Agreement, Scilex Pharma is required
to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. During the year ended December&nbsp;31, 2022, Scilex </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pharma made royalty payments in the amount of $2.3&nbsp;million. As of December&nbsp;31, 2022, Scilex Pharma had ending balances of accrued royalty payables of $2.2&nbsp;million. Net profits are
defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the
sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The
Product Development Agreement will continue in full force and effect until October&nbsp;2, 2028, the date that is ten years from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for
subsequent successive <FONT STYLE="white-space:nowrap">one-year</FONT> renewal periods unless Scilex Pharma or the Developers terminate it upon <FONT STYLE="white-space:nowrap">6-month</FONT> written notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#147;Supply Agreement&#148;) with the two Developers to
provide commercial supply of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement
provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Distribution Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2015,
Scilex Pharma entered into an Exclusive Distribution Agreement (the &#147;Distribution Agreement&#148;) to appoint an exclusive third-party logistics distribution provider (the &#147;Distributor&#148;) and as an authorized distributor of record of
ZTlido in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a 3% annual adjustment. The Distribution Agreement has an initial term of three years following the first shipment of <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> Product to a commercial customer and shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of
the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor&#146;s negligence or willful misconduct. Pursuant to
the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#146;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was
sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between 1% to 2% which was recorded as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> sales
adjustment. As the Company continues to expand the commercialization of ZTlido, it has expanded its direct distribution network to national and regional distributors and pharmacies since the beginning of April 2022. The Company currently holds all
necessary wholesaler licenses and commenced selling directly to the main distributor customers as well as pharmacies in April 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales
Operations Services </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and
detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the &#147;Project Agreement&#148;). In connection with the detailing services, the Project Agreement provides that the vendor will
provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each
of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales
representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor continued to provide sales operations services, fleet management services and sample </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accountability services. The work order was in effect until June&nbsp;30, 2022 and was extended for one year upon the mutual agreement of both parties. Either party may terminate the work order
with 90 days&#146; notice. Scilex Pharma paid an implementation fee of $59.0&nbsp;thousand and will pay fixed monthly fees of $63.7&nbsp;thousand to $65.8&nbsp;thousand for ongoing services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized an expense of $0.9&nbsp;million, $1.9&nbsp;million, and $10.5&nbsp;million within selling, general and administrative expenses for
services performed for the years ended December&nbsp;31, 2022, 2021, and 2020, respectively, including implementation fees, fixed monthly fees and pass-through costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the normal course of business, the
Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the
aggregate, are deemed to be material to the Company&#146;s financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time the Company may become
involved in various legal proceedings, including those that may arise in the ordinary course of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sanofi-Aventis U.S. LLC and Hisamitsu
America, Inc. Litigation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California
against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by
those companies regarding their respective OTC patch products (the &#147;Sanofi-Aventis&nbsp;&amp; Hisamitsu Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false
or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly the Company&#146;s claims, but which motions the court has largely rejected. Discovery
is proceeding. The case is currently scheduled for trial to begin on July&nbsp;24, 2023. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Former Employee Litigation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2021, the
Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#147;Virpax&#148;), a company now headed by Mr.&nbsp;Mack, alleging, among other things, breach by
Mr.&nbsp;Mack of his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement with the Company, breach of fiduciary duty, and tortious interference by Virpax with that <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement (the
&#147;Former Employee Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&nbsp;Mack from further violating his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement and enjoining Virpax from
tortiously interfering with Mr.&nbsp;Mack&#146;s <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement. The case was tried from September&nbsp;12, 2022 to September&nbsp;14, 2022. Post-trial briefing and closing arguments have been concluded
and the case is under submission to the Court. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ZTlido
Patent Litigation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc.
(together, &#147;Apotex&#148;) in the U.S. District Court for the Southern District of Florida (the &#147;ZTlido Patent Litigation&#148;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#147;ZTlido Patents&#148;).
The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Apotex&#146;s ANDA seeks approval to market a generic
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief,
an order that the effective date of any FDA approval of Apotex&#146;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&nbsp;10, 2031, and such further and other relief as
the court may deem appropriate. Apotex is subject to a <FONT STYLE="white-space:nowrap">30-month</FONT> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&nbsp;11, 2024.
Trial in the ZTlido Patent Litigation has not yet been scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases
administrative and research and development facilities under various <FONT STYLE="white-space:nowrap">non-cancelable</FONT> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of
December&nbsp;31, 2022, the Company&#146;s leases have remaining lease terms of approximately 1.6 to 1.9 years. The term of the Company&#146;s leases does not include extension options that were not reasonably certain to be exercised from its lease
terms, ranging from 3 to 5 years. Many of the Company&#146;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the
measurement of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income
is recognized on a straight-line basis and is immaterial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#146;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&nbsp;31, 2022, the Company has no
finance leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of lease expense were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods
presented. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating cash flows from operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROU assets obtained in exchange for new operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term in years&#151;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate&#151;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the Company entered into a new <FONT STYLE="white-space:nowrap">non-cancelable</FONT> lease
agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is 26 months and the Company does not expect to exercise the extension option at the end of the
lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximate future minimum lease payments under operating leases were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less current portion of lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total
loss before income taxes for the years ended December&nbsp;31, 2022, 2021 and 2020 did not include a foreign component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the provision
expense (benefit) were as follows for the years ended December&nbsp;31, 2022, 2021, and 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current income tax expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,851</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total income tax benefit from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used for income tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Company&#146;s net deferred tax liabilities and related valuation allowance are as
follows as of December&nbsp;31, 2022 and 2021 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt related interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expense and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,543</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(253</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#146;s provision for income taxes
are as follows for the years ended December&nbsp;31, 2022, 2021, and 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit at federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt discount and interest limitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(806</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition related charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prior year <FONT STYLE="white-space:nowrap">true-up</FONT> and carryback</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State, net of federal tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax credits and incentives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the
amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains
a valuation allowance of $67.5&nbsp;million against its deferred tax assets as of December&nbsp;31, 2022. Realization of the deferred tax assets will be primarily dependent upon the Company&#146;s ability to generate sufficient taxable income prior
to the expiration of its net operating losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Company had $205.6&nbsp;million and $106.9&nbsp;million of federal and
state net operating loss carryforwards, respectively. The net operating loss carryforwards begin to expire in 2035 and 2034 for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
federal and state, respectively. The Company also had federal research and development income tax credits of $2.0&nbsp;million which will begin to expire in 2035. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal Revenue Code Section&nbsp;382 rules apply to limit a corporation&#146;s ability to utilize existing net operating loss and tax credit carryforwards
once the corporation experiences an ownership change as defined in Section&nbsp;382. For the years ended December&nbsp;31, 2022 and 2021, there was no impact of such limitations on the Company&#146;s income tax provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in U.S. federal and state tax jurisdictions. All of the Company&#146;s tax years will remain open for three years for
examination by the federal and state tax authorities from the date of utilizations of net operating loss. There are no active tax compliance audits as of December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended December&nbsp;31, 2022, 2021, and
2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase related to current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2022, 2021, and 2020, $0.4&nbsp;million, $0.4&nbsp;million and $0.4&nbsp;million, respectively, of the
Company&#146;s total unrecognized tax benefits, if recognized, would impact the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate
would be nil. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s policy is to recognize interest and penalties related to income tax matters in income tax expense. No interest or
penalties have been recognized as of and for the periods ended December&nbsp;31, 2022, 2021, and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that no material amount of
the liabilities for uncertain tax positions are expected to reverse within 12 months of December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Related Party Transactions
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, approximately 14.7% of the outstanding capital stock of the Company was held by Itochu. On January&nbsp;13, 2021,
34,889,868 shares of Legacy Scilex representing all outstanding capital stock of Legacy Scilex held by Itochu were acquired by <FONT STYLE="white-space:nowrap">non-related</FONT> minority shareholders. Thus, Itochu is not a shareholder subsequent to
January&nbsp;13, 2021. During the years ended December&nbsp;31, 2022, 2021, and 2020 the Company purchased approximately $6.7&nbsp;million, $5.7&nbsp;million, and $1.0&nbsp;million respectively, of inventory from Itochu, a previous minority
shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#146;s statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Semnur is party to an Assignment Agreement, dated August&nbsp;6, 2013 (the &#147;Assignment Agreement&#148;), with Shah Investor LP (&#147;Shah
Investor&#148;). Mahendra Shah, Ph.D., who has served on the Company&#146;s board of directors since March 2019, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to
Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the <FONT STYLE="white-space:nowrap">low-single</FONT> digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection
developed using such intellectual property, which would include <FONT STYLE="white-space:nowrap">SP-102.</FONT> Through December&nbsp;31, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2017, a Transition Services Agreement (&#147;TSA&#148;) was executed between Scilex
Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#146;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to
the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the years ended December&nbsp;31, 2022, 2021, and 2020 the total cost of services and insurance, including an agreed-upon markup, provided to
the Company and recognized in general and administrative expenses was $3.8&nbsp;million, $4.0&nbsp;million, and $2.3&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $16.5&nbsp;million for the acquisition of Semnur. The note is interest bearing at the lesser of (a) 10% simple interest per annum, and
(b)&nbsp;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. During the years ended
December&nbsp;31, 2022, 2021, and 2020 Sorrento made advances to the Company in the amount of $27.5&nbsp;million, $6.6&nbsp;million, and $13.7&nbsp;million respectively, under the note payable. All outstanding related party indebtedness immediately
prior to the closing of the Business Combination was converted to equity pursuant to the Debt Exchange Agreement (defined below) and therefore the last day the debt outstanding was November&nbsp;10, 2022 (see Note 12). The outstanding principal
balance of the note on November&nbsp;10, 2022 and December&nbsp;31, 2021 was $47.1&nbsp;million and $19.6&nbsp;million, respectively, which was recorded under the current related party note payable in the Company&#146;s consolidated balance sheets.
As of November&nbsp;10, 2022 and December&nbsp;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $7.2&nbsp;million and $3.9&nbsp;million, respectively, which was recorded under related party payable
in the Company&#146;s consolidated balance sheets. The proceeds from the note payable were used to finance the operations of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
October&nbsp;5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $21.7&nbsp;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#147;Intercompany Note&#148;). Scilex Pharma may
borrow up to an aggregate of $25.0&nbsp;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a) 10% simple interest per annum, and (b)&nbsp;the maximum interest rate permitted under law. All
outstanding principal amounts and accrued interest was due upon maturity on August&nbsp;31, 2026. On October&nbsp;22, 2018, Sorrento purchased from the Legacy Scilex 24,117,608 shares of the Legacy Scilex Common Stock in exchange for the repayment
of $21.7&nbsp;million of indebtedness under this promissory note. During the years ended December&nbsp;31, 2022, 2021, and 2020, Sorrento made advances to Scilex Pharma in the amount of $0, $8.1&nbsp;million, and $10.3&nbsp;million respectively,
under the promissory note. As of November&nbsp;10, 2022 and December&nbsp;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $5.1&nbsp;million and $3.1&nbsp;million, respectively, which was recorded
under related party payable in the Company&#146;s consolidated balance sheets. As of November&nbsp;10, 2022 and December&nbsp;31, 2021, Scilex Pharma&#146;s outstanding principal balance under the promissory note was $23.5&nbsp;million, which was
recorded under the <FONT STYLE="white-space:nowrap">non-current</FONT> related party note payable in the Company&#146;s consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company received $35.0&nbsp;million in February 2022 to fund the payment of Scilex Pharma Notes as described in Note 7. The $35.0&nbsp;million received in February 2022 was due no earlier than February 2030 and was recorded under the <FONT
STYLE="white-space:nowrap">non-current</FONT> related party note payable in the Company&#146;s consolidated balance sheets as of November&nbsp;10, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional funding received from Sorrento was due on demand and recorded under the related party payable in the Company&#146;s consolidated balance sheets. As
of November&nbsp;10, 2022, related party payables due to Sorrento included $61.7&nbsp;million to cover working capital requirements, $100.0&nbsp;million for repurchases of Scilex Pharma Notes, and $18.2&nbsp;million for litigation fees (see Note 7).
As of December&nbsp;31, 2021, related party payables due to Sorrento consisted of $35.7&nbsp;million to cover working capital requirements, $51.0&nbsp;million for repurchases of Scilex Pharma Notes, and $6.0&nbsp;million to pay litigation fees. As
of December&nbsp;31, 2022, the Company had a $1.8&nbsp;million related party receivable from Sorrento related to certain invoices paid on behalf of Sorrento, which was fully reserved (see Note 14). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3). Pursuant to the
Bill of Sale, the Company assumed all of Sorrento&#146;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as consideration transferred. The 2022 Promissory Note
matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and (b)&nbsp;the maximum interest rate permitted under law. As of November&nbsp;10, 2022, the outstanding
balance, net of discount, under the 2022 Promissory Note was $4.2&nbsp;million, which was recorded under the <FONT STYLE="white-space:nowrap">non-current</FONT> related party note payable in the Company&#146;s consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt Exchange Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;12,
2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#147;Debt Exchange Agreement&#148;) with Sorrento, pursuant to which (i)&nbsp;Sorrento shall contribute to the Company all amounts
(including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company that remain outstanding as of immediately prior to the closing of the Business Combination (the &#147;Aggregate Outstanding
Amount&#148; or &#147;Outstanding Indebtedness&#148;), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $27.5&nbsp;million for certain amounts
previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 7), in exchange for the issuance by the Company to Sorrento of Preferred Stock of the Company, (ii)&nbsp;the Company shall contribute
to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii)&nbsp;upon the occurrence of the events described in clauses (i)&nbsp;and (ii), the
Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Debt Exchange Agreement effective
as of immediately prior to, and contingent upon, the closing of the Business Combination, Sorrento elected to contribute the Outstanding Indebtedness to the Company in exchange for the issuance by the Company to Sorrento of that number of shares of
preferred stock, par value $0.0001 per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#147;Exchange Shares&#148; and such transaction, the &#147;Debt
Contribution&#148;) that is equal to (i)&nbsp;the Aggregate Outstanding Amount plus the amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share); provided, that in no event would the
Aggregate Outstanding Amount exceed $ 310,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and
Sorrento totaling $290.6&nbsp;million was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement. This amount was converted to
29,057,097 shares of Scilex Preferred Stock and 2,905,710 shares of the Company&#146;s Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, <I>Earnings Per Share</I>. The Company has two classes of shares, which
are referred to as Common Stock and Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is presented in conformity
with the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. The retroactive adjustment is
based on the same number of weighted average shares outstanding in each historical period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2022, 2021, and 2020,
basic loss per share is computed using the <FONT STYLE="white-space:nowrap">two-class</FONT> method. The <FONT STYLE="white-space:nowrap">two-class</FONT> method is an earnings allocation formula that determines earnings per share for each class of
common stock and participating securities according to dividends or dividend equivalents and participation rights in undistributed earnings. Preferred Stock is not contractually required to share in net losses of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended
December&nbsp;31, 2022, 2021, and 2020 (in thousands except per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Scilex</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Dilutive Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator for Diluted Loss per Share&#151;Adjusted for Dilutive Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and Diluted Loss Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share
because their effect would have been anti-dilutive for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,939,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,967,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,746,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,899,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events for recognition and disclosure purposes in the audited consolidated financial statements as of December&nbsp;31,
2022. Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. Riley Standby Equity Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
January&nbsp;8, 2023, the Company entered into a Standby Equity Purchase Agreement (the &#147;B. Riley Purchase Agreement&#148;) with B. Riley, whereby the Company shall have the right, but not the obligation, to sell to B. Riley up to
$500.0&nbsp;million of its shares of the Company&#146;s Common Stock at the Company&#146;s request any time during the 36 months following the execution of the B. Riley Purchase Agreement, subject to certain conditions. The Company expects to use
the net proceeds received from this for working capital and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for B. Riley&#146;s commitment to purchase
shares of Common Stock at the Company&#146;s direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, the Company issued 250,000 shares of Common Stock to B. Riley in connection with the execution of the
B. Riley Purchase Agreement on January&nbsp;12, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the execution of the B. Riley Purchase Agreement, the Company sold an aggregate of
127,241 shares of Common Stock pursuant to the B. Riley Purchase Agreement for aggregate net proceeds to the Company of approximately $1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2023 Inducement Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
January&nbsp;17, 2023, the Compensation Committee of the Board of Directors (the &#147;Compensation Committee&#148;) of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the &#147;Plan&#148;). The Plan will serve to advance the
interests of the Company by providing a material inducement for the best available individuals to join the Company as employees by affording such individuals an opportunity to acquire a proprietary interest in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company. The Plan provides for the grant of equity-based awards in the form of <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock appreciation rights, restricted
stock, restricted stock units, and other awards (as set forth under the Plan) solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. The initial maximum number of shares available for
grant under the Plan is 1,400,000 shares of the Company&#146;s Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to the Yorkville Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
February&nbsp;8, 2023, the Company entered into an Amended and Restated Standby Equity Purchase Agreement with Yorkville (the &#147;A&amp;R Yorkville Purchase Agreement&#148;), amending, restating and superseding the Yorkville Purchase Agreement
dated November&nbsp;17, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell
to Yorkville pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the lowest daily volume weighted average price of the Common Stock for any trading day on the date of delivery of a written purchase notice to Yorkville. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to December&nbsp;31, 2022, the Company sold an aggregate of 85,000 shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for
aggregate net proceeds to the Company of approximately $0.6&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elyxyb License </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2023, the Company acquired from BioDelivery Sciences International, Inc. (&#147;BSDI&#148;) and Collegium Pharmaceutical, Inc.
(&#147;Collegium&#148;, and together with BDSI, the &#147;Collegium Sellers&#148;) the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB (celecoxib oral solution) (the
&#147;Product&#148;) and its commercialization in the United States and Canada (the &#147;Territory&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the
Company assumed various rights and obligations under that certain asset purchase agreement, dated August&nbsp;3, 2021 (the &#147;DRL APA&#148;), between BDSI and Dr.&nbsp;Reddy&#146;s Laboratories Limited, a company incorporated under the laws of
India (&#147;DRL&#148;), including a license from DRL including an irrevocable, royalty-free, exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> and patents of DRL related to the Product and necessary or used to exploit the
Product in the Territory. Additionally, under the Purchase Agreement, the Seller granted the Company an irrevocable, royalty-free, exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> related to the Product and necessary or used to
exploit the Product in the Territory. No cash consideration was or will be payable to Collegium Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include obligations to pay royalties for sales
of the Product in the Territory for all indications and additional amounts if certain milestones are achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sorrento Chapter 11 filing
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2023, Sorrento, together with its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary
proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. While the Company is majority-owned by Sorrento, the Company is not a debtor in Sorrento&#146;s voluntary
Chapter 11 filing and management does not expect this will impact the Company and will continue to operate its business as usual. As of December&nbsp;31, 2022, the Company had a $1.8&nbsp;million receivable from Sorrento, which was fully reserved.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g454025g00a15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g00a15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I24&AO=&]S:&]P(#,N,  X0DE-! 0
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!93!B         "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _
M@   .$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     T$    &              $W   "<     8 9P P #  80 Q #4    !
M                          $              G    $W
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   $W     %)G:'1L
M;VYG   "<     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   !-P    !29VAT;&]N9P   G     #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     4X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MEZ53\K[-ER;YVU1/J3_.MG;*[W>_7](8[?I4!^5E5O9Z=K@7;I_.T !_PF]
M\K6O'_S?_0EX^)$BO:&XEK/]WU?YO^J\.;#Z+=IS/7_/+B_T^_T(_2?N?21;
M+'!U'KNRMAQ:OYDNW!\'W.W^UW\I=I]NZA_IG?YK/_()?;NH?Z9W^:S_ ,@A
M]W'[Q_Q?_0TGXA+_ #4>O^4EU_ZD\9C/=]J9Z3LHMVV[O5W?Z%_[IV_SF_\
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M *32^W=0_P!,[_-9_P"02]@?O'_%_P#0E??I4![4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M8W*#DI.CI*:TQ=+_Q  = 0$  04! 0$              0(#! 4&!P@)_\0
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MI$[[D>%7_!ZH? GT-6%NB7HQM??R"TK?.,_2K;ER[;=LAQ=\60"81XH>(H0
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M&K]6>=?5&HMKXK=3OS WFCS.^QMM$#H4Z&;9Z).C(XY:"TK<W)&!XJWSGL(
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M7#/E3J*PO^S-3(OL+\4T<;[1[^.A3H;Y=$?1E;.1H'2IOGOI5O?G' >+[BR
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M0IT-$C^Q)T9$6O\ :%I6]O52<GNR;\]X!Q><68@7_50\1/,& ,'SV7) ,X'
MCFIA 0'(9P)0Z_KBYT.L-6#B^JC45CM].ZF<7[IH$'TW/J-H'H4Z&;_I2=&7
M";V)T%I:^^;6I.+<K@^PQS#B\XLC9,'%!Q$9 H;#>NY> R!1Z?*80SD<Y[!D
M.I<ZI.L-6"P.J=19/*MU+)!//PF]ML<SG8VB#T*=#0P>B3HRM?<:#TK?!(Q]
M*1CN-LYQM' O%[Q9YR'%%Q$'R/+CYZKDB #N.<!4Q0'EWR ]0$!P. U4=8:L
MMG4^HDC>_CNIBX[+F:._(C;MB?@4Z&;$'HCZ,A87OY!Z6N=O\$FU_7;:^\2;
MB]XL0R \47$3N!1 0O7<H.G;'RGYBB.#;;B; ^\(X  U?JWEJ?46+[UNIG?G
M<S-B +9-@-K;P'0GT-G;HDZ,<7O]06E?_P!38Y(%]A<8MN^E[Q98S]*#B*
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MU7B3< >=8VM:X[AMN-AWW-[)%X]!.$\/]3!Z0HH^\/S06PR&<CGYTF& $
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MV-F.'7A^1OTA7K1"IBPE14[&0QZ2C5$B*H57.RTLFT0IX%E#%!J_?H%<(1.
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MZKQT<ZAS+J"./-UBK3AE_#*E.S8E2DR_A$T\[U!1;AZGC6K@*4A(24$$6%@
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M&JD@=#VJ,F 2/KWA"Y%Z .!5\8 .&9X^K? PP:O4 U+/==+M^&S' R\'5O\
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MMS].;7YXQ BQ-L\A=._QCLR1VW[XD1YPP)LB.0_%$<@8! !  W#OOS 41V#
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MTQN   YP(]0,.X@ #@H;  %#?N :NPOSY'( QRQ@$[GO)]!CK;7/?O?-R!S
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MTKHS2.EYC0.H9N8TYIB@4%^:9J=.0S-/4>E2E/=F&FW$\:&GERQ<;2LE24J
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MFJ716J4XS,K<1P.N/.-EU*FAPI0>%0*A>-;_ +A)=CI\_-NQ#(B(#3-2;Y
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MW;WW0# ?)FI,9WR(_?M]\>6P" " #I\!%4L1X^I^=_H69O;L'G8Y^V]KQ/\
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MRD$0Y2AN(&Y<<I0$-NNV!#?:>$D7'$4@WOO?.>STW%^=LFT"M"38K3<"QNH
MWY<S;M/.WH-N9FSHOA\R*Q/%$I292/@PF !(!<ADPF 2B   ?C8QV!:Z@+7-
MM@?.(("B;6')7%RN"#L8MA]H\5G$'A"N*RP2D)P23?S1@W[".V.*;9PLX*W1
M156<"(D*BFD8ZICER(E*GR\PB&!S@HB 9R&I"5+OPA6RE&U[<(%RI5KC&;]F
MQQF)6ZVVV7'%I0W9*N-1 195K'CO87Y7-R2#>.HQ3ER.!# AG)3!@V1 2F 0
M 0$1+D0'?L&<Y&D&XP 1@8&X'/.-K6!]/*T5W3?L*A?<7L.R_:!Q8Q8@WM:/
MH19NG!P1;MEU3F(<_*FBH<PE3*)E# 4 R!2%#(F #%+C(B ;ZJ((-R"0 5$D
M?6I!^N]%S<GD-XMK>:; 4XZA !2GB6M( *C9()-AQ+/FC8FXQ>\?.8IB["4P
M";& ')<CL/,([ (CG)0$ V$!SM@8(MOMF]]Q<'OO96X&2=[Q<"KW(]%]_3?D
M+6\X=N-XC?8<CN8 P.,[@'7&,;=L=0[]=%9)L+^;O[>>?4!:^;FT+$WOBVY3
MQ9R<6[C<DYBKT]<RD[15%"UQ6CE^W@V3\8LWLN)D)R1<R-0-G,%$,V,7$MW3
M]TLZDI!JA]Z0,5(ASK+&3124.6VY4I2DI1.3:G$L(<0S9MEQ]U3LPH,-(2TT
ME;BBIUQ(-DV2%<2BE )&%4M,5?6%.GJ%1&Y9V??EQ-#PN;EI!AN7ISC=1G'7
MIJ;<:8:0U*RSKEE. K4GJT!3BDI.P/TXK*8 ?4+J;AG'S25[G'_(OGMYYVZZ
MN>6-(_>ZIO:WBF?O??\ >8\\^ G7-K]=I/\ EAI_^>_'M$_3BLH'5C=3(AG'
MS2UYGRZ!"^8AIY8T?/SNJ8W'BF?OW?VCG[.^'P$ZY_?M*;@9U?0-S_GMHCZ<
M5E,9]1NIC./R2UX/GY0O;&X==PVT\LJ/8GJZIC_!,_[?SC\O.UH? 3KG]^TH
M.6=7T#^>Q <<EDQ_N"ZOVVDKW_0O\770ZRHX_45,^BE3Y_\ PP/05KD?V[2F
M;G[;Z!R_SWXMXGZ<=E!_N"ZG_-+7G^A>_P#3;3RRH_[W5/3XIGR/B8/8?88?
M 3KG]^TIS_;?0.7^>P^G%93_  &ZG7'Y):\#.V>HPN.F_7.GEE1\CJZI?_),
M_P!MOWC'KM#X"=<_OVE/Y7T#^>P^G%93?] W3V_\DM>;_5_67?'4?(.NGEE2
M,_.ZIC<"DSQ/Q,[<K]IA\!.N?W[2?\KZ!GG_ ';V9]$ XX[*#T874^ ?-+7F
M1_\ N7\^<:>65'S\[JF!?-)G]O\ L/EM#X"==?OVE/Y8:?\ Y[_1SB/IQV4_
MP"ZG?'Z4M>;X#(X_K+V[Z>65'_>ZI_%,_;V]3#X"=<C^WZ3OV>6&GSR!_N[O
MB1XXK*!G] 74VQG]*6O-LXZYA?CH=94<;MU2_9XIG[[V_>?>WHN^ G7/)[2G
M.WU7T#-NSZ-]7IQOB'TXK*?X!=3H(_DEKS8 SG/]9?AIY94?DBIGT4J?[N74
MWY\MN</@)US^_P"D_P"6&G^?;]'8]??V&'TXK*#_ '!=3<<?DEKSKM_X%SMG
M<>@>>GEE1\_.ZIC?Z4S_ /J??E#X"=<C=[2G\KZ ;>FTZ?7V1'TX[)_X!=3_
M )I:\_T+IY94??JZIR_8F?Y_\S\>T/@)US^_:4_E?I_^>Q/TXK*;?H&ZG<1_
M2EKS8 ZB/]9>@=\9QD,[B&GEE2/WNJ'?:DSYM;M^<0^ G7-[==I/^5] [;?W
M;V]D!XX[*!OZA=3[+2UX/\D*.@UE1S^HJ@[S29^WMZBT/@)US^_:4_E?0/Y[
M$?3CLI_@%U/J^:6O,XZY_P!9>F/+?;ITR\LJ1<CJZIC_  3/V]O4_+;8P^ G
M7-K]=I3^5] O_P"M^3\42/'%90/[ANIGN'S2UYD/_N7'YA'3RRH_[W5.7[%3
MW/OZFW9SYB'P$ZY_?M*?ROT__/8CZ<=D_P# ;J!MG\DM>?\ 5"CU[=OCIY94
M<[-U0]OTIGQ;TDL@0^ G7/[]I/:_VX:?_GO/WQ#Z<=D_\!NGY;6EKP<#OL.(
M7;I_0=/+*CWMU=4_BJ>]?]IS;-R+[0^ G7/[]I/>WVWT"WK/AMK>_9$CQQV4
M#^X;I_\ -+7G^A>FW7IIY94?]Q4_XJG_ %?VG%^1-AWP^ G7/[]I3^5^G_Y[
M#Z<5E/\  ;J=1#\DM>=O_J7OV\]/+*C_ +W5-[6\4S]__(]\=L/@)USGY]I3
M^5] SZ/HWUYM[<1'TY+)B&?4;J?\TM>!_+"ZGRQI&1U=4N!?[$SWQ?.<P^ G
M7)_MVE/7K#3X[N<\/RQ/TXK*9QZA=7(C@ ^:2O<CGZX0-NV=1Y94>U^"J$#>
MU)G^?I8'XX? 5KF]NOTG?L\KZ!?:_P#=OQ[=\/IQ64_P"ZG_ #2UY^;_ %E^
MOX;==/+*C_O=4_BF?/R,F'P$ZY_?M)XW^K#3_P"&>^2(^G)9/_ ;J?\ -+7F
M1WQ@ ]BY$<]@T\LJ1CYW5,Y^Q,^?D8A\!.N;7Z[2EAO]5^G_ $?W;VX].(!Q
MR63'.&-T]AP/Z4M>?R>Q<_F#3RRH_P"XJELY\4S]C;L/4>ST0^ G7/)[2A[?
MJOH&#V?HWY+^VXB?IQ64P ^H74W_ /)+7?V9S"@ "/D(_7J/+.C_ +W5/XIG
MN[_<>\0^ G7/[]I3^5] _GL/IQ64_P !NI_S2UX'\L+V[_GZ;ZGRRH_[BJ<L
M^*9^USZ6,<][;&'P$ZY_?M*9_P"%] _GOQP^G'93_ +J?']*2O0QVW$84 #3
MRRH_[W5#B^*3/_ZGES.U\7O#X"=<_OVE/Y7T#^>^_*(#CCLF.<,;J#CRM+7G
MY_\ 67?H/YASC&GEC2+7ZNJ>CQ3/W]-NIVA\!.N?W[2G\KZ!L>?Z-VCD''%9
M00SZC=, '/6TM>=O_J7^GVAEY94?/SNJ8-C]*I['_P F\/@)UU^_:4_E?I_^
M>Q'TXK*?X#=3&<9^:6O,=]_]9>FW70ZRHX_453:_V)G\>HL X]'HO:'P$ZZ_
M?M*=GVX:?O\ ^M]_;:!XX[*!OZA=00SC(6EKP0R.-O\ 67KN X^.GEE1S;YW
M5,\O%,_W_P"X]WOFSX"=<_OVE/Y7T#X_HWWWVBX*6XP[*U5/1=.I/*O@G<RY
M(QCWE6T%5E,PZK];9LQ4F):*;1S9R[.'A-"N7")%UQ(W3.*ZJ29[\OJND3+[
M4N%3;"WE!#:IJ1FI9DK4;)07GFDMI4LX2%*'$<#) .OJO0UKBDT^:J3C%'GF
M))I3\PS2=04BISJ&$6ZU],E*3;DRZTR#QNJ:;66VPIQ0X$J4G:3KTUTD>50T
MA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA&-;P?DVJO\ XDWQ]?M%GC^/KK&G/T,[Z!_XDQTVCOMFI/\
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MT6W/I%\DQ38XR>5_1Z]CR//M CYWC-K(-%F+U CAJY(*2J2@>X<HB Y$P#S
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M2>?HYWP8V(S@;Y%R>8. 3:QP2;<OCC O$!@8&@AYAS\\%LL#@ $0^4K8<;9
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MMB"X^'+D!'MM@<#TZ]=@W$-4VSN1@WL#VY'J%KY/KAC?MMZ[;8W_ *(Y&]T
MQ@1$ WZXW'&0P.-L;9QCO@0U."=P +'&W*PVWR3M?>^! FUN\VS^0?BB.40
M,#GJ.0ZB.0^W8,#C; #T\H[=@;8MS'/.QQOWC'.[:WO;LP.0VP?Q@8,[X#
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MQ'WC"(B YZY$>VK5@FP&!C86 MM<C&][W!WY8C>H0E*$I19(2.%('F@ $@6
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M&UR2+Q/D;T:_>0UM]V)_V_6[_%W1(W=XC $ "]CO\7(YI&"[B @ #S]=Q^(
M ^6AJ6H1?Z=*[!]!,<C;.;7((.<'UP.C>C8$?40S8X^S$]O@?N>=[^H\M@7=
MXC,B WL>@/;\$8( SMG]?N4!STW .N^^GC+4-KFM*MM;P-B][\\X-N6WHAY&
M]&OWD,]P\<3U]O1SR?5V7A\[?$;U&]KP.F/P1@M_CCG 0#^7S#3QEJ#[MJV)
MQ)R^+; 9-R>><6,/(WHV ^T=HXY5B?O\GOWQ W=XC!$,7M>YSD>6D8(0Q@.@
M<^=Q\N^ QUU'C/4&/IRJQ&XDV+WMG]5V\C[3 :-Z-M_(AHW_ ,,3P[Q^I'HW
M_)4(R]W$9#/VDH>Z*52),U@64@I>F(QJPE4R#A1FX=,E =-?%((@1PCS&24Y
M#"4Q0,4;C=7U RM+IJ:9D(4"9=V5:0AQ/-LK0KC05"X"A]:<D<CCS6@^C:=E
MW94:6<IBG4EM,_)U2:=F)59MPOH9?26G> V4II5@M/$D$&Q'I9:&[=.7@I<L
M]"B=E(LE?4*CIUV8@2E/2Q"\QV;U(IA'PEB8<Q[LOWA\S.FX0,8IA OH5+JD
MO59?KV+H6@]7,2Z[!V7=M<MN)[QYR%CS7$$*2;&/F#5^D:GHZJJIT^$O,/)Z
M^FU%D*\$J4FH^:_+K(^N03U4PR3QR[Z5M. $ G*NME'*PTA#2$-(0TA#2$-(
M0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(1C:\
M&?FVJO'7U)OCO_?!G\0UC3GZ&=O:UAOWJ3VQTVCOMFI!_P!\+_\ (>C0^DS,
MPJ&-]<!,$"JF OC"GX0+<B@H&4\803P"XI#]\]S8>?)0$!T+?]MO;\Y?X2<'
MK PL(X?]L7. HMGBMP\X]]K/7JITP9?C"[)OP<7'U76-]<!U8*C=D+-TW58>
M:0;"+N:I6](_<++/&/J:96AVA2$JDRAD@**BHB4[/D&9!8$P7(L(00I>*#81
M/RCJ\A3"%+)X2$O<2".M)4WQ^9P72D?6@=:'1QDA0;OB-*^K4JI5M#;+_7+2
M\EXJ52DI0ZH@)!*'N(201QEA35Y[C+?76%X[CO:%1?*.T_9KIL[CY--RW40G
MR.S/ECI@D58A446;=N %.9F>.62<%)S@Z.0XEU;064GA626UI8N05W3]%2RW
M2?-'GI0'5)X%*0I 2V4E1*5T^#ZA7+I:5X2T^S-RZFW$NTXLF7;:>"BB[BWE
MNJ);2^F92ILJLIE)2DF.0JT#[3=*HN6HM&J;))B+]"> JB"1W!5S))LFG.>0
M%,6XD-($*S,03\WWWEU2DMY*BF]VL6/$H>"(2X4A*%(OX2/.XBDJ'$4D7!B
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MP"(XP&_7("&0#;J 8QOTTVM>XY \[=E@,Y]!-P<0/I'K]>V<8OVXCCC(#C8
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M?/UY9YV WSQ  D[$<AOD8[X>BWI.>^W;S-NST1&?//?/81R& P.=L#N'?(
M[#IWC-L7 (M:^]N1W/:+\X6)Y\O>W9VYOW6YL]!R(A@1[![H[XR(]<".>W4/
M>V$9L#8'%SO:UK8-MA:XP,6QCE FPOO8<KCD!L;GM)OMV1(9$ Z!U$<Y ,^6
MVPX <#CK\.P\(%L\N0YCT&U]S>YQ@;1%\$BU@,#U;^S:VX.^<??3E55);JHD
M*ZHQTDRF6*/A2C)ZJ9&$JF'(;Q%8>H2)^\**9?$4C9,H&=PKPWK*'B-U'C-U
M4R_,R$P)Z34EMY X74*XDL330N2Q,6&P&6G;<;"U<: 4J<0O%JM)IFI:8Y0:
MTRIV3>67)6990E4]29U0*43E/*R,JLE,W*DAF=9'5N<+B6G6?0BMJJK&]G"]
M.U/8]*=BJWJ^ER+4@@C*M:=FV4J23;IN$V\VX?,&+< 3;N_5I,D@DS?LCIN6
MJQT727/Z?(S8GI.7FTM.LB8:2X&G4\+B.+!!Y$7!*%I)2XCA<02E22?CO4%'
M<T_6JE179N4GG*;-+EE3<BYULL\46/$@_7(6 0EYAP!V7?2Y+N@.M+ TC)2O
MI.JBMI<BFJO<1SQ[,1]NW]-F/-VZIVJH:097(?\ RE@*0G:$DH]L=NG1</3D
MO+OJ[DG;B04F)9G$2CA8YH5CE\L^BWX?1Z[QIXN10/2*TY7M[6D#2E12-*OO
MG8G;)O6\]822I)><>2XA2K.XBE95>6XL4W/#%:*T&QI"/)!,I()$EPD6S(S1
M$Z$8IDEO3#!3[*0BRR@R 1K",7@W$)PD#40B_AI]>3FWI_ER2E%JIAYEM3L8
MQ?QTZSI)-.3>S:]OZD19! F>_O[X[X1<]/S_ *5][0UXI"J:#DX2J3Q=.!;^
MDHJ6X7*AEDFIGT"66+059?*:E:;>7!1IA6;)/_.S3D+0$E<! \C2+FG:,!A"
M.7Q>P_)\???E:'Q_%\OM]'?B/FGJ+](# V;M1#4]3MW:FK:I++US;VLU8R[=
MIX:?MI<RHZQ2?TO<RNUGES*?IN290<&X7"5D;42=;5#& W68TW3,HD=JB=#M
M]./?\<92I W%M'\:S&M7]G.()_8JKK>0]%U.G6-R[,!1-LJF@U&T:6L:-INF
M.+.6"H8NJB%/.U0WF+$+5U''(J[A:R=^N?(EM'/^G^@^P0]_?XXP+Q353Z26
MU4)/72I%I556.BU)7T' 4[2J5H1&G*5?3+-O0CQBR<M)>&=OW$61U(NIFO8V
M;2;"D6*7+"/W[8YIA[[>_OVQ;["C/2B*3E/533E6WC>6]JV[%$U_542!^&J
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M7./3T_4WYAI+*CIO6S:$)4%@(:H-30E1(%\A()V-^1M>'0-M@R/;;OV$1[8
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MF8D<;#@!S[W8!$?+/GU#8 ^K3MSD# O>UCL;XQ:X W[=KK>NVU_EVWY>B.(
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M6OP+*;3\_1FU]6ZY)K6VUU@;0EEU26 \65N  &S3;H4E?"?-*'+C!BVQ<.C
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M'0Z,H9W1.[_="<^+Y]\6T/AWZ0OW^@[;^35$W_@5O7;U0+Z,Z4#.;ZUMY?\
M9SP<@/<1\<! <;;?G#3R,H=K<,[W?3"</RO8[>=SOB!Z=^D*]Q,4+^35$%L6
MV\"(_#\D/N9TI@,WUK4< & ]>> &0[9!?IG?.,]A#&H\C*'S1.[?="<WYG\^
MOS.;GESV?#OT@W_/Z#_)JB;=I^@AGE[;14HCT:A49)JK.WBK":B"JD%_$N7K
ML[=^@!@,=NL0RX@*9Q#?S$ '&KK.D:(PZAU+,RX6R%!#TY-/-$C("VW'5(4
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MKH!)VK-0/.PWF,YWMR]L1PT+[Q^C[^1&G!8<[6I^]^T;8&V(YJW[7JOZ EZ
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MZ%A87N,[F]C;GC)OG).;NI=N?G:\X'F*!O[#G;.3ZK1)G30  2N6^=M_&)C
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MIRHFTPY:*)BW:-F49'Q;5MZXDMR)L6Q$U516$B0B9XY%P].4" 5,SDR("8"
M88??2^\X[A(5U:4IX^+@;99;EVDE0*;\+;2.)9 XUE2PE/%PC.IU-=DFG4$N
MON/3<U-O.EE386N9?6XD!(4X &62TPGSU<26@H\)40*)ZVU'( Y;Y 0Q]]3Z
M#L.! 1 -QQCIG\PV24_N@0=Q=-^[F";WOR-MS&=U3OG?.W-^&_5D6W) Q<^G
MMSF.0/&N1$7*/3.ZR0B&,!@!$X#L(#@0WQT$.X*2!NGF,$?]Z_+%P,7/+LGJ
MG;?G3@VN.!=R>V]K'-AR[=MP.VG^$-Q''454^8!QU#"@;#YX'&VW3$%:#CB'
M$3V@>T7[#@^DWB.K=)_.W,9MP+!';<\[9N/PP,[:]?6FP#^+LLF.1P  )O?$
M0*(9'(!N/PU5QIOA0Q?/$ 3D7Y6R1@<Q<D9O$EIVV&G+W'ZA0]%\7WM[+'$0
M#IKOARV'&WZNF.<YW#WP#?ZNO0.^H)3@A2<[V4,WL+@G<&QS>^<\Q#JG=@V[
ML,]6JVU^P@>NV+=T =M.AG+<?]Z/C$# ]0S@^X9 ?AU'&<!IQ(S90]!(L;[C
M-CMV7-AVF!:=_>W.^Z%?)PVYC!QS[! '30!$/6D!#(@(BJGN "(_[X1QTWW
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M2=BA*@%9L%)4JQ)/"JQSO&,YJ&HE" W(@/*EW7+]3-EL+0%%.2V+BP-VU .
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MNAJ'E4*V357;<S$JGBKMQ6*5OSK!E- WNN 4$%," )@)MM5+93PK*7,I1?<
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MGU;<^=(Z/^CC^]YI@W.Y15QL3<XJPM>]K8M88A\_W$2'6_ER!P "/WRE-Q^
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M]PNX]8/SNC>(*1ES(%!(*43\VEPNI>(<"))HD-MGS*<&$R8MPVLUX++WL 7
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M&;]JDS]E4S0?R./Z=-/(33G]RO?PIZWH^N[L<^^!^:"Z33O59'!N/I3(8_\
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M2S5(U;"$E!AZCI]^XBY>.&2B'\0^%H]:F360%Y%R#V/7Y#E\5JZ71/\ >U3
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MH6)$=9.2M#<J#DXQ+)22Y-]3.2$IUK+-OGG4J<<2D\91P!2AZQ (" " @("
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MI(3DS-)J)/5-2+K[:0\EE2WD/RZ0E"EN-A:^J6\I*"H<12-P+1Q/2!5JS1Z
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MQ+4UK56L*TKK$-I\*8KZJ J4E62V1=QDTM\3:DMH9;"V>I6\5*#?BFM-;O\
M0[*4^GHJ%/J>M?)>KT42LHX9N7IR*OJA^M(J<X^)2F-(+$NW+LRTDW39=$R\
MMTHEY.3EV^N_2A'L&L6P8QC%+P&,<S;,&: &.<$6K-$C=NESJ&.H?PT4R$YC
MF,<V,F,)A$1]E;0EI"&T#A0VA*$)N39* $I%S<FP %R;Q\1S$P]-S#\U,+ZQ
M^9>=F'W+)3QO/+4XXOA2$I3Q+4I5DI"1>P %A'V:KBS#2$-(0TA#2$-(0TA#
M2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA&);\75^8^SMQ+N#24S71;
M?TR_J52DJ>?0<;,S:3 I3JM&+^I)*)@VJOAB9459"0;HE33/@QU.1,Z$:82W
MI,+9HMZI8QUOZ^:5-3D"2820J,]&EI^5=1=5VXI.N()M(TG5]63;20HV1N9
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M4%Q;\^__ +>?.('S4W1US:KEL8\ ';_QV#WC\,1_4^=]_P!T&E>^?T4GY?\
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3#2$-(0TA#2$-(0TA#2$-(1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g454025g01a21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1664&AO=&]S:&]P(#,N,  X0DE-! 0
M    %7J^5)@X0DE-! 0       << @   @   #A"24T$)0      $.CQ7/,O
MP1BAHGMGK<5DU;HX0DE-!#H      /\    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     X 00!0 $X (  M "  40!4 $$ (  M "  ,0      #W!R:6YT4')O
M;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R
M;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP
M<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U='!U
M=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S
M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!<5G;         "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _
M@   .$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     T$    &              %*   "NP    8 9P P #$ 80 R #$    !
M                          $              KL   %*
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   %*     %)G:'1L
M;VYG   "NP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   !2@    !29VAT;&]N9P   KL    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MAY>GM\?_V@ ,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0E-459*3X30U0T16T_$F16.4-F)D<G.#A-1E=*.RLR<W1L-UA:+_V@ , P$
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MA['.G+NWM4D(D\)<:-QZ:HFT_@';6UW3B20?S9+C0%9(+Z*X301;0QIDQ/$
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MB)1%I*8IR@8ABG*/ Q1 Q1WQL("(#OML/&B:K51$HB41*(E$2B*!,4!*43%
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MZ1^4 @<AY>X=AWK<? ;:N8\C5YY=-A?_ ''?5;(^&#P;@3\*<)%K^+9AQ_\
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MP_\ /ZE3X8/!N-=J<&+3?#Y@(O%QXI8$VG2XNGK\>B3_ "TP/\TW3_N'YJ?
M;:O]C5]8_*X76_\ Q^KL5^-_P<7'PHPDB\>+9A-^7X)>U[3:3H$]?CT2>/JT
MP/,?>FZ>7_@/D^/EQ"GP&VL_8V(_BX7_ #U/C@\&\3\*<)_RV86[?P2WIN>"
M>OQZ)/\ +3 ]V\5=(?E@OTW[AH=AMJQKDU?^+A;=OR]O3]H5^-_P<?XHPD\O
M%LPZK_T2^HT].BK)GIU]$UQ%23=#6>".LLR<I)D+%70 G442.4A0'Q$ 9,8>
MKQX["(4^ VU?[&K\?[;"\-?[=0^%_P ''':C"<#_ $;,(C69&#B./7UJS]?E
MT2?Y:('^:KH_)XBSY^X=AWR%#L-M6/\ <U>+7Z7"Q<QKT_/WZ73XW_!P8_VH
MPDF8'BV828$F!XI>TZ7D1JGK\NB0./KTP.^?VIND. X'.8+;?],;T^ VUG[&
MQ'\7"GV5T^-_P;_XIP@[<-F'./U3@=>7J0>GET2 S]>F!V_V3=/^X:? ;:O]
MC8C^+A?\_J3XX/!O_BG!C6QPV828U 'BDVX\N*!T\>B2/#6F!X9]Z;I_W#\W
M&GP&VK_8V(M_Q<+_ )Z#PP>#<Q_M1A+R1.&S 3'*<)W%]$]?ET2?Y:(';/[4
MW3R_\!W\F./*GP&VKF/(U>?_ !L+_P"XZK\C8W4^.#P;W_VIPEM?P;,..G]T
MX\.?!1Z_+HD8SZM,#C[TW2/EY0/=Q#ESI\!MJ_V-7YWJX4#UFO'%7XX/!O\
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MFKQ/IV=&AQ&SLHSOI9^UMY[",7_@4%,N5#J7 HLC'.&B:3,YW;#MV[A!V^0
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M@1W  WQCCG<<AP'? ;53/'4:&03,2 8@GJ//FL=+@O =9VK00"1IO1,?.W@
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M&XU(,<ARF./6=!:=.!/,BX$D"P %]TQ(; ()@M<X.U+3H!YQT>0!X!OG?;D
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M^M6WI*83GW\2S=3"4)(6XD_63ZZZ<)*.F3R0CR"(X*@Z=1[)97  <3MT\&
MP)%UI.='71>XSQ*DQ842[-!1+"$B<*/6X,F$294\05(K9TB7PF(.LL:)?& S
MV-,LL9DX0,J<3$6-I]$CH]I*)+)Z<L2JH*KN4%?&DZ*B#]T[0?.I5$XRG62F
M7;ILBL[ER"62<B3"[I0HB D6:HZ%:1HI-VPV)!.6;67F)YLP?-S2$>A,3[5%
ME+R";!ZHNT*Y?-T2E5.".QU'"I.JJY<'4*$3WOWLJ!ET8M"(Z=BKE9:<0B$Q
M!CUX=T4STQ(Y48WQ0HNT:G=&:(N5XP"LW+DJ +N42)E744[,@E*JH)T1>CLB
MPE8IOIG$M8N;.U/*1K1W+-6#OP,ZJB"9V;>03;E0!1=4ZJ":9$5SG,98B@B(
MT175O=&;0FU 9EM[3> C$HU.WDXQN@1R+6,+:RL8O"&CFRKA1!BHT7AHI8ZK
M5-)1VHP;'>'7,F T4@?7.I[QU:+D7)T<M%KM8VY&S]B1CUC:3!6*M]L5>0:I
MQ\:NY2=K,"@S=H=LT4<()*G0<"JF8Q R40R E51GZ)W1\4!P5?3:*<@\DDI5
MX#IW+.0>.4%R.4DW@+R!P=,2.4TG 1J_:1_;I)JBV$Y"F I []7'MZUV9I]I
MA8NE4.O V!;[6VX=PZ.]48,U7)T <'*!1%,KE=844RD*4B:*0D12(4I$R$(4
M  =#QZN:J^5KI.1\@KTA-85$F#U5(U^SQBJ)M5U"' 7.QB&!,P"41#&2B8!W
MXCG/J79"HP;,9(.D9/D^B'2]@YVNZ>HS>PT7YT^$ZE7?X0MKMVE5+/+F+<'L
MI.<V[VND6W3:#(L(N'25T4$7);^US_?(!]1.>(<O<QYAQX8#CD=NQ[](WZ1F
MA)A[>V-3!C0<AVQT08:N 6]#6LZ!\B\6@EMPP D.:)=,#>.I*>*I+8?%K_',
M? W.W/'N?(-^_ YH:M*QWZ? [N^WKX3(L!<V=8]2HHX@7-"L3>3T53>!L#'F
M@$$3! M-KB4\5R>?>R0\_@;K/'C[GR ._',1QBITE/7?I@\(>ST6+I[>V>%X
M</6(W1AZVZ29FC5DWL3#0"&B(!WN-]8D8R2W]K9 =LAEFY$1$,AR3[L!^7
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MP&B9 $AP!,"S0=%)HR3#;Q:_Y\63D=Q'[D @.1QRSCABITE,&U2F1J)>S6.
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MDI"#8A[=>9 ,7/&+7M=8G#5BZ10Q#9F0:+CKPD,L   )G68-P@Q<EG'BY_L
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MHJ,FVKVVXV\[3M%N*SZ"KYT8:M!!CS*QF9 !#A:)DQ'+@"H"+DQV&.D!$/\
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MCN(<'2T_TC+ 6WV\"0 8,\)G3LF5B,-7@_(UR"03\B\$&V] W01).Z(B!)F
MGBR3ZHAXN?\ '8/ G/#/(>R[\@/Z[XJ=)3O\I3)XC>:(O',6L+$&+$BZ@HXB
M"SH,0)&Z"*3HB29,M)GYT$$3,6 "CQ7)AN$=(!S#ZC<CD.&WTK?GG;ED>(A5
MZ6D3!J4SK)+VB8T%B8O<S'V(,/B&Q%"LT@_HGFT;M_-$D P8+0!)_.A:@BY+
M;,=(!G([LW.V^!X);AWB''8-@WJ=)3/]HPQ:"]L"]C\X6T%NWJ.?05]XS1J[
MI$?D*@)#2;7:XSJ1<N(@ CC'BR3']KG_ !' BR<^7.?I0XW^?;.0##I&#2I3
MM$>>.NPD]9UN=;E#1Q)D&E6((,$T*A<;3!^3< 9C2!'&RGQ7)_P8^WV$? G/
M+C@!3P [\@#/+AFG2TYCI&2=W1[38D_-,V@Z">'$*.PU: 6T*@,W^2J#YL7)
M((N)N0!Q-PT!XKDQ'WMD,;_YFXR(X$-\)[[Y#/'<=ZIJTQ(#V&]_/$G29.]J
M=(C4P+J"AB20#2K!H  )I/B(.@W8,&02?G-\XBZ@T7)!D1CGX% 0X,G&_?\
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M'K$WN*3P!)(:2 P3 APB--!>?7O0082"/2JTD468O$DR33GK**M5R)E 8UX
M9.=,I0 <XR(AP ,!C?J6W-1KMF,U >PGH6@!KVDQTC#$ W@=7,\)'TOP04:H
M\(>S9=2J- Q=1SBZG4:!^#UA)+FR2XZF0! $!?31=6GMGWLWEFMS0J$FG.6W
M(6C)G,JY;N%[<E5$U9"+*Z:+(.6Z#I1),ZHMU4E!$A1 X8KS(OT&@$S%PL(=
M='?1Z0B[6AI*S6\I&V6NU7MIK*2,Q(EC!:8[)$AWD@LHNT,)$#+LG1UFCE1H
MQ4<(JJ,FID2JO&FC6F3&^T-36EH1:%]MVLLS2N4@+^, ;3C@',FD<PK"FH#A
M0I0**B9S()%*@@*2)2I@2._OYKLZB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M410;@/F'\GEHH=#V=]%C%J((&MZ+,9%(3"B<1$R:8F$>W5'(C@>>_'(<]ZR#
MG 0'. '_ %C[UB&,-RQA))N6MO>W#DLB\&;?O=#\4GW8_P!7NV\VU-YWTG>L
M^].CI_HV?NM]R>#-_@$?Q1/\--]_TG?O'WIT=/\ 1L_=;[D\';_ (_BB?X:;
M[_I._>/O3HZ?Z-G[K?<G@S;?ZG0WX_2D]_/]#3>=])WK/O3HZ?Z-G[K?<G@S
M?X!'\43_  TWW_2=^\?>G1T_T;/W6^Y/!V_P"/XHG^&F\[Z3O64Z.G^C9^ZW
MW+&Y1NW">ML.P1#)I0,=D3]Z$$,AU<8P X'B'#G3>=])WK/O3HZ=O,9^ZWW=
MG+WY)X,W^ 1_%$_PTWW_ $G?O'WIT=/]&S]UON3P=O\  (_BB?X:;SOI.]9]
MZ='3_1L_=;[D\&;_  ".W#Z43_#3??\ 2=^\?>G1T_T;/W6^Y/!FP\6Z _\
MLD_\--]_TG?O'WIT=/\ 1L_=;[D\&;?O=#\4G_AIOO\ I._>/O3HZ?Z-G[K?
M<H\%;?O=#N]R3X=WZVF\[Z3O6?>G1T_T;/W6^Y;:[9OV*WTA'W)3]B)_J#_S
M:;SOI.]9]Z='3^@S]UON5; -FX0L7]3H?8+?@D3FF41_R>8U-YWTCZSP[^U0
M4Z?%C#<W+6\SU*W\&;_ (_BB?X:N^_Z3OWC[U>CI_HV?NM]R>#-_@$?Q1/\
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M)_-P?+EXS/IB_#FJ\GHL&B)9-P]](VHG9JL6K8"]A!]<#H+NE#".97'5$JY
M#&1R!LAPI\56=7_#LOL =:_'_P KEIUVLH/ND-DR8\CYY,QN[F#D$B0)\9OQ
M[Z\_V6O0X.-BZBAQ_88+AO\ [5Y_WYSBI\56=6_#LOD]=8WM:>CB>YB5D?NC
M]DP2#D^>""03N83T2!B28TDZ>Q ]%KT/'_0747.>'8P??]\_F ./DR(4>"K.
M3_?\O]=?G'Z+FI]\?LI']3YY,3'1X0Z"8@8D^=K:05/LM.A_\1-1N(\$8,1X
M!C.)3;.>&:A\%>=<,=EYX:UNOE3.L6Y^N*/NCME) \CY[)$P*>$F#;]9L02
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MKT<=#' "#G3*UW8&D4)8WA;11WUG[8YE&ZIO"%E>L1!0YE$FPY:IJ#UR(@<
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M#1K.I ($3$^I+JH(#];:_=^7I/N 1X[B&([CL&<<?/BGE7*P;9C@+R#^%T)
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MX!@1[P[Z>5,K/^\L 9N3XWA_3_:'@9X1:_!0[/;0[H(R3-]X$"/)^,<&@R2
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M1,%PB:6[ND@ @!M^4B(#275/(9TUO_C_ !/N'@'/:/V$//S#EQQ\JY7(G,L
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M@[V2YLUTDB,NQC06R+;QH<YDV+@038R7J3:IX$?4TOXO_P#3[A#(8P(8".$
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M97C*N#J8BEB\(RG6=2,.J,8\%[6G4;WI(%UCX>B]Z=#^X]>W#/O]!?(/TO\
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M?][X+^!7OV7^K6X6/WRN1M _V8S:(D?AF#/9^;J>%H/!<\?1>].@''J/7KP
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MW" EZHG#O').^GM[A<2&]$<TP7L2*N67MNZ!N%>/:2$S;4$P6ECPZ$M(-XV
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MTGKAV+VO'G#97/P9F!E.-$3<1\B6@M,7W;!I)(,!;GK>->@$!]1O4P.?VE7
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M'B(XNP,8[\^*MO,._P ?"?%,W]M:?]D FQF)K3U>E7[Y>_\ T5BT_P!9R )
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M@;CD1$!$,<]QSOMC;S[9&\W$SIH".761VFVA*Q:3+7$1 ))\X_G$R?HR1;6
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M1E _6AOAJ3 ".. !G >7A6''KO\ 9/V+4[/3U=<=962E*4H"!2E* B(B!0
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M7R21'^44TS.#MRE*@JIV*B9#%#K._>$](7S(=)X,=(?6(=L>G^>'; _YT.^
MX=;&?C"O5&R$G9C(Q8@9?1)FPGSA$\.H2OSF\)P/QA;7%I(C/,7#@P&1O Q
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M(K2B)1$HB41*(E$59,HJN8F2;H$%599DX223 0 3G.D8I2@)A H"(B  (B
M/$:(?7I[?LU5G1$HB41*(E$2B)1%5IH+!-.W(D$$%(YDB13;!E4G#TZA WZV
M2E53$<ACZ+81'."*THB41*(E$2B)1%63*"KF,=H(D%150A (0! !,(*IF' F
M$ V !'<0X<0IW[]_6AT/^OU<59AP#S?IPHB41*(E$2B)1$HBK6""B*TJ90@E
M*XDA72$<?1IBQ8I=<,"(X[1)0H=; _0YQ@0IQ/HY\AS^RR@^T^TPK*BJ41*(
$E$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g454025g01a22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2+D4&AO=&]S:&]P(#,N,  X0DE-! 0
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!<:T.         "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _
M@   .$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-
M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     T$    &              '.   "O0    8 9P P #$ 80 R #(    !
M                          $              KT   '.
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   '.     %)G:'1L
M;VYG   "O0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   !S@    !29VAT;&]N9P   KT    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M4DX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@!A@)0 P$1  (1 0,1 ?_$ !X    & P$!
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M/;.$7 PUN ;@Y!R[YN"UK@,);F;5^$W:.%@)6>U>Q1O$ [NW[,%;Q(2 /F!
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MYRQD!RJ28;D )%J'Y)7#N/R,<;(*M,-Z40D)'</A:6   -^P'@ [Z'8]F?\
MTL(\8Z]--(V_.;3?\SM;AO\ (OF6N8#W$^1KT1404':(;*=(+8[66T_I/E21
MIL_I/DD?7]6P1YZ?D]G_ .EA6;+2WTTG2:C\WM+D?F=JN\J+/KG"7#06-$*B
MO: +=>P.T]R"EEH.(6=[4@AH:._._!*=[WX)A&R;,(&'A,YN0+W#IRF\WFK+
MVW:MP_\ ,[62;@*47MD\C4$6OPJOZP\?1;^F/FZ-65BYMA*X\R)$9AN,5SI$
MA<"0&DPT-M][DE?<L#M"ED*.O)V>)MVQ;&4JW@E)*8&&$D;P$#A<M>U>@[H=
MI8V%VGLQ.T[=N)6"P)#!B\.[.E,?I) !#,S8_#XH[.O](W$<6VA3:Z<U0!#L
M:P9<9E,.(G2T$/1W4]Z5D)3KO3O0'C76'9>RK1AX94_RE0=I/_<1G :/L*[#
M\0]NP>T.VMHQ,$C=4G"R<@A"  2Y8AI 9G<W87K9;#2 @'9 \^0=:^GC7M^_
M]^NZ47+]>/&O#8:-Q($^GTBO;J*O0Z4H=*4.E*'2E#I2ATI0Z4H=*4.E*'2E
M#I2ATI0Z4H=*4.E*'2E#I2ATI0Z4H=*4.E*'2E#I2ATI0Z4H=*4.E*'2E#I2
MATI0Z4H=*4.E*'2E#I2ATI0Z4H=*4.E*'2E#I2ATI0Z4H=*4.E*!.O/2E8J)
M"201X\C9T- CW(W[_3^='I4<7\[ 9]&DJ9<5\ I,J=&8+I"6TOOL, DGW3\5
MQ!5[C0&R?IO1U;X:RDJ2DEF@ EW@6YZAO$ XKVC#PR M24N6^921RN6/[P];
MK3X>2E;3C;J%CN0I"DJ"A^Q05!0(.]@_VZS=27WDD>'G6R5(6'2H'1B"#Q<6
M'[36:WDH'<HE/G6CH ^3]S[G7W\>?;SU16*P.ZA:B&8 7\7RH6$E0 ;,L):.
M?[UJLV,-YXMMRFENI!*VDO,J4@^/TJ0E97OV /;KW\C?C0%12#N*?.)?S;/+
M2J#$05,,1).@4DM;('U;0/9]I2^[_3W@>-%&O)\Z\^^C]=?0?OU5*B5%)21#
MAPVC3XZ5H0X'S7T,_M[^M>;LN/&0%R'VV$[UW/N!'ZCX"1O6SO\ W1Y/N!]K
ML39[W;C;Z512TH'S* YD!S6JY;5J%I9<GQ6WUCN#"I33;_CZAM;B5=NO)"1_
M/CJPPEJ=@HM=@<R!_B-1?GD15#CX0(!Q$38;P!+9AR''[NUCY_G547"VBUKU
M.IT"V9K&QH_J2I <)"AOR2 ?;9/MU;X.*S[F(QS )\B.42TMI53M."Y;$PW@
M?K3Y&89^A7M^90EH4\F:P&64]SCGQ6TM#V&E.E7:G9_TD^-[_;JIPL1+0J02
M 0^O!X]L\JLG'PE@E*TLEGD9VSK=:<0X@*0LK2H!25)4E8T1L$+25)4#KQY.
M]]58BX(/$$>]JT!"@X5?0Y=?S1D#]2_U=P2?<#8!&_'C8]MZ!'GW'4B2!&GK
MG0A@3)($.Q;EUE5;/5%E%WB7I^Y<RK'YOY?=4>#Y)-K)BPVIN-,C54E]E\-N
M;^*XVXD*2@@H40GV*3UU?;*E8>R8Q2=WY52"Q_22  &>6CC7L.XG9B.U.]?=
MK9,1;8>T=H["C%0J4*0O:$)7\0;I&ZI)*2X,1F]5L_#"Y9RKE/TI8WFO(%VB
MVO["XOVY%H\(D$2?@V\IIM*4)4TPVEMI"4(;3K2$Z'T'76=VTXN-L>+B*6I1
M_,XB4W@):&8L',#^*]M^-_8FQ]@=\%['LWP\- V8*(21NI_NXJ4)2  P8"P8
M',F3T*<O*AEY+;EG#2I>M-JF1>Y15YT@*>!.M'6M@_3QUZ=.S+*7W3:[&SQ+
M>[W-?$E[5@H405I<7^9,F(#J#<8^];K,V&_V+9G-*V2DAI]A25%&P1H+5I2?
M][7G>MCJWPE(=.X>>Z3Y%LVGE%7&+AK 4G$ !=TA2;B(),,[WF]Q7JAQF4-Q
MY:%I05)4&GD+TH$;"B@G2DD$$ [&R-^_6921+$9LS/:0\.SA\WN*L%I486"T
M$)(,NTD"';A>&%;;2 V@)V5'R2H^YV2?/U\;T-^P 'CH! WA.;L>OI:KBUWX
MF:S[4[WVC?WT-_WZFIH]#[#J& L *4-#[#VU_3[?QX'1AUU_%*&M?]_]_P#Q
MU-*&A]ATI1 #[ ?T_P#C^?Z?SU5(#0V=GUF\Y32JP>J_);C#/3QRME>.RUP;
MJ@PC(+.MGH0A88EQH;BF72TX=%:%>4E0UXU[$[XVVIW,/$( <()!8:$#RC7+
M*O1=T</#QNU-FP\1*5(Q,5 4"X*F4XU<#,&[&(AE>B/D"\SGTS\1YAE]XBPO
M[RCDOV,U\QHJYTH3Y24 L-J;:[FT]H2EKN !V3[]<3L!>)C;$58BE8BMX@*4
M25!BL2XL]KF#DU<_\2-EV?8>]^U;-L^Y@X"1A$82"E&&-[ P262"!=4@ 2';
M,6[$U")#B \%NH:#JXP6WW:)3M?:5Z2$C>U'0'D^W7:A*P5'YB'L1J,C<6-X
MKQ1Q,,XNY\5(*4J(!(L,];.&9IRK9;FQY+87'E-K3M20MMU"QO\ WDE2"I)4
M@_S^X'5=Y6>&H",HXSKPX%JE*T&RTJT9238>LWX4;<Z.IQ4<O(5)24A;*'4*
M=1W#]!4WON0%C7DCR?YZ!2BWR*$R\Q#*<99E\JE2\(JW4XJ3-@H O/RLY/UY
M5NE1\^%^VO 'G]QYWOS^V_IOJ]6ZZZY40.U;TX/YT$^1O^?'M_/_ "5#<3T_
MW]!7ITJ:'2E#I2ATI0Z4HE$C7[G7[[^G[>_W_MTJ#<<8^K^#>M05ZA,MS'!N
M.+O+,.75B;CU?:6\M%I\<LO0ZV&Y)4VA,=27%.J*-:&_'L"3YUPMUSO $!KA
M]?X/.-1U/;&-CX&SC$P%[BDE147/Z0!D"'9W;EPJ%L1]4-/C&,<?SN9LFK:_
M).38%=98M3T=;?V#TEF?'9?;97%APK!Y@EUU+'QGTLME1"0ON(3URAL:MI_T
MFP]UB6.ZX5:#<<<K6MUNS=LJV7"&)MZM\8S_  Q)(8J#YL68,'+B13I=]8_#
M,?&5YA*N[R)CPLDU*;"7AN90TF83,2MHM2J)IX.,&!+^.$M::2A"G"E+C7=;
M^E8CL,4&+[XELF;G8EIOGK_Q+LI!.ZK]08!+EB"7??9@QN=&N32VGG=-*Y/M
M<R;5 Q*TO:6KP"UIZR\NW[EBUKF9"I5G!@5[TF TW)6IKXSZ$L)'EQ22-=8X
MFR?EV2I>^5 PX44 <K.)<Z7RK?9^U?S#+"2,,$;JB"D+W@9#L2!;F0&<U9"(
MZ7V0[W]P=2EQOW&D.)"T>%(;6G:2#VK'<GV5YV.N,H,?"[,YSS/TU:NZ2K?3
M!#MEQ$&P9[Q:O=M*DA7>ONV?'UT/;7MO^GGS[>^NJK4+AA%FSEK>\6RJ4@AW
M),QRHN\[/[[U[>#]-]8A1W@Y+9ESY,[_ $YU8]-55.3^;\AI.8*3B/$6*MJT
M>Q";G-U;Y"X\S41:2'+3 $5A30!=G2)3S*E*![&&$+6LA/GKL<#9E8V&%H9M
MXI, S!S!-CEQSKH-N[35LNUC9['X0Q"I2B$L2L,3JX><FM)"9:>L7BC$9"<=
MS#*83&41Z+\]L85%#M\B8:@][@6\B7409K7:I*%.-I+H=[0?T'0ZV'9V*<B'
M!.<-E9_VKA'O1LV#\N*Q6E(/RLM+DED[R5%))#6) #/+@Z]=ZW>!;*/2RHV9
M/N'(+B305<9=!DD><JRBEH.1WJMZK3.92GXS&I;["([J7 IMP@D]6_IN+%WS
M@Q)#6Y.+B-:S/?3LQ("2ME%4N@[R00Z=X F""#\A)(!B#2 CUS<13+.&Y7Y2
MXU0.1LBE3IUKB6:5Z5-8[\TU-55R7Z!,.08\J$ZTMI;X=DD@1$OK4VVN_P#3
M%@9$R[&P@C1X<V'U%!WNV3$4 @D(8.HH4ZG>P3O$6S $RTM;/ LWJ.0,8J\G
MHY$IZOLVOB1US*NQIWUH)4 50;6+#G,'])\/1VU$?K[0E2>NNQ\(X.(I!R+:
MD&+\GEVCSKTVP;8C;=FP\=!)"PX)24N):"3,>+.S5&?J0Y%RKBWC"YS7$H<:
MQL**372)4"67=R:M4MMJR0PIM*BJ2B.XIZ.E*22&E'SH@7P$)61O2"VF;->U
MY>/2N-VKM2]FP3B(44D* @:@EB0;*868^M0- ]7C<W,\6B,,AS!IG&$S/[RW
MBL3;6>V]%DQ&W8,6!7-2[%1@M24OR 8R7'/B!D(4MM21RE;("Y 820T7X'@S
M,[.[.[]!A=YTIQ A8)"4C?)^<N YD+)8.7WFD,X84JS?6%0G+L<;K''G\ N,
M1FY)(OW:+((TUIM,-JTA/08DBN9D63;L.0RTXQ$B/R(\COCNI2^E:$PG8V=P
M3S!G)AQ=K$$$D0TWQ>]6 %I"7&&0"5)2Y!W5&S[T$ &"Q,.D;U+4?UR\ RGL
M;AHRNR;?RM"55"GL5RR.AUS\Q-6II];M.D0E(L!\LM,GX)2L$* &^H5V?BI<
MD,):<F=B2&Z?)SNCO7L*]T J<@.2B$F8/S[Q+"6!\':GY3<YMP+BNQW.V?RJ
MYRB\LHF(L5T"ZG,3ZR.H*C29TMJN4S3NN-]I#=LN$%$E*5*]^N*O#""RG!C/
M,^=K>%<Y';2%K2E2"G?("24D.+!1#E20H@?J2"'+L XL>GR =D@C8WK>CY'M
M]A^__IUC7> N =0]!1T#YU_R.OKKP?\ X]R1U!-N<OD';+7+UM4^E56Y>YMO
M,3SK!N,\38@C(<TAVMI^:7KA%?6UE+W&0I<9E27I+T@Z"/@JTVC_ #%$)3UR
M,/#WB!#EG)=@Y#/I_-=%VCVJK 6A&&D)*P2Y!W6F[$L(@S$G,E!G>K_C3"4U
M]5R/EE1!R&5"L9B(V/LVM_$DQ:LR/BR42JR%(2PXH1B$0Y7P)+CVXL=$AY20
MKEI[.Q52/TZA]'_VDC@\'PKK\/O/@8:#\8I4M(45'";$3 ,OO:B4D LQ9R:\
M(GKCX!ET,+)$9E(;K;*[30PU2:')(4EZS<8^.VP($JL;EI;^6'QR^IE+/;I7
M>#XZD]G8C<F!SSN[9EN#/54]\>SRD.5.263\,@[M]Y]XAKY[S!F,TF2O6]Q/
M,<I)%-D+S=-)MY<&TN+;%LWA5J68++_S[<&Q&-K@+D1W&% !Z2A"E I"RLI'
M4GLS$94$Y!G'B=,WC*[TP^]VQXV)AX6'!6H)*E)4)G]+/?F+@L(-6;XWY)QS
MDRC9R3%94V;2R77(\>1-JK6I><<9 4'40[6%$E?+.M*2M$E2 T[M)0H[ZX&+
MLZ\%7S$V"@'R,: WRSN=:]'LNUHVE(*8EB]W#M8J!?5Q.M21UE7,H=*4.E*'
M2E#I2ATI0Z4H=*4.E*'2E#I2ATI6*E!"2H^R02=?8=*@E@2<J)*TK0%)((/M
MO7GSK1\^Y/C^>J[WS!/GY/% 7#B']*Y;>O.FR2VO^*V\;5<QY#2,R782*ZLM
M+6&V@5<,5[<IFOD1BF0N6KLB2%N*^7=<+W8M*%(5Z#8/@I3OXWZ$EE.0Y?P,
M.=-2!!;P/>8XXPU' <8A2(#Y+#@RY8&6,6IG0.<O4SAE!!QVLXZDQ6,;XDK;
M9N;;M/W\R1>F*ZE#:U,384B:_P#%C#YJ B,EY"7TK<=2YIM7-4CL_&*C/S9#
M< X$!GA,.\DB "U=3L_:?:^SX>&D@H"$)8*22IC)45$_Y.201\H.Z9#TH57J
M<]2^0P\1@-<<*6]9WDR#?7SU9(JH"(+#,=U#K5=-L#+A.O+<?0A3JW$J+0 (
M[QUF=BV##&^Y4' 8D BPL4L4Z:0X)O7'[?[86GX>&"5$D.G#+'-G<L0\LU[A
MJAJHM>=L19N;B@-_,R[(*;)["1;2\:LWI%?+7E<.(PS$AKOEUQ"*A4AYAAP,
M]Z&4N%UH*4L<W#PNSB@!02!#?I!4Q,$-9S',29KKMEVCM<8Q(*W4Z=XA8;>(
M=G(%X)&8(#5T-P#.N5WU\AQKAC\Z<QW'Z^7CK;-+(J')\]V-(4Y'<?D35M27
MGG$M[0T&D-=VD.O)_4>HVK!V,*2,*#\0. 06#&,VL#:+$VKW>PX_:7PEG$4[
M87R$A0=0W;R'<$@EY+- FJ-ODW./,.0<?4>6P;&AHV,Z3^;R*JNL*],N*W4J
MG.092$RG'63530F(J=\0Q9H=VV$J3YS&SH288\F&MA;FXSG*NCVO:.TMIVA&
M$M13A[^Z2D*!8J AC=(=B79WEZ7>2XS4WU)TJIU+E\:EPN(Q8RY]=&MW$Y9D
MELEJ)75T0MJ5$%75QR'; O%+96LGR0>M<(( )2$R+D:96>!9Y+RT [;?L>TI
MQL'%/Q?@*60H))WEK2F ')"4DW+NR3#D4TKK C&RGU.OUU+EX<J\5CS\0?CN
M6Z>VQ1CJX\UJH6M2F9,I4Q2GT!H*+CI0$*!3UJ5I  =),[TB2'  D,&#P(=Y
MSPVC8MK&%CK!Q69\$[RG2=Y(999C\K\X'&HOE9QSE,XBR+$Z_'KB.BSL;"M>
MO109 N>_$@U#4^H#,%4U,J&_:RFOE'+!#J&HLEI1^&XMU+2]4X2,5R2!NLT@
M AIAG<-:7B&KSFQ[5VK@HVC#)40I:#\3YR1P*BI@ ;@ <X+W X)Y-YHL\WJL
M+O<4?@XI$HXJ&GI+,MM^)$C5T!3%C+LUN+;ES;":Y,977MI#D1$1*G5K4]I/
M7[3@HP]XPULC$P(!<S?/2O4]B=H=IXV/AX6*E6Y^G=(4DL ^^3F[)(U)@ 17
M0AIWN;6.]"BD'O\ ]7@E))]_).O)&O'[==3G#WR(UAHCVKZ"RDH&_!4DJ#O+
MO(<YFUJK%ZK[84OIXYAM?D8-LU!P7(WEU5HA2J^8IJL?=4S*#2T.J86V@H6A
M&B4J.E#?CJ>VBVRXBBY "B7E-K%B\NVGC?V7<#8]LVOO?W8PMDQ%(Q5=H; $
M*2X4DG:L,;S@&0\ @@-F"QY)>G_*T9WZ&^*X=9@@IK/,LVLL;C#"*^X;H,.C
M/W+Z;>_?1'F.OA,6 B4MCXQ452UM'0\$4[GJ2=@QE%(2#M>*4A( #?+#.3!S
M+MQ,5W?_ (D-B[4V'OLK9\?&QL3%7L*5+5B$ND#%QPEV"7W@D*(#AR2X<-:K
M(L%HK#.?36:2CS%VFD3[N+;S);=VVY(B5U"[&K';Q!?[8J)$[X3C9?!4I2E$
MC9V?;(4D @A(81*7 ]8#D@D/!<17YEQ=AQ\7'V<(^,4 J&.5*6#BDJ8;H!(2
MY20P(9]9J-ZW+.8N-[O*XV-8K?7(BY9R6:EJUK;5UJJBR+6JCP);3ZK!+4^
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M\+4I=9UM0Z4H=*4.E*'2E#_O_O\ CJJ;>)]\N&C-]:55;U=W#51Z;N7K1R#
MM4UN!WTEZOLD..UTQI$1S;,U+02XME>B%I9).O( V=<?;8P<6'.X07S"@0Y%
MPUXEXKT?<X?$[8V).]N[V*D @DJW@HD"&#&RLB+&J#XC<B^],/I R!O'GZYA
M&21IUA48?$M%5U=2HG6"WS\&,I;PBA+;:G$/NG?<K2#M(ZGNB@*V-1(8J)*1
M8;KXCDR<QF9TSKA?C?L>U[-WWQ0%*4M"D%9*BY0=GV51!9(EBG=#9D.2YJ4L
M]YFY'_QGD5QQ]A]I90/\ LL5TNSI;F.EM3UN[%G.ECXP1*6U%7\ZPP6V9;J
MEHK0.W7K=FV3"4I7Q&"6>XD0<[\2#SKXYBX^WK[1QSA)(2C9L7#3O)4&8 E0
M91N06>P?-ZCWA3DSG_#\?Q''(F(W=VQ-N;V=:/7<)]J5,DS\EL$JKH[KD@JJ
MHL2L^7GQC,^8/PW1'"CV];G!V A63AG#,"= 9S;DS%P:PV';.UL()2/G3OON
MJWE%7RH<;Q+M$!P0YN&I!1S#ZC*7(<]SNKP2TN,MMZ_$HS%,8,^-C]"ZJW3!
MM0IN3):5/7"C%:53(KJ6WVP)91VHUT5L^P*1N8>[O, [I<D W.KSD26#-6:]
MO[6PL<XY+DEBR5,D%0D)L/D3NL8DE]YC4TY!SMZH8<//+2%44[3.+5^(NPZI
M>-VTRQL)UT$)LD0WHTY465%@J4M2C\1+C?:01Y3OC?D<!P&3FVZ4EP'<6!SR
MF9D5SQVWVL4K4H[H3ND@X9)FP#0 0Q).A@NU.[TQ\_\ .'(7)DW&>1J!$*A^
M3L7Z^P9QNRH@'X$I;"4/KG39*'Q,CK0\S\)*2"D^X(UAM>QX>'LZUI =+-()
M )38,\3G9W&G8]D=K[=M/:&#L^,7PU[^]\I$A*E."[,&((8NX9IKHQUTE>XH
M=*4.E*'2E#I2O)PD%O7U<&_XT=_]Z_J.I&?(]6/TT?6JC*1J1Z$5!GJ"M^/*
M_CV;6\GR9,3%,HD#&9GRR)BW'U6Q$9$?XD)*GF?CJ6$!SPG]6B='K7"9R_ \
MB'TEN$5U_::4*P-W$*@DF2F^6K\,M;VJ/9'"_#"Y/%<214..6F&515A,B5\V
M^['J((8[69#JP4J2E(:6$/\ ^9WA*DZ4 1R'Q02<,D $;S6B2'<6?ARSKJ<7
M8=CQ,+9DX@69*D.WS2[*&ZS.]F8$F9)TZ;BG@GF/%I,"IC"PQR+F-K8S8\.1
M+AMG(DLSJVP0XESM+B>V9)<4D#L#J4K3Y!/558FTI91)22^H=G8!OY<7O5\+
MLS8,4;B$J "B2Q$N&*74&(8.['= ('&:KCB;$;>CH\<FQ7':R@7"=KX[<EY)
M2J @(BER0A25K 0D%0*3W'SK>]XG%4L_,7/^XW;W/G#OK79_T_#1AA"(2@ !
M,M%I LSN6!T(IV8_D-/.DV=77R"X]1/LP)S/PW4-QWC';=:0VMU#?QO\A2-J
M1W)!_3L:Z*2XBX]M*UP,5"24R&#,_P H:Q<G,9MFPM3CDOHCM..%1[0DN>"5
M[UM7A(TH^!Y'\#W\]8C#WUI'%FMGF;_OXOR,3%2A"EO8:%_*]IJ!,&]17&.?
MY5-P_&\D;F7\%V<W(K78LF'(!@$?.ADRDH2ZN."A;B4*/:D@^1URU[$I.'O,
M &?(F1H+<VT<:=7@=JX>+C?#2HDR2D@B!=B2V<#,V$5O<E\1\;<D6]8]ED9+
MEVQ7R(\.3#GN5]D_6N__ *9 6MI277J][:%2&"5-=R4D@GJ^R[1B;-AG#207
M6HG> -VE+RY ]R^=-NV79=JQ@K$8K.&-T0%'==@Q%Y,O%PY)>#'. /3%:YU9
M8!$I8L3,6<#AQK&OBKDQW4XBN3(C1GDR2E+3B@^5LEQ"B\-]I\ =<D=HX@)<
M))EF#219G)8 FQ,0VG6K["V+% #-D2&,R7*BDS R\"6=Q4/HEX+QN5 GUN.O
M"966+UG%>E6<N6M$V6PQ'>45O%9".R.RKL2$I[QW)T1OJI[5Q 7( #F0)#YC
MYA)S$!A68[G]GK45[JBHR4[Z2" & A @</FN'@"E)WT<\(/U==1RZ!^15U3%
M_&@0G+.66VV\C<D2+79)!<+[DEQQC?\ Y2B@)UV@]5':JW'Z09<Q).9GS\8-
MJV3W7V%#.E1RW=X.;N_RMY :&+6/Q+&J_$J*MI*[XQ@UT9J-##[JWGDLM("$
M!QUP]RUA.@I2R5%6S]NN%CXWQUG$(8JD\2PEYO\ :[5WFQ;(C9,%.$C]"0R0
MU@[C(3Q ;ZQ5Z@GN/XF$.3.2WI,?%TV=:E\QQ-),E]\PX[;Z804XMAUQ]+:D
MD=OD]VQO>FRD[P N,X\+F^K1FS/7"[7PL->%_=*@DE)^6YN"^5C&F7"%V.">
M(:E[';O$)$[%\DO<3G8]BTLMSI\-FHEO)LYS2Z:4XU&"WE/(=693K)6V6DMG
M]&AS?S"@I22E)2DMH_$%U![ YG5F?I_Z1L8P\/$25)5B)2=YQ(4)!=((B2"6
M&=ZSQ7AO@C/HR,?B+<MYW&D.?@-M\F[+JEP7I(0Y9,N1T*+32G5.IE-(0XZA
MMEQM+2UMA)ZA6UD!T@.Q87')G!8\1!9]:G!['V#&W00^X [  L22\I4'!4;&
MP +R^S-]#W DYVK6]0S6_P G<*H'R]S-:0A2K-%PI2DI6E)"Y[:72/ \J^_D
M>TL18 9$ 9$:#5CES+G1M$]W-B0794DL"I+'B73$0&_F:)6)\>9+E5:Q)0\[
M?<?OQ)\=KO?9:BKDL%#"U'M^7ED^%@*[M* )\]<'$*L0[Q(!GA?C<-+#.*[)
M.Q[(%88(G#*6M=&A8N7:8?F:FU;S;2-DG24DG[@)'D^??7C[]8)25$MPS/@P
M^U=PI80'.A+YPTLW'2\--0+4^HOC#(<TFX!6Y"DY766#M?.JGXLF.XB7&0R\
MY$#CS:&5NN1GFGT)0L=S:^Y.MZZYWY'$ *B"0!?@SDP"0 W$%FKJE=K8.^G#
MW@%*4$R&<DL #O,YR/!RU@K<E<<<;<C.TK65QD*GQ')"J29&G*K[%!<1J4U&
MD-%+X:<0.UUMM0"D^% @Z.&&<3#(5F+[SDA[9^-3MF!L>U (Q '+@;I 5F)<
M.Q\=9#57JQ]/OII_QC1X [11(N6OXS<(B1&7934F50S7%Q[1QR6E/PG%EV4Y
M_FE7S <<[@>X[Z[!/:2\,*;=)(+ AMT  2-ZYF'('($5TJ^Q.SUJ1@?,E2V"
M@DCYMYR"Y0PDPV37(IP4_H8X"I846%$QI\MPK6)=1G95I+E/,6,"(Y 8=;4X
MI12ER,\0ZD'2^U!7_I3UC_5<1Y*9#, 6:+G>@Y$!K O %;#NEV?#A6<E27 D
M;H&XQ!>]PU[NO2?2)P^]CU=C3]&])IJFZL[^'"78RE-JL;@.?/NO$>7&7"\X
MIM@DI0I1*0#U8=JK?*2']+?-F07OD6<U8=U]C0$E 4#ADE!"@[J"0?\ R[,
MTY.34\8)A-1@M%!H*1IUJMK&RS#0\^[(6E ':!\1TE92A 2V@$^$H '@#KAX
M^TG'426<L"!PYE[ZP-*[K8]C&SI D[I+$WD\ - 7S>>#YZX]<]_6*:>29A1X
MN[5,6]G$KW[R;^6U3<E909D\I4M##1]BHH221XW]_&NM$82L4D#IQS%QZLTU
MQ=HVE& D*4H,7$V&A.=\[6?4U@E^N[TM0Y[]7.YDQ!F=%FFOE153GT/-2_C&
M.8Q"6%:<#R?A[[O??T&^N<GLK&Q Z03F/FX."SZY!\JZ-7>KL[!7NXF*R@J?
M[:R V3A*F9PYL6AYI?S'U@^G'!946MS'E?&J.>_ CVK,*3,DM.+@2M?+R04Q
MU!;:]I((5Y!UKZ=2GLG:G("" [#>4Y/&%'-]7S%VQVKOEV!A;GQMM0E2@%%(
M&)<BQW<.'!!8LQC.COO5]Z<L;I,:OK_EK&*RES&++D8U.=DRT,V\> IIN6N,
MZED[$=<IL+*@G_S$_0>*?TC:BI1W';,J9V<AAO-8W$V!M6V)WN[OHV;#QE;:
MD(Q$NE0&(Y )!)"<,JC=( 8/)D&O:K]7?ION<;N\OKN6L9FXUC:HZ;ZX9ERE
M0ZER8L-QFY*_ETD*?4H!) /DZU]J'LO:=XNA3[Q 96@ECO0+\))NU2GO7V$M
M'Q!MJ"ADDG^Z6WQ\H(W Y(!,"/6L<9]7OINS%5P,5Y<QJ]5C]5+O;@0)<IPU
M]5 2I4R>]N./\AI"25:!/CP.I_I6T0Z3I^N'.990=\[B\$7E/>OL)1.[M@.Z
ME2U.<2$@20Z!-^)RFZ/2>N+TLWMG6TE+S/B5A;7$Z+7UT./,E..S)TU02TTT
M#& /<H@@$@#?TZT5V1M(#[KL%9S'_N_R+ .0)K#![Y]WL16ZC;D.3 _N2X<N
M58<-Y::C9R'UI>F;%;R;C61<Q8G5W5?(;BS:V3*E-O1ICI 2VO\ \.0HE1T
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MWB"6W<5(#$ B<)F,'G?AI*];'I'1.-4>9<+_ #3Y]=:(ADOF0; /H95&2!%
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M:ZA<QXK*J:+Y15K/:E2S&K46#XC0S*<^7 3\S+"D)WYV?/:/:?Z5M$$/(?\
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M,C"'K206:R?%IHC,EIUH,ONMK7*;=E_,CX:G$N@K3OSUUZMF3B89.%A))"@
M0D.'#[VKEP=U\P&=J]7LG:^S]G[1N=K=HK&/NNRL7&4@@)"-PA*%"% I*D@2
M()D&.JFYX;PQCD;/<GYAPBMS'DIV_L.-;./EMBW5PL?R%U3;K\)R/4H?KIDH
MLMLJD)4^5!);[4 $G96SJ*@R%;H_4-U+Y;K EX D C4/3'[4["^&M8VQ:%K"
MMPC&Q@EE;P5*,,A)9PD$"+M!K1II$=O$:7E:P]1V(R:7'L7RSCQC+UY'=RH3
M&4VMK7V52R70V%K=36*=CO.NH+S8<:6%:( R5A86'CA/P)W4G]*1=\K&1,@$
M\C7!3C=G;1L2MJ':>T!*<16#O?F=H8$)WMR$[P<*40H)*0"9!I!K<@QRUY>Q
M/D+!>=L%=J\ P^A8S9V3E]Q.L6Z^JM7Y-X])<,8+D5\DV*&8R)/>E+H22.X
MC;&PL)*"?A)!+ ?VT"X8<;"<I=@\X=F]I]FX&.-[M/:5)PP%*WMJV@B%:+2
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M36MWD!55;B'4M(%C5K5\5<67M.W6E.#18.@$A*22$[Z@]M8X,JBX!=@X$.
M+.7!<QFU2.Y'=U(9.QX(^5R?AJ?>)<L2LV-B&8%LWK/%O1KZ:,.NZ_)L3X<P
MRBR"JDJF5EE55C4";$DJ:5&4XB0V%%(4RXL>VR#I0/GJ%=I[0H [P&9.1L03
M8OD3;,"M=G[G]@8.*C$1LR$*0HJ2I"5 I)!=SO$D%Y$2'WCEKV/H>]+=M-E6
M\_A#!)-E,D_/3)\FFBNOR9'Q"X7UN=J=NE?ZU+UON_5Y^I/:F.]P0T -E;6
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M'*NK>^?H47RKIMFSL8=@RPZRJ1\:'+078BF!&;3_ *4GM<(G>7G>.6<QJ'>
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MK!2D(\J(3H;).AH>Q))\ #ZDGP.JE3%CF+^.?"E>;,F-*251WV)"0=$LN(=
M/[E!4!U+@C44KT4I#:5+6I*$I!4I2B$I2!LDJ)T   ?)_?H6S9N-*/:#YVD[
M\_3H"# G6-?O2C\$?0C_ ):^G4TJK7JTR?D[#.(KK(.)%1QE4*QJWGDO)@.R
MS0(F)7D"ZF/;/"'*M6H"5*KHBD_$<6'$Q@'2.N+C,!D0]P0[#UAQ9F#D<7@2
M,QPXDZV\=*I0/Q'L?PFOP,7--FG)-G>82W</.4==CV-.6$V1D;^/N-/UUS,B
M6<2?23(+\:8E#HA*$OO0%)3L72?E23)$$AW,079W@Z%H$/63G?,B^@:T.<SE
MX-F:5,G_ !*\7MY=!A6"X/FK>89MQK9YS6W:W\8=K,,,2/9KEKNH,ZR4Y-54
MS:J1"EB"V_&DK25Q2ZVZE:D$\2<@]RY(>0^F9YQR$IX03,GF\%KF-;AA7EP;
M^*3POF5E2<=9W;.TF9UG%V.9;FN4O,1H^-,6LZDA64^.B''2J7$CE<@-QY;D
M5,-]3HC177%H[>KA0+#A)T9S 9@P@Y\XKCJ*@M3:F2)#.0^1M=[.W%>M?7S5
M\;Y+E;63N,9YCMGRG2X7@ZL=M,;J;2' R=59'JB:VRFU]AD"42+-HN"NAR76
MF_+A!&P>"Q=G8L^[=H$M;)A;.(!EP"8 NP$)+EC;)B U)6;?BF<:\:4V06V9
M\8\ATS.+9##Q/(F)4V@2JKR:RE3C1TTV<U:*;;?N:^NL;BN ?^6,%I;:DI6M
M"35!D<>663R;WE@W&M6, E_E+NSFV7%R=*LWZ9O5S0^J%S,G<.P3***HPNT@
M4S]U?/TQ8G2K*AH\B:3%CP9,F<TE,"]BI*GF&QM"P2=>.0!#NPT&LZD2?&^0
MJ !>7L(,@\F  T(OYFY75:EAH/+K042O]*M^VC_TZ5-4>];/(O(W'6&<<R^.
M,XBX):Y/R]AF&V=I+J8%RDT]Z[(CRRPQ8M.QF7&_T.=ZD@ I/=]>L5";'EE#
MR,V:^EJUP0"2Z0;2;9.&-C(:-0;U3O"O5QR\>8XV$9ERCC,[%L!SW+,7RF_K
ML=IXU=G]-5XM69(S819ZF4I@6=4J<NJL(]8MI#SJ6P=J2H=9K40A>;B9+WU;
M1Q!<:6K'%++ 2S/( =A(\=(R]+*^B/U9.^H2XY0H[;,<:R.?09([98XQ1?"C
MR8>'V*0Y70)\5,>.\Y-K2%1ILA0<2M1;47%;WUM@O\,N\6M )BV@CB[S)J=.
MH8_M71#0^P_MUI1AI59O5.?_ *W\<:'FXB^?KO1_G_H#Y_O.1\#X3;S'@#I6
M2[B,[^ R?@)\&EZYZM:[$?\ %VC?W]A]/I[#_EU%5/B^;Z]?:LM^"?((&M'S
M]O/OY_8[!/[^W4-UUX>(J*/Z>?O]/.]>=_7W^Q.P?'@^\TH Z)'N=?Q]O'D^
M?N-^YZ4HMG>O/]MC?CV/OKSY/W 'C?4:>'1MUE2C .QY^_VU]]^Q\_8?T)/N
M9ZZZ^E.LNO+V>AHG8^FM[]B//C7_ -4DD^VO'4?3EZ^]'AN+]=?6AK6Q]/._
MWWY/U\>2?Y]_'4TH$^Q)'CW\:&M:'U\:_P">NE*&B/V'\@_79V3O^IW[$Z\@
M$NNOWH_7WU\:]V 2\CM/;[^= @'M.R0?'G1T/H-_MUGB@*PU!4 @W-O$?Q[U
MGC(.)A+0F"I.Z^A.;EAD3) KF)^)!:3JFIXWD0)\J IRUN4K,60\TIQ9KVB@
M)2RL?J*P.WR//D'6SU]([K[%AKV,%TR";I +G7@2'RU%A7YV_'#MS;NS4[!@
M(WU@ ,4NIS\)!+@)94B0YX&''13CJ1 H.(_1ARKE.-9;DM-"XPR[&;>RQJ-D
M%X]#G7<2K%&JQKZ?XDAQ3CC-BRF6ZRXVTIW96@#9\7WBPDX>WD(9TJ4&$62E
MB&+D7L0S9,U?8.XN)B[7W=[.VG%6&. E13F22H$D* 9H>)IB4/J']0W!^:57
M#]/B%ZQQU%QUJ; @2N,\CN+:!.R^-=9#N=DK;<AB7\E828Z)+"GB0N0J(Y\-
M,=(ZZ'XBA!=*K2TOP ?/Q EG<>T^6[Y_[F!/UR@&S\QX5OKS]4<AC$*J!CD+
M%LCR'#+Z=6XE;\>6D:5>V=-CCMVNRJGIS3!_\99M*@_X=2GYAOO"V6U C>F$
MI6^Q<";C4N1<F\@W+NU2;.0"_%]'\N-*=/Z[O6W:67%[$'AIUZDO\\?J,RR"
MSQB7C,6!5&9#9CQ'8=E",MAKY=YUT6#*.X%K0_021R2H.Q-@2>5_&]1NC0=:
M:>%=WX/QE(9<?!#BH[840H=BU*"5K2$ZV?A':4+5HJ25'M 'BT>?IX\?M)J!
MS):)SSGD&8\]:4>HJU(]](<AU4V6VEY:XL:0^$1V52'S\)I:]LQT:+[J2 4,
MDA+JM)/OUGBE02Z;O(%R&+L>%_K2OGRY=]6'JLY!XTY%Q&XX^S*JHGLGR:#6
M9>SQG;BWL*2NB19-33IHJ5IQ^#+M5+DMM6J73\,1B2.]8'7&=9=W>3+@Q:0.
M7L^LV(+7!!=\\[Z!N?&\=\7^K+U7\/X'R'4<7\;YIG8LKJZO<4K\EP?(JZ5C
M+3N;5#+DQZWNH2D6T=6/RYMHFO?["VS!4PR5O.@=<C!<;SC0DY&&G1QXWM52
M(:VF5M.39:5;:R]6WJB_PU/>R?"BN?\ DN$6GY%CF"7=Q7P7YEK7-6L2=9I@
MM27Y<QN0\\D1T%FJ+20DD*645Q7D2QX:AW%H#D-:0VE2 X%B<A),./.'-KL*
MC&X];GK9;4PX<&DU4>5ES59:./<3W]@K"(4EVZ^/6K98CDY D0H-3(CVT5)9
M;78J0^4EO75]FPE+)*F#*%V$M)+R& +WUN6K/:<8X6QXQ"25G]+ D$[J@D6D
MN[!\B)KH'F^9Y=R7Z%,PRA%;<5>;7O%-\^N!'A3JNWBV_P"53$N?*USK3,Z,
M\7T LM=G=^I"4;&NN!VZI6#LN,I(W@D&?^X!3LSE[$#RNU>T_#G#P\;O3W1&
MU8N'@?$VSLU>(%J3AA'_ #* =\K(")E6\S/.M5U_#HX:IN2_2=@R>>L4D9#D
M-==9%VIS9F<JV;3(N92E-2$3U!]:)+83W)<3\)23W('G?71=VU*Q\'$6HD*&
MT+ <& "((,SJ[".=>[_&_!V;9N^&T(V->%B8?P5J4K!7AKPR58V,0K>PR4D!
M.[F2S?XL!<FY]%7IBO9LF9;\0XJ_-ES5V[\@,NI#\UYD0I#H9:D)::><B!$9
MQ?;VJ2/((3OKV+C<W+$Y.'$9&YMHPXW/Q%3_ !-XE^,L9+DQ!#W@3.51EB'X
M<GI]Q_)LIR&QBW&55^46ANW<6O;&3(Q^LFHD-2(P@QF92$!,%<5@,H6D@)0G
MWT=XA)!EF#N"#D\O]&D%Y:"T)Q%!0(("4B)!(#7O&8?+RM+BG!O%N"-7Z,2Q
M2LHH^3J/Y\Q#4MN+.;^&ZTHNQU/?!0%(D.%2VTI62LJ62H[ZM#0!)S.1DQ%@
M?!SE)S^ CB "_AGR>\::N3&K7H\X#@*C3,<P.HQK(JR*["I\FJ&BBWIE/KD+
M<G5RGENH0\'9DM:7'$J7VNJ[%! &J-+,7,RSZF#?SGQ:M4IW4A(,)L"Y'ZG-
MF,DZ@ #04JCTK\'R,?QFAN,&JK9K$V)L:DEROC,S&$VA<58M.2(SK#JS,=>=
M6^THJ0XM:QVZ/0C*Y9]"'L")S(MQ?46#P6XP^5VS8-=WUJ9\ P3$>-<6JL,P
MJH@T./TK'P:^I@(#4>(UW*6&VV^]92E)6=;4?<G>SUJ& "7!:6YYLYO0R7-X
M)^ELN%KT\OB(]N]&^TJ_U#_2" 5>_P#I!(!/L"1L^>II1E: -E:0#K1*@!Y]
MO._K]/OU!*1<CQ(%C]QYTJ!>3?3MPOS-;U5]R7@=/EUG0L2853-L3(*H428H
MN/L,HCOM-?!</EX.(5W@[43['(%!EW#Y,+Z,2[:"6<RU0W7MX!S'C>H(QWBG
MT=W&4W.2TF&8NYEG&]ZW0ROEHLN'.@6F(H;7%B0Z]10);<%M:767&8SJ7/T*
M0I6QO7!4%%D,3<R[/$ &SP.65ZXV'@(*%$?I)5G:>9AR99R)K>Y_XQQS!_3O
MZAY_%V.BFR3.,8R7(+%_'Q):M+._G5\A#=EIE7QA9K4XIM"HH;<)60#OKB]H
M)?"QHG=4"[O+ [O&7C4@AG?T?=+#PQVILB2I(2K'2IS+,72#+ :FT1-,?TE<
M44'(OI0X6JN9<:7?VU;1ON.1,K$E5JF6J=+4H/+DE,W:D$?I<604D$[!ZZWN
MU\FPJ*@RRHC=4SMO+#M!+W\.-=U^*.R[(>^>TJP<3#Q @8>ZO#6%)"E;/L^\
M/D)22X (?]0 B*EC(_19Z8,JO7+ZYX>Q2=:?*QX0G.HDM?#C1HXAL)*X\AM(
M##&XX3Y4&_ U].Y0E*5K)#06+&8 U:"2Q;G>O#H2VTJ6D%2BE0) @[R1D&F+
M3 >HVQO\-[T[TN3Y/>2ZZUN*?)I"WW\.L;"6<>@]S;20W&BLOI+K;8:;,?YE
M)=0E(T=>>HPQ&1 M-AX:L&L6XN^I\  &ZR]--)M+A7#'%_'UE:VN$XA48]/R
M-#J;IVM#C#4M;BD*DN2(X?,1+JE);<+C+0=<(WW#>^MU$*!22)# 9D9;H#R6
M+W&5GJDD07:"789 OKP/,WNP8GI ]/%9<G)*+CG'ZC*V)DJSA9#"97^9P+24
MZMY5I'6MQP"0B4I3R"M!25#1!&QUB=G3 9LW/*TL.!YFLWO+^K"SYM9I\*V6
M?2IP\]C=7BU_BL7)F:ZYGY-^:6(^':2,AM7"[96"Y493"VG9Z@/C(84E@H2$
MK!]B&"A+%)+OF+ZV.8@ZZ:2 IP0UCX$C.&LQ&?":F#CKC/!^*:'_  S@./0\
M;HU395C^70?B_ 3-F+^++?\ \UQQ7Q'G2I2U!7ZB=_N=*V'&*?W0OE?C2O-W
M78=[UL;T-^YUY \]OGSKJ"[B,YX??V]PJF\_A_TL\M<PYI,L,)QW(>4\0D4?
M^*'[&'-,EIU*1+I7'69#C<2Q"%M?$CJ"'&VBWW[\ ]9@ D,#QB-1<FXB2U54
M[7:P$!Q>W$^&9U=]PO3'P;69"]E<3CJACWLB^CY'(L$_'4M=]$AO0XD]86^I
MI3[,64]&93VAMEEYT)3I75@EC(?3@;W>1.0N"_#,BP)#\[-D>9\+WJ1..^+<
M&XNBV\3 \:A8U%R*ZGY+;QX)66Y5W9.?$G35!3BT)<D. +4&@EO8T$_454&#
M #]5Y$6>7]6?UK1(S9B0(-PW'R>JU^N;'Y-EQ[A.1-X[<Y+"P3DS%,HO(E$;
M!RQ8H(D]M-G(:A5JA+GAMKM4J,VATE*2?AJ'6*E*&[NYNX\/K8M5JH3R-SQR
MAPY<3<WX3QC((&$\KW^6Y?)AW/'&49#;V3U'&:<CQ6T_!<>HDY+(9E16#(89
M4DO-K0RI02DTWER6(!D%AF0,P(N&X9,Q?*&)(;F>;%R"6REO6D*U]>//]'0K
MLABG^"JJ5D-N6\MR#CV]:A9)<*M*.)5XRN+.C-&E4Y!F6-FS=27$-RGJJ-!:
M2E4A0 *4#).980&&1Y,#DQ!+%C1TFU]7=@^5@7:1DUY!"'F/KS];-4W9UV,\
M33<MMX\>L,B8G"IU-55_Q,AM(<ZR9F.Q7HD^.Y7MU3BF8ZEH:+[CJ2I2E@<K
M 4HI5D7!&\P(BTL,_?6NNVU:TKP@A)*2%$D D,"'=G9Q/GRKN5Q1>7V2<?XE
M?93 9JLCN<?J;*YKHQ6J/#LI<)EV5'94XEM92TZI2.TMH*>T_I'6I+@%P7&6
M4YY^<N]<C9U%222"':"&-HA@+ N!:I%V 0"0"?8;&S_ ^O45R:UWT%7E)<"O
MTC_+)&]G0[OIVCZZT3Y'VTJI /\ +?>+95Q>YD]6OJ3KN2>:./*# LILL%K*
MAB'79B[QQ+<53O.V,6!:O0X-<ER7D<1B',2MA;;J%NN*4XD%##JD\':-_P")
M"5$,(9^A(.1GC4@:&)XN>#<0?$U1;T[>HCU,\(2>0Y&$8)R'ESF0H@,L8ID>
M"YE!1(NJ_'I$EZYK+.XAO0ZB,F2EIN3 *OA/J(25J !-\-2P(21R#O?UY./"
M:LX+6TS'RF00SOS+Q(>7LXQZT/61=\53+3.,",.[GXE?2AC%-Q_97RU.QK64
MQ!5:R8$5GY54^ &XI@Q@X6G4J>60'6U#;')_+[P274[B\ ACG[-]*L9;,B8M
MY>GB9K+-/7'ZU*RY^'1\;3J6DD9S54LB,[Q=D%U(Q+%)V118,"R5(1&4J[-G
MCCPO'G&!NK>2J*\ 6UZZ[8L3%5B,M*DC($*"3<7(8,Y),VX@U)FW3%_V87LS
MUU_]-_(M]RCP]B&8Y572JO(K*(XBUBR:R73J,EF0\R'T5TQF.]%9D-MH>;:4
MV/AI6$[.MGN%AB=#KG[]/40+%P(L+^&>L\6%/G/<!Q'D>E=QS-:*NR"F<<"U
M0+%*E,_%3^IIT]A204^VQLCP3[[/%Q Y8G5KABQ(U8,_@<C4Q_!]9!J <A]%
M7IBRQZCD9#P]B<UW&ZQ-#2.*1(97"JDR5S#%:^7?;[PF6Z[*3\;N65.K*C[[
MND$('$ 029 D@-XLXLQK,)&\]_F)N[DL[B "&!CB,IB]C\.7T]1.06,UJ:RS
MKJB-5-TR,'A64IG%U1D.37G&U1F9*'U)E.V$AV4VX5-N*<40DI\B-TRS@ AF
M >P+%M.'A-]T*W7=S<#0.;L0T2VL7FK%X-Z<^&N-KB%?8)@E/C%I6U8IH\NK
M;6R!7,M?+M0W&DNAA[X;"0AMUY"EM([=*&@.KA $VYD6SRL0?$,[98D;RB1)
M-X!ER&;(Q]"QIOV_I,]/=_DL_-;7B_&Y>53K,VTB]D,N.3U6ZRRA4[XQ?T9#
M?PFNP@:4II 2-ZW 8RD@\B#FTN28!((BV1JN[=W #,-;@\#FW$@BMB'Z9^*)
M=-DM%DM(SE\?*\FB95=R;IM!ERK>!$1!K'7%QRRI@5T-I,&)V*V4!6SL$=0@
M-<&\$L#GE%YM?C-7=[&1_P"DEH>WKQUS?G&_$7&_%)OA@>-UN-.9-8HL[XP5
M.=]A8L1(T%$B8XX\Z77$0(D-@*[O"6T@D*WUL\-87X<YD:7MXN+.'+EX!('!
M\HM8$@V<5+/Q&R H.((.]'O3H]O^K1WH]OU^WUZ@3:>52X%R,_2_EG1.* 0H
M]P!*%%)V!Y[201O^_3ZU)=BUV-1)RMPWQKS520:#DO%:O+*>!9QK>#$GJ?3\
MK9P]N,2V51W6U(>;_4H*2H%*2KV&]4(EXM-^+B+07<9\ZLE120'OROJSCW#7
MRJL[_ _HKO[N9QNY@V')N>-/EF7:-Z/+KWJM.8,O3$J:=^(S^9NVHA..J<:<
MD/$LE!.TZ&2T@H6&EFS+2=(.6@SU?+$^98,DE0$ LTY $<&-KFK'X9Q+Q559
M%5\C8UB4&!DK>+,8E!NVVY+<I&+P%]D:L[7W$Z9:6V% %H+T4J/@CK7"<88&
M[NNS@B89LXMH#EQ-W.L6:,K'G=^9XO-'5Z567U3$G (X^@N8A]S]E?\ ?CZZ
MV//F<B7\-?7Z<LVS5^J1%I&6<]3 X\]D%)2-?4#^^M?3V(('V\Z^IZK/#V^_
M7.*>!:#_ #?6# X367GQYW]_WW[[_CWU[@C7[=344?CQ[@>?&OMX_P#D>1_&
MNEW>?O>??J5NNOVHO;?WW]!OV_KYUY]OIL#72G"/XS%NCK0U]O(U]#_\C7[#
M0V->PUTZ^]#<_9O+AU%J'W)'T.MC0^H_?QL;)]B/Z].NN0I1^VO._'T]O/\
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MJON*#!<CGUT]M*5KB/1JV0\TZVT I;BTNA)UV%&R!OR1UU':[_D\42P0I0B
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MA88-(E<T,XG!H+JQDRXN-YK96;C:[&-%4W<LRK6D=<=3!<87%55MH9^;C/K
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MN1W*MMN&E,/Y9%NVRE*C!8+B^P]WPT]R2-)ZW;Y-T2;Z6)-N+\"/>0"%!G8
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M,F' 8=?))++TE*"ZLJ[NN3C$;R=P[PW$L1,L'XABT-P.E98:%)!"B1\Q,YO
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M0@W >!%@?4N-;&WRN:>/$_HOB\=)XI9NLQ8S2#Q$[.G8XQ)Q61!G-6TXK_\
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MV,S<9Q1IQFA;! IZO_+<2Z>RL@MI+J25-N_I8)#C*RIQ*T*2X'5*4% D[/\
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M^N^E*&Q]Q_?I2CZ4JLOJGW_L^8U_^V(FO/\ (V/?R/VU_!)ZF6.D/ZM]:R6
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MH8EW'(6\WR!+5@I3*#"Q#EN,FTEPT>,4%\]<*1VVUR.5^/HZ7)C]>@R,LI&
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M=^/Y _O_ 'G7B/J#]*R6'4G*9>7AAP;AS<:\]6Q_EI!\_0[^FO!^X.SL^?\
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M [W=VU;0K=1@[?L.)BG=*BG"P]I05*3(<@ EAE).54:_"^XP7F'HQPNHS_\
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MT]=W9VG&VG8<9>,2I0VO$ )!!9@6(89DLS1YU[O\8=@V/8.\>#A;'A)PL/\
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M*PY+?D25-,I2$(^(\LA('M[=7)<QHPM9FGC4HPPD3?@[#D\^US3O T-#J*N
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MOUJ(B(B/W_;E6HOG:79CY7-K.!:K9=34T.E*'2E#I2ATI0Z4H=*563U1NA6
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M(F'8I22I).\7,!3D<MT4T/3IA&,<C<0\<Y9B6:Y.QCEK22504U@%%#4PF;,
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M_0_]/<_S^WN5(?/CJ??Z_2B^OVW]0//_ $U_<_QTI7JP"74?N%?7N\=I]PH
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MKCHDD[7BDDF 2SCB[D@OF7 E_=_CS@;$COIB_D5H5A)V90)0A2'4G:,9+D+
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M F9 '">#>9)]JGS)J;"^0,2GU>3QJ')L.M8CJ;!B<IB;33(J.[XGQ5*)CN,
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M?\W;-9#C5!4P\LQZ59?/Q,D8G-S),2;27$QQFWBO/N0YY>DI<E0F)A?CLT2
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M/*Y.M5QZZLY AKR.5B*([^+SH\-IP3/A6+2BIN#+D+:><1+0M*D]B PRY$M
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MLXO+QS;W<-7'7B*2L)"07(!U+YQH/=M*Z,OIV.X;[O(0#O17_I2=#1UL^^_
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MA9+%0)(R'+.SQPK)V4<^1O&DV)&<:4V_Q&<VR_C?A/',OP:QEPLEJ>6<!>8
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M )8BPCV\5:PTEYA^$6DQ'5%^,M>HB"%_HZW"TX@!8J(9^#$%B[DL^?H\<5+
ML  -Z0X8N6#1+AG#L1Q>G[6^L/TM7B)4FNSS%K%3=4BTLGC'1WBJ;^*VVHM.
ML%2RJ2RJ*J/VJ^')TR?\XMMJOO 3(U# .W\ZPV6=K"S_ #06Y $!BSYELYK;
M@^J3TWWD\--Y1B4F,44K,%!CI<L),B[7.:@QVJU^&%AE/R;Y"FRI++C2_C(0
M$]5WDO( $MG):?:!8\:/>"XDLTL7S8.+0)/C4AX%S-PKR1E^08Q@>28[>Y/A
MK03>QJYMA4J#'^(IA#(DADA$=N1WH^&RX&TO[1I*@H'DI<E@9  # ZZ9NTF[
M&1+"A9WLY)<LY,W,B'L(TO4M6^10L:J9=M9'X%;60WYLM24+6XS%CH+KK@0C
MN*PT@>>U)"CKR/;K#%Q0G$(/S&Y;WG*^K2,JU0X2 !''(/&4YG^0*K+%]9WI
M:RFSQ_'3R3C<BVR:6:^NJ9Z%$JGM35UY8=;DMH3"DM63:X@^92TZ)"?A!(<(
MU4 8F1/H'#\"8UORBKF/)YAQP=J4N$/41B_,'(W+>(X;"JI%)Q^_0(3DU2KX
MB+V3:,27'$OA$5E"50_EU!"PM]#FQVND$#K1PD 3 MI?*P)\)?.L@Y5DSOF^
M5S#-9M<ZDKFKD'$.+\!O<WS9ZH9K*B,ZY#:N@VN/,LEMJ7&AI0MMT*>E.-I9
M0&VENH!4M&B-]<7&Q& <AX8"<P22':VN;5N@/#Y<)YC/CE58L ];/IKRC"J2
M]RR[Q7$[Z;30;*=C;Z&''*F';,V$J($.F(VHQ);59/>:66TE98>\Z20-4(24
MA37#AAJ,N-VFL5M\P(L2P<.4P\PQ,V^].IGUH>F*O:<L&<YQV)3M)JT1Y\6O
M=:>?7<,(F00RTW$276945:'V5H"FY"%!0&]J,G%"=;$'(L+PV['EK((%;%I
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MN0+@9YW@%F;C;HG13^Y/W^WC_KUD1\PS;B($2Q^D\;-O5:O5-O\ V?,:/_\
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M31<@K)E._:8_/566L/YEA<9R5!F1U][<I*5*T5=Z.X:<0=D&BT!:E**B"9U
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MW.U.0O?B>F\J/ZZ.]ZWKVU]MCZG?DGVUH>-[+J>NN=3[&]_6_/V:B)'OO?\
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ME,J95)9>*?T$=:XP(0+AU!KRY9K$YP&Y0(S!#F1QOSB0+7+<3PIE(SW\7)G
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MD1TQO(&AEYKCK("RQ(.\3FQ+_5VXAVR?#*Y_XA><Q.6L=YAXHD7-+57N'V&
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MC\BX);8?<Y1D!NG9.16L:=?S7W62J?#7!AY;E\"-7PWTH_+Y<:W9$SN(76Q
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MDL17%Q6IJ([CP6D.-HVH=2%*Q%;J@Z2Y+L)N"+V(:#Q+N:W"0<,J@&&8."'
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M9W;4E+6XORK4+R!:FJZ7D5#C==$3+-?)M8T!YQ&73'$*FL1GTM+0'XS#Z?\
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M-NT\1Y6FUD4$R-81<FH PG/YJ+"9!DIBB)D$=^I;6E1=-2ZCOU[HDG#.\/\
M&0\<WRS.?K7P78R58:RHN=TG,3$L1><]6AJ0.*?6-ZA<+P3"L&G1,?MW:2KE
MO5UO:<7\A2K*&VBFNYE<S<N+S1M=A+@SF8D63(;,42VI?P6F8P0'%\<D[AR
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MA8"V?X* 2^&-T$NSF1S)KZ%?0$I3?I)X(2I9/_WD5W=O93Y2X2HE02I(\CW
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M]VF?S; <.RM_'9*IU(YD%%76RJ>4Y\$NR:TRF'?E'%EA@.N,]@<#3:7>X(2
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M]!^X/L3^W0=/4F'N&URZZ>A]@/;S[^=?;S_7^HW[=1KKY?>\R..8J.NO+TH
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M%Y'R:U!)"B/J,^UAN[+C*20D!,R8+I>Q<N"S0Y)< !SZ'NF1_5-E)3ODXR0
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MM*U1GWHTJ(7PA?P_B--3&&'%L;2H(>;26G=E2%$$*ZU+!),W@MDTW9VU+AY
MO5<-6\HZ 6-P7#18#EPTID<Q\R8AP=BZ,LS%.3+J?F%1BUB>%9=G=L ELN./
MHQ_":2]NGF(S8^(^ZW"^$TWM;BTI2=9%1#R8+%G/BQS#>.I8D[>&1/EY?M>H
M8J_7/Z;[5Y4=K/Y$%P87_CU1M\4RZFCM43=?^;F,N5:T4",,F<KM/IQ$R?\
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MK;8W97N9R).(N1J:H9--7W#5/(ERA/?C2YE[%G082&Y<YQB))<^&5]78L#
MS&<R8F.?$&LB1O$90+<9XV)\_&E2A_#?Y@Q6MRFIA95@-W R2DR>-2MS,QY"
MJ8^)W%[)L%BQCLQL>LF[5BU9G)3:LS(S7R;L=!A"2@D=-TW)<$ /:[-Q&4A[
M34,6&8)N#!<,,G#0WE8M5YO1KPCR5Z?L(O<0S^RQ>=#E7K5CCHQC(,CO8T*(
M]#^'(B+D9'14DIL(?3\1*&8ZF@5D(3I(WHD%AG#V, :]#P-6@ ,P!UF\@^''
MC.9NLG8 !\G7D[WY_G0_Z#J:O38R*%*L*FYA5ICJFSH$N,PF4M]$4R)+#T1I
M4EQEB2XAA! +A9;4YI)_3UBK!<J()&])<EGO:T!FM#9R8)D!Y\-1E?6;"2:H
MZKTU\P3?3&_P9<6?&L6TF,WB)-HQ+R2UIG/F;>1,@1@B125=@RU-BRE,2I*&
M%R*Y_P#S(S<L)2M68V;0O'M8VA@P<-[,>[N#(%N?&PS>^C5%6*?A]3J_CG$<
M?M[;#V>0,:J,EK*S-ZN%:395/'LS._P]3L*G,5[MG!HWI"'ILV>IN7/98[#!
M5\775\=).*C0-/$)_@7,-:L\!1"#_B5%1U*3O*U EIW2Q%.O*^*>8<,]#G+&
M"<H9@.3<\=PS-6H\ZL:F26_A3VY#E150G)3$&;(,&(H,%;T0"0L!(\ ;KVPR
MMDQ D _+9F)<C/0 .Q&4Y5Z7N@2.U-E%B<9&\29(WK,0Q=12(((O9Z/TL\7W
MV1>B3B3C^>#C\N=4Q8E^BR9<;F,TL:[7*L("&D:4VY+0RTE/ZA_K/<0-CKK.
M[N 4[ Y>2682SK@,[ 3H[.[5W_XI[2A7??:5)"3N)P0[BXV? <N,W#&<AK3%
MY$] ^79QF,Q5;F6(U6,T=Y?YC@S#C-L;21?WHQ\NU&2_#A"*U1P4X]$2R_ D
M3I3[3[R%P6/@(+W-P]F4G&6L6&I)>(R.K= #P2MH!VW$Q/\ J(6" "&<)9C#
M\0[VRIRY3Z,N6[3T_CCVERO#?\?6O+LOE3)I#]UE>.8MV6E@N?8XW6SZ:FF7
M9B/H^&Q\9^L; 2L++&T@'D;ICB<[#0. 9X,^I&58:TM$Y'WD7>_"J&<F^B/U
M>8;QO$Q^?D#&=0LBE8O'O&..<YY$-I\Q7S)DJ3:S)L[#7I$".^PY$@N"N@VJ
MP&@Z_';8#DEH00QX@QH7LY$PX!R?.IAKFV?JS,PDWRXF)IY1])W+\RNX$Q_$
MJ"2SDV0R+.#EMTYD^5O4V'4:,27!I_SB\CP(ME:651/W8-KDT<5J1)+;*R@*
M4M,3''[MYWZ9VKP0&!!?P;BY<OI>!6U>_AO>H/*L@M7LEY?Q*ZJ1.X]L:V*Y
M8YC#6_98.^%(R";7-P'([%G-9<4IY+%H\DR8\<%KM6LILD%PUV &\=0[FVGA
MGG52S&-"WEO&3[9S%BIYM^'CSSD=-05]5D'&?YSC^=W.7RLBLN0>2HTRZ=DU
M"*RIDB,WAEFW2RXK9!E-0GELR5,-E;@)44\AF;G=['PTCU9PU8!B2]K,0T-!
MNPY9L78N_7CCBIR#'\(PZ@R>3$G9!1XY35%U-KY$J9"EV%=61XLF8Q,GQ:^7
M(;E/-+="WH;;JBLEQ(5W'J,GUS,GBVF5Y;G5D!E 1!(@-#0TSS  M3]ZBMJ;
M.8P95IC5Q6P8-3:2Y\"5$CUE](D1:6Q<?CNM_)VDF)"L9+,)U*E!];$*2X$@
M@-*!(ZRQ@Z&B5""6>\/J<OI<*Y_(]"%;/QRD8O#B</*:_)KVYK;&K:LI<?"J
MJ[CL*>QS%7Y;41Z1"5+A1W"N7 @!M*GRTVE2M+C!02Q)SMH8X:W$,:HL9VRO
M?, P>.0J>?2?Q1RQP_A][C'*O(</D*0YD]C.QI^$S,;9I<;<9AM0:GXDV/%>
M=6EQE^8\ TMIEZ6XPP\MIE!/(4" )=Y$189W:U8X(^=4$!H<G(Z&P-WYU,G+
M>(V>=8#D&)4\]BIGWT15>FR?;6XB,Q)4EN;^EL%P+>A&0PA:1^E;B2I24[/6
M2@X # Y/9A8&^H&LQ7)F",B_.]<XN0?P^\LRK(\B8JLPQ>CP%T?GF/Q?E;)_
M(49/#QMNDJH%@Q\FFO&/"5'8?EO,6KLHL%:4PPL:ZQ(*2-7UR+,0PEM7UH>L
MJ=N2>DCERQ].>;X#"R?#&N3\[SRGS.;-9N,JHL2@&!)C.28L.QJZ.7=I0_!9
M<0I K2VMYQ25*()W4DA[ /X@L38EB6.1U >D1UX#F'>,A!RH?R=Z*_6!@^!7
M49-S497!R=5/3VM3QYGW)EE=N.M9#8V7YJY)L\(CFOB0ZB<W5!V+'E.GX:73
M'6D!2+)<O%BVEY!,^IM8Z4^G735*O*WI0Y:GX+P1!QW'+!S,+*PI\7L6UY7D
MUA$P7$X5%(C+GY5=Q*N+-L2NT4+!;'RR4IG%*'%^_;9H$R1YAPS1G[9S4DCB
MX=B,]WAZ,"&TBE?E;\.7G[D279Q[;E_$K"@>PG#L88BS;/,(,B[FXRFFDEZ^
MCQZF1$)G38+\(38LY:T0WFWGV''TNMFVZ6.3/K,<K0>$M#BLU$/+!P0'@"-?
M#R/B5Z^] ?-%I@KF,)O>/K&U3R)2YF,CMLVY%9=N8%,N=*A0Y4'_  Q)136,
M1<EEA$FN?>;=;9_44%11T*"695[7\&#$"!/@,@^;6LU@;>,RVI;@,JMC>>GW
MD/+N&N-N-,A1Q[/R+&?D466:O7.23)F//0G4J:M<1^+CB)$ZR=CH,1XV,FK
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M>*LXA6X)5WM;$>*TO9I%C958J<"@0#8VT5UU:$)0VE!2E*2VVT//PTGK'9P
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MS><HM82W[U[V^#<GR[*9)@<E/PH3KB518@A,=L<!L)4 ?AG9*P5ZV?\ 4=Z
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MCQ\*DEK#+C] :V+#!^4I-I/E1>3'HT*1)+D6(FNC)$1D:!:0H,@CN(V2/<;
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M:0J)/,!:)*F&5N/)UWNI2M:"4H'^M7Z@@@A1'7&. H.Z% /_ +5.,G?1]0.
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MTDK>;5"TGY81W5+9#?:D!*$G1\CKKNP-EP=FV7:$8&)\9*MIQ% P ) %B6)
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M^)*?AW"1B]7)EV$B==7F37EM/:::GVM[D5G(MK27)2RI;:"Y+DN%*&UE*4^
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M86S[84 J"DP"Y*5$@/#O#2\&^E>][K;9B=K]C[#VECDX>*M&_P#!$/OQ\VZ
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M&'6SBN*LMM4-.XF=-*!%COAY0^(3W$]PUVZ !ZXW=\@;$I:@ %$;H 8$;RW
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M<S-^IUJ&_P"T.&:>6;0VC95E8\59A-F2Y#'*.11&I$B0\B.V&0VA#PTAL=J
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M^_O^_O\ ;6S_ 'U_/2E#Z_\ P/ \>-_O_P"_4>/1R^V=*'_/6Q[[]];W_/\
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MI:3)9C"4'5N-%9^%_I[B>B<3!&*@+("B0H.EPP(S :\RQTM5<?$3A;+BJ60
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M@U]EM8<879,W>,Y!+1!L3CBFIJ&6IK<J2RU%:=>+ZU%24-'7=UQ\5;J&ZX!
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MLCA9 W9O84PZJG$%Y*&#3N-9"(B)SL5(ARIX86E]([G4NN%7=IA(*%$J$%R
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M'^?2\/-#V(WYWX^WG]O(_<_4_P!M=/./7EJSM3KKKR:A]=[^FCXU]3KZ_O\
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M-@?H7XS]L;#V[WIQ=MV/"5AX*=G^&@8N$K#4XQ<51.XLO (!*N4&[,Q'FO\
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M&P%.+2\V4H!]BHA6@#]"??Z=*EP.NM:(6,%12E$N.M2O*4H>:*BD#N4H#O\
M(2@%:OKVI) .M=*$@=9:\M:(6->2 )L4DGM #[9VK]/@:5Y/ZD^!Y\CI3>'H
M[9]%XURHE6=<APM*G1$N D%!?:"MCP1HJWL?7[?772]'$\+P?>V=#\R@=H69
M<=*%>4J4\VD*!) 4DE?D$C0(WY_;I1Q>PR?.O43891\02HY;*NSXGQF^SO\
M;M[N[6_VWTJ;5C^803WD2XR@V"IPAYL_#2/=2_U?I2#H$GV)'2H<,^5&F=#4
MKM3*CJ5_PI>;*O;N]@K?^GSKWUTHX9[W\6NU>:;.O6=)FQ5$E*0$OM$DJ.@
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MO:G76G\T//GR"?8$?L->?H=>?'ML?VFE>K(VZC:4JTK8"D[2>U)/Z@/?7O\
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M3[3QJ)'KZN>.?"VM)#_IOIGH,&&,JR-!@O/.MNHD,I4L/C3B5_Y/G_\ %/\
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MG"5#?CQY]S[J3PZ,^GK2FG@NI&(_X45D5\M G*GBP4['$L.*7WALJ#'EM/L
M3L#^_2A?)O$?ORI-J/3W3U*+AM.2Y!(1<5KU>Z7GHZE-?&=8=^,UM@]JT*8
M&CY"E ^_2D\/7C^VK:&*\J7T\UE-8-V"<KR*2MI+G:AYZ.I!<=9+!4H? _TI
M1KL'_$-GWZAM6BT,PTSZRH7X>/7IZUYP?3E30K&+9#*<B<<BS&9:6E/,?"7\
M%TNAM2?A$=A4='P=C]O!FIK<RK@"LRJ]GWLG)\@B/3?(8B.QT,QU!L-@M)#
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M 3+"NG?#_I@M>?>#_1?.NUU;?'V"859R,CJG;K(J7(;)^Z8@HBQH[E.([,J
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MYN*V5>ZED[S!*OF8_P!S-G)!X/<,P:NT[_IVA/?):=KQ4XN*?UK0DH0M/P<
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MS5*A(C.2XR'6PI)<=:#:CK13U4=R3O'#)0$).\3\06T']S_]N3,\T/XYXNS
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M0L)$2  %F9N0S/I5L/\ \0VT]H8:L ]H[60L_""3V6L$E2MR_P"6W0"0P+P
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M%8W\PX72 EAK;A05*UI.^A['Q(=:-#*8,,(63:[ LVCFN,G\0.PR5 '&<9_
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M&)6V129./8_:9/:MS,2OZ_X5341_F)JVC*KFA)>2V"6H[)6Z][(22?,*['6
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M)+"[<N%>ZN-,#5!%8,3H$UX6'!#%5#,4.#_]8(_PO@AS>U=X0%=QWO?0;5M
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1AX>&A %BD-<Z" &R O-?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g454025g01a23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %RB^62@X0DE-!"4      !                      .$))300Z
M  #_    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$
M5 !! "  +0 @ #$       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 6O6AP
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      T$    &              $O   "F0    8 9P P #$ 80 R #,
M   !                          $              ID   $O
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   $O     %)G
M:'1L;VYG   "F0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !+P    !29VAT;&]N9P   ID    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MPPW9>2^QM?4'.-3QO#L<,@'AGNC=_7:K'V/J.GZ^=.?T3-5(]3P00+G.I/\
MPS'5C_/M:UG_ $D2K+P;Y]&ZJT-):XL<UT.'+3M/TDC?;\% #O?U/\4#L/J
M#?2S2(# _<QKIVAK7O&[Z.^-RG7BYS;&N?FE[1&]GIM&Z)[CZ"M;6G@!/M8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MMT_A$!( [Y!!UIW#)PEK(+$N$AJU#AB PL;=.N[A>U&!GS?ABP1\11*@P2"
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M0R^?CZ@I2'!\([C(SF1A)Q 4R@ 2"&+OH&(JX!V;E$+XCA$J"1-05%R.\E@
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M!."JE$*HA=5E'M8#W5$^(%O#Q2#@C([:JB6M8<)/(,2?$->MOF(3.(84$_\
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M,=)22IP02SC_ +>8-'Y$T>H>G1G]GN)F3AD2I93, 7\994K,M9( )[I&4 T
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MLS/F<NQ$<V7IMY>^WB]O&MQ[5]AF7%XG(56HE!G5NG+15*5/IZXYAI<<D".
M[*+ <8>6C[XH9()3KKC$R)R5$,2E(2=31R"0"7I8N6/-G\CB^"<5PN*EI2A9
M29AF*2"0%IS)&1PEP#5F8]ZA<!MQ0_"5X@IKVU$>K5NKT^TJ;.NA^H4ZD.PY
M54M!%7J[]3HZ6427%HD(@-.,Q Y#<=<9:Y2%I2=<R?C)(<C4D _[4KX/0OS
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M( #)[I!30 .:D,6!-2/-J1I([+X^3/*EE<P%3I45*4HI#!+]TD$)9)'^.70
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MOSTBT0"$) "4) 3R $@ <8X &!QI$,-K?CUH*W@6T'NA/;'X(SCGUQ]3^?2
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MKJW%QWE0U.%I* 3A((Z1X\A)+9"IV4Y8NDLUV !V>^T<<]A%EDG$S%2PM90
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M55 R@T!:C&IJ]Z5\3M.RO"3$VONV76;!W!?I%#JMG0K:K5&>IS,PMN4J(\W
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M/./A"@2:X?CDM0R@)- P=AH&?U=W.IC4QG8V3.6N;,5F4LE2U*2GXE38.FI
M8 .S4J#%2U_!:+6E[35*A[F*AU_:N7<<6E3Y5&C2(52MFY)*I<NC2H!DI#;Z
M.OI;J*705$))9) S$_BTM2UN 7(HX%FNQ!37I07WMP_L>N5E^#-7_P 164$(
M< * ( &4"A=Z$D$4+1CM3\#M7K>ZD*_W]U(B$P=WK7W5;I;5LL(<>EVRAQMB
MEN2345A2'FG'"MX1FB,E0;/(,'BJ0BC-8 $%Q;=P[MM:\:B>QLS^XC$&<\WX
MHF%)0QS_ ! H=T) +J >X-@0T?3B+4J9%C,1EU",I;#+;2CYG<MI"2?7CC[
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M1>^?[W:[_/\  [Z.=SYF##8>0B'L,+\3B_Z.U_4T<[GS,&&P\A#V&%^)Q?\
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MW/G!AL/(13>A0O)=_:D88;<P?(:&/A/(^#CYZ.=R>3FO*(( !( < D4$>2@
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M!^<1E2[Y0^[![-?I3I$?9(O ]FCX"2@#R6^$'ND?#PD^J1P?4:@)2G]J4CH
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MD(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"*;QPRZ?DTX?\
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M0TA#2$-(0TA#2$-(0TA#2$-(1 ]C]A_MQS^;2((<$;AHLMNY]T1B3DDO_/\
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MS]+4F^&+9FE*?VG=D.70'0L_#T)=GM-,J63QA"A]"3K6F<&,L.DI4 "7"B;
MG5B=*ZGE'9E=K\$I&:8HRZ64ES3<I#<F =Z,\=16EN_MY>3#+U!NVWZDT^E"
MVGH%5ARPYU %)Z4.E0*@>^ >/GK05A9H<I25!S8'0L??L]G"<=P.) (GRG(O
MFRZ?ZD)/G2NS1F%3KU$@0Y-3G5*%&BPV5R'IC\E++##:$%2G'%E:6T #*LK
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M]-X6Y'8RD_A.95T%,<<XM@ITTCX:%Y72""H@&M'U_P!F)/T.AV&[%_J!PG#
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M^KHA5R? 6I !3TH+Y>0.OG!4GCU&<'6%4K 3%.E00P8@UK6KND[4+MKL<O\
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M-!E,MAM)+BU^4\X7$M@$GX<Y&4@XQJW]DEW$Z64E+U6D5)I_EH&J]?&&._4
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M I*&+AI;JCU'I "4R>LY[ %.>,8.-:ZN'XI-I2S4?X$>>W0UCIRN.\-F ?\
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M^'\2P/%)2)BEI0O*D@*8DJT">\Y4Y(&[4#$1XGB&!Q7#9QDH 6C.4J/>!2'
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M0'.H$A1*=6/$,/,'>0@L'9@'(8M8:"M32^D8%]D^U<C]O%)KBH?XJ:59\J
M:.UO"+DFF>.FV'4HIN^NQUVH*%*;;K"3!<D%IPI>;2['D*9*FL(+B@E2DES"
MR $ZA,SA\US-2 Y8A@54:H)+M4UN+4!843PWMUA9X3*Q7Q4A U<DO5WDJ<%A
MZ%Z-'SX^Z!;U>/>R;*MDUV72*';]0K'D3;AVMJDF<M4UD&13X,QUE*7X4>2X
MCJ3T M+(2AU821GU'"\-P=1.0HHP(4$@:6<MFK4AR;.[Q\T[<8[]1\/,E)"E
M2T9B7E+(4LNK]V62HLE@P(2*@U+ =/\ AX\3?CR1L[8[]:V!<O*8_#0XY6ZE
M<\*CU:;%(ZH[\VGR4];$E3&%NI<(*L]2@,G7-XMPWA?]8LH6 "E!H0S@![$A
MJF@Z6H/1]D>T/;(<$D)QT@3L0)TY)F*?,I 6<@)5E.8)NZ!H3<QN9OQ<^+]#
M[@D^$6XY+;9">JFW707^HK2%H#:U26P>M)"D@@90I) ((.N=_:^'/68D=UWK
M4 &E"UW+UZ:#TP[2]I'K@,P>F7,Q>S$N"2U@S@TH'CTQ?&EXG&NKWGX+]T6V
MT$@*CUFV9"UDJ('2A-1ZR2KA/'Q'@9XS0\+P!40)@%1J'K474WJ3HVISH[4<
M>"7F<-5M_F3=M$$V9BVNM(G7X\=XX4=3]2\'F^#2BOH2B/'HTM9YQU%#,M:@
M"<_A =OKJIX3@J%,Q'_D2!RKWC?>@%HL.UO%V.;AT\D&C)F :,SRN=+F)_\
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MF3""BJU4!007+NV9@'(&E:BC&/2]G)OZ@8?#2)*SF"):&*RO.DA(!!7\(/4
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M)"EKXYYQS,3BOB2R)JRE+,<QT>[FM&I<-32-:?PO!8Z6N7/P\L$A22I(2FI
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MEJ8>_?OUB.D(:0AI".#/&EX@KQV=J6TUKV;7;=LV9N).NQ,B];JI[4^C4O\
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M?;3B.$PIFX[ +D)RI)*@*4!=A,)HH&C4%R2S<Z5V4PN-Q(DX#B$C$K<Y<B5
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M*B.>1G6I.X_VHX>I*3@UXA"@ZE 2W!!L'427!T;9]1NRN"=E<>@E/$48-84
MA*BLD@B_[2FFI+D5J;QZT>+VKTA71?&R^XM(4D]3\B%3A4HJ$  *4%PG'%)
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M!J4I]M$:H.28;44O*=907I"0IP=0UU$_^VGF QU9MB].=:@@QKIGJ5,(-@5
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MWTYZ];NWA&([A2FH5/8F+DB&U$BUF0X^M:FFD--TQY3@<?3DM @$]205  J
MXU!6$BNI^0/JY##^(C45:FK[IIU+:QRKLM"J-[3[SJE-G4ZG4.=2WF+6;I[L
MMR6Y+DLNMRIL^>)#R)[:UGK86\RPZ@8^$$\P.^%$:!JD,":!P[[V;TB20&J
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MA#2$-(0TA#2$-(0TA%!*7OBZRWGJ44% 4/A)X"L]U =R#SJJTO66Z5&Y)N?
M>]:@15.>N?*STRO;1W%XGZ59Y(*<#(.2<COCTY^N?TG4@#*Q<G?W7=K=8,<S
MT:F]O"FIN\'N67?\FY_JG4Q)L>AYQ:;>_@>#C_DE#)[_ +XKY'MQVSVQI >@
M<;;-3E;Y4,>&X'%,RZ,XVTIYQMRH%+:,%9_<]X9 4MM)3_Q@7$GMA0[C%-(
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MI8#@'0X/(05#H)1R2<X/[W:K:%K^='ZVVB&[HZ<B'&HI=M/6KQWZ@ (2$CI
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MT>G*I%HTJQT6,E;[3LRKU.Z:Q,I+TR8$G"8#3[;:@.5! /(41J'%1?WK?32
M< "G-O'I<\M?&.AMEMQ;CNNH7K:MX"FKN"S)M*#TNFI<;B38M4BKDMNI;<'4
MVIA2/)"2HDE/4< C3\>_2L10$7K[;=W)+=2;"-8;SUZBU+Q'>$J%3JO39TMF
MY]SE2(L::P[(80U9[25+<:;<4L?&"V0I(PH'.?2#]1MOS_G:L6]^_>D=HZF$
M-(0TA#2$-(0TA#2$-(0U!]^Z^_.$.?G^CC^WY=0RO]@>H^V\(H.,!PA1."$]
M.0#VSD \C(SSCCY9[ZD%8:J<NH8E_%^D5*$J+LRA0$$CGHVM>HCP.TTR0MN4
M6'V%IZ/+4PGE))R%YRE0*5*!!'/S U@Q6"P>*04S) S$,[AK*%FYVJ!=C$R5
MXF2L*$ZQ=+)*5 @ACF<FC4&A+AFCF'<;PCV!>,Q=:H*Y%B71U^?'N&V%KITQ
MN4DE0<=;CEMJ2%J.%H=!2H$Y')SX['=DIDR89F"Q:,,AG^&9:E=X4>A %]A9
M]&'J<!VEFR"E.,E'%RQ1BME .'J07H->6E(U$JY?$IX?W%*NREIWAL6&OXZS
M14*CW4Q$Z@$KE0U!P2U-('4HL\K [?+@3\3Q/LZ#,Q*%XR7+9S+[E$N:.20*
M;%^8,>D$C@7:/++PA'#L5,?+\68%I*FK1(2'J79RUJB,GVV\=NV.X.XL;;N,
MQ,IDR53!,;?JP,(M5! )DTAUMY*2F7'(^-)P !P/EL\+_4[@V+Q(P,^6K"X@
MD!ILU.K@$]W_ "RDW)L&>,'$/TTX[@<&O'A2,3AD.2J3+604AN\Y+E3J#@ W
MMK';3%19DH#D8><V0"'$+04D'N0<XP#V()"N<=M?29&)PV(0)DN>A22D*<%P
M'#@/;\^+?.YB)\I65<B8DNS%@?(L::ZB]H]'GY5TAM?/8G 21@G@D_(=OGC[
M=9@4D A22#L2?&W,1C*F+%*@W(-S8OI732K17!!['^W;^?2+.#:L1TB8ADC/
MPGCMC!S]G/\ /\M(JYKW3;<5]^WB.D6AI"&D(:0AI"&D(:0AI"&D(:0AI$&Q
MZ>[Q9K?_ ()BX&/W[US_ (]WU_Z_GG0^]8)! KX4:E&IITI7SBW7($." V8W
MMH5*>3[(O :DK$=U0CK*@4A+J\(4I84D9_!5P-82 "Y8NY9[@D\M0:5T/2!%
M'V(I=ZZC;?PCB7;"U:E/WKN2HR;31M.M-#KL>D4:+&>J'M$NI);BO5YBH>5&
MIJ4LI:;>]E+/*E'H"5#K,4)\V]2-:<[_ %B6+!B!J*@O5ZB]Z\C5W>-557PR
M;Q4N_KWJ,"M(N>FM6_:\^FRGZ='@N7-5*+74U9^GS7(\I+K\E;C(1YCR 'DK
M\MYQQ()UF 8#3H>?4^OR,0"[@T8];,7J.=(["V"LJYZ/5MSKUN6G/4%W<*YF
M*M!H,EUIV92H,.F0Z<PW*5$#402'DQ/:)#<=H-MO.K:2XZ$>:N87M\WZ6^3U
M'5AS_?VU]2M7QA^&:YY6Y=]75%N.K[SF):EQ38,BV[;2JSX#_P"XD9B$S(9*
M!]Y;\]]X!& 03C#\^_N?2*E@P%"6T(>K>.MSM=X^B_Z?[?32+PTA#2$-(0TA
M#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-
M(0TA#2$4G^67A\VG/]0Z1!H#T,6R@'-(A<8PV1C[%J']&D [5;P^=A>/'6XS
M$R=18LIEJ1&DKJ;#S+S:7$N(<ISH(*5 I*2 0M)24J! (QIIXCY&OT\;[P=-
M=/,CV.GC&-6[M5:-JNU842%[#3:U'6Q/H3*E&AN*<==<6^W375.QV'' ZI#J
M6$MLK&26AG :$;_GUT_-8FN]1JWOJ=SL*1H^5X.=M'*_?]=IS35#-\6_1*,W
M$I5-B,-6_)H4U^H1:I2E'J4B2[*?+KZ20@K2E37E$:?6_HWMH5Y/RUNUW;0Z
MZQMG:C:6/MI#KJI-;F7/6[FEQY5;K-0:;;<E>R,*C1F4-(*BAMME1!!<4%*/
M5@<Y0K[KOJ?PW2.5-Q-E]K; \4OA:NBR[%MRW;@KET;I>^:O38(8G5%,BT67
MEB0]UJ*U%_+BE8&22,#U@T\QIN6Y>?C6);VYCZ%ZF$-(0TA#2$-(0TA#2$-(
M0TA#2$-(0TA%%P+!4I/<-'I!&1U@DCCCGT[ZQ $SP260P?S <<V>]/)C"SW%
M #O5;R]EO6,0K]/JE5HU4AP)$:)5'HKZ8$F3&,AB.^M)0VZY&ZD>8E&>HH*Q
MU$ =0[ZT./8!&-P,Q,MLY04I<.'*2-#4TNP.@&L9^$8O^GQ:%8@*5+$Q*U)0
M2DE*5 L"!J0QUJ3RCY!U#[FGN76KZJ%Z2]U*2F54:TY4Y)BT"?%</FR"MU+;
MC=?0I@>20V@,%M*".HH5VU^>YWZ.8_B/%U<93C/@!2DI" )I;X16Q<8A"31=
MLCFQ,?I+ ?K5POAW 4\%F8!<\ISJSE4EB%F60D@X=:J9/]JAVJ03U&/#AOMM
MNTF=M=O95'_+;:S;-[-*KE$<"$@*8B+#S,J*EQ6<*=<D= 4!Z'/NT=G.-<&P
MX1)Q2Y@2E(H2Y(84S*4YJ6<\[ Q\SQG:7@W&\058C )EYE*.9DY4A1<%DI2H
M%@*BG05CU1_$%OWMP/+W:V=?J]/:(;-QV!)]YMMI(&7GJ:]&:>2C )4E+A*3
MGOK<P?%^+826$XF2M1!4ZR$@A]6"%-\S5^6A-X)PC&'-@\4F2]I2BHNU2#G4
MDBNQ#: BVX[(\6>SUZK:B(KWN2JK(2:3<;2Z)-#IX\L-RDH2I84<I"%JY/!&
MO1R.U$H "<@I54EU9? _\9#5W--WCA8KLYBI1)1EF(<U0"2*L"0_3=AO'1T"
MK4^H,M/0Y+,AMQ/4E3+J'4])Y!ZDJ.00<Y&1KT6'QV&Q4M$Q$Q/?#A(57T;Y
M#I'%FX:=AU95RU@ MF(('KX]&9H]I4G!.#C&00HG)^7&<8^9SCY:V<B5,QYE
MCI0BY;>E/I&!1*7<6U-/2_O:L50<@'Y@'^V>=79J;4]U/S/6 +@'</$=(F&D
M(:0AI"&D(:0AI"&D(:0@>QT@;'W]_D8LMO']R8WT+X]/^7<SV^OIDX^>A\O=
M8JFW7^/&UV#[1)5TH]HI'4@+S4.,G'22RX,C'!/I@]\]\ZJ4OK8ON-.?MZ-:
M)>K;OZ-R]VUBY^R-ESS5X4X$] 5T\AL_A(^)2_A4 ,@8[?7&C5?GI3PUOR;7
M<Q,5%,A2"@JQD$90"CDG(.0HK&#Z!8XXU84\FM[_ !$-\WBM]O\ ;^?2)CD'
M>W_"8\'I_P#E7><<?^1%/'V>H!YSW^6I&W4^0/OYQ79[NW@54N.0-*TN(Z^U
M$6AI")22/3(]3GM\^,'L.?T:0B 6GL2,^H!SZ_3^D#OJ 0:@N(@$ZAO%XAY@
MS@8)YX)Z>?RCL?F/M/;0J 9S>W,\H5I1]^43@DCD8U"59M&B8CJ:O;QA#4PA
MI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"*;
MW[T[_DU_ZITB#0'H8M5O9]SPL\'RU9'_ )Q>D 7Z&WNGUZQ)4B?>MOCL#*F_
M_@'N,_7)^W0Z=?HKW]="U'0_,?CW:^:1,-(0TA'(N^?^$-X1_P#RFW*__)S.
MH.G4?/WM".NM3"*#K_EI4H)ZDIQD]6!SCGL>QR#\L$G2\'2 2HD 7+/UU$:!
MOKQ4;#[95PVW?VY=IVM7 RU(52ZK54QYHCOI<4P\&5M#J;=#2\*"L#I]><;L
MOA^)FAT()V%*UZTY4<[".)C>T?!>'K4G%8^5)":**\P(.@R@$U-'TH3>->5;
MQ^^$FCPGJA(WILYYAA(4ZF'/7+D %81\####BUX4><<#N3CG64<*QFLMC=G'
M6[[;LVK1Q)_ZA=E) )5Q60L!J($Q2W)T0$$EKFT>IOQX>%)]#:H^]5CJ4XAE
MTH?J_LY0V^E*DE06PI?6.M(4@H'23@J&K)X1C%/W#1)53*30@,05  5N_@8R
M2^WG9F>$_ XGAYBE93E*EI("@*L994X) *2 035HV7;?B"V\W$M^X*OM)<%"
MW*F4!AE4FG4&L,!+4B7UB&W.F+:4B$RYY;KCKQ:=4TPRXXEETI"#SL5(Q6&+
M? SJ)('?"1YL;:BX>/28+B6#Q\L3,//0L$. '+NS!R!=]1]'UK"\53<*BR*C
M>UJ0;:F3:W.H5G1(=R/UF+=DFG1U/RG8T_\ 4] ]ECIZ'$(=<C.(<4GX58.=
M8$&<7^)*^'L<X4"7J* $,*\Z6TV4+F*6I*I>5(L<SOX,&W8[\JY<YXD[/8LN
MH77*EV_&EPJ=3I(M]ZY$)GB=4(PDMT^4I--4F,I3?4XPZA$DO-=*RTWU8UD]
M;<NL9*O]QY:GQKIL1&:6KO38UT.4"F-UJEQ;IK]+8JC%LJJ++T]+3S9=4A"^
MEI#RD-I4]T$-/JCI4Z&1CHT@_P VV\AMK>S[1ME"TK'4DY'S].Y'&<$CC@X&
M1R-(E]-HFTA#2$0P<YSQC&,>OS[_ *,?ET-MKUB&+WIM^8I^42<E>1SQT@#G
MY\\ZPIE+"G,S,EWRY !Y@OYO%B0S ,=[^($2^3@YZOS) XSG&01]G_6=7*5O
MW5Y4,.X$@C-5U.:N7M8-8Q5DMWAF-6+D4TH&%/6*G0G&, CY'GZ>N0/L  U8
M@']P"NH%>< "FQ(]VZ6/S=X\JX++@6AQ#:VW/PD*;'(/<$@@$'ZI[9'KK"O"
MX98(5)3W@Q(H_7KK6,B9LY*@1-5W0P#.P\V]+UC4=[[ ;7[@M+;N2UJ3)6H$
M-RFH3<><R2 .MJ8RI#Z'!@$+2I)![:X6+[-X7%$D3#)=FR2R6:SO,#^FT=;#
M<<QF&LKXCW$PN#>P8$::EVK2.<)?A$NFR9+U1V8WCNZV'4%;L>@5XFY+?<'=
M$9;<J6W,89)&/O4@* 4<8X(\Q.[(<3PL]4["<6FJEI.9$DX="!3O,%_')T8.
M&J2STCU6'[5\,Q.'1A\?PB2I8 0K$)G+)+EBI4LRR+&K$4  $6]&ZOBKVI4!
MN!M?2MR:(R2EVM[?U$Q*BU'3W=50JFRMUUTI^(MLRWLG(#A],"N-=H>% (_M
MZ\8!W23/1*-!=A+F-5.I+/8O7.C@W9OBQ*I?$DX%2P5I1\!<P M8O-ET&@#4
M#-6FS;4\9^TU??8IE:<JMB5QTI0JE7K3YM&6EW@+0)*XJHIP>K"BZ@$#)"><
M>AX9VL3C&3BL&<&L94K><9H"BP-I*;%W?SW\[B^R^(D*69,]&)DA2@B9+2$E
M:18A"Y@-0Q8%1#\HW])W(M-BD&N)K-*>IJ2R%2FZBPXR?/6VTUY;C(="^MUU
M" ,)//4<#7=7QOA$D9I^.E2@P+L57+,68C30]'I''/".*J7\/#8&=B%D9@E(
M*"4AR]4D.P=GZ$QE+=6C/-H<9(="V@Z A620H CHR %@@\*! /![<ZW,/BI&
M) 5*F(4%535B1H6+7&@=O"-!7_&5)FA4M220I)224J#A22U7!#,S](JB>@I"
M@@X./7'!^>0!Q\N?H=9UD(_<0/\ ZARV)T+Q5*Y:[+W#E*@*:5JYZ1ZRLC.0
M!@\Y4!Z_4?[OKCG4.O1#_P#U#[&&9-*WM0^[ZQ*IY*1D]/I_&'V_H'^PXSH/
MB$CN4.N;34_MK]8C.C50'G=G;QB8+)&0!GY=8.I4X%G.QI]#$N-QYB'4OJ \
ML8SRKK[?/ Z>?L'K],G6(3%E0 ETU.84\&Z18MH7Y,Q^H]8J:S1$-/K"!['[
M-(@V+;19K?\ X)C?53Y[Y_\ =#O;Y#Z<_;H;E[ZQ";#H/E[VVYF%6_OFD<@?
MM_U&?\2L_(_+OZ'GOJ02'#LXKZP5<<JC35,7K41:&D(:0CD/>WCQ+^#WMCWK
MO-].]CT_^W;DZ10EB!=SY5I^-N<=>:1>&D(Y1OGQC^'NQ+BJUI7/NW8]#K]#
ME"%5Z3/K3$>; ?\ *;<6S+94H+:6 OA.,\A)(.<;\K!&8E[Y@&'4E@PO3I6F
MKQYO']H,+@9A1.FI1EO13 !()*B S.3;1B#I&M+I^Z->$*TXU.DN[LVW4_>%
M4A4SRZ+.-2<CF6Z6_:9"&$*4W%9X6^\H!+;:5K4<)UL2. 8PYF2A( +9E5)%
M0 !6VKD.P:.7B?U#[)8<@*XF[U=$HG9W8DAF(KJ!M3*#X\_"04AQ&]M@!Q2
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M\9]WO8^7\_SP">-1IK4@<K$U\J0-Q;V1[Y4M%\TB8:0AI".1-]/\(7PC8_\
MA/N3^;]1[.>W_5C.D(ZZ4 4D'@8^6?T:1!(%3'GD,(?CK9*NE*@,E(R< @G
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MCG96QG?)::90Z[08;CX#24A*U/*05K*OPB%Y![*SZ8IW&\:M8+I91<N214U
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M*H]P7\=N,ON#Z\G'.#W]!VU!#JS$U^X]^Z15-A[Y_-XFJO\ ?-(.,_MX\?\
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M0B/IIT<.-RRPXZUYZ%Y2YY;JT=0.%*[Z1/BU[-X7'C]XV=I$Q3>_>G?\FO\
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MTA#2$-(0TA#2$" >#J"'#0BS/6[09$CVM^C4MZ7G/M3L"*Y)R""#YZFBYD$
M@E61@8/ U1$I""Z0QU]*^GE U#>_6+FF.RE/0E"0@YRD#"23@$X[9P /L&!K
M(YN]=XAA;2S5;R^>^L4A A!"FA$C!E947&0RV&7%**5*6XUT]"UDI!ZU)*N_
M/.D3^?7W\X]02E("4I"4I "4@ !( P  .  . !V&D(CI"*;W[T[_ )-?^J=(
M&Q^E_"+90@!2H8&<>6K&>^.M7/IW[Z1 L-/%_6*-3Q[UM_/XU-Q\_P"\'OK^
M?33Q'R/M_N8:CH?I%]TB8M=7K5+H,";5*O-8I]/I\<RIDR4ORH\=C*DA;CA'
M2 5)4 .5$\ '(!>_?G$.]J^_P8M%IWK;-\P%U2U:Q#K$%MSR7GHSA*F7AD^4
MZTM"5M]205)*\%0Y (YT@Y.C;[CT9CUWU$<X;Z8_9"^$;U/ZI]RL<<?^TYGG
MC_9CZZ@_4?/J/>D3'76IA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0T
MA#2$-(0TA#2$-(0TA#2$-(0TA%&0\(\=^04+<##+KQ;;Z?,<#2%+Z$=:D(ZU
M=/2GJ4E/41U* R1!H"=@81\W+=\?B=R-P1M#1-I-QK-K-8J$V@P+WJU5VFJ-
M%I<I!?:%3?I<7<95:E,-+;2XAB%3ILL A+\5M1(&J9Q+Y2]!O=FZ/?5G%W#0
M;P:^_A^?2-%W_P"+;>[8;:+?^37;WM^\*Q2KDJ=(V4OB[FJ7;7O9$"DMOUM^
M;!BE,253Z'-1*3'E0O/]L#?0A*UI'79$TDI#NY#ZWNUZ#J&VB0VKZZCWZQ]0
M-A[Z7N3L[MG?+U3@5B5=%E6]69U0IBTNP9%0F4R._/6PZV$MELR5KZ$!*2E)
M'&MF*UW=^E+FA:O*-NZ1,-(19;?)-)C$^JGSVQ@&0Z<8/((]>_VG4DN2=R\5
M3;HPZT%8A5N)-'/((G]P?FRX/Z?IQG04^7F"# AR!U?P(^K/RB]ZB+1H#Q*7
M/6K4VRFS*!)<I\VI5>@T-ZJMGI-,AUBK1($J<59R@QV'EJ2L#X2 20!I$,'Z
MU/.WOQ+WC&O#O7JPNJ[K61-J4JLTJQ;S]VT*KSG2\^]"EP(<Q45Y_P#QRXKC
MZVNK)/4GXB#DZ0;PJ#73IU]2=8Y<\0GB!9I?B>\,S:MJ=^)J;5N#>**X[3=J
M;CDQZTX[:4&.'+=?0RIJN0DMA+RY,%2T(0>IPI/&G7WZQ4GH'%*\Z6'E4U\3
M'3?[*N'Q_<'\3W;J.=D;K['MS[/@CY8QWX.,:;>O*&8L6<LP&Y:]""7Z_P P
M_95P\?\ :&\4 [ _W$+LR.2#_B#]><#L .=2VO-OOY4ZO$N7:EG%=*<M6W+5
M.T3?LJH>.-AO$^<<?]I"[.2,'&?(^P']/.E-SY:^?KZ1&9]14@!M*_\ CKSY
MMRE_950\\[#^*!..X_61NS@]\8#!SZ_8!SI3?T_/V@22*$/N^FI- WIRV+]E
M7"X_N$>)_..WZR%U^O;.&"!\OI^?2FY\@*^=N<0Y(N*.Y!NUP 16E=N<1_95
M0\<;#>)\X()/ZR%V8QQSGR,8^>.,=^3I30^G\^Q$N1<V#M2IJP9@?/72/#4O
M%Y1Z/3*A6*CL9XG(M/I<.549TEW9&[>B-"A,+DRWUA+!(0RPTXLX!.$G U%/
M8_._WY0<OS=KTM0.U]:,:@5T\%N^,ZV+NHE*N2W-E_$Q4Z'78#%4I,]G9"\$
MHF09*4J:D-)7&!#*DJ"OB 4<Y P=/?V@2:U (YZ4JQ%>5KM0Q?/V54+ /ZP_
MB?\ 4<;(79]>3^UQZ>OICY]YIOZ?D>](ARYK3J &KRW(',T+AV?LJX>3_<'\
M3XP<8_60NPYSR/\ $''J.WH/RQ$ARS'0U?PLU6H:M4Q$>*J&0#^L-XGQQCC9
M"["?R_>/IW^NIIJ3Y?D1#EV!=KV 87TIS9_'2!\5D,$C]8;Q/\Y _N(79S\\
M?>,C !/&?7Z:B+ G<="0XY4&^OIN/BKA?_$/XG^<X_N(W9G@Y/\ B./0>IQC
M YU--SRI\ZT]8@/=Z,-7'F!?>PYD6B?%5#"2I6P_B>2D=UG9&Z^D#(RK]X&0
M.1P"<\>O$0!(N7-'N !6]'^[N:!XP]SQOV;&NNGV3*V?\3,>Z:E2)M>A49W9
M"[O:)%)I\A+#TU)1&4GRE./-H[Y&4YQ@D#3?Q#>VB0[7'S\'<5-&)\7O&8?L
MJH8Q_<&\3_89QLA=9 *^0/WD]AC'R![$:FFY\OS[ISB'J+6.I T.VQU]"*OV
M5,/O^L-XGR,#!&R-V<YXQ^\=\@^O?D=]*<_+\Q&8MJ[L>@#NS.!K:P8P'BJA
MY_[0WB@X!_[B%V=AZX+ )/V ]N=13GY>]?2L2Y#U%>=BYY;;M8M >*J$?^X1
MXGAR0,[(7;DG'.0(_ &>,^OV:4]CSU]\H$D"NER"WA:YJ:,P9C >*N'_ /$-
MXG_7/]Q"[3@\<?O'YC]N/I--SY:^?KZ0?F*L15J5W'RK9[.8'Q50P1_<&\3^
M<YQ^LA=N2#D8Y8_1]H[XU%/'I]7^D2"3K0 U<,^QIZMH^I$6.X_&=:UHT2IW
M+<>S/B8I-!H<-ZHU:I2=D;P\F%"93EUYT(C*44I'("0?F<:DAC^&]UI$))U8
MUK44ML&.]]Q>/;2?%[1ZU38-6I^QGB>DP:E'8FPY#>R%W>6_&D-I=8=0%,!0
M0XVI*@" <$$]]*:%]J4/K$DGD[.SMKN0VHUW:HBX?LJ88*C^L/XG_EC]9"[#
M@@\X^\?D]1QG/R4W/D/O$.=6')VOI9P0+]8@?%7"XSL/XGQ\_P"XC=@'<@@G
MR!VQ\\8]?FIOZ=?QY\HESU>Q?2C'UL!<6J(B?%7#(.-AO$_QCG]9&ZP>>1_B
M1@?DSI1N?O5_I$$JII4[G6W[34?0G:(#Q51.<[#>*#CO_<1NL]L_^(P03GD9
M[8[:B)+AJN[7H3OIS'0<ZE^RKA #.P_B?'5SSLA=F?KC[Q]1_1]9IN?+\Q#J
M8,UM"*GTZM:C%WI$>*J$<?W!_$^.,C^XC=AR/0G[R1SC./M.,<Z4W/E^8%WY
M<CRK_B^C4U(9C2,PV>W_ +9WEJ%]TFB4*^K9K.W51I=*NB@[@6E5;0K,"16Z
M:*Q27DP:JTTZ]'F4XEX.-]20H!).>-*:.2_O?WOI-0:E@:WLS<K$WTKH37>[
MIRRZ0<9:60?_ *A(.HB38ZT\_P"8M=ODFCPB<\MJ[]_PU#Z:1(YUB6H_PK0/
M^<SO_P#7O?;_ #?:1WU!-AN?D%1!N/=R/?W,7O4Q,<^>)B@5FX-H;FA4-I^5
M,:?H4YZ!&"E/3*;3:W&FU",VA()<6_":D-EOGK *<?%G2*L7>VX_^YJ^+MI&
M%>&V%)54MSKEA4^91[8N&J40V["G178"UN4VG.,U!]$-QMLMMI=*$'X1YI'&
M>=/;^=/8VK>!=PVO-K5&H=JTUUCF3>K;CQ=U7?CPZ5:E;QV<]3HUW[CO09"=
ML&'6K;A2[>2W"345BHE,P*9"(@>66_,D JZ>L]&AZCP_+?36NL2.KG5_>MQR
MM1HZ1.WWC.(./$-MR#__ "AC?/T_=8]Q]AS^E$^WI3WT,2C;[QH>OB&VY'/_
M ,4,7M_]K=_3\NE?>_OSY1'@?3[_ )@=OO&?Z>(;;GT_[D47Y<]ZMQZ=LCOI
M $Z@^C>68P.WWC/_ .^&VY__ +0Q1QVQQ5_RY^SCY(>?I]?=/./ZWWC/S_A"
M[=?+_M0Q>/J?W7.?IQGY^NHJVCZ^OU9RW0"T+:'S&O4Z<J5B V^\:'KXAMN1
MW_[D,7C[1[UY^T?HT+Z-XT^\.5?/ZN_OI%IN"S_&M1Z)5JM%W\VZJ$JFTV;.
M8@#:)E)FNQHSCK<<%%54L%U20D=(*NHC4U]^]M/6 \1U;\GUC'MMJ/XX+VL:
MVKKJ^]FWMN5*O4J-4)=">VD:4]3'G0L+CN%ZIH6% I"B"G(SCTT]^_?C ^_P
M]/?GF_ZWWC/_ .^&VY[>FT,7O]?W6';_ 'YTA;0WW!?S-O+YQ#];[QH9Y\0V
MW/?TVAC=O_M<#\_Y?J@UK^A\WKY0_6^\:&?\(;;GU(_N11OR XJ^.<#Z<_;I
M$5V53F"_F3]/E$WZWWC/_P"^&VZY[_W(HO&1_P#2V>#CMZ=N=/+3?QW][1(Z
M'Q9_F;<_6!V^\9__ 'P^W)]#_<AC#[2/W6^F!\L]]/8]O$5T!YV-QS-&\HC^
MM_XS@/\ "$VW)_\ "VC82>3V/35B..V1Z]M(G?3:W*MS[:D:H98\=4C>&M;=
MG>+;YN@TRQ:)=4>YQM( Q+J-4K-3ILFCH'O(LJ=AQX34M8"PL(?0I0P3IZ>O
MOT\(GW\N?OY[6.WWC...GQ#;<X [_K113DC_ /JP./3[=16EN?X](CH^FK_-
M_2L#M[XS^/\ A#[<_;^M#&[_ /VL./S_ %[:F%=B/+[GW:(?K>^,_C'B&VZ[
M\_W(HQ_-^ZPX/U_-IO0#:Y]^?E$5&Y\O*[>5>=(B=OO&><8\0VW0YYSM%%[>
MN,5;_;J*\F]_2)\_2OOPA^M]XSN?^$-MUZ_]R*+\_3]UL_[-3"NQ'D?K<<WL
M;P&WOC.]?$/MS]!^M#%S^4^]CG^WVZBNPUU/AI#SWTKR]TYM&&;AT+QN6E9-
MYW32=\=O:U4;<M2M5FFT-G:1KS:M4*53I$UB$DMU13B%S'64QTAE*U$KPD%6
M,S7EY_QS]F#_ &Z$M3UZ<XN5I6MXV;AM6V:_.WWV\I<VN6_1:Q,ICFT4?KIT
MJI4V--D0%]=5#G5$>?7'7U *RV<@'@(6>Y][.+>#\XR'];[QG\?\(;;GZ@[0
MQ?M[BK=CV[<?F&HKJWOWX<X/:A]/6OWB!V_\9_(_9"[==N_ZT,08/Y*OG_9]
MO:8;T/F/,.6]U$0.WOC/4%)/B&VX(((R-HHP[C'/[JY&?F.1^G4&M-"X/OW]
MWG[\8Q&X]B?%?<M!JE E[\[;1XE9@3*;,>INT<:#/;CSF5L/KAS6*HAZ+)#;
MBBW(:6EQ#@2L+!Y%/AIU2/#EO3Q<#PW%@YJ?GL&&C\HYXI'W.C=>G616-O:C
MO-8MWVU6HKL)R+>6V/OU5-BOMN,NII2I]6=5"6IMQ84MA2%$GJ42<9CX:$U
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M,5Z>UUJ#Q8G3VDG 1*<')>_?OEI#4^7D_P!_'HT=&:1,04H)!4HA*4C*E*.
M .Y)[<?7&D(IMO-.C+3K;H/JA:5#_P!$GM_8Z1#VJ_UWM%72)BFMQ"" 5H2>
MY"E 'I )) *@?3N ?S#2'OW[V\9" \E*FUI*%!63R0H%)Z3]<*P>>#W'?2(T
M)O0U%^;7UCYV/;&7ZQOK6:XW;DUA$_<]F^&]TD5.C,TY=JFE1HILU^"NLMUL
MNLRFEJ91[L5#4IS(</.GO\[M"PJ[LP%W+M=M=S3D\?19M?6G//!*3U)*3D?,
M8 _*,I(Q@G2 J(J:1,-(0TA#2$-(1S/XB;+JUV0;1FVO3+FDWA;-Q*J=M2Z
M];K;5/EKC.,K?K K=6A8HZRL"4Y#AU68A(/EPU' T_CSBNI#<Z@V#ON[&W(T
MYYGL=M[4=MK#I]"K4UNHU]^1,JU>F1R/)-7JKZI$III"$H2IIHN)'F!+:5='
M6&TCC2 +G3;Q_@.1<4C<ND6AI"&D(:0AI"-8[QP:M4]L;UIU$HDZOU>H4"H0
MX%)IJZ<F9+E/M^6TEA56J%*IR5=1"BJ34(J$I"E=:E!*%0PV&FFUO?A$$_7H
M&>IZ^V,<TSXM\#:_;W;N3LK?]4B3[9@Q;V;I,W;54R![ 8_E4IURH7_3&G1+
MD,N+F/1I$Q"8A4&TNN++;;*-A?;6\0*9MAU>WXI=ZUCL2WFUM4:FMJIRZ+TP
MF4BEK>8DJ@MM-!M#"Y,-3D9;K:0D+#+S[8*?@<6 %&8 L"1J2W6IL:WHV[FQ
MIZ*#_!,3@?X[D8Y_;#HR<<9/?N=(D6YZ\B:MZ^4258 R:/G/]_Y'VAEP\_3&
MGOS_ !$&X\?F/5VZQ>](M#2$-(18I5LV]/J<6M3:+3956@H4W#J+\1EV9'0H
MDJ2R^I)6A))/ (P?0:JG_+_R/TA%[( 3C& !@ <  =OS:+_:?#YB$3:M"&D(
M:0AI"&D(MU4I%,K<)ZG5>#&J,"0.E^)+:2\PZGCA;:@4J' [Z0;[^C?*%,I%
M,HT1F!28$6G0HX(8BQ&4,,M @ ]"$  $@#)[G')TA%QTA& [GOU:)8MQ3:)7
M$6Y4(4!Z8U6'(PEHB)C(4ZLE@D=?6$]''41GA).D(X!C^+NXMNJ135W5/IM]
M2:[1J56H,@R4T=MMNIS)<60V>IL%UR'[('76D@.-(>3\)P<17P]7]_AXCSJ_
MODS=/&,RVR\<L?<;<>!MXQ8=99D2F)<@UJ'%K,NC!,2"J47$34TWV4L?"EIU
M2GDK#IZ4@CM/O^?9AXOJ_I3=] W,A[Z[W1\1&[M"DN3Z%=U#C,2K5J=Q/T>2
MUTSJ26:_(B1H\2(AF1(G26H[:6'870A]17U\!)&HWO5_#Y'IT@-7T8/O1WZ7
MC+F?'+,I=K^^IEFBJ0HC*6#6V9TA$:?-0REXQU-^QAUF<^V7I28RF4GR4!P8
M2XV%3[]]?2 ',_SR-FV\W(B#'B":NJ31KRBV7:%"KLV,Q6J?56Y":O59]+8J
ML:GO4R4H14.TV9-:=<3";>4E:E8"4D$$AS%-M_+S]M&.8Y 8^-#?[M]M6^B\
M%[VB(P_TE =;0XE*L]00M(4D*R >H @'/.1SSG4FA;:GW]_*T6072-!IT-1X
MUKSI'JU$7AI"&D(:0AI"+55*'1ZVF,BKTV'4D0Y"945,QA#Z6)"04I>;2L$)
M< ) 5C(!(]=(1<FVVVD!MI"&T)_!0A(2D?8E( 'Y!I!F\:Q/I"&D(:0AI"&D
M(MU6I%+KL"12ZS BU.G2T>7)A364/QGT9ST.M. I6G('!!&D(Q61MAMW*8IL
M:19ENO1Z.UY%*9<ID=3=/9SGRXB2C#*.?P48&D(S+R68T0L1VT,LLQU-M--I
M"6VT(;*4H2E(P$I    X P-(@V/0Q;K>_@>#_DC\_P#CJQ^CO]=(?GS?QYT>
MG/26I9]ZT __ +S.'<#O3WOG]F..><#DZ5WU<C>A^\#<4]N/?)HOFD3#2$",
M@@]CP=(1 )2.R0.WH/3M^;T^6D(CI"&D(:0AI"&D(:0AI"( !(  P!V TA$=
M(19K@IR:O1ZE3'$R%MS84EA:(KYBR%A;9 0S(R@,N*5TA+A<;Z02<XR0B"+5
MMZU##;WS,?-B#MYXDK I;DS;RS+J55GI=>9>C52\;6J3?E+J0]V2&Q4KG01B
M!U$D)&,@$=608'RVIR9G^_@T"4TI72A)>Y:GRM;2+K0JOX_C>-IQYMEPEVFN
MK03=,RH7#8T>3"IA>7[R"(T.X9#\AHQDM&.MAM;JI'FH2@D<F?5O+<>R*T@X
MU%3778BVW,L*<XGW0L3=._-RJBJB+O$3:5+KJ9K]*J<6FPV:#)H4H4!N##JM
M0@,3DO5=M,9^0PESR2XISJ 1D3Z^^GC]H"PTTUIY=+W\3%MM&F^-:T[8H5.B
M4)]N+0:/#9F4^=6K5J4N<^(#;;BVJBJNK+TU53+DAX+64!A24(41HWCY'GIM
M_,''EUH]*[/SZZ1?H<SQ5(MJ14=TH<ZG1)#DV!5($.7;;TF-$,*(Y2GX*Z15
MY4MR8[5 \'&T,E"&1APX(S'OU?7Z:.*4@6N=/;_/I=X[OL-5759MN*KW7[V-
M*BF:73ETN>6.DNX  =+?1Y@'961G.=3$^]HRW2$-(0TA#2$-(1# SG S\\<Z
M0B.!\AI"&D(:0AI"&D(:0@0""",@\$'L1\CI"(        #'H!V'V#2##:![
M'[#V&?T#^8:0-BT6>WR#28N,CE_OG/\ ?#OS_1\AQW!TBJ7:OS?0=?==8]$^
M 9IC*$AQA<9X/)4WTGJ(!&#U \$'TU(+?RW4>(B2'(.SZ/4Z^$>84V>,_NQ)
M/?!\MK/)X],<=NPT<;>ONO/I3>,I_P!CZ_>WK>KEX>[I_P#+$GUY\MK/TSD$
M8'V _72FWOG^&AEYGS/W?S<<H"G3^,UB0>/^3:&3\^WZ ?RZ.-MZ:5Z,0.3P
MRG<^K^+DCK2L/=T_^6)/K_BVOR>GI_1I2M&<O?3:U^9AE/\ L?SYVY>MF>[I
M^"!5Y .0<^4UQ\_3U[GZZBE:4YUAEYE^IKX _+Q)A[NJ'\L2,\?XIKYY/&/7
ML.>!CN<DO#WR_+P8W)\ [>-:A^FUF B*=/'_ +[R#\\M-<_^CQ_;\DN-M];]
M?PWG6&4[GU]*[;O6O*(&G3SVK$D<8_>VCS\_P?SC].E-O7WX^A%H93_L?7GS
MOMTL8C[NG_RO(/?_ !;?')QV [9'?.<>FE-O(T]03Z_:!2=%'U?QK]("G3P0
M?>\@_0M-8/Z!S]>WTTIH#Y_@08[^3_4GSVI$/=T_^6)/^;:^OT]>-'&S]7\;
M-#*:]X^N_,GWY0]W3^/W7D<?^+;Y^W_=C[='&WKUY-MIIUAE->\>5Z;ZUY%_
MD(>[I_/[L2?I][:X[_\ @\_[/SZ4K3I7\5@QW^?+F^F^IB'NV>1@UB0>^<M-
M?[,<#C^CTT<;=?QM_.E(9>9/4[?GIRB'NN<,D5=\$XZL,L\@< 'X?0<#.<#T
MU$2V_P!=WW]]*1*:3-/:K.Y'H8[!20?P@H=(R%?QN><YTB&K<Z\Z'2M+_(#=
M[51[,AT!J0Q1WO8&)4AV6^PPPTEE4EY:G'74-@=#9<<6MQ82D=:U*4HDDDRX
MT'G7U\[,U&L(,3KY./1_4["FL7?W5+QT^]'>GY!AD#N3VZ>^23_L.23C86:Y
M%=_O I)>NNH>_NEFKO%FJ]EQ:VW':J3XE-Q)3$R.V]&94TV_&6EQI9;Z0E:F
MUCJ;*AEM>%I^( Z.-C=P"?-]W_EX@(9ZW?3<:;:[AHO*:9/25_NQ)(4HE*?+
M:Z6T\ (2.G\$8^?KI3:G7T?\1.4LSVLS@&UP_P CSWB;W=/_ )8D]\\MM'CY
M'C41+<SYGQN3X;=:P]W3^/W8D_7[VUS^C4TV/G^(C*?]CRON^Y?:ND/=T_\
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BT$>^!#1 BM16UK<2V#\;ARI14HJ420!W).HB0&]^'TC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g454025g01a27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a27.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1WR4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '=:^=C@X0DE-!"4      !                      .$))300Z
M  #_    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$
M5 !! "  +0 @ #$       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5\P8@
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      T$    &              *"   "2P    8 9P P #$ 80 R #<
M   !                          $              DL   *"
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   *"     %)G
M:'1L;VYG   "2P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "@@    !29VAT;&]N9P   DL    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M ^__ &) TIICJ6(TQDM=B.G;%[=C2?Y-WNQW_P!BY6_9IQKQYI.&YI:YH+0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<G-U=X2'EZ2EM]76*&1F=(:BI[.TML/$A:.ULO_$ !X! 0$  @,! 0$!
M       ! @,$!@<%" D*_\0 5A$  0," P8$! 0$ @4*!  / 0 1(0(Q05%A
M Q)Q@9'P!*&QT04BP>$&$S+Q!Q1"4A4C"!87,V(8)"4T-4-35'*21'."LC95
ME*)%9-+3-V-T@[/"XO_:  P# 0 "$0,1 #\ ^_C1$T1-$31%9*[.-UOVK<?H
M<S1;JN^[$T\U.71;+IK%4DTBFJ4?-9E5%3JM%;:;>[E(=*W,$$)'0I>?J1;/
MZ]#9;NR.+%-OBZ+JM>-3ZI2Y%IQ[??E.5=I5/?EKN*G-U%A!@J4X]#+"5%'*
MIU:'3D((3@EGWU]\5' QOK$79R1RPSRN\'6BHH#B"L=4A0YNF>F<]/?COT5<
M.SAU(<024A:"H=P4"1[P#G1'&8ZK33)85S@/-DH^OPH#E\<C.V.\]W?JL<BH
M*@1<1=M/HJE.(+:UH45A*%*^I86LX!.$C?*ML 8W.VIWVRMW8_5GLNEV3?%.
MO.DNU>-"K-(;:JM6I!BW)3W:147GJ1,5$=DQX;RE*=@NJ3EB4V AX J&PU;V
M!G#N>Y4$7,!W^F%\]3P;N$N7'AQ7YLAQ+<:,TM]YXJ 0VTTDK<<4HJ2.1"05
M*WZ [$[:BR5J.$G'"P^-=/K-3L69,EQZ!7IUO5,3XBJ>\B5 *D*E1V77%F1
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M],4?/&PQMH[KK/$OB!"X;V-<E[S8SL]FVZ3\;/06%!#K[0<* $KZ#GPO!*5
M%&>4]Q,?+AW#<3@MC7N*EMVK;=K7/7//X\"ZI]NTFG)CM*F.-5"Y76(T!B20
MK&/.'0AQU144#F5C8Z=Z>2CL;V=@^F+V8B[F3*N>7$)*0I02I9PE)("B<$X
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M(H]HTU-3--HB'DPU5BL.\Z41HZGW IELGG6EM1 Y0,Z!MR6@DL>#/!</:[#
MVQ6[\CY20UV#Q:[\(DBX,S/HWPMXJ6;Q=X?VIQ-LNM,5*T;UH4&Y:#.5RL*<
MI<YM+C2EH6H%!1DH6%@%*@H$#6T.123H98-HTN;S L0M53 L&B(+N>\%WXU*
MGISF=$VQG\4-'&>F0%D_AG6:C]]W4?&E._MZ+MO^;-_YVB*!5*:>DZ+_ (Y'
MM]OL.B(:I3AC,Z+N<#ZNWU_PM$3XUIO]O1?#\V1_+HC@V*?&E-Z^?1=_^&1W
M;^/A].B)\:4[^WHO^.;]O]U[#HBD52G'.)T78X/U9OK_ (6BA(%^VE0*I33T
MG1>F?S9OIG'[;152*I3C_3T7_'-_YVB/?11\:4W.//HN3_PS?^=HC^W?53\9
MT[&?/8N/^[(_SM%'&?=O6'3XSIW]O1?\>W_G:(X9W@*/C2F[_BZ+MU^K-_YV
MBJ?&M-V'GT7?<?5V_P#.T4<>;<T^-*;_ &]%[_Z.WW9_NO8=%4^-*;G'GT7.
M<?FR.N<>/CHHXSU[Z*?C.G8SY]%QO_1F^[K^N[M$<3I];*!5*:>DZ*<=?JS?
MB!^V\3HJI^,Z=_;L7Q_-F_\ .T11\:4X_P!/1>[^C([P2._P!^C1$^-:;_;T
M7_'([OGT1/C2F@X\^B]<?FS?7;^Z]HT1_;I^R?&E-W_%T7;K]61_+HHX]/.W
M5#5*:#@SHN__  R/OYQHJGQK31G\71=NOU9'\NBC@XB;*?C2G;?BZ+OT^KM_
MYVB./OAUMBGQI3L9\^BXQG\V;Z?X6B.._3CHGQG3O[=B_P"/;_SM$<1K;G^X
M4?&E-SCSZ+GP\NW_ )VBJW33[#Z>9AUMU(V);6E8'OY2?'10$&RU=%4T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$75;NJ%2I-O5VJ42DNUZKTZD5*= HS3Q:54I49E3C4!I0W\YED%N
M,D;J=PD8R,8"YC^HSSIB]SY,6F%#T)!;SM]EYD]FBD2ZAQRFU:H4-VS5NSJE
M<*; K%Q4IJYJ//DBL1W79U'0TBI2F&D5FJ)0[(4MU1,=;BBL9UOHJ(IJD0]I
MNW!@V+.=%QZJ*B06+1&(#_OE@0O5ULDMH).3RIR0",[=<'??6L@.="67(IL'
MR'HK<<2;!A\0*-#IDJ34*=*IU4B5JEU*G*!DTVH13Y%#K0.$K4&I#Q 5MLHG
M8'6%5(.!=CI):[8_=I94EI9VX'UT7-6/9M-L.VJ=;-+6\[$@>4*7GSEYYQYQ
M;KCKI&W,I:U*/=DZS 8 ##-2<<W#8<>5_)=D=@Q'L>7B1GR3NI;#1('=N4DG
M'O\ ?HG8.7&9Z-'!4BF4X=(,3'AYNU[?[G1&F9Y6,6RMYRI53H"@0843=)3^
M=F>A&-QR;CV'2Z,+XBVC9+QK^%!^!WX(_"'L4V_*Y(K%K<7;#M>JTNTJY1?(
MMPZ@T\DOQ:;6XG*?/F!(:'DU;+:YAOT&FQV>S-0%9%. 8,PB[6Y23:9,VNUV
MHI.[8?,8<NTMB<\AB8CQT^#X^$FXE_![7)%[&W;9H,F?P=M2X%V;:7%U, >7
ML-2I2XS%-O7G0&TT62%-F//7RH:;62<C&/O[;X573X';>,&SJ&RV&RJVFTVA
M?\L44AS5O- I=WMR7P:?BVQI\7L_#[3;;.FJO:4TBFH@5$DL0)N2#>6!*^OB
MT:U9U[6_2+NM.70J];5=@1JG1ZU2_-)42H0IC0=8>;?92IMQ*D*&.56Q&.[;
MKU-5-8WJ2*J3B)!7WJ2" 14X:X-^,:1*[0(%/(.(4,@^$=G'3'<CPUDLF[\T
M^+X']I1._P#I9GO.?VGCHC-Z)\7P!C\11-L ?B=KV@?K/;I[OSSXP.BC 8 8
M?;JJ!$IF%$189">8J/F[1QR*4E1^L_6J0H'VI]VG83Y1D/*V6F,1BGFE,PD^
M:PL+44I/D&,*."H@'DP=@3MMCIW:(",,R.>/[J?,Z:3CS2&25!&/-V=U%'E
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M!()#MC)'EWR*H+9YTK"\<H*4@@D!"N0J!]8<RB6P4K.Z02!G)R3FV ;AEYZ
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M1Q(MN,@A ?KK:9JC26ENJ2TA4_S<%2@?K,J#\ZG*H#"!.EU3X/:AIH(.(-1
M_P#S7Z KOUM\6K(O&C0+CM.L1KDM^IM)?@5NA/QZK29;*DI678U1@O/Q'T(0
M2M99>7A"2K<:?G4O8MG?7VX/-E#X/:YT' ,3/6D8^A-I7,MWQ1G&UNCS@-H(
M!<*$%HJ(!\FEY+BFE.X)^HA?E5 <Z4%!2LOSZ,JO+W?R5_D]I_=L\[U0,_T=
MWM*M'5.UAP&H\FXH4WB';34^T/*>E5/-;I*9UOAE#*GA4HBYR7FG&528[;C*
M$+>2MYL<F"2+^=3B".+/C@^GFI_*;2PJV9.0-6F=(AB[V8%7<%\T+F=0IXI4
MPA*WT^4C*<82MN(I >:0^IQM:ES6&$MK2%ETD<N!S:?FTZV?#%LB<_7)/Y3:
MYT=:AGG2,C?!C9<#7^+UCVK&AR[DJ\6B1I]?HEJ0WJA+@L(D7-<$MJ%3*$VI
M4K!J#\E]II+6>52U!"%*6>73\X?VUR6$??*9C5#X3:#^O9Z_-5&I.Y:;KFC?
M=%" 3Y4NK:;?:82N*M;[3KODFU,+1(4R]S^LYAMQ1"$**L$<NGYU.56D"2[$
M";CWYW^3VIM5LRX>]5IO\L6Q;!U/IS2/6 ;EE2%I04<C05E0)R.9Y((&,'!S
MDC (WT_.H8EJHP8/ZMWJ'?R6U_NV?_NJZ?IO])L"1KOWC36%A"V)F2VRYS!+
M'*$O1V)"<GR_ZU#Z HC(Y@K!(P2.VI&!L#@+@$7(>#AR=2CP>UKM5LQ-0<U5
M,])(-J3B'&DEEHF^*4!GR$SN '*QDDG Q]7QOUZ]/GU/SZ,J^@/H5M_P_;?W
M[+_W5S+0^S[<9A4^G-,QGS6H'<C ;8)R.X@2-L]V<?=&9_,4-:KROR//A)4_
MP_;_ -VR_P#=5R_HQU4&^J8$Y\TGG;. B,>_']L]Y[^F/HT.WI%Q5Y8V8/+A
M/Y#;?W;,WEZFC7<9#?=*! \VG[XP0W'(W[B1(./]1\-/SZ7_ $U-G'H[_5\$
M_P /VW]VSNUZ[X_]WA^UBAOJE@'$:<HCN"(_WS(QJ_GT,[5#B!Q_NPQ:$_D-
MKA7LCH#7FW_AMYS#757IQ3/[6G ^!1'!ZX&WG'?W=W?TU/YBBS5/DPR>)=M6
ME7_#MN/ZMEP>O_\ =H+XI9 )CS1DXW1'ZCJ,B01[/;G0>(V9L*M8$<7*?X=M
MW_5LN.]4W_V?9%7S2TXS'FG)(V0Q@8QU/G&,;]03][5_/HP%1QPMF [GD+7U
MG^'[;^_997K_ /W:CTZI.^6)HQGJB/OC!V_%&X.1CQR-/SZ,JM(!C.#Z.?1/
M\/VT_/LBQ 9ZQ?CLPH]/*3S<H8G$DXV;8\,][X/3Q'LZ@@/SZ&):J ]@(YU!
M/\/VV\*15LR2S,:\?_H^VJJ:OBF//M,(BSBIY:$)5R1^5*EJY1S?BC(QD$[=
M#MGIH-M00X%1$&PQY^5^A:5^ VU%.\:MGC JJ> Y#&@6_9Q*[F"",C6T$52'
MNT]ZKA+K=RUVEVW1:G7*S+<@TVG,2'I<YIF3,<A,@>3+Z(T1B4I12MULA*FQ
M@+!7@).I\I,X5:Y\V<F;\'##&HL#.8B2#^[7(O<+"BR*I+C\;H=A5*]:'4XM
MLU&YY\&LLVM=C5=K2KGD3+@195<KU7;5;C4NCTRH(EI@4F2Z/,"RHM1' XPC
M?LRP(R=@P$G"W$SE@2ZXNTW152^ZQ)<N3 TD,Q9WW6)<FXSY:2$-H0D)2$H2
MD!*0E(   "4I)2D ;  D ; XUK-SQ.?UGK*Y=-AP&#>0MPP7&5BO4:WJ9*K-
M=J<*C4J$RY(ESZG(;A1H[+22IQQUV0IM*4I2,^)VP"3J(^A].<_OHM6F5:GU
MJ!&J=*DHGP)C+<B)*CY+$AAT H=9<4$H6A23S @[C<=1DJXS[TSXA;[G&,GU
M0<8)4G!ST (4>O=XZ*/W%\N*KT531$T1#@C<9'AC/W-$6BL*5@  >MN<8*1T
MR"002!T! &V#C6%=+A\@?J>(XOZH&'!F]G_?718^]I7@7;G'[A!>G#6X6$>1
MN2EO,PYJ4D2:564A I=5AK2WS,R8,I#,A"DK!*D%)"D+4#]CX3\0K\)XK9;0
MU5;M.]36#3?9D5&J]5P)!D4W7QOBW@:/$^'VC4@5.*Z"[$5O32)W8<06.H$$
MK#'X/7CS7FH5Q]D_B_(+?&W@%^-%0+[K'/=MF-'DH5RP2M]IV2R4OI;?=5'9
M*?J1P0%J'U/B_@QMZ?YW9-5LMIN;T&K=->Z*:WIIJ !%---6]F&&\[_,^%>,
MJV-7\KM7WZ141(WB*16]'S5 DTDU5/E)9@O4Y#R7]FR,<I4E>0M)!]7FPAP$
MI.5I )&Z2<C SU0DT[4[*H-4*140S%G QG'+[]LI(JH&TI(--18&X+7M!PM5
MB.6!W;R^#TX(=O7AHW:/$6).MN]K?4)7#KBY:KOFE_</JK'<<DPIE%J_D791
MC>>EMR5!*@VXDJ5S@!07D9XMD!QT]XA20(SS)CI]AFR^>V^OA$N+?P?U2H78
MY^%<LJ\KTKMM5"SE< NUGPJ>F*I_$_A/0N(EL/W=/O"D1KAMMY=7IUIQGJ?(
MFBD.S5U'+'F:O.W)*,-HVZ':[@DL+'EA'."68 ]478AB 9.K%HN;@=#]8?#&
M^;#OJS[=K_#>X:9<UH5"AT6309]&J<>K0S2I5.8DP'#+0^\\5+BNME1EN>64
MH*3REQ#@ ' =>.,]2^+A[ @7SD.S0-+#NUB!<9*N;H#CN.Q"A^V!22,'N!P?
M9K(%WY&V>.K\F9BJM'SJ/Y7R/E6_+8"BR5H0ZE"B4I66EJ2YR**5!*@@A6#R
MYU>^VZ<;J/\ M#QQ9;C15-$31%!(&>NW@"?HP#GYM$?#Z'ULIT1-$31$T1-$
M31%MQ*9+BV^=/,VXAI?KM^JZXAIQILIY^?F=0Z%-CDW"5$D#E*JW?E/>(4!?
ML9/G.-LBM<$$D9W !(\ <X^\=NOCW:B/#^6.;<5.BJ:(FB)HB:(J%+"<Y!V]
MF!\RE<J=NI];8:*/QZ%4+?0A/,H+QC.>0\H'BIPX:2,;E2EI2!N2-&[[OR1Q
MC'$1UMP4-2$.D@)<3@GE*D9"T;<KH*"OE0O?R8=\FM025!')A1(]CGH>^:K6
MXEL$K/*!U4HI2D#O45*4E.$C=6^0.@/31'SC7#OBVB-N<XW0XVK)!2L)) "E
M!*N9M3C9"PGG3A9(2I(6$K)2" @V6IHJFB)HBQE[5%JW)=U@TR':,:BS[BHU
MW6I=].I-QU6H4:@UP6?<]#N*=0ZI4H5,KZ(+-2IE.FLM3)%MW &97D$IIQ;=
M?>:X^W/Z!@=[%I #7OCK@+E?1^'B=M4Y<"BD-;YB9)9PS 01!+@P1YL<8NS1
MVFN(EZ52Z:9*X=</ZA7J5:[\*JTKB_Q#::X/JH=&7#N6SJ';,"U*-1[LIUT2
M'$EVXY\&VIBH]2ELBB,FG1S+T/E@X9Q.,.TR6>9M *^F1.3EX)+$P"):_*'%
MV73)O8SXLV;;-Y5BA74_4J_ MZ)-MB%!XE7K4I3U29X4NT>Z(D#SZ"K$JOW6
MXBI4&*^]'BI2HJ?D07R6M!@0[XAV<78-FW&68%:]H9M#0# (DW(RD?*!$%I5
MN+>[(?:_JU'X:5&@R;'X?N4RL6%7ZW1T<8^(M3K;;]O2;'-S5J7)J-AO)55+
MFHU%K\&=;+2!#CU"2R\S576*C(?B&9W>UNIOA+!F<"Y*CDR ^#A[9D,'#$SO
M$&XE75J_8CXQP[*@1:17Z7/N672;N])E,<6KZH)JER56Z*56[<J3507;%TL^
M9,-050*M2:A;2(LD<_*^V@N>2$$,T""&:.L086=!) S (:7Q8X7(L6( <.TZ
M=R=D#M-W+482Y]SV'#G/2Z'+E7[3.(UXT"?0Z5$H+E,K/#VE67$M1FVY],J$
MHH<-SIJ$&7SI5(;I;2^5D'AHS=K>6<3')9:R":K.SC'&<68A[VA93< .#-]\
M+J+ M^Y9%O7.Q3J9=T")5A?%R39'F-0G/KI5 ?HTZ@,,NQ!&'F[]8,Q=3;=5
MSMPW4@*-$O8-H ,\!)T8O.(6G_=U&OYOF)P9FAG)<T@!V>,7#/CA3NQSQKKE
M?11JG4;:X=\)6+CG56CV9:][UB\ZY3*948\MJX$46X[PX>TGXMC5HRU.(I"D
M3$PE*>#%0.$9G1[BP#7Q87AB,&T2JL[8LT-)N"9:PJ./1Y#E7NXM]GOB [9G
M#NW.%4FB7A"X?WYP]K](MV_:I#HE/M&V[3D(=ER*'7*%P_N6ISJO4&4.-%%2
MA18RGG5J5+:1RJU0Y<@'O D$ ,.4!EB1N-20+RU.I@NQ?D#=G96E1V=>U!07
M*G5;7MW@)+K]"I%YQ+(15K^N-$.Y3?\ 64K>=N17R35*);*J#'<D)AU9%,NV
M3)G-,O"-36W5!A/D#\Q$\(?@W475/S!CO$$QNZ$$NQ;(G>(!:V??JCV?^,I[
M-?#^S;/F61PSXT6+76Z\@,<1Z[=MJ*D39KS=P(E5YNT;<?DIJ[%2J<I;*[9<
M#$E#326PT.9+$M,MKA(<EG,.;'B'-J8#2Q',#$8DP'>6BX' /A9Q:X-5NYZ9
M4)UE5VT+@K%'=:K$[B!<%6O-#D>AMTRH3$>?V\S2V8$RKD*;M;,6.VKRSPN,
M M-Z8&]S)!&DDEIQC1\AA@\L/[2((+E@"#2'($#0E63OKL-7+==)XUU9-?@U
M*_KVO"ZZSPW9F5>HQ[/H5&KDFW4-3)=0I]&D2'9+3M#?:<I\F37VVRZ$LOK*
MB44@ @F-,"&R!8C4,Y<%A:4G>I8$URQ(,@L+P)=B0T O8S;:G=DCM>)K=^52
MLW/8<RWZ_>E#N1ZQ(?%6](="N^#2KUO"74F)\V-9*:Y9232Y5'CPHM(GU%3T
M^E,L/F*RE,DXG1Y>[$EX.O(L;&Q5 =P7+$NX(#,3>HC,,:7!FE_E8]1E]AKM
M'R;9OFD7-4+?O^HS^)?#2\6J?<'&>\J5;M\46S.*!O&72I H?"9==L&L.6VA
MFW(U:I57O%R7(4I^<VVE*5K3AF,'N29B<2;O'(8<%PX#%M ,39V .\1 /&X-
MB=DOM+V[>=G3[ANB@U6+3[FLBX8MXM<2KR5,X?V=;51K,^Y^%%#LMVRFJ%=\
M"XH<F!2A==?K5&K3;/G4E5,2\W&0]7?&V(B78L(8$,P)DEP98QB&L7#,Q9F=
MR[R/F<G](%(;+U00HA YG5K*6VR5%" 7'&T<J^=25 A/+LV0"HD@GE.XQ(<P
M[,;]2&D$-G+1)E9"IPSB"&<#([HC$2.'ERU2"TS&TY25"+ 3CUB 13XS.3L.
M8\S"U9R04%&"3S)%-3O,, X ,0W5Q.),AX5V5.ZSR=_:5,2;$U.\FT@N3HMB
M2M.>9""D'*B@\QP1@ !1!Z8VP1U([\8F+G44U.#(Q_4 .E@ MH#PP(B0Q'T+
MRSL7<G^THI:59("DCN. DYQCH>8$'<$@ [8\20-5. F(QP9KEA-H83(;(@5-
M<-:2.9)<R>#@%AF2K.3A:4H 4XX&WW$M-Y 4M0:0XM*$DCFY4$ ;JWV(#>&&
M,PS N20#,\\"]SB2*6.9  ERXM22V3L,KB MQY$K<Y,J<4#@%+,CF"3^9N(:
M+ <D)=)PDQD/D#\T0T!J@,PC_P"W7(!CH=%22'=P+N [!KAR:018NV)Q"TTM
MI2\AA#B%/%?(6ED,N(=S@-N,NI;?87N2%O,H96 0EU2O5-8&\$X.2(9PQTG]
M.-X*Q%36<@2?E #-!!QX$[Q>*2%6M)2VETN-EMQ1 *5<R5I2X6ENI)"06T+!
M!3CRB]DLMNJ(3K TD%OE;1P7PL&9[7#7E;')#M5(#TQ/(MGBVJ@LI(2"ZVV0
MWS*2ZZB.6^92@VV\AXMJ96]R?4V7$)=*5))0,GER(()$&Q=_(1$3:^=UB"#2
M_P P9@QIE\(,U6_I#OABM-R,\A+((Y2\P9*$KRD*'D?+%"7%H0VXM((;(:6M
M <]52^4A1K9!F :Y>)(B&E^;%!4\$RXBS.[6-C@^8)TH"?)82\,K6A+P2 26
MTJ<=;!4K ;RLM+*>1:L ))Z\NH2SMEB 03  %B[, !!ULC P7%V9S$XR)O@6
M9\E4""1RMI(W() SGER#DJ.V.7))WQL!C0@U4RP+.(P!=F$&7F,7LL8&T<.V
M[+$$!S<N7L3<RT E:\3]%(1PD?BF/GEW_HF?KM@< XZ]1MG;0!MZ ";L<[X7
M=W#P"S8IXE_R[E@&8OA26+D2#@?FF*:@L@&^AWSO]&PV&P_CWSOC7-V=CQ^@
M77%P=<HD*NTZ?1ZO$9J5*J+$B/.A2BOR4V-);6A4!PM8<0QGE<6M/,M/*CR:
M%*W2FD@DQO%ID8@ ,!@\U8*%B"()8C3(@M.3QCF%A;0^,W9<LR/3J?1(<N)(
MM^]ZU'C0/B^KN56-65*5;58NJ2Q4)CSL^ V4?%;M;>?<94THO1$%*DXW[ C:
M/N&29?D'ZU:EI%G6FK9$D!J&#FDNP#@-\LO4"&DC&Y*SM94E;32T'*5MH4DY
M"LI4D$>L-CL>HV.L#<\3HMU(8 ' 9D^9E6=XG6#=EUT>YHU'K[50;K5M2Z*S
M9-=^)*59BZC)94V*U,JL:R+DO%M]&4CR#%1=C\H4I#2%\I1%&-_E?-NF/!<Y
MPHMRX[4X?VO;ES,4"+6*+36:?+8MRIU.L45092$)7%FU>DT:H. @9Y7H#0!)
M &,:#ERRP\K^2R-W?KY_N\XB N[R(,MYT+:J\Z*@)Y?),M4]2<Y^N!>ANG([
ML\P\0>FK&O7[*,<\=3[=)S=;?XJG[_DDK'7;\3T'8>'Z"[GQ/W!J<_3V0OH.
M1]_?B@I4_ON2L>\1Z"#_ /Z4C[FB3IK'WCS3XIF=UQ5C/CY"@?Q4,:<^4>S^
M:-PTBPZY1]%"J3/PHHN*K\^#RE3%!Y03TSBB!1^GYM8U FDBDM4T'(]"C#(=
M-.^4+1%)JQ/K7)4L>R/0R<=_6B@?=^C6---;-74"W]HOQW@6Y"^D+$BO CF+
M:#T<]%4Y3);:2MRO51X8Y"AR/1$@\_J#UFZ2TX@I)Y@4K&X&01L9M#5LQOTS
M4" S"7.+;I\QG@LB!52::FEYR)@,[@827.1LO)?M]<';TX:71:/;8X.+JK]\
M<+W(D*^J52F679-T\.79*85:9FQH].5\8*IL:8[45MR'6THC1''$NA;2&W/0
M?PMXSP?Q/9U?#/$44;,;85#9C;$;.BH#\RJJB:B:":@-S=.\"Q >W1?C_A=O
MX"JCQ^SJJK%%=)K.S&]702=G123NB@&_]3@@,;L?1O@W?E%XQ\.[3XC6E<T^
M30KKI3-5A.Q?B9X,+?WF4Y\N19R42J=+2_'D("EEMP!*7G$[GJ'QCP=?@/BW
MB/#;2C<.RHII%5$[&N@E]G536Y>JJC=-0/S"K> 9C2.T_"/$#Q?PW8^(IK-0
MVE=?RUAMILZJ2U0J :D#>WMUC86 9[I?%DM.5JKU7<(&4<S%#RA0W*ART3F!
M4,H/JJ(2M7JDX(X7,Z]?I^Z^@S2PY4M[GH%X_?"K?!X=FWMIVSPS?XTU?B!!
MO2PKFMU-I5:R*=2$5!%HW/?=NTZ_X$MOT)KL9#"K?ESYXD@Q)L)^&)["D%AQ
M+F-7S%@[@DN9'42^<7IZ 6AI-,00S9X8V<7:&!-FJE\ %V=J?'HU9[,':*[4
MW9@J=-8<DT2=P[XJ2ZC0 J8EIUOFMBLPDHA06""AFG42;0$H"G5R5RE.M-0L
M#LW:06DW$C*_FZKF0'=K@@#I)EC<L"+&7ZNGL-?#C< &EKX$?"9V!VA:)&D.
M/HM?M+<,WH5:EPTA*FZ<BZ(T+B')P/70I*9%+$@% 7*;PGR>5%)I<EIUPD6.
M+'#BJ2X L9MG?AU >S0N+C_"!_"]=G-^/%[6'P<]7XMT!,E^&YQ%[(UQ0ZD5
MQXR$K0^OA]7&+C4P%)*N60[4Z.)3F&VF#REMC-[XS.9X$^N.)*Q88.'9KL.0
M9M;+(+AI\-WV4[J\TA<4H':F[-5>D*6V]2^.G B?;$.&ZTKE>;?N2#;]5MY'
M*0I04[4&LM@.8"2"8.9G2,QRXYW5G$CH;]>VPPSJX>]MOLA\56V5</\ MA<*
M+C=?4 B(Q?\ PVAS\DX4CS&IM092G&CE+B&VG'$'8M^-[[9"2-7]>9'30K*"
MDR8=>B)GT2]WZW 61Y.;29-IU"&Z#@A3<F)3'V%)WV^J D],Z'O3R]TF7X6_
M_P"C&D*WG$Z][@X<L0YL:@\0+N@276X[TNA.\,XS<.0^\AAAEYNXYUO25K=6
MH%*HK$MH)R7'&S@:-%R;V8'2X;RP0%WMH[WX."X$S^_?Z FL5>E1:A4)5SV]
M-D)*GJ/519SL^$4K*.5]=)AU. 2KEYTF//DIY%))6%$I2[_>/1D&9:UV\P<F
MXWN;KFOBF9C'I%6?'\PH'W!\1_RG11G_ +3C;JTXJ$TN:<XN&MI Z$L6^,^)
MQ\29QMOE*<]VV#HC?^EKS3[G)2:7-V N"M8R1LS;^P(Z[T7IGP!/]R>NG/T]
MN7WE ,(Z8&^./TL5'Q7.&!Z25<$YY06*#G '<!1AG&Q)'NP,C$;4^7LJ.6#'
MU:<M(U4BE3-B;BK!..OD:!U/4C\9#@'PR=NI.KS;I]04878%VPOB7F76)_:C
MX@IX44.TJQ-[2--X22JK?G#NTHL.N2N%=+56H-Y\5++M2XJI%3?M)J"YDJV[
M6JU<J+8@,%E#49R1(\DPVI0I-\'://  8!0>A,SA$R23=KPLG*;%?538+PO:
MH5-@,-J%52BV"Q4FE@%,EMUBE*84VH''.VLA1!(YN8$P^OEY?:VJ<@38 W(R
M=RXSQN3<+7?0B.TEV3=T]A!4E(4\NV4)*U' ',JC\F>_97N.G??>"<6=X^5[
M8W.=\'U6RD5"EQD@NWXIL$@ KG6BT-R-P7J8VDCO]4GIT)&-3GCIQ:V4YZHP
MRINTT_<:"'<^7'3+IM6GHYYO%"%$;*2H.R:Q9;#6=\)\J[3VVPHGH"L9ZY W
MT8W<^7LZ&X#.9/Z><$D,_.;KB3Q$X?(!+W&>W6T=SCES\/T-YV/+SE@@^P]/
M[K5:+GRG6W> @JDX-<9/R=V<].H6R=XJ<,&$\[W&^U8Z#E*''KSX:-H<.>B%
ME"M]CU&/''71GQ;7L'T1]#Y1YK"SMC=K3L=\+;7L]_C!VA[+C?&]X4FGT1<.
MX*#4)SBI$MI"G2S;;3Y$&.%'SJH2&%064Y+JTIW$+ 2W,B9U]"H(),N!+0+6
MO)8S<+L7:=X\WKPNLC@Q4N#=^V=%IG$FXXU/@73=E@U3B/;[MOKI0FTU=.H=
M@5RVJQ5'J@D--Q)$>IR%,ESRSM)G-X:U#6(<GR(;SB^N@2D/@&)B9-_U%YYE
MLU9JF?"%W-9-JW==/&+A[=:3;,RU:7)MVRV;,@7-"34J?/J59N!^C<2[OH]6
MG0U1HGQE%I--14ZU I$EI#]/\LDI0%0,3;3[K,T&D$CG<\)Y1<C*ZN16_A$N
M'M+M"NW[3[5XUU^SH#MGTNW*S2:-PZ(O"Z;UCP9M(M2ATJ16J77$3VH=0:EU
M%^LP:)2F66G4Q:G+D>19=RY'+3TB ;W/)8%\6#OQRS8@N((RQ75Z%\)"8W$:
MMT^Y.$O$E/"F/;/#FNR[N=H% H]:L"1?-5N"DOKX@4R=>C4QZ&Q-IT"+"]"*
M;=3[R'%2"$M@Z*LUF!)<X^<'J[+*7@EVOK4XV7Y+L:%85_V<N1;<Z\+)N"ZT
M6J:'Q$M2EUJ/;]1K=M&W[JKU4B-0ZG+B,/0[JI=NU4"2TMN"X@/*:);TYGUX
MEC.+N<NM%4T18M]K2N5V@\-HKMN5H6Q4JO<UJVNN['(5#J2+/IUTW;;M!J=T
MM4^Y(%0H,N=1XD]QR&W7&':)]4>54HTAH)2CC[>U,/<>=)ZP#? P</I?#@7V
MIP&X]+34XV@#%PQ ? N6<@7\X+8[8G$2R6%T*]+0K/%V7/OB\[/X8\2J&T+<
M'%9^S;GB4</56DT6WET&,[5+6J$"N0YUKTV!;4MFBW(B-%8E4U*JKH T87=\
MW#EPT%P&8EW<!USZMI32_P"HEY^5B!3!#C, $OO,Y^8%EJ</.WGQ!XAM0C0^
MSGYI4JS=%KVY2E7-?%W4JC)B7$Y/FSU7+,9L%RMTFM6\Q0W"VS!H51H7E)T%
MM5<*WIJ8.._^7#/:PC(6(<<S#9+756-HYIWZ0"/[0Y#'Y215 <.?E@OB%?RK
M\;;N3VK[0X/F+5H5IR;!J$FINNVY-J,.IW(VQ$?ASJ=>HC180;HL-<=+BW%-
M+ER77&W$!*0X)^=3+BJ3]"8DV-H,NHT&F['> BI[:!Q.%@,A.(%]]LWC7PZX
MF3[?J=O2JU;%AURZ:#Q)J<:TY8>GS+EBU.9P>J,-YCG0_';7&;I%1:;<:CRW
MJY%=6X7E+0UF":A!8&XL,K:2]\767YE  %5)@08J(=B[DN 6EF=[!EV^E]O:
M_K;JE<M6Y."MQ7'4+0HD@5FO1Y]9I4^77&J;$GE^/:K=LU&FQ;4D+G(8^,J9
M6:G4D*9DK72F7&PVM$R&CE>[L_$&F+ZP;>AW%%19Q#0^35,T91G*V/#SMX<4
M;GXC7K3:EPGJT&F^@=NWG;E+N.HRJ#2*;+%O-RIE&I5W?$Q=KMPSYSAE,Q)$
M&(5T\%:UM2QYH3WS8B/M9AB/1ULVE/YFRI% 8FESO @.;R"22V!PZ+,'AUQS
MC<3.$LJ\XL.A4.]6;:KE:D6K3:K5J^JGR:>B6PT[)37*30:RX@34);+R*0F+
M(?441'7VT^4(\7+\LK2"3SXEXU;#95[,[U1$.1NU$."6$$4\78>]GJ1V@;GJ
M]P\ GT7U29-"NR,W1;R@6A M2LU;TOJ"%-1V[HI#[%0N>E4)A"5,OR*'*BO0
MY/*9D.,R7'A>,2X@L,VQ%WY!UGM"-ZJJD%B'9Q)/]PJ-H+E\3,*S-]]JWCW9
MMZ\=+):I**M)F5-NE]G>0U9DY,&)6XS$=FKP:^]'3*1-CTZ&XNNA3KCL>1'8
M>4V^[(Y&EW!B1)$R+&X8 DZN[W#.^MVJ!DPP9F+BV(8&!<Y$$ +=VQ\(!><"
M1&M>Y^%4BIRJ!:-/5=%[5.?==JMU*M/T'XY-3BVI3>'M8;;M83XK,-<^G3)]
M38<D/(52U\@<6%@"P!F\EL)@898 EUC^8 26K+.*06,XF*@6PQL'R78N&_;R
MON_JM1V4\#(%.MCSNV:?<=RQK\NIV=!J%V7-6J!'<MFF5#AO %?CQQ1(E9=%
M=7;KL5@SE!I:VF4/QF8-+%CAG#7-F<Z,GY@)<N) W;GDY^66+@2V<JCCEQRX
MV4VK\5F[0NINV:%P\NVSJ;5(-%A</$\0%6_.H\^M5*M6N.);;]!J55FU64#&
MI3LNG+5'I]0!4VZU';D@SNW_ !0SN \D"3F?.%N.R)#O:""2 SX N!H[-,+:
M6UVE>*E?O#CE48=4O.-:UGV/#N7A^NJ4/A'1*#7&:A9]LW(Y)JU,GR(_&V37
MI%3JTE8:?IZ:.VRIPHJCDA(CJ.[OB29?$XEW-G)9\F,H-F0VZ:0U($"!'RM2
M,0 00&;)EZ=QPE*F@GR3(2TVXX4)0M;,AR&F;(;!><:/DPDEIHG*TO'E*4YY
M](/D3C#P2&:[$8$!V";E0<'!Q2Q(,4N6C+' $@NY5!6"PTC*.9M3@*/J00?*
MX <YO*\WE$DXP$<@P"%'!&HT2&;0X DEV,LX(!O=F3=(#Q9PYF6# 0;B2Q<6
M))6BI"@E9(2KZFOU4N-9/J*/<O'?X@>W&H+XCD>Y])#K%HBQO()L>,Y&SC]3
MDKF:HZ?/B %#EB0AGF;.,,$XP5 C)42<GWC&K5))!;(Z!GD@#0"]BSK/9EC2
MQO9XDNT.]IP F5QJW!@E*2 5 ^LMHA(QN2CRI)R<'.Y /08UAN,23)RO),B!
MED"[_P!++=O6:>> XL]L]0[%4#E/.OF2 A)7@K!R,I3C"2KE.2/KB$XZJ!Y0
M:Q;!L((9B6QTTLXR.-50IDN-'$\C(O;A#L%9GBU?U2MZ@W73;>\[HUR0K3K=
M;I%V5:U7ZO9U.F0J:\]&$I]RHTJ(_+=<4AJ-$5*)=<40&G G:@&6''$#F9X/
MD&6/YE((!=X$ @AI$ XO#,X)N'6/4_C3=]<[-O#"ML\2*9;5]7<Q$16[KC0;
M??8IYBP)TJ>Y'MZOKGTBE^>S8+$%U,MYUE@2>5E:I*F0H3NB78$6)Q&,XYXC
M,%6DTU6+EG%)%,@%[SBY;='$$,L>N /:O[17$+M"VE:MYR)T2Q:K1I,*I45-
M I]/M]<R!35N+>98D4]J\H5>==0B8[+<=39<AA]#5)>,PEL;!LZC2[QB/F<<
M0P;BXXK6=O0*]VJFH5%PX%+$1B9M P+M$+L]Y=HSC/+KMU4ZBWVWPZ@T6K7M
M,I4^-;M J#U3E686(U'X<L+KL68B"[=+3ZW7U1VF*@\V%^0=;'KC7OC>(I<$
M $N!FS W(CFQ,K94 ::34*B\,XEP\@U,8L9Q9E?.J\<;X<X@=G6DP[QMZ@4G
MB1:]9]+[78I33U7HMW1* Q4PW&K=6JU0@PG(517Y!$%^BNM%]PI,A8"4"W?#
M"!?W:Y<S"Q%3?W522"9/ D&!A%) Q!5O;?XL\:J174U*;?=0O2Q*AQXI/#:W
M';AM2UJ;6*_3F2_&N:I0W[>I=&,^B1JE)1#IE1E-N//&G5119C);;\YN[>1=
MI<<=-6O<\:=H'!^9R,Q L <3S#/BO1V0I"'5(2EQ0;4E*2<<J65,,.H\FI:D
M91Y1UW=).#D=Z<XD#/!V!A\ 7>(D:H-H'BDC7=P%R)%P[,YS<6TTN!)!Y3D*
MW!4UZPVR4CG.XQX'<#NP1&&()%R)+XF(Z6QC!37\XJ9FW0YI:2<Y(R)FPC%;
MN I*JC"W&\B."#A2=G3OSHYD  XRG.1@*("3G60)D$DFQ.0I)O( ,. +2Y<I
MXD#\MZ09I>T$MF,W+DL[4EB(.0:.AW!WSL<]0.OM^GQUS*+'C] NNK9SY46!
M&?G39#$6,RCF>D27FV8["$<Y2ZXXZII"1S+"5!2T@DI2%>+:%J<IZQ;![64E
M^(;[X9L;O%EYL<)*#9%S\9JPS>2*1=EWQKCO"8ER->O"JL6NEE%>ENPW&+'I
M#CMW0IR$!M4E$V$^^S)2I<FJO.I\H,O#.!41! )AX@2"_-YI&+F]=\3%KD-;
MATY05Z:(2$(2A.>5*0D9))P!@;DD]!WDG5[R]$O.?>$=%5HB:(FB)HB:(FB)
MHB:(M%]LNME ."5((/3!2H*!V(.Q Z?0>FK26(/=EAM*=^D@7<$<005LZA3X
M]0A2(,MMIYB4VIB0VMKG:<:<PE;3C?,>9+C9*5Y)!!R1RDC5V6UJ\-M*=K0X
MW:A5202XJ$ A@22"T@0V 6&UV0V^RJV=;'>I--0PFX(<7 8SPE>5? 2^J5V7
M^UYQ&[(%1C*IEF<2O*<8.";BU%-/8F5V,TF\K49D^3+3;357HE4ETR VXE4.
M.&60PX9@6CNGQ7P]'QCX)X3XMLR3XRC;[3P_B0*2]6SV=&UKIJ(>FD&FX%%)
M??+DQN],^'^(VOPGXQXGX=M13_*5;&C:;"PW=MM-ILZ=UQO5-5\PWJR 32"P
ML?5EIX/A*T#""$J2KUL8670G!4$D+Y %* &4!S'?D]%JHJHK-.3 VDDVA[->
MQ#Q@N[T5TUT"L%P79GT9W P)<,X(9:I8"@0H-E&X"%-I.RB.<J.22LCF 4DI
M&X*@HC6P6'#"SZ:+(L>.9+Z19HZ>NHAL(*B GU@CF(3@J4D<N3@XQRA(2D)&
M-SDYV* ,,]<UJ:*K24RA1R>90.Q2I:U((R#]85\N=A@X.!D ;G11LCU<AN#K
M9/TBFR@\F5!AR4/I"7$/Q(KB5(QRE"@MD\Z5)V(<Y@1MTU7]&0T@OKH(U$76
M*G%GL#]C?CE'=C<5.S;P<NU+BUN(DS+ MV/5F'7<EV3%KD*#'K$26M1)\ZB3
MF'4DY2H'?41B[O#6^J\U+S^  [.$&XE7EV8N.O:@[)-QM(>^+XO"WBW7IUJP
M'7LDN1J7<K]3K4/E</.E-+N6G!..5/*CU=$.-N>>J\A_A)NQ+\-7PEMFQ+?L
M7MD\;.U?PR%8#952ICMEWO;U4:D,BB3KHJ5/N)FL7&USX49M0N:6D)2?*4QS
M/(4W))M)GD,GQYLSH&M Q8=-'Z8<%Z!<+>!__5&DWA-:5)?[7'9KM&=Z/PV!
M(NZP*?==[4Y(:'(U7JD_8U6IE4J3*"D/R7VWGW5C#[CN,D-[,"Q<T\WSF(.5
MI4B0 2+%CCU .I=\UV^C]CO_ *H&J+K@O'X4#@Y2VFRDQU6QP$L-\K5U&6D\
M,J.RR,[$(:*2?6QS9)9ST<8>AR\LZT,Q;5C]25VIOL#_  S520MZM?"X>95$
MY3R4;@?9K4932L)4IM+4.GMM$)Y?K(38Y\YRKUU [2>.1NV?>CJ09W9Y G!Y
M(C0]%L)7P5'PF-P,*C5OX:;CI2F77"^Z;0X>Q* Z7UX\J$O4&\J"HM\PV20D
M@[G?.C0SFT8F^O7$*V. PEG+69CZ^2FG? S=L24B2;X^&<[:-RR/J(IK]-J-
M8H'F+;?YHE:57[53*+H ]=;C9!*BKG)V8OW[H!P?'7+O#!<Z/@0[[FH<<K_P
MGW;KJDZ0M7G4MGB"B('6%J)6TE"Q+<2M0*@7W'G7"25+*U$J+'M^JJ\]^W?_
M -3DS[MIO#BZ+![9O&BY9D"_;"LFMCM UER_12:7Q%ONW[#37;3F4INW%4ZI
M4UVX//?-%QI3DE:@T)[&$22;K%O:;]5'Z9]^OV?-&RO^IN^R?;D:D>D?:([8
M]X/TZEQ*=*@O\78M%H[]0C)0ER728D&VXM0IS*U!:DQD5F2D(*0'EE&5F]3.
MC\^[);#D,[P[ \1/'"Z=/_ZGD["$5WFG7#VEZW&P2(-1X^WHQ&2YMRN)%(?I
MJPM'ZT\QP?6SG&(PUZGT[R5796O^I^_@ZR0*E;G&FMM@Y2Q5^T%Q<E,HWV"4
M>E2-@-L$D'O!&VKU\O9_/W3ITGG/MBMZC_J?OX,58\G4.$?$"K13DF'-[0''
M=J.%=RDHIW$2!Y/'=R<I!W20=].\/9WYJ%\"W+OT*[#0_@%/@L;?E/2XG9J\
M^<>0E ](N*/%ZZ2R$XW8<N*^ZF\@G&_,ZL;G;?2'?OO-D(U;O6.]5WJ!\"Q\
M&72GS+C=E2Q7G5$!?QG/N>J,E)VQYM4J[)BDC.4E;*RA6%M\CB4+#OOCBC%[
MD\?LPRP6+':W^!;^"ZJ]L6<JH<-K7X'R(5YTAV'4K3NENQYM?B^>M+G4&IFL
MRY,6LPIB4%,@K:3+;:Y_)2$[),J;=/<_<^[A8UNQGR;'$^0BV!N/9NV>&_#R
M!:=A6]2:)1*K;=@TVDL6"MT,5J-3&*;#1%@3:;4'?+*;4W#;0R)+,E0?:Z!7
MUNL" 0(WI<.YEYP#3B?)94N!@VA=W,X <&$<HZQ?_ O@%Q(F2XG$+AAPUN^H
M5:3!J4B/<EOT6KS9+]/9<B1ZBQ'E0WI7G,5IQ4=$QA+#R6\?BAL)!U:0#48
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MU5.X:71'OBB,Q5[<%7H;$:<8 =74*U27*@XTQ3V'II+[CA9=2^DIT @N),
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M#AUL0X7<Z!V8^)-)=?,WM!WM46WN#C/#=,>0M7(S76T/I=O<DR KXY<6ZA9
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M27.D#FAER@<>8*_RAG\.[1ZO[?,>RHJIS(C+')G\^F*>=RM\0"<8_IECO/\
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MRNL>ONH$5.^/(-+?7DM)VM5)8"DDC=DD/,$D@XOD )NR]6F5E3#3AW);2M6
M-\IR2.7()/< <?3K546JJ#%P\-JS9O@MU)>D$X@'JM7F!Z;]1G.,'; /?O[C
MTT?0ZM+='D8JJ3M_'[M50EN4GA*GKHJFB)HB:(FB)HB:(FB)HB:(FB)HB:(J
M>49YN_[VL=T;S^6N?>,HH4@*()/3'3KL<]<]/9C0TTF2'(QT_?52?[B!D&OG
M.D+2<8#F<K(&,!./5!R2#@$$D9QU&VVL337)IVAH,LU-) Y'[*M28JH%0=S<
M$VAQP5O[ZX2\/^)E*D42_+5H5T4V2TIM;-7ID>6I'.""J.^X"]&6GJE3#C:P
M3D*SOKF^$\=XOPC"C;5DTN7)@N09H;=;#& 0N'XGP'A?$[V_LJ0*KL)T^9P>
M^#>&_;0^"NBTYBE7%V;;@GV53G*Q%:N>VIMPU=JE)<E2$B#4:.&Y(0P\P^YE
MU!2ZM7(G&3@'O_P/\74;(;GCO >&\49--55>TV9+7!%.]9N89@[@=%^-?A7:
M[4FKPGC_ !/AP8--&SV=;$B""2P$ 68'B5>VA]B+MQT.C4JF4+MS7!!C4^GP
MHZ8<N@4^H(;=CLMH=;1(DP%27F>9/*E;JRXH))5WZQ^(?B;X)XGQ!V@^!^'V
M&]12*J:*S4'#C\PDD%ZG=F=FE8^!_#GQGP^P&S_QGQ&U(J-0KJ H(! ^04TE
MHM.KPNU#LU?"(PU!R+VNZ'4.0!/)4+1C<KA2,<RBW&1@DX)PD#IL=]<0?%O@
M)@_#=E2&)OM8=K$$$$'!X9UR/\)^-R?\2VI):_Y5A!@C$=C#;*X-?"<TUY*8
MG:&X<5%I8)5YY:JTA [@D-) 5S'KLGW$9UC5XO\ #VU>H["FEK4[FU)'"JHN
M3BYX"S*#P?Q_9-33MZ]H _S&K9C>>SAF#:-:\KCC9/PL4"5B/Q$X&UB RZ%(
M+]"E17I*,;I=(=RC?F3LD[ *WSM?YC\/$CY*2P D;4,&P<@#*!I+*?R_XA8_
M-4)_IJV1)+LY^6]R1/"5RH?^%6ISCCBZ=P-JR DI2VW(D,$ $CF!R5 X.<$9
M&1L-9?E_A?:  ^(-!)=ORZV!-QO;Q<!XC,O@MHVOX@H('\J*XW23M*'+!G84
M@@D%S<2,E6+U^%-@)#3G"G@Q5,-\Z7D7*65J)3S<ODR"4#8  ^NG<<N1K(>%
M_#-<CQFT#.#\M3'@]5RX;J^"5>)^.T__  @)+,-^DD"[-NOAD6<@V988]KKC
MQ\)O#H]A1*QP4H]HTI5\V=,9D66]Z9KJMTTJ[Z'5+/14"RILP8;-R4VEN.1D
MAP3E.)2XILI"3]KX-\'_  MM*JR?B==19J@=@"P/Y@(G:!OE(D2T.'<\';?$
M?Q &&T^'T 55-2VU(<4P"^X?U&D:%I*S-B=IGM^0(4#XZ['Z*E+<B *=I-S,
M84_MEYYA3?*R0?UG.H;[GKK@^,^"_A*@[3^5^,[6L M_NP=T TG=/S""]1#6
M:[!;?\4_$5.X3\,H 9P=XDU7+D@7_I+L'P-AR"^VMVRJ:2FH=AN\)2VDJ6I-
M/K<5]2D(!40R D*6ZH)PV@#F4HI'>3KY]/X<^ U!Q\;VK$W_ )>FPDQ^:Y#Q
M86S9;_\ 6'X[20*OA.Q<&QV]0(! M_E',$O#V=<>U\(AVCV9 74NP7QSC4]M
M0\X?:B-.N)Q@J"&R %( !RKF!/4#?5/X9^"M5N_&=IO,32*O#T@$C-MH2,;N
M PU6='XB^-;]--7PK9"EP:C_ #%3BDD Q^6)I$W!,LUUSB?A*+[CX<JO8XX[
M0&%9Y5)HBWU]^.=+:2$^W!)]G=KCG\,^!8;OQ0FHD.^RI G([Q[Q*^@/Q!XU
M_F^' # _F59 N?E+"7T\U0[\*7#@Y;J_9HX\P) '.4FSI[C*6NO.IY#2DC;[
MN!OD9A_#'A2?E^)TD-<[,._*IO-QE*G^L7C/_P 7!W@?FER';&D3RY9<:CX7
MCA67DLR^$'&NGIY_)OO2K$K7D63G!*EHB$<H.!S#.^#K@U_ ***MP^-V9)L:
M:"V<E\IZ9A2K\2[< _\ 1U<"?GD81!!S#L&5J^-?PM_#$4BB1+=X=7[.GR;I
MHR'TUBWZK2HS$)$MKRK[$F2PTR^ZH8Y64943A..IU]GPGX,V6VV.VV^V^*44
MT4;$UT#9;+>KJK!_34*S2U-G9R^E^+M/Q1M_D.S^'ES4-[?VA  L_P M)<BY
MPL7F/6*K\54T?A.]Q49H<ZI1D6U%N!FBLD,S7$2HS<KD7Y< LJ:0O#PW"$I4
M<$C&NG>(\+3L/$5[ [1]RLTFH %V( 9BQ)!>2 NU^$\35XG8T[;<W=ZD5;I)
M@D$D.6M $.1:ZQ^N/MA5"WX-K3C9-*FMUJBU"XIPBW7 >Y:5!D1&PBD>3*E3
MZA(;F-EN&I+;H<2M*TI SKG?X5LZO"[3Q&SVYJKHKV=(V9H !WR=YZB8(AF!
M#W7$J^)U[/Q-.QVFQ%--0J._O$EPVZ-UA=R^41<"]MU<=:=0)?#UJ!3$5F+>
MUTP+8G2(U3A<]N2*A#\Z9\^9#BEJ>0?4=92.9 !)&<#7!H\'M*]^_P M.] =
MP[6=R ;KDGQU :UV-PT ^9+!V=H70X?:8JM0N%BCP[$<<C7"_=4&R)2ZFTAR
MLU*TTK<FQ9[7+^-R7XT:=-COK):5&BJYE!U01KF4_"F%1VNU-!I )+ @DEF!
M>]^<8@KC;?XI^6*/RMF-K574:=US2S4NY@P]X@/SO-PBXB/\3;3-Q2J*J@RF
M*W<%!E03(1+:\ZMZJOTF2_%DMCD?BO/QG%L.X!6WRKP H:^?XC8T[&O=IJ-0
M8%R #<B0"6MYSKS?">(J\1L]^J@4'($G"DN#8B?0JZ.N.N6FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+
M;/-A86#Y/+@*$!S)05)2M:3RC8[Y*N\A/]R!K 7,QO!M#>,+Y2,64,AHEQ/
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MS)Z04_/UE5Z9_0*M8(WWS\7XQL<G. 0!MG!/C]#Z75:6?S&6=M?2(4>D%/\
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MN/)DJ2N2XAMM"FHL>4\@%:TI*E,I0@'F6I*05 J_JVN>N&;-P9<UHJH5L"?
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M7(+-O"[L?0NUF@L^:OE7;M[1U9X@\<XW#@TF0FS.)UH6K*I%9>;#T'AC\F]
MN-ZOVU29#2Z=/KM8N"YKBB-*F!1J#= :A-/QW8O,BD."V,#.=._;AU5D-B1\
MQ-PSD-K? N&TG!:]>(=Z1.*-?AUWB%QYC=GUSB+2&^*E>C0[RIUV656#1K^4
M[0Y1IM.J<J.RJY8-ITMY5DHJ%$;HZJ6\'E&IU%2!$D7(++8)IR##.(>9LS8Y
MRLL>(O'SC3PGX'=G&>LS:94+LLQZ3>5YUBT*O=;\BY:51*"[:]K5:BTY$ZIT
MNJWXN1+;E2UM<U&53Y!5*BG)U%<[V9A'/VLRWZ.T5QKI'9HOKC9Q>3*L6NMW
M73J;;%HVY9LZ?-M=U=4BTQB)5668M9J-3I<]^:TU/J*HDU-.BE4E22EL@,+Y
M_3W\D=N$2\#MA&KK%WB3QPXQW<W8]T6G==X2.(M3X<U&3=EK691KZI]M&V':
M7/2W<UJQJA38%.74VF@N3669R8M7AUIEB/2X+T)U1#OOO'*UI+D9/.!@CL^:
MN)P1XS5NUZU2*RU?U^UOA',O]ZWZ)4>(L>X7JI,H4BV:(Y6YKS=6ALUR0U#X
M@NU9B-+D10&VGFV&P8B4'3$OE![X9XOHL=K%3@XVSF6RD/(RBRNMQ]X_<4^%
MG:&;@6K-K=>H-5M"BU-CA]$LNKUQ=9@(B5217;@I-=C,-TVE3J.TU$6Y3I,Q
MN545<@2VM2D@+Q)PQQ:UN]5S*!2?#[0U 0'!-P=[.\.>3X0L5*=V^NU%*<CU
M%J@)JU"1?\BCTIA%BUJF7-?-$FTYI^E4ZGPYMLF'"J#$P/Q:F9+M.0T05FH/
M* )=]]\%Q8[UG[K:U#M>]KB^[=J\]^SYEOU6R^(%,6Y;=MHKQKT97DYC@MRO
MQV;?IS$NG-AIA,Q4&J5-DJ(07TA6Y6@?,,+N8!X1$KM][=L'MG</*70F)]HV
M]436D6O4)-Y2Z'4Z%3:;\>T\S%V_,CQ[=N:0Y*:FJ%,<D^9)4A0*U2(^RP6S
M=IF)E@X'!FX0LC.UGVHN*G!CA]PPJ5AT&;4.(5SP:36)]&8M6I7'09P>%/\
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M(=]]\2I\[XKX_0*PL^'I+7M]^[\C7AXZDO@S<W]DY>GNGG?%C[!6#T^V2O\
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M_?W;:=]^2/H?+K?[Z()?%??-"L'IM^22O=?X-:*\O3W4>><6/L#8/\):]_\
M#6BCZ'RZ7^VJ>=\6/L%8/?\ LEK_ /\ #7?_ !')&VB<CY>Z>=\6/L%8(]]R
MU_Z=K:Z'Z=$Y'R]U/GG%?;\8K"'7/Y):]U[C^EKIX]^D\OW^WFJH\\XL?8&P
M3_\ :6O?_#7TZ)R])\_55>=\5S_4.P0<]]R5\[?-;/7\/<[[[^Y1YYQ7[Z#8
M7O%RU[!/=C\C6<>.1\VDSY?=1]#Y>Z"7Q8SO0K! _OEK^?=^EK^315//.+&!
MBA6%G?.;EKWS?L:_#P&BCZ$]/J0GG?%C[!6#[?R2U[Y_V,]_=]W1,+'A#^K>
M:GSOBMOFAV%UVQ<E>Z?P9U"^#,VKO[=55'G?%?/Z!6%C(_9)7L@=Y_2UCW;]
MW35XMR4?0^7NGG?%?[!6%G'47+7L9[A@VUGZ-27P;'/ODKR].E_MJAE\6.ZA
M6#_"6O\ AO\ L9\?O:JG+TRQ],4$OBQMFA6#UW_))7^G\&O?]S17EZ>Z&7Q7
MQM0[!)_ODK_L\;9'M^YHB@S.+'=0K!_A+7O'^]H=W\>BCZ'R]\?W4^=\5]OQ
MCL'H<_DDK_7N _(S]/=[=%>7I'GZ.@E\6.^AV#CO_))7_P#X9_#&G!.7./=_
M)#,XL=U"L'Y[EKW_ ,-:@?%N2CG(^7NH\\XL8S\16"#X&Y:]].UM8^;)U4Y'
MRGS]64B7Q7[Z'8(']\E?_P#AK1'T(Z?0E//.+&WXPV%[?R2U[KX_I:Z'N[_$
M:*IYWQ8']0K!.^#BY:_].]LC;&WCG?IJ3@W8]_+JBDR^*^^*%87L_))7LY\?
MTM=/N^S2=+C.V/-[(H\\XL?8*P>OVRU[I_!KKJ]]W[S4<Y'R]U/G?%??\8K"
M]A])*_USM^QG.PW/B=AI./?9=7EZ>ZCSOBQ]@K!'ON6O_P 5L_AD>TZ)R]/=
M1YWQ8^P5@^[TEK^?_P!M8_#IHH^DY1'FI\[XK_8*PNF?TR5[<XZ#\C7CCKCW
MZ)R/E[H9?%C;%"L'H,YN2O=>_P#8UTT1]#Y>Z&7Q8&<4*P3X?DEK_P!&]M#?
M[FBO+T]T\\XL?8*P>F_Y):]U_@UTU)TO'#W4?0^7NH\\XL?8*P?X2U[V;_I:
MZ=?;_'4?0^72_P!M5)E\5\[4*P?>;EKW_P ,]_=]WV)['W3D?+W0R^+'=0[!
MZ;YN2O\ 7P_2S^'CHG(^7NGGG%C&?B*PLYZ>DM>Z?P:(S\^BO+T]T\[XKYWH
M5A8]ERU[/_[:^G4EL'\M>V1!,XL?8&P1_P#:6O;>TXMD[>[?53ESCW?R3SOB
MOD?C'8..\^DE?\.GZ6?'W]VB*1+XK]]"L(;_ &RU\[8_O9ZY^YJ3IA]_LG)N
MGT)4"7Q7[Z%8(Z?LDK_7.^,6SX?=U43SOBQM^,5@GQ_)+7Q@Y_O9\-%">?3Z
MD*//.+&3^,5@XSM^26O=/X-:<4?0^7NJC+XKY.*'8./$W)7]_F%L[8[\_-J3
MBVBJI,SBSW4&P>GVRU[<^'Z6ML=_=X$ZJ<O3W4^=\5]OQBL+VD7+7O;TS;(]
MA]Q\=$3SOBOC] K"S[+EKV/G_(U][2>^7W\E'T/E[J?.^*^WXQ6%WY_)+7OF
M _(UJ%\&?7S3D?+W4>=\5_L'8/7NN2O^W?\ 2SW;;>_5X*H9?%CNH5@]-_R2
M5_K[/R-=-$0R^+&WXQV"?'\DE?P/#]C.D\L/JB"7Q7SO0K!Q[+DK_C_>UIW[
MIR]/=/.^+'V"L'^$M>]N/V->[/W/8GO+'ZIR]/=//.+'V!L+^$M>\?[VO#V=
M?HTGO)O?R4?0^7NI$OBOWT.P>G=<E?Z^'Z6?#[O?ITOY?OY*JGSSBQWT*P>A
M_9+7_#;]C7CUT4?0^7NM_P /[EGW;;PJU28IT2:U5[CHLN+2Y3\Z$B5;UP5&
MAO*8ER8T-YQ*W*>M1"XR,%6Q(&Y7OFN,IR >+UZG)21PXX79*0G)";HXO* )
M*22,D[#Q[C@DL2=68/;+Z=-#=7';0EM"4)*B$C *E%2C[2I1))/4_<P-%DJ]
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%;GA6@(M22$YP;WX
MH'=2E')XF7<>JB3MT S@ 8  P-%!CQFWTT;54TT$\7+V/_8WX8#'?GTFXO=-
M^_OV[AN.\H?ZO_29Z]^F*N1HLDT1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$6W>=+2DDJ:2A0*4A2L+<=/UJ$ X&P!5@**E8Y0D?7:*'@_?D
MK#57M0\ J'7*E0JMQDX:0YM%?;A5QER\:#ST.>ZH(1#KI$_DHDHJ(Q%JBXLI
MQ1"&6G<E22.<NE_-N@!L1>U\:948U5B,SX4J)-A2FFI$*9!?3)BRHKR MF0S
M(;RVXEU!Y@6U+0$X(6H'.B#N&YW\KC%<AHJFB)HB:(M)Y2DI]7(4KU$J\F7$
MH4KZUQQ*5)/DT'=?K)!&W.GKHG???WI8>\H,'',.=6V,%ORKB&7!@GU7D(\H
MG<^J=]._=0/[]8C6^EEKZ*IHBZI>M\V?PZMZ9=5]W3;MFVY!+:9E?NFL0*%1
MHBG20@R:E4Y$6(R,)6OZH\GU$+5T2H@H2PPT=6GH7:N[,US2J3"MWM"<$;@F
M5[R2J'#HG%&S*G-K"'L!I5,B0ZP\_.+BSRH3%0[S_K2=$=NWX83:6MPE7*O?
MB+:/#>U:G>]\U^E6Q:5&2VY5+@K$MF+38C+[[49AQZ3SJ::2Y(?::'E5I4%+
M2"G)QHDX-CW[]A=JI]0CU*+"G1'F),.?$8F19$=P.M/,26D/L/-+  4R\PM#
MC:]BH$'&-]%9[SX_9;MU:D %*>8J4E(R%D#F[SR)60!WD@)'>H:*$L'[\@5;
MWB#Q7X=<*Z;%JW$>^K2L:#/GPJ7 ?NNOTB@-5"ISY#<2%3X+M7G0FY,V=)=0
MQ#B-*7(D.J2VTVM:@DDR[Y]YKO@D M!8( )Y0M8\F-]DJY75()2LYY,$A0PH
M$IWT1SH0WGS(#<W5HX_:#X*3+2N:_6>*MAL679E=JUL79=$VY:/"H5O7!1'D
M1JM3*M5IDZ-"A2Z<^XAN0P\\ESG4E"<J(&G??%'ENEK]7C'M]S)XY\*X='X<
MUZ5?EKQZ3Q<J-"I/#6>[58Z85ZU"Y8QG4:+;DGF*:J[-@H7*9$5*TK:/E.<-
MI*S6USR?1YA_= 3V[7.)O&GK%U6W%..+&4A"3A*2"',I*DK2I).4@?4EI61Z
MZ'!A.,*,[[[^QY[Z>AX&RW&BJVTR2W"BORWEI;8C-EY]Q?-R-,-^L\ZKD2HX
M;:"UG;'J^LI"<J24.E^\E:6R^T%P/XB7-5+-L3C#POO2[:)(?BUJUK1ONV;B
MN"C.L+D\R:O2J54Y,^G.A$9SRD>5&:<:<;>2<AI1%(^G?) =/(ZR>+#JKQZB
MJV51J-/I$"75*K-B4VFP&')4V?.D,Q(<2,TDJ=?DR9"VV&&6T@J6ZZM"$@94
MH#1%T[A_Q,L7BC0F;HX>7A;E]6Q(G52F1KEM.JP:Y0)4^C3':?48\6KTJ5-I
MTAV/,COLN-M2EN-K;6A0RDZ*/+1V_8#NTKOVBJ:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*W?"W:U9/]^_$_OSUXF7<?';KTV]V
MB@(+MFQXAEITU6.+M[)S_6WX7JQ[KGXOC.<[=3W;^.VBA%S'Z2/W<6Y\E<C1
M9)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(L"?A+N*]T<&>
MQWQ9O&RZG*I%T/TMBVJ)4(2"N7%GW#)1 0['4%M^07Y-;J#*4LB.%>40 O"@
M4+W#8YOI;![]5</LI<'K1L/LR<*[)A42*[39_#:A3+@C5)PU@5>MW;1(M1NN
M96'9H=-0D5.5-D(FR)27'W&"E@K4UD*>O-8AR\NXTO9\78,\\I 'F#V2NT6S
MV67NWOPFK<UST"X"<;K;I/"6BR/)S*;;*.*"WO(4<RGZE3&:9:;%=G4SR$;R
MM-I=&AE]J,I#SH2\U]_W^JR&0L+@YD9VY ,%Z#7OQ\X]<,^$/&"]KKL6WJK<
M/"JCV]=2%VA1ZQ4;=NBV9R:C(K3]N,2KCC52I5"F1*>I3T%]RER8KK\4/1WD
MR$#1,8:+^7T/T73JAVP+^:O'LBTR'!L,6CVIZ32W*7<LN//$:EW"_;$J]GK>
MF.IN=M^#4JO;RH4:WHS--K:'*XQ/A3I;(,4N$);OCY' O>[,5=6X.T[*L%OC
M/7+]A4QBV+(ONU.&]C.49I#E2NB];S:H3-%M7$NOICR*Q\97%1V9RU_$U/@Q
MJK&EORTPX57EP&>FDDX-]?>".G8Q^WLZM3PI[<:OE#XH<(.-KUGF]^'_  KJ
M''B)</"2-,N7A[<'"NE+FBKJIE3B7!<E3=NZAF&Y'J%!J$&CRI3[9>HS%2@/
MQ93J/V[P[*.<&B[Y:-[>8*O!V?>-?$SBA(LVNW+2;0E</N*7#&9Q1L&YK&;D
M2HU+AF?9J8-E7K5'Z_5*;&OA4"Z_*/0:*9]'F/4:MJIU;>127DN.W[GRX(_V
MUQC##L%85=E+M3]HABRNVYQ>XWT.#>%N\#N+O'RFUREV.JGFM4NH<'A$@3:)
M9\:Y;PI=/=LJ)0Z,_4J<)]334ITIZ4YYYS2&8S;.+XZQ]/HH"[%Q?R?UB]KW
M7;JOVWNTHK@G5NT+;W9^J"N%\7@;PVXS4BISZ!"G5.O1*LW&G<1H%/H=$XI2
MJHF7;M$D+KT&%48M,_&B#-EMSJN4,M/%7U&/JVG/6%EBQQTNRM0^S'(M1%HW
M!\ML!=;KCM/CU*1':MN/;D2LR[CH*OC-GS6D1)50ID20_/-0=;<JU-C^04Y(
M\HD<&T?'BUI[E'DC'[D8/%IU6^[9J43NR3VBT26&UM'@W?JO)/M94'FJ#4.5
MX!14E ;6$/1G$J"PXA+B5$)P7??[!1XF(Y@EQ RR5CNQAPUL;BG\&]V9K%XB
M6U2+PM2O\ [)AU6CW#"8J<&4W(H;(>>=9DMN@RT *>8F)'G3#X#C3J<J!(8W
M<-2SL&C.=,0.6"/9ZX]SN O9_P"VYP\XJT*N<8;.[(_&&?9]J4.LL4F\7*98
M5173GK=A5AZZ*];\&X*5;U2GPT,0UNJG4Z!Y!%/AO>240S[_ 'X#BF('&]VP
MPB;\)+KTQO'CY7H]?X1\,>%RK%;XE<0.';G$:%"O5N1%MN9;U.CPVYM*H;E(
MJT63Z0!Y\1XD#E>ID:/R.2I49E)>(\NO5L\VDQ>Y00[GCYER<V;0<PMW>W'V
M_3"X4VA9EF&'Q7XK1JK4(4:][;JKEE6Q&MA*_CQN[ZG0JM(33)4QX!F@-P9]
M25)R'7BVP0]JY,[]VY*G%YR #GC,>VJP![9W'*)QT[ =1NE=*?\ 2*QNTAP_
ML.\:;0V8C*$7E9'$JCM5F/:KCM;J15'F%R.FF*F51I:TO*$Y$-.0F*,! '!W
M(YOJ+#BLH+*[7_$VD=H*G<&>/7"6J\-V.*D.I5/@/568UMR&;L;I"4S'[?K5
M=HW$BZ*;!NJ9!>6FFTNHLTCRDD)1S,A*R2HRTF&XEQB>*X][C%;O&KLD]M"1
M;]AR+!;M%SC58]2M]VBT&DS958IML(75JK56;4K->I=2JE2E25N2Z@Q,\XDH
M0T7&&G4KYC]]]YBRAN[\HY,#P,WU96]X8\8[>X0]E/X-VF7#PX?NQ?$:9P$X
M<VQ6E6S;E:IMGW17Z?%C,UA#-7JE-N6BW"FF,RH]'K-*ID]$61("IC)B%3B'
MFV'TN&59R?7(Q?*P.+M.O:K7XO\ :=KOPB/'GAA'EV0]PSL'A3PWJ]O6[+-4
M;>9IUTSI;LJN.(;J(0]<50GQ)%);62W"$:'&;$1+B7)2R8XB9Z,)M@(?D[+O
MG"_MC79>O 'M \3ZY1J!1+SX$7->=I7!9S])J<"HTRM6/'349D6I4-ZX9DR2
MJX8+\)BSQ"J32JY4I;$=I*/*@ A-M3^_[VD8+.:V%7)4+2H"KUC4V%=,FD4Y
MVXXU)2LTZ'6UMQW)+=.3,=EJ+$>45^0$AV5A3:0M3V"%VW']_.S(?+GF/N[\
MX=>3O8A?30>V#\*95H=&G5N53^+%H28])I":<BJU%7Q1<KKE.IB:A+I=-3*G
M/,(4VW(F0V7Y1!<?259U,^\[=]5#<">/2\-C!&)9<Q;WPD%Z5RPN /'U?"JH
M0.SSQ)OMSAU>=RR:70W;DIM;J]V2[/MJI4.D4WB?49*:!"K+3--N:6Y3JM);
MEA]5.BNM!)2[[Q]?,++'O3[Y<+K+2\^.MW7/?=U\*."-+MVX[AX:4>FU3BVN
MYX4Q5%81<E+55+?LRWI46KP53KRK])4U4VH3T=REPZ=,C(K%1I<V0W'U6.5I
M(]QZF1A!6+YEG$-GB1U#>BP#^#WXYT?A%V#+ D2)%)C7;?\ QHXU6M9%-K4F
MG4^";F<ONZIJGKEE5.KT5B'2K?C0W7[EE-5,>21Y"+2Q-G2X45^=]]X=:TO/
M0-/ /<O)UP+9-<-.V'Q)OR)QUX>1J!:->[07 6'3;AK-$M.%+F65>5JUV.]4
M[?GV#4'+L>56)%8I\*='BM5&IT98J0CM2(\=MP*+LOV?;5'MKVY79^S3VL;O
M[22N'LVU8%K.4F509=6XL(-+K,.HV#5VI\N&S9%0"JU.C4N]6@TR[-HKRZGY
M%D.2E2$1GXKCA)<Y8:^?'!9^Z*IHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB*W7"W/HK)S]N_%#Z/E,N['X?-JGZ#TE08\3GIG^RHII/R
MO7LD=_#?A>?G%S\7P/O^!_EB'$V@ST]E<C15-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31%CMVJN!M&[1_ OB#P:K<HTV/>U">I\.L)9?=71
MJJRM$JG5(*8*5-!B2T@*<*D@(4O?H"4)8< 3W^XZ.K%<&>)O''A9P@MOAOQ/
M[/\ Q&N?BA8U!CVE3*G8!M2KV/Q!C4"$FGV]6(=RRJ_38]NIJ<.-#^-6;ICT
MI<-WG=:=GY5RE+S@2']C<&8+,]L)L+P<[*-X\,.&''2[^+G#"C<;.)O:QXIT
M*X>-O#> ]1:E I'#^747J2[0J5/J]8HE-JU6LRTZA*=FO4ZJ0S.G0FW:6'WD
M1VW'???!4SD]I$,;MF6'N5=CL>]GBY.#56XV\/Z?4+ZE]D^IP* WP?LOBS+>
MK%7M67+9JS5XT:A?';SUUL6-'872XU,C74I4V6[YPZT VRMZ:32?1AI:W7R6
M(D;L(<=6N!7%2V$3XWIAV<;^K<OL,8>)?H]!@7G3>*U*;J<Y3JW1(J,M,"QV
MI@5SPK>B5&.&BB=YM&/IP//SYZ-9)#>;,UM2X;3(Q*R8[3O9OXR7%V7^'*.&
MU)H=R\=>%/%*SNT>]9%1?C,6M?U]PJW+N.^;&EU><74_$%3FU^LTVGM3)JW!
M1HU+I7GCL:*MQUA^[]\)\D; &.0%Y&!''#-71M/B)QGX@6S>%=H_9&G<'YE&
ML&[/(V]Q0J7#EZI<1;S-"<51.'M);LZZ9B8]I3*^RTBJ7#=-3M>-/BQZ?3H]
M,;:FR9U"HGO&PRT]2ZAC.#KQU?R$LL>.#_9EOCA%VCJ#='9:I=_\&>"%]T.I
M5WM#\%.(,AFH<.*#=KM^V<0WPMHK58J5-H-WUJVHU\_'#UG5238=)CBBFB06
M35GH\:6((T\N.1?VP02[M#CK+6C 7O==3L+AKQLL3A1\)QP@F\";VFUKC)Q2
M[65^<+;CI<SA])M6\J-QBHM0:X>TFCJDW-%J<>I>>S!#G4VLT:+1J$B.\)=P
MF6]$BR:8P>[&3!M8"V<:H)Q B0X$O-[N2V>3NZSW[+%J5&D=E3@EP]XBVI/M
M^LT#@W8O#V^;9N9N$^Y\:TRTJ3;5;IE4D1)TNDU9E;C'F;,V)/E"5DH94D%;
M*S>FHZ:^38O82<!I@<[VM:XE[M.-?8"X(W3PVK7%BA7!6FKFL+@[>=[\'. $
MQUP5%V'P_3=L^Y*TF;+\X\G\:Q*E4(O#ZJ1([0;C_)U$;=Y"VAO376_#]PJ9
MCFW..-CCQ!65_:\I-R5[LT\9+5LVUJK=]S7;8-Q6E0Z#17*7'?D5"O4R13HB
MW7ZM.IT./$9=>3Y5PR.9 4D!M0*E(B$/QS9\76*/9GNWM"<&NR3P1X-L=D_B
M9-XK6-PLMRSI*Z_=/"2W^'T"XJ73$0U2ZG<Z+]K-6^*([P2\M=)M2KSGT LQ
MX2U<ZVY?/HWJ$XLX E\3AZ=1$*S5[=C+B9P_["7:@LZFT:3Q<[2G:9K3U]7J
MFU/-HM,E7A/KU%DKA4V;<\VCH9IM'I, PV9SZXIFK92^Q#:Y_)(O>?#Z/E=+
ME^#00>O6.L%7LXX\$Z1QVLOAM8G%3@GQ!$>VN%D&HVMQ5L6HLT[B=PHXJTR)
M%IT:GPI]/N42X1D-,^>L3(\:MT)R4RE-2\@D-2=,=#(C]AR8*2!SF3Q#NY&#
MB;NK5(I';8L]SLE6]Q2LCB-QUX;0K8NJG\;8EA5^SXUT5B\W9OF]@3N)JJG<
M=GQ;FH2:$AE^[/)U*H4^94U/"HTB<L J-G9.&%PY?.]_(O96=/9T[0\_LM<=
M.#L7@%5Z%<<?M50^,5JT]FY[!:H=PV>F[Z'<KE,LF2_7X\2%5*5 I[C2Z=5(
MMM4=R0CE@U=S()K%VQ4?%X.(#@')Y]!RE9W7[9%T=H;C%V=[UE63>=BV9P'N
M"J<3:E.N5NF4^X*U=KU#DT2CVK1:53*Y794EAIVHO5.HU%Y^/;Q8@^;L2YY?
M"D3$18:-Y3W>RI$$.<X)?@SX@<- RQ]X5<+N+U#[._;ELRY^$-WTZX.*_$?C
M9<=@43- F.733+NI;%,H;K3\*OU&W*>[45M><J75E4I# 6?.$J<;#VJ#>\Q@
M/,X7=F<9H,PP_JDN.D!H</K PZS<7"KCB]V<?@V++8X/7PJ\> ?%G@#<W%&B
MLSK,4;8I'#2GNPKBE29HN_XMK:&W2TIE%MRZDMQ9YW&VT-*;3.7KW/[)S!.#
M,[R[ DVQ.LX/D5;-G\3;+^$+XI<37>%5RUWAOQ>X)\*;.I-\4.I6@*-:M7LB
MMW%.KL.\&*C<L&LQ%18E79=A.TF#57)LA(C-LH2HOLI?']]=9B272!=F XLQ
MF-(EL)D+H=V=GNZ5?"#QY]F52CL\(^-5EVOQ6X_6L6Y+CK-[=GNZJ-/X7UZ.
M4&(RR;QNUVUH\VG+0X;BMRQKK*Y02?J+O#OZYXJP9^ISRMP/!EZF/<T&/*D<
MJI+;*2ZQ%90@27$M(:4W&0[)D(0\^Y(2^6"ZZPA2Y+;2E-ALNKLF,7CGF^)S
MCZJ$ 39F?D1Y,+29+79>5/9+LWB[PY[3G;UOZ^N"M^6_:?&>_J+<G#JH2)-F
MR55^G4*G7$T^E2*3=D]VEN2E2V$1W9JHZ8[C[2Y"VF@M:9BS'OOG*I O&KO(
M9CBV OT6-]/X!]HF-\&1V?N!3W!V[SQCLOC/;%QUVU456PFW:11[3XOSKM?J
M#M8:N]BA5%OX@DM>3:HE4EU"4X)*E-Q9#:G4KC'*T]!./M 2#.&.46G1C&LK
M)SAM1N-G9R[3O'NX&N"-\<6N$G:-EVE>5I7%8U0LUVLV->#- AT>NVK>%.N"
MZ;>BTVWFG(S*H%9A5)PPHL9N,N+4'BF3I;!\>/5_9"!-IOQAOHL0.&G9N[6G
M#GLZ]G*\(O!/XSXF]FSCYQ8ORL<&JS>-G!CB'PZXFSZBF5#H-?:JSM":K%'A
MR8$R% J3K,:14&E%^I@I6A]?]N^J<XCG^\6ZKT]MKB)Q8JUHW)?<'LK7!PY5
M!IZ6K7X=W&OADKB5<EQR!Y2*U,<M2XZG9%OVE#E+ ?DS+GG5-]A#LEM<&2MJ
M,MR^_?MJFIX^7#[^BL'P=X3\:>S+VEEU6V;8N'B!PA[1-%8O'C:[ =M*FP.&
M?&@Y9E7%1Z(W.IZY5%KK8$2J,T1%1,62PU(C1ULO/+0/F7AC'&&"CY!P,;X7
M$X#)WPS7JL%$A)*%#F*<#]<D*&<K&W+R]% %6/;HJ)P;OOF_$UZ*IHB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(K=\+?TJR?[]N)_P#[3+N_
M#[HVT4&/$XOETX8*BFX^5R]__!QPNW]GI-Q@^C'M'?MT.BAO_P#35IEC;VQ5
MQ]%DFB)HB:(FB)HB:(FB)HB:(FB)HB:(J%+" <@DA)7RIP5*"?KN5(/,HIR,
MX'520,DXT14)>2I?)@YPE6V<@+YRCG20%H"DH)"E)""I*VPHK3@D[]?;ADM5
M))&2DISW'&1X@XR,@Y'JE0(P0H@Z)WWV5.B)HB:(FB)HBT2TVIT/%*"ZE!;"
MN5"B$$\V.<I\H 3O@*"2=R#UT[[[P4QP<>3^?HZTG6T^5"P!Y12<%1#@Y@D@
M\OE4 ^33D \I*D+(P6R=].^^X0^O'D'%A..L+9K0VX^M:D8YF@T\5L,E+J>8
M*RE*/Q9Y0%.1Y9'D2E*CR#U2+IQQZZ&!A=[FRADZ1A>[:WNX;S6];',E16XM
MSRO*02CEY4+&$H;"4X""05Y45+'-AQ6R<1.DOJ)M,1QX!:J$*3DDH*RI16H(
M"2I)4LMI.%9RVDI&3GFP2 GFV*M]W8O>.6$)Y)!"<I1E!4I)"$@H6K)4M&<\
MI)*B>N2<D]<D:7TC34?LM!V)Y1Q#B'"TM+9:+@2E;J4\JN1;3CG,4N)<Y2KR
M@>:>0%-O,N<R5(KPVKX_MY.C!WR  T;S]Q!"TDTR*70\\TR^I#C;K'E64+\V
M6S@,>;J<\HME+&%+90VI*6W7I"T !Q*&XGIEWW?1M40T\O(H\R"#]=Y1PA>$
MX6 ^Z\@_5 IU06A86YY-:^9;?.JOV9\VR [*;HQGKEQ.O[RK.\=>!]/X[6$J
MPIU_<4^&S)K%$K3-U<'KYJW#Z\X<FA2%28[4.M4I9:1#EEQUJHPWX,B-);4T
MZEMJ;"@RXT1LH$N!#]/6Z[?P^X?6_P ++3HEG6K'=;H= @(A0T27W9U3D.J4
MIV7/J=8J4E^HU6HU*4I<N;/J$J1/GU&3(ES9;[CQ6W7ALO/[_0(S.0')?+H^
M4+NR76I2$^36/71Y1/*XA8Y5!24E7DW%!:"2<<JBDJ3]<"!J([]\1PS3S89Y
MBK"@?UB0WE(*B$J*?74GU@%I*^5?*#A)SDA -]?/OL.\-Q6VUNN#D*WEI+BB
MRRE7(D>JV%-(;4H).Z5.J=4-]SM@C7U+X7O@!YNJ41"E:E%UPCFYD?5'RL%6
MZTK6X\YEOGPIMI ;:0/5*%IVT1K28QQZ^1:XNJ?,4!:%Y0.1*D'$>/NA2N<H
M"E(4I" KUPE) \H2I7,,)!R+%D;.>($=]=5#C;;92\XOURXCE4.0))ROD!Y\
M*>&%#".9;H(_$_*=%&SO!];O=L;-@ 66FD)\KZR&4H6C;GYP%/$)7SIBEQ32
M4NIR0MPM/I+9;*5!?,+.'EAA?NZ09/  V)S9SRQNZW0Y7% ) 2&\HY2 5-N
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M)T1L'/4]]Y,%J3J+#J# CRHL&2UY1)*)<-J8A+:,A);:D!QM+^.5)=*2.7F
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M%4?CR@$G<H9Y)JI8Z8S=VZ!0/AT>+O=P?LK/]U4ZH-AT[O$>&_?XZ?[(JO\
MQMJPRHKTO,7],U/]?=G(_+H&'ZJ6!EY/.Y#3DI/PZ'%W8_(]9.W=\:508 )Q
MG8^P_-X'0_PBKEMMM8(G<KD0]V^MVP0?CRD@OLZ#!_JI)!!GHY!M&@A_OZ/%
MT8QP>LDCJ/QSJ@P.O@<]._OV[\:?[(JL-MM;?V5&>MD_U\H 'R4,7,&DP1<'
M@2^ \U'^_H\71C'!ZR<'']4ZJ=QD^ Z'W9 /=I_LBKG_ #MI'_#5_P#M>0=0
M_CZAA\M!)$32'!Y:2>%I0?#H\7 <G@_9(Q_QG53[.N/;X8]NG^R*K_QMK_[*
MO_VE#^/-FQ)V='$UT@.3H/K?!;.=\.GQ9;8*E\'K+P'$%/+5*H#S;\N^"-CL
M1WCNSK5MOX4U>&V=6U_,VM6Z"].[4(+\3('M:<Q^-:/$$;.FFFFHG><54N"X
MEF%X9G7L_P!DWCAQ5[2_!&U>+@C6;;1N%4P*I2FZK,4SYLZ6L%P*"%<Q&0H;
M@#Z?)/CWP_\ P[QE?A@#2=F9%1+%V R)O!-WAUWOX5XG^:\.-K6=YR+1Q(Y<
M9ZK)=,/BP0#\<65WX_&ZJ;#W\_7Q/?\ =U\JF:-<#@)+QZ##R/TBSDB!D?J>
MO55>9\6/LQ9?[WU3_/UDHK:\8+OXJ<,^&EYWXY)LVJ)M>@U&L" F+4XYDJ@Q
MUOI:#O,>3F4@#./?MK1XGQ'\KL-KX@VV5)K,/ O>!&)C-?;_  Y\&_UA^-_#
MO@P-0J\?XBG84FEWWJGW?TN6W@' !C!?.Z_\/3Q@1)94WP;L\>52ZTI7QE44
MI(94H<R@ -U%.=N]6XP,ZZ%XW\?^%\(115LZ7)8'\VE\,+"\7XN67[Q^$?Z%
M/C/B7P79_$!XK;BFLG:#9CP^WJOM=IL@!4TS0Y<W,,JS\/5QE]57R.V< D)R
M/C2I8(5L3LD=X'=U'O.N)5_$?PHV56UIHH@@#YZ7D[IC!W8N;6DK;X;_ $(O
M';;P^UVG\SM?D- _ZMMR#O5$,Y)9@![V3_?[.,I&1P=LX=!M5*D<>J3^UWPK
M"?#!Z=^N)_M+V+_H P??I#.<@,=+YH?]"#QW_F-L2T_\UVQEP,\CY'1#\/5Q
MG(/Y3EG=!@?&=3ZG&!T.YR .F_3&#J_[3-@8_+I!8N-^G_Z0(?*^BH_T(/'/
M_P!9VL6_YKMVO:#Q?[JH?#U<93TX.V=@>%3J6=P,8]7N/3?&#XZG^TO83_ET
MV_O$.3?Y1,PS",;)_P B#QW_ )G;/KX;;7FTXC[P%2/A[.,N KY';-R<$@U.
MIXR0-OK>OL)P?<<A_M,V))!V8X"NGK8Z3=C?!#_H0>/D'Q&VB/\ JVVL^8/M
M-H 4_P"_U\9MQ\CMG9QM^.=3]GB"-L[Z'^)FPEZ*;@L-I2+OF/.<+AF?\B#Q
M]_YC;.X8_P MMO>^2C_?Z^,V/U'K..^"?C.I_,#ZO?[-_=JC^)>P<?Y=(_\
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M&WV]==%%=.Z8%1!?> -P"U@,!(6[!S@C./;U[Q]'WL?1I.T.UI&[2*=T$?,
M1)N&M8_4&ZY556PK(I&SKI_+<&K>I+DM;$"#R(:7"C8G.X._7;PZ[;XR-/\
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M_;/\6=]9@FIB0#3#EF)%K-(PX<E020&!XN)!Q:6:[/EP4[H">8D$@Y'3 P<
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M/S#!0=R,;]!OD ;$'J<C/><=03DG.J(RB<#+^_O*%G#6@ .0!))!>Q9G-@7
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M'I8R:Z"QP^8-D[LTN;!X7V7?!. 'L6\,5]"355#QY52U=1TZ?0-NH&OQ;^.
M:?C_ (X0?G!#M@ ^-O9PO;_PJW^&[,C,B' XMQSY2O2O747D#-YX=]RW9TU4
M6.W:S_ZW'C&#L#8-R9.W04R03N>@V[O=KY_Q4MX#Q!RH^H7:?P4W^M7P1_\
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MEK O#D$R",%[^!E2GTO@@)\DE&-^;U5<WAC!'MZZ[P"[Z$CI;U_=?BT!ZM_
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MCEI4E02Y)=4EM!6<(0"<J60D DXU\SXP2/A_B6!FD" [/4 [:.Z[;^!Z-_\
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M#_@]""NU?@EA^*O@I8?]=V6CRYF#A@>2_/H>26Y< E62I<P*4,$$!3Y2#D8
M'3W9).OR]\4!'Q/:/8FDM;_NJ&:W!B1S(G_0S\!'_,/@[ #_ "O%D[Q:VTVD
MB2,G-L1++<G?)Z)R,$#)YB""<I*<YQGUCD]PSE.N/XC:4_GT4@$DBN[ $;M.
M;\&&)$W;ZNS'_./&8%]@ -[=)^1P\$B0T.9N%3A(W4DD <N0-R-R#N%)/09R
MGUB,9)!&E1+$.'>Y,0P8LQ=I$M):%N-1L*@"=XR20;.!5!L7-R!@S-'*K/+M
M@<P WR, C&.F 5#! />K/.3@&(!S-A/RS!-R8J)<!V8?*S0$,\V>8)O4SRY
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M'1.M6V &RVE50):FHOT+ .2&>[-YE;**A35156#4*3O5  8#!ZFSB>*^IKX
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M"!G'/-'0X'K/']:1D$[$;'?F).Q'Y?\ C/\ VEM# ?=:09_*HL"^%W?H2O\
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M<8/3! '7H,DGO'>J8BHBHER(-[DPSN&=RUGO95MYVJ)!$ ?J$@V(/"Q/DJ0
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M8H:CO2 01_4UB/E)DM9I(+&0(>>_.P).>7;&"0?:00,<V ,X.#E.-'M+\IX
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M/EV=1( V= +DBD2<ZC?"5_H2_"7B? ?$?@GPKQNQ^+?"MEL=ELO$4UC;^/\
M#[/:#\SQ&WII:D5UT7H+@U @$$.Y9\:,*!/*^4J*2"0T1M@$##NY]0Y QGOP
M"=<.K8;?:UT>(IV&U&SV>\*C514*_FIW13:H7+NX(!!#DKZFQ\9\.KVGBMK1
M\7^$[M7Y1!'C]@&W:*@]1WR ^#$N. "I-3CD\P;>YAT&&P!W;!+P.2D#((Z#
M8A( &6[M&;\C; &X&SJ)@%IW:@VH;@[K:/$?#PP'Q;X0Q%4?XAX8FH@EZ2=Y
MV!=JBTD."3,_&<?)Y6WSD<VR6R5>N-B Z,#ER ,J2"2"<DG6)&U+/L/$&_\
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M$S+# .89KDB<2W/0G( 5G;8)!*0!L,X[^H[N\:.<79Y?.'GH6L[."H9 ()#
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M[^\X[R3J)&ZPT,V#7:9-F:T*, YV_7;8V\.\X\-\=_S:KNTV&LW;U9( _3$
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M<+<^BLK/V[\3\;YV'$N[0/\ 9HH,>)\Y^N/%44P?ENWL>_Y-^%XSX?DGXO\
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M3TPXL;L\+D%[&6!<2YDL\F6@*<XQMML>AQX #O!\?83C'329&5QUZLTY0F]
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MMQJC0%>;N.QY5$=M^'(,W\V;<HT"74'X24>7#E1F)DH <C-*!@>KL=+3@>(
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MW&>FA]%"V!!!Q-KR;%FS$VG*!GKD9[\ $_<.Y&?]1U8B"W&_D(Y*&TD$BF1
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M 9&Z U08E@T-^D9B0:@7%P7=2<9RK(!]N1T'4CEW'78YV .VK@S"'F7OY7Q
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M^2&D;>_\6;:(GIW9'VY6K_"&D?SS1$].[(^W*U?X0TC^>:(GIW9 ZWE:H_\
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M5\/0:4_:U@TFENK*_),1I$BWZC46?+.2U35S(,13KU[X>L,70  XYVT9M+6
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M&!%X:' ^9[6+C(C\VSS(Z X<3X^N <D==QG&W3<[P Y'H8U[^RAVE$$54.2
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M!O-[(/@K>V<!A7"!G'4_C_3O5 VZ^5VSL?=TZZI_BO\  ?\ S)<L8HVDE_\
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M,=WM^X2>\:;NT_NJX./9O-6/[1Y^ZGE7^W/SG^0';VG!]VF[M/[JNH]OLD9
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M@"U('S^(V-?S-74Y:D":1&+E>I%#X'\0&^/7"3C-9G#BL\%KFK-1N&;VJ*=
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MG62)HB:(M%]"W$<J%%)YDG( .P._7;IJ@L7R6%8)#"[C*W-:9;:6CR3F'"
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M?#?/3&/U.L8[^G74Q^C!O14 "!@I'#^O 8'%[B9_B^&W_1U^'=JDOET ]$
M?6\D^J?)_7LD_*]Q,R<9^I\-N[;I\G/T^.H@#)\GU=/]=WB9_B^&_O/];KO.
M_P![ T?M@C#I]']RI-@5X_UWN)8]S7#;_HZ_#W:K\.@]HY*;H=\N.'/Z*#P_
MKIZ\7>)?L^I\-]L]?ZW6^1MOGV8.^CG3H/;[JBD"T<S[H>']>(P>+W$P]/Z'
MPWSM_P"3KZ<Z/PZ!&]\1,O+ZJ/D^KN^>+O$PYQGZGPWWQTZ<.MOFQGOSOD_#
MH.\.W*,.FIU]^V"?)]7<8^5WB9CO'D^&^_3_ +'6>[.VHC!P<K<U)X?UT]>+
MO$O_ !?#?_HZT1A)S9^2@\/JZ=OE=XF=<_F?#?<^/ZG7W.GLU7.G0>R;HUZG
MW57H!73UXN\2R/#R?#?^+AV#]W1SI_[:?93=IR\S[J/D_KN<GB[Q+.,XRWPW
MVS[N'0^[G1SIT'MW@KNBWU.NNI4?)]7?W7>)>V?Z'PW[Q@].'?A^&='X= A
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MZCY/JYDGY7>)>_4<G#CW[?E=Y_CU'[8>T<F1A&EI*D</ZZ!@<7>)8_YOAO\
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36"HH;5[:->V:2^C>>73J>B__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g454025g01a30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1]J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'TZ^@!0X0DE-!"4      !                      .$))300Z
M  #_    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$
M5 !! "  +0 @ #$       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 659VP
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      T$    &              'I   "<0    8 9P P #$ 80 S #
M   !                          $              G$   'I
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   'I     %)G
M:'1L;VYG   "<0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !Z0    !29VAT;&]N9P   G$    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-
M! P     %2@    !    H    'T   '@  #J8   %0P &  !_]C_[0 ,061O
M8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/
M# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,#/_  !$( 'T H ,!(@ "$0$#$0'_W0 $
M  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q
M!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-4
M9$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q
M(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,7
M9$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='
M5V=WAY>GM\?_V@ , P$  A$#$0 _ /54DDDE-;,HR+O1-%OIFJUMCVZ@/8 Y
MKZ7%O];<J/V/KSW2<MK*V6DLKC4L8_=5OM;[MME7LLK_ /!?\&M.V]E4;N3P
M!RA?;:OW7?</[U'+/C@:E( JX"==6FS#Z^ =V=67'72L0"/3'M_S;?\ KEGJ
M?F>BFNZ=U=U%%=6=L?70*;7D$[W0PG(GZ3;7/K]/_BK[?\+L5[[;5^Z[[A_>
MF^VU?NN^X?WH?></[\4^V>Q:WV#J(ZA]H9D[<;9 QB7/ ?M?^DEQ&]N]S/T?
M_D$!F#]8*FN+<UECW>XA[2=9L=L9/M8UV]GYOZ/8M'[;5^Z[[A_>BUV-L;N;
MPG0S8YFHR$B@P(WL.:S%Z^0"[,K;($M-8=!  ,/ J^D[W_0_D?\ ")VX?6A<
MU[LUCFR-[0R);%37;![FL?NKMLW.]7^=_P &M1)26BO/[7-NQ.L6/.W,:QFY
MQ: P?1WUOI;^_P"R@75V?I/TEGO^A^B4/L/6S5L?G-W!I&YK ),5;-QC=],7
M^ILV?X/^;6JDE:J\_M<MV%UIXJ<<QC;*W6$[6G:0[;Z+7M_/])OJ)[,'JME-
M33F_IF6N>]S6[&N;KZ56RN';&^WZ;UH6VMJ;N=\@.2@_;F?NN_!1SSXX&I2
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M;\5NVRO_ (^BVW_1^G;_ #OT#/JZJ^L5MMV.-#6FP.;/KPT.L:[9O8S?[O\
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M&G]QOW!2>P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM2\9=,J5LNW'3HU151:ZKZ/4*<\\RE3T&6T"X"I@D<=:>HJ/((R2Y)!+5;0
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MN(6H!"@_UI6@J=Y[_"KJ!0 /,!Z,>G%52UA@U3N-7 85<_!N]Q&8XN0H @I
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M!(/*E8PD<Y/WXUMX-24S0"U=2QL#0.*%_DSZGC<<ES)V GIE!6;JU  4J;J
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M?I=.K-2J3,BDVE%D6Z* S1Z&'T-_5BYHKC,=QF(X)3+*.E:E-'3#30J7)((
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M\;@UBQQEJ0<@ !47%';M,"[D7&CW O6W1C"XR3C53<:I<Q1!()<@C-)#I-B
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M:C58T"3]9U"34W)"':C4J>@?"J:^Z\$'K2G R(5-E,X*0HE(S=DN&8M=C<4
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M-5-JDTY$UA) 2KR'TQ4K:44#HZD$$#MSSJ>N79Z; EO&M3%$\.PR59DH 4P
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MV@/T")-?B&H*FQQ3/K)+@"H)>?6V_%<0ZX ^A;"NJ0AP)">H-IN>'8I1<H+
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MW*LZ]MK+UH=)HU(HE5H=V67<]/FSH=P,?39#]/,#Z+(C.4VIM/+^D/27UO\
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MB,I&HKF% !4@.2' <^Z[T#[EN,E2\Y5D*2I"@L@HZ5<J 1PD)))Z0!A/]@)
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MG[N_;/KR/0=B>,G(R,^^LI"E!RL$$$.0*=U>50;5JT7:8!13 N;!G?2^URQ
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M!?\ *_1L))QE7.%'U[Y/;UUZ3H=T XEQKC0Q$R6M4N:N2P"5, E,T6?</NS
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ML9Z.LWK&/O<*PHVK_JW(N"#4DU%(#C6)!?LU)>CO?_%2_P#G>!V@M,X 8D8
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M?^7RUK'T;]'R5'+.#DNW4T%Z?<@7OLU.4CB$^EO!P_@YIRM?>'V=6S_U-/\
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ME4B4HE,W$C,2A))(Z\MFJ2 S.*5#:\V>0M8+NZ@Y+UJ&'=M:@-FCU#M3;1&
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M@QNH]_6XI]=/6?@&>IV$.OK<ZZGER_0]^\#:>V<Y**ER,'%<K8^X\5+' ].
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M6.]<KS;K';XC6'L?%_V2]#S^&VU>;1/VF6Q_VG&SZ?I6C_\ OC'XXXU'VI<
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MVK:'L?%Z2IEMS\ *L+/3F+05N9:^<IJ<50[##K9/!)X/5R,#CUSSK65Z4N
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M9BV2_&6XA75JO33H^G@L^7*PN1+X3!8DK1E2DG$X:7B2D!122$F:$@$!9 %
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MENP:4D%*3+G2U/.U%9" XI!?*>AO/O>'=(>'89&"7U("Y"7Q&:8DHGK3,<3
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M/45ZF4&=0D&HEPC+RS.\U!0>EI2  #Z>R3TV0G#8649;*E=8I:E%!2LKF9F
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M0S%IL*.(\2,P@)0E$=EM02VVE"0A*1\ !) *\8PXF=.Q14J8)Q4IW("KOF)
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M?X;4@I2TJ*D)2"4="5%*@$C.%?VOB4Z!TJ)ZB$J*1C)SS\4CB&$Q7W<M2_>
MSHF*(8L?="0>XMM:D8)DS#8?W5[$YE(J: 65V6>I:M#'*Z\_DA:2C)*R$H"P
MI2N%@E)R4J_9)Z1W&.,=/B)Q>)PA$R6J50^XA:7<$$!PQ=VL#8O6,:9TF>>T
M4T24N"EM]R ?T-F-.%+Q"4I+:3T!(22V>"GXFU82H?$@\A1^8.0KI/-PLR80
ME"D3"$@)<H(<)H Y #Z$M7F;;"3A!<J[/-!9F<W>PH*[C>.3Z0I/Q)2 >GI)
M*,DJ"NH+!4KJ!2,A/^PL^_'3*EH2>Q,<@4*%[@N2PI=C9GV:)ZS"%0%:ES5
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M$((4,O9.8-)1<5_M]QKYO#VSB'';-&H"SD:^Y<QPG9&@%9"0^$D8)*O0?+S
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MQHS,?/F%69:B%$FIW/</#O?8Q?+3+;*0E P ,<9[#\?Y.O;2,-*PZ0F6@)8
M4#4'B>?<](TRHJN7CEUGB(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&
MD(:0AI"./H5T_K#J[]73C[^W\^^J*0X.5DJT.U;M:%/#O_5OTB4AP?K*![>@
M''KV&JH1,!.:9F'^Z'\._P ;1);1_$O^@B<*_:_<-69>B@W=4_"D1#"OVO\
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M5FEYB]\RG+N]3ROXQ[Y"N,']W?M_Y_P^>NT0IO> YD6Y=WD?E&.(PK]K]PU
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M'D6N*TJ/&K1!+->NT6'N$4*MNJ +1GZ*XH#K )'&,#U)R./OY'.O#]-D)Q.
MF2D3I"59%?Q)R$"S,23?N>.A@ KKD@)4ZBP8'0$E[;ZOX1<%N+;%'IWZ1)(@
MQ@0""00RV,8&3G@Y'?Y<'7=X"J6,!A$";*4I$B4@A$Q"JB6 68U#F_\ *-:>
M")BZ'WE:%[FEM@]AW1["I325%)*LCV2?W:[:IB4$ NYJ&&Q _6D8 7W\1',E
M04 1D9[9!&K)+@$W^OTB8G(]_P">?\#J81.D(9_G^>?\/7&D(9_?[\:0AG]_
M&D(CJ'O\L>OY=SI"!.._\"?X:0AD?EGG'''STA#(]_Y/\_SD:0AD9QZ_\?\
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M"76U*(*@$M$]0! R,D@ *(&<]_3U%OMJZ1FHES\K9B1*#,+D@S1H*\GN;1[
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M+M2O='']K5V '+Z.YSEL]CV/Y?=P/GJR?3?Q\@*'7+!L<@90-E!YCD5'B;-
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M2"^E<HTTV?S/C3]K5XXQYS)X.!Y)SGD]PK\2/[N]AZ;./J?*)I)<TE@VL*S
M*MJ3O2(/ \._N$C7E0%F;F;ZEXO6VMY)*7FF:VPE"5*2CZ0V<X/ +CB2?A!P
M3@=LDG@''T'HQZ99_6R4\2F"2E>0O-9!J$L7*BX-=+C8&.=B>!*[75)*F<@
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M$-(0TA#2$-(0TA#2$-(0TA'5G9^A3,=_HLC'W^4O7/XNXX5Q,I]X</QN7O\
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M) P8F8'#B1PLI3*"T"<%EDC,D8DY.L9@M@X=3E@'I#K5'-4ILU*!TAQ0/H*
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MPHJ$K$,Y*:JU-+2V!\C^H<>ED@&:G9JB[$.: V:AVK1XG[-[PP!]7S#R#CD
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M#Z&^DU'EXDFHNLU-ZE M1W\-#$'CJ7(*Q=OQ @"@U_44#VBL[<W:HCS*=+4
MGI^).<).3C))/<G@8'?&!J\KT.=( K[V3B"G*R0HJ('G+\F9HD<>ENX4.0.:
M^P#CXN]15HD;=7:"E0ITKJ;R$D#)3P?U2.4C'8 @=R1CML_8]QC21.'*^C5)
MEO5ZB@H&%XD\=EFZD\PY OL% [U>E!:(^SJ[^I1%/EY6!U%/!4!\("NGDX&<
M$X[\8!&J+]#O&\IZN3/"]&)\@R'8^)>D61QV6D@N +:U<%B*\F_1HI1MK=R0
M0BFR4#J) "0@=1P0K&1@C'ZV<C ],C6K]CG24?U>)\"NM-LEV<./\\XX]*:L
MU+N:=H[!F!8 ZM9QW0^S:[PE*?J^7THRI((5T@CGX0#\)]0>Q/.>3J#Z'.DF
M4O+Q*DBX)745_P #4+O6OA$>WY=&F@YA4GFP;>G>3>T$;;7:5%2:=)S@J"@/
MBS@@GJ!!"L ]CDY..^M[ ^A[BZ1F,F<Y9W!>H+$M+T+M4GN=XO[;DD'MIU(.
M:]69GLQN""UGN>G.L>Y(#2I3D&8$QT$I45*"@D)!5A225 8(S@@=Q[ZY_%O1
MKQ7"@_=30$NZG4PHU04#?0.^Y@.-RC0*35K&O:8&Y',U/D\=F/8%V/L-/-0)
M?0^A+P([%+@ZLD#U((R>^><ZVY/HBXO,E2IHD35!:$K!J0<P%6R-6[ =SQK+
MXY+S$9A0L"0S"O,,^]#2\<Z=O;L"NH4^6#@#J P2GT22!U $9XSCC'OK(?0]
MQEA_H\\,!:M 2S/+-#0%N5JB*^W9?YQ4ZYN5?>-W+W:IU>*/LVNT$J13I0*L
M\I!23]_/.?7)P>,:C[(>D +(DX@)#T&9GUM+RU[M=2!&=/'964=L UHYOK1S
M0=[W[H@[:7;TE/U;*Z58ZATY! 4%<_C\0&."!TX(&7V0](V4.JQ!<BY+,#0/
MDK<FU/\ IA[?E'^L!+&ZB6H0XYT%S8^(G[.+M[FFS/A3@<?JCV!!!"<9&,@8
M_(X9GH>Z1S"&DXD )8U6 ;%FZLOR!&FNF*9QU%&6#0LSW/DY-V8W%":F/LWN
MU.%)ITOJ&2/@[=7<A61CYX/IQZ#6/[&^DVDO$5N77Y$=6& H[4-MA&/VZ@_C
MY ]KG<.*!^XN7T@-M[N2<IILM)([I203P."003ZYR<C!QI]C?2<N>KQ-:743
MK2B+'1OTC*CCLI^TM/(D$Y34TJ+]]_A2=M;MP0*9* 4<J 1@$]LXSR?F3G!^
M_0>AOI+;J\2'NY6.YW1H3IIIK&7V]*8O,2X<T)TT8'4T/B!H8Y!MQ>!SF!-&
M4A!R5$E/'!SW'R[ Y/8Z*]#72508RL40[>\L[M3(#7GLT1[=DD_Q$M< $L"Y
M(%[F@+N"SZ4I1MM=S:@6Z=*!"B04I*"DGLH$8((Y^(#@<8&>8'H9Z2H8B5B3
M1W=8+&E>P]S3NIRH>-R2:S$@%F!/Q<&VE1<@WJ*E;<W>I06:=,*T@("B,J2D
M8 2%X*@@#. /R&>;?8_TD!;J\0'H>TM[M7L#Q'R8Q(XY(J.L2*T]YC6[O?PJ
MYH(J3MS>*5*(@3 5)Z5*'PE2/V5%)RH?(CG'MK*KT*<:665*GJYJ)+G1@9=N
M0Y"D3[:DT=8T)#GN'=J=3</I$?9S=B3D4Z2E05U9P <J&">LDD$ =\Y.0">>
M,LKT.\7D*+R)W9)J7+5<6EBKEW9]#J8#C,D,#-&]RYK76C-2EH@[>W>>H_5<
MH@IZ%*.22@=@K/ZR2>0D\?(Z@^C+I8E2DHX=,4A)RH4)4PYDBSM+ )9CL^D8
M3QZ4]PSEKDBA9^U\0(D[?WB,GZME@D%*L!7Q ?V3R<@ \ G'/([C4?9ITNI_
M\.FARY^ZFZ]R?ES:*GCR!8@!JBM>[M&U.3@U@-N;Q6DGZNFA)!24\I2!Z@)S
MC' SG_RU57H@Z38M77+PT^6I:6*!G2&L*% ()VOWQG1QZ44C,M(+ZDEC\=[N
M;7$0C;2[F\I33)B0I/20D8!SZ'&!@#/'KSCV.,>A?I+5I6*._:5Y>Y4;D5L1
M%_;TDD#K$#FYT:M2PY;5.T$[;W:W\(ILH'C@ C /*L?"1SCTY]2<G627Z&^/
M2P>MD3R2S DFC-1T:7T'>&C%,XY+S A:2P9ZEF-=>;$BA>PB?L[NU(($"4!S
M\ '2,DXSWP59/*@,^PYSK,/0]Q@"F'G'4B[@;O+-_(>)BGMV6?Q"Q>IU;90(
M#\S?6D4C;J[DI*$T^4$+5U%"4@)<6,?$1GXE<D$\D#C[\:O1%QN6 )4B>%*[
M!(*A2Q!RH?0."&T:L2..2B25$6&JJB]W5N];D>,2=N;M&":;*X(P5 G'K_:[
M8(&,'TX^6(>B#I-ACUB9>)!(-BH>\U.RAW+5[GJ0XRGC4@4"Q\;59R&8#:M>
M=ZE[=WBZ,KI\MQ Z 0H%8PWUE(.0<!!<=*4GMUN=(!4K-!Z(.E"IHQZ</B9R
MI3D)49BP2I)E^Z4$EFH01=S%1QF0DOUC&C;DN =3< /SN6 :D;>7> $BFRP!
MCI2G*0/F$@X!/'OW^[6P?1KTN+?_  V;2A:5, #&Q!1:AWH+&+CC\H'WZO6]
M6#'Y<Z4T>)5MW=R@<TZ424J^(A9)ZCE>25=E'!(.02"59QJJO1ITN4E25</F
MI"@I*CU<RCGM&J+M4&C, 8J>/RPY"P'<4?8T-0S.0/@U6H&W=W$$"GR\XY[^
MWR5VQG'H!V]M:8]#O251I*Q!;7,NFGY'UVL=HP>WD6SW(T4'KK6OR?2*_LXO
M!9'73IB\ Y"@5 Y2>#U$Y ) /K]_IM(]"W213%4O$?\ 4H@$ZMU9TT&UXGV[
M+ ]\"MGH'U]Z[T%*1>MM;/5:6II=3)B-)6%KC@96H#!Y*?U/8@$$>F>-?3NC
M7H8GOA_69+*0)9F9DH42H!&97:E.Y4Y)J#0$4:-3'<>"TLA56 =U.SF]=BPK
MR,;-6];\.AQV8T9I#:&4X2D 9STD94H#*E'NI2N5>IX U^H.C'1C#\ P\N7*
MEI0R0V5,L$D)*220A)J#H:1Y'$8E4]9=1)YYN5G)=JT/GJ+F0,)'.2<DGW))
M)_C^';7KC7X? -&LD,&UN3S,5:1,-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$00""",@@@@]B#P0?OU! 4"DAP000;$$,0>\0BE+;:<=*$C'; QC4
M(2E"<J $IV%!Y1! -34V\-OK2D5=*?8?EJ6#NU?H1,4>4W^P.?[]8^HDN3U:
M22222'<FY/??OK$YE#4^9B?+;_9&G42?[-&UA!SN?,P\IO\ 83^7RQ_#C[M1
MU$D_U2/+DWUYW@YW/F8>6W^R-3U$G^S1Y"#G<^9AY:/V1IU,H6EH'@(9CN?.
M'EH_9'_#4]5+_(GRAF.Y\X%IL]T)/WC4&1)5>6DMN(.=SYF(\EK]A/'R_G/X
MZIZIAZ?=(IROS/.D'.Y\S$%EH@@MI(/?C0X3#$$&3++_ .$?5(9E;GS.L4_1
M8_\ JD^OOZ]_75/4<+_8H_Z1^T3G4?Q'77>GRIRTB/HL?_5)_?\ X\_CIZCA
M?[%'_2/VAG7^97F?H^,2(T<  -)P.PP?7/S^9T]1PG]BC_I'[0"UB@4:<X?1
MH_\ JD?EIZCA?[%'_2/VB>L7^8[>45^2U^PGCCMJXPF&%I*.[* /H:;:17,H
MZGS,/):[="?R_#3U7#U^Z16]-PT,QW/G$AIL<!(U=,B4D94RT@;-\X.=SYF'
MEH_9&IZJ7^1/E!SN?,Q!:;/= U56'DJ]Z6DM:EKV\X.=SYF'DM?L)_+4>JX?
M^Q1Y0<[GS,06&5#!;21G/(]?[M5.#PIO)1R[(IW<N42%*%E':\4?18_^J3Q]
M_P#CJOJ.%_L4?](_:&97YE>9_?D/**A'82<AI((X[:D8+"@N)*/%(@5K-U'S
MBKR6OV$_EJQPN'/]4AJ48-0O\=8ASN?,P++1SEM/(P>/30X3#%WDHJ&]T<W;
MF7K#,H:GS,4",P#PVD<@\<>F!^'?'SYUB3@L*DD"0@"H9G#?IKM6E2"TE:S=
M1BP-P8[35MU-;;80H1G %)R#^SP1VXX)^_)Y.O"=.\%A9?#9BT2$)5E4R@&J
M$EO\HW<$HF: HN' J;"H\7U'STN2WF&54>FY;2?\@C=_;RD '_ YS]VO2<#P
MF'7P[!%4I*GPLEW!/]6G>@J&H&+W,:\Y2@M0!( 4JFQ!TJ2+\CK6/;^BQ_\
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MJ!?$$=DS 5)&7M&87*6NY!42'YG4%WBID(!- ')8AG-:M2P:Y !8Y07$3^F
MP'#@>@)&>,>QS\QC'J=09O$/[1P:.ZPU&W?7G;O$5$F618!KN":!ZD!(>Q\F
M( M&721^D.".,DC. 22/GR3R,'\22ZSB%?O!:PZRU#<Z6TTJ2])ZE#.<HTYB
M[48N6NY86N"(G+Q."X2 ,A63SGTP#_>,8SZX,F;CQ7K&.W;IM4GZT>)$F7H
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M0M,"C7)3JC(*'$J4A2$QGUI>*T#K0VR7''$D)0E2R$DK <5EK"W6H)?,R)Q
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M6Q' .'RI>$5.6E4N;*E39@2$$H"E+*D)!8$I 4= Y#EW,3ZTHYAVG=5>T 0
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M/>&&9BY+3R6<4H2HU8W 9@VO[>A6E*@]&'G5A>IHXH13RB D@'L0<@=CCO\
M"3DC(SW /;WR=;"DA)(#,DJ (U;0DG8#7E4QA#9J.P% "[EV(8'4VJ*,2"(
M]ON(';@>O8=O8]SD?+5"2X)#!B*$,U+UO6H-2]VK%7#MN[WN]':M#=@-6!AP
M2"#GV !R,_=D=QW^[L1H' =)<T#"[LY<$T#LQ%7K5JV>CY7H' ):AJY8BH(S
M $ER26+B 'S.<\D\9[9X..K Y&<]N.VH!<6(+.!=P3H!7^=!$.+C:Q!(26-
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M7XFQ@E3BLD GC6QO2B;.DR)94/NI")0RDAP!,)*NR.T"LCRI:)]GBK7S%P&
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MJ]*E,*42H9)?3.8G$+6.J G(ZH@"9E#Y>T$D$A0R[M=D@%H>KD  W!>E26-
MX9Q444W>==;;L>KMX^(S>FN7-?>Z>QUVBY8UAVQ;]>\/UV[N4BY+)M5AB!0[
MIH=W6K;<VA4F'=,Y$ZMBF5&IE]F-.;^G"$\IQF/ZN7,DXC"HQ/78=:>K0M4R
M4OM.N6F8J4J7,R3>LE%10I2900HIS2US)82M5DR#9E.Y<,!9^TDI<,16[BK@
M&D;G2_#CN!OK:^QM0W8OH4VX-EKZ:O*VI--M)FAR+D8@*(I<FL44UB<W26I$
M<AMVEM/*<9PVZ'&5.N16/-XWI6<+,G864V6:D((7G*D#LJ)00@#-F%- "07)
M),R<)FFI24G*SN#0FH9B010N":G4N UX53P86G=F[^_>Y=_U]=T4[Q$[;T_:
MV^+1534(I#=KT*,U#I!A/+=0^BH,M1F7TK4V&@H)2$((ZTZ@Z7X@(D2TS #(
MFS)LI<LJ$T*44E@K*&;(#0)RDJ+EHV_9R0"R0>R 0H#<G0J%2X+/Y5BFC>#:
MEKV_L7:"\K^JMX[6;>52@U"WK;JL-E,^3&MB0@V[2KBKS9>55(T!,>.MYEFF
M1FEMH;2CJP6]8)G2:>5S)O7=7,F=:HE.8 =9F"@D"71\Q'9!RCL@F)]01VDY
M"0FJ31151Q7-:@?,Q)?2L<VZ_@YMS>2C73:-ZW%];VA<MU1:]$C5&@QG;AM"
M'],95+I]GW.F29-+CMLH4(S7T- $?K2E;*U!.L/#NDT[#*"Y<PYDJ24U)]WM
M,Q00S@'*H5HX>B1P"6/8!S)-B*&PJY<. %9;.=P8]=KPNI;\0%Q;_MWO)9JE
M9V[5M@* W 2AJ-:SK."\S(#A4FL,/]+[+OPMAQ(45$D:G'])Y\V29.<9.LZP
M$%15[A2;I9B"^Q9)?2)/#TN"D/:X U=S4$I.HKWM'2B^$.WIM\;2WS>MQ-7'
M7-IJI-J-!K4&@1Z7<%45(IDVEL0KOKB):Y-6I;#4M3JV&F0LRFF'.AP(5K'C
M^D\Y>"7ATK=$V0F4L*#CLI"@>TE.50*!V_>8D!@HD7]33< 4-7<6'X2"1H
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MP;32*.23A8X[]N.^ ?RYS\^^L9"W+%P;6I\ 81.%9QU?N&=.WOW6J=M.?E"
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MH93CM7=Z"D'&_+QVB2<]B >_W?A[8]_OU-?S:TH+&WURM"(R/10Y&/3.??\
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MN;SC:3Q>4_OA@7% 7(-NSK<VM6L><YXG]E8\6XYLB]:=!1:]$IM?KYG*?;5
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M*CRBZ*S(C1.I4R3]%:9ZULQF4AY]X ,-I4#UJ4 DV3P]:7 <.IW<E]@:@O\
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MJAQJ!0!G[1HQ)!#/VFI\:Q*>"XA>4A0"D#( #0)((J3+(<N34&@#U8Q;]I>
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M:[/^&[P^W!LM3MR8E7J-+J2[TO\ K]Y4Y$4K#<%FLON.IA. QVB?)"\K*?\
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MJ.PM"D+:0I*P0H*&<A1R>3R.>00000"""!AE%:7O4U^OJYB&&P\O'YUBH,M
M !M  2$@ #A([#[M&&VC>'S^B;Q+?7=' I#:UJ;Z!_9P4CD8R<GY<D=L8U(<
M-4T^M&^#1"D AR YU8&S7\['O@IIL*"%MI6E1R5%/.2I) X_L]24Y3V.!P<<
MB3I39M.YX@(2Q! .I=GY<S:.1IE*.L$ @K)2" < CM\A[#0L6^/?^KZOS%J1
M"4Y7V)IR%F\&V\3IR%M![H3P<]AWQC^'!]]0PV'U2+_7U\8H4TSP5(1@<#(
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M6C1$ICK6$CI .63*"RP:]7-:&A[C4[NS,"!''Q/$YDN:4YE(.8A( 9)#@%J
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MN-J5(6\^ZEC"F5^86RC*U!7;3U)8!?\ "[ECYW\7J#I \;<I8 !1[-0RB"Q
M)2'<[>>D*5XV*/;*KIG73+O"[&)&]Z-J+>I].M.EP7:96)I0W HOF-S$*FL/
M.I<\J;()?<ZD@I0/B%_5 U0!V 2[^!8,7\6)!!)%8UT<<&93J4HIF!.F6Y[+
MY2=6-* NX>._>?C1H53MUZ3;]1NRPJK;F^UK[172U*M2EUY^/5Y578CR*8]&
M<D]$>!5D.")]9MK5)8#OF,-)6D+$#!MH[C<AB::DVM47CHR^*)6]T$$ I)!
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MDJ!"JZ^\6N*&CC<7C*=L^$>%:=L[XVU1[UN-@[X7+5[KJ=5;4PU/HM8K,"#
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M'2E/--?44.\UJ55E!Q#(\Y^"EQZ-25I"!#C29",+*TD3ZZH$EDNIB6'*_>:
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M,XSWP.V/E_?IE47J^E[CD;$>,6BGR4!04>Z>$'('2GD@8  ('H",=SR=62%
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M >"%<$9[I)'<D$9';G!SQJ&5:KW=S0V[CS8OM8B%!=OE0?M\(HR%!6,$ISU
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M6VS*1YGD.J"2DI.=47@)02HIF%T78%R=6!=OY4CHRN-3%&6E>'#3+=H  Y@
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M;?@R9!B%V1+6J4V2^H +/4KCOK8. ET/6U<,P;-0TN.^EQ0Z1FE<8FS'"<.
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M;^V%UKC3E&>:G5ZC!I$V=3(A;Q+C4^=-R4]2''(R%.)3G"3!X<D&LX.0[Y:
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MC.&N1)U&;IL.+'>2_P"2856EKF(#+LE"'?A05BTJ"J+S*!!LU7H^9S>[/R8
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42F3+"!IW7YGN^KO=NJ1FAI"/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g454025g01a32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a32.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %D*^5I@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@   .$))
M300-       $    6CA"24T$&0      !    !XX0DE- _,       D
M      $ .$))32<0       *  $          CA"24T#]0      2  O9F8
M 0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M     0 U     0 M    !@       3A"24T#^       <   ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H   X0DE-! @      !     !   "0    D      .$))300>
M       $     #A"24T$&@     #00    8              0\   *
M!@!G #  ,0!A #, ,@    $                          0
M   "@    0\                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   0\     4F=H=&QO;F<   *     !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   $/     %)G
M:'1L;VYG   "@     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M5:XMJ_S7+)M^O643^APF-'\NP@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MV! M;]ZP[[P%;_K53M-QK>)O!RSSOB,V5>5]M3HXX09S3^^I<9&=GT1Q0'P
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M5<DV7IFC7&TI2O F)2H; PR^6?>7(E?BM8(*0>#]$]F^T.Q;X:UU/:Z+^/\
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M+JW)\9H^8 <1W[CLK[HJ%P)'GTU^J@QSCQ F.]?)+TNE:4&9EPM8)2@O("E
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MOARCEZ[K(@Z&+"'_ '1M9,XQG]WU7SQSW#H)&<9'8XY\\HGT+:(G\!BPN?\
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M[O(9,DD##CRMGQBZQ.^>PE*CL-7:?O=3BHL>]L,I <3&AP$1@D7@";SA<O\
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MW52W=V@K.V5KF;-6/'P.+GEM3AX3[[G%Q#P&N@VXIBP"[9N':15V9C'$%[!
M,W+3#H[FN) &+CDMHASSCOCCT\_/U[=^/(>9C15L"C!$@B01((J+Z0IM1YR!
MQR1C) \C\8 >\#B_A?ICKU.4DM!(Y'KX7E:DM4UJ/M-]#,D<:-7NC(3@;1/H
M  [^I&<]\GG$9ZDUOW02TV),$G30\Q.0<]3)7+MY5'GMALLEL&@T_A ))?4!
MO;E( &<!;8V!O8;&2<ALXY )+2%GMQR5YQ@CX8 $8&H)<6DQ<B 2,=W+O[Y7
M3:4&DRW[H\S<GQ-^F,!5S+H7GOC! PM>1DG) "@GD]CCL,_"+?LV6F?^=PDV
MS<2JS)U@P!G'@-8UF\=\TC+(3P5*/(_EJS@'/;/Q//QA[)F@=C5[S_\ ]6^?
M51#HR,]1;PCQ^:D^C@*))..<)*E'S'/&#V&,#/?U),2*5.,/Z_M'?"\^'Q5/
M"\F9 SDFT\HF.2BF7RH<E0.,^^L8*>_(5G!^!!&/B8&G3$V>>7ON)\;\^OCJ
MD/U(C/C?E!CY:3I47+#'"BCY+6K@GMA1Q\3Y_$XB!39F'=W&\',_Q1GX6L%,
M.T(Z9OWR2H)ET X<W+\@=ZQM^!VJ /\ BX^,^S8='>+WY'_BQR!F I#3>7'I
M!/KY]ZLW& D\+5@$@9))P.W8_C\>_G$<%+7CQ(BH\2/$_KT5):\X<(&3%X)'
MEY]T*NED>$D[U;@D9RH\<)QY@Y X [CF);3IV,.@@&SW3) DSQ<[VCF(0-J$
M1-SW_3Z&>9*BB7!^TLXXS[QR!\ DX)(['N,]XDTZ48?IE[P/'WIU/+E:R!K\
M%WB)Z:3X7ZG.:_T5&#WR<<[W.PQQ]K'EZ<_#M%)93.IM;^\?X3[WJ$X7?Q?$
M^??T4Z)="/[8\8&5KR.^?Y1[\1+6L!EN8_B+K>)/GGJJ@TZDD=Y!G37OY>*C
MX0!&T<>8*E>H\\^0_0.^3%?EY#U'3"$6L3/,N/T_)<+OV29FK6KH>0XHMTR;
M.&WG4#!:5@82K!XY.Y)S@#C(QZMB,;33Q#H:;:"< &)OD"<]RQ._*3:FZ]L#
MN(\-"J6PXC]TYYZYQ:]EKD]D>$JZ169@I_*?OMZS(!_DA(ONJ\;1[N<C.2GN
M3\8]>_'$52VT>RFPUXWQ<1/F0,@<]4^SD<6X15<2YS:[V@N.![&@8C4\4WL5
MM0WGT'Y_UQB.!O+XG\UT-87=>'&D%N_\:E@X_P#::_YLQ4FOJ5F13#FFT\^L
MC*'CM_$-]HDY/>?FH;@=P^2OHA2D$2")!%!20M)2H9!&",D?G&"#Z$$$'D01
M6SR0D@@G)XP23V\^23\_4P40#H/YJC!4\$$$'7UZY?&O+E6#GO@$^F[SY_&"
MKUZW^D_17,$2")!$@BD7_)^*T^OKSV(SQGOD>>.(*#IWB?7J<:K!_34?Z-77
M$X&?W"VB,XY_C7^Y\_S0SZY!!]3\_KGQ6<<%*01((D$3T_;R/X1!RWO^A104
M>#\C^K^>(<?=)&(.HB-?+/@BPLZD]8Y*PYVF4*>H%+NJG5A#JJU1:LIM4JJF
MMGW'$,.I<:?=+X2E*5H..#P<&/G#[6/M2WE]G^\=EK[+7IMH4S2J&F:I:9<6
M20&;12((FQ(YW.%NG9KLG_6!CW$$3Q,:>'B_#Q'!:01$ZBUI 6!MSZ*]!NO*
M@JOV._IA<4Z5%RLVXXJDI1..<N*> 0_(.$J&"I+"$D'*>Q S'8O_ $W:&V[Z
MV#9=OKN'LBUK*E=_%08T%T!SSM X6MF1)<9-S!@8;?WV+M;MCJC-G=4J$DDT
MPVF'W(-G4G $FPN (O<R<4M4?9(74MF=JG3]JM;NHU.>]Z4H=PN-4BL)1MW%
MHS<GXTH\GGPPE2D*5P2E!R!]@=FOM_V#>>TTA[?9'EX;:E7I',:&L7&UY@P.
M>O+]X]@S0=Q&G4 8Z#--TVQ)]GPSI[IS8%; ?99])5>Z>['NZY=2J JB:C77
M7WZ6F3F_!>F).W*,HLRR4.,I"2W/NE4T7RH*?VH4XE2AQX^W?:NGOO;*'LC[
MI;Q2!,U "1[S20.%O%/>+R LKN?=#-D'&6CB#2!,<0!@NRT6)QIA;;DA Y2$
M@DDG \SP<8\R0._(C0A#O>.>7*/KY:66?LWN\('J,GF+JI%2E((D$2")!%3<
M_D@;LDG@9P0,$YPE1[=AP">"8*#CRUCX_E><<UYZ/:/Z8]076%U?Z'=/]<T@
MU'8Z$M+YB6U1UENFA4R7FY75:YI2:5,4BR9:4;G$S4U(2<RPD5'AM2 ^IY'B
M*0DI@SCK: ?$G]?(X0&W*WES'A\.BV1Z?ZAWM?NGG4!*)T*OC3&RK/IZ].M&
M;2K="DI&Z+MHM-M);,]5J;1D3BFVJ3-U9YN3HZ9B80]]#8\1UIE;N!(UR>MO
M7ZGP0Z8UZ]>E[#'?>%K=]E7HEKAHY[-77G175#1R_;*U&FZMU"5BD6S4:=+(
MG*_+W[4*]/4)-$2W4'TS4XXB=DFMCLU+@!U21V)B.>I\KP/6JGY>O7Y1?#+0
M'I6ZK*+5O8XRE3T+U"M:9T)ENH6F:N5V9I\JF7TZFKSL"YZ':$U5PF:(F9&8
MK-0D)A;94ZU+J8!'*$F \1GOSWG'E<1:R'6X[Q8"WKEW+CU@]*74S3:=T*V=
M6.FG48ZC=/W67J'>VLVHB*-39N4GK8KE1G7J1=<C77IQMZMR#C,RU,^%X4RN
M5(+;F64J1",6QZMR_).?+3UK\-/'GR.B[K0G:';FD8MRXQJY(>TV:Z@)W6-V
M?\.A,Z,2ZWI\W&NX4+3,K<G*2E%*:H:,%N;'T8I\$%)&X_/Y6\CFR2/5\V'F
M5ZP)9M3:2E3H>6G:EQ>-I6X$)"EJ0"4-J6K*REH)3E78Q)]3?U94@03J?&TW
MU)[_ !5U!5)!$@B01/YNT$@'(E2J2E0(4D$'N",YP01G[P/P@BP5]H#H$SKK
MT[7Y29252_<UO4MVZK2+2$F:36J$RN<:8;64A24SC2'&'DH4/%:46U$@XC8N
MR^W.W?O>A6+R&N>&@$EK&DM< 29 N2/$RL!OW8Q7V=]0-!+&@F .)PD2(B8#
M9.M@;KQQO*2U-LRZRXE7Y=+B%)VJ06O=PM P0K"<J&>"3QR8^PMV[RI[WV0
M-ASF^\Z\$9!!!,'!E<@?+*Q@BQM,"3:T9/42#D3:3%P%Y)P5 %0W)'N[L$#*
MAQGW< 9[ F&S[.1M,2'-;<G,  6!OK(,S).<K&L;[-Y,$'BB8OQ&"+ 6'O3J
M+"!&-IGLD]87-/.I)5F3TT6Z'J90W:0II:U )K$DZY4*4Z$9""ZX%SDN7#[W
MA-I;^R$XY/\ :QN.D-DJ[Q:/>I^R<.$<1@U. B )P21-M5OW9O;WMVO9J1<>
M%P<UWO23[@@9_=(F=9S 7JOE9@.E0"]WNH<YX(\0J2 />.$Y;40#SS]P^="
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M<0^?3'?"D,TT%(!W +!(44G:,*"3N/D-W&>V<>H@IFTP8UZ9T$^/*>A54O-
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M4YYY!\R8^/MII'9]NK4W2"Q[F.F]V/(Q:+_.+97;Z#C4V6F^/Q,:X= 1,?S
M-O$\H1W5QYI&?7"1Y8X'IZY\HH7I4\$2")!%1?\ XLY[<1(L1WA#@]Q^1ZCU
MSPM1^JG^N=:'\XSH]?'KW^GI[\]NPQV^UV/,9ZB?[*)Q\;6[O5]%RG>7_7+9
MY_[.VPF)]H_O%O/X+;1+)PP@8S@-C '! 9:'( 'I@\C@<#G P#[OF,N=G2\V
MY^7E8KJ=/^ZI_P"1OQ&GA'C.BZ<U@DM<)P45O1F;T_IKJ79F8K\]?LC6ZFTJ
M788/T*FTN5HM2IBV5SDP<S,Y,.3:& $J$NHY$7J3FBSCDXC,Z]","/*3*\^T
MTGN$L)D-MTC2T"#F""">40<7=1M;;IT<TWGKIZAJ=9UMU^?JK]O6I3[1^NKC
MEWOITNPR)U]2I0SK8:F=\R\&4E+; "5DXS&1IO9 $G+28,1SR;S)!$<KBRU/
M>%6O0;4<^FQSB',HLX2XCB/"YSH(X6B&.: Z22X8"ZDZ=Z]I)9O39?EZZ:RE
M3N"7M:IW/4ZM7IN@+D)JX-1*PM,[4TTFG3S(<8DUST]*MLD("74A')))-[:=
MI$W@@ 6$BT6-S<D\C8 YU\F[]@#-F>YM$BID57M#B:M07:P$.X:;&PZ<G, D
M!<;O;2VQJ;HII+8VI6IE\:577>M6F[J-RVDEJG3;=]7>IVK5"4G)DRKTE*(E
M9RI_1V4O)3D,2Z4J"U"+M#:8!, XRZ),7BYM^G->/:]U--&BQSZC'\3WN(IM
MJ-!<6M <"YAD@"XFQM*^A9UE7'5M*:9H_P!0]V,:A(K=VW58U'N:H4]FFS]Y
MVL_*/MT2JSLF4ED5"5#J5"?:&R;FF$.HX)CT#:6-)<(EUR!$3WR#_*X!6,J;
MOKUJ=#9ZY/ VM48UX+@0QS>%K[D$-94(<SBR!!E8:5JA:HTGH:U:T\U1I\TN
MH:/O3&F5GSSTN\_/7+(TVXZ?]#K5/0V@+6MNDLMR:"@;%MH*\#:HQ?;M#'4J
MK8$D02!<"# G0Z6F.^%B=IV#:_N=6@X<08[V=*FXD%KG.)?$#]T R3>79A;D
M-/ZC)MZ"4]]3F&CI=(IF'&U*4EHHHC;:RV%>\%%P*4M!]\*4!@1@/8C[Q+79
M))S&3.;]PO<1@2M]V%SJ79T;,6D%F[VTC$R'BDVF.H)=<@"TDQ$1@)[-G4FW
MM).DVKU&\)M<G.2.I&IA535M*^LWS/7=-NR*)615A]9FF5H6SA/OA7<QD-LI
M"K3H-;' U@D3$D.=-H/\3=0-;3;!=B>/=5#>+*H/M*NVOJ,:Z2>%VS[,TFY:
M0 ZF[N(B\".*2E'U(U9OGVA-I6_=MTT!;+=BUC2N9;J,UBCUE5GFLS:J.'$A
MMIF<J(1)U*32H@J0IM13G KV6*+'#^(%A-C8AT$VP#?3,8Q9]E7J;QWI6I E
M[F>UI7<6FI3+  #-R6\;03,2#T%C=>I6NIZ0+4U=DZ/7;4NNL35@6U?<KNJ<
MW-2=HT>HHD:[7')=#H?D55GZ)XE57)C<S*KX40"N*PUEKB;D$C))P" +#B@2
M)B]\CSU=HWM[#V_LR'/>*/LV>T$M:UIXW$EQ]][#Q0&B6V@&#?77-:V4B@4&
MZM.-3[4U)I-&J]>O]G3"OFO4FV[@LF8HWT"H6Y3;F;G)BH.UFW')T5:UT/!0
M566FE.)#;6V*N)E,/=($MB;3/$'8(Z";01U(BU1J[P=5I4ZSFO:P&K[(^U:P
M$M  XGBF2\ D!K72".($D%RVW=.%RB[=&[%N'ZGK% %7HDO/BB5Z9^FU:F>+
MN496<GE!*YM:%$E+[B4NK3CQ.08U[:G!]4O$7Y6'/$6N;_S75-SO<[8Z?%(S
M =G(&=0<BWGD]AWL1^YBXB"/ZTS8SD]RTL?ISVR/6*=C_P!:9),6[LF<9\?#
MFJM\VW7ML#_<5#_Y3:WY+6[[(PC^"#+'D8U:UE!/)[7[5_B/TA/D3'OWQ)KL
M!C^Z'>/??TL;"==01)6I?9N1_5TP('MR;"X_L^SWOKW'.NBVIX/J?S?JC$KH
M$GD?A^:PIZ\/[#]N_P#&I8/?G'^::^<#!/R$%*S)I?\ 6RG?^8RG_N[<2<G.
M=<^/50,#N&,>"OB<#//W#)_"(4KJ"[=:[(LRKO4BXQ691J68\::JR:)4)BCR
MRSDLR[LXPRXCQW@%%I"0K)3@X/ >OGGP^?.RBQ&)&G7U\;Z9Q_ZC[5MS5K3Z
M3KM F[DF;NK+M+3IXQ+SD]2W)"HN3@2BKFG)+#GT5AE*U3BGFREME7B+QE)#
M7X=+:WYIZ/T%AI-M>^ZZ?ZA;6O\ Q:%7K&F[NK-D6/9<LW<%1H=^5BW:K)3K
M"0:_/-R=*G6UU0I\$EM;C.Y("BG.,A\9_GX8U_)!Y7M:+8 ]=W16VNJ'J2WI
MSKIIBBITR6TPHMF7!.4U<U/NJF[)J;PE9Z5JC3\R&)EZ28=6I+LPE1<*%EPC
MDQ&.[OUZR=;1E/'N[O7S4NM5SIOC6GI:NJ0G)TVE<]Z.4RFM-/+89?D$R*7Y
M@O,2\WLG"J96EM#F,<**>$F!CPD=#(-^?A;239,3XGUC.O6;K(/K?4N7Z;M0
MYR4*V)NGRDN_).RRG$.LO)G6D.%"VEE2][1V*2D9!).3RF)09OF.GCS.>L7'
M>NX;%<E9'2BV6V'6$)F+,D4,J>6EMN8F5T!EQS"E%,PIQ2U...! 4K 7R2 2
M('@1Y_+N_-1)F.I[AKF3WC32VF&&GFO55L?0C2^]:%;-'IMD5W4NO6Q=C]1J
M%9K9MV3<K4[+BM"=<?0ZIF=F65K*2A#,H7FF0I7),"0(ZVL)B.<QW@ 8D3*.
M!)D$"P'Y]?UFZ[CN?J-K=#N2S+-E:-(U*KWA2+INJ5?8EY^8ETT2D);71)=N
M60%O/5"MMKR7 I2&04[SS$S&GCRS'41WWG"HX2X1 @1R-[3H 0 +VF9N3CY?
M\)VJ2UZVY:=S4*7TVF+FI-"JU$=NIB=\&XJE/K4S5Z(S/M-?1:9-RGY)R51.
M+0IY6W P#AZO_,?-5\(C&G?>(M/+2;<UG"RI2VTJ4 ,I21@YSE().1[O)SC!
M.1SGF"D&>7K]0<:!1<!.S'&'$'GTSS^/88\_Q!#IWC]/C'JRP@TT_P!6KKEW
M_P!(MH_+^.?SQ\QW!Y')&83/KD!^B#ZGY^OUR<XX*4@B01((J3R5*2 D9PK)
M'';!_/G'YX'!G&JJ:0"2>5N_U.5QJY7_ *'2IZ85D(;DIDJ4 .!X*R@@$8Y6
M,D_R0,XQ&K=L]J&P=E=Z5R2/9[+M!,2>'^S5B#:";M&(UO:]S8J9J[PHM D.
M<T$$_P#&R(L9.8/,#4VT+W757JQ=->J3RRXN:JLZM1.1G\LM QZ< <C^3[W.
M #^,G;O>[-Y]I-YU7OJ.I^T<QI<#,L<^;$ P2.LC)U7V'V79]VW9LK&@-AK7
M6@9B"")BXF\7^/'C[JB0,@#@G/D!DXY[DY/'<Y\HYXP!M4DF*7%!S); FWE
M.!\-L.T.J,B"3!D6M)U) $1KI\NYNGF@)N#5:W)1:/$:DI]$ZX<$I*I-&]O<
M2?LE>W!Y'GY9/T#_ */FY';X[3[*_P!C3?3I;10<>-S9@U XB'%IOJ+B ;Z+
MFGVB[;[#=%>F][B\L<UK8,&6AMW "(D$7Z G7=?+L,H;EY=:4^ZD)6L\H!(V
MAO804J24Y3@\$=A'Z][NV=VS[OV2BT-:QFSTFGA,@0QF!K$1/[MIF\_*CGT^
M.I[Q+W/(CA-QQ.(DDP"(MSS*\9?LM[TU2M#7'VGU/T[T2IE_4*X.M^T[7NZX
M)IVFS,M8EIU>X[ND*O4G:#.TZ<F:HV])E7TIB36TB40PE2SA()]0SYZ=?T\<
MV4F+>?P'AX:=8MM@?ZM+NM+JKU@Z!.ENA4+3RR>DGIGJNO=QW#5Z7]<O7%>-
M?GYNKTBQJ=30J6DZ7:K#DVM<Y--.?3GWWD,RS[#<N4.3/0VYZ]V!ZN941(O%
MQ\///6TVZ+&>L>V5ZCM0=%?9WZHZ*V?IW1[AZK=6M1-"-1[2NRGU.<IEO7OI
M[,,2T[7*-4Y:>EGA0_I+RU.2*_$=5E#:9EX@K@?AT$F;>/PYQJD#QSKS)'?%
MYYY*[5ZC>L[VDW25=O1/ISJT[T\5^].I[J)K^E=8%N46X)N@R-FF=E56Q7Y9
MOZUIM18JS$K/LN5:07.O,.B6+(=*G"4QSG'KU]-2C6_Q^7Z?%=)5_P!IMU\4
M2W/:5R":WH[-W'[/ZY9>KLW6NQI^39U-M>9FY52K8-OJK\TS0'_H+KS;=3$W
M/+0I(F/ =4C:J?7\O@EI',R->^/R^"R8L[VF>OU^=5WL[]*).CV92-/^L3IH
MGM6[CE':.].7+:]RRUFSM=:9DJB9MIEV3<GFI9XM*E_$2G<R0D^\5\3_ #T-
M[6OE.IT_(3I\OY:W.JWK.UAZU/9:]6==U4HUJBLZ+=>=KZ.T&=MZ0?IK4Y0+
M<O61EY&HS:%NN!52*EXG/#4VTD.)2M1W9B.[U\U(L9\2.>(F=(&DYQJMC^OG
M6_U%=/-I73)TYBT+1M#2OI%TZU0TEG5-R5W5[56]D4>03<]MW#:DI,35=H5O
M4QA)0*O+MR+*'%*4J=RV )GUZSX?FH',SD^4Z6L#$_FN#:C^U,ZGZE:OLL+P
MT?H&G%(G.OB633[QH]UR%8G:;;%<5(.%JHTZ98JI>3()>;P6WBZMUM#9\4J<
M.UZY>K_31( F_/N_E\=>:Y1U2]7WM'>@_3KIYU)ZBEZ%5JT+CU\;TUUOK>GU
M"K"&;7T]K]=#%J7-(3%0FWOH\Z[)$?6;,QOETO)6TA0*,Q'+X^OR^26,P;BW
MCW8G]1*V]=.5^7MJ5;EX7S5:Y1JY9=8NNI)TIF:3("7;<LN25X,G4YN94L?6
M0J+F]YIQE*4[0D#D@IG).GA;6V>X8\526X@7L.+E$7\AZE:(NFZZ[DUJ]OMU
M(RNJTL[4V]"M'GZ/I+;=>F''9&VY*:J] 3,W%1J5X"Y:4=FY%YQ/T]"E3&)\
M)6OPEJ24DDDC6]\B-)'H\]:K!MND'.O0C/C*VL=8;FCW1U;^K?M'';,;J>I.
MEFB-S6P*?1_H]+-]2L[/2-3I- J,RRRMQ4[]<2K;4A47FBJ6E7WVW2,I4F;>
MM?6M^Y0#(B3<>(S>?D8Y<UA-9GM&->*)>/0#;VI!M.HL>T*TEG+LH,U2J(]+
MR^E-]U"08J-MTJ59>=2[5J*N6J4@Q/"<*7VYEN9=2?#.(C\N1CIK>+'OT4Q\
M)@]^?R[M59='7M">IW7*O:F]/>J\[8%F=4ND'4K,:>W3;E+M5T4=W1JC.OSE
M0N>7:F9P3 G)RBL"?8GMZ9-Q$U(O,'#X3"<SU)]>O!(  R8$:FQZ#/E\ %UY
MIG[6?J"UJGJ]J1I%I16+WL^A]654T)_>IM^RJQ5*E):34>MBA5C4^IWHT@RD
MM6VII*ZHY(?369.5I2T2_P! #H4J)).<G-^?KHHX0;8ZBV--=;QSOE<PL+K*
M]HWU"=4G61T[:')T ;1TNZH6+(T^LWU2ZY(3MPV+7IR4?N"D3/T.8,HS5I"F
M..F2GD@>(^-FU) 5%-^?+3S\_@JK1>UC)GG\NMUQ/J7]I]U2]-UOWW>5X4C3
MB3NBR>J"Q-):;HW2'&[HI5QZ27-)I3,WS6KDIJIVIVG=DU5/&13://U26EUR
M\NA+DEOF<IDDQ,21R$8]64<(QIXGZXG/U7.-=_:5]0M%U;ZN;2MJEVQI90NF
MKI8M77:Q!=M#F*C,:V5ZZ:<Q/_5"5S" X:%3YA3M&<:H,TQ.FH;''9MKP7&'
M'KYJ )%Y]?3H9'>(7#Z![5C76ZKPZ2M";@I=*LW5'6KIBJO41?=SVUIY7ZFN
MD3<_(S:[,LJW;(F9N?J:)-$RRV;DJ55F%K53RMV2\-Q(B/0_GY3:W60ICIZ.
MGPQBRW"=%6L>J&N_3[8&I>M.F,WH_JC7:=,INZP*A*S<I-4>HT^>F))3S;4X
M/';E:DTPBHRS;^7&F9I+1)V@FW6E[6MIP7L,D&PB1<$R)$&WR5MD,K5"2""T
M1()= !U&E\3\I6DKVSNG[-%URL#4*6EU$7?;,W3IYY*,--O41:2RMPC!4XXT
M\0=P)VCR['Z ^RC> J4';O8YWMFO<6@V:6N(-GQ#0""(N3GE/.>U-#AVPUN%
ML/#3,22,7D&Y%Y@_O3<%:<\]B">XX)]3S@<GS)^?8G.1W@M#?PV,8$7@P;SD
MZ1R*T-U-^2 1[VHT,@XP=><3>Z^?4U@RH"20I3B-ISC"D.(4#GL!P,GR\CDX
MCS[33IOV>LU]YINL!.A)$C2]S-C)4T2YM1I:;AXYXF;29.IF+XM9>V#HBO-=
M]]*NAUQO/!Z=F=/Z*W..DY F99M4F^V5>:D+EMJC@ X!Q@Q\6]J:7LNT&\ !
M;[RZ#B.+\4 Z2(Y3H(A=RW-6%;=VS<+BXMIM#K1< P?(D]QF2"LLP<C/'W?(
M1AEE%&")!$@BHOG#9/I@Q(R.](D$8L?D>Y:D-5?]<ZT0/)(T>O@#'''T\'C.
M,D]CS@#)/H,]1_U4:#4YOZDQD8,V7*MXW[8[,2<4& 1(S4J'%A]>E@MM,E_$
MH/;W6QMSP 6F\>0Y[CX^1QQ&OU/[SG[QO$3[P,_ \C&8PNHTO[MG^4*\[Q*N
M+C59MBD5WP$56DR%2;8=<<:1/2\O-MMJ4.'$_26'%M.$X]YGD 8)(Q%UM1S=
M9\-==8Q/CW!>:ILE&M'M "!S:'9)G+A?'32 K:6M*CR<D]3V:/26Y!]P.S$D
M)*7;D7'-H6M]<LRA*''%.ML^\XDJPTE1P0,TU'E^+9S.IF_.,XSS$*JCL].F
M "VT1   $6QB3SS@=1\JXF++>5)R=SFWEEUQ'T&3K1DMK[Y3A7U<B> +SRVT
M\,RVY]*4I+8"MN);5<UA;)OKSQGX\\Q$*EVS4GN!<T%LSPD D2#$$FUX&F+X
M5.;8M1-1DJ3-?4+U49\)VE2#IDVJ@RPW@I=E)=\S<VI+2$DA]A#;24X;6I"L
M$A4=@DQIW1X> (S:TJ#LFS. EMV\,>Z#?0@D]>>NH7TYVVK?F6RW-2,B_++>
M4^\Q-RLNM#[RPDK\9#[3B%.*5M4O*4JSC'<P-:L" PV,!U[]X$=YL1%A&JMG
M8MCG]I39'$YWO,F7&"9-KR)L8)$GI\5B9MEFL+MY2Z,V\[2$N(HR/H;<R_+I
M?#7B"22L/&6"E);61(AE)VI+JB1B35>"")F2 1%N<#Q&IZ*\ZGL$!K&PT@2W
MV9B(C!-R('+P$!3_ +C;3"%EFVJ&P&UN.%MJE2C3/CAS>%#$NEPO( )<4VR0
M% D$^=;=HJ@ .<2,B2"(P)$3&LQW3"\S]AV0NFA3:&_]V&.+IF2071>0+X F
M#*^O(VQ0)=Q^;D:5)R[LRI)FIN48:;F)OQ$H5F:7X*%OAI)\-I2E*!02DA*D
M*S!VBJ=1>#FP $6Y3:QO-IPJF[!L;8+6 .N'.#(),@QQ3)L8!+0;$77TYFW*
M7,2GT!=.D7)%2%-.2:Y-A4JM"S@_TN2&MH07$%!20HN%12H I5#:]0&>(^9[
MXU-^_ERM=?LE!S2WV3(F0 T 3$8$ '-^ID%?+-CV\B7:E6Z!1A+,G\BPB0E&
M4R^_'B> $,%I(44IW(0RRA2=W\H#(UWD07&W608TC2]\GK*MC=VRF>.DR"-&
M-D.MK(@0,CRU7)Y&0EY!D,2S+<NP@;4,M)2E" ,_82G"$IP<!"4) 'ES%DES
MG7O.LSW#G\Q%EZJ=-E)O"P #H([[3'+$3$]W'+V _<U<7EFE3)SGG^*</?R&
M>,8^\<F+^R6VIA[M>_GW'6->H\&^?]F;;_W%3_TG7U"UN>R- /2#+#GG5K6;
M@<<"_JP.YX/;\YCW[YDUZ?/V0[IXW'&1F#X$2%J/V;_]7#G^_/\ _K[/Y_FM
MJ7W*_P +_P#ZC$7Y#S/Y+H$#D/(+"OKO_L06[_QJ6#_\37^WRB4U'C;GCQ\O
MYYCTO^ME._\ ,)/_ -W;B3DSF3*# CD%>J"CC8H)(()R-P4/-)[$9\B#P?41
M"E6JI)AYM3<RRS,(63N;>;2ZTL!64;VW0M*E(3A*5*R0,XP#B"B)SU'@<^?P
M^>/FJ?39;NJUPREQ5.ZKSHLS3:?,2%+E[>K3U,E:>)I"&WWV&F ,/+2C .=J
M<D)2,P4JK)=/5!I-;E*K*75>;4NFAL4*?HGUXXY1ZK+,-I:6_4)1\+4Z_,@J
M5-O)<3N)4<)"H6//P[_RM\95)) R)OIY9/QP"1WKF$UI90YR9J*)UYURW:I;
MJ+8FK:(ES1S24I4VVQMVAU1;WEQHX(2X>_JC.O(:XZ>>?@DZ&T1>1\R9@XQS
M74]Y:!4>J5;2>9HLT[2:?I+,2KUM2<N26)=+82TMU004[W7$[BXM0"<$Y .8
M@C301G,@^NI.H55B._I]+6]0NT]2]+J=K#9]1LBZYZ:EZ)5MGTQNCD2CCZ&G
M$O)WK<+YRIU(62G:#VVX[RG7NYD?/7HK-&B\FMZV5SMTW'.2UHRGT6BR*IEI
MJ49*)%5/8?>9:90E]QF75A)6,$@$@XB(&;SUCPBUHOKJ47S*'TZV-1=+'](5
M)FJI:4U//U&8EZDIMUQ<W,3R:BXL%MMM*4F;0AS:$@?; QOXFWAI?&.0'T-\
MJ+\QY'KUSB5>7MH):=XU2QZ^U.5>V[AT]"F;<K%OS0DYJ7D'D(;FJ:Z%-N-O
MR4PE"0IIQ"B@##91F"0;:\[9]8[E"O:$V_<X5+UZJU:KT]VJTJN.RE1<:F5"
MJTAUM^7FY696T9B2*W66B\U++;9<0DI4@A1A&)FWY$7MUZ*;^A^J[O;1L0E'
MNX1@("00$I VI2 2>R>/CWP(* -3GZ7CX%'.R.,_E$>1/GWX[8]3Q\^Q(=._
MIR//Z76$&FG^K5USP!_I&M#)SDY+KYY'EY]N#^8$'U/P)6<<%*01((D$4J\[
M3C]A^WIS%%2>$QZL?AWHNL-7)Q<AI_<\VD[2Q1*B2K=C"W)5]MGDXP$K][/H
M"."0#S;[4ZSZ/87?+A/^J;1C7^S;3!F?/S%PLMN*G[3>^PM )FO3%LD>T;Y:
MZZQ<+0T%*42XM0)=4M:U $9<6LE2N4YY.3G [@D^GXN;YJ&IO7;WN=?[YM N
M1AM5VL&X%HD38A?7V[:?LMCH,BXIL(UCW1@ Q\P(QH*@"3SV/VL<Y//?'/[$
MX',8H 0#)$&3-IS!B_3D3>)B5F:4F=<1$V(B>7.)$W"R^Z,)!,UJ'59PI2$2
M5,8&5)45>,XM(4L*P-H(&"#GX'M'U_\ Z*&[S5WT*Q$GVLC2&^T>&Q!F   +
MS(M%PN,_:OM ;LW!Q&^+C X2?R)U@&8B-K<W*S4S3IQNGSB9*??EGFI*<+27
MTRLPI!#3Y97A#H;4 HH5PH9!()X_460QE.EH&-:/_"T6SRZ97SFUH+G/F27&
M_CRZ6ZSY+6AT->S7E>B'4KJ$U MS5BL7NUU*WE,Z@:@T6X*1),R[5T.SE0G6
M'Z.[*E*Y64975)UHRZMX4VXGG<@$+3?QY^O757""0<#$:W%^2Y9K![/2V;UZ
M@;PZF-.KQG]-]3]4=&IW0G55V7DVJA1;OLJ9+OT*>^KUEOZ'<E&$S,F1J*'%
M-K5]'+["RP"J(SG77U?K""0(,>'T]?1=!W+[&_2HV7T=Z?Z<WS7;"MOHYNJK
MZ@6DF6EV)V?NZ^;C>E'+BK5U33P'TCZX,L7IE#"6CXRSLPCB)@=VM@AGH>\_
MH5W[U=^S^DNK74_I8U/K^I-6M>H=+=^R^H]OTRD2$NY)W!<(3+?2_K13Y4X)
M5Y4NG8VT4E", DG)A^48\KSC-H2X\3SQ.=+W^>@"QZJ_L?;<JR.NA"]9;F9:
MZ]'T+U)833)%UNV&D/MN);M53H4XV$H9;:!FU.X0IX'(6 (O:XZV^5U.N.[G
M\OY]%]"I>R5DV+BZ-;YL?7.Z+,OWH\L:<TOMVY9:CTNH+N:QI^E.4>8EJA*S
MK3C,O4S)NK0U-LY2R=JD-Y',IWZ^.<Y_1<$;]B-8<MTVZM]-DMKOJ*Y;6LFN
MTOKY<]3G9>E/SLO=3,ZFH+EJ:AN7:0S(3,TQ*/3#3A<*U,;=P00 C/T]38:^
M@N"+ ]_\K_!?0OWV--/O35#4[49GJ.U%HK6L.@EOZ$7W09:2I4TQ-T6VZ0U3
M91ZE3D^Q,S-"EJ@]+LSE4DJ6J7#[A>2AU*7.(  PG@.9[_".O)?5D/8_TJ0M
M?H9MPZXW2^.A)U$W8,XNF2*'+E?3/OS'@7"A*=ADFI)_Z TVP$K#32%*4I62
M9]>O7R2^OYKG7M%YJVM>*/4.@N\M%-7+SE.H*QIN8HNIMJ6?5:G8-N792:C+
MEB5K-U,RC](MBI,RB':G(3$]-RS8*79< OK2($B (OIR&>FO,WT&%2 9G&3;
M6<3-]3:U[K9%I7II1-)M,[$TRMEB5EJ%8EHT*U:8TVTKP_ H\BQ*%X97N*IE
MQD3"RI1)6I1))/!""9F(CK^9'*\+"?6_V>-!O;J0MSK$T9O^K:(]1]"MV9M"
MIW52)&4JM!OJUIHI\2CWK09I(;J;:$M2Z9>8;>:?8,LPM"_$;2L/7KUW*1(
MDR5V16NC]>KEBZEV?U)Z@57525U3LJJ6'6J-*L(H%HT:BUA(^G.6_0I8J#-4
M+J4/RU4G7IN<E7$@,N)05(+O2.4#'E]=?.9E=*Z4>S,LZS;ZZ;KPON]*EJ&S
MT?V5,V#T_P!,G95N49HM'?*6FJG<>PK15Z_)2#4I)2D\TF60RF4;<#>Y2L0
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MSB<=P!^2L)PA+#9[8?#9^.X;L]CD@\8]._(B6R"2?X'MQIP$XD8P=,1.5XK
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M>/+/J2,<DQFMW_8[VLWFWCV?8JY$$!K6V.+CW@>9$1'SP^V]IMT;,XBKMP:
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M,:DT'2^U[DK#R#.4/2BE.T^@,)EV4MB<<J3[$M4JG/3"00I^:1XC2 AM#NQ
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MT!]1K'-8<DZAT";P3(%R;SB;>O9V_MF%P :7R2X6O, B[B)R3<3C0>XGI:M
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M:=T!<JWC_P!<=GB3^P89.8XZD3\?B9Y[:I(Y93@@X#0[>C39[YY[Y!/SQS&
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MY$?(.\M@K;OVZO0?BFYS)O[P#G .$@$38&9Q'1=>V#:Z>UT&5&$&UXBSHDB
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M+PVYN2TBX_SXOWVF.7KH_:!M?LVD[@VL@  0^J38 $?ZD,'H8F)557M2*@C
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MD@-%>U-I6X5 A:4<_P!42?=]XJ' .!@DGB);N0D7JM&9,M(^%0_/7 5L]O\
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M\2;6!6WOH[]J3>6E+-,L?7!=3O.R)28:I\I=/Y1^OT&64 EL3CLPH3%0DI=
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M< G) ^46ZK>)H'$YHG]TWQU!Y*(;_"#X?E"^1,4^5F&U-OMAYLIY0\EMU)!
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4$2")!$@B01((D$2")!$@B01?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g454025g01a33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a33.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1804&AO=&]S:&]P(#,N,  X0DE-! 0
M    %?2^5B X0DE-!"4      !                      .$))300Z
M  #_    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$
M5 !! "  +0 @ #$       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5KY%P
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      T$    &              %Z   ",0    8 9P P #$ 80 S #,
M   !                          $              C$   %Z
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   %Z     %)G
M:'1L;VYG   ",0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !>@    !29VAT;&]N9P   C$    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M'QGP<K:9WT3\$E, 6D2-WXI_;X._%.SZ#0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$['!X3+Q!Q1"4B-BTB0S<J+""!4E-$."DN(6LD13<__:  P# 0 "$0,1 #\
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MEYCI^D]YJ.O%_L?G^W_H(_T_;+MQ\X5)X%)=_:.OX3KQQ]CT_P ?^IC^'?\
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M[LCL2!S;O^R4WJHDF:MIK,^F*[D/)I3$>@_035235,N387#"H"W<+-3[6!$
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MT78X&#:$!W .X-WH[OS]U<LN:!,TQ&L=YT6(;K& FF.M<<!E&,XX\:BI -Q
M1P(; X#/'?M<0X=V[T;ZXS[W8V9A[FM(R+JXQIJ(6UMG,&(&$Y?G[\2 OGK+
MDVN<,)$P(4X><<I@ 3  @&"CG X^?M$:C-I71MG:/?;-8&;L@N )F<,1-:8^
M\?=[1[V;@WI!J00!IIC43@M;]4^4=%V!>%G6\F#5TA-.Q/.*"J7GHQ@LFDU9
M& @#@!4?*[:IU,B5-/9+@!&OFNUOXE['V?>Q8OO-C@"9M;,&#9V9BH!D;TG'
M$>?L=F_"-\O]UM+?<<-TN8V&D[[FN=XFF8W31G,$F*+'NO?*A:6G'0S6QI.-
MD)AX_+TXX&*X208)*D Z92G\TSASDR1!#.P([9,"&:\K\8_QKV?L:[[+M=G%
ME[?;WM[+063K!VXUC X/<+01!)(D:1F2.UV#_#R^;6M+]9WC>NGR+!MHT6H?
MO.WR6_T&D4-3A$@2K;U(Y6$<MIPY-:9WS>XI1@FBS<%(8I&SH3H$D!2<!LF*
MJS,/-#@V1!;OKRFT/X_OM+I9BQN5L;1WR]^6W6-XL<708H9 :(FCB8$ KL=G
M?PQO#;X]MO>;)EE9_,W7;UH2_=M&-:' &8<)=,2-S&'&;;CN5;)):3E*^CY9
MU.I-SQBDT!14;"Y.B8A55EA-SIE-H-QLB(#OXCBNLO?\<-J6NQBVZ[.M[2\?
M.L8+;.[N.X6B?"!/AD&12:D+L;I_#JY?]],L[YM6[V-V:VT>_>=;-DM,!@<:
MB<1GC&BZO)_Y2IX>%D8FZS2KXZ+AS)D>)E6=X14YQ14#*+"<X%3(&03*&R7&
M0P(9KD[!_CAM.P:!M&X6[&PV2;.[MF-^9@&!!$SF1P6>WOX;7%[FG9&T;M:D
MEV^SYUH9 : TR[/>D@4%"8$ K)&FW*TA;@N&ZF-QNB,XPTBJ>U7'1A044C ,
M<2E6' \\=(I<G,<-L2E$QL!D ]KL_P#CELW:%ZL[@^S^1:VY+6.)L-X0'/P:
M-X^!N>65%YN_?PPVI<KJ;W8N;>&68#K5K3:@M!.Z2"Z [Q&!NTDG(2?E17*R
M;.M9 B%7K$+'?$".9/U"@7F'R8X*Y75 =KF7:@@0A1#9+G)>RNLNW\6+M;?$
M-G<Q;LW7VUE9R7,/Z[0,FE9X#D%MM?@R\V6QS:.8XVS&OM# +2=UH=N@DQ($
MB>=)J=W8JYH>;:@Z82+)T@"A";;=RBX NT4HD$>:$1(;)N!PVMV_T?=[OMNZ
M6EVN]LZT9_B,L23OM(FT8UV]3^DSEB#1?/+6[VEDZT8X.:\!P@B"#O$&AQJ"
M 1F%TIV];5M@K=6X[@BXLKM<C9ITMR1+GE5#[)") <><,H;(9#&P @.\ K9:
M[;V<UP8+:S).!WP:Z#B,M,9.6JSN=LZ2&$P)((B *@U&>L\@KD(]*JF51L=(
MR1RE$JA!*H G,?"(&$N2"BX ! JA-Y=H,;QKL;M:6-X;O63FOI) \1 \4F1G
MX28SKD(6JT_PHW@8) GG  YDD#AGQ^MZZW(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1% @ A@0 0[A#(?
M/1$P&[T;P]'$/R"(43OOOFIHBMFTO@1KP_LB7[-_PP][>&/10>_U\N]<5B!A
M_P (&-.GW4W9OAEB[_[+BAW#C]]&OISV?EHJ8DSF!3S.M,QW$W+15*(E$2B)
M1$HB41*(G'C1%PF02/N4*54,B(@H4ABB'$ $-G @3 ;.0R& '(COHG<J>92R
M80(!3'$HG,7)3GV,[&V<H@8P%VC;(&$0#(@ 8&B*DS=(^!,4#><4P[0%.!A+
MO 1*8#%*(C@PB0"F$P .:*1WY1GAY0N>B  " K-OP,V^4/M[:V/7Y31./U'=
M162VHJ1AGP5XEX!Z@_)1%-$2B)1%@K6'6N-TBA>M9---TJM*HL&C!,X$762$
M1.X6 #GR/,(8,8V +M8QD*\)\8?'%Q^%A8[]I8%SW6;7MM+6P!:2;4/$/O%C
M! LH -09F:1Z'X9V!;[?M[Q8Q:-^2VU>',LWN!:!9_+%&.,R^2:AP  B=X?8
M0UDL=2)CYIS=UK1S1\U3<$(^F&22QA5(!P*4HN #),B0X#^Z :[+87Q?L;;=
MP9>;M>;.TMG,:YUG96]V>02'& UEO:&(%9=(A<&_[#VM<+ZZ[6EW>QK7.:#:
M6-L-X QO!PLPV,SC'D0,0ZJ\IRR(:SIMS;<VWEI86JS!JI'(N73<'ZQ0%#F'
MZ29HYR4A5-HYVSQ4J:I3HJ&373.0O@_X@?Q&9\,[)^?N WDM<'L<QL-B\71@
M.XZ\6+@-RW!,N%:U @^J^%?@^VVUM;^3M+06;+)S2]TGQ;UC:VC0"&.<*V;J
M_+(IA!!6$N3QRCKIDX%2V7$%-WO=K1TLY+T=U"-#BT<JJ+B5XI)S+$&R;?:Y
ME Q2*B*) $0$>/@?@+^+5I\36WRK*RLW7GY@#=UK-T VCV;I99WRV>?TT(F)
M@-P"[WXR^!3\//;:6MO9B[EM9<\OGY;7P"^PL6F0[].-)G);+A>>N$N@?HEH
M67:PBF51-:XKL,].D0QSE\Y&&8/&IS@4NT)"OTS 8# 82!LF'[8ZW^++0MW+
MM=!9/8UP?_+WTG=</#+@(WMT@QJ12,/G8M?ARS'^):WRT>!4LM+FVS+JS&];
M[T2"*Y R9F,*:@:NH63SQM4>5/I=8)$$075A8F-BU+A<)"8Y3#'L7%T2$R_,
M"A5$R+-8-0%#$YLJ *E,%;+/9FV;T)O)#"8WOE,O+3)@QXK,D"7&M((C&5UU
MOM[8=@7&[VC"6DM'S;:[VDXSX;*U.  F0 "2)R6!'_*#M*Z2-V^G<-RL.40+
MHBH(NK1LB;L"UG"X"!DR*79?%MZ?PR:1A(;*\?/R2)2$,"JJ)S)D5Y1^"V7J
MX7LWB]7UEH'60LV6=X=9%X+CO>%UW+B&TPFF)J)XC/C"T9>[%MTNUC;,A^\\
M6&\QL"@D6M'5,"*Q(( ,Z=ZXRDI8VH%JV_J+;MPV5=FK1X\+&LY9&;O!T]6>
MKII,8!.ZX="8@'$I&&2%:4,%QIH,0=)K*D,D8,?D?XD_A9MN\;8<-_:8LGEA
M&Z^_S!NM@?U,N;V_J$3C2"9"^_;+^.]GV.RV[XNPM@"*B[-#O\>T .Z;P''?
M9#I  G"6D+X7*HT^Y7&D\'9UY6[IW&WS"/B-(1\P9-!=7#;#L%$T8YY,LFT@
M'.-G9S%64>M2.3M1 3.$  -_U7X1_@/L"\,-IMZVVW:AEFUUDU]\L]UEIO@$
M[MZV:0V0:!L$@ 3&'QKXU_BS\9[-MKDWX8N^RMV^7MUC?7VUSOMJ]M@YDLAU
MTOK0QQ>Z ;0%F0&2RC?W)/Y7#3DTLM1(V<@G.K,8P1N%?2N*@59:+/'/"])?
M-(N5=NDP>7$1J"<B9N#,H/%&AHA$4G#Q-9/Z(/X+? >X+,6=_/RXW2;;9Y/A
MALF;A4Z@B.07G-I_Q!_B18;/%]N=ILY][(9:6UBZ[;3+2Q]DY[OE[M[#B\6D
M;K#.ZT.DDN#5=6FW(BUYO7DWO)V_[YD[&UVF6CF9M>#A642$) BNV*JPBKDC
MG$<]1E%%A  </&CN/!NLKT7FP%!117NMG?PP^"]G/#+.ZVEJP,,_/&S[1N _
MI%R#2^!-0(FE3"Z]_P 0_'&V=CB^;0OANM]>ZRM&BXG:-VDEOS',=\RW<YH=
MO$P'$BC7-W@2OG<FOD.\I$;*N>Y->-09:+U'6._8V;;#52WT[>;LR)+L2NKE
M<0<4+HZ$RH<AFZ3-RDLQ35 [@KD"F34PVI_#/X2O;7-%S-G,1\FSN3)\3<"+
MH8F(PS,B)<,MD;>^+;JTVEI?[8O_ /39;V]]M*^($O#[=I:""0RF,.B 9M[D
MX:#\I^^M3;G@-2K.::4VKIZY=6^^N4CAQ-JW1*G26*1U:D>=1(JL09 Y%%9!
M=<Z2R9C<T4AQ 2_/;/\ @?\ "G_>-C>=_:]DZQ>3-G>KJV#\LLQ&SP9B9APB
M=3!^@77^*7QBVQM+L]FS'6>%K\V[7NU)\9< !_.P[Q95$"IH"?HQG)>Y4AN4
M6ZT_?LK70TDC#-),^J!FB[=:2CA4*H1A&P@23@1FD0R"?/O$&XK 45-A,1&E
MW_[/'P1=]ILVDV__ !0;RRT9:@.VK=#8ES'A[98=FM);O4(WP2* C%:;S_%K
MXVMB=GFZ; ;8D%IM&[.O8(LWL@N#S?MS>(,@&!O4D&HVV3Y$VM46[D)JU>56
MZAU7 E.DUEM+FCHJ"") .FQ;DMJ]K;:"0X?0C.7L=(/@W'!0Y@V1^D/^$-EV
M-S;=S;[2-E=K(;I%XL_FEMC9&S;+FV4%Q;68JZ"NF&T;]?+8WFW%W-J7&T_P
M[)]FS>+@^K/F6IW=YT?KG=AN-3J%K)$7X%[2#'4>[VM^W! MB19IJ-*Z9QK5
MD("GL&BE"LBQ+PV<F422DU2B.1>B8-L/R7_$7XXVG\,;?_D=CV-[O%W;;.9O
MWJSMK=X:V\&R;X[*\6+?TM&0DR1#5][^"?A38FW-B.OFTGVUG>19AP;=K:QL
MK,N-@+1Q#+6SM7[N^2*ND#$2MG.2CJMJ)IY8+V(NF/OC4JS8Z4<)VM*0$4UE
M9>UXTK91T_C)MP,THI*-6*VRE#F*U(Y01VDG"CTVP8GU_P""?CZ]VFR[*WM[
MK>G6I;O.:VQ.[_O;PPDM=;S#6 &"1'ZIC'YAM_8ETLMHVMWL+=[;-IAA>]LF
M;*S<)+;.)+SN@AIB10@K:*Z^6?IE;L,9]'*R-QRI5TVBEOL8B2:/V+E1$#&"
M8/)MV:3)LW7$6KEVW%^DFJ @7;$!+7T+:OQM=MD-#KV^PLP0"0\V=G$M:ZIM
M;>R%-\"A,R#0$3T=QV3>[^[=L+)[C2"&6A$$D']-FZH(RD<<5>6A_*8LW6Y"
M1CXE5O&WK;YT0N2TW#@YUF";G(MG,>]4;MDIM@J4,'?,$Q*@?G$E$>>(FFOV
M.P/C'8^WO!=[S9.M9C<9;W5TRYK:;EX>2 75%"8@5,C*_P"QK]L\;UO9.:TT
MWG6=LT;VZ7 $.LV&3$"D$UF(6?W#Y0A3@B9,3)G$IS'(?< 8#)4@-SBH#D//
M2*<H;\CN&O4B\78%PM+9C-TN!!>QI\-?ZC6F@J<*T74VS+>SLV/8P'>#23#G
MBLY-'A,C]).^*$B#*^*WNR.<OG<8C,0CJ3CR H^C63Y%>0:)C@!.Z9<Z"[<J
M8B&WM%,?/F[ #NKA"^"\WDW>YVUV>1,ASP]U!($6;C6A.$UBF60:^RL1:WEC
MF@@$%H<T0<72\ 8^0'%7(U<&<H%63%,Q3EVB'*(&(<!$0 Q3%$2B @&0[L@!
MM^:Y[VVMFW=?N_-;2T@.#0Z10!P#A HX&*X4JM5E:V=L/F,)-DX L/A)+3,&
M6D@@Q(KAH:*E1RH4X@38,0H@500 PF()B;1<  "42CD-HQCD*7AGMK*SW7-(
M+AOQ.+0,<Q,C@ )-,JH]UHQP\/@C$ATSE%((FA)( K*[*)S'*(FQDIMD=G:P
M.XHY 1  -QXD$Q,[@,(@.( X2'1,F(G#+$ @]>:V2#$:<,<\/RN6JB5*UF.'
MY1*J)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB416Q:(@,(UW?W1,;_1UR]#\V:+$9:;OMS'>>7)=>Z%7'O=108'[JM/]OS44
M=C,3%3T=PI&7-7'19I1$HBX5C*E+]"(4YAR ;9MDH#LFV,CW"?9*/;OP&_%!
MQ[Y(>'?-6W+WG;, H"<W<,%#JG YDV\M*L8U90B8[)U2E=N$SBED!,!P3P)1
M( ><;%%)G".X^QIK.B[%LW9;UXQPRUL2[";C.?6;%?1KA-TU,NW$"KI%63$2
MB=(PE Y0SL[11R(&"BO?[]_FXJ(E$2B)1$HB41*(K.OOX +]W;6_G-$T&(S6
M+OTGO-7@' /4%%DIHB41*(O&+E_Z@(6S>PGO60;6W;$2W9&AGTB8P-)(7YWR
M:R@+%*<B*IWJ2L>9,Q1,BU;"Y-YJI"A^5OXL?#.U/B._WJSN3[4FSO+]UK7Y
M,M;X( ;9O(_WHR%,:57V?X)VSLC8.SF7FW?9?.M&O^:"&DA[VV1:*N:Z=VR;
MO1(F1.G!R=]0[O:Z:QESZ:\G]#6F.>OA&%GF<TQM809D.<B[CIDK$.U7R*:I
MA!!9(A.=*F(Y$!*(=Y_!SX,VMLD?)VG\TMAL.M'F6Q96H(&_9-;!)\B*<?"_
M'GQC_.WI]YV;9VEI&^-VRWFL,N96!:$4$FAJ<9HK&Y;&HO*W>:9(7@AR>("W
M(&V9!1W.L$[S=7,^4C3$1 \JBPBVL0"",,J FDR+*.3KMU4E6XH@4X#]M^(?
MX1;*^/+U:7.\6UD&/%F&;QNH:06V5H9%M8/:"779HB!,TX?(K7^*'Q/\'6)V
MQ=[K;,(,/%F;YO$L)L02+"V:Z@MW G>I+8H2M5>0G=G*NY0-UN)NS8R$TMMJ
M.1=1DAJ,U;.Y86:ZJZ@F2B(R66=QL@ZV@R91=LJFU5$4UBJ&*;:Z79/_ &>]
MA?P[O;+Q=K:R?:!S7M:T7$D;KC:8V%WLR 2\S!&6,*77^-OQ7_$=KK&]65M9
MV-F(?:O=?VM9O19_^O;VDNAE UNID"J]?PY#9+Q15-K#K1K!JJ1Z5,SJ.D+R
M=VK!;9<'$"PEE]11IB'$QLE4;FVBFYM3:*0H!]+;>;%C&69L+,FS8U@.X#(:
MT 5SUY\# COANTO=H+:\7NW?,EUG\PALNDDT&]/BUK #J"#FG3KDB\G_ $L4
M3=6;I=9]ORA=DYY=C!1YY=RJ"::1EWDFJ@H\=.#D3(519PLHH?9 1,(Y&M;K
MW4%EFT4PC= _^,<)CABNTN^P+I8M;+!O-P>8>[6=YS2<9I-,EGQI QK0!(@G
ML%R!BD*BBF4I@ 0$P F0N=H!W@?(>C>-:'WQX+6N )<' GQ5 @ZP(R(BM<5V
M+-GV+*MI4$0& @YF@D[P-09\A1=>0M**DEX]P\:-W2L4N+F-5622,=BN+=5L
M*K;),)'%%PNF)B8'94'MP(:BRZO<'ONUBYV,FS:XX0(<Z3$13#$8$K(V%I0"
MT>&B@ ? C@T0,2Z::$&0"OJ!$-1,EMD(KS1R*""B21O.+]:.1)G:#&0$N,#V
M\:"T!HP!HQAH@:4])]-%D+LT%KCXRT@^(--1G, DA=KH*0Y YCJ$RH8$U!VB
M@*F #9S]:4@!YA"X(!L'QM%*( 2#(->SCBN3:!MHT-<QD-  @1@")(%'.,U<
M030945!V+?;*<4R#A(J E,4# 9(AA,5/9$! "%,(F "X\X1$<COIO.F9(.H-
M03C!2&_*^26M-F"';I QB 8PP$21E2%R$9H .T*28F$HE/E),!,&UN 1 H;@
M+D@ &[ Y'(X&DG,DTBI.D>W09+7\JSQ#&C#!HK%!6)PD>?*((Q23^M$<")A$
M# 4V=H0[3 (@!0R4I0$  HXQN#"> RKG3ONBGRFCE600(()PX#$:5-% QS?:
M P% H /UH  EQ@<!@<[@$<ACM"KO&(GWSS\U/D6<@QY4C*,LH^V"[!TR@B8@
M%*)0(8!*/ 0V1# @& P(;A[,=E8.AP<'P6D$.WH(W2#O @TB)D&D+9&ZTAHP
M%(I4"!AAADL23FCVEUR2!IF;LNWY"54$IE7KN%8N')A+P#GUD3J"4.SSMP>F
MO%;7^ ?A3;5X%ZOFRKC:VF\7EYNEVM"X[YM)+G63C5TG7$ZKO=G_ !-MG9]@
M+O=;]>;"SW TV5G;6K&&&[LEK7 .,4J,!& 5S6[9EH6DU4C[;@(V(:*+J.%4
M&;%!LFHJJ0"F$Q$R 4=K ".0$!$ $>.:[;9_PW\/7&R%WN^SKBUK9 _V>P;#
M27$@@, J'.BF!JNMO6T;[>K5UK;6UI:/.Z2YSG$DAH -3C  G&BT/Y8VDEQW
MK<MM2]GV?)2SMA&N6+F6C3E.@FT<JD<*("T%TBW,8ZWGBMS0K ;<"@% 0KX%
M_&/X;VSM"RW=ELMI#2)LG/;/^'=Q(#&N J'81@2 2"OI'P)M795R<YU_M+,
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M624:ND"+-UDW"8IKI.$A'9<(K@/T9)3)5"E(4?-*.98VUO96CK6SMWMWMT@
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M#("(8XX^/MJ@ 8#SS37/[<:?=2<HF# &V>\<9W;]W$*J"!EG)RE +@ SO$
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M' BVM7 P#:N-*"0\@R*ZGIAKZ&!@Q/-W@/#/'C7,>"6TQG*NN2WB($8=ZJ2
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MCHJHJ@JCC9 HE$W':2+63G!J>>1G$GZ30RL'M<9@@@C#[3'?DMR^2:RCHO3
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M?XHYQD<9[QQO$0WX[-^\*S1=!Y&INPV3C@HF$QR!@"JF,&!!4! P&((;C$
M P<1XUK-FVTI; .;D !0FA,D'*G7*AP>"X0#&/GI-#@5I-K/R(]/+[D#W;:3
M^2TFO\ZO.DNFPR)M2.U"96,2:@# 2.G4U$T1*9-0$%@$PJ HH8,5Q;QLR[6X
M(LVBS,1--'5@ 35PD: 5K3@6MBYC@\NK(,-!K&\ZE023G)G(3B=5D-3N5'R3
MU%BZLPJMX:=-@ $[^MML^FH%!JD5-,Z\K&#SDU:BRZ@F47%9N$60XCMN )S>
M>AO6RKY<F_/L7"V<70+-@>7;KI).1 $09$\ID9V6T@'-L;2RM+*02+9Q:+,[
MM(Q+MYT@@&"!,T"WATFY5NG.H\=&ODGZ4<$H@59HZ.NDO&O"F+M"9M(H'.US
MGZY$RA52;P.0H@-:[OM6TL'AMYN]LW(DC=&%(F-1QQ%:$\^SM;.V'A<PDU&[
M!.<S!X??1;2(R;1R0%&RR:Y3%(<O-*$/M%4+M)B E$0$#E\XH@(@(?)7IKO?
M;O>1X;5C3-6N<-X5Q@5KB,B(@U63[.T8)+'$$P*1,8Q,89KE*Z$QMD&ZX8W"
M)BX#AG<.<&[0W5RR !(<UVFZX$YQ.DK0VT+G;ORWMXD0/(Y^2YP.(F !(8,Y
MWCP#=G>/IX>NM M7%X;\JT .+R!NBD\^&&*W4_N;.DUZ$=BJY*W*)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%;%I"'4C7<(#TB7'?QQUR]W8_7N
MHH,JXC",<*^N"Y+K$ A'&0XNHH,YQCZ:LASGT44./*#K/ZJ>:N.BR2B)1%TW
M0C@"E IC&*("&SDY2&42(*Q0R *$1$Q3J(#@52A@HB8 (>CCAW3S5'G3N.!.
M1['F%RFKRUV1U9D(^U]1YG2ZUH2&C'J3R(T+9ZF+2=L.6#=6X9T9ER!'Z8QD
MHL=F:UD08JK%!RN5PX*F0E<5I/S*U(BHPKY5DP8)D1JL78'D>QW[K9+D6R4G
M,:*QKZ9GY6YWP3,XD2<EK5&RE))J=X51%\TMTQ45&4>\(":K<CE CA,X.$]M
M0I<US[4T;2A KJ0(TD 210P<342L+//&.,GUS//RS6V]:5L2B)1$HB41*(E$
M5G7U\ %^[MK?SFB:HQ'/O!8NP*O$. >K]>-148#EW@E%5\^0>(,VZBRYRI(I
M$,HHJ? $33( &,;:$0P !OSW!76;1O+;O8EIIO-<!A&1J-X&*Y UPJLV-DS,
M1W6 :9>:\S= @<:S\K#5S5U8AU;?TL9KZ?6FJ?9Z+Y2S"QNL'28@*A@>1T2F
M=NL8I1 K.=3$IC&.<A.IV%=8O+KV0"UQ)P)D%['"/!61_FI7F-=Y$?\ %NPV
MH$%P(&I$$@X;P%8"]/D?VI+S1)]#)Y@XR3S0\T=D3%R7@.R8P9#<(AOKU1F3
M.,F>:C!#6@" &@1I3#/ZE<E19)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HBXU4RJD$A\B4<Y !$HB&!# &*)3%'(@("4Q39#C
M@1R6+FAU#AGA7TFF/-?&D(9%XD<N"%%0Q!5VA%,BA0*8@D#!#[ " CM>:8QP
M' G ..QELVR)=:;I!&[+X(!- 8<0TG&)PQ7&MKJ+5I#):XN!HXMD"9$M:2 <
MXJ=5HUJSR&;-G%I2\-*)I;1C4-VKTY>9MYH69M*X7>V)Q2N_3UV+6&EDES#A
M9Y'+P\T81VR21#@7'!OURL+^TEC6,<)/A8QH-03^EKC(B<*3A6G#;='W27L>
M1NX2][Y,D000-W$ $$T!EI*UTAM<-5^3O-L;"UJ.WM;FSD3C;T;Q,N_Y/EV*
MO3$6 T3<"9I&\=,7JN3!)0=^LI2%C9!%\2'NTT5T$CCQ^T-B[3V=9MO%WMG5
MM&6>X'6[FEKVN<X[K;%L3N-$R#7);&?$;&6W\I>;(-\)<+8V='2X'=:\V\R
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MFF%KW7%6-<-Z0L3=LV* 1L$Z7.#Q<71E"M@.*:9T&QG HJ<P5TL@98""*8&
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MB70&[KJ(-Z1@7)<_^D)LV,</KASQW<*J*>AW.(YZ\B2_]D+?<&__ *AG2_\
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MO"#ON\.+3$PZ#X!!)&),U7465WVEL<EUUW[:QF39O!+O$3O%I)$P#NDD F3
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MA))$UK4QW25T89:C>%I,AT!L8"G?T7T5%1+]8 &'_@/9Z-X_%Z:VEX=(:9/
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M #&*4W29.:X=[<&V=H9@_+>:8P&F,C@[K,+H\EJ/".T4T_1-G;5M]B[] C)
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M-1'+/"N7'3BM\]^[U[_5@?SXK0FG _8C[I150;(%'9QG XSPSC=GT9X^BB'
M_?#S6JUZ:UWS;'*5TPTB"WX#R'U!MVXI,L\L^<A<)7T I' JDU9%,#46^'Y-
MHYBF/LCO$,;G2OMZG[<ECB 1(YU!K2G'@?,T6U5%DK*U!4YFVQ5'&$YRUC"
M\!#RFB0]':(<**.P[RKRP&=-5]SKV(P7,C'!G &*+YID QPP*P8P/8/#UUC3
M>P$F,ZYY8X1AC* '=EW&9DYZX>J\^>68_AKLO7DL:<*O$U$)36J7O1VJ5RW.
MQ2:6+I5J2[0*\$Q%1YH\Y*P08(4<*@@<@@<B8ATWQ8/_  L@Q6341/\ LUN
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M .31-!B,EB[ _CUG'UK"^TB/[)=]X()#GLXCW>K_ &5H_P#X+B-;6O58M_\
M,.X,LAZ _=>5.C EN;6W6.ZVPX\I.5^R@&QA$!%=KIMHP=5V(=@H(O'3M,H
M."KF.(X.(UT?QD ;+88 F;QLHCC#+T<AJ>E(@+J_@YV]?_B%[R!O?SV[2 18
MVMWLR <B 6 X5<O6P. 9[@KT8P$+N%-$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$Q5L6D/TD:AN_LB7X?=EZ&/FWAWT'O\
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MB41*(E$2B)1$HBMFTO@1J'^$3 ^C?,O?G_7MH/?'GW'!0:TPXGUT]3G@J[J
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M(@&[B =HCG=6M9UD\^E,^SBNNLZ2;D.JL)4TTRF.=10Y"$*4H9VC',8"E >
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MP;9CRX.3/-MRO^LI2TM2&TL9-Y*!&*DC/)PK51"),[6BFY@(Y$YE4$SN#E5
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MO#=]([=SV_5-(_%CZE:J*>E7;G?!V_C_ !FD!'/9_!4/34KPZ]<D075V]D)
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MEATZ<=>PM5F*N/EYTGASC4 U6RM:UN2B)1$HB41*(E$5F7Z&;> ,9S.VMNR
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M%9R5!U"$^N-CXA_, ]]:;6WL;&MJ\,Y@\- =1U5 )P"X0>-AVOHQ?-#(YR&
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MD@<YKY"IZ'[BVK'ORWK^C59."66$S5^ZBI1D[2YF0C9)@;8=,GR &'F5D3B
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MVVRMH7"[6OC 8T#]3GM-0#F:#R]:A?/?BWX!^)-IW9HN^UK>\EMI)L[5MJ0
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M6G9Z>M%HRZ$BD]U&NJ/U-M&1O!Y9O/K'--&D[(C[M9\_&F3!ZWE4(UL ](5
M"JQZMI%J=(.YV+CM/=<K%TED-3KQN 8QA8CZ?N1NWGXNW@MQVE"O%B"Z09F0
M<HF>(G4>02J2C<Y1* C4KHAJKJO71^XI"-Y08/-(=:KBNDFF%IM--KC6MZ7<
MR3J]$6SB.<3,,NT<D8A+)"K$K/RH!E%HV<^:*B2N1RQQ[G@IF<<CP]@9]^71
M0MF\(&])&2AM&N4!%1+#4_1.9LDZUKW0WA8>!2LM@RU<<N$5%C@TZ5<K1_)2
M9W@BC(&7262*4@#G(4-)R)-:4K3#G@.0*U6LE@,P=[.!F8KEA-,5Z&<G10\Q
M=^M%Y1@K$M"Y;L:=1$62V07=QS$6\R_1.4 (*;IULFYP RN8HG$1V=PF9XXS
MJ/H*T$E86,;Q-<(&D8P?/'C$+;&HN2E$Q5LVD'TD:]W2)<,]OPP]W?J&?310
M9<1AEEPXZ^2JNS?"+ / 7D5Z/WU9C^:BA$S_ ,/^H*Y*+)*(E$2B)1$HB41!
M$ WB. [QHB@3%#(B(  9$1$0#  &1$<\,!O'/ -]21J.J*D%$S 42G(8#@)B
M"!BB!BAQ,40'S@#M$,A513M%V@+M%VA*)@+D-H2@( )@#.1* F* B&X!, ".
M\*(A5"'^L.0WG'+YI@-YR9A(H7<(^<0X"4X<2F 2FP.ZB2->QBJJ(K-OP0"W
MRY$ #KVUN(X#^V6)[: B0<8(-.?X6+XW3) YD#/B0L5OA3D-<(@ ,4Q8:T'B
MP"4P& AW;[HJF1#( ;&X0$0$ XU\^MW!U_:UQ (>3!-<X$&L1PZ+O6,>RXO<
M6O9\P>$N!:'@D$%I(AV%(-17*F?$\ !3 (;(HAYV=VT( .,\,]N..,5[JPC^
M7L]T@CY;8(,_TB(BF$8+I'_[UQRKR_45VJWHE$75%(XG,/FX$1$/K@XB.X=W
M=QQ_L&M?RR227O$DD .@"JN\Z( :8$ D&F7'+ER4[)BB/FY]) 'X^.!QPX!C
MC66X!_4\X8N)P_*P\5)W8X3*J*8 XI'SVCL!O^/.=WIK*3A6!T\N7+JD 8M!
MSH 14$QY8'"O-<N0_BFW>C\V:),8-..04@& XB/;O'(T5!G(CG1315*(E$2B
M)1$HB41*(E$2B)1$HB410(#V8 ?2&=WJR'Y:*?N:8]^E,E\-O 13!P]<L(UB
MS7EG/2991JP;IDD5"B;8.^(7!EE\*"(N R<ZFVJI]=@+Y=]ZRI7C$S&[R@5(
MPX89Q5?:3^L+YAD]V-@VP!B@&X $$Q,0-P!@"B( & W#NJ++ON%71$HB^/+Q
M+28:/8]^V;/63YL+1RS?M^G,'22N2F(Y9J% AB@&[:(H ^=MJ &P0:*9S73'
MUCAPK5=YH@@V3YANB1NDB5))-%),44$B)(IID201  1213(4I2IM\I%P(!YV
MU17OOO\ /9$<=@CZ@S4)C(GD)1 '.[ _&&ZIO?Y7=$7 L0QM@2  ;(B(@)3>
M<'=N#?\ '2A#P&P2TB8 Q.1\L0L3,M@D0X$QG ./V72Z*&1.4JA#YSDH;(<<
M[\!G>./D#MKK[#9MC9V[K=XWGEV\V-TP=\/_ *F BHR/);;5[BP;IDX9S@<0
M(\SJ5VTR'*<H&(02[&=K9$3 .[<)A[<YR%<ESK5UX%D6M^06.=O!KI!#@&AS
MCX 8F@DGZX-$,J73($$]203/+6DKLX#N#Y K=\MO'T]D3(YQV8[NWU\.WYJC
M)FLQ&<QB$4UL1*(E$2B)1$HB41*(E$2B)1$HB^&YA6+B8;3)F#4TDT:KM$),
M4B _;(N"X42;*F3,44U."I5=H.X!#S1*&9IAF,_+[R<!1?9(4"@."E)DPB(%
MX9^MS]:7>( &=P!W"(><)!G.??">PJZ*I1$HB41?/DFJ3UL9HX;I.VK@12<M
MUB"HFL@9-3;3.F!3$.!AV0$JFRF(".39P T9SIWF.?V6NT!+0(FM17"#I]X&
M4KKQD>UCTF[9FS;LVS5+FT46K4&;5 H9*";=J4"D0W#O,D)P.4! 1#-4X?:F
M6D98F*"M)6%F*X4 Q@@33(Q!R)$S%:0OL5BMZ416Q:(_21KQ .DS&[LSUR^[
M>_T<**#(\/;(4Y^2JNP,PJ^X!P[B1WC]M68>G\GQ[J*'/&H IC3>-,/J9PA7
M+19)1$HB41*(E$2B*DX;1#!W@(;]U$6"M>]6%-);,;S4;'$FKFN6Z+9L>R89
M4RQ&S^Z+GEVT2PZ8= R:H,6IG*C]Z5)0BJC)FL"9@$<AHM#NN%)DTRBFNNE8
M)Z)CW&'?GYJV])]5+LNJ\=0-.+\AX6/O.P AWKD]MJ/"P4E&3S<'\8[03D%W
M+]%0"* BX3.X.D*A#;)2B(!7*@!@=@3(B).?D!2IJ?)0<Y]?+]UB"]N5-=$"
M\U-N^"M>!>Z1Z+W3!VS?CURM)%N2;=O7,$>ZY*W2H.4HTC*U;?ENLW"$DT=N
M'2C(R3=1,WG%PGTX]YRLG-H)K.N0&4$<O57Q<NNMZ6WRB])-(CVU$KV;J5;,
MQ*-[O5DSGF73N";0RSM)O#D $6R(*RA045,.5/KRY   +/#E^<SPJM+I#AB*
M"<R8. DYX&DE;A5%M5BZAJD3MPPJ&(4A)FV3F,<0*!2$N.).H<PB. *0@&,<
M=P%(!C"(% 1KAVUL+!LDQ,4F,8\\_JJVR=;'<:)S/(5\N?D<5JI8&KUN73R@
MKQ9)+I)M6<.TA(]<5$^;7=,W)EY 2GSL& YPR @8P#GB/&OB&Q_CO8VW-LNL
M!:M#VVYLI@2"RT<R)+SB6XTBDY@>YVG\.[7N.S[%UK9VALMUKP 'RT/:'- ;
MNP *9CPP>6YH2<;S0;#YB %*4P_LM ,F*7>'[9OW  ?DX8K[FQS6W5K[,#=;
M8!S=W Q9@@4\O*J\.X%KB'RT[QG>I%8.(&%5VNM(SQ%C[6W]Y6\$0)(P!-=5
MBG6<;XBQ]K;^\I(U")UG&^(L?:V_O*2-1U1.LXWQ%C[6W]Y51.LXWQ%C[6W]
MY4D8R(UE$ZSC?$6/M;?WE5$ZSC?$6/M;?WE)&J)UG&^(L?:V_O*(G6<;XBQ]
MK;^\HB=9QOB+'VMO[RI(PD3I*)UG&^(L?:V_O*J)UG&^(L?:V_O*(G6<;XBQ
M]K;^\I(UX^6J)UG&^(L?:V_O*DC4(G6<;XBQ]K;^\JR,)KHB=9QOB+'VMO[R
MDC7L8HG6<;XBQ]K;^\HB=9QOB+'VMO[RB)UG&^(L?:V_O*(G6<;XBQ]K;^\H
MB=9QOB+'VMO[RD@X&43K.-\18^UM_>41.LXWQ%C[6W]Y1$ZSC?$6/M;?WE$3
MK.-\18^UM_>41.LXWQ%C[6W]Y1$ZSC?$6/M;?WE$3K.-\18^UM_>41.LXWQ%
MC[6W]Y1$ZSC?$6/M;?WE)&O'RU1.LXWQ%C[6W]Y1$ZSC?$6/M;?WE$3K.-\1
M8^UM_>4D8371$ZSC?$6/M;?WE$3K.-\18^UM_>41.LXWQ%C[6W]Y1$ZSC?$6
M/M;?WE$3K.-\18^UM_>4D:]X_2J)UG&^(L?:V_O*2->S@B=9QOB+'VMO[RB)
MUG&^(L?:V_O*(G6<;XBQ]K;^\HB=9QOB+'VMO[RB)UG&^(L?:V_O*2-43K.-
M\18^UM_>5)&H1.LXWQ%C[6W]Y51.LXWQ%C[6W]Y1$ZSC?$6/M;?WE) Q*)UG
M&^(L?:V_O*DC4=43K.-\18^UM_>59&J)UG&^(L?:V_O*2,9IJB=9QOB+'VMO
M[RB)UG&^(L?:V_O*(I+)1QA I7[(QAW 4KI 1$>X !01&B+N\>%$2B*V;2^!
M&H;O[(E_7\,/?F'M]-.?'#T6(RQ_2.7[Z>?!1=N^&7#?CI,2.X,X'K9IOW?)
MBB'&>0C45GI0^4*YZ+)*(E$2B)1$HB410(9 0'@("'RT1:V\IK3:X-0+$M\U
MG)-G5W:<W[9NIUKQKMR1JE,O[-D4UEHGI2I3(MG,E'N73)DX6#FDGBS<Z@@0
M##6BT$NIB,LLN-8H?3-095RRSC@K TUM;4N$O35'6NZK#E6\]J!Y*0,+INPG
M[*<ST/!VTR0CS.9*:5N4EL&%14%9(4$)]TN"9]DA55S=')RP0;,"DBID'/ #
MF9QPU%51]\_O'#SCBL/7AH'JQ(QVM&CT%;#1Q9'*!ON.NAY?YIJ)9-[)B7Q8
MB.O:&D89Z_-<KJ;<P<&Y"+<14*YBCKR20]/( "8-:R>9 UK3(R)Z B*5UP*R
M7J=8^HB_*:Y/UY6YI],7!8VG=NW?#3MR,Y^R&:3)2Z7$"0#':S]P14JX)%]4
M<T=)HR5="0QBH(JGV0.)H> I*T$2\:34FH-<)B 9, '2%O,(^;GO /GK%IEH
MGNJS<8'G'="L8:JM)N1LBY8^W&J;V9=Q+AK%HJJ-$2 ^4)@IS'?F*B4/.#>;
M.[& WYKSNV[1[0X,$F,H!!AA-3G!$ 8G,'#L]FBS%K9NM7;K:ETA[A #FR=V
M8$S)=$8DKR]M?DV:[6Y<;">:VNU1=-)%%RL?KZVNCN,GR\ Q EA'>03@(; ;
M^!>P/RAL+^%.U]@;<_GGEV[:7MUN XW4 _,M76O]-\>2/$)&Z3J,E]\^)/XC
M;&VAL]EUN[07_P JRS):+TTB+)K [QW9H EIJ21G.$^M,;$1RT8T,XB(U)<S
M9 5B@T9*@FJ*!!43YT,E4 AQ,&T0QBFQDIA <U^PMD%PV?8LM/Z+*S86SX9;
M8V0-&D@C$5-1G$+\[WMWS;5[@7.#G.()\1(+G$'Q!LR#,1CEB%]<86&\(C!_
M]@T_.D%=A T'1:1.8/.GV)3J6&\)C/8&ONJ0-!T23H?3W3J6&\(C/8&GNJ0-
M!T23H?3W3J6&\)C/8&ONJJ2=#Z>Z=2PWA$9[ T]U4@80(TA).A]/=.I8;PB,
M]@:>ZJI/ ^GNG4L-X3&>P-?=4@:))T/I[IU+#>$QGL#7W5$DZ'T]TZEAO"(S
MV!I[JD#1).A]/=.I8;PB,]@:>ZJ0,8$ZPDG0^GNG4L-X1&>P-/=54DZ'T]TZ
MEAO"8SV!K[JB2=#Z>Z=2PWA$9[ T]U4@:!)X'T]TZEAO"(SV!I[JD#0))T/I
M[IU+#>$1GL#3W56!C%=4DZ'T]TZEAO"(SV!IO_\ VORXJ0- D\#Z>Z=2PWA$
M9[ T]U523H?3W3J6&\(C/8&GNJ)/ ^GNG4L-X3&>P-?=423H?3W3J6&\(C/8
M&GNJ0-$G@?3W3J6&\(C/8&GNJD 8 !)X'T]TZEAO"(SV!I[JJDG0^GNG4L-X
M1&>KH#3W6/GHD\#SI[SZ)U+#>$1GL#3W5$DZ'T]TZEAO"(SV!I[JD#1)X'T]
MTZEAM_THC-W^ -/=?EQ1).A]/=.I8;PB,]@:>ZJ0#B 4DZ'T]TZEAO"(SV!I
M[JJD\#Z>Z=2PWA,9[ U]U1).A]/=1U+#^#QOL#/W=(&G#RT54]2PWA$9[ T]
MU123H?3W3J6&\)C/8&ONJ))T/I[IU+#>$1GL#3W52!H$DZ'T]TZEAO"8SV!K
M[JK T23H?3W086&\(C!_]@T_.D%$G@?3W3J6&\(C/8&GNJ))T/I[IU+#>$QG
ML#7W5$DZ'T]TZEAO"(SV!I[JI T'8CZ4Y))T/I[IU+#>$1GL#3W5(&@KCQ2>
M!]/=.I8;PB,]@:>ZJI)T/I[IU+#>$1GL#3W5$DZ'T]TZEAO"(SV!I[JD#1)X
M'T]TZEAO"(SV!I[JB2=#Z>Z=2PWA$9[ T]U2!HDG0^GNG4L-X1&>P-/=5(&@
MZ)/ ^GNG4L-X3&>P-?=54DZ'T]TZEAO"(SV!I[JB2=#Z>Z=2PWA$9[ T]U2
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M3*NEUC"?:54%038=^RJR+1$HBZRX@4<@*N=VV"0%$=C!L[>0$P%_[1 YTO\
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MXX$=XAVC1%-$2B)1%& SG 9W[\!G?QW^G 9]5$4X#NHB41*(H$ '<( (=P@
M_EHB@2E'>)2B._B #Q# ]G:&X>\-P[J) T4@ !P  XCN  WB.1'XQWCWCOHB
MFB)1%28A#%$IB%,40$!*8H"40'B @(" @/: AOHBG 9S@,]^-^_&=_IP'R!W
M!1%-$2B)1%&R7.ULAM &R!L!D"B(")<\<9 !QPR =U$3  (B   CO$<;Q'&,
MCW[@ /4&*(IHB411@,YP&>_ 9XYX^O?ZZ(HV2YSLER' <!D./;CTC\HT1541
M*(H$ '&0 <#D,AP' AD.X<"(9[A&B(!2E "E  * 8 H    =P &X ]%$@:(
M &<  9XX  SNQOQZ  /4&*(IHB410( 8," "&X<" "&0'(#@>X0 0[A#-$4
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MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%!AP4PB.R
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M^>'H8Q37F?.IKYXK$#]/_#'TSPR4W9OA5P'&.E1(X_RLSW^KXN-$/ZAH:?\
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8 ;(!C %#]UDV[&\?BHH! C\>F7?(?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g454025g01a34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a34.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1F$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &6B^900X0DE-!"4      !                      .$))300Z
M  #_    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$
M5 !! "  +0 @ #$       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 6)%'P
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      T$    &              $Z   "7@    8 9P P #$ 80 S #0
M   !                          $              EX   $Z
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   $Z     %)G
M:'1L;VYG   "7@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !.@    !29VAT;&]N9P   EX    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MT.^;BX.1?U-ES=E-CZA?[MD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,U+A"#1#4V*2\1@E8W(F1$54@C4V1E56<Y.BLK/29(/3=*.DM,+_V@ , P$
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M]WD*+S2>%#N!(\'@*/L-49-9+6+.)O#\)_G6AMK+$/O'@P$@^<W MH]5R'U
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M<S*/=4HA@A3;K*@W9G%ZW'Q7IIW#J*2M@+ZA]U&G(4"%&<=5,AOJ<>CLMH4
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MCO$/$UQ1NL'8:6\8R\S?8=4 H(?QO+8I;)_Q7''J)#2%#GR%+''X\<'3U<F
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M\I*N.0?!*>?(Y/@_XOCGS]1]=9(42X+,)GG\;T) (>^D.9[AX5-W)^A'L#_
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M>!SY]_[?K^.E4S>>^:<CGCGV'/Y ?G]/[=*C@/IJ?K6WPJ 2GWX!_ GS_9K
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MAF%Y>'\>5>CVAA:+#P")AQ=]TQ;3B:OF'NE@D]:!$S3&9"5*2!Z%W6.<E1X
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M8\?Q<:ZW [B]<TJ=O^9EKZ%!M>N C&6E4H=O<G$A_,/1!>8M/2HUK;QY+_\
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M&'B=T$F7<C=)$ZFY-[U^-VMT%S.T<V<P,<H#N$E>- W4I2>SC(22SLUB S$
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MJ>[CGCNX'/'))XY]N23^)UU-RW&M)]U/</-IJ;4JU@?JF_Y,?4;X]]B-W?\
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MLLCJ78DMYJ*TNJ>C12^M(0E$UV-(EKCO)6)+33@*!Z$@;I+%Y$.!Q9R6;O\
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M>H_RV._?GNVZPA7('/,^W//CD<'T_IY/^7C@ZR.AF5NRG',#@+;I.MVK(_I
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M"?YMM;('9>>S&14"^ <*2U\3"1C'A_>M8O).M?Z=Z&[</2/8>2VP6?-G,V
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MT5 \'N(\GGN!\'R0>//(3]>W\_'D>8#FR7!<B/=D,Q#GB[\'NUA44C+A)^T
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M"'+5#E8''>"" D\CQX/N"2?!]SQ_5 YYY(Y?M9/OA]TV0QU >;N SR7%-W+
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MN" 0Q8LX/-[<?"_/!2I0*>4@?O'CD>0?W\_7WU2<W=V!@$@\1S_&;2U<^JP
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MP=@,=@'.\ DYD#>)#D$)#) &\7(J:O@<;FA20=[\7'+C:7!^A\OU$./N%+*
MD9*II3R^#_-J>04\)'?]]*QS_3_#MN*M_$)@1^Z$.[6:=(.O]G#-0?7LN!O;
MQ3N8\.KLL/6FW]2"J& !(8@/@<;FJ;5_AOQ8+2VE2D_HE+]%*SW!*4O+R1)[
M24*2%);[N4DE"1VDW]/DEOLR)@]D%R6(_<LP)GCK-0?T<<R=XC/X!<,0V-N
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M'K"XDR+TNN<L)4Q 9P_%_P"B,R(F*P9CDN5)^22@C?*93)&^Y4PWC: ="&O
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M)6$!"4Y3V2W)RO =HI>XNQ.Y^63MN1U ;V;99%MKM_CVUERRYE6=7UW#V\W
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M*MW),:-%AQ.F&H%"75(#ZZ%^ )8,/%VM6AA9?$[2\,XBE'>*@I:7(+D[J2D
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M@>3ZGM]/7/U/Y>>/W>//TT+<V&K$:'AX_#B*@4SP'U9)N3J-V'XS'*H!;1Y
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MWQR6/CM1/9CWN*XW66=).#^07-@E5?+ES(\QQ"43T-N&0TV0\VZA(4@(6O\
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M?"T]*74J\7'G/0+F)T)=[F2%,M\)M7'0E"''DH<6$J;>6I+"5)<4X.*=C89
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MK#S@9TO8F"S[V" T)&)B1/!XX%I;4BN>%Z4]KI3NKV#TCQU.H[QV?E,(,4P
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MM.N*#>6Y,RSWNJ;4XM26FFT>2?*>!SK[&V\UF%9LJ.-VC"B5+;W4,S%V9P?
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M._:#>_I+W3WSKHFP.VEGFUC"3<OS]ZL9P^9'VVQZ78_-3)#:,LD-1XMK.NW
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MA>0/K4P\Z^\J%7-2[*2S4UR%/N*;KJIN'!2L]XC\I2 '1]1)9G L56MXW[K
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M9]*^SAM_36E/,92$?,U-Q365?:P'GFP&Y/RTQH/I)#P< X.3L#$,WB).O,7
M\'X"LCTJ;-2Y3U@WFWCU))8?PI*H/#@":Q7F/5Y\+K/KRKR3+MK,TN[BFC4C
M$&1-PW)W65+QQYB11R[&(BW;C6<RL>;[(\J>B0\6.$+<4>3J_H^=>)+ M'XW
MNU]&845Z5L@06ZQ)XIRY+$#@2 SNXLUA6O6U74ITB461[B*W3AV&28OFL>^@
MS$XYBFZ,>=DE;=6<6QB1\CQVXOI&)4LK'Y$6-8TUCBL:'-C75=!G,.L)+[2J
M>CX:(+,V\6!:+N]P&#-QM6$^E7*DIWE$AW)&6() ((![;" H$AR23P>MF5];
M7PW9./XIC$_#=S[&EPVP>LZMBRH\WL'94B3.8FR&+V9,OGY=_ +L&N2F':R)
M49;4-AEUE3+:6E0='B>   L7YM:+ACR@M%;'I6R+G>.)<$O@-J00.U;27NYD
M-5Y[L?$4^'WO>O'G=Q\6W&O).,2U2J2?'Q'(:>Q@%82F1&:GU%G#E.PI:4)3
M+BOOK8?2GM4@@G0]'U$>$3W3Q/U>*B?2IL]+SB$64^!S;13!YT8#2:PMD74K
M\*/)LJ=S&UVNW)-V];8W=..PZC/JZ,FRQ)M+6/36X5?DD>(E^L0DHCD-%"4K
M7]SE:BJ_HZIF! (_Q,#J8X3Q@ZUK]:N0N#BD EP<&6%@V]>-=(M%=*QZQ.A*
MLI++;S;[%L@I-L-Q<];W&W=B7F%YGD.07&30+VHR.'98^JUL;.OCS;"RJ^VY
ME3B%AA??#['R5I'H^0XN6_BX:NVHX%WYQ6#Z5,GBL4. &_ZL2I@2X;>8.9!T
M.C5L1NU\2WH,WQV[G[4;G8_N1D."6GV?\_1)P[(*MMY55,C6, "55V4.2E$>
M9#8<2T%ALAM*2W[:>P%;MV:7<7!!WM!(C@S\*(]*FSL+$!?%<C<4CJ(,-=W9
MY+&7!)-S@&RZD?A56U5DE--V_P!VWH.6Y11YED"3'W#4NTR'&4QEX]92G#DA
M5\Q3NPX:H13P&A"A@]Q:YU/82I929U"C=[.1H-3#UU_6ML]3D;[Z?8F1NI(!
M.\]YBX9VEJEE?5-\++-YS]C?;<;ENS964P<UD28=1G=:X_D]?3PJ"'=N?)Y$
MTGYYFLKH:"]V^I(DQVYLE3DH>J:=A$L-X EP>T[\V+<C +364^E;(V[:@..7
M(N1'O,&9@U]8BL97^^?PTJK$<D@[18MN+AV76&*WN+4]M:T.X-O51:V_D?.6
M5=*KSDG<84^47'I#D<"4AQY;S2O5">8.CQ-R2+>\P,]QCOTO-1?I5R1!""I*
MG#;V6)'(2KDX-W#:BLK])WQ#>F/I^Q>SK+=S+F95PF"F118CC.XMSB<,PF%,
M&9 =SNYL;IJ3-"@[,;#J(Z5\!EOM2DZT.CY W0Q)=R5$.UM/E,O# 5@>E3)*
M).(I8"5=G=R[%,.;J.M@^EW,=]CK)^&-&8SV+'V[W$C1MR(ME6Y.U$QC*HS0
MK+EU$FW@T+3-NAO&(EK);2NRC8^*YFP\&8E]021CV 1J)8.2Y=Y#"68A^Z:Z
M_K5R#SUA O\ 8,X>"98$$,"(:;L_-MCUH?#2V>RA&9;?X7NU17S>)8O@PE_9
M><34'%L/:BL8[2F--O7V%0ZN/"BM,)4@K2VA2"KM<6#H='U:*!X268%XB3KS
M(:*'TJ;.((*5MK]C91) 8$P^A=[F;U-N[UH_#.WUOK+)-RMO]Q+F]MX-)!L;
M)C%LIJ7I;..6!M*3U_LFVA>J:^<3)CJ<6KL=2D^>T<171Y3N5.Y=@98@MI?R
M>8O61Z5-GA 2!B )!2%*P23=[%5G)#1P,"K/A]27PI:EA]%7MGN?!D/Y8YG"
M[!JOW"5:C)I+:&9MDBX7DB[5'V@TVVFP81+$:=Z+)DM.!I(#]'RUS#75I/Y7
MK*_2ILY:"&Q)8!L"Y<?XGMX>[J'K8K-OB>]"NX6(1\(RZBW*M,:C(;:;@_H?
MD45T,M->D&U38MFS.4EQL]D@F03)0I:'N]*E<!L D;N\!,'>#WGX1Y$<*N'Z
M4MG89WAUKDR^!P>YWH \KCE6NSW4K\*%>0R,N1M=N5$R64Y3/+N:^HSN#,0_
MCU6[353K+T3(V2PXQ7NF,X8Q;3(;;CF0AU<=E::>CR@390:V\\&)( +M;2.)
MKNKTM9):&!7?3 ((*4\U6D%XF QFK48WD^$2TIM;>U^[K3S<O.[!IUM>Z2'&
M9VYRX:L_DM.C+0KU<H77L/V15W)>?]5Q0/>=#T>(#N)O))L&NUF/ EP-*Y?K
M6R!+G?)+1U)(AP6[7W@? N6(@9=V]Z^>BO;W,L.NJ9.XL;$MJ,+<PC:3#V\#
MNIK6-5\TMKLYDRPL9<B=*E=K0@0 E_TF*]2D+27 @@.CY YS)5$:LS.1#<3W
M&N9]*>27OA144FP3ERX<-*MZ=;"!<Q6T@^,[TJIX(:W)X)\?X/['E//''O(]
MN1YYY^G&K[ 6')4D>(T\;D6&C></I-V8?NXLV/56#1K+GQFI_P"6?Z5?8M[D
M>#]< L!Y_'GY@'S_ &?AJ>P<2^\-W4N'^9M\)I^LW9=MW%Y?9WXM/G\*E/QH
M.E4>?3W)/CC_ +P)_P#;_P (Y^GD_GJ#8.*;*2Q.I/#O9HL_SI^L[96J<6..
M$0>#W^51_EG^E4_^#W)' "O^\">/ _ ?,>>>#]#S^8XUH[!6P[:9L0=-2W(?
M'NJ?K.V5_#C&W]D>#M?7YEA:!^-!TJ#_ ,'N1[=W_>!8>Q\CVD#D 'R/[CSJ
M'8.) WP>(<@F0(YG1FJ_K.V5_#BD7?JB1W0?H5 _&@Z5![M[DD#CGC )X]_S
M^8^G'GC\?KSSJ^P%QVP_>1YB+V'.U/UG;*ONXI'_ +H]^AT'\YJ'\M%TJ \>
MGN23_P"C^P/_ -L_V?VC\=3V#B 2I+D..U'B>)T'*\T_6;LMB=S&+?\ "+SR
M<<>]JF3\9[I7*B>-R A7'@[>V)X(YY'(D$>_'CZ'D>_M?8"RD%P>Y6H/"3R<
M<.^NN'Z1=GXA!2,0)/'"B'?[W(_Z-5B[H_%WZ8,QV\S?&JY.XIF7F(9%3P?5
MP*>TTJ=:T]A$8;<<$A98 5]]2W$A*4*20>""?9D^C^*<9+E(25,2563+EIN'
M$0&+F[>/:WI V>K*8R4C$*U8:AA@8<*40 Q)):X))AG8Q6_/0+P.CSIQ0GDA
MK:3#F4E7@J#-2VR5  DI"^PK /)3R$D\@Z^1MS!&6VGF\!)WDH.#W,K PE@C
M4^\7):XK]1T*S:L]T=V=FB@(.*,T=R(W<YFL,.T%P@/6X^OCU^OII2FE*:4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*PGOW<TE/M7F4J_Q*/G-<:]40X=):C/I
MR27.?:APZI+,A7H_TN0\A*WG 0PT%.E"@% >;%.\Z6^\ 7+ZJF"X<D7T+:QM
M)*75P!-OA(;N[O&O/_I/I-XMOMT/L;,MI)73[AN4H<<H\2H\QKLYQ:2U71WA
M65I#M="DXK(AQWTAVLA29%8I2"VTWPE+FNN GJY("A+7$:-Y#@>#.]<<8[S
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M"-(00%,N^E&4&G?/^]J 6./(!'&GKV9?]YYCCS_G^%7V-LLC^J8##3J\/_\
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MK4%*)PP5 ;L#"P@(EF  YAC4Z)G ]B9,Y9!P\$^L[B"=XI_:LP%$E@YWMXF
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MN34MQZ=FO;] %.%9=1 40H;VFZH$CP%K$0"0' H,3*:8LV8+23XD*TYMX7K
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M0[45V.XRBTP:!N$C'7K3<:?99)67,VHD*A5;M$Q<(92\6@KU]8>66#+B7D*
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M?:>7XD')UDAB(=TCQ/#73A'?P#N5L1@!//W=J,8">!SSVXK!X[@HGGGTD D
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ML [S@M#AO^8%N V3Z6%$OC]'X8DE&V"D1O.4G W06!(44E79ATL:[JME?C%
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M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2L!]1V*4&<;2Y7B>28''W&J;QJ/
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MGR<>BN4=4($J'+=HDU3>1;BOOS81BPYU:TAII:'0]1EDWZQ1T#K)<38->+O
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M2VD)4J>K!3$XJQ-]]]6GLZV:3&@-;&:Q,H3A8^%AXZB K?W'[!<  J5O=EC
M! (</%;4];LG,-O^JW:O=; ,MK=O[MW8[<V# O<EJ+S*:/(,C:ET4ZBPX4HR
M*JIX-CDB([\5B>V@S&EJ';'DGDFG*@EQBJ!=X4;CD4EASXZ.*S[1"4%"LLE8
M$.4("MV"!O)4E1 X$N;%A6&X_7;U3UV<4U!F^38)B<BRW<V/I)F*.;87<F[B
MXANOALB5:LI=&4//MS\7R-+ >NG*Q=>F \AM^ VX?6 Y=IZY<'^/5K>Z-"#.
MK\!42G,YA\7"",+",!"@L$;A2E09)([1"E7)<N02:V6Z?MY]Z:'X>^[&\&6;
MD8UEN[.'RM_;F-:93C4BEI,8FT.999+IZ*XAP;&QE64.$CY9M,MJ7#*JYR%%
M]&.^PZXY.H2#NIQ,22)WX%R8W2SS#/:J<#/N0K$PRI5B-\^[I)))"0  1#0[
M,-:MN_B(;Y76/)@9)N7M.]:91B6P>4.9S385;*Q[:=O<FJ=3F"[BK&3/.9##
MH+A$-#858T<IANP2)B$-!,E=.7+?O3_F<AV$$H8&!X6N#63FA@*&%C9=&)B8
M<+5NJ*5DC>#]O>+ @3_"7>!67]K=\^I+,NI;82LS/<JD3@<BNW.K[(8WA<V-
M1;LO4DKY2IO*Z0]D<A%*J0PY\PU'*[9"1$=2AYWN#BM'+"%=:219E7UL 1K#
ML/$51M) "DC*(&\2[X8=-H!*E$#67+%CHV*/B;[O9!<WMYMC9WU;C%!MEN'T
M[9/2X<[0Y*_E6ZCEEFU7+E7=/=TUS5I@5F/_ "\N'*8^1O&)"FN+!F&#&4O)
MRP4Q.*J8 "VG66@/:^L$O7H2C.J0G%P<1&&A8+ =<G=223ND)+7^Z#-X-4.5
MUB]:VYL;J7C4"]O]N<3Q'&=R*C%HJX-=(W,Q=.,&/%H\H3CJLJ<M[%O)6UKD
MMB=55C<=L*#;CCJ0H#EG/[Y=C 4VHX@&0&/>PEZ\R\': DXF&YW223BR0[%P
M?NSNZRSU,GKTZC<(R"!CU%E6);O4F,[(2I%Q%C[?6]/.5EU=M0]G4?))M@[D
M<E4J(IRMFKFUU=72U2*Z+/FM3&YGHU2J<L$QUI,,Q5Q]VZ;N3)8[LGD]=" ,
M->62I>&67B!*B<12&"CO'$=B0=ZW!@2#5(ZB]RLNF99T0YM,ZE-H<QS&/O-N
M8YA&Z5+C5W4XG QNSV-F*57Y#B"<I=KI%U59,J"$M3+-;37SU:EXUS\E7IY]
M6WF?$4X)8[PC2&2Q$#G=P9K7M%"0H>K89!8$;FC27W]_><FY-G!&M[P.OCJS
MSC*=AJ[;N#M,]67FW]/E&:3;AUFC@[BVKMF[5W\'%C;74.;7NPVV/GXT:O8R
M:26Y#;;J."%ZUZN( QB-"-X!W>\7BQ8\6U\(SRF4/5;E_<AC/]X+NY:YC6J9
MMQO3D>[_ %];"YEF=]4.VZ*W=_$E;>5%%E46=M]%KYC,>O&03!<N5,Y^S89+
MD>384E9PGS'6X>!J'*B_6</O2P!+$ "6T>Y=^.TYU2BE RY220D*ZL@I.\ %
M;Q4[/J+6 N*RIOYOCN#MX[UY;\55AB#>X/3E.P#"]FZ[-H\YJ@H\2N:'$[2Y
MFEB%(0NUL\QL[JP2VZE*"MMNMA]R4Q$>GGJ$F=];F0=^6'&+^8@V(>OH>K9\
MB5IW5DF3BD!Y[0?[PDF [R9;&6#?$&WM&XL*IR?=O9+(L5@]0>W>UK\6LPVP
MJ[+(\>W&PZNR61):EN9-/8IGL;DR9461-2S:1[$,H:<CU16IQ&QEP;8I+ _?
M.O%P07-P7<3>V3D]HI#[^'O !3GK3 (((L=Y+#GH-TUW<TZ^^IFAP'--RJ&X
MVHGRW-OMS\CE[:9)BN0U]OL9D>#W5;"QNHS2= GSG;A[*8BYD1AC[/IW&KR7
M71V3.;2XIR# O]JL.1]\$<#$%V:SMPKF,OGKE>$[/;$#@EB 0\,)%SI$"Y;W
MJ[ZRH.]^T&V>./[27%!?[<X!N58Y)=1F,/JL^C9I8+18XSB)N,E:LF9E!!]%
M27X<*\MI[SJ#+H:9"@H!@)!#XRSRWB# +N0"'UYP]G$5@9YE'K,)1N[8SB&W
M23Y@N6!'"LH=>.6[C0=VMNL7D[AQ,0VARG9W=5S+:0TMI)8R&VBTDAV(Q(R"
MJOJN34-A:VVV)R([KG<GN2DI4I.G4!0)&*M@X+K:^H[.@N;MP>NV6P\\H$X>
M)AI90!;K Q',00) DZN*TMV.ZS=R]K=GT[;5&[NULMQC MO']NGH^(WUU.Q.
M3D=S+K9E?9MC(P<G[66@LS["SJD,*5WN)60 ,KRX&&H=<H"P[?$ZOJ-1.EZY
M9@9S!Q!BXO5XF'A]I:2,4J4W9 !*@"Q()!-HM7"/B8]54W L(G6.:[(81>KZ
M9]W=R\E3=8U:3[65N+MGN)68[!QE5,QDS$*MCY;327DPXD2YNI[<AIV42E@%
M"?1E\J2@CK?= 91(XW/9)T9Y-Y85E.?PB2HY9()#MN0"20 &Q(%C9@=((&6>
MN[-46F\70=NGC.<XUAV37^#R<DE9!=?;%GCL:FG9%M?=P9BZ-JXJH3D-$Y;[
MRGEM,S$LP)45,Q"'W#KS'+)ZY1ZPCLVWR)WV*F9H9M-6 8BO1U^-C(&%EAU2
MD+.(%[I2=S="2@J02HRI^UO, V] :WLU^(]OW&P'I[R/$LLVWMKRQ^RK'=>O
MKL%GR(F35)SV/B5F_4V;^216\;^3B27)'HM(OI#3I8>+R6T.=^_5TN_7*,O"
MC8"\AB7<#PKEU&T/=ZS#:=T-B_>(>;,H .P9YF*PKDTC&\@LMU]O*S=K!<<Q
M/)/B7Q6,CQS*:F5G]3E]!;XU7+D19[%SDT%:J43VYCBV'8TF!ZC:0VEE2$JU
MO#RZ=[]XJ03N[Q,-%@'(Y1J#J"\+:.Z#UR78 '[: 8(A1=H#.!%C7J-U ;D9
M1TW5.W^TNT%M@^T>._H3?9!39?D&*6N38J[88ZI$F#A5?7-7<9R&]EB5/1X!
M;M)3T)"VT1(3X0$:\V)@C>24XB@"6+DDR9(@D%HAN)O3#P\\O^TPU'W5/UA+
M0SAV@7#:16MU$U(ZDNN7:]O>3+<"FQZ_IZPO<&#LY-Q-UZ=CN8P\FMIK5IC>
M3,Y8S84UTZ$0[1Q_[+>G1H;S<-L%A1D.^@Y=/4@]:LAQ 7).Z>0^K FNF)A;
M0P\,-BH2GK$[P Q@\$.74 \ $L2*P%U<9EN1(R_JEJL^W@KHR=N^M[HS8Z?Z
M2QI+NLK<1JIV,;<R[F[8G0,@81D-,VC)<W@SH4V&$27:B_E275NHC&-S.72I
MOM%;MP-^ PLS: E[ @2685UPL+:0PW&)AI*DF0K&#;X"B\MVX41(@N8%78]\
M0WJXNK#$<(P.SV;N[*#FVX-)D.YMA'A8U@^9(Q;((<*JJX'V]E\=5;)MJ::]
M81WXDBUD/JK2AJO]):W&^R,!+$G%5"2?>)).\G_"3JP8->6BO$<MGU+*=_"
M23&[B<X)(%SP ?G6]_6;U);L;,0^FTT.4;;;=UF[>7)Q+/<URZMF7\'%C(QE
MZW:L:]EBPI(4V&F8UZ:G5V"/584"T0?O:\B\!UL,4@3)69#W]T2?B1K75.!G
M%NE"L(E+;P=9D@.0(8@B7 +:--:+9?\ $4ZGZ%.Q#S,G XUA8N4\?/Z*1A5J
MAG)Z2YSQ[$8>;4M@[D,+[*K9D ,7%=51V\BD>73(D-LJ:=7ZE9<;B/M" [/O
M7;_PO\[CA/I(QLH@JS",/&&(62P62&$J=:TD%B)&D\*NK;;J;ZC:NGL<7R3?
MG#Z&]R[J#W1QR-N/GVW<MVGPJKQFQ#&,8F_7L93$8+>3I;Y@SWYJ7HL91<8B
M2G'>&<#+@.^(H/(!4\V;W8):/&:^>K:2%8@_9DLP!^S "0'+DA0)9V))&CB'
MJC[6[OW&W?7/NE"Q[=#;IRLW-WKZ>\4W%QGY7(;AW+[K,MIK2'=RL-LK:_6Y
MC<.!F,&/-8C-QI+2F[!48MM^D'EP99()5UI8@.-Y_NNUA!#LQ)B[UZ<7'S&:
M&",!*,'JGW]Y)25[VYNR@F0 MB1 5V1-5CJZW5K=CNKOJ5S+&)NWCF6O=*6U
M9NJ?/7;JWJK IW9LVI#3%,[),(6GZ/.,/1T0D1T1TH:?>]5*NQ+J$F>L6-YW
M[0@.SF''")M+4P4;0(!1BI2EV2D'&#-IV=' -H)CEK5U1_I+G._FZF?X_OU@
M#E[MK/V&LL"CQ=L5RL@V^I,DN&DW*\9RFMSJ#.A5T:LEEJT3'CH:L4+0E<:.
MA"PY?5@_[U<,W:,>#1HU^(8O716!M%3?:)X$$XYERY,:B9OPM6RN5=<6ZF,Y
ME*PW&=P^G&EL++>W%-O[K,IF-V+EF_B,[#5SU93-K6;IM,RPBSF@E]J;8-M1
M4/-M>JYZA6W?5@+8RAJ>V 6XV+L]N((!XY]4V@\K06#@DXO9.C0SD$NTC7A5
MDVGQ#.IC)\(V"BX/N%M-5Y=G%':HO\C3A#UU22\DI<V?H'C;UMME]"YBU"_4
MQG9")D.;D#OV@4Q@RVRGUE:RV %9@HZU1!"7[7(N_9O8]S6TYXXP\#+MCI2O
M')4Y#LQ*2E@KM""7)!<O,5[2;K+E/=/6:R;&5#L;-S:[)G9EE :$*'.DG%9@
M=E1V&GWU1FI*N7DL(F20R5!"9#P0E:NV#DTKSB'6H.K=?>8=I)1_"[ EY#25
M-I7PMJXJ/9N.M* W58BF82&#@B 7 9C\=+(Z">3T>=-RT]W)V=P7DN+6Y]T4
M<;@=[BU.*^[Y!4M7"C[]O 'MVU@C VCF,*24G"DWG PB7XR3W?/Y?0Y>_L#(
M*$?UH0(9.;S(#"U@& AF,.PW$U\JOUM-*4TI32E-*4TI32E-*4TI32E-*4TI
M32E-*4TI5.L!VQY+HX04QG.7>T+([$*7Z?ID<K2L?UT CN XY!\C*_=/C+.T
M&6^O-JJ?>',@?&/F:\F^D9C>.9U$[C9!;QMRI&V3\O)H-<M^FAX3MO42XEW-
M80BOH+"0]<7LZ2EL W3#3<:1R9#:U(<2HZR[!)@&(#W,$EQP ,@?C6<RSL;3
M+ ->&/$]Y$<F]8)U/5W%>_76T")95\UCT9<"QC1Y\-]E8_G&7XTIIYAYM8)0
MM#B%H4DD$<:I@GO/UQ\R:)+ -P%4*#MW@58S51JS#,6KH]#)=F4;$#'ZB&S3
M2GTE#\BI;CPVTUS\A)[7W889<>'AQ2AR-4*(MP:99^7&BAO^\Y\3;AW0*QIU
M3CCICZC.TE!&QF[7:4A)X(P&^7SVJ2I)Y(\]R5<^Q]_.?KZ^M: ,3#"P/(R8
M?0DMY6JI8#PG8G;T)'A>U&+%7X@G%JTGSX\<NK''MP1Q[#6\-W'(B' ?1Y\C
MK-WOY,V?LL30*1B/#@ 'RLHWB):M6/A?(1^Q'LDZHJ24X[<'N'WB/]MN5 D>
M//''*0?W#C@Z^GM](]< WE,%7WBY&YAW_"[<:_*= 3O='\JHCM%"S$_V^8 ;
MB[/9_"!5, 7,O>I7-[ZDE*M,3DT"ZJQ2VBS@?8E]5R$MNL6<26DQI4BP_P!]
M8?BA*4I!YY!YUO>0G+(DDPSD%@Y%G'.2782!:O2C"S.+M+%<$X:0MF!2 Z1!
MDN7!-A=M#5J]+*4Q^H[K,4D!:3NG2,AUQL<%8PVF"D( !*P@K4/4*4<_NYUR
MS8;#205 +""7469U<R0\1HX[Z^5T3ZS$Z1])$J W<',X@PU) 2KL8*5R21O,
MIY@D0&(%;AY[NIM[M-32<HW,RJHPZA;?;:D7-HZN-';4L>JTTVE#2WGE*:;>
M6X&PM;+:%.J2&T*)^:I(XDC<LY80'M(N[G@S@5^_RR%+&-C,"0I23%ANN29=
MYA[D>)M7;_=?IWS>WR3%]M<MP"XNT54?*<JAXPJ DO,6):;A6\QY,9B+8+<<
M],*<<=>=9>6T'TI*R#AK!U,'9S^;\-(\*VZ]5KXOOJ<&0"'/"\,>%ZO&JN=I
M\SS*YC4\K$\DS/;EV/$LQ$173\AQ%V^BF8EA<@LJE5AMF/YY;;4A*9@0CO2L
MCS6?[Q'B8:Q!$O\ D*RKM0LK4F"$*42'2Y!9R"T$,2Q:KZE4%'/FM3YU/ DS
MPP[&1-D5T1Z4U%D(4EV+\PXPIYMIY"BVZQWEEU/W5I(/F $/VE.=7FNB5%(8
M!(=P8$@G7PJS+J?M?LOBSMM:.XOMUA]<\/6DHCUF.4[,J>^AE*5,Q&8L9MZ0
M\XA)4V@..J/DJ/.L@3[RKVWKL/P<\[:7Y[@)WD@!4ONAHARS]SR".-A5P3+^
ME@1Z&1+LVD(R*PB5U*XVJ1(9G3ID65.BQX[R$+[3)A1)#B'7O3;"4'N<25)"
MKU:2;KXDA9)9K7D<=6UAZRRXW29N'4S N02238:M9QRC&QC%W[U&4HH:=S)'
M(ZXR<D=JX/VV(:D(<3':M?E_GBPG_>P@O(946%@IY">'5INZG @A1C2(80[1
MK,UH%8(!)4'+A9)"6#@ $D."P@ L%,U=HT&/LVCUZBHJV[AY@0W[AFNA-VDE
MI@AQ#;D_TDRBTPIOU?26\I!6VVOR&DZH2UBK0WLWRT^B:3;<20'D)%U%,WTF
M>)T:J!;JP"SE(PO(8M)8?-19%XS26L!F=#<33R6Q,L7$3HKT0N0Y+\59D/K+
MOK%MUHJ["X*0X#DP3KIIS;X!@VK[.\F7W2?O))026>2A@)D"VLE@*#&O-I=P
MKJSP3Y_$\NN\1;K;>SQAQJLMI=$E\!=/-?K7F7TPENH[783Q;2I3?8ZRH)X
MF[;M$\W,?RUL[N[Z\0M;_O,5P(.^=/&9N"_%[@71(P3!7YRKB1AV,NW#D-<%
MVU?H*ERU<@N-EIV&):X9E.L.-(0VJ,72TX@=A3V@#5(XDO9W+\+B]=DK6WOX
M@AO?6#IKO3K,:1K5$G;9[61X+$)[!,"8K&YT:=$8D8MCZ(3%F\MN.R\RRNN,
M9$^5PW$BR4),M:U*8:*G"RVY &L3J&?N\((ULYJDJ4)Q,0: A:WXM)T^H)JQ
M,ZMNFK9Q.((SF-MKA2GW30X<F=1TL9^,;B0B,_ I6XD NP8\AV6I$TQO0C.%
MQ2Y2NU[E65'M .=(<V=N^PBPCF:J4K8LO$9S_:+F&B1H$BT6>*JF7JV P3':
M2GS&)MIC>+WU\Q#QNGM*RBA5%CDMB2(;=;6.01"?LI:0E8?$53P5]XN<@*UO
M=?4_D\%N)X"3=JYJ4L#]YB @ECO*W@;,_,<7:2'N)J'*MA\SEU&0X[(P7)I@
MNIV'T]_!K*^UD1+>G2/FZ.!;(A.KA.PEIX]$2&6TGA)[5$#4*6U5+&YY_'OU
MY7)5O!SVF) *^V9T<NK=>0"3<EQ%96ML?Q[)68B+N@J+Y,.4S,B(NZJ'8MQ9
M;![D26DS(\@1I3*P%MNLA#K2TI*5H(&C%B-Y3'@>7*SZF]&29W4N"\I!:0]G
MTL)KC5B6,.VR;E_'*5VZ;#+2;=57 <M6T,J'H)$XLF4E+20"EP/ H'"0D#@!
MNAF))AO>+MWN#R[HM0J6Y;>2DEV22D7?W0P&]J6>9)D52+VOP+'<7R"1=0J"
MLQ-EJ;:Y*W/AP8M"['>0Z]<V5Q&$=,.4W(:4Y]HR9C3K4AQLJE'A*G-"+2J(
MOSUX_P"MG-:"5J*3OXA5V0^\IQNOK#Q<6(N+UJ6QU ] %!65\D9?L-2UF8S#
MC;3HJ*6!#N)S<N+#=J)D44[;:0)?R3"/MAB,EQ)82@AOTQINZNH:ACJ]^+W,
MO^-1;I44* .Z64I0WE$[I+DW,<R U;G5^,XG\K2/UE'0HBUK*'*%R%65@:JV
M9#?=ZE.MB/Z<-N0VODJA^FVXA7(\*T;_ !*.@.\;<N7?4#%B$)#^\-T<B'9M
M6;4N[TM,%P^\LXEU<XW1VMQ7MJ9K[2RJ:Z?80&5N)>6U"ES(S[\5M;R$.K2P
MM 6XA"U<E".($L7WE?YN9/XUH*41V<18!T2I0'!@EV'E\*@K!,/58V%R,<I4
MW%M"%=:6Z:JO%I8P "!"GSS&,J;$"3VIC2G7F$I\);2.>:0^I'<3]?45"%&.
MLQ!=F6J'N!-CSJ2/M]@T1YB5%Q#&8\J-%$&/+9H:IN4S"$9Z&8;4A$0.HBJB
MR)#"V$J#2FGWFU)*'%I4(?57^8\"/Q[H$589BE)$^\ 7<N229))UOYFJ2K9_
M:=<6)!7MI@*X,!V6_!@KP_'E083\\CY]^'#-<8L1^<$H3->CM-.S$MM"2MWT
MF^PQCM*AM3+<?K4U $C[J=?NC75V?@>\54(^VNWL7[*^6PC$F#1+=<I2SCE.
MT:AQ[CU7*WTX2!"<<[4][D<-N+X'<LZ -8GS/DUOI[S5(!=TID@^Z+C41'-F
MKO1L)P^%:R[V%B^/PKN>I*Y]Q#IZZ+:3E)!2#-L&(S<N6>"?^$/.?B."!P(<
M,Y;D3Y\SWT#"=U+\=U+\8+0Q#AF8VK'-GL/M_<9[,W FTT>1,O*>/0Y53SHD
M.PH\JCUTE4FGE7=9-COQYDVJ<4KY"6XGU([78A/(;:].;O\ B5W;Q9OK6_.A
M4L67B /8+4VLL"6B(;015R-;-[3,*:7'VUP)AQF6)[+K.'8VTZS8):# GM.(
MJTJ;FB/S'$I!2\&"IL+"21JMS/F9\W^#7/$UHKQ""#B8DAB=]3\Y?77\YJI/
M;:8!(5<JD8=C+_Z1EM60!VBJE_;I:\H-T3#[K?M4$N#[25* <0AQ/"TI4)NB
M)+"P<L(;QYDS6.T;KQ"S$.M4-P((,ZN3X5RJV\PA8IPYBM XG'NS[ ;<IZUQ
MNC[&PVD4S:XI15)2E*>$UXC)"D)4 ".3JUB=#<Z!A\_.C$OV\2;DK4=Z")<_
M3!FKO6F'XQ>=GVW1U-P6FW66E6M; L5-M/@AYM!F1GBA#J"6W$)X2M'W5 C4
M(YJ#\">+UI)6D,G$Q  [,M5SK>]6Q'V9VEB%PQ-M,#C)=1';>;CXACK#3S<5
M?J1FG6FJU"'&X[O\\RA8*6WN'4 + 4(4@@@NQY_7UX5E3J+J4I3W"E$I/!TD
MD1<1>:YI&T&U$Q:%S-M,!EJ;:>9096'8Y(*6I#R9#S8+M:LA#DA(?6@'M4]R
MX4E?D:22@,E2@'>YCD.6K4W4_P *=/NC2VGT:[EIMAMU=H@-W.#8C;(JH::^
MJ398U2SDUD! 0$08 E071#AI]-!3%8#; *4D-_='&=T;Q4ZG(W?>-OKBX\S6
MMXLP.[>4=@SQW6!%H(:!PKJ,[1;81V(L1C ,.9BP&I#,&,UC-&VQ!:EOF3+1
M":1 2F(F3((??3'#:7'4I6I)*1JM:51S/T_Y1%9.\7^TQ&(9NL4WS?X\K17'
M)V=VKF2%RY>W>$RI3D]-HY)DXK02'UV:$J2BP4Z]7.+^=0E2DHE A]*5%(7Q
MXU1V2X?S)^#M104K^TQ1Q Q%S\3\&JYK+$<;N6(T6XIJZUBPGVI4*-80XTMB
M%)8 #$F&T\TM$:0SP"R\P$.LD M*00-8*$J+EW[R/)C#VCP:@<$D+6Y@GK%N
M?'>KJ?H#A7VV,E_17'ADB6TLHR(4M8+YMA# C(CHN1%^T4L(C@,H;$GA#02V
MGA"4@;#@,Y:8<ZO^9YS0[Q!!Q,0@EVWU,[-9^9Y\ZX;7;G KUUY^]PW%[M^2
M[ ?D/W%!4VCS[]7\P*UYYR=#?6Z_ 1*E-Q'UE3T=N0\AI:0XKG.[:5 "&!T=
MV[OJ\UM*\1(W1B8@ 9NVK1FUY-Q:-!5.:VBVOCQF(<?;["V(D64F=$B-8M1-
MQHL]  3.8817I0W+''F0D!T\GE?DZV"0[$L0S/'ASU[ZYD*=^LQ!;^T4 &[B
M.\N3,ES6&=^^E;%=_P#(-I;K)L@M*Z'M+E?Z60:!J!43J?(IH@NUX@WT*SBO
MLRZU49Y:#'[0 #]PH5][7$X0)?>6_P#S?R^%H%:!6  ,7% &@6H3+DRSE[MQ
MXFL[N[>8/*57.3,1QF4Y4QF8M8Y(HJMY=;'CE*F8]:7(JS7QVU(0IIF&64-E
M*>T#M3QUG=W74W>?QXZUHXBB2%*4IQ99*@.;$D/QKGL<"PBWB/0+7$<9LX,B
MP3;2(=A0U4R,]:MDEJR=8DQ'&UV#1)]*:I)E-D\I>!\ZSN_XE>=8W4P=Q(9O
MNC3PJE+VFVQ7:,WHV_PQ%Y'F1K%BZ;Q>C3;-6$)"FX4]%C\@98FPTJXBRO5]
M=@!(0X .-5K28L7//\ZI<LRE)8DC<.[)3NW#&T@6!>)+]BVVQV\OY\FTOL(Q
M2\LID=$.7/N,=I[*;(B-_P!2(_+F0GI#L5 "0B.MQ3*.U)2@$$DW,\;G\/E:
MB2I/NKQ!>-]3!W<@ PX+%N K@8VGVSBR),N+@6'Q94QA$:7)BXU21WI,='IE
M+,AQF A3[:?1:[4O%80&TA': !J;K?>5YV[JT5XA!'68C'AB+%O'YN9-<<K:
M#:F<^J5-VVP.9*<6''9,K$<????<2T64N/O.URG'EH:);0IU2BE![4D)\:K/
M<J\S\6N^KO3?7';7%NVK@W&8XUK3N7T3[=YON#19K76"\0KZRE3CMCA5)BN*
M/XO;5'S;\UQA,>96+-,_(?DN*D3*DQ9#OW2M:E)!.4IZO$.*@JWBVK@,#HXO
M+N9)$URQ4]:EE%1,@DDE3%H<G0@7,#XYBWIJ85'L#N%4US 8@UFV>6PXC ((
M98CXW.::;3VCCA*$!*0GA*1X  X ^ADB59E!423O OXL.6KW!>1R^5M9*</9
MV,$@,G"6 \O'&\> TK&701S^QUTV]PX_P/X0D#GZ"CC <^?')^\?WD\^PUZ-
MKK5B9[,K7)4K#+OH,+" N2>5W%C%?)Z&'>Z/;/40 5#-N &_ZWF; "!PB!QK
M<;7RJ_74TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E4RS>4U&?<;<:9<9
M8D+;7)*4L-N)944NO%2D\,H\]ZBI*..>2.-8Q"R8N\>1_P!)K2 ZI@:\6!Y.
M^D7\:\]-I-QNHVPW>#6<WN)';B58751C]54?HFXNZBQIUDMR],VKDKDQ0PEJ
M/!B0VT*=?4F2]8*"T=QZ94;R2XAHY,= .<MH0UZY9I@0QX.-2"-;:'\K1Z.(
M/*$G@CE*3P?!'('@CZ$?70W+\:TFP[A\N=3:E6L"]4WCICZC1[ ;%;M@$G_\
MG]_Y_>/?V^GMI43<\7$VT&O>_%O*JA@7 V)V\2?)_5-BWD?B,6J0?X?F/<\?
MB-;PY4D@ZI\B;_A;5C7ES?[I;_W>+SCLWLXU:_C6K7PNP3T2;( ^/]@;3P/J
M#E^4\_7V\?0?7G\]?6Z1LG/'D?FC"GY/,?+\AZ.S_P!&\H2+H6/_ /(S+'CX
MDE^-;])B0VE22PRPRXMSU'BVVEHNK /\XZIM*2XL#QWK*CV\C7QU*+(!)(,#
M6ZK"6X0-:_:HW4JQ"D)"I)8 /!N2.8DORM7A]D>5YKB6==8-OBAS2)33NH_;
MZ'N#=8)!ES,TQ[;^5BD6->W&-PZQB7:&="E)K4N&MBR)PB+>D1F'70!KZ>;C
M PP6< <Q]X#Z#S< 37XWH8O#/2CI4%)24!>9+D.R_5L/=W00'U9@8FL+[LP+
MS-3T:,;L;B=1]QC\#?\ W'76W<3&LX7>9'LHBDRF'C>;[HP*G%9B(MRZIVDI
MRS?0(]U(JYB'W:U+JI+B?G"!)T(YN' <-$'NBOW>S<0'+YXEMXXF($EV) PP
M ;2- X!)>6((J>P.T#*?AU]9%=M;,WM=W)DW6[5;C=GDM!E^,9_6542TBS\>
MBX,J\H**\56V$9E2F'Z]*V)4AI)4@%*!K'U]>5<2SB6O\GG35Y_&L(XWEV6;
M.[OV>1[?W_4E1V4C/>C#')T.3M3N),B;E4GV$C'MV;O.;-G#Y3%DS25\E\N3
M9D](9EQ4S.\K]])#J ^O]*O*!!MI_#R\-6BM]N@?,NL?+=^MUYV_VX4Q%2W<
M9E!G[/6F$;BPF\1C,9!,1AEI19->,_H*]'ET?V:5Q\1G2_FTNK?GL1Y'J %
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M2<$O!XD!MUID>DH\*=0020KP$J.L#\_E^-5,21J/A $V# 7)9R:K6WWWMBL
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MQ@N(@MU0^Z"[->1) OASKTZNU>F5]"&<(^Z2DHRZNX#R>6^4(;KBL@LDMDN
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M)SXZ#LWXX/)5E56E)7S_ .!)K.5M<$#E1*P2/<$D/9NS&_>8S@,1O$.>)[#
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M.$!J?W&"6*F>2Y#RS!SK^Z]'V8.;Z*;'S2L$Y8X^%F,16 I8Q#A;V<S784L
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M2%RTL%T)6XM)3U02M"7)!&\'#^.\P&K 2 'U=JJD9XD-ETD 1.7!@,4ID:.
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MPQZMGU3K^4W\MEF:W83674N):ELCQY62DE*B?/ZC;^R<WC9G%6I)4H%!1C,
M%$H0("3N!B-UB6(M)G^9=%.F&P<'9^7P1M3 3&(%8:P,)0;$Q%'>3BI"G.\]
MIU>];?O=:?0P+:1DB-]]B59(Y 57_;QRS%_M541/*VXOSPEJDJCAP]P94YV>
M/(X\:^5E]F;3*4H[:T;SD)W (,CLDEV'=KPK]'FNF71=(65;4R:5A*F*EK#%
MBQ#AG=M6.I@UH'M9OQT@Y5N#U@5&YV[NV)Q#<7<&A?B_.YY3PA=P8N-T[C-O
M3SZRWBV$"17V,),BOLH$F)/KY<9J1"DL/-(4/K9O9&;.&@I"E$@]CLI&'NR
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M?&J_'HC\W/*IZ7,,!AEAZ>],D3"Y(F3G65S[(N*]<.RHTB0AKYEDKW[%SR6
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M[GG=Q]''0L CV1AC_P#>SI[O[>1.K\;AQ$_#3Z'3P?V?<:Y'(^[8Y:$@^1P
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M=?K+"5?>DJ4#JJ9RTNT]PGG\A^'/#EG(?47#O !:8>#)@[TBKNUFO132E/\
M7_7^W2E.!X_+V_+2C?7U?QII2FE*:4II2FE*?Z_VZ4II2FE*:4II2FE*T-ZH
M.H7!]HMU]K(]QMTSF64T<2=D<.]D7T7'Y&%8UD=A7X7<V]%\[!FM7M@\].BL
M3*9MZM<<A)+@E$I"2J,-9Y7[H\Y(\6%;QUDEN9 C2V>?2DM(?;[D*0KL=2%I
M*DJ"2%$*!/ ">3XY'DJ"WU]?45W]*M-*4TI32E-*4TI3C_7^S_0-*4TI32E
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#K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g454025g01a35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a35.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1564&AO=&]S:&]P(#,N,  X0DE-! 0
M    %3J^5#0X0DE-!"4      !                      .$))300Z
M  #_    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$
M5 !! "  +0 @ #$       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 6
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      T$    &              &?   "(@    8 9P P #$ 80 S #4
M   !                          $              B(   &?
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   &?     %)G
M:'1L;VYG   "(@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !GP    !29VAT;&]N9P   B(    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-
M! P     "Q,    !    H    'H   '@  #DP   "O< &  !_]C_[0 ,061O
M8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/
M# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,#/_  !$( 'H H ,!(@ "$0$#$0'_W0 $
M  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q
M!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-4
M9$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q
M(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,7
M9$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='
M5V=WAY>GM\?_V@ , P$  A$#$0 _
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &? B(# 1$
M A$! Q$!_\0 '@ !   ' 0$!              $" P4&!P@$"0K_Q !H$  !
M P,# @,$ P@,!0T+#0$! @,$  41!@<A$C$($T$4(E%A%1=Q"18C)S*!D? D
M,S4W0D-'4E-7H;$8)3;!T2@T2%156&)D<W>$E-0F.$1%1I67M+?A\1EC9W)T
M=7B"AY*8HL3'_\0 ' $! 0 " P$!              $" P0%!@<(_\0 1Q$
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MBWH)W_/X5@<SZG\J'L#7/X6;CX?2$[Y<\/@@\=LXY/'H$] /+W'DF7J?4I[
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M'0\W*0^VI2D^>E+B$%84I("TJ:2IOMCWD](Q^41TJ5QJC:E-Y86"1 /?;8D
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MPJ1*GNS'_P!MDNN.K45;QQ/!NDGAU%KB">Y6JM(B([PJ--W&\;C8S%' .,4
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MH&DBIB*9)=D.5@ S03G:""NEM*[B:?UA:;5J&Q7:VW*QWF Q<[7<XCS;T&=
ME(+D>;%DM2'6W&WTEL)9R%CJ4X7#T^6>JQ?#\3AZV4L<',)#J;FO+A+6GO ,
M @ R"+.!#P=6COL!QK!8ZC3KTZ]*I2JMS4ZE-[.S< YS"0_M' =YN4L/>:X%
MIN;99],P@0GVAG)QA0*2GGD X=]0"0<@'!P<@BN+V6(O-,BYU94&A (/=-[_
M $78_P WAYCM&Q _O9<D'0Z1OIIOR)O4-1Z1(BE6#D"0T""/BE;B.,YXZNK/
M !Y(&CB=J1/4,J:^! \KG97^:PQ( JL-[@OI@@>)?KM^G7:Q43>(8SF0Q@$
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M3P,($S?:TNBW28ONH1.I=80.\;"\;Q:=_.53,..5*6I'6M?=2R5G@!( ZLC
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MK;WQMX4?\(3:A>?>*3LJ221[P "M6XX5QG*>>4]@:@;6_P"4^3=];Q(\CL+
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MK:+1<'30!<);I>&/4.E[W.W<\-4V#H?<%8;>OVDU-H8T/KEE#B0\W-M;*@Q
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MWF?@ L#IX6,I!<2YRE8Y /2H]))"N>![)N:H168X&@]HR -L2[OM=)AT%A
M( U.H('F)#3V3@15;=TR##>ZX$:2':W)!L5Z_P!?U_7^\5FJE$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$5DU(<6"\9_P!S
MY8]/Z%?S!^S'(.#@@&FL^!]^6O@%#]Q]?OIYJ]T52B)1$HB41*(E$6D=IO\
M+3Q&\$?CHMO_ +#=E_\ -CY_'':J?L/H%BW5WC]S?3K\ENZHLE3<!*"/0\*(
M44J"20#TD)/.,_#G@*&>H)RWY7TF^WS4(D$<_IOS^GHN>]Y?#]8-TOH^^1[E
M.T=K[3;R)FE=>Z=\IN_6B0A'0I"S(:>1<(<ALJ8DVZ:MR-);6K'DNX<'C^.?
M"F$XC4&-I33Q='^HQV=X&9C:8!.62]T4F7=)M&D@^EX1\1XWA[*F#<6UL%B)
M94I. /<>'M<QF8%M)A[1\AC8)<3%X&BT^(?<O8;4L'3'B-T]#F:(E+;M%HWJ
MTA%>9L2I)*?9E:VL;ZE*TU)?88F+>DVR1=+8I]"0L1/-0!U7#^.<4X1B3A.-
M-8_A[*1IX>IA@'5?Y@5&,I]H:E/#T^R["G4+BVJYP?<TW$DM[K%<"X5Q?"?S
MG :M08[,*F)PV)(;1% 4B7BEV;Z]1M7MW,:QM1@IEDD5&-#&+MZS:EL^H+;%
MO%GF,S[9,:;>BS8KK$B.\RZD+:=;=8=<0I"T*"DJ"B.<'"@4CW.!Q^&XBPOP
M[Q CNO+ XYF9Q :]\]W6\@@KQ&,PU; U74L0PL>VQ@$@0[*;F/[@1.AB02(*
MOB5!6<$''?!!^..Q(YQV[_$"N:01JN."#HIJBJ41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%8M3$?0%V![*@2P>W] X1WXX(!/R
M!SQFJ-])@Q/T\Q*Q=-H_Y"?!7VHLDHB41*(E$2B)1%I':@XUGXBP?7>NW)'
M[G8C91W/IQTJ SC.1SG\HTF?E\@!]O<K$;]28UYGT][Z[NJ+)2J&4G'Z\UBX
M2"BIO!6$](R,G(Z>H<@]QD=SP3@\$C&"0=C8,@Z$;D1K?4&;3;\",72((U!V
M!G2VA$7B_P"3.*ZKTU8-26>59]06V)<K9=T^PSX,Z.P_#D,2$+2IB0P\VM"V
M5DY4GI*@<+SD"NFXAP+#\28]F4 YC4D9&B 'BQ%)SM7@R"P@@.#I: >=A.*5
M^'5*=:G4>QP(:TMO#G:Y@YP:6P""'![2#E+"#;@&ZV?7?@MNDJ[[?6*[Z]V
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ME-/1GG$M+<<H$Q8B;\S%]AKY<B=%!5G2+Z<B8!UF($.)OR ,QFZ)+B0<%2
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MN\&R\Z>!\1I=H#AJO])F<@L#1&;*"UQ.5Q=#LK6%SG@.+ X E;#]J;\Q"/.
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M=P=C.3&84N0PMMJ8[!1)B"<6'2AP,KDL!02 '$XP;/LP=YMR^ZD:^>Y&O/\
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M</VC&E[_ .9:,C0>T>UI<&BW0VF/'/MW#N:--;P6'5>R>J5J2A,'741MJUW
M];;;DBUWZ-.FVYV(VXI2.F6_$F*"5.(C*:;>6W[O!?&5 5!3Q6#XI1)(&:K0
M !)=S?BB8#;N DWD @E>'QOP?7%/ML)C>'X@:AE.J \M#23&2@UKB3 !.4$&
MYFPZ_P!/ZZTIJJ*U<-.WRV7B ^ &)ENGPI<=U12%!*'8\EU'5@XZ5%*@4J!!
M[CUV$XSP_%V9793.7-_6?2IV.6!':..8AT@1) ,:7\MBN&8[!_[V'J1W@<C'
MN RD@DN#<F46EV;*"6R>];(Q,;(4H(=(2 3@((P21^4%E'&,D=61GXY [-KJ
M3_T5J+]/TU6G730R!;4V77%Q$@TZ@(O!;'H9@\XF8(WLB9C9..AU/Y)2I2,)
M6%<@H5G"N,$XY 4GCWA5J!U/*<KJF:?]H9\N6+OC](,F)UAT:(U[7$B<L1&?
MNAV;_B39T:D"X!$BX7I2H*&1G'S_ %_7TJ R)AS>C@0?,;+/W:ZF!SGY'%5$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%8M3'IL%W
M."1[!*SCTPRLY[C'( S\2.*H$S'(_0\]?#Z:J'[CZ^_WT5]J*I1$HB4147$+
M4>D%/E'\M&2DJRE[J&0G*<K4TKJ"L^ZKYA;WI[Z^](0>D<O6?4Q/FI0QRLJ4
M5AQ2BXA2W5-J2H="4!MQQQM" T3UH0A*77 ',(RI)O[>_?S2/O;8^(F/?DO1
M456D-J03K3Q%GCC>VW+Y^'U";)M=N3GJ23S@=)X)(( V^7S$K%N_1Q\_QK\N
MJW?19)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB@K\D]NQ[\#MZX]/C2V]QOO;>QL?-#H??T5FFVB!+6'7H460M*0CS'([#KG
M2>KJ*E.,N _E$$=R%%1)/%=?BN$<-QS@_$X6@]XDYG4*#_\ E%ZE-Y_N<9D<
MMY7(HX[%X9A91K5&LF2QM6JT38ET,<T3(!\;G2#5,!AIA#++45I#>2!Y26D(
M!4<G*.CIR"4I(;(Y((.<UR:6&P.'I]FW#4&41_;V5%K=20"T4PR,SK6U@ZZZ
M:M7$5GFH:KC5)_5GJ%VT][.7R0.O*(TL6I-$Z:U;;U0-1V&Q7F(H*2N+=+="
MG10E25I]U,N(^4$A9&4E)'42DCM76X_@F"QH!91I-=$ BG2; RG0LI.=^J#8
MM-ID$7YF#XEB\&997J4[YG9*M3*XR(+V%X8^!:'-((M$&W)^J/!'MJ[(7>-N
MKKJ#9[4 Z@Q<]OM23;1%)4%*\J797$2;5+BK>2T^Y'$=A3CL=K#Z$!Q#GE\=
M\%XNHP_R.+J4'!X=#:U8 , =8Y*!<0)%I L/^(GTN"^,&X<_^<PN'Q;7!S2:
ME*DU[LP$7SMIAP(UR26EPU.883Y'C@V;#99=T1XA-,1>D-@^9HO7KC#8"5+!
M?+UE?D2D.IZBS[42N.%J2RET!7 ;0X_PAHSOK5FMD"'XBH[6.[G:QY)[0 0(
M&43H >74K?#O%WEW9##U'@3&2A3! )'>8YU+^TD%^0NS& X@QFVG_&)IY,U%
MKW7V^W.V>NI#87)U7I>Y/:20X 4OA>M+>9=E;9;46 7KF+.VYYR RJ24/AGL
M,)\:##/=3Q]"NPU,G9ES7$#+FS$BKB6GO%S;,;FT))O'$K_![\2QM3 XO#8@
M4PYSFTGM#W@D0T=G2>UV4-+LSZD&X:&@#/TUI7=/;_5R$*TWJ_3M[ZTCI%NO
MUIFKRH((;Z&)SJNL!:#TA/"5Y P<#T^%X]@L: 6/:TD PXTV&3  [U69)=?P
MZ2O/XK@^-P3BVK2J6)%FO>+3>6L+8[I DZ@])SY,EH](2I2NH \#J"0K\G*@
M2GCCW05'D'%=LQ]-XEM1A!__ )&DZ Q$SH1KSN5UC@YI@M?._=, 7N3$;;2>
MD*"Y#:<D^8D_#J0,CMG)7@^AQGJ'8@'*:V]D3<.M:X)CZ?37:5@:C1J#X6GZ
M^H]1*KLN)=;2M.>E6<=6,X!(YZ21Z<<\#O@Y Q+<MIF-_&_(:3&BK7!S0X:'
M28YQL2/GXW52BR2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
ML>I@3I^\!/)-NEXX'] O/?@<9_N]:2!,Z0?I;YPH?N/J%?**I1$HB41*(E$2
MB+26TW.LO$8<\?79 2!DG\G8O93)YQC.>0!C()R<U3]A] L6C4\R?J??IR6[
M:BR2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%
M!0)20D])(("L9P2.#CUP><>O:@UTGISZ*&8,&#%CK!YPI.A1 "E]1&/>Z0#G
M !/&!R<G&.,X["HX9M+:]>8^A^2"=S/RV_-_-1*5$I]_W>>I)2,JR.,*!!3@
MC/8YR0?3&5H((O:\GZ;S]M-909!FUY$:\K[1^>D1Q\\^H&. ><GX\YS@GCT/
MPFW6]_?)7S_94E-+6?>=!2.4I+8X/.#D$$XR0!P.WJ,UJ#:P>7"M#2" TTVF
M"3,EUB8$"+"UU3D( +;\\QOY?OSZ1$L\ =2L8(P5+.,_#W\#'S!'88P,5F6Y
MO]PY]=!D_P#B1Y[GFH.Z+6\>]'AFF.FPY+PNVIA_AX(=:4%)6TMH=*DD =.4
M*0K! PH$JZ@<<#(5HJX'!5FY7X9I(! <*E4:Q^H!XS?I&XWW,K93KXFD\.9B
M'  YLN5L C0MM8@W!@P8.RYXW$\(VR.Y3RYEZT=:K?=%<IOFG6'=.7YM04ZM
M"A>+%*MTQTH6X5#VA;W4K)7U9 3YS&_"M+$YC0Q7\F3FREF'%0MG-'ZZP! !
M N),&3#B%WV#^(\5ALO:4QBH(,5:C@#!:=6 /!M_:]H%H @SHJX^'+?_ &?/
MM>P^^$W45N4@!W1>\+"+Y;FAU'I:M-_CR8]T8);;;90U+1(4GJ>>]L6I:64>
M4Q?P[QC@SP_"<4.+8X9BTX3"X>,SLA8,U9^8M:)#B!(M<YI])1X_P7BS12XA
MPEF'>P#+69B,57 RB7.+6T\U-KB3/?<T22[*&MF6-XK-XMNTHB;U>'O4L1MA
M267M3;<RF]76&2G)<,U4%$5JZ6Z.E#B?/0M<]7F(=*/=6A"9AOBGC>!<*=?A
M)J9;2W%X:G,S< T729?LZ)%B X-;R7?"'!.(,=5P7':8>2<M-V&KU6B2;.>R
MI+0T"&AS,QLUSG$$GH[;?Q+;3[FQF?O7U-:5SU.J9<L<R6[ OD9U+A0MM^R3
M8D>[M%)]Y+CD!$9Q!"VY"@3CUV#^*&8IK#6PW\O4<8>Q]</+9< +TZ)S$@S
M&Q$YK+R6-^%^)8*I493I'$X=DEF*IY64JC )<[*]_:TR'!S0RHQKG!N8"")W
MD;G' 0>X< Z??;3R03C"E)4L]@"VEQ*NZ5$5Z.EB:-9H<RH+@&"' R8M< &Y
M G0S8KH'M[.<[@T@D03<Q)VF]B"-01<:D>Q#Z5(*U#RT@ GJ*2<'//ND\$8(
MSA1!Y2D\5OV'G:- /<]-UKG4FPYVOZ3TC>^BJY^7IDG[?0>I/YAGTYXHJF>_
M&#C(!(^?PS@=N>>_;/%/?O1/?O52!2B0"@ 9QD+SZ$YQT@X...V1R<=JL"-;
M\H]^]"5),Z6YS[]Z@*?)^'&,@Y'/Z_H^=8WG2W/T_?T50$^HQ^B@\(]^Y^4H
MHU42B)1$HB41*(E$2B)1$HB41*(E$2B)1%8]3$BP7?! )M\H9.?Z%?''Q^?'
MV=Q1O(FQ^GS]ZZ&';Q'U5\J*I1$HB41*(E$2B+2&TY"=9>(M(&>K>^ ,_ JV
M%V2=).!Z?D_H)/I5/V'T'U6(/_R</F3[A;OJ+)*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%Y7&%*?#R
M'O+6&@CI"0HD!2R">HD8RO!PG/'Y7(QFUX RD9A,Q)&L#;PM["UNIDO#P[*8
MR_I!F"3O;?83UO:"HK)20M"%!0(*2@="0K/6 D<]*R25)6M623@X 37'=2H[
MLM_[B8F8)'C&E^2WMJU6W#W V,BT%L01OJ =9ZW)7-^Y/A:V8W5G2)^HM'Q8
M][4TA#&I;"]*T_J.,M#:$(6S>[/(A3R6P>EMF4](BI2!EA04>KS>/^':..J/
MQ--V1SP,K0TDM+&ALESJK'&2T&8L# D!=]@_B/BV#IBAVQ=AVAV6F]E!S3G)
M+@#V1J-DN=8.N2YVL1S\?#-O?M0XXYLCX@=2JMK2E%O1>Z<6V:UM$L(5AMOZ
M9D.1[M;VDMH0@)BJ1TI2$X2$DCS=?X;XO1)_E7/@FS11IN! FY/:/:[:))B1
M>1!])A/B'X6Q.4<=P6=^4%U48C%"*AR%\"@*3V"14_3G@D1F  &9V??3Q":3
M\N#N?X==0S4QD);D:GVKF0M76^>I*<><U9BS#NT5#O2%>61(+25!*EDI)&_#
M\4XUA(97X?6A@#'5!3:V0V6F2RBX3!$"\@Q,@K@8CAG L4Y[\'Q1@8\EU&G5
M<1E:[O-@5JE.JX"2+@DN/DMI6OQ6[*S;G'LUYU6WH^]N*2D6K7MON^AIR2M:
M$@)8U/;;3YBBH@)0DDJQD<')[S#_ !5ALS*>(!H9W-:]]8N:U@)NXGL W*T&
MY+F@ 7.I735OA_%CO4LF(C]+:+@YQ/++FF21:,TFS96^86IK%=8K,ZTW2!=8
M3_269=OF1Y,9P'!"FWVG%-+3R.0KI^==U1XKPNO_ +>/PKQ($MJM(DQ$D6 Z
M[+JZ^"QF'<&5L+6IO(S!CV%KB+B0TW-P1I'571$AE92IOI4".5)4%]''91;\
MQ&2,8]_G.>P)'-:^B^7LJTWY=V/:X7%M'6D&;C2ZXSFO80'L<PF\/:6D1KM'
MS4XDLE:4)6E2E JP%)R!\<9"B">. >3SBKG9,9VSRS"?JG^55"DJ['/ZC_3^
MN#5#FG0@^!!^GB$4U5$HB41*(E$2B)1$HB41*(E$2B)1$HB416+4W[@7?ODP
M)0&.^?(<P<>N#S@D D#)JC1VGZ3KI^TZ3?718NV_[A[^ZOM19)1$HB41*(E$
M2B+2&U SK7Q&$_P=Z[:X,9[G8?95G!SZ=*0>,>\3W'>FWH/F 5BW4]"3H-Y^
MWGUBRW?46241*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B*'2.KJ]<8_-^OZ\G+>??L[^ 14PT <E;BODI9
M*?7GIQCU)X'/&<@ "DR(RM]%B&P9EQ\3;T4@C(#A<"W,D@]/4.@8"0,)Z>/R
M<G!SDJ.<F@AK0T!L";Q>_A ^7C*02XN+WF8[I=W1  L/*_B>:B[&8>&'&T+S
MW)0C).""<].<G)/!'/(IF.Q/A)A7*W=C''_J:'?41\MRI!#:'6,J(7W'N#&"
M2.E:4)<'3V!Z\X &>*UU*5*J"'4:?> #B&@.=$:G>8OYJM+VV[1Y;LUQ!:T7
MLT18";7D0+V6$:VVOT)N'99-AUOIRTZDL[Z%]4*\084QAE7EJ0E]@OQUJC/M
M!2E-2&5(>942M"TD CH,=\,</XA3JTJAQ##6IOIAU%U*G49VC,DTWBB7M<(:
MX$$D. (Y+LL)Q;&8&HRM1JAIIO;4(J#M:;BQP<#4IU2ZF\6N'M(()!$$KD&Y
M>"&P:=D.W38[<G<7:.\!7M"(FG]23IVF%J;4I;:'K%/9FP3'"PE+D=+)8<;4
MIM;!25(7XRI\!5>'_P!3 <0XL][22UM7%U*C9_4!-/"-,9J;>I:71?+'JF_&
MC<:&4L?P[AKJ<!KWT,-3;5<!(S&F^L*,R]QD!K6D-,0T@^2)J+QD[/+$34NF
MM/;_ &ED>:X;YIN:[I75D.&VA:%)EVZ:T[ NTLCH<9;AM04J*5-A)6I(.AN-
M^)>"UV?S3&5>',+^UJ9<:ZJ.XZE2)J.=3I@FH*9>ZH!,G+)@+:<'\,<6P]0X
M:M5PF/=E#&5783#X<.+@7]T,>7D#M,N1Y)'9AQM*YPNOW2B:SOAI&T/6";IS
M;]#<>U:NAZA@"!?6KW-CS8KS#T9<E;D5JTW%VW3G9)<+2H3#XZ,+ZAX\_P :
M<-1XFW!8D85E-L,<"6MJ2,/VKKNXD!9^43V1M((DB/HE#^!V)Q'"#Q"A6QE6
MN0YU+LV5#0@X@TJ<L9PYQJ33#B7-KM8Y\.:0P$+ZQ675UHOT&+>+!<[;=;5/
M2A42=%EM2V9"5@$%IR&Z^E75C\HAM 4"E72HC/V[AW'.#8NDW$4,4Y['L[KA
M5PKVO-K#)6+AU/>#3,@DB?A6/X5Q7 5WX7%8<4*M,]^E797HU& 9A)S,R$&
M06F"#(W65LR5+1U*""<$]#:DJ*.D)RE2DN.(*LGL%8] 58)KNJ=:C7_V7AW_
M +V.Y:]FYX$2!-P9Y+KRVHS_ '!U$-<+1_U@$[G06M?54TSDN*Z4K9;Z?RP\
MM*5$$''0$K.<$97DC (X]X$;>SJ-_7E,S 9)TU)G[3&_-:V5J+LV9Q;$1):
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M[<'H NUJOTJ_Z$0FUWM:UI=-RNFH$7:YVV.ZXXE"F;@^I)<45'EL@AVL;&(
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MP7'55OUMI&=I>SN3V;MJ2'J2S2K!:W;5@W1JXWAB:NW0G+:"#/1)D-*AY'M
M;R*(KY:;U9[]:X5[L=VMMYLMR8;E6Z[VF?%N-KGQ7OVF3"N$-UZ)*8=R/+>8
M=<;7GW5&B*E:-06'4#,J18;W:+W'A3Y5JFOVBY0KDS$ND%T,S;;*=A//(CSX
M;Q#4J&ZI$B.Z0V\VA7%$7NES8<"+)G3I<:%"ALN2)<R6^U&BQ8[*5*>?DR'E
MH989:2E2G'75I0VE*BI0 ."*R7V3'FZ9N,J'(8E1G[;(=8D1GFWF'FUQUE"V
M7FE+;<2L$%"T**2"% XYK(&,T_\ $^_D?3FL77B-G"??FLDK%9)1$HB41*(E
M$2B+2.TW^6?B,XQ^.FW>F 3]1NR^3Z<GN?CP><Y-.VN@^@]^BQ;JZV_K<C[>
MI.T+=U19)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB'L?U_NHBP_7=EU!J+2MVLVF=1R=(7J<W'1!U'"@VVYR[8IN4R\ZXU!N
MS;MO?\YAIR*L/I)0V^MQKI>;;76RDYC7ASP8$V_Q-XF-IB^XT8EE6I1<RD0U
MYB# ,7DV,#8;Z2OGMO-X7O%-JG:[6.F[;XJM1.72[V&7;(1DZ-T39X<J5,4V
MS%@R[C966;O;XTEY:(LF9 =$AIEQ:T9!6E7HN&8WAU+%T'8@N%+.14<VG4<1
M+'@5,HB<KWAQ()> TD!SHGPGQ!P;C>)X9BZ-"L'/>RD&,-1C!4_K4R:.<N ;
MVH!IRX"G+^^0V2/FMX!_"+XH&MQ-771J[:K\.#.@H,3;[4@9T]8KHWKJ_,3H
M\UYR"C4*GX=]M-E#+\Z!J]M,B5+^^9ZW-REMMSVFO2?$7%> U\.RG@L0[$5
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M$ZFN&C&=N6;SK)3OM[MRN-]82BW0/91*;=>0'N +S:UCY;SE%M3O8;FR[NE
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M1V@J.ZB.$ )2W7Y'XSB?CG#?%%;&.P+OY(8FH:=?^<X07"DW'U*K2*9::_\
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M6EGJ]B8)3CW_ #$-CLHE02IT%*1Z)RG [ 8(/ K<"X5B79JE-H!(=KB#>_\
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MV%Q\/4CODT\_K^-O\2KY?3\[_P"83Z:\:OIMMX7_ $QG>K=7U[YQL+W'KZ?
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M6:3?IH6\OVR\/6V'&<N,HF0[UR)BGG7%*\UQ:WQYM93:($<O?O;2RD>_?/\
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@X4(6KHR1U80HXS@9Q3GX1I/^(4.WCSC_ #X*Y457_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g454025g01a36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a36.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1B24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &':^8F(X0DE-!"4      !                      .$))300Z
M  #_    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$
M5 !! "  +0 @ #$       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 6
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      T$    &              &    " P    8 9P P #$ 80 S #8
M   !                          $              @,   &
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   &      %)G
M:'1L;VYG   " P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !@     !29VAT;&]N9P   @,    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M>?<[;^]8BAN)(-6-Z=AL]6Q\MV[7NEH_E;8^DF?BAP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^% 2FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0'_P  1" &  @,# 1$  A$! Q$!_\0 '@ !  $$ P$!
M  @%!@<) 0,$ @K_Q !M$  ! P0 ! ,% P4)!0X3! L! @,$  4&$0<2(3$(
M$T$)%!4B46%Q@18R-9'P%R,E,T55=:&Q&!E"MM$D)C1#25)68I*3E<'2X2<H
M*38W.4946&-D97)S@H66T_%99HFF:7:$HJ2SM+7$R=G_Q  = 0$  @(# 0$
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M?PN?B%U_F"1^-PMWX_Z>>NAT^O8D=32W,^0_*7Y#S/X7'Q"[Z_0#WW?$;?\
M_,U2W,^0_*7Y#S/X3XA=_3'W_P ;C;Q]/H\?7?X?>0%N9\A^4OR'F?P@N%W/
M_<^^.FSNXV[O].CQ'TZ[^OTZK<SY#\I?D/,_A/B%VT/X ?/4 _PA;NG0[/\
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M@?D6H%6I'ZH?_IJ@1J&O-AKJP&TS>VMU.?!?_P!](F9(+VVDP#_[AL2([P0
M;KAV]6R Q)>>DQH\6+'?F29+DML18[$=EUU]Z3*<);CM--L@K4M02A*DJ4 F
MA;4C,]K@;P' @D W/Q!L"3?D=8N@K4&G*Q[2V)+@X$"QD$YB) :!!(U$65&C
M\1<*EOX_$AY;BTR7E<!RZ8O'B9':7Y.2VUI#SKD_'HJ)!DWJ&TTR5OR;:Q(9
M;"DJ"E(YU(@-!, _2=!M/Y//=9GG()-[^-Q(L)F9 $3)TY*\1(:)0.8!2QL)
M.@I(\OS27 3M "=;YM'9'31W58]>O6O))!CK\K3=/.1K?4CY=%.EDDC92$-E
M:R4C7, GH"%#:0HB8[O773G%]DGH;^?EK;>WR5,9R"S2I5R@0KG;IUPLPC&[
MV^+.C.SK4)<=<N+\2C)<+MN$J,VMR*J<F.A_E(2H)"EI1>)CRZ1OU\KW4%P[
M_KU_'?8PJ-C'$+",U7,:Q#+L7R=ZW.J;N#./9%9KVN#RNEKGE"US988"])<0
MAWD=\MUE3B&U.A(CUZ]<^2GUZF/]7W5U^\(Z[Z*2HIY20E1/,4) V0-N'E4C
MF*04+2O?*=U,=?7UC6XFX2?Q_@==-8L95LVS.<3ODAZ)8\DQR]RF)C\!<>TY
M#9I[R9<1E,F9%<9CS%O-2X,9:'YD5QM+T=IQMQ22VHK"W,=>GE/A$I/3Z=^Y
M&VLJX&+C!DAU4>5'?0Q(>BR%LO-N(CR6%\CL=]25$-/(5^<VOE4-=1U3N-=+
MI(&OK_=XYPNYN0APJ UM!Y5)V"I*] ZTG>P4J2I*TE22">;E(T9C\^'KYV4!
MP/K?[CJ+:KN!WZ$??K]?0GO^OZ@5"LJ8=?&AO^:S]?\ OM/;T[D;]>@UZU;^
M']OLJ_S_ *_=52JJRMV\'5XQ,?6ZW ?_ )?NY_'MVZ]R?2GYGY$??ZJ-QW'[
M;>H\5<5%*M+.K==[QA64VNPR8$*^7&P72'9IEUC2)=MBW21#=;M\B?%ARX,Q
M^(U*4RX^U$FQ91;"A&D-/A"Q#I )%E!T]#3\+7%>)?$+A8ISA]=N+7@YQXAE
M*[SAC7"B[M/754EI,ORY5K?S:6V[+FQUL.)EWM<Z;(4M;@Y6GW''*M))<#M%
MP/#8:[&>5]5CJ.+0T@"Y( N3L=3TM D[DD0%LDQ*Q6C'L?MEGLD2+"MD)D>Z
MQX+2X\1"'5JE%,6.I;ACPP[(6J'&#KJ&(Q:;2LI'*,IL2+<K=_G.QG;I"LPY
MF@F=CKJ8GRO('*)O(5P^0WLJ"0"ISS%'25%2^4ME1*PH[+9\KF&E!H):20A*
M4BJM'K7ZRN4-(1OD2E.R-Z2D'Y>HV=;5UVK:BI7,I1WUZ)//UI]+) Y!?2DI
M6DI4 I)UM*@% Z(/4$$'J/IT[C1T: PI(E8 \+:0.!6!:Y0$MY*A(2GD 3^5
M]]  0-)2 $C8Y=@].G7<#3KWS_M1_GZ_92!J5*41*(E$2B)1$HB41*(E$2B)
M1$HBB9XGYKC\#$<786%.7F\M?YG(!=6?-;B,J(ULHVL@I(&UD$JZ:K;PX(#B
M-7$ &>0!CO.8#U*EKHV!'_R (F2-#\N<\UGG*\8BW[";OC2FR6Y5E?@1D@_O
M@>8B>5! 5HE10\VUW"NO,=;/378]S:P(.N:2;V( <=C_ ")!MM/6LDW)N3M:
M"3&VE];V.\*P/#I/=?X=HM4DI\_&+S=K M!T'6VH<CS8X<3^< &WPEHJ /(@
M) ^4DWK"' @$!PD\BZ3FC:UICOM*DB"=SN=YZW,=!ROO)SNDD[WZ'7ZM5@!F
M>A(1?52B418^XJQ\PE\/,JCX!(1$S)VV\N/R%B+R-3O>&#LF:V[%3MD.I"G6
MU!!4%I 6$D==[64>)5^S_$:7"'%G$7MP_P"F<&M<06XS#NJPU]2BTS1%07J-
MUD28:>4X,[ ,XGA7<3:7X$.?^H:'.;+?=5 WXF,J. ]YD)ACK3(B5!!_&?'#
MS+)RN#R.*=YAO$BI*!Y:6DM."T;#A25^8I"T[41KJ!OYRXQP;VM/,X3%U<Q@
MP*&%) SNL''BF:S8B\D1RA>K8/'>S5@'ZG#-($QGKXLAQ %G,9@7!P+A)S"V
M702%9MAP_P :J)MW=CWJZQ'3-7YK]XN5GFQI+A0P"Y 1,CR6XT8@ -QXJ6XR
M%AQ:&$*4KGZS@N >V=HJ5#BJX=[QPDX?#$EI:VY+N+ND20)).X.ZYC%<7]F+
MO=TQA:'N P$AKZIRNS&P#>'"#%S;32]EG[A'C_BHC9@Q(XF9)#N.)B)*$QAI
M5F0ZX^I"?)++<")$Y^0@)7RE*M\Q[DD^L]D>%^T&H]HXSB:CVB2Z*="G(]XT
M1+.(5!.1T%H;K,F0NC=I<3V,]PX<'HM94)^ A]=Q:0TW(?A:;B,UXELBPD&#
MA^V< Y$G&E<29]DXMP\\Q3BK)3C-ECVO&+88E@O'&>T9-.O\"S6^TMW2]"W6
M-AZ=;I&3W"Y):91SL1G3H)]XI-<VE3:X',UC6F=RU@#B2"9,S-R+3)7FSBW,
MXB()D1R.EC?2(W5Z\/\ *?$?>Y^&6?([AFUGEW&P9A,R6'=;/@B<DLIPS(;E
M+Q"0Y%-A<@Q%9O9KI:8LE=QCAVX.X^^8KT-U2GF\GXWY=VT2+D>,Z1S)GIL/
M/?0VGOL%9L+*_%I&N>,0[O:.,0QY./WE&83+?CN&2L@>9C<1([%LN^.O*L:3
M:;K<<71,E,8[<!=I+$,M-W)U2VHBTM@+P2)B=1O,S8'2?J G6T@=T#EW3T\-
M5U<<5>)#)9.>X@QBW$G)N%.0>'[)[ U;IF/8K-NMZSNXVS#W,=FS6K);K6;/
M>5SIF41[FAM#J&G([#C#$9,<- =?5M[ 6U/3[)X??>!K?QOIKNLY\?K=DD^3
MP!D6K%<^EKL<RYW"]W+"<7LV27/'H,K$E6IMA^VY+%?LZENW:7#=DP'X;X6F
MVI\U/EH2A2\"UQJ+2)VFPVZ:&W-O\Q>01Z/TN5B[)LI\1UKOD5GA/BO$BQX@
M]PXC6W';-<<1P)K',7SH6Q4FUW&X0X]OMJVL65;7DQ[XR9OEVW+7&W%%BTQ1
M%1%QL>4#0&2;FU^L#<7LE^8DZ:D1:^OWOKN53;!>_%<F\J1<;MQNO%EMO#>#
M-DS3PYP?&7;A?3Q&@(O4*U6V9:;G,5DL;AL;H;*B[J4W-O+<)]]A]MQ2%SH/
M\3TZS(WU!,WB2/376Y/6.Z^UQ'6RNGB/?O$ W#N3> HXV+9:QG"9]NGWC%\.
M1=;E/;EY>+W8YLBUXS)F17Y$5=E0[(9@O"*^[[P6XS3K[M.4 ];:>I U-[:!
M0.9.IM?G'H1ST&@R5X;I'B"FY'E4KC/?LDD(!ND=&-W' +%C^,662Q=FT6O\
MDLMA3OBF5Q56CE1,FR+5&BRI0<D@M.)2VMZTWZ>A]%(V\=SIUF]C Y]UPIAT
M4K /%B#QGDW>$YPRN,2!;FX"OB >:MBU/3"ZCRE'WR(^XI2$ !"0K0"2I(&S
M6YASALD5HS9CKF(@ $0!(%Y!.Y(!D+.QM'("X_$9!TM<Z2"=(TB^\A8.RFR^
M*)YE@S+O=)X0XKD:QN5;[8[I2OD#R[-$A+4H) YEN*4>IYB05&LX?@1,-$7U
M+R=MW,-C  ;H!:;DBX90,WTO<@6+29 ,&Q(((W ML?79K)XJ8]JC(A7U<7;2
MR6;[)LTZ</W]I927IT)^7LA)"@A:?DY@HJVH@7X$D_"#K%W\N8I@1>+GX3?9
MJ@MH"),G:'2-1J1.XW,$$P #*JF?VKB[+X&YG9\TAW7+LHNUZQEBS0L6M=JN
M=P9B-WZSW.3(8:9M[D8)A,6]^9YLZ))CH>:;2XRI*_EUL2:!+10T^+-K!$C+
M8@=3IOJ1$8J@8,N0[F=^MM(UTO;EH, W6W>(6R\2<X:P";Q)Q.VY)F=OF7+B
M!*X.6/)+ID*6<;8:L<5R!"C6&"FT?$8]S3>KE;;>VW!<>C.3V%,R?EUAX\])
MN!OMXE8C'.]ARUY=_P!1K(D7[BY\2>19[=AGC7$"'C-GXZ8I>L.:-LQD)CX4
MB1D%HO2+E<K1;(:)EH3[K FJ92VL-Q)!?YW%NAY<7'=/@8!WZ2!8P9/1!?OC
MN(F-K\CKIU6Q!(TE(T!I(&@  -#L "0 /H"0.P)HI41O%S;/$-<N".:P_#->
M8]EXR2!C8Q"=-79G([ ;R:SOW\/B_P 2[6D)793>8Y,N%+006^1/FAI:>2X:
M["MJ X@ M^+]SB+6O8./(3$3$& 2NJ]K:?%W\.Q#> U74\:?=>Z,,J Y:Y+B
M&U'X<9<O[FN>RP.QRC3&OAG[>-SRE'B;BC>W6$E>^"R1RE]O:G GAXI02E(*
MB0%* 2"DH*4J3WFCBNRC:<5F,>XR(%2H(F9(RT"3&P %I-Y(7@53A'MT=5]X
MWB(;2@0T8#A )=F9!^+BLM;#7$YC!<X7#6M<;2Q#A1[="/88[,'/XT&*)UV7
M[IEEWX:7V\H<<N4M3[BYV089=+@(#SA\ZWL^\B/'AK9:B,,L);16=V/[(DD_
MIV@EH'PUJC1.QRC"MF&C7Q,@ '6H< ]MM.F&LXK5<WWKWQ5P?#JA +1+6OQ'
M%JKV NB8AI=F+0PDE3?\%F(^TVQSBO=9/B_RRR9#PM_(:]^X6ZU,</%RG,Q]
M^LJK6M*<6Q*Q7-:4VUN]-)8=GN0GEO(2Y&4\VPNNO\:?P"KEJX!KJ;@QK"WW
MU5[?_<S3#Z-.26N(M>8,W@>@=A\'[1<)BJU/M77;BL-E?4IG]+@:#G.]RYON
MP,-BZX</>AI:'9+2TN(:Z<P_N=<=N'EHL+_!2RS%XZQ@61Y!;;%D;$,Y5@&>
MW!S'!D-CM,.8E]);OUH-YNMEM\OWIEBZG2"L+0RKIU$M?4()ADNO$18  R )
M.;4_^4DV<5[OC31.$:,.T_J :5R201>2&F""V8<"Z0X/< !E*]-UOWBFE7;.
MEV=[CVU8F.'-XN7#R/)Q;!&;K+RA5TM2K;;LC6<:2V+JT\K(@EJ,(*'K5%MT
M=24LK#BZP9W/G:\WZ;=Y&Q@:_KU]>[964YF/C7<B(1 MO&>3/=.?P4S+KA'#
M]N+;84;,L/DX)=PA5F=:7=9&,.9&)3RV75D.)0TTT8B%(G[>O4I -]=^>AM'
M4B]K>)OFGA/8.-&1X]QG5F=GR&R\1LPX08]8X>8W6&QCS%QS;\DY]D0[!C0P
MER&N+<#:G[I,C168S:FV'"$!(!>9MTZVVF;C6!%]4M(O%QI,V(OOTGOM9>IV
M=FD3#<3N/#?@KFG#V?BXQ_'<\5'Q2S#B"SA+P0+Y;,#%SDW.+EMP:E>ZOPKB
M\@^4DRGFF_>424HGY2!/7NTW&O+6)4;W(ML-ITGJ9Z3)UBV+ORJ\:T%E\")Q
M,N%V%XM:;&R]BF&+LR\9F1LX\LW]V/96)(OB8(PY5Z4W*0B!?6YS;0"5((CS
M^6GWYR3/R G?SW)W\A_N-#-J''^/DJQ<>;18<6XRV']TZU\8KPW/N]EQ:%>K
MQ=G^'U@&*?$)=CM4#X?=)U]8FP66K8BWHD,/N1I;<A+:0AOWS]ST&NL#P4&T
M2?MRGF=A-]MI*RC;;]XJTO085OLW$6W6M%_=C0)ETQK$4W:8MANP*MJLOD?#
M&6G<9CQ6KQ"?E1VXLV2"TZ]<'9386I),#4Z:0#H.M]-=8Y7$V G2;_?>_.UE
M;2LG\6[]JFV^.>-C5U<N7$&1#E2</PV2R;-&S^2OAW#5(@6:+(A?$\85*9E7
M%7O+SL:-"4ZML(1SQ>X-OKZ_T1S==8[XVY:VT^H*V48<]>)&+8\]D$=<2]NV
M6U.W:,ZMIQUFY.V^,Y/;>6PAMA;J9BWPM3*?+)[?-S 2@T_S-N_UUNJA_+7<
M]+9U'IUEC1^_H=:'WD=-V_C_ &^RC^7]?NJI5596[=_TOBG]+7#[>GY/7CI]
MG77ZM'J:6CK(CR/KP[E&X[C]0KB/8[HI5,N]R@6:UW"[7.0B+;K;#D3ITE:B
MA#$6*VMU]U;@/,@-MI4HK!"AHE.ST$.( ),QTL;F/6_*Z7VN=AS/C;S6K;/[
M)Q1S_C#FV5<++UQDR+ ;VSA\R-(X)Y]P4Q;$Y+;<-4:9^5T3,PUD%ZDHC,MQ
MUB"')SD5DL>;Y?E(,4R2YY!G>Q(WWTT -Q$2 =5@K@Y0-H+M()@[1K!((D$$
M03,6VCV1#K=JMZ'T/MNIAQ$N-REI7)0XF,TEU,DH ;]X#H6'BVI;;C@4ZA:@
MY5S_ +[_ #/V[ED8"&B;6%O ;0(O-K\YNJK4*Z41*(H^^%KKP(P(]OWO)>GW
MY??OO/3MW]?6H&FGEX_7SZ"X4?Y^O</7/52"J5*41*(E$2B)1$HB41*(E$2B
M)1$HBB9Q*9&0>(/AC9"D$6R)'OSJ'$A;3C42XB0M)2KY22&M;(Z]M'M6U2)%
M%Y&P?<$@@D"#;>VMH@;PG<=#)\A8?([](NI5O*" ".1/S@DJWKE2I+KQ&@2%
M>6A9'7JL ]]FM7^0U-B-SR \ 8^04'PN1XWD^, GYJ-N#RDXAQRS_"D$F'E
MCY7!2D<C,92HSK\EI#2?D3IZ4J,DHY=MQF$ZTE*$;#X=1:3,C2=3H#X6F>@\
M9 L3U.FP^%M]M8C>9%X4ED?X?4D\_4'>@>5/0;[#6CKZDUJM_E_]CX:"WKY(
MNRK(E$7!( V>PHBZU<I&@I21H#E3H#0]-:(ZCIKMKITZU'O&C6#X$Z]1^>IT
M$1'4CN]>O.>M"6T'6U$[YAS $#8T2-) 2?J1UZ:!T=%[UI.4 -D:-!$CPG32
M#;O,%0&1>Y@ZF-8VL+G61?PLNY20H%)2E0.]@@$'IH]"1O>];_7WJ1;2W=92
M0#J >^ZY"$)"0$I 3KE 2 $Z3RCE &AI/RC6M)Z=NE%, :"%TIAQ$.J>1%CH
M>4AAI3R6&DNJ;B^:8K:G D+*(Q??+""2EGSG?+"?,7S$@<M-%W)0A.RE"4DZ
MV4I WRCE3O0&^5("1] -#I1$Y$:(Y$Z(4".4:(6=K!&M$+/50_PCU.Z) Y>C
MKYH$(224I2DJ_.(2 5=2>I V>JE'KZJ)[DT2!R7/*DG9 ).MG0W\I)3_ +DD
MD?0DD=:(N V@!"0A 2WKRP$@!O22@<@ TC2"4#EUI)*>Q(HBY "0$I "0
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M??F)5W.Z(N>5/4<HT>8$:'4*.U _^D>JOJ>IHD#EZ.OFN=#KT[]3]IUK9_
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MM<&&IL34\LORQ%:0U[TC82B1Y2$%Y" E(7S="2I:L[HDQM;;[ +)3_:.H'E
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MXQ92DI4E-QDVYMYPJ!6J3<I?EI8 "AR,-6QGSR>3E2['#:%[6$;E;X6,:9T
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MB)1%Y9;Z(D:5+6H)1&C.OK*M!(0RVMQ1*CKH DDC8UKKWJ6@%PO$D ]!)O\
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MAQNP+@7J!-O4[*[5>KDQD4Z1<+:;S;O)MUJNZ[A'-O8BH<=2M#&&AF#W F0
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M=>!VUIDI4B6XB0A7/S;9+:_G94S\JVW4C6EN<R5(6E87HC:4J&;WA'[!DU$
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M<AUQI:9B8RRTN.EU"EI5MSETI6#%34:6-I.:&/#B\N)S&7-<T @-S?%F@ND
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M&B76RMEHSN);F(=-VEI#BQH_B-%S79'VCX3%D\+XY6PV#XG18XN96K%GO13
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MT.P7LXQ7%G5*V'XC6QO"Z=/$8;WIQ#:.*J4?@95HU*#J;7Y:V=K:OQAP#FU
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MBG1HEV2G3IYRTO\ =TVMS.DY2[*T202X@F2"3N3/3@2X-DDY0<LF8$08DF)
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M.J]J.R> [3\-=@:M"C3JTZ[,50Q+:5(5:%5LL?48]U-Y'O*=1].K$%U)S[R
MM-'"CCIF7LY+HWX1_&S'NN;<%[E<'I/"#C+;&9V3Q[5C][=:,?'+O%:E?$(4
M?'Q&ED"-&=<LZ)18<;%C;@.GM^*P>&XSAVXK ?\ 5B@',?;W0J!GO &NEKB'
M$%N5XV:TB#=>,<"[9<3]F7$V]F>U7ZK$X7$U&/PF+#W\0;EQU:@T%CSB&$TJ
M;Q7]Y1%"DZB'%UP^';:\0RRZ\,&;==Y%W_*C@KD;$25BM\M+AE)M]MGL)E6B
M4V@N(3[C+;<\UUV("S+4\9:$N-N(574J^&%&A[IYG$X=]1E5SW9ZA^)Q#7.
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M"8=PCZF*86\7XR7HKV+R]>MYMX)!ZG2>^P\MS][A8L\';-\:\.'"L9(Y;%Y
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MYU77YU>:L$JVDK.B5*%:Q<ZHX W!,!L<^@U\_%9:SP6DFP:V=8CF3>Q$@WM
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M,DM@(27 4*D,!:4\P= <3R)+2@LJ4//NT_L\P/%J.?"EE+$,+W@D5Y<12+6
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M%Y%SSW9O']@<%CV^]# XN#65JC\46 Y*H!SFKE;+BV2!E!N88"5;'!7.\_\
M#M%"N+>/Y3;L&N[:$V^0X&)L3'GE);,=LMI;+T)AYIE[F8>*70Z GRBO93Q?
ML]XOVR]GU05^U6#Q?_'8B@_!,;^EI4"W%.&&?3?F;@6R?=X*L US@"#J8@[_
M &PX;V9[1YJ?9[%87_D<.\U7 UWO:^@'U!4:2:]2,M2O2.9H.63,B5L5PWB'
MBN=V*/?\;N[-SMLGG#<AG25)*>I2ZRM+3S;B01T6RC:=* *?FKZGX'VJX3QV
M@VKA\13IN+GM=3J56!P+7M;S:;YVQ B)(,77B6/X;B^&U33Q-)S2 ' Y26N!
M;FEI&HB]H(S $ RJ+Q+X>V'BGB608?DUIMN06"^6N7;I]INT5,N!<(\IE398
MD1G$^2XUYJ6'VU$+=:>:2ML<W(1VK 8C$8+&#$4ZH-*:;F-;DD91! >:=3,T
MN<7R28(+8+;'K7'>$X3C?"\1@ZU(5!7IUJ+V.SY2'-@:5&.:\. <US0"TM:Y
MA#I7Y>$>$WQJ^!?Q'RLXX/8=D67\,\(:;R:[/8F^Q\#O_#IR2[.R3%XEINGE
MR7\C8E-SG68<=B5*=*HTAA*BXR*]8X;C^"\6P3J/$GL&(=1-.B7ULH%9U)^1
MP%-]$91493_<V!_)L2#\D\2[,]O>Q/'6XO@M*IB,#AL2S&5WX;#%U-V#I5Z?
MOJ>>KAZSX=2J5FO:',?#26YF_$S;[P@\5WA=\<+CK?#B_P!QPOBA9XSTQRW7
MZ&+!=BB.IMJX>6Z&DPKNW!E@,3G;/*ERX3RV4W!EEIU0'2<;P?'\-<) JT\Q
M^)C9F7%K?B)>1F@&"ZP('\@OI'LI[2^"<?(H_P#90KY9-#%/;2<7-IBI4%,D
M4B_))&C:EB[+D:^)6V;/LZX5,1X'$J"G(<;0HQX&761P3O+;6?,(GK3\S:(Z
M&EASGT-^2GS 2@5Q=3#X:O3 I!]/$ EU2F\$-+1^UP#H<V2X"0'#6;DKT)[L
M+48*E"I3AQ@ /#C;]TD/<2)+9=%I$])'8SE=@RV"+CC]R9N<8\H4ZV'$+23S
M<J76G6VW&U:2=;1R+(5R*5I1''OIOIF'B#MN#W'T;B5@Z@R#H1IZM:8)%X5Q
MC?K]O]OW#^S]?>J(N:(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*EZ/QH'?3X6
MH:UV/O:3LG[?0?8:M_#^WV5?Y_U^ZJE55E;MX_3&)_TM/]/_ +O7CU]*G;Q'
MT/K_ %>-QW'[>O\ :N*H4KJ>T4:(WM2==CHA0*5 *2H$I.E#8V" 1HC8J[0^
MO4(M5?&7B)DV <:N)$!F)QJBVG+%X0U'F\/F>$<+$Y-SN%EFK7;[_(SFVWJ]
M3)[;92A9M,RWR76EAMFW@I244PX+W5))!(DW%N0-A)@&QF_4P->N0 ($DF2)
M('+XH%R !%YCN@[2;8I:X4=2PZ%J:9*Q(2RB2%J8:*Q)$?3(?"BH.!M*$A7R
MI0A(T,[IF_KPVG6.JRT[M^W(P)$[P=S!V($+T%D+*E\RAS[Z'2BDE(;)1SA0
M0"E*>9 '(H[*TJYE XP ?BYW$ZCNO8&!(&N\J^X/+N_$_/8+A,9(+2E+5MH:
M2E'[TT1O8YF4GD)WI1.OSP%)Y0$I3>;$ "#?0$^9N/\ -Y4 1'01:P\OKMTL
M%Z:A2H_^%L_] C __0R/J 0#K+K^-CH- ]P" =>G0Z@3 GD)[T4@*E$HB41*
M(E$2B+Y*@#KIT[[('3N3U]!_]==-Q-XW_P 3Z\]$5%F9)8H"7E3+O;(Z8Y4E
M\NSXB%-J2HH*5(\TK"@H$%! 6G1VG8(%VL>[]K''N$ZZ7T$[20KM8YVGT,>)
MB!J(O>1N0#&.3?<OXY9$_C]B$RR\+XTGR[C>VV%LRKL(J@LJA27 V/=Y#HTA
M+:WD@%)VZE))WPVGA&AQ#7U"VQG*)(!AH@@@$07@"=XDQC-HW\"8/B1'S $Q
M)@*1.)XA8,)LYLV.01!AEQ4EW]\4M^5*6AM+LF4\L@N/O>6GG*0AI('*VTE.
MP>/=5+WP\BP%YT!C;_,F\J=+Q/3G<F#Y[Z#14G.LGM>)8M?<@R*[0+'9[5;9
M]RGSYTV/'9C0H;"I*G%.N*9',6VB=@J.CKJ%$TX?1Q&(QS&MIG*:U-K7$YFP
M^6R8!(#?W&Q^&;2 1Q_&,;@\%PO%XK%XAF%;0PU:J[,27/-)CGY&?$V'/(:&
M@;O@-=$'11[.JU3_ !E^(3CGXT.(\24[;(616O!N%]LDHY6;1:+5%<E1H3:@
M0B2B&PZS*DN>4V7W[J)JPUYJ&AL=N.$,JUN&<,?B/>X-F#&*J4C3AE2KBJ@:
MYKF^\(EIP-%SJADD0/A+05YM[)^)GBO$>T_:;%X6GB,0,?3X'P]SRU_Z6CPU
MG$'NQ=,NIN.7&T>,BD* %,4!@F5*E3$>_+6_H$3 ="4I1) 3RIYTE@*2MP <
MR@CS$I3OEZ I44ZT%$=*XP43[^G5I/\ =4:=+W7Z=K8:8S0[,"P @.:(]V?V
MB"-O6:4,M4 JAQ+GS\)<2!O#H < Z(/*=U6*VD2B)1$HB^='>^;\-?\ /^WW
M54AVS@/"?N-T72TTZA)2MY*SUTH,A!&__;5OL/4=AU[:L\R?AAHY'XN7+*.>
MV^JJP.'[W9_#*=23>3K*I]VM,6ZV]^#-3'>CR$A$AN3';?C/,EQ"G&WH[I+3
MB5)!2/,YD)V%<BN4 Z./X;@.*86M@^(86EB:%9H%1M1C'26/;4ID9F/_ &/I
MTW1!,L!!! (S4Z^(P]6G7PE=^&K4GM?2JTW.#F&1):0YI#B) <#8NF#$'6WX
MGO#LNS,1<HX2XY<''ITSR\AM5A;DO-2^8$Q7TP4RBAEA!&C&C(;1S*#BR- #
MYG]I'LUXJ:U/$=E,9B< P$M_3X;#RTYJ]0#XFX_"Y6LI'+H20P?MT'LG8[MK
MA7T*F#[1T:'$7? ZC7KO#:C0QC<X,X;$!Y.0&99$G-FS$CZPS//$OPCL5HB9
M%P]N&98]$B,**HZ7U7ZWPUKYA'>6P'PIR*V AN&8I6VR$!<A2B2GB^SG&O:)
MV9P[:7$N 8_B?NZCBVO6Q[,/\#FL ;!&+<W*YM1X=[PF'P6B 77XKPKL5QG%
MFM@N,87ASGTP#AZ>&J5LSVEX+Y!HTV@MRL(;3!!9F+G.<Z)%8AXML!OJ?=<A
MC7#!;F%>6(66(D6QQQ1)TM"I41E+B""D]%$ :YBDJ":]:X9[5?U R\2X#4X:
M\:YN('$6+P ?AX?3(AI!N)(T!VZ;Q'L57HN<[A^,I<0HW(<RD:+K-T(=4<W]
MP(_>"#'-9_MN<6"\,(?M-SM-R0H @0KK%?.O301LDD;T.GH"1M._0<%VHX#C
M:(K4^)X8'+-1@+R:9EP+3+&DD%IF&S8F%U'$\-XKA2?>\.Q#0)^)S2UMH_F6
MY+R(^+ES"]JLLL33#K\BZVV,A@ZD*<G,:8(T5!P['*I.R% Z">A4I()(R'M)
MP$->_P#Y;!EE,AKW!SCE+G!K06Y0Z[B 2)RW)L%+.&\2>!&!Q.9PEK12>9 $
MF'!L6%QI-@-;15X@^*F,T\[CO"RPRN(&3N/%B.+2),BWL%"E%UYZ1%B+;?9:
M(;*G8DA^&HJY%R$E;5>5\?\ :AB75G</X#PU^+>:@C%TL6ZF,M)];-\#L*#\
M36,,"I S@9G#]W=^%]B:3J0QG%^*4N'4@T_];Z#JM0N?E#02*@:P?$XDN^,&
MF0:;3\0M&Q<*N-W&)E$WC!F$S%+&I:C^2&+L"UNR&N8%*)K_ )CTI "20H+6
MLKV3I(TE7&87LYVO[0UFXSB''\5@<.PECN'NPCJXJ#,T.?G'$:0 #6N:9P[K
M5-8$++BN.<%X12.#X3@*6->\%YXBZNYKV.RG(P-J8>H]PEP?\-5@!8/A)<",
MLP_")P50W%3(QE,AR,^T^'W9EP<?>4SY1Y7G%2^1;;I1_FAI310[S*V #JNS
M4?9#V8Q%1F(XE0I8]XN?>X2B"[^0,N-3*<SZA(+23G,D_$3Q;.W?:"@UU.AB
MWTF.#AE94?E!, .%P20&M EQ$ 2(D*15OL%IM<-B#"A1V(T=M+33;;80$(0
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M+\Q$TV')IF,%TI4W"P7Y#ONLFVW N,)2$M/19: I:5Z*OWQ0V0I)+C24/'D
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MV%H4:F9].G3%0E](_$9=&5I<X- $[U*#:-GH/30WU WV'+OL?7K_ %5@:W0
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MCZP'_+_"ZC2?6( IG%T \EFC8 (($#1>YX_M-V#XKP6A2Q%5M+%U</[MW_\
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M%?\ @^$T<3AN">\I-JUCAA694,U&@/R!CJ]9QJL<RG2K.+26',UQ=4$QN$O
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MNW@XE:VP=)4CRU.!0TD:YMCE&DD$]?SNXT 9?4:^FZE4I/<'2# =!:X.!$M
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MO'Z6Q?6MFZ3P._?\G[N0.G;M]1Z>NJ<CL'"><0[FH.O@?MR5Q44KX=*@A12
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M+G.%*20G8JG]36I4G 9148V-9S.9( ,3<1 $3S!6.HRIAZ&,Q0?\+:#JK1F
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MMM*4)2D)//T=54M:=0#Z]1RV7J;;0TD(;0E"0  E(T   D?J2 /N I).IE2
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M6N6BTI/.?(@%Y!"5(.QSM?*DH"4J!/,O4QO$:C:@HTV_];Y :T$-@%T?_L;
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MWB02 (B]S,R3$%>ZN)<&@R0S21MRTDBYM-IT7J"N4:/-W(&D+Z)*CRC\WT2
M">P/4]"*OO\ Y^^BF1MI'(CY>NX2%]<PZC2NFO\ !5Z_0ZT?MUV]:A)]0?7X
MW3G'7HKH-_F+/T[:3U/7L.O?Z&D>I&WKQV43W^1W]7Y;IS#>M*W_ .@O7Z^7
M7]=%*<X/HON!_%K'?[T]OJ>P]:)/J#ZV]2%QYB?HO_>W/^311/?Y'\+DK ]%
M?@A9[?<D_P#/Z4CU([_7EJD]_D>[EZUT0+!Z:5^*%CM]I3K_ "^E(]2$GO\
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MOJVL>@/JD=>O;OO8[@Z(N.<=>B^G_BU_=T^7K^'W]J*)[_(ISCZ+Z]/XM?\
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M@TDEN:6D#0$$D7D@W D"00)F)A:TO:&>$?VE/%#)>']TC<4<6XN&*["8FQ^
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M_P"F([=-?=23S];>2C*/0%_EW^90<._:1CH/%GX(0-$$#V>O'( [_P#Q,/\
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MHO$:7Q*Q'A>^\T_#QNW<:>&66>(+$K1%B27V[S*C6'&^-7!&; D7QUN*J.Y
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MT6[)-S!(2V_$:\D%I]U&G$8LI-IWF^AD@ZBP<2>8UF8!* QJ-;&#MH; $1O
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MB41*(E$2B)1$HB41*(E$2B)1$HB41*(J<67_ (J)"4#R/</)*R4_QOO25\H
M/F;\KG.^7D)Y1S [!F;1U)^0C[JL'-/2)\>7W51';MK[#K8^PZ)'ZB1]M0K+
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g454025g01a38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a38.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1IX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &ER^9T@X0DE-!"4      !                      .$))300Z
M  #_    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$
M5 !! "  +0 @ #$       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 8>8,0
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      T$    &              &"   #<P    8 9P P #$ 80 S #@
M   !                          $              W,   &"
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   &"     %)G
M:'1L;VYG   #<P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !@@    !29VAT;&]N9P   W,    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MI_E_A
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@K-'=H23I#AUA8:4EK5F9W=XE:.EIK*TPM+4_\0 '0$! 0 !!0$!
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M\E6E;2:AI%,JAJ"8PTME,KAHB83&.BGT,P\-"0[2W(A3JEFZ>1#94CD4"HZ
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M\DD8>9+FGLBTM25%JD"Q<Z: AWV3CGI]Z_A^-PHD21ZSA<1)"C,4:S92TT+
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M>P(Q63LDAF- XH-"Y?E0 4=P##,JE5$N]%*+]HT&F4@BSG4"I>0D658)%KZ
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MI$==2K,1V:.R@%,7#BNS@@NUGB4I2K7E%];!/+8*&HMS6)[C>VNY)5I" D@
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MFF+PCGS%R^?T1#P:H:1OPS\<XU$PKK[2(*73N%3V<V,6HI2OLTDZW!^(8A;
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MU8*>./F1<C2X[RD62-R0=+WOJ;=QZ6T$Y@$U-0!0%GL#J;"C.G45OA)*!*0
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MTAV'2R[#1\2HEP'F/T2N 8B24D*L'>C$Y2DZUS);>H%+/M.)](4K$8&>%RT
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M C =FAV&Y%7%&>@;P+$N7C$J0H%R PJ"4U 8AP6JIQ9W!.Z6<Z!<<P -R05
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M%6Q])0E]R"=N8G?IBGIOQ W!;NT8"E.ZS%[ZQ]/Z"^C 2P,P!FHM+MS^;?\
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M]()6"P<N45I&45#A@Y4=[%_X:^4/35T&XWQGC4Z?P_"8F85%!!0A1)2E,E(
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M6J82MD94@R4D9NT ?G&  < ]E@ VP)[R%^>X5SJK^ACSZJ[.%FP22>;TN5*
M !TTN"?4,<+3T[2%]E0+N:T+:B_9 9K:1W&C\F?$R)W7IZMBSISABH$J"C\W
ML2"223F))+4@>0MSXY0KY0:*(Y>L-.#8&Q%O0%C8 $]V^,_S\03=(H.0<78L
M172SUK&HK\FW%J)62@E2E$DS'8J(+!TAB  "UP #:)_ 5Y\$%0S HPFU@/-Y
MML!R\Q/)T!N#>VVI&F(>GDM_:3X7J7% VPN+$V<1!^33B0" $!P"?G$L0*6,
MLN6+BI H6=P0\A;GQI>OZ*(OH1#3?90 ZIZ:';573%_/R71B* ;DBQ!+5<M4
M$B*G\FO%L0Z,JE$CYQ(%0S',A3D4(9BXML_ 69];C,"B38<O\6F_CJ2$7) !
M]N^E\/S\E,64DTOH&WLSWKH:-#^37C#0B60 4CMLX;*02 20U*:.[AQ#\!9G
MT=!F!1(UT_<LV MO8'D&VN]S8VV"</S\E"Z@P'WACS;4U'@2(A_)JQA&5I>4
M', X8'D,H HX%'ML(G\!;GR""<P*))'_ $>;$W4?I:(/30Z$:7W Q/S\EFN8
M%]@=P?':^A=P8H_)KQ(*20C,*YBL N=?88&ATV(J','R%>?)3_? HHZW_BLU
MVTWNV-1H!U%];]+^?DOZZ;,;AGUT(I?0.',!^35BK@2P')HM(J[CZ)LP;5ZN
MY$#Y"W/C4&OJ*TMJ(:;^.M^34WN5&]P;7L+WGY^2Z=M+['6NSAK-N[MRI_)J
MQ1!!2A@S 3  *@D^Q4E57[G!8DOP%F?!*A\H%%>HPTU]Q ;[MQU.NHP_/R70
M%0!N[%F W:M6?\*F?R:\5H$,#[(F)H>0" SI[)II6H8#Y"S/BZK5_15QJ"8:
M;D;6TLD@]^EK]01?%'3Q%.VD:.2Y8/=R- QIIX0_DUXK,5,@DJ=RNH-]4FKD
MGQB?P%F? N/E!HLW/,!YM-1KU&J";;DZWL1;;$_/R6[E2*$.P4 ?N>MB!HT/
MY->*K1%69YJ3E(# ATNPU=V8@EPX@^0KSY(US HD7ZB&F^@N-QR;Z:'3K;O%
M'3V6:%236[,QIRL-14, &8$1B?R:<43F:6Y J9@46>ETBI+L14%U"II/X"S/
MBX/Q_HDVL;&&FX[QK9/C>X/0D @WP'3V6S9DD5>EM;D:-;1RQ,#^35B202F6
MX()[=[C5+NHERI[@:DP'D+,^=?[H-%WV $--M56WY>0VOII]&][ !5L3\_$"
MA*? ?8:O1]O%J9_R;,58A!>[S$L]6+9&<$AGH'(  48C\!9GS<_E_1%B2"##
M3<C0 ?HW'?<6N.NV+^?LL_32Y#@U!:N@H0:) MRL^/\ )JQ8(I+(8@@K2?HY
M17JZ,+%V(-Z-#\!9GO;^?]$@7L#YM-CJ-"?HC3Z)Y=;$:6 L Z>(^NERP +@
M-<E]0PN-*:Q#^35B3=,NE#VAH& ?(["C))(H*4K4/(6Y[@6-?T2=;W\VF]P;
M7N;IUU[K#06&^(>GDOZZ')9N?F=W=S=BS1D/R:L4'[,LW.;.*N7)<HL1H&!V
MJ1$?@+<^;C^Z#10T.OFTVUU[^S)!M8"VEA;E&M@Z>RR7*D^\^- 'WYW<TB_R
M:\8#0H30L1,2&#O0E#@NXNW:]D$F(_ 6Y\:CY0*)ZC6&FVNO^H>^QVVL#J<4
M]/)=&4FPLY)OW/4"E'J6($8I_)JQ0)/S;DN3G2&/?D<$ UKN#4M$CR%F?-S>
MOZ)U_P"C34"]_I7[/<C;30B]M3@.GLO10 %ZFU:&Y8>-R:,(?R:\75\A=(2.
MTD%P16B '9(RAJ$9A5R:?P%F?%_Y_P!%'4$_N:;:WO?3L]!<G8;#NO=^?TL@
M=I+5[M+EPQHY>Y+ZB!_)JQ9(?+H""L$974<K9""EZ@ !F8:O/X"S/DZFOZ*.
MN@$+-@"#?35OV'0;D @C%'3V6S!26(&_)KTK4UH39V:)_)IQ;NZ1?V5 5T^C
MHPYAG!!B#Y"S/F_\_P"BK&Q%X6;BPU'1 3MH1;U@^E>?GVCZR=03< CP?>PJ
M6#QD/R;,8'I+#[+:E15@'</H*/HY@GR%F? N/C_11\?-IMUZZHZ$6V)L>\ X
M'IY*-E).M"SU#V -BVE;U<Q!^37BT@^Q8AS,W<NQ#$OF/>:-$_@+L^+W-?44
M;Z*_<TV]=_H7U%[C5.N@!N,3\_)='4FH%AN.5Q0Z/=ZQ?Y->)^K+8$D@K#.3
M6F0'O%A3=B'D+,^#;\OZ*N1UAIP%>PA)-[D:G>WT;8?GVB^=.S,_CMW[6-HG
M\FO$F@"&N/G7(848E)-$LW+=X?@+<^;!(S!HD=;&'FU^N]T6ON+[[&^+^?DK
M<7/<*_A2KL>Z'\FO%4#2S0L,X)8N=4W+YB0'.\2KR%N?'+85_1(-B;B&FRK#
M70CDM:VECW:C<@.GDL'VA=M=&/F?"A>@$4_DUXK+E EA@H@E:: @@T*!3E8U
M<%Z4CR%F?7_*!1)%MO-IL=QL3RVN!^OJ=,0]/93>T!S9A=B!J]];BXM$'Y-6
M*!H$$:C.'8UIV6%2[@<[U%1\A;GQ<7KZB?6F&F]MS<'T"+:C<$V ](X#IY+8
MC.&8N_@+T-Q0.:[:4_DV8M1#B6PT"Q4.2Q&0CZ6H+T/=3^ LSY.OR@40/_9)
MOMK9-BC0:Z@WV'J-_/V6X&9+TH 00:5VT>U1?>)_)JQ5V0:DLI8*>U0@ HL7
M% :D Z!GX"S/D@DU_1/2W+#3;6Q&ANC<7MI?2Y-CJ9^?DL5*@U]7O8[4>M/(
M 0/Y->,4P)EG2BP&+BH[!&B0[E[N%%XD^0MSX/\ E_1(-Q_@TWL.O5) L-S?
M?NL,!T\1]86LST-Z,UP6>UP#<#^35B@WZM)!/LK31Q0#LV:A:XHP!8S^ MSW
M&AK^B18:'S>;$Z;?F]PM86N!H!H<4].Y9'M#N%#</N>[NJ\/Y->(JZ91))<E
M:27.M4OWM0BC!Q#\!9GP !\H%%;W)\UFYW/0%!T'>22+7[[S\_$7S)+\J,_*
MQ>X%6U:*?R:\4 D$2Z$N2L,7)+@93:ERH!@;M$'R%N?'TDY@T4-.D--K=;FY
M23;N'-H#;?7%_/V6[%23RUV!T HSN'H-'C$?DU8L *24)(H")@T9OHYF#%@[
M,PT)+\!9GR;GY0**MJ !#S;3>^Z"3KL=QM<='Y^2A0J3H:OH"]CRU?<O4QD/
MR:\55@C5B%)\'[!=JU#&IJU(#R%F?%S_ '0**-[?X+-@1N+Z-@'>VH%[7 !L
M<0]/9;>TD6%7KS<VMS.CL3!/Y-F+!)&2_P!%:1H [I10M38W%7@?(69\C49@
MT41U'FLWO>^NO)M;NL.IVTIZ>RW/:2]"+A@X%*!NYB"=;O#^37C/[%->L!)+
MJ)))27K5A1PYJ01 \A9GS8WS!HLDG<0LV UMT+=KBQ-]+WW/,<0]/9>A3N>1
M8GFPM3;9HO\ )LQ5SE*B2RC,#FH9^Q4@B[@DFIB5>0LSY(']T"B1TL8:;&X%
MK'Z %]"2=/  :8HZ>RQ]))9^?=X5<%[O6Q$5^37C%..P :#,M)U2=4@$EJF]
MF9C ^0LSYYK_ "@42=?Z--R- =19 -[]=^^_5^?DO1:;&I!9F%>0+4+:D;Q?
MY->*)J)9<AP9@<FIN$@O4$N[$ FM8?@+,^-#\H%% @ ']RS?N%_S%7^V^NHP
M_/V73M)N&:AU)T8,X\ -#$_DU8H', @%@*K%!04=#L6+5)<ER[&'X"S/FX5\
MH%$@Z7"H:;V.I(%@@=X'L-@,/S\E5=0)?1P13R;;G4/ _DUXIP1U8 +@9TD7
M>G9!%0'8T # .(X8GR&&?#3+CZLP*)*60M92(6;7*0DE7YAT"==K6WZXRG=/
MT3TR)#@90E+@D.RW=B0'J6:W*,/Y-N,D";/2I'TELI2&!R  /D/9#5<%P=7(
MC4SFGE_,<H\Q:QROFL;#Q\VH>?1M.Q\7!!P0L1$P3P:6XREP]H$+6H<B5IYB
MHFX'HC'.\%Q"5B^&IF%094M+N0"^0&KD5MX #=O/?2;A>,X#QG$\'$M<R;(Q
M$R2>K2M<NDPH*@0EF<.E]25&@KL(\G5Y.ZH>)>IH&OZ]@)A)<G91,!$I=650
MT56$4P\4_!TN4ML\T('$+3,)@H!IJ%4(>%YHEQ3K7">DG29$N0<.A04M ,M@
M:  *!4H)=R"P J_@6[V]$OHFG\2Q.'XGC9:I.%(ESU*RG/,*Q+F"4@K3J"I2
MRP"7<AV!_7I1E&4]E]3$NI>F93!R>3R>#AX*!@)?"-0T#"L((2&&&V FUQJM
M=A<GG5S:G'3V*Q*L1,4HN5$Y@]22:#D Y--!L*1[AX9P^1PC"RY,A")<N4D(
M"$@,& %0SJ)>JB2Y#DFL7 &@'30>-O;UQ\\;D*@'>((TW4->E[]=-C8>JVPU
MP^/CX[XGB?=^$"/%7LL-].X?V;Z;X1&YJ\W^T'XO$%)/YZOJ]V@&GWOJ<'&V
MG/SO?E[HK&O:/D&'Q\6AR']-73J/;T^]M]<5QL/?^/QSB,K?[-^[;7?32!UU
MNL6TT %_&Q'3P&NXO:^(#R?O?[B(K'<^[W4>/&UQ)XV=4=5,HA2IV(F<@F\"
MPRNY#CT7+XAAM*@A-R%+<2#;QTO8X^G#3DRI\F:4UE39<P$ 70M*GJUB'%:[
MM&U\5PDW%<-Q^&2HJ,_"8B4$_6,R0M&6VKMH]M8US<"/D\J.X7):NK)[#,SS
M-:HXAV9SR?*AU*AY4U%O,Q(DTF,4PW$PT.VXTGM5%+;T0YS.O$!*$#?.*](,
M1C09>8J0ITD9BH,<X<]H@T5;8.:&O >B'HWX9P:8GC$Z3*3Q%02QF(EB;+'S
M<Q03\VA0=26*B<WT0227V?LK20"AM:2%E)!2!L+A0&@Y3L"3K?N-\<:4D$@D
M FBAJSN1X_9YQVBA>=)2Y3E# '^RP!')JBS]Y#_8I)58@GOL?9X&WW\<::D.
M0U-_/[.0C*)"0/$]^*E #:GX\?QA%6,X1"@2+ D>(MA$()L6]\4J.A YMMP-
M;C8[:GV'#WP()# E]_X<O>T:\O*"<)$ZXO*+H#+J!F#4LE4/7,#-ZCF3H<6Y
M"R>&3S/IA6T-+!C'RD-0Y=Y6FU**UK'*G&^<'XJ>&KQ"T=E4V4E!(.4EE!37
M8@>.G..L_2%T+F=+Y7"<(5/)D8R9-G$L0$KDE-04*H2!;*-SOD=D7D30/#ME
M_*\O\OZ?^"I/ -=FM<)#)7&S*)YUN/1\RB.1*XA]]QQ2RX\2M=R?1%DI^/'<
M0G<1GE4U98%TYR0D!@*$N'=W<OW".4]'>CO#>B. EX/A^'14/,,F6EUK)*B5
MY<KDE9>C.](OD&V41+KRBX%<K14'+!!]'E3R7M<IOZ8N+$];G&W )2#0"M3X
MZFQY$O'(C+[07F!"G=+BF4,'!#AW>I8[7>A]F"B.1Q<,A]>H!2T'%).R>:VV
MHN 3K;;KC50N8D$)F%(+/4C\;?%XT)LN2HI498F,:Y4YJ4%=*-8\[1JWX[V2
MQ6M')!L%4\\I"0GE"4_"#X2D) %B-=M!O?<'7E#$K!*)A" HA1S* )8'05H#
MJ]1:)B)> 7U?6X)*U)3ES=4%  FNK@G:]7UK@2V#RBWCO8G?H+=_4 "]]M<9
MM/=C/26T$PC3<"K1\W5<+(+8!&KIZD!5[,[@=_=%^.&!D/9\T.VL!25QCZ5"
MQ-T^9Q *>NENEK6.W7&A-.(2JL\BB799J*"A(%R >]^;Z@P'#B$S481$M:5,
M&E)!&6KGF68*8"MVOO#:E<)#@N(AF^< 'F2@%SU)T'4;=WMO\ZC.F#*N:H@G
M4N!XG[.9[H^E,B3+)4F4E]PD%1Y!@_Q>/J86MU("V7&B ;<Z"B]B;7\3IH>E
M]!?&(24DH<J 'M7!<Z$T(_?&HE68/E4GDH$$5YQB?Q:\*= <5>7<SHFMI0EY
MYUAUR33EEA(FD@G"&71!S66Q0;6XA3+JDJ?AR>RB4W04J)TWKA?%)W#%B9*4
M04EV<L12A#C85#EHX7TQZ(8+I3@UX;$RDK4I*@A90"J6HA0!?*737M(+A5"*
M@QJ)\F/PLYE<*'%KG%0M>RJ+5+Q2;<73-2M0CZ)54TJAIRTTB+AG'6&4A]*$
MA40RDGL5*-P+@GDO'.+R^(\,DS!/EJGS4(7.E]8"M"RE>8$%14X=M36KF.IO
M1KT.Q717I-Q&1,P,^3AI*\0B1/ZE0DS)6;#E!1," A25!&9+68@BAC]%+*N;
M\QP)(%BI-DZV(()W Z']F.OTA14HJI6C. 0_OM71N<>CB06<$N'L2][WK^/?
M'-S6N++[M$FW=II[K>O&HQW]X^.6_C$=J,? 4'QR@5;:+T_T3W['3]736_7!
MM/O&O>?M[HK\CY'[OO:'-X+TOIRG7ZM=]!?IMA$S<E>4"K<67ZPD_40.O[>G
M2MW>8AFY*\OCXM2(YNMG/ZI^S!CN/,=V_P!GXQ<W(GP/WQ//;HLW_P! Z>X#
M!N[S'+5_OWVH?O\ (_A\>4 J_1>ESJDB_AMKX#$;\+@_?RN;>,3-R5Y&(YO!
MS^KO]7WZ8K-MM<'[_>89N2O(^?Q7E#F\'-/]$F^OJ^P6VQ"*=_,/7QIXVBYN
M1\CY_%>4.:UA9S^K>_K-OVX-2_O#^5_/[(/R/D?PB>:_1S^KW7[Q;7[,4@\O
M,?<8F;DKR/G\5Y0YO!?]7Q]7W&OCB-S]X^.^^QVAFY*\C$\VNR_5RFWOM;QW
M_:,"*7;N(>A^-*B&;DKR/Q7^+1'-MHO^K^O2X[OV]<&^':W<1[KPS<E>1B.;
MP<_JGK[+:?[>N&4W?;4?%=?/01<W(^1\OBG.)YO!?]7^S[^O!M7]X[K/7Q?>
MT'Y'R/X0YMM%_P!4Z^NP^K3U8,=]=2/W4Y^^&;D?(PYM-E[_ *!O^K;Z\&._
MO3!^1\C^$ OP7[4'[!]_'#*=_P#F%+#?XK!^1\C^$.;P7_5OU/@?]EN_4!SO
MN0-!W-^+P<;'R/X0YK=%Z_Z)TU/A^N^EL,IWVU%;;^]FU>&;D?(Q-[@Z*'L-
M_9H?OKXXC&SGW:\VT_C$S<E>41S:VLL_^'0^VP_9BMJ_@X^R_E2*_(^1\J?P
MYPYQW+'_ (3U]G3PUP(._D4G\??!^1\C^$ J_1?M3;]@^X]=Q'._,'\=OAX.
M-CY'\(<VNSG?]'V]W[;^W "@^\A_&L,W(^1^/X=T.;I9>_Z-MNE[ 6_7WX-K
M]X^Q^?PT'Y'R/Q_'O9S^"_ZI^S^S#*:5YW \"S>1@XV/D?PB.?P<_J'[,&.^
MVH^[WZ>^&;D?(Q(5KLO;JG3;U;^W?!F_B/N@_(^1^.?[Z0YK]%C_ ,-OUC[V
M]>*S;>8/V1,W)0\#]T.>WYJS_P"$_L'W]^#$Z@>(Y[_%M#6OR/D?PAS>#@MI
M]'O]8UMW_7B-S]XT[M]C>S:0<;'R/X1', =G#O\ FFWZK^J^*QW'FFOQRB9N
M2O(^7Q3G$\_@YU_-)Z^KW=,1BU[[D/MR;W;Q7Y'R/X0YM3HO0?HFVMMK#4CQ
MOUP8TK[Q[_+E[Q$S<E>1ASZ#19_\!O[=+>[]>*QY>8_'X\H9O[*O*(YKW_A!
MM^;X[#3W^&YVQ&M7WCW_ +_ 0S<E>1B>;P7_ %?#KI[?7ZK8 7KYD#\'BOR/
MD?PB.86V<Z]#?7O]73[1@W/WC1_M_#E!QL?(_A *\'.NZ?M'3I]QBMW>8_&)
MFY*\C7XYQ//X.?U#K]7V;>]E.X\TPS<E=S'^'OAS_P"BOO\ HGUVVMX?VXA!
MN_@"GN[SOJ-;17Y'R/X0"O!?M3_9?WG7UX-S]XKY?=:&;D?(^7Q3G'71)4\U
M&H"5@):>;LI-NT2MHBZ18DIOH=O'0XB$99R%9G<A3/0',+V8ZWYOMIK5GDST
MY"#E4*@N>PJH!+5)8:&[Q^8JD?)T3_B5XX\^*[S!ELQE&3,HSDJ1Y]U;,3"Q
M=81,/&:RR4NE@!,,K0QLQ2X"W"\\+!([9UZ)1V,KCR<)PN7)DST*F=6!E2L'
M*R""I@I@6(#-6[U:/+R/1@OC_3K'8WB&"FR>'#%S)AGSI!0B<58A*DIEK5+[
M25)<J4E12D!S4"/TF4?1-.T!3LNINE9-#R:32>!9@I= RZ$:8AH5AD(0AEF'
M:0FW,A%UKY?2-UDW..!8K%3<2M2UDDDDN7)-[UW/-NX!O2O#N%X/@^&E8?"2
MD(E2):4(0A-$A(:C!] Y)<@.7K'MD!!;U;4!872I-E7TT -CH1I]6F/F -RS
M\MK_ ,?AMP?,"X/B"#[^[NM'/BQ880AA"&$(80AA"!T!/=A V.L4%0*0>6]P
M#:P-C:XO]^N!+%GK4?=[_?$': <?9^_\8^=43#M+2EQYEI9T"%*2E1O?0 D6
M/3V$WMO>KF*[02H@&I8M;D'-*L];=V"IDI!RJ6A)V) /EX17YW##4Q#-O^T2
M-]OSNNOWW9)OU3_A5X??#K9?UT^8AYW#?TAG_P!XG[< A?U2>Y)_?SAUTK]H
MGS$/.X7^D,_^\3]N&29]4Z/V5>/\*<X=;+^NGS$!%PQVB&?5VB;_ *]!Z\.K
MFNV0M_=43[J7I\-#KI7UT^</.X7^D,[7_A$;>_\ V89)GU3_ (%6;^/A#KI7
M[1&WM#X,/.H;^D,_^\3]N&2;]4_X5>/WPZV5]=/F(@1D*1<1#-O^T3]N+DF?
M5+TT+.>=>?Q6'6ROKI\XL_G;G70V1U(?'RN)@J#I^$F<HEL7%LAMU,,J?3:!
MDD.]$!2TA,,W$S!EQUPFS:$%9O:Q^G#8.=B5*2E)H-B#8DD7V\'OMMW$N,X7
MADD3)TU 1,4$YB4L[T9U)#EZ>-ZQ[^GY_)J@E4#-9#'PDPEL=#LQD/&P+[;T
M/$0T0 XT^AYI:FW$K2KG24%0%_$'&E.DS)*B%H*1S! I>_WQ]>"Q6&Q,D3),
MQ,Q)2""D@@N]7'<YVUC6EQY/!VMZ2(-TMT_$)-K&P3'O:Z'N4>M[:G&,G%*!
MZF7])7: W%*LJO(LS Z/$FXB7)4HK4$H <E5J.[DG1OPI& #,5"+=$*F)AS%
M$JY6 ^WVW-Z)MV85S\VH('+<WT&HQ]JL%B$HZ[*6(!M1Z%_(NW,L7CY4<7X5
M,64)GR>L=F*I;N#6@V</9GK:,AN%M*DY_4&""G]W/:*T/\3?W/772W4C?N^!
M945=H,H!JW8$@??_ !>-R0I"TYD$*2=000::,6J&UUC>AC&,X80AA".L7+(9
MR*5&J895%=FIA$1V;8BDP[BPMUE,007$M+6 M384$DI%P2!C(*(IM^_\?!A2
M-!4H%1.4%Q?ON'Y_>:M0=F- !W8QC7% !M#"$,(0PA#"$,(0PA#"$,(0PA#"
M$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0
MPA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(120#?2]QRGU'0_P!O?;7;"(1=KFGQ
MX6NT?$Q P\'VHA6&V$NN*B%]DTT@+B'%$NNE+:05.N7NXZH*4JY))VQ7JY^/
MC74[O6,,@ 8.&+UJ*N["W\-!'W"]A< &VPV'JT&GLQ(U!8?'X?8(G"$,(0PA
M#"$,(0PA#"$-\(1UTR?=8@(IQA-UMLNA 21<*2VL@CTA8IL#;<>S%DIZR<@+
M< J KN5 4+-6H?WQH8A:I<B8J6'4E"F:I#))>E:-W_;'XMN(7R@?&'3F>6:=
M.2+.6J9=)Y#FA64FE<!#IE18A)?*JEF<%#PX[>6/N+2AEEM(0IQ-@D$J[N[N
MC_1; XW A:T!:U2V3<',9<O*]AJ7)S UVCP3T[],723AO2#%X3 8F>)>$Q,S
MKY:5J(")>)Q$I;?.4JD )<,0;4:TY\I-QJ@7^7.J D%043#22UT%(4+_  9K
M:XVN-?;C<?S0X85]7E3G=LH4"7:WLZ6Y>;<*F>GWI7+2%*G8E*68E:BD.P9E
M=87%R%:A)(HRCQGREG&DDB^>M4:BY/FLFV) U_>W0[#46]=B1D>AW#D$ R\I
M-G+.U7%*^#_?$1Z?>ELP RY\V8&#E*RP)85)G48G4%^X&'X2WC1O89Z52+7W
MA9,#OT_>L]+D^O?>T_,_ANLL/K5S:UO#]UM5/IXZ85!F8D,"Y*U5=F9IA(#$
MN2>YVBD>4LXTB?[^=4ZB_P#%9+J=/^K3J1??;U8#H?PT5"!2C.7;>@<V&NOA
M$_3UTO=NLQ#J=OG  ]@ \YS4*&FAU+2?*6<:5],]*IN"=?-)/Z7CK+!H;[#6
M^FM]7YG\.L9?<YIRT\13\(OZ>>E[.9F) 2[G.HZJ<L9H!RE@02&):A$5?A+.
M-([9Z53O_19,1;KO++Z7WZ@Z:ZF'H?PVYECF!ORH:&P%[>$'I[Z6US3,0 "V
M;K206(!<"82"'#AP]@22'C\)5QI&]L\ZI/AYK)P3MI;X,Z \U[:VU (TOYG<
M-MD O4&W-PD5LP<<C&!]/G2P *$Z>JE1UA"GI3+UR@&J7:H%6) CQ.8/&YQ.
MYMTW&4;F'FI4534M,50QCY5%0TL$*^N$BF9A#><AF6!82E^#0I"^T1R+2E0!
M) QK2>C& D+!0A.8N,Q+D,'(;*U06(H1OK'RX_TQ])N,8">J=B<04892"$9^
MPM4Q3)4KYTU0 2&(<58@D1GUY,CR@=?Y<5Q261%5LSJM:&JB9,R>0>8MQ4UG
M5*1#Y4D=BRA;KD1*W%+"7D.]FB%:"EH60"D\5Z5\&PTN0J8@!*DI+@)%0"[*
M( KJ'[VN([9]!_I.XUQ#&IX?C.LG8>:I*4GM**22K,N43,-W8I9BG4MFC:EY
M3J>S&G)0Q/I,VXJ9P%!Q<:P$H4N+;=>BG6PXA %U+918J2?H@6)OKCKC@&#D
M3L<H3"D!,Y(&8Z%2-A4-YV+Z>J>G>(GX'HQBL9ADJ,T8=:AEJHJ$B:JM: $
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M  A"0 -!?4D:XX9BL6K&3E3E%S1-;T4KEJ]*!WTT[?P?#Y'#,-+PF&#2D)!
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M*EWW 'W;=VNL4CC@SR)4!\4"4)"O1E#ZKI4!R$#SO\\:IYK%0OI<'&7JZ7-
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MS3BGI=/HR82]ZH:9 "H.+FD4D3)L0[2EC0,F?JI)?8G0\P:5H]14F-%J6'F
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MJ<=<?,= PEE)2IQR%+2=%CEBJ D .+%N?P3[XC@6V9CN2Q;2U-#M6/%2[/\
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MG<;0A5@7FAV+AL$\K2"D7)2G34H((2DAAJ X)-34!M6T,24E,M&30 V%JO0
M"Y>@H_='-\@F<I^EEW4E[#F @SJ0+$G6^IVL.H(M?$,UJ%G-[TWJ&H2/LTC4
M)HXT?1J;-XVJ2Y>P<<A<Y+?WO*DL>GF1.XO?Z0^O\[76^+UH &QH#86]U>=6
ML*F,<P>M2*T_!JAK!J.-@(#(3.37^YW4@O8']Q*T]Q %_$:;'K>=96A!-F8U
MJXI]X>GG%*NYM-6TJ2_=I7N #Y!,Y3OEW4NG7S(C3KI<6)(.MNF]KG#K*NX&
MU+M3PN=C?00<=]*W\BQJP 8!K@M:"N'_ #;<24KRWJ9274=D^VY!]JVXSU2M
M#ETFQ-PDWMI?;2];8TJ._P &&M;5/E&.:[FW(ZL*G:E[6$<3W#YFPZEUM66,
M_>3$-]D^(F7,/)<0@H[)QQM3)2_V0[;LV7#R-A:N10[11#K0;%O*FFK$FE ;
M;L8S?G4WH='O<,+<]J5IAN'K-B"2$PN5\[AV^<*4F$EC,.UHV4!Y3(:6EU]:
MOI**@4C5*@<3K+LQ-!XO=C<U)!#!_=CFU[S8FXKSJ UW'??G^03..]QEW4@O
MT\R)T[K!5]3_ ++8"94AMZ-R'D+,#W:12L915^?.MFN?.SW=I.0F<FA^3NHQ
MI?\ B9ZV&EU ;:;="<7K!JU68#5]7?;7NMJ>ES^(=]KN7N379VCY!,Y-+9=U
M)K?_  (D'4:_2)Z:V-Q;;7$ZQM10#[::_9I?2([[%[:?@ -^?C 9"9RG0Y=U
M(4GT?2@BK16BK>EN!?E ZVO;? 3&)&M=+,^_-WJ:N6O%S @&AY@$.]&IWUH+
M,\4?-_S>6H=IEM42PTI"T!4&5)4INRVE*2L^@L$?PB+K3;F2;ZB";5FM>C C
M]VA I>T,U+DU?N-7YOW:DO6*CP^YLJ0M'R;U)R+/,H^8 (2HGF4I+%N4K62
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M>P>M_@[-:.QR4XH<D,[8"'B)9,);3M0QE=UY0<MI2>/0YFLRFM U?-**F#[
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MK+(!THP\[FE 0\>L@HMB/8:B89QMUAYM#K;K;B7$.)6.8%*D:%-B""#>Y%M
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MN WZV &$5O=2*L(0PA"U_??W&XQBJQ^/@;\H"OO]Q:,*N,[^9M"%6@^63*X
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M,Q?FDQ7*(N.EL=YQ)(-<#-6$/-*0&2#<WQW>[WQ7 %3H#>I^Q[>.HC);R?\
ME9F!E!D_45)9CTZ_2TX?S?S7J662R(FDOFUZ=J6K(R:R%Z$BI='3! A%RQYE
M28>*B/.X4K+*VVN4I)@WC[OBP[^40GM M=A4%W.WN?:NIKG-$'\0[_J*U]F_
MV>/OQA+!,SEF/=<.^WX=T2;^K75NR:QA/PP?WY^+6^_RHRG;;2D9./9L>ON%
ML;KC".HDL_M>78%']\<=X._REQ/NEZ7^<F>5=/QC-[&V1R:&$(I7]$_[>O=C
M3F>P?C0P%Q_#WZ1JDX[S^7%)]?WB7>__ 'QT$:W-_P"W308\3?E*_P"E>'Z'
MY,FC_P#>G5K>_-M&+QZ3]#'^B>(L?^L$VVZB60:??X",#FOSO]8GZSO[==/;
MOCR;P]VG4OF:SDLFU& -/&[QZ'D@]6G5T.#M1(=P=21L P85I?+ADL<]:. -
M[O/['_FG- !;4#KX;]3VWZ$Z]-L/7^DD@^$Q=6-+OHP+@QUMZ5P_1"<+4G#>
MC2^\4!-*\Q6-ZD-;L6]-[GP!!(_8;=WKUQ^F!)RHK="2=/HI/+W5CQ8@N#1F
M4H?\Q,?0-A^W?VXU(H=@]_C:&$6&$(80AA"&$(80AA"&$(80AA"&!#P@?#7"
M(2P)V#Q@9Q\5Q(Z9RB@H.:N1*8N=U5+)?*H6#@HJ81,;&);B'G6&8>#:=>66
MVTJ62EM2=-2+C'5_I9Z)X[I9T55P[ $JQ'KN'Q 2$(+HE"85U7,EI%5 .Y8F
MG+?^B?2WAO13C2.(\3IANHFR,PSJ^=F9<@:7+F*!I?*PJ2VNFA=8-/--K--U
MHDA*2;T=4/*"$$D$_!X.@4>AO8G3IXTE^@WI<.-R)HPJPF7.0<_S%<LT$ENO
MN15R^@-:#O;$^G;HC/X4N4F<M(,L@I$O%$L99 !_FPW!-CWQMYRFXQ\G:5RW
MHR1S&*J=$P@)#+X6*A%475?.PN$A&(=?,IN3N@DK;( O;7>P%_>7H_Z.<6X5
MP'!X+B"!*3)D2D)7FE**IB),A&7)+669*"7*J5%S'E_CG3/@O$N+8R;P^8N>
MM4V9,5+ZF?+RH5,5VLTR6D*.8LPW>P87%^?/DGK^Z*FTV_(ZKK'V_ 6_<+6T
M.N.=_)RZ?."SOE'N=8?:]=.>T_G!*_8+]_W@>^(^?1DE?^,5-[*.J[PUUD7M
MM[+Z$X?)RJ_.;-V1Y>V?@&D7\X)7[!?O_"'SY\DR=(BIK:Z_$VKN@)U_>/07
ML.[?6UB7R:NW65<T"/\ _H'?]UX?G!*_83#\=WA^Z'SZ,DOZ14VA'^1U7:W_
M /H+I[?&V'R<O]IO] ?^OSVB?G!*_83#\<P(GY\^2=[><5-N 2:-JX '6_\
MB([6\.^^ML/DY?[0?X?+Z7O/\7YP2OV"_CPT^*P''/DD;_NBIAW7HZK;'_\
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M#FT!YU+*K@J!#A/,+*)%B+ BUCJ;:V$BMMN^OC\6>L<;<&RT+-@I_P#$JU[
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M5HH1AM,'(+%ZH-^;#SU<W8$1/8="\;[;)Z7.VH]>VOLMB\__ .9XLF[9T/\
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MOM]:27RRDU<AU&@CQETXZ,8'H_C"C!8V9B92S-5EF]4%I5V%LZ&"D@K9(;,
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MBS-X_)V421B15#+IS!RN<U''4Y+865P%255#TQ$P<-4#J1"M,1W;M+EIC6E
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MT()UWWK$^3^#V^4\?L_KP<,*5*#06L_=>*$95\*17VB.(:KU+1^+4D<2L\4
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M@,K KF+P\X*]8PTR<RR%!+"7-0WB7>S-'..AG!NBTR;/1Q''<1F)64H248U
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M5(-_SDQU[':_3];Y&+#^888V#=1+UO0I9MZ]\3Y8P7];F#6DTWV% ;#0=[Q
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MBLNIG-(JHX*2S"826H8H2VGI)&1$^AI=-X*904S>,,MB&[%^,>==A$^<'+K
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ML8^X^EM^%B>U>6N(2R[SAU+84,TN%$O4FHIH[ L'M9N]Z$%2A5Z5J"JC,2[
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M7A].IS=H5-A?^<,OZ]_X[U@ @:Z^&!P,]FZM_':@J[MY-6@$/EK :ST#O/\
M&YL+Z;//SI>'R^F;M"$VU'Q@E]_'4.Z7T'7V@8@P,[]FUM7O_'EYB!XU@&I/
M3YV^/Q[X?.DX>SOF[0HT /Y0R_6^O_"G8^&Y&NHQ?49P9I?=7:S[/_&L7Y9X
M?^W1Y_9^^NC5#Q\Z7A\&HS<H4DG6]0P&UN\.G6UMS;73H,!@)VLMO']XWT?6
M(>,X 6GH--S3W5TVUY1/SIN'VP)S;H74Z?E! #ZB\+Z=Y&^@-L/4)W[/W_:Q
M^Q^9A\M8#]NCSK^X?'=X#,O//(:O:(JBDX;.#+.'=J*414H;?G$3)I]*VC%I
M#3YF$EC(AN&F4 [#*=8?AGUI2\AU;?,-5#(8&:6!11GO8-9SJ^FPM80'&N'B
MJIR"QW(N];$@#4_C&K6F^#_A"IJLLM9Y*L]LO('+R@LS:PS*=R93/53:A6EU
MIEE\G<UI^G79C/')C+9%'1KLUK-Z4LH3+OA*/>@_-1+PE2I\G*OE)=P'+;Z6
MH-=1XQ#QO#@D2IJ @ 9254L"0#E+DJ)IR?41D9G%E]PUUY1<90M*\0].TK*H
M[-#+',!F4Q=0RV<4[3#6648R_ 4Y1$@2_"0-.2:8!@(=AX18;:<_&L@ %*JG
MAZB/94'J#H 7HU#Y@D4=Q&"N.2DM\ZDD$@W>P9NR0SL=-=3&-IX4<B*-G&8]
M2Y0\6M TI45<RFIZ7E+]204LJJ!E5,YBUK'UQ6DFBH)%12EV+3,XR/7)X>(5
M&LNIE >4A"(E33C+Y/4;H5MINP-VT<]XO&H.-8%AGFH*M:EK5#4('.FT9"51
M"T?F9P^9O\-&9G$]E!'TC6-%TU1=#SBFY/3TB13C4-3\)#SJ/=IUF=OPCD ]
M/8;MH"7HBT.0L.I;2W4H2EYQ\GS+92PW+L*'ZUP#5BQ--'BGC?#_ -HB[$9G
M%:.7-GJX+!]HQ0K/@DR%JVH:BJ5/&'1=.3Z>SJ>U"]&2)J72LOQLXDU$RN%E
M,0(6>LO1$CERZ+AWS+TN@Q0FD2E'8>;H[0>'J^JK8-7=G+DMS/<^\'&>',0)
MB$TH78$C8UMLSCWQ<Z0<-7#=3>>>7^=,JXD\O)<]1D^RZGC5/0$4D,%VAJ/J
MNF)A+H2/CY],IE#PL\^-;LRB!$Q+I*X9N#4.10*7R>I_84[ /0;FM=32CD4Y
M,^6N'7*T$<R'H^]0^CT85WCK,R.%+AQS!JG.RI?G7TQ)7,[*]S JB,A(*(E;
M'P#!9@4#3>7DUB)>IN9I3%5!(D4PW.J?FZTPRDQ4;,H!SF;=<BEX_)\PMV3H
M_+5G?E5P+BE8HXUPXUSH#"E6):CO8OR ?O!BWLCX&.'F1SB.GC'&33+Q5.IM
M.I;#*=ES)BE1V9TLS#$#4<0S-U+F\"J(E0@9LTMG]]'%N13KC:[).7J"[A)(
MIR-1WGE>P/C \9X=K-18TS.QML6=C0FH>M*7&I[@ZX.975&4]5O<42'8S+%B
MBWW_ ,HY6N%JR=4C'5*S&1TW#\<LK@)_3=5?%%^'6%%4H@&6T^FM)&/J"_J*
M8[WKR)K2A9VN*"!XUP]FZR7J_:+4;W6;<BC1=+B9R.X5.).NLR:RG'$#0LEB
M*PX?97DY3T3#/RA^<41,I;4LTG,!5\BF7GJ(AJ*>9G$1+(B&ATPRW(0NH$4@
M.+(OJ$P =@N:,"];U<O2SON=(GRSPYS\X@M5R:$48,UW8\J.8QLJS@<X::PJ
M2#J-7$UEA)0PU0JHV62U+,5!-QU+BJ79J]#1$ZJ6-C4PE2QE3N1L3!F([)F*
M;YRW8C%^3UW*5;4&G=FTTNPL[Q1QGA[OUB+W<AZ:$Z'3F""-_"S7R?V5$ZE2
M9),N.FCD2V&RUJ#+F![*6RQAQF73^D9!2;D4ZXU.FTS"(A'Z<:F4.8@J<6M:
M6>U0VE'9P\/7;(>=!=DU-2*<_#F'&>'5^=E"AU/[W[M=.7MIWP/Y S6:3*:0
MG&!0L%$SBHJHJ"+,.S+UKBU5/666M8)E\8H39E<6S)HG+M,/ NOK42B<Q:TH
MARP$/!P]=R@[<^9#&NH (=C>L4\:X:;3)8M7,3J"W=J7#N^U?&9H\(E!R2!J
M6HLHN)#*BIZHJZIWHZ.EU2S* DTH9E,\S1J3,&83&*BX:9ON3:/ED/4)I^7E
MV#C2J& ?#-F1R48!1#E)K;35@[DW\:&)\M\/9A,2X#$.?&YJ *$T\"(S)I^B
M\H9Q1O")\8<X\I:'F60]*512=69:P\^9KFA9M!U&[3SJU0,=,(^6QWPM(II2
MTKF<FG,0P5M.QD8A*D%M),]06/H$C<7-"7O1S\:E\M<.=NL1?4VL&?<MM371
ML9(/@6X>V9?)Y>]Q>T%'0DGC,M8TP:H65,P4R8H3,K,G,IF&C"F;J94)^NO%
MRV.=[%26X>"!#3A44K?)ZJ$H5NS5?5@[@69FN[[AQGAUNMEU 8Y@U0]^YA=@
MS&YCFRGX)LA<L:LI>JU<9M&5,B33:FUQ=+U% 2R,IJJ953U(1-'+A9O+USP)
M==#+XCI8^4K$MB8-DL$)6LIOR>O5"MZ5H1WWW#<KP^6>'*M,EZARIK4)8EZW
M))9J->,W\[**X3\W,PH#-&'SWI.GJA8R8K#)^.AH6<RIV3SJ6SB#>AZ9F<?"
MF-[!+U&Q$PGL1+0EI:W$S1QE2^S8;L& F$DJET(L#[F)%;#:[QB>-<.9NL02
MXJ"69QJ*$,&THUZ-A;3/!7P]4^NAPUQBTZV:7BLL)K44&U&0<? 5)/,MF)1*
M82;,0,PFKCU/JCI;(X& CX65Q_F$P#344[!MQ+""MZ@MZ)+Z.!9G-<W(6MKN
M,SQKAP[76(+$6))9]:6.C,=HOGPT9.</O#GF!0E;-<4%&S9VEJ)C*&F<LA)E
M!RZ55'+/.(MR31<9+(F8QD/+9K)W(IXB;R<P+\0PXJ$CTQ#(0Z-#$+D</E+&
M(9*EC,@FI &K/6HM76CM!'%,+-F)$E:,KLH!6I-'2QTH]KO8-LQA^*CAZ;2L
M.YPY?\R";A-32NZQ<I"E%40DJYR-5%-E:%)4 "=D1QSAZYIE]< 7RNSZ@5L1
M=ZT&\;BN:E*.L*@S/JPN6MHQM0Z1]:.*7A^-TJS<H1*N:P":CEI]$@$*)#I%
M['6QT[\;W)DC%($V0TU%LP(;-0D7:Q!K6-M/%\&A13,G(2H&SZ.UV%0>1H#4
MQ4>*7A]38?*Y0IOJ2:A@-3:]OX;?2PUMI8]^-7U"<07EMW-]Q?XH\3Y9P'[=
M'GX@?<='U$2>*7A\(TS=H4=+?&&7WN+[_CB=2._]N)ZC.?\ 5WYTKN+#QB_+
M. 9^O0*V)T^Y^=-](CYTW#Z-!FY0IWU-0P'ZB]?VZ;^^^HSW'S;=Q% XVI>O
MF><0\:P#TGH\_P"&XHT3\Z7A\.ORO4-W:5#+]/<[K]A'7 X&<''5N-W^#Y6@
M.-8!OUZ.]]^5>^_B]('BEX?AI\KE"'Q%0P \/^&[]=.FNVH# SF?(1RW\R'N
M;Z4@>-8!_P!<EN\?=;WQ\SO%+D"V/0S:H5?,;J/QBEXL"#O^-)N+7)M;UW(P
M5A)@!"F3WD.WGKMK&,WCF EY'G)J!0N*5Y'PM7E;%SC$S[RAK#(>J9)3V85)
MSJ:3"-I1F7RN5SR#C8N/?-7R(EN%AX9QQZ(*$)4ZXEOZ(;-[ :?7@\(HZ&I%
M6# 5-6MN&%ZFT<?Z2\0P^(X;.0A0)4$Y0_M'.DL"0Q8$$U !&M7V'4Z.63RM
M(-_W#"WTMLPC\V^GJZ$:W(QMTSVCXZDZG?Q[[QRS!TP\D6^:EVWRBE*5K]L=
M]C"/LAA"&$(80AA"&$(80AA"&$(80AA"&$(80AA"&$(80BE7T3]^N-.9[![M
M_A^[QTA&J3CP/Y<4F=_WB7K;8B,=^YOO:X&/$_Y2O^E.'TOPR;M^WG4?37X,
M>D_0P/\ )7$>7$4AJ-^HE\Z7]VU8P-:OZ6M[*M?3O-^@'[?J!\F\._I>8(OJ
MPKJVEVM6/0TJLH#9)8C1+)U-+W[Z4O?3AE']W6C][]L^3_[ETCUZ#ZQII?';
M7H3_ .F^'M^ME:/_ $B_W4UKRCK?TK?]$)Q?2<^M<DM]0]].X/2-Z,-8LMZ=
M3W]+_M /CTTQ^F)]E%O80X)9^P!MS9Z,_EXK18\E*'_,=-.[[H^K&<9#S]T,
M(L,(0PA#"$,(0PA#"$,(0PA#"$,(1! (U /W^K$(%2U6OK]A^PPC"WCGIV2S
MK)9Y,RE,!,@U/Y8ZT(R%:B>S<*(E)<;2ZV[R+Y=.9*0;7%^F.L?2WBN*X?HB
MM7"\1.D8KUW##/( *\A$W,*A0TK39B* <HZ&<-X1Q#CTJ3Q;"2,3ANHFKR3@
MR1,29>13A2:BK.6KK&E=ZA:40V$?%>3<A#:2D2B$4I7,I/HV,)J2$B^]P-P<
M>+\#QOTB?+LI*^+\45)Z]+RU !)3UR0Q'46;0D[.U8]#XKHKT 5PA8^1^&%0
ME$)4'"G$H@?TSTL*._?&\C)+)7*:898T4],,M:&B(A=.RIUQUVEI*IY:W("%
M4HNJ,"%E96I2EA5O2)T%\>[N@F,QZN$X=>)F3/6#AY>:8KVE/+DDN69\V8FC
MEWM'EOI'P3@Z.)8B3)P>'&'1.64(2ETAU* RN39+"Y9FN3%V/D%R7!/]RZ@]
M0!;XK2;;U^9_[#]?.O6\3^U58#33X_"./?(G"_ZE(_X?EKYU/A$?(+DQURNH
M0Z:?DM)M/_A/';W8>MXG]JKW=VV@WA\B<*MZE(_P#3WGG#Y!<F+FV5]" '<?
M%:3?K\SOZKXGK>(_:JYBE>^D7Y$X5_4L/_@'PWP\2<A<ESOE=0?6_P"2TFW/
M_L?U?7B^MXG]LNEK4]T0\$X5_4I'^ ;';X\6A\@V3%K?)=0@_P#JM)K::?T3
MJ-/'7V/6\3^U57N_#X:'R'PK^I2/\'=S[_OYOD%R8T_N7T(;'K2TFMX"WFFE
MO;B>MXC]JH^7X0^1.%/_ )E(_P '@-6[Z;/O%*\@\EEVYLK:#) Y1>E9,;)U
M(%C"$:$J(T]$J44V*B2];Q'[55"XM2_+G \$X57^92:_V/N'=YVJ8K1D-DPV
M0497T(GE((Y:6DH((!2GE(@[I"4?BP!8=GZ%N2R1/6I_[57GX?</)[UC-/".
M&@ #"2<HJ!E87S'F Y=M(J^0G)NUCEC0I%DIL:6DQ'*@DH%C!D ))NFP%MNN
M'K,^GSJJ%Q;3PB_)/#P_\UE%]T$ZO6OX/IM%*LA\FE!05EA0A"UA:@:5DMBH
M)Y0I0\SLI01Z 405!!*;V)Q1BL0+35CN(V;;;\;QB>#<+-3@I)?=%7._D+V:
M*1D)DL+VRMH,7)/\UI-N0H:CS.QN%$*_2!LJ]AAZWB?VR]1IK?2,?D3A5/YE
M(?\ N4U\!X\N42<ALF#8?)=09LOG232TF)2NUN9)\TNE0  218I  388>M8@
MDDS55OYNQW'>_FT4<%X6 !ZE(N_L4J_[]:>+1"<A,F$\Q1E?0B5*^DI-+R<%
M74E1$)<DFRB23=0"C=0!P];Q+OUJG\#;O!^*6 $/D3A6F"D"C>P^[$^9!WBI
M60^3*B"K+"A39)2?R7DURD\QY2?,[\MU*58W',HJW-\/6\1^U5[K;6=HGR)P
MLAC@I&I'88#3?F=1$?(-DSSA8RPH4+2"D*%+R<*"2KG*>80E^52_24!HI5RJ
MY)P];Q _I5TM6Q\OM^X0/!.%_P!2D,X/ZM[6L=X#(;)D I&5]"\I 24FEY.4
M\H4%!/+YI8@*2DBXT*01L+/6L1^U7YC\(?(?"@7]2D/9\FAN/M[AR$2,ALF
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MQ#MM,L--I;;990EM"$H 2 $) 2 $I2  !8"VP&.42),C#RTRI"$(2@  ) %
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M:-IAXM,D4*LJK 5\H!"9=-E(21I86ER@3>_4#6]@-<>WSZ:NC:9<N5UH$S*
M5--(<)2Y_P V86-,QUY/Y2E>C[C\Y2U)PF8).LV4D4_O3147)9JTK6.1'%MD
M:@ *JM5QU^#)P4@FP(TEUAH0 0 ,/TU]"Y78Q6-RST^V.JQ1NQ3[&&*3V2'
M)?O!C5_1_P!(0P3@V&KS).U_UKG;>.7YWF1:24_&M9M:Y,IG_L^C+"GK8<OZ
MR<:R?3AT#(_TES;U?&$ZC^I[AB+ O6D/T>=(U/\ S,EC5IDEB+/^N%*!^[76
M@\6^12O2^-BAS#3][)UIW6YH $:;"PM]6*?35T%)?Y0)>H/48P/S'\UI\:QE
M^CWI&*>J@$ !C-D@TT+3;^8OH8?.VR*Z583TN)7.=!K?_ -OV7.V*/31T&=O
M7SO^JQAH;_ZMSL^L0>CWI'_5D]W6R;U?^E:K[MW14GBXR+2+)JQ23;3]ZIN?
M'0?!QZ;?MQA+]-'01*BW$%)<ESU.-42Y>@]6.I-*::QA^8?2$DCU04I1<IG!
MN_6"KAZ[@Q2KBXR,)!55JE 7  E<X1M;8B6@>_3QQ)GIPZ")<?*!4Q!;J<8*
MZU&$<6_@8R'H[Z1D.G" 5']-*!'>\UJ,^NEBQBA/%OD=TJA8 )!O+IR1OW&7
M6N=[].N]\1/INZ+J_I3R+3F;1SZL* =Y/(TA^C?I&AB<&U#3KY#=_P"O(YL/
M<\<@XNLD1_E60-1_)DWT!W.DMOWZFYUTM;&H/3)T8/:,\)0*JI.+ .]$X9Z"
MM'?F[1C^C_I "WJ;EQ:;)\S\\0 ]]FYQ3\[3(N]_C8=^DLG()&PL1+QUN+$[
MWWTP'IIZ#4_GYT;YG&ZG<86CE]HS'H^Z1_U86UF2?_<9^7NB?G:Y$_\ &Q5S
M_P!6SD]QUO :DZ6M]8P_31T%/^OJK3]3C:Z_U7Q?WQ?T?=(Q3U9-_P!K)-R=
M1-L/L87I#YVF16H^-A)\)7.?#6_P>;"QVT\._%'IGZ"U_GY</_0XU^5L+Y=T
M3]'W2(_ZL/\ B21[C-\Z:\J1\[;(P7Y:K-[V%Y;.+:GQEY -K]+'PW&)]-/0
MH!Y&,*YE,J>JQ0=W>JL+E% ;Q#Z/ND1OA0;..MD@[WZS=GKI?>#Q<9(B_P"5
M*M-+&63<';0C][?VGU'IIGTS]' "H3A2M$3';1AZL=36@(%38MC^C[C[A/J=
M?]_(Y?[7G]VL<:>+;(P*].JEBX()$MG)UN#]$RX;D$G2XMOC!'IOZ)+7DQ&)
M*$97*LF(-0.R&3A0:L6J=HR5Z..D<H=:<(&=OUTD@YM&ZTD_%:UYSQ;Y%&P^
M-B]K ?!DY%QH#:\O!Z^K2VFF-?\ 3;T%2SX\_P# Q9'_ /JNWA&G^C_I$:#"
M:&TZ50/;]9\ =T0>+3(JP JM6H %Y9.3H.X?!^XWN=#O<W!(>F[H)-[(Q]JT
MD8T.U'?U2SG4UYU;)/H\Z1 D^JZ7,V41R_I&>CW.NKP^=ID4?\K#>_\ FR<B
MQN+[R\WL?5H=",7]-'05_P#/B6_V.,T_\+]AC,^CWI%7^;#8M-DZ/4?.UOH\
M4JXM<A[CFJUPZD@)E<\(ZC\R7:'4'7333$_3;T%EVX@=S\SC=-OYH0UO(5C2
MF>C[I%0>J.S@-.DC0?[6WEK6L5IXN<B#<(JQP6OO*IYKIO\ C):!I:VFGB-L
M8_IPZ".7XB!_]'&:_P#@]^3,>45/H^Z1:83DYFR3X4FEQ9WK76*AQ>9'@$"K
M =+DJE<YT!T(NF6VOT&N@-P+G341Z9^AV(!5AL:%I26452\2AB7-E884:KMW
MMKJ#T?=(5?ZF56]F9(#-:\X,07M_&A7%SD:KZ55J"K$@)ED]U\3:6"P!OIW:
MWMC5_3#T82W\[0!_=G:LS_S;:K^^T8*]'O2(D_S%1J/Z:4^HTGWTO4TTBD<6
MF1MOYUKUUUED[!L01:RI>#M<#<=W<,%>F;H8"!.QP"P!1$O%%.73V<,SW!UW
MBH]'O2("F%RN22%3I)-6H?G39F%C3:)^=KD61858?6)7.3K:^G[W@=-00---
M>N ]-'04BF/+?[G&?_U>7?:,OT>](OZL-?Z65_[OEMRA\[7(O3\K%7'3X-G(
M !W))E^HOI;2USN-</TT]!?Z^H4_8XVSM_5=3ISVB_H^Z1_U9/\ Q)/W3?CO
M>'SMLBMQ5J]MC+)R-P!;^(#H!WV[R1BCTT]!O_F"AI^IQH.E!_-1HVT/T?=(
M_P"K)_XLG_W8D\6^2%ARU4HI%P#\%SC5(UZR[76_4'2]\:2O31T72294_-+^
M@<D\$AA4A6&"@]F+?9&/Z/>D))_F8?0]=)8EV_:CO[M:Q\ZN+?(Y5KU4JU]?
MWNG&AN38@2VP)(V]AMH<:9]-W1I/]*?\,[7_ ,+N]6^V,AZ->D2ZC!AGOZQ)
M:MF^>VTJYTM'*WQ;Y(-BZ:K6;?1O+9OI<C2RI=N#I;^W&K^FGHPI(/74O[,Y
MO$C#4H>7WQBGT==(4*(]4=G!!G26%P:=;]S[ZQ4OBWR1<!"ZJ(O:Q$MG M8#
M2R99:W34_LM1Z:>BX#B<UG#3K\GPXYG5](+]'72$T]3 %Z3Y.]*==8UY<H#B
MTR+/^5:CI_FV=;]Q_>\W  &GCW7.,_TT=!C4X]3G3J<9XU]5^YK5J(OZ/>D0
M+>JI#4_6R2S?_5.[/[[.^=KD6-35JK$[B63H7-QJ")?:YL.ZQ'=<XGZ:>@M_
ME!37?J<;?_\ 2[L/?<0_1]TC_JP%OZ61_P"Z;:^Z)^=KD5?^=BK6O_)DYN;>
M/P?;4@;]_34X?IIZ"W]?5N_4XTZ[C"[C[X?H^Z1?U45_VDK[>M[[>%P]*N+;
M(NQ(JQ1-CRVELY!UO;_%^AZFX.^W7&*_35T( )EXXJF!\B3)Q@=7U75A6N=2
MU:W@/1[TC4R?5@784FRG/)Q-U:I_=$IXN,D;V^-)M8[RR;@D:WU,N']8WZCN
M&,)?IIZ-32XG6/U9H-!_^7! >S?>\8J]'G2%-#@P"UC/DDZ_[4$]X=F+Q5\[
MG(P#F75"K:;2V=&XUV");<W.EP"![;XUE>FKHG*253L3U:$BJLD]1%F=*<*2
M0':@[R QA^CGI&2XP=*#]=)&Y']-[WU.CP'%]D202*I<%^HE%0'K_P#-NIN>
MG@.NF ]-_051#\1J:MU&,MI_J;;?N-(A]'W2)'^J%KGYV26KMUW<.[WR>+O(
MIP<OQK(!UO\ !,_&Q/5<L2+[]0=/5C(^FCH+?Y0?2DK&&]7/\UY&IYP'0+I"
MHA/JK$UK,D@4K^U_=%!XM<B[:58=A>\LG)N"-]9?TN1N;W[K8OZ:.@M6QY8?
M['&6(O3"G0^_OC,^C[I%_5AX397W37YT\=1$_.TR*.OQM/LEDY!!MI_@%M+>
MK3N)(@]-/04NV/50._4XS_\ JZ?PA^C[I%4^JI'_ -24]6LTU]N=.4#Q:Y%G
M_*M77>63@[D;'S =_38V&+^FCH,17'J_X.-KJ2 <+9V?OUB_H^Z1?U9/_%E?
M^[_'2.-?%KD8+6JI9U-K2V<CO'^;SX7%AUM8[Z4STV=#9;>KXOK"7S/+Q20
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MH2 VE7(8,#M'L9K0%3REE;\9*'TM,L0S\4ILMN%AB*0'(9U9"B4I=0M*SS
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MV((!/,+VW!()ON-_'O&"U\,)"0I8-O97M4>TU^]F(;?&:G (EE8D.5!Z)62
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M-G+ EB =7[WU H8Y+-[ B_=S'I:PT)L#H-L99^'6"I@.G96]"-,[#>P#<A&
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M A ;#*/_ '5D6#BII0 6=JZQ-F;ZZ WO=1T!L2?7ZK:]YTPS<-W6;T"5T=M
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MOG:M_"#U BP-[W)N=? >O8V/V-PM-&!:_L'0!JJ/?IJ.<:"1B%!P [:T<OS
MTO3\(%QJ]^T%N@)]Q]VYVUUWU?Y+_LO2^1KU/M"EO W>D99<1J!K0&K-2K;
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H@/ "),6J:I2IBE+4HDJ4HDDDW)//6.8) %@+#PTQK1@ !81.$6/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g454025g01a39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01a39.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1-^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $V*^26(X0DE-!"4      !                      .$))300Z
M  #_    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$
M5 !! "  +0 @ #$       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 6*84@
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      T$    &              $=   "8     8 9P P #$ 80 S #D
M   !                          $              F    $=
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   $=     %)G
M:'1L;VYG   "8     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !'0    !29VAT;&]N9P   F     #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M!4%181,B<8$R!A0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( 18"4 ,!$0 "$0$#$0'_Q  >  $   <! 0$
M         0(#!08'" 0)"O_$ &40  $# P(# P8&# <)# @'  $" P0 !1$&
M(0<2,1-!40@4%2)A<195@9&Q\ DC)3(T-4)TDJ'!T20S-D64LN$71%)D<W63
MT]4F4V)C97*"E;.UTO$80U2#A:*CU!E&5Z2EM,/_Q  : 0$! 0$! 0$
M         0(#! 4&_\0 /A$  0," P8%! $"!@(" 04  0 1(0(Q05%A Q)Q
M@9'P!*&QP=$3(C+A\11"!2,S4F)R%32"DD,D)5.RTO_:  P# 0 "$0,1 #\
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MK:CS^$WA^W#>O07*&;>@<>BHIZ_SFGIT'][=Y(V[L]>N#:CS^$WH=BPU!]U
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MOE'ZLUIQJA61.E],7*R<:F-8RW=-6YAR\7:[,ZCBWW4 MC;2%AE5K4LI4A!
MH8/$#H+GEO6TS@+L>+:@VOSD-=I%]EZ)^PLZ/X?\#[-PVTMKFP6+B#P_UQHC
M6/#7BY T.XF]2$<+]1R]2Z)@<2(:KZ["U:B"_.DLSRP;.B8XZZXEH$8)FQ)M
M?"&_;B[IR;OM_P"">HN-_D+:HXP<6^%O&I/$^TZ<UMH#@QQ0X17B.WHQ,C3]
MXC\4HT3SJZ6ZVL7-J3 ,&1#*T-.+<!Y@K*2E7-?TD/KZO_##$ 9+D:R_88'8
M_#C3>@;EQN86T[PHMW!#B=-MVC)49_5G#RS:O<UA%3IB//U+(1IF_O2WE0I%
MU4);2VDH4S&8*4D.^_/L([QC%X)'D><397NQ_8DM<V/CQI3BQ!X[:=3I_2GE
M.6/RA8VF5</IC]XFL6C3,;1\?3+M^3J:/$0D6=/:NSD0'1YVHO*BO%);6R[/
MK-\;\4-VAV<.][9>[Z+[K)"@E(40I0 "B!@$[9(&^,G<#Y-J)//2!)OR'NIJ
M*I1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%1D_@[^>G8NY[_ ,A7
M=WT0V+*W6#\2VS\T:^BB*CJ/:V#_ #G8>O\ GVVT#N&_W4^H?R4-CP*OM%4H
MB41/UU#8\"B^5/V1;R,>)?E>Z_\ ).?TY#X=S>'O!#BTKB1KVU:SFW)B;J6#
M)L-\TQ,L%L9API+"2[;;N\I$AYQ)[9U22C"$J/E%)^J+!C2YEA]U6=^(<@N3
M@CZ/'Z G1^$+CNX_8KO*49X)ZC\F73O%NS,\&]&<:[-Q>X"26KUJ&RZSLUGB
MS&+G=.&>J[K!CH?FVQBXF:Y9KY'DF7'0\V0P?-TU[.>G#H\<%'QSP9C@)US/
M7-8%Q*\EN[\)O*?\E;@SPRT9.N\ES@7QRL<R7K6-K[B#HJR7_B!#G*+MZXB2
M[=->6TFYRIDR)#GSFNV)4@LQPZT51'?1I?U!)'4'C!MGG#_[#=JW2'%?A9J#
M4W%B]:YX?6/A_H#3VJK#"UOJO0Z[/JKAQ<_3UHNMCA6A;Z;Y9T7#*S:9ST7F
M:6IEPJWIW_*;PG2,7UAL-'6T++]CH\H>X^5_PW\HW7_$+A_=;/HV[^4I;Y\:
MV6J7;9<S0'%N)IZ%HFR18#6&6U:>CV,)F=LXM4R?,N$U9+\QP41_=M6\_+V?
M,M->0?QGT)]BIU/Y!]HN?#N?Q!NN@N(G#B!JB2FX6S3B[/KC5.J9L:\74Q83
MLAR?;[1J1B.\WS+4Z_#6\'4H7RHY54DU$N,.C23S)N9 T00&PPQ8D^SAYEIL
MN=N*7V,WRGM?VGR:X\6;P7@S^"GDJ<0/)[NS<ZY7J6W>;MJS3=OT\Q?+>M5H
M*F(5KC6X30V>93AD*;R@@J/>DAY>X,9CV+E',N+:B1GIW=:VT-Y(_$W6_'N/
MP2F.:BL$G0WV.2^>3-K/BY:=/:CBZ7C:\EWRYF$]8+U,MT!G4$=V%+9FGS.<
M9+,<JCM.<P&)5^57'#^(R;#!DC$ $G&[L&:X.%L\X6ZK%]B?XI:8X'<.X5@U
M^Q&XZZ!XM<*>)EY?U1K35VO.'G$L<+HRK-;K;<;9J(*<T_ G6IWF-NBHEMQ7
M0AL=J4@F69O6V/KT4.746=XQ.>NBZ:U_Y$.O;OY4W#CRD=+Q>%UJMNFO).XN
M\ [_ *!9MC[5LMUXUG?[#K.U7?3[[<= FQ7;O <9GJ>996VV^LMJ*EK:%P;7
MGW\KJ*J=WE!O#$23:]H89NN)]!_8C./&D>%'#O1TC7W#RX7YGR=-2^3MK%,C
MTR]8]-QKOKAG5-OX@:#0H"0N_%EGT;)1),9MQ!9<[9*/5 :F)SNW!LNV7FK!
M?[0+"8 9SQB^ #G,N;'QQ^Q'>4OK;BAKO56C-5<*A:+[%\F2TV:XZDGW>/J=
M37 *3$D3IT[S:VNM*N6I0TZEU]$A:D!:F^=:1FL[&*JJC_NJ8LY9WC1NV8CJ
M(%.$!W:\01W9?I,M[<AFV0&98;$MJ%$;DAHE30D(9;2\&E*"5*;#@4$*4 HI
MP2 <U-H7!.9Z2ZJ]]:%ACKFB41*(E$2B)1$HB41*(E$2B)1$HB416&'_ "AO
M73/F-H^;,_K\I/UZLN\3W'JZF?'V"OU%4^3VCW[_ $?MHIB0UF;7E@Q6"+TG
MIC5-M3$U#8[9?(T6Z2I;4:ZPF)K#,GM5#MFVGT+0EPC'KXYM@=J=]]_*@#O)
MN<3IB]M(:0JDVR6>R,::AV>V0+9$C7YL1XT&*S&99$B).6_V3;2$I1VRTI6Y
MR@<ZDI4K) (F7&.A]G5@@-(CR.OGCS6;U54HB41?.[R@_+E?X$:_UGI%7!W5
M>J+7P\X?VKB?JS6#NI]-6JPJTO-U!&L4OT-:XR;_ *DEWJ"[(2MJV38%CB3
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M16&)_*&\]?P&T=??/Z>S]N:9</<Z^<98*"YX^PNK]15**-).;*SV3 BN@?\
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M1T"-S*5&4IJ&DEKF!024X&^/G; @UDR 34,/]V =F<,'S!AR1[-K412 2\"
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M7<><RQ$9Q!4KF6=@I0YP4(SG<Y) ) (!P[[_ &H^G7 1 B3: \P]E7]-(/\
M-MXV_P 06.[/>H9^3J>F:*OH?+Y_2CZ91\77?IG\ 7_XLY]F,_)1'.1\OE/3
M2/BV[_T!9^A=5M1Y_#>:/_Q/E\H+R@D#T==QDXR8"\#?&2>?&/;TQO41]#Y>
MCO[KR_"1D*C)-LO*3*+R4 P',I+.>8*'-GU@,I.V1@]3BG?#BCZ="-;$M9IQ
M7J]-(W^YUWV\8#GCC;UL_JHCG(^7RGII'Q==_=Y@O_Q8'RD41SD?+Y3TTCXN
MO'N]'N?^+'ZZ(YR/E\J55[2E/,+9>%'*1RB OF.58)W5C894=^@\2*O,>?PC
MG_:>;>KE2*U!'0ZVPJ#=@ZX"I"! 62H *).RB$X"23S%)V]N#&[[S4?0W(:-
M,SK@JHO2#OZ.NX[]X#GT<V?D.].?K\*N<CY?*&]('\W7<^Z X>O_ $OG[AWT
MY^OQVW!'.1\OE/3*,X]'7??O\P7CY?6V^6B/_P 3Y?*>FD9(]'7?8$_@"\'
M)P#S8R<8 )&Y .,T1]".GR_<KS*U(PAR,RNVWA+DOM.R2("C_%)4M7,>?8\B
M>8  G!'MPRU\IQ1SEWIGY+T^F48SZ.N_N\P7GYBKZ-Z(YR/E\J'II'Q=>/\
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M@8<@O%^,W?V'EZ1>@"/(TZ&UMDGT[,L\ EG#AYP%P&8D9^J\VT N[,0(O(C
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MT>:MV&3Z+E-3T-0Y269$=YE\+6$.$I0XVI3>03C 4<$[UFLD4%I@L/+O@K0
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MGAMIZ5I316G=.S8-OMDJUQ$1WXEI=<D6YIX.*?>\V?<CPW74OO.K<*E,I&5
M$$@Y(&+LX8^_2>LX.M@T52B*FZCM&U(V/,!L20#@@X)200#C!P>A.QZ$H;9_
M&/DN"=;>33K_ %G\,),U[2DIU_C(WQ6TU:Q>=20X-R4U87K Q#N\V Q;9D&1
M9^W3=+>IA4ALW&#$2XI3!<-!R>'Y/;24!<Z-? O[AL'Q77/#/3=QT9HK3>E[
MQ<Y%\N=IMC4:5=Y2U2),IU!<6L.R5I#CR(W.(C$AY1>>;:0IS*E$D@=SEAG+
M/YYA[K8-%4HBI/@EI8 R3C YE)&>8')4DA02.JB-^4'8]#*K&_*\%^_=%Q;J
M?@WQ:UI>)^K;W'X?1-66Z_6FX:7E-2[Q-A/V73UTN;D#3]Y2Y!B*2U(9NCDX
M\C<A E8"EIW4,T/)(9\,I//7GF2D,(G'4_PT^BZ$X1Z*D\/-%V;2LR69TV,Y
M=IT^6WVRH[T^\729=Y/8J=;;*8K"YICQDD;-MI&YR:ZU$'T>/;,N3&6<P.P>
M^.9XNYQ[LMIUE5*(O%/$HQUB&A"Y!0\6>U5B.ET,.*9,A(^V.,J>#;:T-@KP
MOFQRA5%*@XQY8Z<UQ7>?)^XB<0K)J\:RNMCTOJ"^2U3DRM(.JNL*_O"))B6]
MB]L:BMG;QF;3VJ>S:B2RWSC*$XW!OG@CV/+*YU\L<KKK70UCEZ;TCINP3YRK
MI-LECMEJDW);:&C+=@Q&8SCJ6VTI0A!4UZB4@  #Y'?;('Y<29R<Y-YZ%\LH
MJE$5HOB[FW;)B[-YKZ53%DFW^?\ ;"#YV&5>;F8J/EU,;M>0.E"%K"592G(%
M%"^ <]N_2ZX.UYY.7%;B!88;DUC0-GU7)U:_J6ZS;7=[\DB>Y%:A(N";HBW1
MIDI,5$-A,>R/K>@.(<7YQ_%(%3SGU/L#T0!O(3I\OI/%=R6.+(@V"- EK2]*
MA6B)$D26DK0S*>CP4LO/-H*&T(*WD.*4AI"0DJ .]47&"& = ?3O->VP;66V
M#PB-?U:*BPP5'4>/1@SL/2EA_P"_;;]?;1V8Y$>HXJ$.",PRU[QWT_J#4W"O
M65FTN'7+W.M*V8D>.I*),U(<;=>M[#BL)"IK;98*'%=DYS!"\ Y!",B;\<#A
M8#/Y98GY/^EYMATCJ%E[3$S1ECNNH9<G3FD)X8C2[%:%0($1QIR-%48\53]P
MCRI*6FB!AT+.ZS2IJJ-V6<N.C2TQI=V4!JIK!9[,6#!ISSSOA9E;_)/=N"^&
M,]FYQDQ9</7_ ! A]F'TOE3+&IIR8[REI4KUGF>592<$9P>F!Y=AB#A546XF
M!Q=^C77HVY>OD.<<.DVZGIH=!]/CCO\ EZUZEPIMU]2O!<D2G(DE$(,"9YN]
MYF9*G$,&667>P[5;(6\AI*PDO%#:E%M2@D*4.4D,CWQ&H9<D^3QHOBMIGB'Q
MKN7$6S6>/%U1<-,W2W72SW.XS(D^7 BS6%)B,W%B,\Q%:;<:/9!HMI?+W*XH
MK4 SXQKKP\],H7: S#$L WO%X!N25V(@J*4E0PK YA_PL#.-SMGIO1:4U$5%
MPX.0,D9QORI[0EM*$K(W)42 "00!D';>BA[<L.'-XO*X'\G7AYJW2O&KB?>+
MGHFY6>U7J3J62+Q.@F.3+E:MO,R)&-U8D%.M&)=O>C3H\R4VE=J9D-6I!Q 2
M:8O9\,O73'48NN(EHGAB[9N<<-%WVWGD3D '?(!R,Y/3/T=W0;"BHL%/1%B^
MJV69.GK_ !Y,!VYQGK+=8\BWLQU2G+A'?AO-R8341*T=N[(0I+*0I0YBHA)2
M<FBA#MH>^>1P7 =IT?(D\$.!VB=1\)-<1=26B#IMMRY6_1TB5<=#.:6N0E.-
M0))>5*LMTN"UJ"I[#RX7F;;B$IY.S"H7P/'J;0='>#-G2QDX'VY=QBOI R<M
M-$]2V@]5'JD'JH!1]Z@%>(!R*O?;*]]NJE$7EEA!C/\ :L><M=DOM8P;2[YP
MGEW;"%;*)&0 1@YZ4639\IL^/ZY9M?Y3WWA=Q/NVAN&]JM&B=36JP:8O_$NY
M/Z,^#L3S.Z:IF7-ASAXK4MB$GS.;HF-;A<TRI:2(B%/(#L<J(IR[REAP/%U<
M\8MH?5VU\U]3K2):+;!\_8C19PB1A+CQ0$Q&' D\Z&   $)/,$I'WH"1W;DL
M[#C?KBY:[23=72BJ\=P*1 FE;*Y*!$DE<9IOM7)" RLJ8;:RGM%O)RVA&1S*
M4$Y&<T4,COOCAG"^95_X:WB^/.W_ $UPNU?:M-OZ^A7'5'#?X,HL\==MCQ(<
M5]^#99;1;N;MR@0I,B\RHZ'A/EW-#27%%129,8SY3Z1ZW34-/GER79G +35]
MTWPTL]MOL25;'E7;45R@6.4I#CFGK%<[[=7].V%&"0VFR61ZWQPD8*.Q4WU
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MC1W@L.!YAET.)&$K#C:5A:1W!0/,!X&K27II.=(/DO?M *:ZZ0& KJ &0!(
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M>WJJ*:JBPI)/#)>5RZ6YD$O3HK(20%%Y]MH)*B D**U)"2HD!(."HG S7/\
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M5I (4<FO/L/Q$EQ46:P$M'#'@,U]SQ_W"AA2!5LZ0'-]T4@G_C,'%I9;-#B
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M&YR7MK=\9542:13K<MP%4RY+G@(#[*T9;-56V)(&K+U$O4Y]32D.0;:JUQF
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M#44'?/XV:#+O:,8@\E%$_CK,;2I.E='65:DDEF9?)ET#:M]G%068Z%)WP2V
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M2AP!Q:^52E!(3ZB%9))&.7.<XVS7F^O2/D0&+03P/,66OHUY=LX-[9FP5O\
M[H^DEN/,M742'(LI,)\-Q9OVN2I00&U9C %7,0"4E21N20,U#XF2XJ.#BTA\
M[8X,%L>'J.5,.QRXV7D?XD6AAQ*$Q+R\3,3;RIBV2%(#BG USE7(,H02"58Q
MR@G(H/$Y8$[LAB[<W&(UU3Z#FX#XO9A:<ST]?0UKCSA#*F=/ZA=#\AV/A,1
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MF-9[4GSA._*ELK944<N2,G).QK9HVI:3GUOD'8/+<\>>]L@8I=W=WA[X&&L
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M@XC4 $3!5TLNAV]%V'3NGT7*=/88OZWRXXY@*7,5-?& I2E(0PI:4(0"1RD
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M#D6#DD\@P?5N*R<*!W&>N-P1OX;BLKJ*J38S:Q[PGS5DB?R@O/YC:,[>V?\
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MB0" 207$8E4[+:;:GZ@ :D$$O2&9S8MGP/&VVVR@H'( E(V"0.4#V 8&V^V
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M*5 A1E!:R%#*7)2W'%@#M,'<8'AO$&EJI.1JI !#EW#EG9@&U8.$^I1_;Q<
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M1]NQ]M1ME)!KD=KMMI46IW0U)F]@<@-7 =A.2Z;FQHII>HU$DP(< LQEV);
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M>&OQVX?M%51#6!+ LQ+ ^[%L#/B7JCBI>TYTUH"/98JCCTAJZYM1%G)(R;9
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MLFGISJVE51)!+', 6TE@, YS5^48-M3RI;992V@)4AMM+;+313S!(*4H;Y4
M8 ',<#/*":H\*[$4TR"&) !!,O@;-)TE>>OQ-.S@U&;M;XQPS;-:_3QHX8,+
M<8D:PM@,52VWWU+6F*EQ"E H$E+9B*+)"FW>S>/9.-J;<Y7$+2.U'AVH#LX+
M-,XV#C$!EY1X_8&IM\D$$N0W,EK._P"\+M;N+G#6[)2;9K;3<[F^]$>[P'%'
M"BG9"7^8;@C! .>ZK5LZX8B-3I=QZZ\]CQWAS_<1QI(64Q]46"2$]A=H#I4-
M@W+CJ4=\9P'<CQP0/HK0V58I#W.KG/T6QXG8U6J?DWJRN";E$6,H<YA@D%)2
MK./#E4<_)3Z=>76/7/\ EE?ZC9?[O=M()G1>E+[2D<Z5<PP#@8YAD9P4YR",
MC(/0[=:R:2+@Y<>!L>2ZTU4U@$5!C-Q&,Y-B+A3)=0H$YP!UYB![<=>M1CDJ
M2!<B-0W%1#B#T4#[M_HK)J8D;M4:*N+O!L>-NJE[9K /. #G![MNOK#*=O?3
M>TJZ*.&=PPQ<-%^F*H.SXK".T>=#2-O67CE&<[E0)0!MDY5L*ZC9U&P?F!ZL
M>H7*K;[.D/42!FSCJ'6L[SQNX9V5Y41[4T>=/ /W/L;,B^SPH >JY%M#<QU@
MDD &0EE.>J@-ZU]':,[!N+8.TM/%>>OQ_AZ8>JHD0*:#4[\)XY,<EB+/$7B%
MJ,J;TEPUND1HC NFM)D:Q-).  I-KCN3ILX)V/,AYG;?&*H-)L+.9#6N1TOP
M=EQ&UVY<44AWAR:0:6N0SF7%HO*KG0_%Z_*_W1<0(]EB+*%*@:2B%D@#!4@R
MIB2Z0K=.1@CKW4WJ(,[V,<>C"[#)ENG8^+/Y5TBDG\::BS,-&,C17F+P/T05
MF1?(,K54U0(5,U1<I=Y6/O2 S'D+\R9',,@",2 2DJ*5*29]0!F?G[Y\(?-=
M:?#DAJV+B22[R&9@&S:0MB6S3-ELK/FEGM-LM4,)9_@]N@Q8+!4VK)/9PVF!
MG&,'EZ[]36-^KOAV>*[?1I>P:,&,6D-S.-F5_"<;<HQ@=YQMN-COL??]-<R:
MY9L>,\V?/AP?J*0+#W]5-OX#V[_V;U'KR'?-51K:)1$HB41*(E$5AB#_ '0W
MD^,&T?3/Z>S]H-,N'63908\?8*_454JCCE_YP'SG'M^OA10^X[N.\"K+8 $P
MECO\[EY_T[F-LG&V._Y!5)MH&\S_ !R4#/5Q]O6[JCJ$\ILQ W],Q1TSU0\#
M]/ZO945(=N\0?8K(J*I1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(J,G\'?\ \B[_ %%44-CP5NL'XEMG
MYFU_5IWU5[R5+4)Q;4G./NI8=SW'T[;<'Y#O3D^BAL<F+]GO@KY15*E5B_JR
M*P:B0B78[O"4V5^=6^;&4,)2G#T=:<%3BDI(5SXR#@$X/+4V'Y^VLMH_&.+K
MAXC_ $:QF-&'%R.6K8LM$</N)VF=/<&M!7>]WF% 3,TC:),-EV0RJZW3FCQT
M)CV> VZJ5=)CBW6H[;$%I]2GG$)ZJ->S:[)ZWX/! #"_XE[1G"^?LO$G9[&F
MEXII:))<V SP<.Q?$%3Q[#K+C*1<-5HN&B.'_;-O0-%MON,ZDU4TT4N-2M93
MVEYMMM>#@0C2\!16>P<=NLZ290@0<"KZ;-<,18D.YCI.3KT;,;3;@U5#<I+A
MJMYR;%P0V+.,C %[;J2S-<(]=V76-CAQ+=H^^HMFEM86N RB/$1*=E*8T[J,
M-H;#+#L&1*D0YBCN]$?2[(D)3&0$@^T()-H8S: T%PQFVH8.O+M][PVWIJI)
M-&Y320   7^VIL\/R)@80NDX<V.MEOE6CUR.0!0.ZR2$@J5E2NI &^.@P,UB
MNBH$DB[FWQ'<KZ.RV]%= .\"<@1R <A\P)++66MN+-CTI/\ 0\5$W46J'4H$
M+2MA;5-NTA2TA06\VE28T&.E)#BY$Y^.@M?;&NT!&;32&#W+P>$:SEA=<-OX
MBJC:&F@&JH ,!O$2!):(G$'"TK$D: UGQ.6W/XEW5-IT^%]I'X?:<DO,LN)0
M2E+6IKXCLY-R<4M':OP(K<: P5F(XF;V)E/W>II@6. X03GW*R-AM-LU6U8C
M"EC)EY+,S$$YG%;EA:0T_!A,P(]GMC,1EI+3<5N!##"$ 8Y$H#"4@#Q !)))
MW))Q]0S;SMK.B]%'AJ*6C N&I)E\0!\J@[H/1[[9;>TY9G$$GU56V&!O_P Q
ME)S[<YVI]2K/!N^ITDPA\+L3>D58A\#>,@^'FL8=X-<.7'7'D:.LC+SA)4_'
MCAAPJ\24#V#?KUVV%=!MB&9^! ,8BX/#T6*O"4&U-(O()$D-;=,>8<LK+*X!
MZ!E/HDF#<(SS9!:,&^76(A&-P"VS)2A6" !ZH3C.$C)!?6,W['EV2YM/Z.G0
M8N"7!G3A9LPRI2^"W.E2+7K76ME&2&_,-1S@$H_)2$.*4 E(P G)R.IR,F_6
M#6,6LP&3=<5YO_'[8FK_ #]H 2X&] F &#@-J<;J$;A7K*"V$PN+6L0M*4I"
MK@[#NX(2,94BYQ92,[ Y"<')&  *GU:/]IN3@3+ZS?,2'>4_HO% _P#M5D9/
M&$2-,O=R-#<8(I66N++-T2I1*&[UI.SI2D$^JGFLC=I<5RC"0I2RI0&5$JW,
MWMF;BJ[@ "#Q>5K^E\:S?U .;C#+'F7!*\CFC..$UY]F3Q&TI:;>M.$/:?TB
M^F\).V5><WN[7>$E1QD'S$XR>ZF]LX8$9Q2><$64'A?&2^VI$,&@R<]V&RGG
M)4T'@59)#R'M7W?46N9*4X#FI+K+?92.]*8C2VH8 Q@ ,  ; ;5KZ@ ^V][N
M#8$-%[S:6R72CP];O74:@V=3YWL]L)YN=H6K1MCL; C6BTVRW-(!2@1X;"7>
M7DP"7DM)<)*_65VQ>VR!C;&3MCSZ:@09;,;J[T^&H (-( )<6JDL^ RL7; P
MLB;B!L82< 8.P3@GOY?5R@9[DG?YR>1)X !F#MCK>?E=1LP P.N$E^$!HCC@
MO9475*(E$2B)1$HB41*(E$2B)1%8HF/A!>>N?,;1\@S/QCV=3[R:9<(C4]?Y
M4&/'V'3LXJ^T54CGY'^43]>A_9[Z*&>H]>^:UO<]>:=T)IZ1>=2R)4. S.DH
M<<:@2Y2T\THMI<4VPTM:8RE*&):@F(<* >Y@01(CN7_A,3K;I/;8B<O0-5V'
M5,#3MTL5P:GQ)5]0RTIO*' ]&0^)32VW0A2'(RAAY"L*2K  42**&>1$<Z3@
M]NXE;#_5]?91:2B)1$HB41*(E$4"<#."?8,9_614?R#O@BC51*(E$2B)1$HB
M41*(E$2B)1%#.^,'WXVZ9^OMK(J?"H<0VN/8Q9%&M=]Y<V1*(GU^OU_;1$HB
M41*(E$2B)1$HB41*(E$2B)1%1D_@\C_(N].OWBJ"X>V*AL>!O;FK;I_\2VS\
MT:Z^[Y:=]]]518?RJ6I-K6-\?=2P_P#?UM^OLJBXXCU4JL>!5]J*I4(<$?KY
M1>9]A3J%I2KE44+2E>W,DJ(.05)6!C .>563N4G%-F-P@EN4N)X3.?I.-I2:
MZ2 6)!8\1FQ;H5H_AGY/>B.&L2WI91,U+=;4PW$MM_U2^U>;K;H4=#[$:%;'
M7(K+=LB,1'BPB-";:95E;CK;KSK[K_IVGB*JHI@,QAB8$$@RU@6#"S0!YMCX
M.BB@"L"NL&J8(+EQ_:-'<%;PBL>;H4WS%2>=2D94I7(E022@%>5A(7S\J5..
M<J2$H*&@AEK@2Y?KQY1T ]SZA2*0P$ ,+6C3OH!8]4Z=@:JL]RL5SC1Y$&YP
MI$&6ET#G#,IEUD\BU-KY#APGM$8<;P2@%6#6J*MT_<2SP '%PY8D!V'!V>!/
M+;[(;6DA@Y<.1(<$7 ) )9X)9V8.N<K%H?CG-MQT7.U!;M(V*R*<M7PTM"E3
M]:ZDLL8\MO3#-QMB[5IZ2J$6H<Z?YO>YCRFERX3]NF.!QKT';;,WIJ,P"Q88
MP[QQ#]5\NGP7C06W]A30Q!--6U^H0\!SLQ2'&(>V#K>>BN'6FM#VT1;-;66Y
M;WK7"ZR7)%PO-T>))7*NEYG..W2X2W"2IQ^7)>6HG&>4 #A76]3TP.CG5B0;
M<U]/8[ 44_>!5600:I);":AO69WRP6>(3R)Y<E6ZCDA(^^42!A*4C"0>4$@J
M( *E*5E1YDNNX#!AWT4]9(,LW,G3+&+JIO\ 7Z_7Y=GW_P#'S1*UQ1*(GU_=
M129MI?S[PUA1)?!IXZ>[J3[9X(QD_P"%\G=U)ZG]1S4G3%_;]JH>?N",[['/
M?[0/'KZN_6I]V.[I=%,,XWQGOQG'LZ^SY_96D4:*%\&YI\OU]_[Z*J!!(P#C
MV_7%$4:(E$2B)1$HB41*(E$2B)1%88>/A#>NOX%:,[;9S.[^\X SX;;=YIPX
M3U*@QT,<&"OU152J&>7I]\#O^SV^%%#[CU6MVM":4U U*FW;3UIES)+DN*].
M7"C-SI$02E*1&?G168\M^.@@\K#[KO(KU@X3]Z(?FE[$ACD-#8QPCKCDEHTE
MI^P0XL"T6>%$BQ'Y$AAL=HXIM^8KGER>U?+SKDA]>"IQQ96?\,=*.R,[O8QZ
M2==9L-5DU%4HB418O/UGI>V2G84^^6R)+93SNQI,Z,Q(0G&>;L'74.J!!&"E
M)R=AO5;40V.<^D\\X7"OQ&RV;[U5GZC+$N8< KP#B+HT[_"&TXQG>Y0>AQ_C
M'=D'?<"M_3JS&!QL<;>G"\+S_P#DO"V^H(O-&G_.+XE^*'B)H[?_ '06GNW%
MS@=Y&,?PC'?\P.?;?I5NT>8OQ .&2G_DO"LYK%_]U.?_ &[TEI1Q"T;L?A%:
M]SS8])P?D!_A'3;IG?OS6300[FD-F3?*!=4?XEX4M_F"=:/_ /0R/17BWZFL
MMV:6_;)T>X,H667%PY+$E"'0 HM*++BSVG*0HIWPD[XZ#%08&Q?(NV%KZA@V
M9!7>GQ.SK -)<9AC-V@S$\%AFC^,&D=9R=6Q8#DJ"O1]W;M5Q7=6VHC,D/ML
MNQ[A =+RD/V^0V\DMO$H((4E:$J2106#=]>\UW) #G0]\'GR69.:LTZT2ER\
MVM*@\N.4JN,))#[.%26<*?&78K2@\ZV,KY-FPM?JT\U5%K56GI 9,>\VQ_SA
M;S<<,SXCG;K81VKJ6BAXA92R4ND))(0H9 .U.>(',A_3)1]#WWBU\X5-.LM*
M*"B-164A"FT.\MSAJ[%;JN5M#I2\0@J5D#.QP=\41P+QQ[](R6)7?BC'M'$/
M2W#Y>E]0RG-5VZ5<HFI8JK*K3\1F)DN(F*=N[5S[0CD*/-K=(00XDE8'-RE5
MFR]1V9N3)B*N,(2(79JFLF7&2]#;<0I:793*G0\RWD)1S+0,J6@#(.04?0^4
M^?JRU[Q#XR:?T%I![64>WW+6<%B[P+*[$TK(LKLQ$RX3D6UGF5=;K:X:6T37
M66'2J4%(4ZDE.,D#%^^V[='GOOG;)Y:?AQQFTGQ)L1O$$2[%*8N=ULMPL.H%
M08EWM]WLQ'G\!Y+$R3#?6T@I<[>%+DQ2A0/;YR 5[[XK,K9K*P7(Q64W&#'N
M$I(4FV.7*W/34I67.Q/)$ER&W.W;;[5KL7',MJ&<*"DI*/+<?+OMPLF2L*]A
MRH8V/WO7<$CO'?153$@#).!D#)\20!\Y(%._A%YC+;2@.+2M">4*5S<N4@MM
MN$8"B5%*%DGDY@>S6 2< Y-5%()WJ8R(G5['X8V4?BIP^@I2K! 7]X"4@K)&
M0 .;()3A6#@@9! 4"*@VE# [PG7R[XJS,'/B,^14_:H R5)"2<)5S#UCOD #
M?(P=L=QH-I0<1C+ABU^F**DN4VD$CU^4^MA;8 '.$E1*E@8 YED9YL(4 DJY
M4F[U,_<(#F18O\%)LQ?+%<PZT\JBSZ(N_$*UW#AIQ(F-\-XC4^\W&!$TX8<V
MWNR+"T9]I1)U%&F2H;4;4$6>[(7%:;1&CS 5=NQV*KO E@7[/Q@C&[,!Z?MQ
MG'EM;3W%.VWJ=J.)<+-==+-:=N,"TFX:AD61B!=Y\VTQ;NIBT/1+M+5*5"8F
M1F994AH(D.AM': %0O??[4<83>VF(YQQTE99\,-,AP-F]VT'M%-9\\CX#B"E
M*FR0X1V@6H)+?\8,$E( )!'&?Z>S\5@&K.-VEM.Z"N_$2TQ;CK:R6*Y>B[FS
MIE=L,R.^BX(MDE7+>+A:F%HB2UH;>2A]3ISEIMS!P1^^\\[876PX^IK:N%:9
M<YUNSKO+++D6'=),-B3VCS3;PCX3(<:=>0AP%8CN.I24D<V<9=]]\$>'F[>;
M*D=76%QRX18%QAW2XVZ/)?=M=OFPW[@M45UYAYA$;SA*DO)D,EC[=V;9>4EO
MGY@H)>:/RM?4MY>>#K1G"WRI-%<3K@_:_0.I]&2T6:1J"(-7(LL=FX6B)>9%
MBE2V9-KO-SCQNQN$<MF/<'(<E86@MLK]8)8\K^@Y^6-U7\NSTQZ76ZSK:Q-2
M)S,R;!@MQ76FF)$B[6@HN!6TEUPQF69[LIHL!;8<;FL175!Q*VD.-A2TE-ZT
M&=/A^#7?!92T\V^D+:4E:% *0M*DJ2M*@"%)*201OC(V/<2*("_?? Y%5:*I
M1$HBHR?P=_\ R+O3K]XJBAL7R*MNG_Q+;/S-G^K01Y^9=46'?JJ6H_Q8/\YV
M'_OVVTQ#Y@1J0.\<E#8MD5?:*I1$HB41*(H* 4"" 0000>A]_7;Y#10OAR['
MI\J4)!(4H>MCN4HI'N!P![^4&BK=]?E3T1*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HBL,3^4-ZZ?@-H^F?U\3\^V/<*<.'N5!>KC[!7
MZHJI5;D 9V4DG;N^HP310_#/B9CC'H<%9; GEAN#FYB)<KNP!]O<('T[[9JG
M#A[E!>KC[#3)L_17RHJE$2B)1%KJ^\+]$ZCGN7*]Z/T?>9KHPN9>--VFYRU#
MICMIT.2K&,#W#H*V*A -(+"\/Z=ZKQU^&-1)%5(=W@Z9N'S9E0'!KA,  >&/
M#TX _P#R9IO&1T./1?3Q'3H<#%7ZM>?K\K0\'X8?_AV9S^RB3_\ 74I_<:X3
M_P#Z9</MA@9T;ILGKGXK]_ZAOW3ZE>9XR_=])0^#\.?_ ,.S,?[:<'O]O?K$
M<&N$PSGAEP_R>H^!NF^7KD8^Y>0![*&NHW.#=O*H\'X83]'9NY(^RB)P^V.7
MG+^F;H2/#TQ>=/:%8L.B%W2+)::DVNQ16XT>3):+)EKM\(P&W'$-D!!2\VH<
MH((Q7*H$XM^\('G-R++U[&CPVS85;(FDU/531NTAF:'!<W@@ 8&ZY[A>2>(2
MKK$>US/OEAU)HT:=U-9]0PS=DSKS%>>EVS4<"5+DOOVMR')=;:\P84J.N(PV
MV3S U6\K$SS62!O5-^)L(MJ&B(N?(+#M3^1#'U%>= :E7KQWT]I -R[LX]9@
MS;=0WR'<O3<.[)MMKG6Z/;7WK@AJ'< @24O6H*:Y5+]4IP;']?M3VMTQ[R7F
M<\C*]P+=PO\ 1FOH"9O">WVQ%M3#TE%C*OTZU3W92%2'57," U<8JTP;@!YV
M7&4I!RE(JIC[8<;76F]%^0QJK4>G[A"UK(B:'N*]1(NZ78K-NN4N[DMRXTB/
M.<L]\EL/6MF,^AVWN/.1IC,Q =4P !10&<M&F[27TRM8D KL[4O!36\[46A[
M]ICB+!L9T7I1[3+#%TTLG41F&2EMM^8\Y*NC"BYR-(*"HJ4% A1*5$4[[[_=
M8>OF_P KG36?D;:GC'B;K*UZMEZZUEK?3$FS+@7)N-!4Z_<G[6NX",],N+%L
M:@]E#D-1(4P"/'2\E+C[;/:*23V/7M^H66Z:\E[4%U\FP<%[TY8=$N7'5B;]
M/8AV.%.CO6IJ9&NQM]QB6F\F N=)N<9I2Y\:XNMH92"AI:B4*3S1N<G)KR-<
M;XX@LLIUGY)35[O6C+AI+55MT=;M(1U*:LR-*Q[I#EW-_D3.N#O;W!EQ2KDV
MDMRD/./ (("2K&:(0X;-GPXV[Y+ =)^1-J#2VH]+:B;XEV5Y_3%RT]*CF/H6
M/"EKA6%R:X+>F8+H\4)FF:6WWBTM?9-(0!@;%?0W7T%2A2>7F4%D9RK'*=P,
MX R-R,G)VZ"B@#:^5S-OB2.E.22&E;E(VYE#JE/, 3GNV)W[NM>;Q1JIV9-+
MO%K@;U()&9 )9:#.'+#OM\+KEYW5WE%)N=_9C\*]-.PH>HQ$L$I>M6U.7'37
MG\EM%W?C*1B)+3#0R_YJHDE9[,K&<U^7&W\:-N*=VO=&!JJ( %)(O4Q!($X%
MH,+ML:15M!36  7WK1%1#/>6#@0 ,PJU\UCY0<6?=FK#PQT]/@Q]0Q8=JD/Z
MN:9<N&FG(3+LR\/M!!4Q+9GJ7%2R3@MI*DG  KU_5\2; F) ),?[B00^ >&=
MK+V#9[ $;QEW<T@5/@-T@BP=L8LX5"3K'RC&W&NSX3Z;6V=1"(Z4:Q9<5'T[
MAG%U;24$.R,K=26P.8[D* !K=&T\4*S!&@-1 #6#D@$YPS6*"CPY >MH)<C=
M)+D8!XRX'$JY-:JX^>8Q%JX8:>$I_5,B#.BC5K"1!TR"PY&O49]:"U*FN*4]
MB(O 2ZEL.*2@DC?U/$;L/^69^VQ%7Y2!#$O<@Q"AI\.X!J/XN6:X<&].(!A@
M;-+DXCJ'R?W^+]RL.K]8S)6B=03K _IS76FK4XFY1+]8D2[M,3;WIZWVRTQ)
MN9L=P=,=OF,:V)MOJQI#H'I\-5M:MOLC61(KWJ9PIK^Z[!RW4-8KCM1LQ1M*
M:?N#T[E4 ,30]+ 20'<ELC@I[CY*:IFB='Z6^&0ESM-.WPS;I>K,U=D7=-]2
M_'>F*BOR VQ=X4)<=%MGCG7$D1(\A(): 5]=>(!B3FWDL<@>1FS;[==(K>I[
M$]<9NMHVK(=]DZ+@NW&%%C1[=$%J7S2NQDK<9MR'#<%-H=1+>D2"VXMY>64F
M.^^2N.G??QCFSWDV7"-PFU5POT_JZUV16IM22;TK4#>E(RWFH\R[-7B1'E08
MLV B>^J4WA#JY+3;:%$=DL[@I,LT^OQY^V'Z_P#)/U5Q0F:-N6N>*:9TC1DA
MU$"!:--(LMED0%MQU?;XK-R>E(N"WX4;,U$M:F65/MM((>)288S83,#CWT0Q
MDV.#=^O463R;. O$+0>LN*-_U-9;'99&I!>(ENO1]%7*:IR==G;Q'F056^Z3
MWG+?YVXB0_#NZ(,HNL,D$! 2I;!+\N'7IPO975CR+;7"X6O:$MFH+/;=07*Z
M2)=^U@SI5MZ1=8,J\3;N[#,-^XJ1&Y7YRW&^P<2V'D)5R]"DKWWWESPJY^0G
M?+F^5O\ $^SO) AN(>DZ"BNS/.H6G5Z?3(4\+LG+KR7%2G73S*+S3*@GF25"
M?OO]WZHNZ]!::F:1TE8-.W"Y-7B99K3"MCUS;AIA>>*B-!LOJ82XX$J=(*U#
MF)YB=S519A1$HB4149'X._\ Y%W^HJBAL>"MU@_$ML_-&O;^3X]]!\^ONJJ.
MH_Q8/\YV'_OVVTRXC+,9QW8H;'OTGHK[1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%88G\H;S^96CYLSSM[-S\N
M?"F7>)MW=U,[7]A?7V97ZBJE4<$;'?/3V G!]_2BC3TN'MWROBK+8E+\S<*T
M%"C.EIY58R$AY>%;=01C'?TS5)MH&]2/50-)!$X1$:<SV5>\^((_7]'U[NNU
M15QPXX0\\E&BJ@3CN)]U$[[[]VCFB)11^(XJ!(&Y^@T53/78[?K]U$[[>%&B
M)11QZCF,$HJF1XT10.#WX[MCX[?L.**."T^=V5)#?(GE(R >7./76D8"2I6Q
M)SDD[#%$Y>7/MGE53G!QUP<9SC/=G&_S'/A1(L<?-4RC.0HY24\N, E)4,*(
M4=\8VQO[:(S<)8-G>>-K99**$% Y0I1&1CF() '4=  .X8Z9S1+<,!)U^?(*
MI150S[#W^'=\O?W44?0]./><\6$X&<'NV[]Z(_*_E[*58"D\I"B#@^K["#@Y
MVP<8(/49%0@&"'P5[[9>,,'FZ$9005I0D*"N5"=CU(SVBQS#/,H$8 KE5X?9
M'^P#4 /U:X%C@CD6=VEH?T4Q8',%)2E)P4_Q8RH'\A6 /4_*Y1^4,U/Z?9C
M,TL!A8<-,V0U57^XG4CU>[0_*RF[!'0H.$@%)  5T5D$GJ!DD [#.XVS6AL-
MF"/M#,UO4B2!E_"&NIH)?(\0_8T&(>'8!(5R)QD+Y0H92%$E221X<Q]8 X
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%+#1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g454025g01b34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g454025g01b34.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[12T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %)B^4G(X0DE-!"4      !                      .$))300Z
M  #_    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$
M5 !! "  +0 @ #$       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 55U@0
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      T$    &              %B   "#P    8 9P P #$ 8@ S #0
M   !                          $              @\   %B
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   %B     %)G
M:'1L;VYG   "#P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !8@    !29VAT;&]N9P   @\    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^% 2FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0'_P  1" &. E # 1$  A$! Q$!_\0 '@ !  $$ P$!
M  $"! 4( P8'"0K_Q !R$  ! @0$ @8""@@,$ @+"0 ! @, ! 41!@<A,1)!
M"!,446%Q(H$)%1<8(R0R-)&A%B<S0['!T? F0D=24U18=)*3L^$E*#4V-T17
M8V1G<W>#E[+Q.$955F*WTM,92&5R@J*FM,?5UV9VAY:CI;7#U/_$ !P! 0$
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M;:R4S[O]N)4BW +#A&NAN;:GOU@5-O.SZR5P'OW[^X@! " $ ( 0 @! " $
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M=BQ%0YQ5C?LM8ITS;4@$%E]5[V)OPCUZQ@]GQ<WAXB4Q^2N<^CX<?$VT]J[
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MBFN5375A8BPZ]R&W34Z5DJE.7-6.[(?9<OP/-+MOP.(5;SL3;UQTJ,?!Q/\
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M=%VIKZZ<R8PBZL602FF*9!2--0S,RX(/?P>-M8\-/;&U*+8FJET*<^=_)3'
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M :C])W U&QW6LC*%6O;!,D_F8V\M5+J*Z;-MN!E"@\F92%DA)(NVE-S?T2;
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M[Q10;^Z)FV;V.N+Y<ZC;3VD-N[EH3$A<%PRTX$ESRZ5-^B@>]XHQ4#[HF;0
MO:V+Y<6W!N/:0#NM?Q[H0G-L\RRY_9\.D9].DCWO%%U'NAYM^9Q=+WW'_D2U
MK[[]_D22R7,-OK;F[^"=B?>\477[86;(TY8NE^[E_02Q/EK^"+'Z^D"\>'//
MRG[\A[WFB@G[8F;=S8?UW2]M.=Q1"!^")"RA6R)+BROS57Z2R/>[T2P^V)FV
M-3MB^7OJ?&B7TY7%A%A<.?CQ*FXOGX\>:]\DSD'1\I@M]LS.#36_V7R=][Z_
MT"U\MH%.;W Z?K]LS-[74_HMDO\ Y%  9"4\?JE9NGSQ;)?_ "+\_68 >X)3
M]+YEYNFVG]=LE]?] OS^F$9\_?M@>X)3]/MEYNZ&_P#7;)?_ "+\_HB1](!
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ML>1W//2_JYP4M2JDU*NDH?&'%_#^,ENN'9OPE%S&91 " $ ( 0 @! " $ (
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M,_([; IKQG3<8VR&L=\Q1]'9F?YSX0,8O+XVY6CU<67ZFP\#(0 @! " $ (
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M]?? N.VR^W$;Z7'"JXOKK8$>?+QBJ^3I?2NG]1\:B8^:>&Z_>I4F9:4I21Q
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MU48&^L^FQ'>$C?78\]X!S*CCZ:OJI]<C-#8;;#;0>KP@%DNBRR\"8%$ ( 0
M@! " -><Z"/LVR'ORS&3X:]F9MR-]_ =\#&+S&OE*AZWR6G238:!D( 0 @!
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M-._3SU@35]5II'&U_%P;#P*( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0
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MM+G.5SZ([.!VWVAA;O\ XFNFFE.53#E2G?>>L7=CR2L=$C +S3PPQ4*W@N:
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M]_J7YORMOK?N_+ &O&=-_LWR%YWS%'J'96>[R^ON@3CGFOM/A#R\KW-AX%$
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MLF $ ( UWSHO]F^0]@?[(J;FYM8RK.WX_'?N@8ZQ-V^F24]?7EE)L1 R$ (
M0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @!
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M?Q^+,_DY0,6KJ,W=W>2C3+4V'@9" $ ( 0 @! " $ ( 0 @! " $ ( 0 @!
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MVE_[69^C^?S@2\OA/'DLEUDV'@40 @! " $ ( 0 @! " $ ( 0 @! " $ (
M0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @!
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M " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! %I4!>0GAWR<R/\
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M " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $
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M"B $ ( UXSH%\;9#;:9C ]W]JL_3S[]QW:"+-^&CO;CE[?$V'@40 @! " $
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M " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $
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M $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ (
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MLDOJWF[\\HV+@9" $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! "
M$ ( 0 @! " $ ( 0 @! " $ ( 0 @"E2@FU^=^1-K>0,1N/YCZV]4!Q C0V\
MQ;ZC:)O4\?*7]@4I4!H5\1U.Q!MIY[6/TPWZ>/U'..15Q#4C8>?U  DVYZ:;
MQ4T\GG,>!&XTMXY\(2?MDI-Q?\OXP#]47VR^_<Q[L3 " $ ( 0!%];6/U_C
M&O+4QCO/_;]5]4A] #?\Q^*\53JH\9)GD_%0R8>'OWT6K@HO^=C">3\JOT B
M@0 @! " $ 6D_P#,9V^H[),7&U_@5Q5=KJB59/H_H6U%N:5($F]Y9JQ)!N.$
M6-QI$?*X3GS:=YRL<%5^=4?]_I[NX=]OR]T ].O/@^'\&;@%DN@@40 @! "
M$ ( UWSI'Z-LA?\ .,+^/Q9G\]>Z!&X\6HY](OYZLV(@40 @! " $ ( 0 @!
M " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $
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MTTM\D<M[^.T0I;U6_:J/8@?'Q>_=PBX'C Q?^,Y3ZZ>&?H9H;#R$#)9(F $
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M9SQDP..\EL;8VS-R?QR)G"#<G@&@X@I59IL^NL,+GA6)5V14U3Y)5.*W)92
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M"4BP(U.U]+GN'=Y1EOIYY^?JL_$)1-\R4H0E*4)0E*$ )0D !*4I%@$C8
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M/^_A?4C]*/I\C /3+-9_;T7*9,T-0#>^@U[_ !@59*<]28 0 @! " /!Y_I
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M/UC?6K3UB]1Z*;JUV@"X!!N 02#8@$&QWL;;&Q!L>^ )@! " $ ( 0 @! "
M$ ( 0 @"TFI^1DD\<[.RDHC0<4U,LRZ;G8<3JT#7EKK %V"#L;^4 ( 0 @!
M" $ ( 0 @! " $ ( IXDJ2++%E A*DD&^^J3J"1OL=M1 &%I.)</UU4PBB5F
MFU=4HYU,T*?.,374.<TN%E:D@BQ)%[@ Z&T![\/<&<@! " $ ( 0 @! " $
M( 0 @"E:T-I*W%I0D DJ6H)2  2222   "22= "8 X9:<E)QLNR<U+S3044E
MR6?:?;"AH4E;2E)"@="+W'= %Q " $ ( 0 @! " $ ( 0 @""0D$J(2!N20
M.6I.F^D <+\U+2P29F88EPM8;07WFV@M:C9*$EQ20I9.@2+DG81)4Q*EY*5+
M!P3=4ID@6A/5&1DB\H(9$W-R\N75G9#77.(ZQ1Y)3<GNBDE<47@4E7R5)5H#
MH0=#L=#L>1V,"EM/ZR,[^])G^17%IS75?4E63Z/Z%M12HTF0XA8B5:!]21KZ
MX@67C5]6<%64!-4:]]9](%AWI&_</S$"-3&4IZSEK'IR,W JR4YPI$"B $ (
M 0 @"ARX;7:Y/";6'$=OUH4DGRXDWVN(!Y/^/70T1SIG9G%&8V/L-51<Q2*3
M@/*AK%U"JDK-NH=76ZA.SJGY@-!2D<<AU3;*.,-AU "T$)4D0<3IR7&%FEE/
M'F[\HLLFKO/K?[Q[G9#(/%E4QMD[EEBFN2;E/K=>P3AVH5>6?42][8.TJ5,R
M^I2D)XS,.7=-K\ 6 HD[.?&?1Q[])$J;=,K3F^K^D:-P>PP*( 0 @! " $ (
M 0 @! " $ >&9XX9?KF&*DJ4P;4,PJ@J0<EZ;A65JDC29=^;7JB>FIR<J-(4
MV)8^DE")T!PI XDE5@)KEGK^ML^"^AW'*:<;J&66 9]F?FJHU.81P_,MU*>E
MU2D[/H?I<LXB<G)1;TRJ5F9A*@Z_+&:FBPZM37:9CAZU;/R7HHT"LO%Y=7]#
MT*!1 " $ ( 0 @! " $ ( 0 @/?$UDZ4M3KDCEO*T##=63AV?QUB_!N!7*\O
MCZN@R6)\02%(G)QM;3\FIEU4K-O-LJ7-RB"\M 5-2P)=2)^UGR?UOZ<C$]'^
M6K&&:MBC+:IT;"<L[A)-%F9/$>#TORC%=IDVVWP&L,3YGIENJ\"BJ99$P4JN
MH(? (4)RA93GKK_/,.+7>?G]9X\HSB3;&*40 @! " $ ( 0 @! " $ ( \BS
MQ7BAO++%2L'RRYVM+9I;:I5-^N<HRZM*)Q(FFI;X7%U1>'551$@@+%YTRUU)
M3QF+[7CQY1[S,6IG6ZE/)1?U<3G9FLO1LJ\O,YR8[IF"$UY.7;&$:',3LE69
M:L20I6,7YE"YPLLUR7E9EQ3[4L\S,HETN-,.K;6E:T.<1DJ?#Z1)<E>^K\.B
MO$+KZ&^C964)+@ 60.()N0#SM?6!??O,K@! " $ ( 0 @! " $ ( I4 I)"@
M% [@BX-C<:<['6(\G>.?\V!HSTWY,IP-@:NRU7JLC/TG,_"4LA--G%2S<RBI
M55AM;$ZR@]8XTAM"=$"X*TDCA<$>:E+XM+NXWI=EFY:U;=^KL\V2K)]/%\/>
M?#0]1SDP1A.NX1GYNN)GYRNS^'V:7A9B0F9A,_*5KLX<E)RFR[767=:FW6')
M^:>2E#$@'U+''U95ZIEJV=LKYSYY*+99Z&K=2X72B_"SO>V;3M?_ !>OL67T
MA4J7@S#-.J\P)NIR5(DI:>FNL+ZWYAMD]9UCUDE:D^B"LC50(WM#V^7J94N7
MFX4I/.<VYX6B.C.U5#YA.\OBDSKO]Y7RBK-:71G5D^C^AP4@$4N0O>_96@1X
M\(]=_7$"R73C/\]2WJGSJD?OX?@'Y_7 /3KTT?\ ',S0V'/3?O@%=)\4(%$
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MB4^PT\MOB"7&"EPA02("+I7<7O=:ZOAY^$FW$"B $ ( 0 @! " $ ( 0 @!
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M " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $
M( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( M*A\PG>?Q29T_T*XJS6MT1Y/H
MSAI(M39$#82S8^@"W>?KB!.8Z)YW]\RUJH!FZ/<7^/ @VO8A(^@]T"5:?]R,
MV-0#WP,EDHRT$ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ (
M0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @!
M" $ ( 0 @! " $ ( 0 @"TJ'S"=_>DSOJ/N*^7.*LUU1*LGT?T.&D6-,D3_@
MS6MK:<(Y<O*(%9)<$6E6^=T;4@]O&@Y^B+WT.GT'N@'IEFL].G.8,V-A;:PM
M +)1E"@F!1 " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ (
M 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @!
M " $ ( 0 @! " $ 6E0^8SO[TF?Y%<56:ZHE63Z/Z'!2+^UD@=AV5K2VQX1Z
M_"T0+)3PN6]5MVJC]_;A;^"+P)5_C_W(S(V'D/"!5DNB)@40 @! " $ ( 0
M@! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! " $ ( 0 @! "
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M<[:=3$$KCQ?EF!B&CDV$X"?!B9\_V'P,"S[=A]D5&U/;18"]^HF;?3U-OSM
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FH"%E'OWZ@R[!%BRU;_)I'U@7@(7!>1R@!(L  !L  !] @7(__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
